

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number
WO 2004/013311 A2

- (51) International Patent Classification⁷: **C12N**
- (21) International Application Number:
PCT/US2003/024669
- (22) International Filing Date: 6 August 2003 (06.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/401,469 6 August 2002 (06.08.2002) US
- (71) Applicant (*for all designated States except US*): **DI-ADEXUS, INC.** [US/US]; 343 Oyster Point Boulevard, South San Francisco, CA 94080 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **MACINA, Roberto, A.** [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). **SALCEDA, Susana** [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). **LIU, Chenghua** [CN/US]; 1125 Ranchero Way #14, San Jose, CA 95117 (US). **SUN, Yongming** [CN/US]; 551 Shoal Drive,, Redwood City,, California 94065 (CN). **TURNER, Leah, R.** [US/US]; 939 Rosette Court, Sunnyvale, CA 94086 (US).
- (74) Agent: **LICATA, Jane, Massey**; Licata & Tyrrell P.C., 66 E. Main Street, Marlton, New Jersey 08053 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS RELATING TO OVARIAN SPECIFIC GENES AND PROTEINS

(57) Abstract: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and noncancerous disease states in ovarian, identifying ovarian tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research.



WO 2004/013311 A2

COMPOSITIONS AND METHODS RELATING TO OVARIAN SPECIFIC GENES AND PROTEINS

FIELD OF THE INVENTION

5 The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the
10 nucleic acids, polypeptides, antibodies, post translational modifications (PTMs), variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovarian, identifying ovarian tissue and monitoring and identifying and/or designing agonists and antagonists of
15 polypeptides of the invention. The uses also include gene therapy, therapeutic molecules including but limited to antibodies or antisense molecules, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research.

BACKGROUND OF THE INVENTION

 Cancer of the ovaries is the fourth-most common cause of cancer death in women
20 in the United States, with more than 23,000 new cases and roughly 14,000 deaths predicted for the year 2001. Shridhar, V. et al., *Cancer Res.* 61(15): 5895-904 (2001); Memarzadeh, S. & Berek, J. S., *J. Reprod. Med.* 46(7): 621-29 (2001). The incidence of ovarian cancer is of serious concern worldwide, with an estimated 191,000 new cases predicted annually. Runnebaum, I. B. & Stickeler, E., *J. Cancer Res. Clin. Oncol.* 127(2):
25 73-79 (2001). Unfortunately, women with ovarian cancer are typically asymptomatic until the disease has metastasized. Because effective screening for ovarian cancer is not available, roughly 70% of women diagnosed have an advanced stage of the cancer with a five-year survival rate of ~25-30%. Memarzadeh, S. & Berek, J. S., *supra*; Nunns, D. et al., *Obstet. Gynecol. Surv.* 55(12): 746-51. Conversely, women diagnosed with early
30 stage ovarian cancer enjoy considerably higher survival rates. Werness, B. A. & Eltabbakh, G. H., *Int'l. J. Gynecol. Pathol.* 20(1): 48-63 (2001). Although our understanding of the etiology of ovarian cancer is incomplete, the results of extensive research in this area point to a combination of age, genetics, reproductive, and

2.

dietary/environmental factors. Age is a key risk factor in the development of ovarian cancer: while the risk for developing ovarian cancer before the age of 30 is slim, the incidence of ovarian cancer rises linearly between ages 30 to 50, increasing at a slower rate thereafter, with the highest incidence being among septagenarian women. Jeanne M. Schilder et al., Hereditary Ovarian Cancer: Clinical Syndromes and Management, in Ovarian Cancer 182 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001).

With respect to genetic factors, a family history of ovarian cancer is the most significant risk factor in the development of the disease, with that risk depending on the number of affected family members, the degree of their relationship to the woman, and which particular first degree relatives are affected by the disease. *Id.* Mutations in several genes have been associated with ovarian cancer, including BRCA1 and BRCA2, both of which play a key role in the development of breast cancer, as well as hMSH2 and hMLH1, both of which are associated with hereditary non-polyposis colon cancer. Katherine Y. Look, Epidemiology, Etiology, and Screening of Ovarian Cancer, in Ovarian Cancer 169, 171-73 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). BRCA1, located on chromosome 17, and BRCA2, located on chromosome 13, are tumor suppressor genes implicated in DNA repair; mutations in these genes are linked to roughly 10% of ovarian cancers. *Id.* at 171-72; Schilder et al., *supra* at 185-86. hMSH2 and hMLH1 are associated with DNA mismatch repair, and are located on chromosomes 2 and 3, respectively; it has been reported that roughly 3% of hereditary ovarian carcinomas are due to mutations in these genes. Look, *supra* at 173; Schilder et al., *supra* at 184, 188-89.

Reproductive factors have also been associated with an increased or reduced risk of ovarian cancer. Late menopause, nulliparity, and early age at menarche have all been linked with an elevated risk of ovarian cancer. Schilder et al., *supra* at 182. One theory hypothesizes that these factors increase the number of ovulatory cycles over the course of a woman's life, leading to "incessant ovulation," which is thought to be the primary cause of mutations to the ovarian epithelium. *Id.*; Laura J. Havrilesky & Andrew Berchuck, Molecular Alterations in Sporadic Ovarian Cancer, in Ovarian Cancer 25 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). The mutations may be explained by the fact that ovulation results in the destruction and repair of that epithelium, necessitating increased cell division, thereby increasing the possibility that an undetected mutation will occur. *Id.* Support for this theory may be found in the fact pregnancy, lactation, and the

use of oral contraceptives, all of which suppress ovulation, confer a protective effect with respect to developing ovarian cancer. *Id.*

Among dietary/environmental factors, there would appear to be an association between high intake of animal fat or red meat and ovarian cancer, while the antioxidant Vitamin A, which prevents free radical formation and also assists in maintaining normal cellular differentiation, may offer a protective effect. Look, *supra* at 169. Reports have also associated asbestos and hydrous magnesium trisilicate (talc), the latter of which may be present in diaphragms and sanitary napkins. *Id.* at 169-70.

Current screening procedures for ovarian cancer, while of some utility, are quite limited in their diagnostic ability, a problem that is particularly acute at early stages of cancer progression when the disease is typically asymptomatic yet is most readily treated. Walter J. Burdette, Cancer: Etiology, Diagnosis, and Treatment 166 (1998); Memarzadeh & Berek, *supra*; Runnebaum & Stickeler, *supra*; Werness & Eltabbakh, *supra*. Commonly used screening tests include biannual rectovaginal pelvic examination, radioimmunoassay to detect the CA-125 serum tumor marker, and transvaginal ultrasonography. Burdette, *supra* at 166.

Pelvic examination has failed to yield adequate numbers of early diagnoses, and the other methods are not sufficiently accurate. *Id.* One study reported that only 15% of patients who suffered from ovarian cancer were diagnosed with the disease at the time of their pelvic examination. Look, *supra* at 174. Moreover, the CA-125 test is prone to giving false positives in pre-menopausal women and has been reported to be of low predictive value in post-menopausal women. *Id.* at 174-75. Although transvaginal ultrasonography is now the preferred procedure for screening for ovarian cancer, it is unable to distinguish reliably between benign and malignant tumors, and also cannot locate primary peritoneal malignancies or ovarian cancer if the ovary size is normal. Schilder et al., *supra* at 194-95. While genetic testing for mutations of the BRCA1, BRCA2, hMSH2, and hMLH1 genes is now available, these tests may be too costly for some patients and may also yield false negative or indeterminate results. Schilder et al., *supra* at 191-94.

The staging of ovarian cancer, which is accomplished through surgical exploration, is crucial in determining the course of treatment and management of the disease. AJCC Cancer Staging Handbook 187 (Irvin D. Fleming et al. eds., 5th ed. 1998); Burdette, *supra* at 170; Memarzadeh & Berek, *supra*; Shridhar et al., *supra*. Staging is performed by

reference to the classification system developed by the International Federation of Gynecology and Obstetrics. David H. Moore, Primary Surgical Management of Early Epithelial Ovarian Carcinoma, in Ovarian Cancer 203 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001); Fleming et al. eds., *supra* at 188. Stage I ovarian cancer is
5 characterized by tumor growth that is limited to the ovaries and is comprised of three substages. *Id.* In substage IA, tumor growth is limited to one ovary, there is no tumor on the external surface of the ovary, the ovarian capsule is intact, and no malignant cells are present in ascites or peritoneal washings. *Id.* Substage IB is identical to A1, except that tumor growth is limited to both ovaries. *Id.* Substage IC refers to the presence of tumor
10 growth limited to one or both ovaries, and also includes one or more of the following characteristics: capsule rupture, tumor growth on the surface of one or both ovaries, and malignant cells present in ascites or peritoneal washings. *Id.*

Stage II ovarian cancer refers to tumor growth involving one or both ovaries, along with pelvic extension. *Id.* Substage IIA involves extension and/or implants on the uterus
15 and/or fallopian tubes, with no malignant cells in the ascites or peritoneal washings, while substage IIB involves extension into other pelvic organs and tissues, again with no malignant cells in the ascites or peritoneal washings. *Id.* Substage IIC involves pelvic extension as in IIA or IIB, but with malignant cells in the ascites or peritoneal washings. *Id.*

20 Stage III ovarian cancer involves tumor growth in one or both ovaries, with peritoneal metastasis beyond the pelvis confirmed by microscope and/or metastasis in the regional lymph nodes. *Id.* Substage IIIA is characterized by microscopic peritoneal metastasis outside the pelvis, with substage IIIB involving macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension. *Id.* Substage IIIC is
25 identical to IIIB, except that the metastasis is greater than 2 cm in greatest dimension and may include regional lymph node metastasis. *Id.* Lastly, Stage IV refers to the presence distant metastasis, excluding peritoneal metastasis. *Id.*

While surgical staging is currently the benchmark for assessing the management and treatment of ovarian cancer, it suffers from considerable drawbacks, including the
30 invasiveness of the procedure, the potential for complications, as well as the potential for inaccuracy. Moore, *supra* at 206-208, 213. In view of these limitations, attention has turned to developing alternative staging methodologies through understanding differential gene expression in various stages of ovarian cancer and by obtaining various biomarkers

to help better assess the progression of the disease. Vartiainen, J. et al., *Int'l J. Cancer*, 95(5): 313-16 (2001); Shridhar et al. *supra*; Baekelandt, M. et al., *J. Clin. Oncol.* 18(22): 3775-81.

The treatment of ovarian cancer typically involves a multiprong attack, with surgical intervention serving as the foundation of treatment. Dennis S. Chi & William J. Hoskins, Primary Surgical Management of Advanced Epithelial Ovarian Cancer, in Ovarian Cancer 241 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). For example, in the case of epithelial ovarian cancer, which accounts for ~90% of cases of ovarian cancer, treatment typically consists of: (1) cytoreductive surgery, including total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy, followed by (2) adjuvant chemotherapy with paclitaxel and either cisplatin or carboplatin. Eltabbakh, G.H. & Awtrey, C.S., *Expert Op. Pharmacother.* 2(10): 109-24. Despite a clinical response rate of 80% to the adjuvant therapy, most patients experience tumor recurrence within three years of treatment. *Id.* Certain patients may undergo a second cytoreductive surgery and/or second-line chemotherapy. Memarzadeh & Berek, *supra*.

From the foregoing, it is clear that procedures used for detecting, diagnosing, monitoring, staging, prognosticating, and preventing the recurrence of ovarian cancer are of critical importance to the outcome of the patient. Moreover, current procedures, while helpful in each of these analyses, are limited by their specificity, sensitivity, invasiveness, and/or their cost. As such, highly specific and sensitive procedures that would operate by way of detecting novel markers in cells, tissues, or bodily fluids, with minimal invasiveness and at a reasonable cost, would be highly desirable.

SUMMARY OF THE INVENTION

The present invention solves many needs in the art by providing nucleic acid molecules, polypeptides and antibodies thereto, variants and derivatives of the nucleic acids and polypeptides, agonists and antagonists that may be used to identify, diagnose, monitor, stage, image and treat ovarian cancer and non-cancerous disease states in ovarian; identify and monitor ovarian tissue; and identify and design agonists and antagonists of polypeptides of the invention. The invention also provides gene therapy, methods for producing transgenic animals and cells, and methods for producing engineered ovarian tissue for treatment and research.

One aspect of the present invention relates to nucleic acid molecules that are specific to ovarian cells, ovarian tissue and/or the ovarian organ. These ovarian specific nucleic acids (OSNAs) may be a naturally occurring cDNA, genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally occurring nucleic acid molecule. If the OSNA is genomic DNA, then the OSNA is a ovarian specific gene (OSG). If the OSNA is RNA, then it is a ovarian specific transcript encoded by a OSG. Due to alternative splicing and transcriptional modification one OSG may encode for multiple ovarian specific RNAs. In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to ovarian. More preferred is a nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO: 249-396. In another preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1-248. For the OSNA sequences listed herein, DEX0443_001.nt.1 corresponds to SEQ ID NO: 1. For sequences with multiple splice variants, the parent sequence DEX0443_001.nt.1, will be followed by DEX0443_001.nt.2, etc. for each splice variant. The sequences of the corresponding peptides are listed as DEX0443_001.aa.1, etc. For the mapping of all of the nucleotides and peptides, see the table in the Example 1 section below.

This aspect of the present invention also relates to nucleic acid molecules that selectively hybridize or exhibit substantial sequence similarity to nucleic acid molecules encoding a Ovarian Specific Protein (OSP), or that selectively hybridize or exhibit substantial sequence similarity to a OSNA. In one embodiment of the present invention the nucleic acid molecule comprises an allelic variant of a nucleic acid molecule encoding a OSP, or an allelic variant of a OSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid sequence that encodes a OSP or a part of a nucleic acid sequence of a OSNA.

In addition, this aspect of the present invention relates to a nucleic acid molecule further comprising one or more expression control sequences controlling the transcription and/or translation of all or a part of a OSNA or the transcription and/or translation of a nucleic acid molecule that encodes all or a fragment of a OSP.

Another aspect of the present invention relates to vectors and/or host cells comprising a nucleic acid molecule of this invention. In a preferred embodiment, the nucleic acid molecule of the vector and/or host cell encodes all or a fragment of a OSP. In another preferred embodiment, the nucleic acid molecule of the vector and/or host cell

comprises all or a part of a OSNA. Vectors and host cells of the present invention are useful in the recombinant production of polypeptides, particularly OSPs of the present invention.

Another aspect of the present invention relates to polypeptides encoded by a nucleic acid molecule of this invention. The polypeptide may comprise either a fragment or a full-length protein. In a preferred embodiment, the polypeptide is a OSP. However, this aspect of the present invention also relates to mutant proteins (muteins) of OSPs, fusion proteins of which a portion is a OSP, and proteins and polypeptides encoded by allelic variants of a OSNA as provided herein.

A further aspect of the present invention is a splice variant which encodes an amino acid sequence that provides a region to be targeted for the generation of reagents that can be used in the detection and/or treatment of cancer. The amino acid sequence may lead to a unique protein structure, protein subcellular localization, biochemical processing or function. This information can be used to directly or indirectly facilitate the generation of additional or novel therapeutics or diagnostics. The nucleotide sequence in this splice variant can be used as a nucleic acid probe for the diagnosis and/or treatment of cancer.

Another aspect of the present invention relates to antibodies and other binders that specifically bind to a polypeptide of the instant invention. Accordingly antibodies or binders of the present invention specifically bind to OSPs, muteins, fusion proteins, and/or homologous proteins or polypeptides encoded by allelic variants of an OSNA as provided herein.

Another aspect of the present invention relates to agonists and antagonists of the nucleic acid molecules and polypeptides of this invention. The agonists and antagonists of the instant invention may be used to treat ovarian cancer and non-cancerous disease states in ovarian and to produce engineered ovarian tissue.

Another aspect of the present invention relates to methods for using the nucleic acid molecules to detect or amplify nucleic acid molecules that have similar or identical nucleic acid sequences compared to the nucleic acid molecules described herein. Such methods are useful in identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovarian. Such methods are also useful in identifying and/or monitoring ovarian tissue. In addition, measurement of levels of one or more of the nucleic acid molecules of this invention may be useful for diagnostics as

part of panel in combination with known other markers, particularly those described in the ovarian cancer background section above.

Another aspect of the present invention relates to use of the nucleic acid molecules of this invention in gene therapy, for producing transgenic animals and cells, and for
5 producing engineered ovarian tissue for treatment and research.

Another aspect of the present invention relates to methods for detecting polypeptides this invention, preferably using antibodies thereto. Such methods are useful to identify, diagnose, monitor, stage, image and treat ovarian cancer and non-cancerous disease states in ovarian. In addition, measurement of levels of one or more of the
10 polypeptides of this invention may be useful to identify, diagnose, monitor, stage, image ovarian cancer in combination with known other markers, particularly those described in the ovarian cancer background section above. The polypeptides of the present invention can also be used to identify and/or monitor ovarian tissue, and to produce engineered ovarian tissue.

Yet another aspect of the present invention relates to a computer readable means of
15 storing the nucleic acid and amino acid sequences of the invention. The records of the computer readable means can be accessed for reading and displaying of sequences for comparison, alignment and ordering of the sequences of the invention to other sequences. In addition, the computer records regarding the nucleic acid and/or amino acid sequences
20 and/or measurements of their levels may be used alone or in combination with other markers to diagnose ovarian related diseases.

DETAILED DESCRIPTION OF THE INVENTION

Definitions and General Techniques

Unless otherwise defined herein, scientific and technical terms used in connection
25 with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid
30 chemistry and hybridization described herein are those well known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various

general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. *See, e.g.,* Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor Press (2001);
5 Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2000); Ausubel *et al.*, Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology – 4th Ed., Wiley & Sons (1999); Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1990); and Harlow and Lane, Using Antibodies: A Laboratory Manual,
10 Cold Spring Harbor Laboratory Press (1999).

Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and
15 pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

The following terms, unless otherwise indicated, shall be understood to have the following meanings:

20 A "nucleic acid molecule" of this invention refers to a polymeric form of nucleotides and includes both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. A "nucleic acid molecule" as used herein is synonymous with "nucleic acid" and
25 "polynucleotide." The term "nucleic acid molecule" usually refers to a molecule of at least 10 bases in length, unless otherwise specified. The term includes single and double stranded forms of DNA. In addition, a polynucleotide may include either or both naturally occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide linkages.

30 Nucleotides are represented by single letter symbols in nucleic acid molecule sequences. The following table lists symbols identifying nucleotides or groups of nucleotides which may occupy the symbol position on a nucleic acid molecule. *See* Nomenclature Committee of the International Union of Biochemistry (NC-IUB),

Nomenclature for incompletely specified bases in nucleic acid sequences,
Recommendations 1984., *Eur J Biochem.* 150(1):1-5 (1985).

Symbol	Meaning	Group/Origin of Designation	Complementary Symbol
a	a	Adenine	t/u
g	g	Guanine	c
c	c	Cytosine	g
t	t	Thymine	a
u	u	Uracil	a
r	g or a	puRine	y
y	t/u or c	pYrimidine	r
m	a or c	aMino	k
k	g or t/u	Keto	m
s	g or c	Strong interactions 3H-bonds	w
w	a or t/u	Weak interactions 2H-bonds	s
b	g or c or t/u	not a	v
d	a or g or t/u	not c	h
h	a or c or t/u	not g	d
v	a or g or c	not t, not u	b
n	a or g or c or t/u, unknown, or other	aNy	n

The nucleic acid molecules may be modified chemically or biochemically or may
5 contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those
of skill in the art. Such modifications include, for example, labels, methylation,
substitution of one or more of the naturally occurring nucleotides with an analog,
internucleotide modifications such as uncharged linkages (*e.g.*, methyl phosphonates,
phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (*e.g.*,
10 phosphorothioates, phosphorodithioates, etc.), pendent moieties (*e.g.*, polypeptides),
intercalators (*e.g.*, acridine, psoralen, etc.), chelators, alkylators, and modified linkages
(*e.g.*, alpha anomeric nucleic acids, etc.) The term “nucleic acid molecule” also includes
any topological conformation, including single-stranded, double-stranded, partially
duplexed, triplexed, hairpinned, circular and padlocked conformations. Also included are
15 synthetic molecules that mimic polynucleotides in their ability to bind to a designated
sequence via hydrogen bonding and other chemical interactions. Such molecules are
known in the art and include, for example, those in which peptide linkages substitute for
phosphate linkages in the backbone of the molecule.

A “gene” is defined as a nucleic acid molecule that comprises a nucleic acid
20 sequence that encodes a polypeptide and the expression control sequences that surround

the nucleic acid sequence that encodes the polypeptide. For instance, a gene may comprise a promoter, one or more enhancers, a nucleic acid sequence that encodes a polypeptide, downstream regulatory sequences and, possibly, other nucleic acid sequences involved in regulation of the expression of an RNA. As is well known in the art, eukaryotic genes usually contain both exons and introns. The term “exon” refers to a nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute contiguous sequence to a mature mRNA transcript. The term “intron” refers to a nucleic acid sequence found in genomic DNA that is predicted and/or confirmed to not contribute to a mature mRNA transcript, but rather to be “spliced out” during processing of the transcript.

A nucleic acid molecule or polypeptide is “derived” from a particular species if the nucleic acid molecule or polypeptide has been isolated from the particular species, or if the nucleic acid molecule or polypeptide is homologous to a nucleic acid molecule or polypeptide isolated from a particular species.

An “isolated” or “substantially pure” nucleic acid or polynucleotide (*e.g.*, an RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components that naturally accompany the native polynucleotide in its natural host cell, *e.g.*, ribosomes, polymerases, or genomic sequences with which it is naturally associated. The term embraces a nucleic acid or polynucleotide that (1) has been removed from its naturally occurring environment, (2) is not associated with all or a portion of a polynucleotide in which the “isolated polynucleotide” is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, (4) does not occur in nature as part of a larger sequence or (5) includes nucleotides or internucleoside bonds that are not found in nature. The term “isolated” or “substantially pure” also can be used in reference to recombinant or cloned DNA isolates, chemically synthesized polynucleotide analogs, or polynucleotide analogs that are biologically synthesized by heterologous systems. The term “isolated nucleic acid molecule” includes nucleic acid molecules that are integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant vectors present as episomes or as integrated into a host cell chromosome.

A “part” of a nucleic acid molecule refers to a nucleic acid molecule that comprises a partial contiguous sequence of at least 10 bases of the reference nucleic acid molecule. Preferably, a part comprises at least 15 to 20 bases of a reference nucleic acid

molecule. In theory, a nucleic acid sequence of 17 nucleotides is of sufficient length to occur at random less frequently than once in the three gigabase human genome, and thus to provide a nucleic acid probe that can uniquely identify the reference sequence in a nucleic acid mixture of genomic complexity. A preferred part is one that comprises a nucleic acid sequence that can encode at least 6 contiguous amino acid sequences (fragments of at least 18 nucleotides) because they are useful in directing the expression or synthesis of peptides that are useful in mapping the epitopes of the polypeptide encoded by the reference nucleic acid. See, e.g., Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1984); and U.S. Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. A part may also comprise at least 25, 30, 35 or 40 nucleotides of a reference nucleic acid molecule, or at least 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides of a reference nucleic acid molecule. A part of a nucleic acid molecule may comprise no other nucleic acid sequences. Alternatively, a part of a nucleic acid may comprise other nucleic acid sequences from other nucleic acid molecules.

The term "oligonucleotide" refers to a nucleic acid molecule generally comprising a length of 200 bases or fewer. The term often refers to single-stranded deoxyribonucleotides, but it can refer as well to single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs, among others. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19 or 20 bases in length. Other preferred oligonucleotides are 25, 30, 35, 40, 45, 50, 55 or 60 bases in length. Oligonucleotides may be single-stranded, e.g. for use as probes or primers, or may be double-stranded, e.g. for use in the construction of a mutant gene. Oligonucleotides of the invention can be either sense or antisense oligonucleotides. An oligonucleotide can be derivatized or modified as discussed above for nucleic acid molecules.

Oligonucleotides, such as single-stranded DNA probe oligonucleotides, often are synthesized by chemical methods, such as those implemented on automated oligonucleotide synthesizers. However, oligonucleotides can be made by a variety of other methods, including in vitro recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms. Initially, chemically synthesized DNAs typically are obtained without a 5' phosphate. The 5' ends of such oligonucleotides are not substrates for phosphodiester bond formation by ligation reactions that employ DNA

ligases typically used to form recombinant DNA molecules. Where ligation of such oligonucleotides is desired, a phosphate can be added by standard techniques, such as those that employ a kinase and ATP. The 3' end of a chemically synthesized oligonucleotide generally has a free hydroxyl group and, in the presence of a ligase, such as T4 DNA ligase, readily will form a phosphodiester bond with a 5' phosphate of another polynucleotide, such as another oligonucleotide. As is well known, this reaction can be prevented selectively, where desired, by removing the 5' phosphates of the other polynucleotide(s) prior to ligation.

The term "naturally occurring nucleotide" referred to herein includes naturally occurring deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "nucleotide linkages" referred to herein includes nucleotides linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. *See e.g.*, LaPlanche *et al. Nucl. Acids Res.* 14:9081-9093 (1986); Stein *et al. Nucl. Acids Res.* 16:3209-3221 (1988); Zon *et al. Anti-Cancer Drug Design* 6:539-568 (1991); Zon *et al.*, in Eckstein (ed.) Oligonucleotides and Analogues: A Practical Approach, pp. 87-108, Oxford University Press (1991); Uhlmann and Peyman *Chemical Reviews* 90:543 (1990), and U.S. Patent No. 5,151,510, the disclosure of which is hereby incorporated by reference in its entirety.

Unless specified otherwise, the left hand end of a polynucleotide sequence in sense orientation is the 5' end and the right hand end of the sequence is the 3' end. In addition, the left hand direction of a polynucleotide sequence in sense orientation is referred to as the 5' direction, while the right hand direction of the polynucleotide sequence is referred to as the 3' direction. Further, unless otherwise indicated, each nucleotide sequence is set forth herein as a sequence of deoxyribonucleotides. It is intended, however, that the given sequence be interpreted as would be appropriate to the polynucleotide composition: for example, if the isolated nucleic acid is composed of RNA, the given sequence intends ribonucleotides, with uridine substituted for thymidine.

The term "allelic variant" refers to one of two or more alternative naturally occurring forms of a gene, wherein each gene possesses a unique nucleotide sequence. In a preferred embodiment, different alleles of a given gene have similar or identical biological properties.

The term “percent sequence identity” in the context of nucleic acid sequences refers to the residues in two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different algorithms known in the art which can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using FASTA, Gap or Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin. FASTA, which includes, *e.g.*, the programs FASTA2 and FASTA3, provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, *Methods Enzymol.* 183: 63-98 (1990); Pearson, *Methods Mol. Biol.* 132: 185-219 (2000); Pearson, *Methods Enzymol.* 266: 227-258 (1996); Pearson, *J. Mol. Biol.* 276: 71-84 (1998)). Unless otherwise specified, default parameters for a particular program or algorithm are used. For instance, percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1.

A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The complementary strand is also useful, *e.g.*, for antisense therapy, double stranded RNA (dsRNA) inhibition (RNAi), combination of triplex and antisense, hybridization probes and PCR primers.

In the molecular biology art, researchers use the terms “percent sequence identity”, “percent sequence similarity” and “percent sequence homology” interchangeably. In this application, these terms shall have the same meaning with respect to nucleic acid sequences only.

The term “substantial similarity” or “substantial sequence similarity,” when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 50%, more preferably 60% of the nucleotide bases, usually at least about 70%, more usually at least

about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases, as measured by any well known algorithm of sequence identity, such as FASTA, BLAST or Gap, as discussed above.

Alternatively, substantial similarity exists between a first and second nucleic acid sequence when the first nucleic acid sequence or fragment thereof hybridizes to an antisense strand of the second nucleic acid, under selective hybridization conditions. Typically, selective hybridization will occur between the first nucleic acid sequence and an antisense strand of the second nucleic acid sequence when there is at least about 55% sequence identity between the first and second nucleic acid sequences—preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90% — over a stretch of at least about 14 nucleotides, more preferably at least 17 nucleotides, even more preferably at least 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 nucleotides.

Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, solvents, the base composition of the hybridizing species, length of the complementary regions, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. “Stringent hybridization conditions” and “stringent wash conditions” in the context of nucleic acid hybridization experiments depend upon a number of different physical parameters. The most important parameters include temperature of hybridization, base composition of the nucleic acids, salt concentration and length of the nucleic acid. One having ordinary skill in the art knows how to vary these parameters to achieve a particular stringency of hybridization. In general, “stringent hybridization” is performed at about 25°C below the thermal melting point (T_m) for the specific DNA hybrid under a particular set of conditions. “Stringent washing” is performed at temperatures about 5°C lower than the T_m for the specific DNA hybrid under a particular set of conditions. The T_m is the temperature at which 50% of the target sequence hybridizes to a perfectly matched probe. See Sambrook (1989), *supra*, p. 9.51.

The T_m for a particular DNA-DNA hybrid can be estimated by the formula:

$$T_m = 81.5^{\circ}\text{C} + 16.6 (\log_{10}[\text{Na}^+]) + 0.41 (\text{fraction G} + \text{C}) -$$

$$0.63 (\% \text{ formamide}) - (600/l) \text{ where } l \text{ is the length of the hybrid in base pairs.}$$

The T_m for a particular RNA-RNA hybrid can be estimated by the formula:

$$T_m = 79.8^{\circ}\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) +$$

$$11.8 (\text{fraction G} + \text{C})^2 - 0.35 (\% \text{ formamide}) - (820/l).$$

The T_m for a particular RNA-DNA hybrid can be estimated by the formula:

$$T_m = 79.8^{\circ}\text{C} + 18.5(\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + \\ 11.8 (\text{fraction G} + \text{C})^2 - 0.50 (\% \text{ formamide}) - (820/l).$$

In general, the T_m decreases by 1-1.5°C for each 1% of mismatch between two
5 nucleic acid sequences. Thus, one having ordinary skill in the art can alter hybridization
and/or washing conditions to obtain sequences that have higher or lower degrees of
sequence identity to the target nucleic acid. For instance, to obtain hybridizing nucleic
acids that contain up to 10% mismatch from the target nucleic acid sequence, 10-15°C
would be subtracted from the calculated T_m of a perfectly matched hybrid, and then the
10 hybridization and washing temperatures adjusted accordingly. Probe sequences may also
hybridize specifically to duplex DNA under certain conditions to form triplex or other
higher order DNA complexes. The preparation of such probes and suitable hybridization
conditions are well known in the art.

An example of stringent hybridization conditions for hybridization of
15 complementary nucleic acid sequences having more than 100 complementary residues on
a filter in a Southern or Northern blot or for screening a library is 50% formamide/6X SSC
at 42°C for at least ten hours and preferably overnight (approximately 16 hours). Another
example of stringent hybridization conditions is 6X SSC at 68°C without formamide for at
least ten hours and preferably overnight. An example of moderate stringency
20 hybridization conditions is 6X SSC at 55°C without formamide for at least ten hours and
preferably overnight. An example of low stringency hybridization conditions for
hybridization of complementary nucleic acid sequences having more than 100
complementary residues on a filter in a Southern or northern blot or for screening a library
is 6X SSC at 42°C for at least ten hours. Hybridization conditions to identify nucleic acid
25 sequences that are similar but not identical can be identified by experimentally changing
the hybridization temperature from 68°C to 42°C while keeping the salt concentration
constant (6X SSC), or keeping the hybridization temperature and salt concentration
constant (e.g. 42°C and 6X SSC) and varying the formamide concentration from 50% to
0%. Hybridization buffers may also include blocking agents to lower background. These
30 agents are well known in the art. See Sambrook *et al.* (1989), *supra*, pages 8.46 and 9.46-
9.58. See also Ausubel (1992), *supra*, Ausubel (1999), *supra*, and Sambrook (2001),
supra.

Wash conditions also can be altered to change stringency conditions. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (*see* Sambrook (1989), *supra*, for SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove excess probe. An exemplary medium stringency wash for
5 duplex DNA of more than 100 base pairs is 1x SSC at 45°C for 15 minutes. An exemplary low stringency wash for such a duplex is 4x SSC at 40°C for 15 minutes. In general, signal-to-noise ratio of 2x or higher than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

As defined herein, nucleic acids that do not hybridize to each other under stringent
10 conditions are still substantially similar to one another if they encode polypeptides that are substantially identical to each other. This occurs, for example, when a nucleic acid is created synthetically or recombinantly using a high codon degeneracy as permitted by the redundancy of the genetic code.

Hybridization conditions for nucleic acid molecules that are shorter than 100
15 nucleotides in length (*e.g.*, for oligonucleotide probes) may be calculated by the formula:

$$T_m = 81.5^{\circ}\text{C} + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\text{fraction G+C}) - (600/\text{N}),$$
 wherein N is change length and the $[\text{Na}^+]$ is 1 M or less. *See* Sambrook (1989), *supra*, p. 11.46. For hybridization of probes shorter than 100 nucleotides, hybridization is usually performed under stringent conditions (5-10°C below the T_m) using high concentrations (0.1-1.0
20 pmol/ml) of probe. *Id.* at p. 11.45. Determination of hybridization using mismatched probes, pools of degenerate probes or “guessmers,” as well as hybridization solutions and methods for empirically determining hybridization conditions are well known in the art. *See, e.g.*, Ausubel (1999), *supra*; Sambrook (1989), *supra*, pp. 11.45-11.57.

The term “digestion” or “digestion of DNA” refers to catalytic cleavage of the
25 DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes referred to herein are commercially available and their reaction conditions, cofactors and other requirements for use are known and routine to the skilled artisan. For analytical purposes, typically, 1 µg of plasmid or DNA fragment is digested with about 2 units of enzyme in about 20 µl of reaction buffer. For the purpose of
30 isolating DNA fragments for plasmid construction, typically 5 to 50 µg of DNA are digested with 20 to 250 units of enzyme in proportionately larger volumes. Appropriate buffers and substrate amounts for particular restriction enzymes are described in standard laboratory manuals, such as those referenced below, and are specified by commercial

suppliers. Incubation times of about 1 hour at 37°C are ordinarily used, but conditions may vary in accordance with standard procedures, the supplier's instructions and the particulars of the reaction. After digestion, reactions may be analyzed, and fragments may be purified by electrophoresis through an agarose or polyacrylamide gel, using well
5 known methods that are routine for those skilled in the art.

The term "ligation" refers to the process of forming phosphodiester bonds between two or more polynucleotides, which most often are double-stranded DNAs. Techniques for ligation are well known to the art and protocols for ligation are described in standard laboratory manuals and references, such as, *e.g.*, Sambrook (1989), *supra*.

10 Genome-derived "single exon probes," are probes that comprise at least part of an exon ("reference exon") and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon but do not hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon. Single exon probes typically further comprise, contiguous to a first end of the exon
15 portion, a first intronic and/or intergenic sequence that is identically contiguous to the exon in the genome, and may contain a second intronic and/or intergenic sequence that is identically contiguous to the exon in the genome. The minimum length of genome-derived single exon probes is defined by the requirement that the exonic portion be of sufficient length to hybridize under high stringency conditions to transcript-derived
20 nucleic acids, as discussed above. The maximum length of genome-derived single exon probes is defined by the requirement that the probes contain portions of no more than one exon. The single exon probes may contain priming sequences not found in contiguity with the rest of the probe sequence in the genome, which priming sequences are useful for PCR and other amplification-based technologies. In another aspect, the invention is directed to
25 single exon probes based on the OSNAs disclosed herein.

In one embodiment, the term "microarray" refers to a "nucleic acid microarray" having a substrate-bound plurality of nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed. Nucleic acid microarrays include all the
30 devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical Approach Series), Oxford University Press (1999); *Nature Genet.* 21(1)(suppl.):1 - 60 (1999); Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000). Additionally, these nucleic acid

microarrays include substrate-bound plurality of nucleic acids in which the plurality of nucleic acids are disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, *inter alia*, in Brenner *et al.*, *Proc. Natl. Acad. Sci. USA* 97(4):1665-1670 (2000). Examples of nucleic acid microarrays may be found in U.S. Patent Nos.

5 6,391,623, 6,383,754, 6,383,749, 6,380,377, 6,379,897, 6,376,191, 6,372,431, 6,351,712
6,344,316, 6,316,193, 6,312,906, 6,309,828, 6,309,824, 6,306,643, 6,300,063, 6,287,850,
6,284,497, 6,284,465, 6,280,954, 6,262,216, 6,251,601, 6,245,518, 6,263,287, 6,251,601,
6,238,866, 6,228,575, 6,214,587, 6,203,989, 6,171,797, 6,103,474, 6,083,726, 6,054,274,
6,040,138, 6,083,726, 6,004,755, 6,001,309, 5,958,342, 5,952,180, 5,936,731, 5,843,655,
10 5,814,454, 5,837,196, 5,436,327, 5,412,087, 5,405,783, the disclosures of which are
incorporated herein by reference in their entireties.

In an alternative embodiment, a "microarray" may also refer to a "peptide
microarray" or "protein microarray" having a substrate-bound collection of plurality of
polypeptides, the binding to each of the plurality of bound polypeptides being separately
15 detectable. Alternatively, the peptide microarray may have a plurality of binders,
including but not limited to monoclonal antibodies, polyclonal antibodies, phage display
binders, yeast 2 hybrid binders, aptamers, which can specifically detect the binding of the
polypeptides of this invention. The array may be based on autoantibody detection to the
polypeptides of this invention, see Robinson *et al.*, *Nature Medicine* 8(3):295-301 (2002).
20 Examples of peptide arrays may be found in WO 02/31463, WO 02/25288, WO 01/94946,
WO 01/88162, WO 01/68671, WO 01/57259, WO 00/61806, WO 00/54046, WO
00/47774, WO 99/40434, WO 99/39210, WO 97/42507 and U.S. Patent Nos. 6,268,210,
5,766,960, 5,143,854, the disclosures of which are incorporated herein by reference in
their entireties.

25 In addition, determination of the levels of the OSNA or OSP may be made in a
multiplex manner using techniques described in WO 02/29109, WO 02/24959, WO
01/83502, WO01/73113, WO 01/59432, WO 01/57269, WO 99/67641, the disclosures of
which are incorporated herein by reference in their entireties.

The term "mutant", "mutated", or "mutation" when applied to nucleic acid
30 sequences means that nucleotides in a nucleic acid sequence may be inserted, deleted or
changed compared to a reference nucleic acid sequence. A single alteration may be made
at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at
a single locus. In addition, one or more alterations may be made at any number of loci

within a nucleic acid sequence. In a preferred embodiment of the present invention, the nucleic acid sequence is the wild type nucleic acid sequence encoding a OSP or is a OSNA. The nucleic acid sequence may be mutated by any method known in the art including those mutagenesis techniques described *infra*.

5 The term “error-prone PCR” refers to a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. *See, e.g., Leung et al., Technique 1: 11-15 (1989) and Caldwell et al., PCR Methods Applic. 2: 28-33 (1992).*

10 The term “oligonucleotide-directed mutagenesis” refers to a process which enables the generation of site-specific mutations in any cloned DNA segment of interest. *See, e.g., Reidhaar-Olson et al., Science 241: 53-57 (1988).*

 The term “assembly PCR” refers to a process which involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR
15 reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction.

 The term “sexual PCR mutagenesis” or “DNA shuffling” refers to a method of error-prone PCR coupled with forced homologous recombination between DNA
20 molecules of different but highly related DNA sequence *in vitro*, caused by random fragmentation of the DNA molecule based on sequence similarity, followed by fixation of the crossover by primer extension in an error-prone PCR reaction. *See, e.g., Stemmer, Proc. Natl. Acad. Sci. U.S.A. 91: 10747-10751 (1994).* DNA shuffling can be carried out between several related genes (“Family shuffling”).

 The term “*in vivo* mutagenesis” refers to a process of generating random mutations
25 in any cloned DNA of interest which involves the propagation of the DNA in a strain of bacteria such as *E. coli* that carries mutations in one or more of the DNA repair pathways. These “mutator” strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in a mutator strain will eventually generate random mutations within the DNA.

30 The term “cassette mutagenesis” refers to any process for replacing a small region of a double-stranded DNA molecule with a synthetic oligonucleotide “cassette” that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.

The term "recursive ensemble mutagenesis" refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. *See, e.g., Arkin et al., Proc. Natl. Acad. Sci. U.S.A.* 89: 7811-7815 (1992).

The term "exponential ensemble mutagenesis" refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. *See, e.g., Delegrave et al., Biotechnology Research* 11: 1548-1552 (1993); Arnold, *Current Opinion in Biotechnology* 4: 450-455 (1993).

"Operatively linked" expression control sequences refers to a linkage in which the expression control sequence is either contiguous with the gene of interest to control the gene of interest, or acts in *trans* or at a distance to control the gene of interest.

The term "expression control sequence" as used herein refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operatively linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (*e.g.*, ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

The term "vector," as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Other vectors include cosmids, bacterial

artificial chromosomes (BAC) and yeast artificial chromosomes (YAC). Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Viral vectors that infect bacterial cells are referred to as bacteriophages. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” (or simply, “expression vectors”).

In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include other forms of expression vectors that serve equivalent functions.

The term “recombinant host cell” (or simply “host cell”), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell” as used herein.

As used herein, the phrase “open reading frame” and the equivalent acronym “ORF” refers to that portion of a transcript-derived nucleic acid that can be translated in its entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode the entirety of a natural protein.

As used herein, the phrase “ORF-encoded peptide” refers to the predicted or actual translation of an ORF.

As used herein, the phrase “degenerate variant” of a reference nucleic acid sequence is meant to be inclusive of all nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to that translated from the reference nucleic acid sequence.

The term "polypeptide" encompasses both naturally occurring and non-naturally occurring proteins and polypeptides, as well as polypeptide fragments and polypeptide mutants, derivatives and analogs thereof. A polypeptide may be monomeric or polymeric. Further, a polypeptide may comprise a number of different modules within a single polypeptide each of which has one or more distinct activities. A preferred polypeptide in accordance with the invention comprises a OSP encoded by a nucleic acid molecule of the instant invention, or a fragment, mutant, analog and derivative thereof.

The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) is free of other proteins from the same species (3) is expressed by a cell from a different species, or (4) does not occur in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A polypeptide or protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well known in the art.

A protein or polypeptide is "substantially pure," "substantially homogeneous" or "substantially purified" when at least about 60% to 75% of a sample exhibits a single species of polypeptide. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein will typically comprise about 50%, 60%, 70%, 80% or 90% W/W of a protein sample, more usually about 95%, and preferably will be over 99% pure. Protein purity or homogeneity may be determined by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel with a stain well known in the art. For certain purposes, higher resolution may be provided by using HPLC or other means well known in the art for purification.

The term "fragment" when used herein with respect to polypeptides of the present invention refers to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion compared to a full-length OSP. In a preferred embodiment, the fragment is a contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally occurring polypeptide. Fragments typically are at least 5, 6, 7, 8, 9 or 10 amino acids long, preferably at least 12, 14, 16 or 18 amino acids long, more preferably at least 20 amino acids long, more preferably at least 25, 30, 35, 40

or 45, amino acids, even more preferably at least 50 or 60 amino acids long, and even more preferably at least 70 amino acids long.

A "derivative" when used herein with respect to polypeptides of the present invention refers to a polypeptide which is substantially similar in primary structural sequence to a OSP but which include, *e.g.*, *in vivo* or *in vitro* chemical and biochemical modifications that are not found in the OSP. Such modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. Other modification include, *e.g.*, labeling with radionuclides, and various enzymatic modifications, as will be readily appreciated by those skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such purposes are well known in the art, and include radioactive isotopes such as ^{125}I , ^{32}P , ^{35}S , ^{14}C and ^3H , ligands which bind to labeled antiligands (*e.g.*, antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation. Methods for labeling polypeptides are well known in the art. *See* Ausubel (1992), *supra*; Ausubel (1999), *supra*.

The term "fusion protein" refers to polypeptides of the present invention coupled to a heterologous amino acid sequences. Fusion proteins are useful because they can be constructed to contain two or more desired functional elements from two or more different proteins. A fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, more preferably at least 20 or 30 amino acids, even more preferably at least 40, 50 or 60 amino acids, yet more preferably at least 75, 100 or 125 amino acids. Fusion proteins can be produced recombinantly by constructing a nucleic acid sequence that encodes the polypeptide or a fragment thereof in frame with a nucleic

acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.

The term "analog" refers to both polypeptide analogs and non-peptide analogs.

5 The term "polypeptide analog" as used herein refers to a polypeptide that is comprised of a segment of at least 25 amino acids that has substantial identity to a portion of an amino acid sequence but which contains non-natural amino acids or non-natural inter-residue bonds. In a preferred embodiment, the analog has the same or similar biological activity as the native polypeptide. Typically, polypeptide analogs comprise a conservative amino
10 acid substitution (or insertion or deletion) with respect to the naturally occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally occurring polypeptide.

The term "non-peptide analog" refers to a compound with properties that are analogous to those of a reference polypeptide. A non-peptide compound may also be
15 termed a "peptide mimetic" or a "peptidomimetic." Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to useful peptides may be used to produce an equivalent effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (*i.e.*, a polypeptide that has a desired biochemical property or pharmacological activity), but have one or more
20 peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH₂NH--, --CH₂S--, --CH₂-CH₂--, --CH=CH--(cis and trans), --COCH₂--, --CH(OH)CH₂--, and --CH₂SO--, by methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (*e.g.*, D-lysine in place of L-lysine) may also be used to generate more
25 stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo *et al.*, *Ann. Rev. Biochem.* 61:387-418 (1992)). For example, one may add internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

30 The term "mutant" or "mutein" when referring to a polypeptide of the present invention relates to an amino acid sequence containing substitutions, insertions or deletions of one or more amino acids compared to the amino acid sequence of a OSP. A

mutein may have one or more amino acid point substitutions, in which a single amino acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the sequence of the naturally occurring protein, and/or truncations of the amino acid sequence at either or both the amino or carboxy termini. Further, a mutein may have the same or different biological activity as the naturally occurring protein. For instance, a mutein may have an increased or decreased biological activity. A mutein has at least 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are muteins having 80%, 85% or 90% sequence similarity to a OSP. In an even more preferred embodiment, a mutein exhibits 95% sequence identity, even more preferably 97%, even more preferably 98% and even more preferably 99%. Sequence similarity may be measured by any common sequence analysis algorithm, such as GAP or BESTFIT or other variation Smith-Waterman alignment. See, T. F. Smith and M. S. Waterman, J. Mol. Biol. 147:195-197 (1981) and W.R. Pearson, Genomics 11:635-650 (1991).

Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity or enzymatic activity, and (5) confer or modify other physicochemical or functional properties of such analogs. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. In a preferred embodiment, the amino acid substitutions are moderately conservative substitutions or conservative substitutions. In a more preferred embodiment, the amino acid substitutions are conservative substitutions. A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (*e.g.*, a replacement amino acid should not tend to disrupt a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Creighton (ed.), Proteins, Structures and Molecular Principles, W. H. Freeman and Company (1984); Branden *et al.* (ed.), Introduction to Protein Structure, Garland Publishing (1991); Thornton *et al.*, *Nature* 354:105-106 (1991).

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Golub *et al.* (eds.), *Immunology - A Synthesis* 2nd Ed., Sinauer Associates (1991). Stereoisomers (*e.g.*, D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α -, α -disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, *s*-N-methylarginine, and other similar amino acids and imino acids (*e.g.*, 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the right hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

By "homology" or "homologous" when referring to a polypeptide of the present invention it is meant polypeptides from different organisms with a similar sequence to the encoded amino acid sequence of a OSP and a similar biological activity or function. Although two polypeptides are said to be "homologous," this does not imply that there is necessarily an evolutionary relationship between the polypeptides. Instead, the term "homologous" is defined to mean that the two polypeptides have similar amino acid sequences and similar biological activities or functions. In a preferred embodiment, a homologous polypeptide is one that exhibits 50% sequence similarity to OSP, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are homologous polypeptides that exhibit 80%, 85% or 90% sequence similarity to a OSP. In a yet more preferred embodiment, a homologous polypeptide exhibits 95%, 97%, 98% or 99% sequence similarity.

When "sequence similarity" is used in reference to polypeptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions. In a preferred embodiment, a polypeptide that has "sequence similarity" comprises conservative or moderately conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (*e.g.*, charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative

substitutions, the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. *See, e.g., Pearson, Methods Mol. Biol.* 24: 307-31 (1994).

5 For instance, the following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Serine (S), Threonine (T);
- 2) Aspartic Acid (D), Glutamic Acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 10 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Alanine (A), Valine (V), and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet *et al.*, *Science* 256: 1443-45
 15 (1992). A “moderately conservative” replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix.

Sequence similarity for polypeptides, which is also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions,
 20 deletions and other modifications, including conservative amino acid substitutions. For instance, GCG contains programs such as “Gap” and “Bestfit” which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. *See, e.g., GCG Version*
 25 6.1. Other programs include FASTA, discussed *supra*.

A preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer program BLAST, especially blastp or tblastn. *See, e.g., Altschul et al., J. Mol. Biol.* 215: 403-410 (1990); Altschul *et al., Nucleic Acids Res.* 25:3389-402 (1997). Preferred parameters for
 30 blastp are:

Expectation value: 10 (default)
 Filter: seg (default)
 Cost to open a gap: 11 (default)

Cost to extend a gap: 1 (default)
Max. alignments: 100 (default)
Word size: 11 (default)
No. of descriptions: 100 (default)
5 Penalty Matrix: BLOSUM62

10 The length of polypeptide sequences compared for homology will generally be at least about 16 amino acid residues, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35 residues. When searching a database containing sequences from a large number of different organisms, it is preferable to compare amino acid sequences.

15 Algorithms other than blastp for database searching using amino acid sequences are known in the art. For instance, polypeptide sequences can be compared using FASTA, a program in GCG Version 6.1. FASTA (*e.g.*, FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson (1990), *supra*; Pearson (2000), *supra*. For example, percent sequence identity between amino acid sequences can be determined using FASTA with its default or recommended parameters (a word size of 2 and the PAM250 scoring matrix), as provided in GCG Version 6.1.

20 An "antibody" refers to an intact immunoglobulin, or to an antigen-binding portion thereof that competes with the intact antibody for specific binding to a molecular species, *e.g.*, a polypeptide of the instant invention. Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include, *inter alia*, Fab, Fab', F(ab')₂, Fv, dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv),
25 chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide. A Fab fragment is a monovalent fragment consisting of the VL, VH, CL and CH1 domains; a F(ab')₂ fragment is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consists of the VH and CH1 domains; a
30 Fv fragment consists of the VL and VH domains of a single arm of an antibody; and a dAb fragment consists of a VH domain. *See, e.g.*, Ward *et al.*, *Nature* 341: 544-546 (1989).

By "bind specifically" and "specific binding" as used herein it is meant the ability of the antibody to bind to a first molecular species in preference to binding to other

molecular species with which the antibody and first molecular species are admixed. An antibody is said specifically to “recognize” a first molecular species when it can bind specifically to that first molecular species.

5 A single-chain antibody (scFv) is an antibody in which VL and VH regions are paired to form a monovalent molecule via a synthetic linker that enables them to be made as a single protein chain. *See, e.g., Bird et al., Science* 242: 423-426 (1988); *Huston et al., Proc. Natl. Acad. Sci. USA* 85: 5879-5883 (1988). Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same
10 chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites. *See e.g., Holliger et al., Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993); *Poljak et al., Structure* 2: 1121-1123 (1994). One or more CDRs may be incorporated into a molecule either covalently or noncovalently to make it an immunoadhesin. An immunoadhesin may incorporate the CDR(s) as part of a larger
15 polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may incorporate the CDR(s) noncovalently. The CDRs permit the immunoadhesin to specifically bind to a particular antigen of interest. A chimeric antibody is an antibody that contains one or more regions from one antibody and one or more regions from one or more other antibodies.

20 An antibody may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or may be different. For instance, a naturally occurring immunoglobulin has two identical binding sites, a single-chain antibody or Fab fragment has one binding site, while a “bispecific” or “bifunctional” antibody has two different binding sites.

25 An “isolated antibody” is an antibody that (1) is not associated with naturally-associated components, including other naturally-associated antibodies, that accompany it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature. It is known that purified proteins, including purified antibodies, may be stabilized with non-naturally-associated
30 components. The non-naturally-associated component may be a protein, such as albumin (*e.g., BSA*) or a chemical such as polyethylene glycol (PEG).

A “neutralizing antibody” or “an inhibitory antibody” is an antibody that inhibits the activity of a polypeptide or blocks the binding of a polypeptide to a ligand that

normally binds to it. An “activating antibody” is an antibody that increases the activity of a polypeptide.

The term “epitope” includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of
5 chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is less than 1 μ M, preferably less than 100 nM and most preferably less than 10 nM.

10 The term “patient” includes human and veterinary subjects.

Throughout this specification and claims, the word “comprise,” or variations such as “comprises” or “comprising,” will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

The term “ovarian specific” refers to a nucleic acid molecule or polypeptide that is
15 expressed predominantly in the ovarian as compared to other tissues in the body. In a preferred embodiment, a “ovarian specific” nucleic acid molecule or polypeptide is detected at a level that is 1.5-fold higher than any other tissue in the body. In a more preferred embodiment, the “ovarian specific” nucleic acid molecule or polypeptide is detected at a level that is 2-fold higher than any other tissue in the body, more preferably
20 5-fold higher, still more preferably at least 10-fold, 15-fold, 20-fold, 25-fold, 50-fold or 100-fold higher than any other tissue in the body. Nucleic acid molecule levels may be measured by nucleic acid hybridization, such as Northern blot hybridization, or quantitative PCR. Polypeptide levels may be measured by any method known to accurately quantitate protein levels, such as Western blot analysis.

25 Nucleic Acid Molecules, Regulatory Sequences, Vectors, Host Cells and Recombinant Methods of Making Polypeptides

Nucleic Acid Molecules

One aspect of the invention provides isolated nucleic acid molecules that are specific to the ovarian or to ovarian cells or tissue or that are derived from such nucleic
30 acid molecules. These isolated ovarian specific nucleic acids (OSNAs) may comprise cDNA genomic DNA, RNA, or a combination thereof, a fragment of one of these nucleic acids, or may be a non-naturally occurring nucleic acid molecule. A OSNA may be

derived from an animal. In a preferred embodiment, the OSNA is derived from a human or other mammal. In a more preferred embodiment, the OSNA is derived from a human or other primate. In an even more preferred embodiment, the OSNA is derived from a human.

5 In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to ovarian, a ovarian-specific polypeptide (OSP). In a more preferred embodiment, the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 249-396. In another highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1-248.

10 Nucleotide sequences of the instantly-described nucleic acid molecules were determined by assembling several DNA molecules from either public or proprietary databases. Some of the underlying DNA sequences are the result, directly or indirectly, of at least one enzymatic polymerization reaction (*e.g.*, reverse transcription and/or polymerase chain reaction) using an automated sequencer (such as the MegaBACE™ 1000, Amersham

15 Biosciences, Sunnyvale, CA, USA).

Nucleic acid molecules of the present invention may also comprise sequences that selectively hybridizes to a nucleic acid molecule encoding a OSNA or a complement or antisense thereof. The hybridizing nucleic acid molecule may or may not encode a polypeptide or may or may not encode a OSP. However, in a preferred embodiment, the

20 hybridizing nucleic acid molecule encodes a OSP. In a more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO: 249-396. In an even more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to

25 a nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 1-248 or the antisense sequence thereof. Preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a OSP under low stringency conditions. More preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic

30 acid molecule encoding a OSP under moderate stringency conditions. Most preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a OSP under high stringency conditions. In a preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high

stringency conditions to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 249-396. In a more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule comprising a nucleic acid sequence selected from SEQ ID NO: 1-248.

Nucleic acid molecules of the present invention may also comprise nucleic acid sequences that exhibit substantial sequence similarity to a nucleic acid encoding a OSP or a complement of the encoding nucleic acid molecule. In this embodiment, it is preferred that the nucleic acid molecule exhibit substantial sequence similarity to a nucleic acid molecule encoding human OSP. More preferred is a nucleic acid molecule exhibiting substantial sequence similarity to a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 249-396. By substantial sequence similarity it is meant a nucleic acid molecule having at least 60% sequence identity with a nucleic acid molecule encoding a OSP, such as a polypeptide having an amino acid sequence of SEQ ID NO: 249-396, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. In a more preferred embodiment, the similar nucleic acid molecule is one that has at least 90% sequence identity with a nucleic acid molecule encoding a OSP, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. Most preferred in this embodiment is a nucleic acid molecule that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a nucleic acid molecule encoding a OSP.

The nucleic acid molecules of the present invention are also inclusive of those exhibiting substantial sequence similarity to a OSNA or its complement. In this embodiment, it is preferred that the nucleic acid molecule exhibit substantial sequence similarity to a nucleic acid molecule having a nucleic acid sequence of SEQ ID NO: 1 - 248. By substantial sequence similarity it is meant a nucleic acid molecule that has at least 60% sequence identity with a OSNA, such as one having a nucleic acid sequence of SEQ ID NO: 1-248, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. More preferred is a nucleic acid molecule that has at least 90% sequence identity with a OSNA, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%.

Most preferred is a nucleic acid molecule that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a OSNA.

Nucleic acid molecules that exhibit substantial sequence similarity are inclusive of sequences that exhibit sequence identity over their entire length to a OSNA or to a nucleic acid molecule encoding a OSP, as well as sequences that are similar over only a part of its length. In this case, the part is at least 50 nucleotides of the OSNA or the nucleic acid molecule encoding a OSP, preferably at least 100 nucleotides, more preferably at least 150 or 200 nucleotides, even more preferably at least 250 or 300 nucleotides, still more preferably at least 400 or 500 nucleotides.

The substantially similar nucleic acid molecule may be a naturally occurring one that is derived from another species, especially one derived from another primate, wherein the similar nucleic acid molecule encodes an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 249-396 or demonstrates significant sequence identity to the nucleotide sequence of SEQ ID NO: 1-248. The similar nucleic acid molecule may also be a naturally occurring nucleic acid molecule from a human, when the OSNA is a member of a gene family. The similar nucleic acid molecule may also be a naturally occurring nucleic acid molecule derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, hamster, cow, horse and pig; and wild animals, *e.g.*, monkey, fox, lions, tigers, bears, giraffes, zebras, etc. The substantially similar nucleic acid molecule may also be a naturally occurring nucleic acid molecule derived from a non-mammalian species, such as birds or reptiles. The naturally occurring substantially similar nucleic acid molecule may be isolated directly from humans or other species. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by random mutation of a nucleic acid molecule. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by directed mutation of a OSNA. In a preferred embodiment, the substantially similar nucleic acid molecule is an OSNA.

The nucleic acid molecules of the present invention are also inclusive of allelic variants of a OSNA or a nucleic acid encoding a OSP. For example, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes and the sequence determined from one individual of a species may differ from other allelic forms present within the population. More than 1.4 million SNPs have already identified in the human

genome, International Human Genome Sequencing Consortium, *Nature* 409: 860-921 (2001) – Variants with small deletions and insertions of more than a single nucleotide are also found in the general population, and often do not alter the function of the protein. In addition, amino acid substitutions occur frequently among natural allelic variants, and
5 often do not substantially change protein function.

In a preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that encodes a OSP. In a more preferred embodiment, the gene is transcribed into an mRNA that encodes a OSP comprising an amino acid sequence of SEQ ID NO: 249-396. In another preferred embodiment, the allelic variant is
10 a variant of a gene, wherein the gene is transcribed into an mRNA that is a OSNA. In a more preferred embodiment, the gene is transcribed into an mRNA that comprises the nucleic acid sequence of SEQ ID NO: 1-248. Also preferred is that the allelic variant is a naturally occurring allelic variant in the species of interest, particularly human.

Nucleic acid molecules of the present invention are also inclusive of nucleic acid
15 sequences comprising a part of a nucleic acid sequence of the instant invention. The part may or may not encode a polypeptide, and may or may not encode a polypeptide that is a OSP. In a preferred embodiment, the part encodes a OSP. In one embodiment, the nucleic acid molecule comprises a part of a OSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that hybridizes or exhibits
20 substantial sequence similarity to a OSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that is an allelic variant of a OSNA. In yet another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that encodes a OSP. A part comprises at least 10 nucleotides, more preferably at least 15, 17, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or
25 500 nucleotides. The maximum size of a nucleic acid part is one nucleotide shorter than the sequence of the nucleic acid molecule encoding the full-length protein.

Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences that encode fusion proteins, homologous proteins, polypeptide fragments, muteins and polypeptide analogs, as described *infra*.

30 Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences containing modifications of the native nucleic acid molecule. Examples of such modifications include, but are not limited to, nonnative internucleoside bonds, post-synthetic modifications or altered nucleotide analogues. One having ordinary skill in the

art would recognize that the type of modification that may be made will depend upon the intended use of the nucleic acid molecule. For instance, when the nucleic acid molecule is used as a hybridization probe, the range of such modifications will be limited to those that permit sequence-discriminating base pairing of the resulting nucleic acid. When used to
5 direct expression of RNA or protein *in vitro* or *in vivo*, the range of such modifications will be limited to those that permit the nucleic acid to function properly as a polymerization substrate. When the isolated nucleic acid is used as a therapeutic agent, the modifications will be limited to those that do not confer toxicity upon the isolated nucleic acid.

10 Accordingly, in one embodiment, a nucleic acid molecule may include nucleotide analogues that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogues that incorporate labels that can be visualized in a subsequent reaction, such as biotin or various haptens. The labeled nucleic acid molecules are particularly useful as hybridization probes.

15 Common radiolabeled analogues include those labeled with ^{33}P , ^{32}P , and ^{35}S , such as α - ^{32}P -dATP, α - ^{32}P -dCTP, α - ^{32}P -dGTP, α - ^{32}P -dTTP, α - ^{32}P -3'-dATP, α - ^{32}P -ATP, α - ^{32}P -CTP, α - ^{32}P -GTP, α - ^{32}P -UTP, α - ^{35}S -dATP, γ - ^{35}S -GTP, γ - ^{33}P -dATP, and the like.

Commercially available fluorescent nucleotide analogues readily incorporated into the nucleic acids of the present invention include Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy3-dUTP (Amersham Biosciences, Piscataway, New Jersey, USA), fluorescein-12-dUTP,
20 tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade Blue®-7-dUTP, BODIPY® FL-14-dUTP, BODIPY® TMR-14-dUTP, BODIPY® TR-14-dUTP, Rhodamine Green™-5-dUTP, Oregon Green® 488-5-dUTP, Texas Red®-12-dUTP, BODIPY® 630/650-14-dUTP, BODIPY® 650/665-14-dUTP, Alexa Fluor® 488-5-dUTP,
25 Alexa Fluor® 532-5-dUTP, Alexa Fluor® 568-5-dUTP, Alexa Fluor® 594-5-dUTP, Alexa Fluor® 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, Texas Red®-5-UTP, Cascade Blue®-7-UTP, BODIPY® FL-14-UTP, BODIPY® TMR-14-UTP, BODIPY® TR-14-UTP, Rhodamine Green™-5-UTP, Alexa Fluor® 488-5-UTP, Alexa Fluor® 546-14-UTP (Molecular Probes, Inc. Eugene, OR, USA). One may also custom
30 synthesize nucleotides having other fluorophores. See Henegariu *et al.*, *Nature Biotechnol.* 18: 345-348 (2000).

Haptens that are commonly conjugated to nucleotides for subsequent labeling include biotin (biotin-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA;

biotin-21-UTP, biotin-21-dUTP, Clontech Laboratories, Inc., Palo Alto, CA, USA), digoxigenin (DIG-11-dUTP, alkali labile, DIG-11-UTP, Roche Diagnostics Corp., Indianapolis, IN, USA), and dinitrophenyl (dinitrophenyl-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA).

5 Nucleic acid molecules of the present invention can be labeled by incorporation of labeled nucleotide analogues into the nucleic acid. Such analogues can be incorporated by enzymatic polymerization, such as by nick translation, random priming, polymerase chain reaction (PCR), terminal transferase tailing, and end-filling of overhangs, for DNA molecules, and *in vitro* transcription driven, *e.g.*, from phage promoters, such as T7, T3,
10 and SP6, for RNA molecules. Commercial kits are readily available for each such labeling approach. Analogues can also be incorporated during automated solid phase chemical synthesis. Labels can also be incorporated after nucleic acid synthesis, with the 5' phosphate and 3' hydroxyl providing convenient sites for post-synthetic covalent attachment of detectable labels.

15 Other post-synthetic approaches also permit internal labeling of nucleic acids. For example, fluorophores can be attached using a cisplatin reagent that reacts with the N7 of guanine residues (and, to a lesser extent, adenine bases) in DNA, RNA, and Peptide Nucleic Acids (PNA) to provide a stable coordination complex between the nucleic acid and fluorophore label (Universal Linkage System) (available from Molecular Probes, Inc.,
20 Eugene, OR, USA and Amersham Pharmacia Biotech, Piscataway, NJ, USA); *see Alers et al., Genes, Chromosomes & Cancer* 25: 301- 305 (1999); Jelsma *et al.*, *J. NIH Res.* 5: 82 (1994); Van Belkum *et al.*, *BioTechniques* 16: 148-153 (1994). Alternatively, nucleic acids can be labeled using a disulfide-containing linker (FastTag™ Reagent, Vector Laboratories, Inc., Burlingame, CA, USA) that is photo- or thermally coupled to the target
25 nucleic acid using aryl azide chemistry; after reduction, a free thiol is available for coupling to a hapten, fluorophore, sugar, affinity ligand, or other marker.

 One or more independent or interacting labels can be incorporated into the nucleic acid molecules of the present invention. For example, both a fluorophore and a moiety that in proximity thereto acts to quench fluorescence can be included to report specific
30 hybridization through release of fluorescence quenching or to report exonucleotidic excision. *See, e.g.*, Tyagi *et al.*, *Nature Biotechnol.* 14: 303-308 (1996); Tyagi *et al.*, *Nature Biotechnol.* 16: 49-53 (1998); Sokol *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 11538-11543 (1998); Kostrikis *et al.*, *Science* 279: 1228-1229 (1998); Marras *et al.*,

Genet. Anal. 14: 151-156 (1999); Holland *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 7276-7280 (1991); Heid *et al.*, *Genome Res.* 6(10): 986-94 (1996); Kuimelis *et al.*, *Nucleic Acids Symp. Ser.* (37): 255-6 (1997); and U.S. Patent Nos. 5,846,726, 5,925,517, 5,925,517, 5,723,591 and 5,538,848, the disclosures of which are incorporated herein by
5 reference in their entireties.

Nucleic acid molecules of the present invention may also be modified by altering one or more native phosphodiester internucleoside bonds to more nuclease-resistant, internucleoside bonds. See Hartmann *et al.* (eds.), Manual of Antisense Methodology: Perspectives in Antisense Science, Kluwer Law International (1999); Stein *et al.* (eds.),
10 Applied Antisense Oligonucleotide Technology, Wiley-Liss (1998); Chadwick *et al.* (eds.), Oligonucleotides as Therapeutic Agents – Symposium No. 209, John Wiley & Son Ltd (1997). Such altered internucleoside bonds are often desired for techniques or for targeted gene correction, Gamper *et al.*, *Nucl. Acids Res.* 28(21): 4332-4339 (2000). For double stranded RNA inhibition which may utilize either natural ds RNA or ds RNA
15 modified in its, sugar, phosphate or base, see Hannon, *Nature* 418(11): 244-251 (2002); Fire *et al.* in WO 99/32619; Tuschl *et al.* in US2002/0086356; Kruetzer *et al.* in WO 00/44895, the disclosures of which are incorporated herein by reference in their entirety;. For circular antisense, see Kool in U.S. Patent No. 5,426,180, the disclosure of which is incorporated herein by reference in its entirety.

20 Modified oligonucleotide backbones include, without limitation, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates,
25 thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Representative U.S. Patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Patent Nos. 3,687,808; 4,469,863; 4,476,301;
30 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, the disclosures of

which are incorporated herein by reference in their entireties. In a preferred embodiment, the modified internucleoside linkages may be used for antisense techniques.

Other modified oligonucleotide backbones do not include a phosphorus atom, but have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts. Representative U.S. patents that teach the preparation of the above backbones include, but are not limited to, U.S. Patent Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437 and 5,677,439; the disclosures of which are incorporated herein by reference in their entireties.

In other preferred nucleic acid molecules, both the sugar and the internucleoside linkage are replaced with novel groups, such as peptide nucleic acids (PNA). In PNA compounds, the phosphodiester backbone of the nucleic acid is replaced with an amide-containing backbone, in particular by repeating N-(2-aminoethyl) glycine units linked by amide bonds. Nucleobases are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone, typically by methylene carbonyl linkages. PNA can be synthesized using a modified peptide synthesis protocol. PNA oligomers can be synthesized by both Fmoc and tBoc methods. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference in its entirety. Automated PNA synthesis is readily achievable on commercial synthesizers (see, e.g., "PNA User's Guide," Rev. 2, February 1998, Perseptive Biosystems Part No. 60138, Applied Biosystems, Inc., Foster City, CA). PNA molecules are advantageous for a number of reasons. First, because the PNA backbone is uncharged, PNA/DNA and PNA/RNA duplexes have a higher thermal stability than is found in DNA/DNA and

DNA/RNA duplexes. The T_m of a PNA/DNA or PNA/RNA duplex is generally 1°C higher per base pair than the T_m of the corresponding DNA/DNA or DNA/RNA duplex (in 100 mM NaCl). Second, PNA molecules can also form stable PNA/DNA complexes at low ionic strength, under conditions in which DNA/DNA duplex formation does not occur. Third, PNA also demonstrates greater specificity in binding to complementary DNA because a PNA/DNA mismatch is more destabilizing than DNA/DNA mismatch. A single mismatch in mixed a PNA/DNA 15-mer lowers the T_m by $8\text{--}20^\circ\text{C}$ (15°C on average). In the corresponding DNA/DNA duplexes, a single mismatch lowers the T_m by $4\text{--}16^\circ\text{C}$ (11°C on average). Because PNA probes can be significantly shorter than DNA probes, their specificity is greater. Fourth, PNA oligomers are resistant to degradation by enzymes, and the lifetime of these compounds is extended both *in vivo* and *in vitro* because nucleases and proteases do not recognize the PNA polyamide backbone with nucleobase sidechains. See, e.g., Ray *et al.*, *FASEB J.* 14(9): 1041-60 (2000); Nielsen *et al.*, *Pharmacol Toxicol.* 86(1): 3-7 (2000); Larsen *et al.*, *Biochim Biophys Acta.* 1489(1): 159-66 (1999); Nielsen, *Curr. Opin. Struct. Biol.* 9(3): 353-7 (1999), and Nielsen, *Curr. Opin. Biotechnol.* 10(1): 71-5 (1999).

Nucleic acid molecules may be modified compared to their native structure throughout the length of the nucleic acid molecule or can be localized to discrete portions thereof. As an example of the latter, chimeric nucleic acids can be synthesized that have discrete DNA and RNA domains and that can be used for targeted gene repair and modified PCR reactions, as further described in, Misra *et al.*, *Biochem.* 37: 1917-1925 (1998); and Finn *et al.*, *Nucl. Acids Res.* 24: 3357-3363 (1996), and U.S. Patent Nos. 5,760,012 and 5,731,181, the disclosures of which are incorporated herein by reference in their entireties.

Unless otherwise specified, nucleic acid molecules of the present invention can include any topological conformation appropriate to the desired use; the term thus explicitly comprehends, among others, single-stranded, double-stranded, triplexed, quadruplexed, partially double-stranded, partially-triplexed, partially-quadruplexed, branched, hairpinned, circular, and padlocked conformations. Padlock conformations and their utilities are further described in Banér *et al.*, *Curr. Opin. Biotechnol.* 12: 11-15 (2001); Escude *et al.*, *Proc. Natl. Acad. Sci. USA* 14: 96(19):10603-7 (1999); and Nilsson *et al.*, *Science* 265(5181): 2085-8 (1994). Triplex and quadruplex conformations, and their utilities, are reviewed in Praseuth *et al.*, *Biochim. Biophys. Acta.* 1489(1): 181-206

(1999); Fox, *Curr. Med. Chem.* 7(1): 17-37 (2000); Kochetkova *et al.*, *Methods Mol. Biol.* 130: 189-201 (2000); Chan *et al.*, *J. Mol. Med.* 75(4): 267-82 (1997); Rowley *et al.*, *Mol Med* 5(10): 693-700 (1999); Kool, *Annu Rev Biophys Biomol Struct.* 25: 1-28 (1996).

5 *Methods for Using Nucleic Acid Molecules as Probes and Primers*

The isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize, and quantify hybridizing nucleic acids in, and isolate hybridizing nucleic acids from, both genomic and transcript-derived nucleic acid samples. When free in solution, such probes are typically, but not invariably, detectably
10 labeled; bound to a substrate, as in a microarray, such probes are typically, but not invariably unlabeled.

In one embodiment, the isolated nucleic acid molecules of the present invention can be used as probes to detect and characterize gross alterations in the gene of a OSNA, such as deletions, insertions, translocations, and duplications of the OSNA genomic locus
15 through fluorescence *in situ* hybridization (FISH) to chromosome spreads. *See, e.g.*, Andreeff *et al.* (eds.), Introduction to Fluorescence In Situ Hybridization: Principles and Clinical Applications, John Wiley & Sons (1999). The isolated nucleic acid molecules of the present invention can be used as probes to assess smaller genomic alterations using, *e.g.*, Southern blot detection of restriction fragment length polymorphisms. The isolated
20 nucleic acid molecules of the present invention can be used as probes to isolate genomic clones that include a nucleic acid molecule of the present invention, which thereafter can be restriction mapped and sequenced to identify deletions, insertions, translocations, and substitutions (single nucleotide polymorphisms, SNPs) at the sequence level. Alternatively, detection techniques such as molecular beacons may be used, see Kostrikis
25 *et al. Science* 279:1228-1229 (1998).

The isolated nucleic acid molecules of the present invention can be also be used as probes to detect, characterize, and quantify OSNA in, and isolate OSNA from, transcript-derived nucleic acid samples. In one embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by length,
30 and quantify mRNA by Northern blot of total or poly-A⁺-selected RNA samples. In another embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by location, and quantify mRNA by *in situ* hybridization to tissue sections. *See, e.g.*, Schwarchzacher *et al.*, In Situ

Hybridization, Springer-Verlag New York (2000). In another preferred embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to measure the representation of clones in a cDNA library or to isolate hybridizing nucleic acid molecules acids from cDNA libraries, permitting sequence level
5 characterization of mRNAs that hybridize to OSNAs, including, without limitations, identification of deletions, insertions, substitutions, truncations, alternatively spliced forms and single nucleotide polymorphisms. In yet another preferred embodiment, the nucleic acid molecules of the instant invention may be used in microarrays.

All of the aforementioned probe techniques are well within the skill in the art, and
10 are described at greater length in standard texts such as Sambrook (2001), *supra*; Ausubel (1999), *supra*; and Walker *et al.* (eds.), The Nucleic Acids Protocols Handbook, Humana Press (2000).

In another embodiment, a nucleic acid molecule of the invention may be used as a probe or primer to identify and/or amplify a second nucleic acid molecule that selectively
15 hybridizes to the nucleic acid molecule of the invention. In this embodiment, it is preferred that the probe or primer be derived from a nucleic acid molecule encoding a OSP. More preferably, the probe or primer is derived from a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 249-396. Also preferred are probes or primers derived from a OSNA. More preferred are probes or
20 primers derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-248.

In general, a probe or primer is at least 10 nucleotides in length, more preferably at least 12, more preferably at least 14 and even more preferably at least 16 or 17 nucleotides in length. In an even more preferred embodiment, the probe or primer is at least 18
25 nucleotides in length, even more preferably at least 20 nucleotides and even more preferably at least 22 nucleotides in length. Primers and probes may also be longer in length. For instance, a probe or primer may be 25 nucleotides in length, or may be 30, 40 or 50 nucleotides in length. Methods of performing nucleic acid hybridization using oligonucleotide probes are well known in the art. *See, e.g.*, Sambrook *et al.*, 1989, *supra*,
30 Chapter 11 and pp. 11.31-11.32 and 11.40-11.44, which describes radiolabeling of short probes, and pp. 11.45-11.53, which describe hybridization conditions for oligonucleotide probes, including specific conditions for probe hybridization (pp. 11.50-11.51).

Methods of performing primer-directed amplification are also well known in the art. Methods for performing the polymerase chain reaction (PCR) are compiled, *inter alia*, in McPherson, PCR Basics: From Background to Bench, Springer Verlag (2000); Innis *et al.* (eds.), PCR Applications: Protocols for Functional Genomics, Academic Press (1999);
 5 Gelfand *et al.* (eds.), PCR Strategies, Academic Press (1998); Newton *et al.*, PCR, Springer-Verlag New York (1997); Burke (ed.), PCR: Essential Techniques, John Wiley & Son Ltd (1996); White (ed.), PCR Cloning Protocols: From Molecular Cloning to Genetic Engineering, Vol. 67, Humana Press (1996); and McPherson *et al.* (eds.), PCR 2: A Practical Approach, Oxford University Press, Inc. (1995). Methods for performing RT-
 10 PCR are collected, *e.g.*, in Siebert *et al.* (eds.), Gene Cloning and Analysis by RT-PCR, Eaton Publishing Company/Bio Techniques Books Division, 1998; and Siebert (ed.), PCR Technique: RT-PCR, Eaton Publishing Company/ BioTechniques Books (1995).

PCR and hybridization methods may be used to identify and/or isolate nucleic acid molecules of the present invention including allelic variants, homologous nucleic acid
 15 molecules and fragments. PCR and hybridization methods may also be used to identify, amplify and/or isolate nucleic acid molecules of the present invention that encode homologous proteins, analogs, fusion protein or muteins of the invention. Nucleic acid primers as described herein can be used to prime amplification of nucleic acid molecules of the invention, using transcript-derived or genomic DNA as template.

20 These nucleic acid primers can also be used, for example, to prime single base extension (SBE) for SNP detection (*See, e.g.*, U.S. Pat. No. 6,004,744, the disclosure of which is incorporated herein by reference in its entirety).

Isothermal amplification approaches, such as rolling circle amplification, are also now well-described. *See, e.g.*, Schweitzer *et al.*, *Curr. Opin. Biotechnol.* 12(1): 21-7
 25 (2001); international patent publications WO 97/19193 and WO 00/15779, and U.S. Patent Nos. 5,854,033 and 5,714,320, the disclosures of which are incorporated herein by reference in their entireties. Rolling circle amplification can be combined with other techniques to facilitate SNP detection. *See, e.g.*, Lizardi *et al.*, *Nature Genet.* 19(3): 225-32 (1998).

30 Nucleic acid molecules of the present invention may be bound to a substrate either covalently or noncovalently. The substrate can be porous or solid, planar or non-planar, unitary or distributed. The bound nucleic acid molecules may be used as hybridization

probes, and may be labeled or unlabeled. In a preferred embodiment, the bound nucleic acid molecules are unlabeled.

In one embodiment, the nucleic acid molecule of the present invention is bound to a porous substrate, *e.g.*, a membrane, typically comprising nitrocellulose, nylon, or positively charged derivatized nylon. The nucleic acid molecule of the present invention can be used to detect a hybridizing nucleic acid molecule that is present within a labeled nucleic acid sample, *e.g.*, a sample of transcript-derived nucleic acids. In another embodiment, the nucleic acid molecule is bound to a solid substrate, including, without limitation, glass, amorphous silicon, crystalline silicon or plastics. Examples of plastics include, without limitation, polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof. The solid substrate may be any shape, including rectangular, disk-like and spherical. In a preferred embodiment, the solid substrate is a microscope slide or slide-shaped substrate.

The nucleic acid molecule of the present invention can be attached covalently to a surface of the support substrate or applied to a derivatized surface in a chaotropic agent that facilitates denaturation and adherence by presumed noncovalent interactions, or some combination thereof. The nucleic acid molecule of the present invention can be bound to a substrate to which a plurality of other nucleic acids are concurrently bound, hybridization to each of the plurality of bound nucleic acids being separately detectable. At low density, *e.g.* on a porous membrane, these substrate-bound collections are typically denominated macroarrays; at higher density, typically on a solid support, such as glass, these substrate bound collections of plural nucleic acids are colloquially termed microarrays. As used herein, the term microarray includes arrays of all densities. It is, therefore, another aspect of the invention to provide microarrays that comprise one or more of the nucleic acid molecules of the present invention.

In yet another embodiment, the invention is directed to single exon probes based on the OSNAs disclosed herein.

Expression Vectors, Host Cells and Recombinant Methods of Producing Polypeptides

Another aspect of the present invention provides vectors that comprise one or more of the isolated nucleic acid molecules of the present invention, and host cells in which such vectors have been introduced.

The vectors can be used, *inter alia*, for propagating the nucleic acid molecules of the present invention in host cells (cloning vectors), for shuttling the nucleic acid molecules of the present invention between host cells derived from disparate organisms (shuttle vectors), for inserting the nucleic acid molecules of the present invention into host cell chromosomes (insertion vectors), for expressing sense or antisense RNA transcripts of the nucleic acid molecules of the present invention *in vitro* or within a host cell, and for expressing polypeptides encoded by the nucleic acid molecules of the present invention, alone or as fusion proteins with heterologous polypeptides (expression vectors). Vectors are by now well known in the art, and are described, *inter alia*, in Jones *et al.* (eds.), Vectors: Cloning Applications: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Jones *et al.* (eds.), Vectors: Expression Systems: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Gacesa *et al.*, Vectors: Essential Data, John Wiley & Sons Ltd. (1995); Cid-Arregui (eds.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co. (2000); Sambrook (2001), *supra*; Ausubel (1999), *supra*. Furthermore, a variety of vectors are available commercially. Use of existing vectors and modifications thereof are well within the skill in the art. Thus, only basic features need be described here.

Nucleic acid sequences may be expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host. Expression control sequences are sequences that control the transcription, post-transcriptional events and translation of nucleic acid sequences. Such operative linking of a nucleic sequence of this invention to an expression control sequence, of course, includes, if not already part of the nucleic acid sequence, the provision of a translation initiation codon, ATG or GTG, in the correct reading frame upstream of the nucleic acid sequence.

A wide variety of host/expression vector combinations may be employed in expressing the nucleic acid sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic nucleic acid sequences.

In one embodiment, prokaryotic cells may be used with an appropriate vector. Prokaryotic host cells are often used for cloning and expression. In a preferred embodiment, prokaryotic host cells include *E. coli*, *Pseudomonas*, *Bacillus* and *Streptomyces*. In a preferred embodiment, bacterial host cells are used to express the nucleic acid molecules of the instant invention. Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from *E. coli*, *Bacillus* or *Streptomyces*, including pBluescript, pGEX-2T, pUC vectors, col E1, pCR1, pBR322, pMB9 and their derivatives, wider host range plasmids, such as RP4, phage DNAs, e.g., the numerous derivatives of phage lambda, e.g., NM989, λ GT10 and λ GT11, and other phages, e.g., M13 and filamentous single stranded phage DNA. Where *E. coli* is used as host, selectable markers are, analogously, chosen for selectivity in gram negative bacteria: e.g., typical markers confer resistance to antibiotics, such as ampicillin, tetracycline, chloramphenicol, kanamycin, streptomycin and zeocin; auxotrophic markers can also be used.

In other embodiments, eukaryotic host cells, such as yeast, insect, mammalian or plant cells, may be used. Yeast cells, typically *S. cerevisiae*, are useful for eukaryotic genetic studies, due to the ease of targeting genetic changes by homologous recombination and the ability to easily complement genetic defects using recombinantly expressed proteins. Yeast cells are useful for identifying interacting protein components, e.g. through use of a two-hybrid system. In a preferred embodiment, yeast cells are useful for protein expression. Vectors of the present invention for use in yeast will typically, but not invariably, contain an origin of replication suitable for use in yeast and a selectable marker that is functional in yeast. Yeast vectors include Yeast Integrating plasmids (e.g., YIp5) and Yeast Replicating plasmids (the YRp and YEp series plasmids), Yeast Centromere plasmids (the YCp series plasmids), Yeast Artificial Chromosomes (YACs) which are based on yeast linear plasmids, denoted YLp, pGPD-2, 2 μ plasmids and derivatives thereof, and improved shuttle vectors such as those described in Gietz *et al.*, *Gene*, 74: 527-34 (1988) (YIplac, YEplac and YCplac). Selectable markers in yeast vectors include a variety of auxotrophic markers, the most common of which are (in *Saccharomyces cerevisiae*) URA3, HIS3, LEU2, TRP1 and LYS2, which complement specific auxotrophic mutations, such as *ura3-52*, *his3-D1*, *leu2-D1*, *trp1-D1* and *lys2-201*.

Insect cells may be chosen for high efficiency protein expression. Where the host cells are from *Spodoptera frugiperda*, e.g., Sf9 and Sf21 cell lines, and expressSF™ cells

(Protein Sciences Corp., Meriden, CT, USA), the vector replicative strategy is typically based upon the baculovirus life cycle. Typically, baculovirus transfer vectors are used to replace the wild-type AcMNPV polyhedrin gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5' and 3' of the expression cassette on the transfer vectors. Following co-transfection with AcMNPV DNA, a homologous recombination event occurs between these sequences resulting in a recombinant virus carrying the gene of interest and the polyhedrin or p10 promoter. Selection can be based upon visual screening for lacZ fusion activity.

The host cells may also be mammalian cells, which are particularly useful for expression of proteins intended as pharmaceutical agents, and for screening of potential agonists and antagonists of a protein or a physiological pathway. Mammalian vectors intended for autonomous extrachromosomal replication will typically include a viral origin, such as the SV40 origin (for replication in cell lines expressing the large T-antigen, such as COS1 and COS7 cells), the papillomavirus origin, or the EBV origin for long term episomal replication (for use, *e.g.*, in 293-EBNA cells, which constitutively express the EBV EBNA-1 gene product and adenovirus E1A). Vectors intended for integration, and thus replication as part of the mammalian chromosome, can, but need not, include an origin of replication functional in mammalian cells, such as the SV40 origin. Vectors based upon viruses, such as adenovirus, adeno-associated virus, vaccinia virus, and various mammalian retroviruses, will typically replicate according to the viral replicative strategy. Selectable markers for use in mammalian cells include, but are not limited to, resistance to neomycin (G418), blasticidin, hygromycin and zeocin, and selection based upon the purine salvage pathway using HAT medium.

Expression in mammalian cells can be achieved using a variety of plasmids, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (*e.g.*, vaccinia virus, adeno virus, and baculovirus), episomal virus vectors (*e.g.*, bovine papillomavirus), and retroviral vectors (*e.g.*, murine retroviruses). Useful vectors for insect cells include baculoviral vectors and pVL 941.

Plant cells can also be used for expression, with the vector replicon typically derived from a plant virus (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) and selectable markers chosen for suitability in plants.

It is known that codon usage of different host cells may be different. For example, a plant cell and a human cell may exhibit a difference in codon preference for encoding a

particular amino acid. As a result, human mRNA may not be efficiently translated in a plant, bacteria or insect host cell. Therefore, another embodiment of this invention is directed to codon optimization. The codons of the nucleic acid molecules of the invention may be modified to resemble, as much as possible, genes naturally contained within the host cell without altering the amino acid sequence encoded by the nucleic acid molecule.

Any of a wide variety of expression control sequences may be used in these vectors to express the nucleic acid molecules of this invention. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors. Expression control sequences that control transcription include, *e.g.*, promoters, enhancers and transcription termination sites. Expression control sequences in eukaryotic cells that control post-transcriptional events include splice donor and acceptor sites and sequences that modify the half-life of the transcribed RNA, *e.g.*, sequences that direct poly(A) addition or binding sites for RNA-binding proteins. Expression control sequences that control translation include ribosome binding sites, sequences which direct targeted expression of the polypeptide to or within particular cellular compartments, and sequences in the 5' and 3' untranslated regions that modify the rate or efficiency of translation.

Examples of useful expression control sequences for a prokaryote, *e.g.*, *E. coli*, will include a promoter, often a phage promoter, such as phage lambda pL promoter, the *trc* promoter, a hybrid derived from the *trp* and *lac* promoters, the bacteriophage T7 promoter (in *E. coli* cells engineered to express the T7 polymerase), the TAC or TRC system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, and the *araBAD* operon. Prokaryotic expression vectors may further include transcription terminators, such as the *aspA* terminator, and elements that facilitate translation, such as a consensus ribosome binding site and translation termination codon, Schomer *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 8506-8510 (1986).

Expression control sequences for yeast cells, typically *S. cerevisiae*, will include a yeast promoter, such as the *CYC1* promoter, the *GAL1* promoter, the *GAL10* promoter, *ADH1* promoter, the promoters of the yeast α -mating system, or the *GPD* promoter, and will typically have elements that facilitate transcription termination, such as the transcription termination signals from the *CYC1* or *ADH1* gene.

Expression vectors useful for expressing proteins in mammalian cells will include a promoter active in mammalian cells. These promoters include, but are not limited to,

those derived from mammalian viruses, such as the enhancer-promoter sequences from the immediate early gene of the human cytomegalovirus (CMV), the enhancer-promoter sequences from the Rous sarcoma virus long terminal repeat (RSV LTR), the enhancer-promoter from SV40 and the early and late promoters of adenovirus. Other expression control sequences include the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase. Other expression control sequences include those from the gene comprising the OSNA of interest. Often, expression is enhanced by incorporation of polyadenylation sites, such as the late SV40 polyadenylation site and the polyadenylation signal and transcription termination sequences from the bovine growth hormone (BGH) gene, and ribosome binding sites. Furthermore, vectors can include introns, such as intron II of rabbit β -globin gene and the SV40 splice elements.

Preferred nucleic acid vectors also include a selectable or amplifiable marker gene and means for amplifying the copy number of the gene of interest. Such marker genes are well known in the art. Nucleic acid vectors may also comprise stabilizing sequences (e.g., ori- or ARS-like sequences and telomere-like sequences), or may alternatively be designed to favor directed or non-directed integration into the host cell genome. In a preferred embodiment, nucleic acid sequences of this invention are inserted in frame into an expression vector that allows a high level expression of an RNA which encodes a protein comprising the encoded nucleic acid sequence of interest. Nucleic acid cloning and sequencing methods are well known to those of skill in the art and are described in an assortment of laboratory manuals, including Sambrook (1989), *supra*, Sambrook (2000), *supra*; and Ausubel (1992), *supra*, Ausubel (1999), *supra*. Product information from manufacturers of biological, chemical and immunological reagents also provide useful information.

Expression vectors may be either constitutive or inducible. Inducible vectors include either naturally inducible promoters, such as the trc promoter, which is regulated by the lac operon, and the pL promoter, which is regulated by tryptophan, the MMTV-LTR promoter, which is inducible by dexamethasone, or can contain synthetic promoters and/or additional elements that confer inducible control on adjacent promoters. Examples of inducible synthetic promoters are the hybrid Plac/ara-1 promoter and the PLtetO-1 promoter. The PLtetO-1 promoter takes advantage of the high expression levels from the PL promoter of phage lambda, but replaces the lambda repressor sites with two copies of operator 2 of the Tn10 tetracycline resistance operon, causing this promoter to

be tightly repressed by the Tet repressor protein and induced in response to tetracycline (Tc) and Tc derivatives such as anhydrotetracycline. Vectors may also be inducible because they contain hormone response elements, such as the glucocorticoid response element (GRE) and the estrogen response element (ERE), which can confer hormone inducibility where vectors are used for expression in cells having the respective hormone receptors. To reduce background levels of expression, elements responsive to ecdysone, an insect hormone, can be used instead, with coexpression of the ecdysone receptor.

In one embodiment of the invention, expression vectors can be designed to fuse the expressed polypeptide to small protein tags that facilitate purification and/or visualization. Such tags include a polyhistidine tag that facilitates purification of the fusion protein by immobilized metal affinity chromatography, for example using NiNTA resin (Qiagen Inc., Valencia, CA, USA) or TALON™ resin (cobalt immobilized affinity chromatography medium, Clontech Labs, Palo Alto, CA, USA). The fusion protein can include a chitin-binding tag and self-excising intein, permitting chitin-based purification with self-removal of the fused tag (IMPACT™ system, New England Biolabs, Inc., Beverly, MA, USA). Alternatively, the fusion protein can include a calmodulin-binding peptide tag, permitting purification by calmodulin affinity resin (Stratagene, La Jolla, CA, USA), or a specifically excisable fragment of the biotin carboxylase carrier protein, permitting purification of *in vivo* biotinylated protein using an avidin resin and subsequent tag removal (Promega, Madison, WI, USA). As another useful alternative, the polypeptides of the present invention can be expressed as a fusion to glutathione-S-transferase, the affinity and specificity of binding to glutathione permitting purification using glutathione affinity resins, such as Glutathione-Superflow Resin (Clontech Laboratories, Palo Alto, CA, USA), with subsequent elution with free glutathione. Other tags include, for example, the Xpress epitope, detectable by anti-Xpress antibody (Invitrogen, Carlsbad, CA, USA), a myc tag, detectable by anti-myc tag antibody, the V5 epitope, detectable by anti-V5 antibody (Invitrogen, Carlsbad, CA, USA), FLAG® epitope, detectable by anti-FLAG® antibody (Stratagene, La Jolla, CA, USA), and the HA epitope, detectable by anti-HA antibody.

For secretion of expressed polypeptides, vectors can include appropriate sequences that encode secretion signals, such as leader peptides. For example, the pSecTag2 vectors (Invitrogen, Carlsbad, CA, USA) are 5.2 kb mammalian expression vectors that carry the

secretion signal from the V-J2-C region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins from a variety of mammalian cell lines.

Expression vectors can also be designed to fuse proteins encoded by the heterologous nucleic acid insert to polypeptides that are larger than purification and/or identification tags. Useful protein fusions include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as those that have a green fluorescent protein (GFP)-like chromophore, fusions to the IgG Fc region, and fusions for use in two hybrid systems.

Vectors for phage display fuse the encoded polypeptide to, *e.g.*, the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13. *See* Barbas *et al.*, Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001); Kay *et al.* (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, Inc., (1996); Abelson *et al.* (eds.), Combinatorial Chemistry (Methods in Enzymology, Vol. 267) Academic Press (1996). Vectors for yeast display, *e.g.* the pYD1 yeast display vector (Invitrogen, Carlsbad, CA, USA), use the α -agglutinin yeast adhesion receptor to display recombinant protein on the surface of *S. cerevisiae*. Vectors for mammalian display, *e.g.*, the pDisplay™ vector (Invitrogen, Carlsbad, CA, USA), target recombinant proteins using an N-terminal cell surface targeting signal and a C-terminal transmembrane anchoring domain of platelet derived growth factor receptor.

A wide variety of vectors now exist that fuse proteins encoded by heterologous nucleic acids to the chromophore of the substrate-independent, intrinsically fluorescent green fluorescent protein from *Aequorea victoria* ("GFP") and its variants. The GFP-like chromophore can be selected from GFP-like chromophores found in naturally occurring proteins, such as *A. victoria* GFP (GenBank accession number AAA27721), *Renilla reniformis* GFP, FP583 (GenBank accession no. AF168419) (DsRed), FP593 (AF272711), FP483 (AF168420), FP484 (AF168424), FP595 (AF246709), FP486 (AF168421), FP538 (AF168423), and FP506 (AF168422), and need include only so much of the native protein as is needed to retain the chromophore's intrinsic fluorescence. Methods for determining the minimal domain required for fluorescence are known in the art. *See* Li *et al.*, *J. Biol. Chem.* 272: 28545-28549 (1997). Alternatively, the GFP-like chromophore can be selected from GFP-like chromophores modified from those found in nature. The methods for engineering such modified GFP-like chromophores and testing them for fluorescence

activity, both alone and as part of protein fusions, are well known in the art. *See Heim et al., Curr. Biol.* 6: 178-182 (1996) and *Palm et al., Methods Enzymol.* 302: 378-394 (1999). A variety of such modified chromophores are now commercially available and can readily be used in the fusion proteins of the present invention. These include EGFP (“enhanced GFP”), EBFP (“enhanced blue fluorescent protein”), BFP2, EYFP (“enhanced yellow fluorescent protein”), ECFP (“enhanced cyan fluorescent protein”) or Citrine. EGFP (*see, e.g., Cormack et al., Gene* 173: 33-38 (1996); U.S. Patent Nos. 6,090,919 and 5,804,387, the disclosures of which are incorporated herein by reference in their entireties) is found on a variety of vectors, both plasmid and viral, which are available commercially (Clontech Labs, Palo Alto, CA, USA); EBFP is optimized for expression in mammalian cells whereas BFP2, which retains the original jellyfish codons, can be expressed in bacteria (*see, e.g., Heim et al., Curr. Biol.* 6: 178-182 (1996) and *Cormack et al., Gene* 173: 33-38 (1996)). Vectors containing these blue-shifted variants are available from Clontech Labs (Palo Alto, CA, USA). Vectors containing EYFP, ECFP (*see, e.g., Heim et al., Curr. Biol.* 6: 178-182 (1996); *Miyawaki et al., Nature* 388: 882-887 (1997)) and Citrine (*see, e.g., Heikal et al., Proc. Natl. Acad. Sci. USA* 97: 11996-12001 (2000)) are also available from Clontech Labs. The GFP-like chromophore can also be drawn from other modified GFPs, including those described in U.S. Patent Nos. 6,124,128; 6,096,865; 6,090,919; 6,066,476; 6,054,321; 6,027,881; 5,968,750; 5,874,304; 5,804,387; 5,777,079; 5,741,668; and 5,625,048, the disclosures of which are incorporated herein by reference in their entireties. *See also Conn (ed.), Green Fluorescent Protein* (Methods in Enzymology, Vol. 302), Academic Press, Inc. (1999); *Yang, et al., J Biol Chem*, 273: 8212-6 (1998); *Bevis et al., Nature Biotechnology*, 20:83-7 (2002). The GFP-like chromophore of each of these GFP variants can usefully be included in the fusion proteins of the present invention.

Fusions to the IgG Fc region increase serum half-life of protein pharmaceutical products through interaction with the FcRn receptor (also denominated the FcRp receptor and the Brambell receptor, FcRb), further described in International Patent Application nos. WO 97/43316, WO 97/34631, WO 96/32478, WO 96/18412, the disclosures of which are incorporated herein by reference in their entireties.

For long-term, high-yield recombinant production of the polypeptides of the present invention, stable expression is preferred. Stable expression is readily achieved by integration into the host cell genome of vectors having selectable markers, followed by

selection of these integrants. Vectors such as pUB6/V5-His A, B, and C (Invitrogen, Carlsbad, CA, USA) are designed for high-level stable expression of heterologous proteins in a wide range of mammalian tissue types and cell lines. pUB6/V5-His uses the promoter/enhancer sequence from the human ubiquitin C gene to drive expression of recombinant proteins: expression levels in 293, CHO, and NIH3T3 cells are comparable to levels from the CMV and human EF-1a promoters. The bsd gene permits rapid selection of stably transfected mammalian cells with the potent antibiotic blasticidin.

Replication incompetent retroviral vectors, typically derived from Moloney murine leukemia virus, also are useful for creating stable transfectants having integrated provirus. The highly efficient transduction machinery of retroviruses, coupled with the availability of a variety of packaging cell lines such as RetroPack™ PT 67, EcoPack2™-293, AmphiPack-293, and GP2-293 cell lines (all available from Clontech Laboratories, Palo Alto, CA, USA) allow a wide host range to be infected with high efficiency; varying the multiplicity of infection readily adjusts the copy number of the integrated provirus.

Of course, not all vectors and expression control sequences will function equally well to express the nucleic acid molecules of this invention. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must be replicated in it. The vector's copy number, the ability to control that copy number, the ability to control integration, if any, and the expression of any other proteins encoded by the vector, such as antibiotic or other selection markers, should also be considered. The present invention further includes host cells comprising the vectors of the present invention, either present episomally within the cell or integrated, in whole or in part, into the host cell chromosome. Among other considerations, some of which are described above, a host cell strain may be chosen for its ability to process the expressed polypeptide in the desired fashion. Such post-translational modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation, and it is an aspect of the present invention to provide OSPs with such post-translational modifications.

In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its

controllability, and its compatibility with the nucleic acid molecules of this invention, particularly with regard to potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the product coded for by the nucleic acid sequences of this invention, their secretion
5 characteristics, their ability to fold the polypeptide correctly, their fermentation or culture requirements, and the ease of purification from them of the products coded for by the nucleic acid molecules of this invention.

The recombinant nucleic acid molecules and more particularly, the expression vectors of this invention may be used to express the polypeptides of this invention as
10 recombinant polypeptides in a heterologous host cell. The polypeptides of this invention may be full-length or less than full-length polypeptide fragments recombinantly expressed from the nucleic acid molecules according to this invention. Such polypeptides include analogs, derivatives and muteins that may or may not have biological activity.

Vectors of the present invention will also often include elements that permit *in*
15 *vitro* transcription of RNA from the inserted heterologous nucleic acid. Such vectors typically include a phage promoter, such as that from T7, T3, or SP6, flanking the nucleic acid insert. Often two different such promoters flank the inserted nucleic acid, permitting separate *in vitro* production of both sense and antisense strands.

Transformation and other methods of introducing nucleic acids into a host cell
20 (*e.g.*, conjugation, protoplast transformation or fusion, transfection, electroporation, liposome delivery, membrane fusion techniques, high velocity DNA-coated pellets, viral infection and protoplast fusion) can be accomplished by a variety of methods which are well known in the art (*See, for instance, Ausubel, supra, and Sambrook et al., supra*). Bacterial, yeast, plant or mammalian cells are transformed or transfected with an
25 expression vector, such as a plasmid, a cosmid, or the like, wherein the expression vector comprises the nucleic acid of interest. Alternatively, the cells may be infected by a viral expression vector comprising the nucleic acid of interest. Depending upon the host cell, vector, and method of transformation used, transient or stable expression of the polypeptide will be constitutive or inducible. One having ordinary skill in the art will be
30 able to decide whether to express a polypeptide transiently or stably, and whether to express the protein constitutively or inducibly.

A wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and

prokaryotic hosts, such as strains of, fungi, yeast, insect cells such as *Spodoptera frugiperda* (SF9), animal cells such as CHO, as well as plant cells in tissue culture. Representative examples of appropriate host cells include, but are not limited to, bacterial cells, such as *E. coli*, *Caulobacter crescentus*, *Streptomyces* species, and *Salmonella typhimurium*; yeast cells, such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Pichia pastoris*, *Pichia methanolica*; insect cell lines, such as those from *Spodoptera frugiperda* — e.g., Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA) — *Drosophila* S2 cells, and *Trichoplusia ni* High Five® Cells (Invitrogen, Carlsbad, CA, USA); and mammalian cells. Typical mammalian cells include BHK cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, COS1 cells, COS7 cells, Chinese hamster ovary (CHO) cells, 3T3 cells, NIH 3T3 cells, 293 cells, HEPG2 cells, HeLa cells, L cells, MDCK cells, HEK293 cells, WI38 cells, murine ES cell lines (e.g., from strains 129/SV, C57/BL6, DBA-1, 129/SVJ), K562 cells, Jurkat cells, and BW5147 cells. Other mammalian cell lines are well known and readily available from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (Camden, NJ, USA). Cells or cell lines derived from ovarian are particularly preferred because they may provide a more native post-translational processing. Particularly preferred are human ovarian cells.

Particular details of the transfection, expression and purification of recombinant proteins are well documented and are understood by those of skill in the art. Further details on the various technical aspects of each of the steps used in recombinant production of foreign genes in bacterial cell expression systems can be found in a number of texts and laboratory manuals in the art. See, e.g., Ausubel (1992), *supra*, Ausubel (1999), *supra*, Sambrook (1989), *supra*, and Sambrook (2001), *supra*.

Methods for introducing the vectors and nucleic acid molecules of the present invention into the host cells are well known in the art; the choice of technique will depend primarily upon the specific vector to be introduced and the host cell chosen.

Nucleic acid molecules and vectors may be introduced into prokaryotes, such as *E. coli*, in a number of ways. For instance, phage lambda vectors will typically be packaged using a packaging extract (e.g., Gigapack® packaging extract, Stratagene, La Jolla, CA, USA), and the packaged virus used to infect *E. coli*.

Plasmid vectors will typically be introduced into chemically competent or electrocompetent bacterial cells. *E. coli* cells can be rendered chemically competent by treatment, *e.g.*, with CaCl_2 , or a solution of Mg^{2+} , Mn^{2+} , Ca^{2+} , Rb^+ or K^+ , dimethyl sulfoxide, dithiothreitol, and hexamine cobalt (III), Hanahan, *J. Mol. Biol.* 166(4):557-80 (1983), and vectors introduced by heat shock. A wide variety of chemically competent strains are also available commercially (*e.g.*, Epicurian Coli® XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, CA, USA); DH5α competent cells (Clontech Laboratories, Palo Alto, CA, USA); and TOP10 Chemically Competent *E. coli* Kit (Invitrogen, Carlsbad, CA, USA)). Bacterial cells can be rendered electrocompetent to take up exogenous DNA by electroporation by various pre-pulse treatments; vectors are introduced by electroporation followed by subsequent outgrowth in selected media. An extensive series of protocols is provided by BioRad (Richmond, CA, USA).

Vectors can be introduced into yeast cells by spheroplasting, treatment with lithium salts, electroporation, or protoplast fusion. Spheroplasts are prepared by the action of hydrolytic enzymes such as a snail-gut extract, usually denoted Glusulase or Zymolyase, or an enzyme from *Arthrobacter luteus* to remove portions of the cell wall in the presence of osmotic stabilizers, typically 1 M sorbitol. DNA is added to the spheroplasts, and the mixture is co-precipitated with a solution of polyethylene glycol (PEG) and Ca^{2+} . Subsequently, the cells are resuspended in a solution of sorbitol, mixed with molten agar and then layered on the surface of a selective plate containing sorbitol.

For lithium-mediated transformation, yeast cells are treated with lithium acetate to permeabilize the cell wall, DNA is added and the cells are co-precipitated with PEG. The cells are exposed to a brief heat shock, washed free of PEG and lithium acetate, and subsequently spread on plates containing ordinary selective medium. Increased frequencies of transformation are obtained by using specially-prepared single-stranded carrier DNA and certain organic solvents. Schiestl *et al.*, *Curr. Genet.* 16(5-6): 339-46 (1989).

For electroporation, freshly-grown yeast cultures are typically washed, suspended in an osmotic protectant, such as sorbitol, mixed with DNA, and the cell suspension pulsed in an electroporation device. Subsequently, the cells are spread on the surface of plates containing selective media. Becker *et al.*, *Methods Enzymol.* 194: 182-187 (1991). The efficiency of transformation by electroporation can be increased over 100-fold by

using PEG, single-stranded carrier DNA and cells that are in late log-phase of growth. Larger constructs, such as YACs, can be introduced by protoplast fusion.

Mammalian and insect cells can be directly infected by packaged viral vectors, or transfected by chemical or electrical means. For chemical transfection, DNA can be coprecipitated with CaPO_4 or introduced using liposomal and nonliposomal lipid-based agents. Commercial kits are available for CaPO_4 transfection (CalPhos™ Mammalian Transfection Kit, Clontech Laboratories, Palo Alto, CA, USA), and lipid-mediated transfection can be practiced using commercial reagents, such as LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ Reagent, CELLFECTIN® Reagent, and LIPOFECTIN® Reagent (Invitrogen, Carlsbad, CA, USA), DOTAP Liposomal Transfection Reagent, FuGENE 6, X-tremeGENE Q2, DOSPER, (Roche Molecular Biochemicals, Indianapolis, IN USA), Effectene™, PolyFect®, Superfect® (Qiagen, Inc., Valencia, CA, USA). Protocols for electroporating mammalian cells can be found in, for example, ; Norton *et al.* (eds.), Gene Transfer Methods: Introducing DNA into Living Cells and Organisms, BioTechniques Books, Eaton Publishing Co. (2000). Other transfection techniques include transfection by particle bombardment and microinjection. See, e.g., Cheng *et al.*, *Proc. Natl. Acad. Sci. USA* 90(10): 4455-9 (1993); Yang *et al.*, *Proc. Natl. Acad. Sci. USA* 87(24): 9568-72 (1990).

Production of the recombinantly produced proteins of the present invention can optionally be followed by purification.

Purification of recombinantly expressed proteins is now well within the skill in the art and thus need not be detailed here. See, e.g., Thorner *et al.* (eds.), Applications of Chimeric Genes and Hybrid Proteins, Part A: Gene Expression and Protein Purification (Methods in Enzymology, Vol. 326), Academic Press (2000); Harbin (ed.), Cloning, Gene Expression and Protein Purification : Experimental Procedures and Process Rationale, Oxford Univ. Press (2001); Marshak *et al.*, Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press (1996); and Roe (ed.), Protein Purification Applications, Oxford University Press (2001).

Briefly, however, if purification tags have been fused through use of an expression vector that appends such tag, purification can be effected, at least in part, by means appropriate to the tag, such as use of immobilized metal affinity chromatography for polyhistidine tags. Other techniques common in the art include ammonium sulfate

fractionation, immunoprecipitation, fast protein liquid chromatography (FPLC), high performance liquid chromatography (HPLC), and preparative gel electrophoresis.

Polypeptides, including Fragments Muteins, Homologous Proteins, Allelic Variants, Analogs and Derivatives

5 Another aspect of the invention relates to polypeptides encoded by the nucleic acid molecules described herein. In a preferred embodiment, the polypeptide is a ovarian specific polypeptide (OSP). In an even more preferred embodiment, the polypeptide comprises an amino acid sequence of SEQ ID NO:249-396 or is derived from a polypeptide having the amino acid sequence of SEQ ID NO: 249-396. A polypeptide as
10 defined herein may be produced recombinantly, as discussed *supra*, may be isolated from a cell that naturally expresses the protein, or may be chemically synthesized following the teachings of the specification and using methods well known to those having ordinary skill in the art.

 Polypeptides of the present invention may also comprise a part or fragment of a
15 OSP. In a preferred embodiment, the fragment is derived from a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 249-396. Polypeptides of the present invention comprising a part or fragment of an entire OSP may or may not be OSPs. For example, a full-length polypeptide may be ovarian-specific, while a fragment thereof may be found in other tissues as well as in ovarian. A
20 polypeptide that is not a OSP, whether it is a fragment, analog, mutein, homologous protein or derivative, is nevertheless useful, especially for immunizing animals to prepare anti-OSP antibodies. In a preferred embodiment, the part or fragment is a OSP. Methods of determining whether a polypeptide of the present invention is a OSP are described *infra*.

25 Polypeptides of the present invention comprising fragments of at least 6 contiguous amino acids are also useful in mapping B cell and T cell epitopes of the reference protein. *See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA* 81: 3998-4002 (1984) and U.S. Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. Because the fragment need not itself
30 be immunogenic, part of an immunodominant epitope, nor even recognized by native antibody, to be useful in such epitope mapping, all fragments of at least 6 amino acids of a polypeptide of the present invention have utility in such a study.

Polypeptides of the present invention comprising fragments of at least 8 contiguous amino acids, often at least 15 contiguous amino acids, are useful as immunogens for raising antibodies that recognize polypeptides of the present invention. *See, e.g.,* Lerner, *Nature* 299: 592-596 (1982); Shinnick *et al.*, *Annu. Rev. Microbiol.* 37: 425-46 (1983); Sutcliffe *et al.*, *Science* 219: 660-6 (1983). As further described in the above-cited references, virtually all 8-mers, conjugated to a carrier, such as a protein, prove immunogenic and are capable of eliciting antibody for the conjugated peptide; accordingly, all fragments of at least 8 amino acids of the polypeptides of the present invention have utility as immunogens.

Polypeptides comprising fragments of at least 8, 9, 10 or 12 contiguous amino acids are also useful as competitive inhibitors of binding of the entire polypeptide, or a portion thereof, to antibodies (as in epitope mapping), and to natural binding partners, such as subunits in a multimeric complex or to receptors or ligands of the subject protein; this competitive inhibition permits identification and separation of molecules that bind specifically to the polypeptide of interest. See U.S. Patent Nos. 5,539,084 and 5,783,674, incorporated herein by reference in their entireties.

The polypeptide of the present invention thus preferably is at least 6 amino acids in length, typically at least 8, 9, 10 or 12 amino acids in length, and often at least 15 amino acids in length. Often, the polypeptide of the present invention is at least 20 amino acids in length, even 25 amino acids, 30 amino acids, 35 amino acids, or 50 amino acids or more in length. Of course, larger polypeptides having at least 75 amino acids, 100 amino acids, or even 150 amino acids are also useful, and at times preferred.

One having ordinary skill in the art can produce fragments by truncating the nucleic acid molecule, *e.g.*, a OSNA, encoding the polypeptide and then expressing it recombinantly. Alternatively, one can produce a fragment by chemically synthesizing a portion of the full-length polypeptide. One may also produce a fragment by enzymatically cleaving either a recombinant polypeptide or an isolated naturally occurring polypeptide. Methods of producing polypeptide fragments are well known in the art. *See, e.g.,* Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. In one embodiment, a polypeptide comprising only a fragment, preferably a fragment of a OSP, may be produced by chemical or enzymatic cleavage of a OSP polypeptide. In a preferred embodiment, a polypeptide fragment is produced by

expressing a nucleic acid molecule of the present invention encoding a fragment, preferably of a OSP, in a host cell.

Polypeptides of the present invention are also inclusive of mutants, fusion proteins, homologous proteins and allelic variants.

5 A mutant protein, or mutein, may have the same or different properties compared to a naturally occurring polypeptide and comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of a native polypeptide. Small deletions and insertions can often be found that do not alter the function of a protein. Muteins may or may not be ovarian-specific. Preferably, the
10 mutein is ovarian-specific. More preferably the mutein is a polypeptide that comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of SEQ ID NO: 249-396. Accordingly, in a preferred embodiment, the mutein is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more
15 preferably at least 80% sequence identity to a OSP comprising an amino acid sequence of SEQ ID NO: 249-396. In a yet more preferred embodiment, the mutein exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97%, 98%, 99% or 99.5% sequence identity to a OSP comprising an amino acid sequence of SEQ ID NO: 249-396.

20 A mutein may be produced by isolation from a naturally occurring mutant cell, tissue or organism. A mutein may be produced by isolation from a cell, tissue or organism that has been experimentally mutagenized. Alternatively, a mutein may be produced by chemical manipulation of a polypeptide, such as by altering the amino acid residue to another amino acid residue using synthetic or semi-synthetic chemical techniques. In a
25 preferred embodiment, a mutein is produced from a host cell comprising a mutated nucleic acid molecule compared to the naturally occurring nucleic acid molecule. For instance, one may produce a mutein of a polypeptide by introducing one or more mutations into a nucleic acid molecule of the invention and then expressing it recombinantly. These mutations may be targeted, in which particular encoded amino acids are altered, or may be
30 untargeted, in which random encoded amino acids within the polypeptide are altered. Muteins with random amino acid alterations can be screened for a particular biological activity or property, particularly whether the polypeptide is ovarian-specific, as described below. Multiple random mutations can be introduced into the gene by methods well

known to the art, *e.g.*, by error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo* mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis and site-specific mutagenesis. Methods of producing muteins with targeted or random amino acid alterations are well known in the art. *See, e.g.*, Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), as well as U.S. Patent No. 5,223,408, which is herein incorporated by reference in its entirety.

The invention also contemplates polypeptides that are homologous to a polypeptide of the invention. In a preferred embodiment, the polypeptide is homologous to a OSP. In an even more preferred embodiment, the polypeptide is homologous to a OSP selected from the group having an amino acid sequence of SEQ ID NO: 249-396. By homologous polypeptide it is means one that exhibits significant sequence identity to a OSP, preferably a OSP having an amino acid sequence of SEQ ID NO: 249-396. By significant sequence identity it is meant that the homologous polypeptide exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to a OSP comprising an amino acid sequence of SEQ ID NO: 249-396. More preferred are homologous polypeptides exhibiting at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97% or 98% sequence identity to a OSP comprising an amino acid sequence of SEQ ID NO: 249-396. Most preferably, the homologous polypeptide exhibits at least 99%, more preferably 99.5%, even more preferably 99.6%, 99.7%, 99.8% or 99.9% sequence identity to a OSP comprising an amino acid sequence of SEQ ID NO: 249-396. In a preferred embodiment, the amino acid substitutions of the homologous polypeptide are conservative amino acid substitutions as discussed above.

Homologous polypeptides of the present invention also comprise polypeptide encoded by a nucleic acid molecule that selectively hybridizes to a OSNA or an antisense sequence thereof. In this embodiment, it is preferred that the homologous polypeptide be encoded by a nucleic acid molecule that hybridizes to a OSNA under low stringency, moderate stringency or high stringency conditions, as defined herein. More preferred is a homologous polypeptide encoded by a nucleic acid sequence which hybridizes to a OSNA selected from the group consisting of SEQ ID NO: 1-248 or a homologous polypeptide encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule that encodes

a OSP, preferably an OSP of SEQ ID NO:249-396 under low stringency, moderate stringency or high stringency conditions, as defined herein.

Homologous polypeptides of the present invention may be naturally occurring and derived from another species, especially one derived from another primate, such as chimpanzee, gorilla, rhesus macaque, or baboon, wherein the homologous polypeptide comprises an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 249-396. The homologous polypeptide may also be a naturally occurring polypeptide from a human, when the OSP is a member of a family of polypeptides. The homologous polypeptide may also be a naturally occurring polypeptide derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, guinea pig, hamster, cow, horse, goat or pig. The homologous polypeptide may also be a naturally occurring polypeptide derived from a non-mammalian species, such as birds or reptiles. The naturally occurring homologous protein may be isolated directly from humans or other species. Alternatively, the nucleic acid molecule encoding the naturally occurring homologous polypeptide may be isolated and used to express the homologous polypeptide recombinantly. The homologous polypeptide may also be one that is experimentally produced by random mutation of a nucleic acid molecule and subsequent expression of the nucleic acid molecule. Alternatively, the homologous polypeptide may be one that is experimentally produced by directed mutation of one or more codons to alter the encoded amino acid of a OSP. In a preferred embodiment, the homologous polypeptide encodes a polypeptide that is a OSP.

Relatedness of proteins can also be characterized using a second functional test, the ability of a first protein competitively to inhibit the binding of a second protein to an antibody. It is, therefore, another aspect of the present invention to provide isolated polypeptide not only identical in sequence to those described with particularity herein, but also to provide isolated polypeptide ("cross-reactive proteins") that competitively inhibit the binding of antibodies to all or to a portion of various of the isolated polypeptides of the present invention. Such competitive inhibition can readily be determined using immunoassays well known in the art.

As discussed above, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes, and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Thus, polypeptides of the present invention are also inclusive of those encoded by an allelic variant of a nucleic acid

molecule encoding a OSP. In this embodiment, it is preferred that the polypeptide be encoded by an allelic variant of a gene that encodes a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 249-396. More preferred is that the polypeptide be encoded by an allelic variant of a gene that has the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-248.

Polypeptides of the present invention are also inclusive of derivative polypeptides encoded by a nucleic acid molecule according to the instant invention. In this embodiment, it is preferred that the polypeptide be a OSP. Also preferred are derivative polypeptides having an amino acid sequence selected from the group consisting of SEQ ID NO: 249-396 and which has been acetylated, carboxylated, phosphorylated, glycosylated, ubiquitinated or other PTMs. In another preferred embodiment, the derivative has been labeled with, e.g., radioactive isotopes such as ^{125}I , ^{32}P , ^{35}S , and ^3H . In another preferred embodiment, the derivative has been labeled with fluorophores, chemiluminescent agents, enzymes, and antiligands that can serve as specific binding pair members for a labeled ligand.

Polypeptide modifications are well known to those of skill and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as, for instance Creighton, Protein Structure and Molecular Properties, 2nd ed., W. H. Freeman and Company (1993). Many detailed reviews are available on this subject, such as, for example, those provided by Wold, in Johnson (ed.), Posttranslational Covalent Modification of Proteins, pgs. 1-12, Academic Press (1983); Seifter *et al.*, *Meth. Enzymol.* 182: 626-646 (1990) and Rattan *et al.*, *Ann. N.Y. Acad. Sci.* 663: 48-62 (1992).

One may determine whether a polypeptide of the invention is likely to be post-translationally modified by analyzing the sequence of the polypeptide to determine if there are peptide motifs indicative of sites for post-translational modification. There are a number of computer programs that permit prediction of post-translational modifications. See, e.g., www.expasy.org (accessed November 11, 2002), which includes PSORT, for prediction of protein sorting signals and localization sites, SignalP, for prediction of signal peptide cleavage sites, MITOPROT and Predotar, for prediction of mitochondrial targeting sequences, NetOGlyc, for prediction of type O-glycosylation sites in mammalian proteins,

big-PI Predictor and DGPI, for prediction of prenylation-anchor and cleavage sites, and NetPhos, for prediction of Ser, Thr and Tyr phosphorylation sites in eukaryotic proteins. Other computer programs, such as those included in GCG, also may be used to determine post-translational modification peptide motifs.

5 General examples of types of post-translational modifications include, but are not limited to: (Z)-dehydrobutyrine; 1-chondroitin sulfate-L-aspartic acid ester; 1'-glycosyl-L-tryptophan; 1'-phospho-L-histidine; 1-thioglycine; 2'-(S-L-cysteinyl)-L-histidine; 2'-[3-carboxamido (trimethylammonio)propyl]-L-histidine; 2'-alpha-mannosyl-L-tryptophan; 2-methyl-L-glutamine; 2-oxobutanoic acid; 2-pyrrolidone carboxylic acid; 3'-(1'-L-histidyl)-
 10 L-tyrosine; 3'-(8alpha-FAD)-L-histidine; 3'-(S-L-cysteinyl)-L-tyrosine; 3', 3'', 5'-triiodo-L-thyronine; 3'-4'-phospho-L-tyrosine; 3-hydroxy-L-proline; 3'-methyl-L-histidine; 3-methyl-L-lanthionine; 3'-phospho-L-histidine; 4'-(L-tryptophan)-L-tryptophyl quinone; 42 N-cysteinyl-glycosylphosphatidylinositoethanolamine; 43 -(T-L-histidyl)-L-tyrosine; 4-hydroxy-L-arginine; 4-hydroxy-L-lysine; 4-hydroxy-L-proline; 5'-(N6-L-lysine)-L-
 15 topaquinone; 5-hydroxy-L-lysine; 5-methyl-L-arginine; alpha-l-microglobulin-Ig alpha complex chromophore; bis-L-cysteinyl bis-L-histidino diiron disulfide; bis-L--cysteinyl-L-N3'-histidino-L-serinyl tetrairon' tetrasulfide; chondroitin sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; D-alanine; D-allo-isoleucine; D-asparagine; dehydroalanine; dehydrotyrosine; dermatan 4-sulfate D-glucuronyl-D-galactosyl-D-
 20 galactosyl-D-xylosyl-L-serine; D-glucuronyl-N-glycine; dipyrrolylmethanemethyl-L-cysteine; D-leucine; D-methionine; D-phenylalanine; D-serine; D-tryptophan; glycine amide; glycine oxazolecarboxylic acid; glycine thiazolecarboxylic acid; heme P450-bis-L-cysteine-L-tyrosine; heme-bis-L-cysteine; hemediol-L-aspartyl ester-L-glutamyl ester; hemediol-L-aspartyl ester-L-glutamyl ester-L-methionine sulfonium; heme-L-cysteine;
 25 heme-L-histidine; heparan sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; heme P450-bis-L-cysteine-L-lysine; hexakis-L-cysteinyl hexairon hexasulfide; keratan sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-threonine; L oxoalanine- lactic acid; L phenyllactic acid; 1'-(8alpha-FAD)-L-histidine; L-2'.4',5'-topaquinone; L-3',4'-dihydroxyphenylalanine; L-3'.4'.5'-trihydroxyphenylalanine; L-4'-
 30 bromophenylalanine; L-6'-bromotryptophan; L-alanine amide; L-alanyl imidazolinone glycine; L-allysine; L-arginine amide; L-asparagine amide; L-aspartic 4-phosphoric anhydride; L-aspartic acid 1-amide; L-beta-methylthioaspartic acid; L-bromohistidine; L-citrulline; L-cysteine amide; L-cysteine glutathione disulfide; L-cysteine methyl disulfide;

L-cysteine methyl ester; L-cysteine oxazolecarboxylic acid; L-cysteine
 oxazolinecarboxylic acid; L-cysteine persulfide; L-cysteine sulfenic acid; L-cysteine
 sulfinic acid; L-cysteine thiazolecarboxylic acid; L-cysteinyl homocitryl molybdenum-
 heptairon-nonasulfide; L-cysteinyl imidazolinone glycine; L-cysteinyl molybdopterin; L-
 5 cysteinyl molybdopterin guanine dinucleotide; L-cystine; L-erythro-beta-
 hydroxyasparagine; L-erythro-beta-hydroxyaspartic acid; L-gamma-carboxyglutamic acid;
 L-glutamic acid 1-amide; L-glutamic acid 5-methyl ester; L-glutamine amide; L-glutamyl
 5-glycerylphosphorylethanolamine; L-histidine amide; L-isoglutamyl-polyglutamic acid;
 L-isoglutamyl-polyglycine; L-isoleucine amide; L-lanthionine; L-leucine amide; L-lysine
 10 amide; L-lysine thiazolecarboxylic acid; L-lysinoalanine; L-methionine amide; L-
 methionine sulfone; L-phenylalanine thiazolecarboxylic acid; L-phenylalanine amide; L-
 proline amide; L-selenocysteine; L-selenocysteinyl molybdopterin guanine dinucleotide;
 L-serine amide; L-serine thiazolecarboxylic acid; L-seryl imidazolinone glycine; L-T-
 bromophenylalanine; L-T-bromophenylalanine; L-threonine amide; L-thyroxine; L-
 15 tryptophan amide; L-tryptophyl quinone; L-tyrosine amide; L-valine amide; meso-
 lanthionine; N-(L-glutamyl)-L-tyrosine; N-(L-isoaspartyl)-glycine; N-(L-isoaspartyl)-L-
 cysteine; N,N,N-trimethyl-L-alanine; N,N-dimethyl-L-proline; N2-acetyl-L-lysine; N2-
 succinyl-L-tryptophan; N4-(ADP-ribose)-L-asparagine; N4-glycosyl-L-asparagine; N4-
 hydroxymethyl-L-asparagine; N4-methyl-L-asparagine; N5-methyl-L-glutamine; N6- 1 -
 20 carboxyethyl-L-lysine; N6-(4-amino hydroxybutyl)-L-lysine; N6-(L-isoglutamyl)-L-
 lysine; N6-(phospho-5'-adenosine)-L-lysine; N6-(phospho-5'-guanosine)-L-lysine;
 N6,N6,N6-trimethyl-L-lysine; N6,N6-dimethyl-L-lysine; N6-acetyl-L-lysine; N6-biotinyl-
 L-lysine; N6-carboxy-L-lysine; N6-formyl-L-lysine; N6-glycyl-L-lysine; N6-lipoyl-L-
 lysine; N6-methyl-L-lysine; N6-methyl-N6-poly(N-methyl-propylamine)-L-lysine; N6-
 25 mureinyl-L-lysine; N6-myristoyl-L-lysine; N6-palmitoyl-L-lysine; N6-pyridoxal
 phosphate-L-lysine; N6-pyruvic acid 2-iminyl-L-lysine; N6-retinal-L-lysine; N-
 acetyl-glycine; N-acetyl-L-glutamine; N-acetyl-L-alanine; N-acetyl-L-aspartic acid; N-
 acetyl-L-cysteine; N-acetyl-L-glutamic acid; N-acetyl-L-isoleucine; N-acetyl-L-
 methionine; N-acetyl-L-proline; N-acetyl-L-serine; N-acetyl-L-threonine; N-acetyl-L-
 30 tyrosine; N-acetyl-L-valine; N-alanyl-glycosylphosphatidylinositoethanolamine; N-
 asparaginyl-glycosylphosphatidylinositoethanolamine; N-aspartyl-
 glycosylphosphatidylinositoethanolamine; N-formylglycine; N-formyl-L-methionine; N-
 glycyl-glycosylphosphatidylinositoethanolamine; N-L-glutamyl-poly-L-glutamic acid; N-

methylglycine; N-methyl-L-alanine; N-methyl-L-methionine; N-methyl-L-phenylalanine;
 N-myristoyl-glycine; N-palmitoyl-L-cysteine; N-pyruvic acid 2-iminyl-L-cysteine; N-
 pyruvic acid 2-iminyl-L-valine; N-seryl-glycosylphosphatidylinositoethanolamine; N-
 seryl-glycosyOSPhingolipidinositoethanolamine; O-(ADP-ribosyl)-L-serine; O-(phospho-
 5'-adenosine)-L-threonine; O-(phospho-5'-DNA)-L-serine; O-(phospho-5'-DNA)-L-
 5 threonine; O-(phospho-5'rRNA)-L-serine; O-(phosphoribosyl dephospho-coenzyme A)-L-
 serine; O-(sn-1-glycerophosphoryl)-L-serine; O4'-(8alpha-FAD)-L-tyrosine; O4'-(phospho-
 5'-adenosine)-L-tyrosine; O4'-(phospho-5'-DNA)-L-tyrosine; O4'-(phospho-5'-RNA)-L-
 tyrosine; O4'-(phospho-5'-uridine)-L-tyrosine; O4-glycosyl-L-hydroxyproline; O4'-
 10 glycosyl-L-tyrosine; O4'-sulfo-L-tyrosine; O5-glycosyl-L-hydroxylysine; O-glycosyl-L-
 serine; O-glycosyl-L-threonine; omega-N-(ADP-ribosyl)-L-arginine; omega-N-omega-N'-
 dimethyl-L-arginine; omega-N-methyl-L-arginine; omega-N-omega-N-dimethyl-L-
 arginine; omega-N-phospho-L-arginine; O'octanoyl-L-serine; O-palmitoyl-L-serine; O-
 palmitoyl-L-threonine; O-phospho-L-serine; O-phospho-L-threonine; O-
 15 phosphopantetheine-L-serine; phycoerythrobilin-bis-L-cysteine; phycourobilin-bis-L-
 cysteine; pyrroloquinoline quinone; pyruvic acid; S hydroxycinnamyl-L-cysteine; S-(2-
 aminovinyl) methyl-D-eysteine; S-(2-aminovinyl)-D-cysteine; S-(6-FW-L-cysteine; S-
 (8alpha-FAD)-L-cysteine; S-(ADP-ribosyl)-L-cysteine; S-(L-isoglutamyl)-L-cysteine; S-
 12-hydroxyfarnesyl-L-cysteine; S-acetyl-L-cysteine; S-diacylglycerol-L-cysteine; S-
 20 diphytanylglycerol diether-L-cysteine; S-farnesyl-L-cysteine; S-geranylgeranyl-L-
 cysteine; S-glycosyl-L-cysteine; S-glycyl-L-cysteine; S-methyl-L-cysteine; S-nitrosyl-L-
 cysteine; S-palmitoyl-L-cysteine; S-phospho-L-cysteine; S-phycobiliviolin-L-cysteine; S-
 phycocyanobilin-L-cysteine; S-phycoerythrobilin-L-cysteine; S-phytochromobilin-L-
 cysteine; S-selenyl-L-cysteine; S-sulfo-L-cysteine; tetrakis-L-cysteiny l diiron disulfide;
 25 tetrakis-L-cysteiny l iron; tetrakis-L-cysteiny l tetrairon tetrasulfide; trans-2,3-cis 4-
 dihydroxy-L-proline; tris-L-cysteiny l triiron tetrasulfide; tris-L-cysteiny l triiron trisulfide;
 tris-L-cysteiny l-L-aspartato tetrairon tetrasulfide; tris-L-cysteiny l-L-cysteine persulfido-
 bis-L-glutamato-L-histidino tetrairon disulfide trioxide; tris-L-cysteiny l-L-N3'-histidino
 tetrairon tetrasulfide; tris-L-cysteiny l-L-N1'-histidino tetrairon tetrasulfide; and tris-L-
 30 cysteiny l-L-seriny l tetrairon tetrasulfide.

Additional examples of PTMs may be found in web sites such as the Delta Mass
 database based on Krishna, R. G. and F. Wold (1998). Posttranslational Modifications.
 Proteins - Analysis and Design. R. H. Angeletti. San Diego, Academic Press. 1: 121-206. ;

Methods in Enzymology, 193, J.A. McClosky (ed) (1990), pages 647-660; Methods in Protein Sequence Analysis edited by Kazutomo Imahori and Fumio Sakiyama, Plenum Press, (1993) "Post-translational modifications of proteins" R.G. Krishna and F. Wold pages 167-172; "GlycoSuiteDB: a new curated relational database of glycoprotein glycan structures and their biological sources" Cooper et al. Nucleic Acids Res. 29; 332-335 (2001) "O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins" Gupta et al. Nucleic Acids Research, 27: 370-372 (1999); and "PhosphoBase, a database of phosphorylation sites: release 2.0.", Kreegipuu et al. Nucleic Acids Res 27(1):237-239 (1999) see also, WO 02/21139A2, the disclosure of which is incorporated herein by reference in its entirety.

Tumorigenesis is often accompanied by alterations in the post-translational modifications of proteins. Thus, in another embodiment, the invention provides polypeptides from cancerous cells or tissues that have altered post-translational modifications compared to the post-translational modifications of polypeptides from normal cells or tissues. A number of altered post-translational modifications are known. One common alteration is a change in phosphorylation state, wherein the polypeptide from the cancerous cell or tissue is hyperphosphorylated or hypophosphorylated compared to the polypeptide from a normal tissue, or wherein the polypeptide is phosphorylated on different residues than the polypeptide from a normal cell. Another common alteration is a change in glycosylation state, wherein the polypeptide from the cancerous cell or tissue has more or less glycosylation than the polypeptide from a normal tissue, and/or wherein the polypeptide from the cancerous cell or tissue has a different type of glycosylation than the polypeptide from a noncancerous cell or tissue. Changes in glycosylation may be critical because carbohydrate-protein and carbohydrate-carbohydrate interactions are important in cancer cell progression, dissemination and invasion. See, e.g., Barchi, *Curr. Pharm. Des.* 6: 485-501 (2000), Verma, *Cancer Biochem. Biophys.* 14: 151-162 (1994) and Dennis et al., *Bioessays* 5: 412-421 (1999).

Another post-translational modification that may be altered in cancer cells is prenylation. Prenylation is the covalent attachment of a hydrophobic prenyl group (either farnesyl or geranylgeranyl) to a polypeptide. Prenylation is required for localizing a protein to a cell membrane and is often required for polypeptide function. For instance, the Ras superfamily of GTPase signalling proteins must be prenylated for function in a

cell. See, e.g., Prendergast et al., *Semin. Cancer Biol.* 10: 443-452 (2000) and Khwaja et al., *Lancet* 355: 741-744 (2000).

Other post-translation modifications that may be altered in cancer cells include, without limitation, polypeptide methylation, acetylation, arginylation or racemization of amino acid residues. In these cases, the polypeptide from the cancerous cell may exhibit either increased or decreased amounts of the post-translational modification compared to the corresponding polypeptides from noncancerous cells.

Other polypeptide alterations in cancer cells include abnormal polypeptide cleavage of proteins and aberrant protein-protein interactions. Abnormal polypeptide cleavage may be cleavage of a polypeptide in a cancerous cell that does not usually occur in a normal cell, or a lack of cleavage in a cancerous cell, wherein the polypeptide is cleaved in a normal cell. Aberrant protein-protein interactions may be either covalent cross-linking or non-covalent binding between proteins that do not normally bind to each other. Alternatively, in a cancerous cell, a protein may fail to bind to another protein to which it is bound in a noncancerous cell. Alterations in cleavage or in protein-protein interactions may be due to over- or underproduction of a polypeptide in a cancerous cell compared to that in a normal cell, or may be due to alterations in post-translational modifications (see above) of one or more proteins in the cancerous cell. See, e.g., Henschen-Edman, *Ann. N.Y. Acad. Sci.* 936: 580-593 (2001).

Alterations in polypeptide post-translational modifications, as well as changes in polypeptide cleavage and protein-protein interactions, may be determined by any method known in the art. For instance, alterations in phosphorylation may be determined by using anti-phosphoserine, anti-phosphothreonine or anti-phosphotyrosine antibodies or by amino acid analysis. Glycosylation alterations may be determined using antibodies specific for different sugar residues, by carbohydrate sequencing, or by alterations in the size of the glycoprotein, which can be determined by, e.g., SDS polyacrylamide gel electrophoresis (PAGE). Other alterations of post-translational modifications, such as prenylation, racemization, methylation, acetylation and arginylation, may be determined by chemical analysis, protein sequencing, amino acid analysis, or by using antibodies specific for the particular post-translational modifications. Changes in protein-protein interactions and in polypeptide cleavage may be analyzed by any method known in the art including, without limitation, non-denaturing PAGE (for non-covalent protein-protein interactions), SDS

PAGE (for covalent protein-protein interactions and protein cleavage), chemical cleavage, protein sequencing or immunoassays.

In another embodiment, the invention provides polypeptides that have been post-translationally modified. In one embodiment, polypeptides may be modified
5 enzymatically or chemically, by addition or removal of a post-translational modification. For example, a polypeptide may be glycosylated or deglycosylated enzymatically. Similarly, polypeptides may be phosphorylated using a purified kinase, such as a MAP kinase (e.g, p38, ERK, or JNK) or a tyrosine kinase (e.g., Src or erbB2). A polypeptide may also be modified through synthetic chemistry. Alternatively, one may isolate the
10 polypeptide of interest from a cell or tissue that expresses the polypeptide with the desired post-translational modification. In another embodiment, a nucleic acid molecule encoding the polypeptide of interest is introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide in the desired fashion. If the polypeptide does not contain a motif for a desired post-translational modification, one may
15 alter the post-translational modification by mutating the nucleic acid sequence of a nucleic acid molecule encoding the polypeptide so that it contains a site for the desired post-translational modification. Amino acid sequences that may be post-translationally modified are known in the art. See, e.g., the programs described above on the website www.expasy.org. The nucleic acid molecule may also be introduced into a host cell that is
20 capable of post-translationally modifying the encoded polypeptide. Similarly, one may delete sites that are post-translationally modified by either mutating the nucleic acid sequence so that the encoded polypeptide does not contain the post-translational modification motif, or by introducing the native nucleic acid molecule into a host cell that is not capable of post-translationally modifying the encoded polypeptide.

25 It will be appreciated, as is well known and as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslation events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular, branched and branched
30 circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl group in a polypeptide, or both, by a

covalent modification, is common in naturally occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention, as well. For instance, the amino terminal residue of polypeptides made in *E. coli*, prior to proteolytic processing, almost invariably will be N-formylmethionine.

5 Useful post-synthetic (and post-translational) modifications include conjugation to detectable labels, such as fluorophores. A wide variety of amine-reactive and thiol-reactive fluorophore derivatives have been synthesized that react under nondenaturing conditions with N-terminal amino groups and epsilon amino groups of lysine residues, on the one hand, and with free thiol groups of cysteine residues, on the other.

10 Kits are available commercially that permit conjugation of proteins to a variety of amine-reactive or thiol-reactive fluorophores: Molecular Probes, Inc. (Eugene, OR, USA), *e.g.*, offers kits for conjugating proteins to Alexa Fluor 350, Alexa Fluor 430, Fluorescein-EX, Alexa Fluor 488, Oregon Green 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, and Texas Red-X.

15 A wide variety of other amine-reactive and thiol-reactive fluorophores are available commercially (Molecular Probes, Inc., Eugene, OR, USA), including Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503,
20 BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red
25 (available from Molecular Probes, Inc., Eugene, OR, USA).

 The polypeptides of the present invention can also be conjugated to fluorophores, other proteins, and other macromolecules, using bifunctional linking reagents. Common homobifunctional reagents include, *e.g.*, APG, AEDP, BASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DFDNB, DMA, DMP, DMS, DPDPB,
30 DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS, Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS (all available from Pierce, Rockford, IL, USA); common heterobifunctional cross-linkers include ABH, AMAS, ANB-NOS, APDP, ASBA, BMPA, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMUH, GMBS,

LC-SMCC, LC-SPDP, MBS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED, SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC, SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS, Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS (all available
 5 Pierce, Rockford, IL, USA).

Polypeptides of the present invention, including full length polypeptides, fragments and fusion proteins, can be conjugated, using such cross-linking reagents, to fluorophores that are not amine- or thiol-reactive. Other labels that usefully can be
 10 conjugated to polypeptides of the present invention include radioactive labels, echosonographic contrast reagents, and MRI contrast agents.

Polypeptides of the present invention, including full length polypeptide, fragments and fusion proteins, can also usefully be conjugated using cross-linking agents to carrier proteins, such as KLH, bovine thyroglobulin, and even bovine serum albumin (BSA), to
 15 increase immunogenicity for raising anti-OSP antibodies.

Polypeptides of the present invention, including full length polypeptide, fragments and fusion proteins, can also usefully be conjugated to polyethylene glycol (PEG); PEGylation increases the serum half life of proteins administered intravenously for replacement therapy. Delgado *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.* 9(3-4): 249-304
 20 (1992); Scott *et al.*, *Curr. Pharm. Des.* 4(6): 423-38 (1998); DeSantis *et al.*, *Curr. Opin. Biotechnol.* 10(4): 324-30 (1999). PEG monomers can be attached to the protein directly or through a linker, with PEGylation using PEG monomers activated with tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) permitting direct attachment under mild conditions.

Polypeptides of the present invention are also inclusive of analogs of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred embodiment, this polypeptide is a OSP. In a more preferred embodiment, this polypeptide is derived from a polypeptide having part or all of the amino acid sequence of SEQ ID NO: 249-396. Also preferred is an analog polypeptide comprising one or more
 25 substitutions of non-natural amino acids or non-native inter-residue bonds compared to the naturally occurring polypeptide. In one embodiment, the analog is structurally similar to a OSP, but one or more peptide linkages is replaced by a linkage selected from the group consisting of --CH₂NH--, --CH₂S--, --CH₂-CH₂--,
 30 --CH=CH--(cis and trans), --COCH₂--,

--CH(OH)CH₂-- and --CH₂SO--. In another embodiment, the analog comprises substitution of one or more amino acids of a OSP with a D-amino acid of the same type or other non-natural amino acid in order to generate more stable peptides. D-amino acids can readily be incorporated during chemical peptide synthesis: peptides assembled from

5 D-amino acids are more resistant to proteolytic attack; incorporation of D-amino acids can also be used to confer specific three-dimensional conformations on the peptide. Other amino acid analogues commonly added during chemical synthesis include ornithine, norleucine, phosphorylated amino acids (typically phosphoserine, phosphothreonine, phosphotyrosine), L-malonyltyrosine, a non-hydrolyzable analog of phosphotyrosine (*see*,

10 *e.g.*, Kole *et al.*, *Biochem. Biophys. Res. Com.* 209: 817-821 (1995)), and various halogenated phenylalanine derivatives.

Non-natural amino acids can be incorporated during solid phase chemical synthesis or by recombinant techniques, although the former is typically more common. Solid phase chemical synthesis of peptides is well established in the art. Procedures are

15 described, *inter alia*, in Chan *et al.* (eds.), Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series), Oxford Univ. Press (March 2000); Jones, Amino Acid and Peptide Synthesis (Oxford Chemistry Primers, No 7), Oxford Univ. Press (1992); and Bodanszky, Principles of Peptide Synthesis (Springer Laboratory), Springer Verlag (1993).

20 Amino acid analogues having detectable labels are also usefully incorporated during synthesis to provide derivatives and analogs. Biotin, for example can be added using biotinoyl--(9-fluorenylmethoxycarbonyl)-L-lysine (Fmoc biocytin) (Molecular Probes, Eugene, OR, USA). Biotin can also be added enzymatically by incorporation into a fusion protein of a *E. coli* BirA substrate peptide. The Fmoc and *t*BOC derivatives of

25 dabcyL-L-lysine (Molecular Probes, Inc., Eugene, OR, USA) can be used to incorporate the dabcyL chromophore at selected sites in the peptide sequence during synthesis. The aminonaphthalene derivative EDANS, the most common fluorophore for pairing with the dabcyL quencher in fluorescence resonance energy transfer (FRET) systems, can be introduced during automated synthesis of peptides by using EDANS--Fmoc-L-glutamic

30 acid or the corresponding *t*BOC derivative (both from Molecular Probes, Inc., Eugene, OR, USA). Tetramethylrhodamine fluorophores can be incorporated during automated Fmoc synthesis of peptides using (Fmoc)--TMR-L-lysine (Molecular Probes, Inc. Eugene, OR, USA).

Other useful amino acid analogues that can be incorporated during chemical synthesis include aspartic acid, glutamic acid, lysine, and tyrosine analogues having allyl side-chain protection (Applied Biosystems, Inc., Foster City, CA, USA); the allyl side chain permits synthesis of cyclic, branched-chain, sulfonated, glycosylated, and phosphorylated peptides.

A large number of other Fmoc-protected non-natural amino acid analogues capable of incorporation during chemical synthesis are available commercially, including, *e.g.*, Fmoc-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, Fmoc-3-endo-aminobicyclo[2.2.1]heptane-2-endo-carboxylic acid, Fmoc-3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid, Fmoc-3-endo-amino-bicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid, Fmoc-3-exo-amino-bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid, Fmoc-cis-2-amino-1-cyclohexanecarboxylic acid, Fmoc-trans-2-amino-1-cyclohexanecarboxylic acid, Fmoc-1-amino-1-cyclopentanecarboxylic acid, Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid, Fmoc-1-amino-1-cyclopropanecarboxylic acid, Fmoc-D-2-amino-4-(ethylthio)butyric acid, Fmoc-L-2-amino-4-(ethylthio)butyric acid, Fmoc-L-buthionine, Fmoc-S-methyl-L-Cysteine, Fmoc-2-aminobenzoic acid (anthranillic acid), Fmoc-3-aminobenzoic acid, Fmoc-4-aminobenzoic acid, Fmoc-2-aminobenzophenone-2'-carboxylic acid, Fmoc-N-(4-aminobenzoyl)- β -alanine, Fmoc-2-amino-4,5-dimethoxybenzoic acid, Fmoc-4-aminohippuric acid, Fmoc-2-amino-3-hydroxybenzoic acid, Fmoc-2-amino-5-hydroxybenzoic acid, Fmoc-3-amino-4-hydroxybenzoic acid, Fmoc-4-amino-3-hydroxybenzoic acid, Fmoc-4-amino-2-hydroxybenzoic acid, Fmoc-5-amino-2-hydroxybenzoic acid, Fmoc-2-amino-3-methoxybenzoic acid, Fmoc-4-amino-3-methoxybenzoic acid, Fmoc-2-amino-3-methylbenzoic acid, Fmoc-2-amino-5-methylbenzoic acid, Fmoc-2-amino-6-methylbenzoic acid, Fmoc-3-amino-2-methylbenzoic acid, Fmoc-3-amino-4-methylbenzoic acid, Fmoc-4-amino-3-methylbenzoic acid, Fmoc-3-amino-2-naphtoic acid, Fmoc-D,L-3-amino-3-phenylpropionic acid, Fmoc-L-Methyldopa, Fmoc-2-amino-4,6-dimethyl-3-pyridinecarboxylic acid, Fmoc-D,L-amino-2-thiophenacetic acid, Fmoc-4-(carboxymethyl)piperazine, Fmoc-4-carboxypiperazine, Fmoc-4-(carboxymethyl)homopiperazine, Fmoc-4-phenyl-4-piperidinecarboxylic acid, Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, Fmoc-L-thiazolidine-4-carboxylic acid, all available from The Peptide Laboratory (Richmond, CA, USA).

Non-natural residues can also be added biosynthetically by engineering a suppressor tRNA, typically one that recognizes the UAG stop codon, by chemical aminoacylation with the desired unnatural amino acid. Conventional site-directed mutagenesis is used to introduce the chosen stop codon UAG at the site of interest in the protein gene. When the acylated suppressor tRNA and the mutant gene are combined in an *in vitro* transcription/translation system, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing that amino acid at the specified position. Liu *et al.*, *Proc. Natl Acad. Sci. USA* 96(9): 4780-5 (1999); Wang *et al.*, *Science* 292(5516): 498-500 (2001).

10 *Fusion Proteins*

Another aspect of the present invention relates to the fusion of a polypeptide of the present invention to heterologous polypeptides. In a preferred embodiment, the polypeptide of the present invention is a OSP. In a more preferred embodiment, the polypeptide of the present invention that is fused to a heterologous polypeptide comprises part or all of the amino acid sequence of SEQ ID NO: 249-396, or is a mutein, homologous polypeptide, analog or derivative thereof. In an even more preferred embodiment, the fusion protein is encoded by a nucleic acid molecule comprising all or part of the nucleic acid sequence of SEQ ID NO: 1-248, or comprises all or part of a nucleic acid sequence that selectively hybridizes or is homologous to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-248.

The fusion proteins of the present invention will include at least one fragment of a polypeptide of the present invention, which fragment is at least 6, typically at least 8, often at least 15, and usefully at least 16, 17, 18, 19, or 20 amino acids long. The fragment of the polypeptide of the present to be included in the fusion can usefully be at least 25 amino acids long, at least 50 amino acids long, and can be at least 75, 100, or even 150 amino acids long. Fusions that include the entirety of a polypeptide of the present invention have particular utility.

The heterologous polypeptide included within the fusion protein of the present invention is at least 6 amino acids in length, often at least 8 amino acids in length, and preferably at least 15, 20, or 25 amino acids in length. Fusions that include larger polypeptides, such as the IgG Fc region, and even entire proteins (such as GFP chromophore-containing proteins) are particularly useful.

As described above in the description of vectors and expression vectors of the present invention, which discussion is incorporated here by reference in its entirety, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those designed to facilitate purification and/or visualization of recombinantly-expressed proteins. *See, e.g.,* Ausubel, Chapter 16, (1992), *supra*. Although purification tags can also be incorporated into fusions that are chemically synthesized, chemical synthesis typically provides sufficient purity that further purification by HPLC suffices; however, visualization tags as above described retain their utility even when the protein is produced by chemical synthesis, and when so included render the fusion proteins of the present invention useful as directly detectable markers of the presence of a polypeptide of the invention.

As also discussed above, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those that facilitate secretion of recombinantly expressed proteins into the periplasmic space or extracellular milieu for prokaryotic hosts or into the culture medium for eukaryotic cells through incorporation of secretion signals and/or leader sequences. For example, a His⁶ tagged protein can be purified on a Ni affinity column and a GST fusion protein can be purified on a glutathione affinity column. Similarly, a fusion protein comprising the Fc domain of IgG can be purified on a Protein A or Protein G column and a fusion protein comprising an epitope tag such as myc can be purified using an immunoaffinity column containing an anti-c-myc antibody. It is preferable that the epitope tag be separated from the protein encoded by the essential gene by an enzymatic cleavage site that can be cleaved after purification. See also the discussion of nucleic acid molecules encoding fusion proteins that may be expressed on the surface of a cell.

Other useful fusion proteins of the present invention include those that permit use of the polypeptide of the present invention as bait in a yeast two-hybrid system. *See* Bartel *et al.* (eds.), The Yeast Two-Hybrid System, Oxford University Press (1997); Zhu *et al.*, Yeast Hybrid Technologies, Eaton Publishing (2000); Fields *et al.*, *Trends Genet.* 10(8): 286-92 (1994); Mendelsohn *et al.*, *Curr. Opin. Biotechnol.* 5(5): 482-6 (1994); Luban *et al.*, *Curr. Opin. Biotechnol.* 6(1): 59-64 (1995); Allen *et al.*, *Trends Biochem. Sci.* 20(12): 511-6 (1995); Drees, *Curr. Opin. Chem. Biol.* 3(1): 64-70 (1999); Topcu *et al.*, *Pharm. Res.* 17(9): 1049-55 (2000); Fashena *et al.*, *Gene* 250(1-2): 1-14 (2000); Colas *et al.*, *Nature* 380, 548-550 (1996); Norman, T. *et al.*, *Science* 285, 591-595 (1999);

Fabrizio *et al.*, *Oncogene* 18, 4357-4363 (1999); Xu *et al.*, *Proc Natl Acad Sci U S A*. 94, 12473-12478 (1997); Yang, *et al.*, *Nuc. Acids Res.* 23, 1152-1156 (1995); Kolonin *et al.*, *Proc Natl Acad Sci U S A* 95, 14266-14271 (1998); Cohen *et al.*, *Proc Natl Acad Sci U S A* 95, 14272-14277 (1998); Uetz, *et al.* *Nature* 403, 623-627(2000); Ito, *et al.*, *Proc Natl Acad Sci U S A* 98, 4569-4574 (2001). Typically, such fusion is to either *E. coli* LexA or yeast GAL4 DNA binding domains. Related bait plasmids are available that express the bait fused to a nuclear localization signal.

Other useful fusion proteins include those that permit display of the encoded polypeptide on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as green fluorescent protein (GFP), and fusions to the IgG Fc region, as described above.

The polypeptides of the present invention can also usefully be fused to protein toxins, such as *Pseudomonas* exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, ricin, in order to effect ablation of cells that bind or take up the proteins of the present invention.

Fusion partners include, *inter alia*, myc, hemagglutinin (HA), GST, immunoglobulins, β -galactosidase, biotin trpE, protein A, β -lactamase, α -amylase, maltose binding protein, alcohol dehydrogenase, polyhistidine (for example, six histidine at the amino and/or carboxyl terminus of the polypeptide), lacZ, green fluorescent protein (GFP), yeast α mating factor, GAL4 transcription activation or DNA binding domain, luciferase, and serum proteins such as ovalbumin, albumin and the constant domain of IgG. See, e.g., Ausubel (1992), *supra* and Ausubel (1999), *supra*. Fusion proteins may also contain sites for specific enzymatic cleavage, such as a site that is recognized by enzymes such as Factor XIII, trypsin, pepsin, or any other enzyme known in the art. Fusion proteins will typically be made by either recombinant nucleic acid methods, as described above, chemically synthesized using techniques well known in the art (e.g., a Merrifield synthesis), or produced by chemical cross-linking.

Another advantage of fusion proteins is that the epitope tag can be used to bind the fusion protein to a plate or column through an affinity linkage for screening binding proteins or other molecules that bind to the OSP.

As further described below, the polypeptides of the present invention can readily be used as specific immunogens to raise antibodies that specifically recognize polypeptides of the present invention including OSPs and their allelic variants and

homologues. The antibodies, in turn, can be used, *inter alia*, specifically to assay for the polypeptides of the present invention, particularly OSPs, *e.g.* by ELISA for detection of protein fluid samples, such as serum, by immunohistochemistry or laser scanning cytometry, for detection of protein in tissue samples, or by flow cytometry, for detection of intracellular protein in cell suspensions, for specific antibody-mediated isolation and/or purification of OSPs, as for example by immunoprecipitation, and for use as specific agonists or antagonists of OSPs.

One may determine whether polypeptides of the present invention including OSPs, muteins, homologous proteins or allelic variants or fusion proteins of the present invention are functional by methods known in the art. For instance, residues that are tolerant of change while retaining function can be identified by altering the polypeptide at known residues using methods known in the art, such as alanine scanning mutagenesis, Cunningham *et al.*, *Science* 244(4908): 1081-5 (1989); transposon linker scanning mutagenesis, Chen *et al.*, *Gene* 263(1-2): 39-48 (2001); combinations of homolog- and alanine-scanning mutagenesis, Jin *et al.*, *J. Mol. Biol.* 226(3): 851-65 (1992); combinatorial alanine scanning, Weiss *et al.*, *Proc. Natl. Acad. Sci USA* 97(16): 8950-4 (2000), followed by functional assay. Transposon linker scanning kits are available commercially (New England Biolabs, Beverly, MA, USA, catalog. no. E7-102S; EZ::TN™ In-Frame Linker Insertion Kit, catalogue no. EZI04KN, (Epicentre Technologies Corporation, Madison, WI, USA).

Purification of the polypeptides or fusion proteins of the present invention is well known and within the skill of one having ordinary skill in the art. *See, e.g.*, Scopes, Protein Purification, 2d ed. (1987). Purification of recombinantly expressed polypeptides is described above. Purification of chemically-synthesized peptides can readily be effected, *e.g.*, by HPLC.

Accordingly, it is an aspect of the present invention to provide the isolated polypeptides or fusion proteins of the present invention in pure or substantially pure form in the presence or absence of a stabilizing agent. Stabilizing agents include both proteinaceous and non-proteinaceous material and are well known in the art. Stabilizing agents, such as albumin and polyethylene glycol (PEG) are known and are commercially available.

Although high levels of purity are preferred when the isolated polypeptide or fusion protein of the present invention are used as therapeutic agents, such as in vaccines

and replacement therapy, the isolated polypeptides of the present invention are also useful at lower purity. For example, partially purified polypeptides of the present invention can be used as immunogens to raise antibodies in laboratory animals.

5 In a preferred embodiment, the purified and substantially purified polypeptides of the present invention are in compositions that lack detectable ampholytes, acrylamide monomers, bis-acrylamide monomers, and polyacrylamide.

The polypeptides or fusion proteins of the present invention can usefully be attached to a substrate. The substrate can be porous or solid, planar or non-planar; the bond can be covalent or noncovalent. For example, the peptides of the invention may be
10 stabilized by covalent linkage to albumin. See, U.S. Patent No. 5,876,969, the contents of which are hereby incorporated in its entirety.

For example, the polypeptides or fusion proteins of the present invention can usefully be bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose, polyvinylidene fluoride (PVDF), or cationically derivatized, hydrophilic
15 PVDF; so bound, the polypeptides or fusion proteins of the present invention can be used to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized polypeptide or fusion protein of the present invention.

As another example, the polypeptides or fusion proteins of the present invention can usefully be bound to a substantially nonporous substrate, such as plastic, to detect and
20 quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention. Such plastics include polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof; when the assay is performed in a standard microtiter
25 dish, the plastic is typically polystyrene.

The polypeptides and fusion proteins of the present invention can also be attached to a substrate suitable for use as a surface enhanced laser desorption ionization source; so attached, the polypeptide or fusion protein of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the
30 surface-bound polypeptide or fusion protein to indicate biologic interaction there between. The polypeptides or fusion proteins of the present invention can also be attached to a substrate suitable for use in surface plasmon resonance detection; so attached, the polypeptide or fusion protein of the present invention is useful for binding and then

detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound polypeptide or fusion protein to indicate biological interaction there between.

Alternative Transcripts

In another aspect, the present invention provides splice variants of genes and
5 proteins encoded thereby. The identification of a novel splice variant which encodes an amino acid sequence with a novel region can be targeted for the generation of reagents for use in detection and/or treatment of cancer. The novel amino acid sequence may lead to a unique protein structure, protein subcellular localization, biochemical processing or function of the splice variant. This information can be used to directly or indirectly
10 facilitate the generation of additional or novel therapeutics or diagnostics. The nucleotide sequence in this novel splice variant can be used as a nucleic acid probe for the diagnosis and/or treatment of cancer.

Specifically, the newly identified sequences may enable the production of new antibodies or compounds directed against the novel region for use as a therapeutic or
15 diagnostic. Alternatively, the newly identified sequences may alter the biochemical or biological properties of the encoded protein in such a way as to enable the generation of improved or different therapeutics targeting this protein.

Antibodies

In another aspect, the invention provides antibodies, including fragments and
20 derivatives thereof, that bind specifically to polypeptides encoded by the nucleic acid molecules of the invention. In a preferred embodiment, the antibodies are specific for a polypeptide that is a OSP, or a fragment, mutein, derivative, analog or fusion protein thereof. In a more preferred embodiment, the antibodies are specific for a polypeptide that comprises SEQ ID NO: 249-396, or a fragment, mutein, derivative, analog or fusion
25 protein thereof.

The antibodies of the present invention can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of such proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, as, *e.g.*, by solubilization in SDS. New epitopes may be also
30 due to a difference in post translational modifications (PTMs) in disease versus normal tissue. For example, a particular site on a OSP may be glycosylated in cancerous cells, but not glycosylated in normal cells or vis versa. In addition, alternative splice forms of a

OSP may be indicative of cancer. Differential degradation of the C or N-terminus of a OSP may also be a marker or target for anticancer therapy. For example, an OSP may be N-terminal degraded in cancer cells exposing new epitopes to which antibodies may selectively bind for diagnostic or therapeutic uses.

5 As is well known in the art, the degree to which an antibody can discriminate as among molecular species in a mixture will depend, in part, upon the conformational relatedness of the species in the mixture; typically, the antibodies of the present invention will discriminate over adventitious binding to non-OSP polypeptides by at least two-fold, more typically by at least 5-fold, typically by more than 10-fold, 25-fold, 50-fold, 75-fold, 10 and often by more than 100-fold, and on occasion by more than 500-fold or 1000-fold. When used to detect the proteins or protein fragments of the present invention, the antibody of the present invention is sufficiently specific when it can be used to determine the presence of the polypeptide of the present invention in samples derived from human ovarian.

15 Typically, the affinity or avidity of an antibody (or antibody multimer, as in the case of an IgM pentamer) of the present invention for a protein or protein fragment of the present invention will be at least about 1×10^{-6} molar (M), typically at least about 5×10^{-7} M, 1×10^{-7} M, with affinities and avidities of at least 1×10^{-8} M, 5×10^{-9} M, 1×10^{-10} M and up to 1×10^{-13} M proving especially useful.

20 The antibodies of the present invention can be naturally occurring forms, such as IgG, IgM, IgD, IgE, IgY, and IgA, from any avian, reptilian, or mammalian species.

 Human antibodies can, but will infrequently, be drawn directly from human donors or human cells. In such case, antibodies to the polypeptides of the present invention will typically have resulted from fortuitous immunization, such as autoimmune immunization, 25 with the polypeptide of the present invention. Such antibodies will typically, but will not invariably, be polyclonal. In addition, individual polyclonal antibodies may be isolated and cloned to generate monoclonals.

 Human antibodies are more frequently obtained using transgenic animals that express human immunoglobulin genes, which transgenic animals can be affirmatively 30 immunized with the protein immunogen of the present invention. Human Ig-transgenic mice capable of producing human antibodies and methods of producing human antibodies therefrom upon specific immunization are described, *inter alia*, in U.S. Patent Nos. 6,162,963; 6,150,584; 6,114,598; 6,075,181; 5,939,598; 5,877,397; 5,874,299; 5,814,318;

5,789,650; 5,770,429; 5,661,016; 5,633,425; 5,625,126; 5,569,825; 5,545,807; 5,545,806, and 5,591,669, the disclosures of which are incorporated herein by reference in their entireties. Such antibodies are typically monoclonal, and are typically produced using techniques developed for production of murine antibodies.

5 Human antibodies are particularly useful, and often preferred, when the antibodies of the present invention are to be administered to human beings as *in vivo* diagnostic or therapeutic agents, since recipient immune response to the administered antibody will often be substantially less than that occasioned by administration of an antibody derived from another species, such as mouse.

10 IgG, IgM, IgD, IgE, IgY, and IgA antibodies of the present invention are also usefully obtained from other species, including mammals such as rodents (typically mouse, but also rat, guinea pig, and hamster), lagomorphs (typically rabbits), and also larger mammals, such as sheep, goats, cows, and horses; or egg laying birds or reptiles such as chickens or alligators. In such cases, as with the transgenic human-antibody-
15 producing non-human mammals, fortuitous immunization is not required, and the non-human mammal is typically affirmatively immunized, according to standard immunization protocols, with the polypeptide of the present invention. One form of avian antibodies may be generated using techniques described in WO 00/29444, published 25 May 2000.

As discussed above, virtually all fragments of 8 or more contiguous amino acids of
20 a polypeptide of the present invention can be used effectively as immunogens when conjugated to a carrier, typically a protein such as bovine thyroglobulin, keyhole limpet hemocyanin, or bovine serum albumin, conveniently using a bifunctional linker such as those described elsewhere above, which discussion is incorporated by reference here.

Immunogenicity can also be conferred by fusion of the polypeptide of the present
25 invention to other moieties. For example, polypeptides of the present invention can be produced by solid phase synthesis on a branched polylysine core matrix; these multiple antigenic peptides (MAPs) provide high purity, increased avidity, accurate chemical definition and improved safety in vaccine development. Tam *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 5409-5413 (1988); Posnett *et al.*, *J. Biol. Chem.* 263: 1719-1725 (1988).

30 Protocols for immunizing non-human mammals or avian species are well-established in the art. See Harlow *et al.* (eds.), Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998); Coligan *et al.* (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (2001); Zola, Monoclonal Antibodies: Preparation

and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From Background to Bench), Springer Verlag (2000); Gross M, Speck *J.Dtsch. Tierarztl. Wochenschr.* 103: 417-422 (1996). Immunization protocols often include multiple immunizations, either with or without adjuvants such as Freund's complete adjuvant and
5 Freund's incomplete adjuvant, and may include naked DNA immunization (Moss, *Semin. Immunol.* 2: 317-327 (1990).

Antibodies from non-human mammals and avian species can be polyclonal or monoclonal, with polyclonal antibodies having certain advantages in immunohistochemical detection of the polypeptides of the present invention and
10 monoclonal antibodies having advantages in identifying and distinguishing particular epitopes of the polypeptides of the present invention. Antibodies from avian species may have particular advantage in detection of the polypeptides of the present invention, in human serum or tissues (Vikinge et al., *Biosens. Bioelectron.* 13: 1257-1262 (1998). Following immunization, the antibodies of the present invention can be obtained using any
15 art-accepted technique. Such techniques are well known in the art and are described in detail in references such as Coligan, *supra*; Zola, *supra*; Howard *et al.* (eds.), Basic Methods in Antibody Production and Characterization, CRC Press (2000); Harlow, *supra*; Davis (ed.), Monoclonal Antibody Protocols, Vol. 45, Humana Press (1995); Delves (ed.), Antibody Production: Essential Techniques, John Wiley & Son Ltd (1997); and Kenney,
20 Antibody Solution: An Antibody Methods Manual, Chapman & Hall (1997).

Briefly, such techniques include, *inter alia*, production of monoclonal antibodies by hybridomas and expression of antibodies or fragments or derivatives thereof from host cells engineered to express immunoglobulin genes or fragments thereof. These two methods of production are not mutually exclusive: genes encoding antibodies specific for
25 the polypeptides of the present invention can be cloned from hybridomas and thereafter expressed in other host cells. Nor need the two necessarily be performed together: *e.g.*, genes encoding antibodies specific for the polypeptides of the present invention can be cloned directly from B cells known to be specific for the desired protein, as further described in U.S. Patent No. 5,627,052, the disclosure of which is incorporated herein by
30 reference in its entirety, or from antibody-displaying phage.

Recombinant expression in host cells is particularly useful when fragments or derivatives of the antibodies of the present invention are desired.

Host cells for recombinant antibody production of whole antibodies, antibody fragments, or antibody derivatives can be prokaryotic or eukaryotic.

Prokaryotic hosts are particularly useful for producing phage displayed antibodies of the present invention.

5 The technology of phage-displayed antibodies, in which antibody variable region fragments are fused, for example, to the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13, is by now well-established. *See, e.g.,* Sidhu, *Curr. Opin. Biotechnol.* 11(6): 610-6 (2000); Griffiths *et al.*, *Curr. Opin. Biotechnol.* 9(1): 102-8 (1998); Hoogenboom *et al.*, *Immunotechnology*, 4(1): 1-20 (1998);
10 Rader *et al.*, *Current Opinion in Biotechnology* 8: 503-508 (1997); Aujame *et al.*, *Human Antibodies* 8: 155-168 (1997); Hoogenboom, *Trends in Biotechnol.* 15: 62-70 (1997); de Kruif *et al.*, 17: 453-455 (1996); Barbas *et al.*, *Trends in Biotechnol.* 14: 230-234 (1996); Winter *et al.*, *Ann. Rev. Immunol.* 433-455 (1994). Techniques and protocols required to generate, propagate, screen (pan), and use the antibody fragments from such libraries have
15 recently been compiled. *See, e.g.,* Barbas (2001), *supra*; Kay, *supra*; and Abelson, *supra*.

Typically, phage-displayed antibody fragments are scFv fragments or Fab fragments; when desired, full length antibodies can be produced by cloning the variable regions from the displaying phage into a complete antibody and expressing the full length antibody in a further prokaryotic or a eukaryotic host cell. Eukaryotic cells are also useful
20 for expression of the antibodies, antibody fragments, and antibody derivatives of the present invention. For example, antibody fragments of the present invention can be produced in *Pichia pastoris* and in *Saccharomyces cerevisiae*. *See, e.g.,* Takahashi *et al.*, *Biosci. Biotechnol. Biochem.* 64(10): 2138-44 (2000); Freyre *et al.*, *J. Biotechnol.* 76(2-3): 157-63 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 117-20
25 (1999); Pennell *et al.*, *Res. Immunol.* 149(6): 599-603 (1998); Eldin *et al.*, *J. Immunol. Methods.* 201(1): 67-75 (1997); Frenken *et al.*, *Res. Immunol.* 149(6): 589-99 (1998); and Shusta *et al.*, *Nature Biotechnol.* 16(8): 773-7 (1998).

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in insect cells. *See, e.g.,* Li *et al.*, *Protein Expr. Purif.* 21(1): 121-8
30 (2001); Ailor *et al.*, *Biotechnol. Bioeng.* 58(2-3): 196-203 (1998); Hsu *et al.*, *Biotechnol. Prog.* 13(1): 96-104 (1997); Edelman *et al.*, *Immunology* 91(1): 13-9 (1997); and Nesbit *et al.*, *J. Immunol. Methods* 151(1-2): 201-8 (1992).

Antibodies and fragments and derivatives thereof of the present invention can also be produced in plant cells, particularly maize or tobacco, Giddings *et al.*, *Nature Biotechnol.* 18(11): 1151-5 (2000); Gavilondo *et al.*, *Biotechniques* 29(1): 128-38 (2000); Fischer *et al.*, *J. Biol. Regul. Homeost. Agents* 14(2): 83-92 (2000); Fischer *et al.*,
5 *Biotechnol. Appl. Biochem.* 30 (Pt 2): 113-6 (1999); Fischer *et al.*, *Biol. Chem.* 380(7-8): 825-39 (1999); Russell, *Curr. Top. Microbiol. Immunol.* 240: 119-38 (1999); and Ma *et al.*, *Plant Physiol.* 109(2): 341-6 (1995).

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in transgenic, non-human, mammalian milk. See, e.g. Pollock *et al.*,
10 *J. Immunol Methods.* 231: 147-57 (1999); Young *et al.*, *Res. Immunol.* 149: 609-10 (1998); and Limonta *et al.*, *Immunotechnology* 1: 107-13 (1995).

Mammalian cells useful for recombinant expression of antibodies, antibody fragments, and antibody derivatives of the present invention include CHO cells, COS cells, 293 cells, and myeloma cells. Verma *et al.*, *J. Immunol. Methods* 216(1-2):165-81
15 (1998) review and compare bacterial, yeast, insect and mammalian expression systems for expression of antibodies. Antibodies of the present invention can also be prepared by cell free translation, as further described in Merk *et al.*, *J. Biochem. (Tokyo)* 125(2): 328-33 (1999) and Ryabova *et al.*, *Nature Biotechnol.* 15(1): 79-84 (1997), and in the milk of transgenic animals, as further described in Pollock *et al.*, *J. Immunol. Methods* 231(1-2):
20 147-57 (1999).

The invention further provides antibody fragments that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present
25 invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention. Among such useful fragments are Fab, Fab', Fv, F(ab')₂, and single chain Fv (scFv) fragments. Other useful fragments are described in Hudson, *Curr. Opin. Biotechnol.* 9(4): 395-402 (1998).

The present invention also relates to antibody derivatives that bind specifically to
30 one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of

the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention.

Among such useful derivatives are chimeric, primatized, and humanized antibodies; such derivatives are less immunogenic in human beings, and thus are more suitable for *in vivo* administration, than are unmodified antibodies from non-human mammalian species. Another useful method is PEGylation to increase the serum half life of the antibodies.

Chimeric antibodies typically include heavy and/or light chain variable regions (including both CDR and framework residues) of immunoglobulins of one species, typically mouse, fused to constant regions of another species, typically human. *See, e.g., Morrison et al., Proc. Natl. Acad. Sci USA* 81(21): 6851-5 (1984); Sharon *et al., Nature* 309(5966): 364-7 (1984); Takeda *et al., Nature* 314(6010): 452-4 (1985); and U.S. Patent No. 5,807,715 the disclosure of which is incorporated herein by reference in its entirety. Primatized and humanized antibodies typically include heavy and/or light chain CDRs from a murine antibody grafted into a non-human primate or human antibody V region framework, usually further comprising a human constant region, Riechmann *et al., Nature* 332(6162): 323-7 (1988); Co *et al., Nature* 351(6326): 501-2 (1991); and U.S. Patent Nos. 6,054,297; 5,821,337; 5,770,196; 5,766,886; 5,821,123; 5,869,619; 6,180,377; 6,013,256; 5,693,761; and 6,180,370, the disclosures of which are incorporated herein by reference in their entireties. Other useful antibody derivatives of the invention include heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies.

It is contemplated that the nucleic acids encoding the antibodies of the present invention can be operably joined to other nucleic acids forming a recombinant vector for cloning or for expression of the antibodies of the invention. Accordingly, the present invention includes any recombinant vector containing the coding sequences, or part thereof, whether for eukaryotic transduction, transfection or gene therapy. Such vectors may be prepared using conventional molecular biology techniques, known to those with skill in the art, and would comprise DNA encoding sequences for the immunoglobulin V-regions including framework and CDRs or parts thereof, and a suitable promoter either with or without a signal sequence for intracellular transport. Such vectors may be transduced or transfected into eukaryotic cells or used for gene therapy (Marasco *et al., Proc. Natl. Acad. Sci. (USA)* 90: 7889-7893 (1993); Duan *et al., Proc. Natl. Acad. Sci.*

(USA) 91: 5075-5079 (1994), by conventional techniques, known to those with skill in the art.

The antibodies of the present invention, including fragments and derivatives thereof, can usefully be labeled. It is, therefore, another aspect of the present invention to provide labeled antibodies that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention. The choice of label depends, in part, upon the desired use.

For example, when the antibodies of the present invention are used for immunohistochemical staining of tissue samples, the label can usefully be an enzyme that catalyzes production and local deposition of a detectable product. Enzymes typically conjugated to antibodies to permit their immunohistochemical visualization are well known, and include alkaline phosphatase, β -galactosidase, glucose oxidase, horseradish peroxidase (HRP), and urease. Typical substrates for production and deposition of visually detectable products include o-nitrophenyl-beta-D-galactopyranoside (ONPG); o-phenylenediamine dihydrochloride (OPD); p-nitrophenyl phosphate (PNPP); p-nitrophenyl-beta-D-galactopyranoside (PNPG); 3',3'-diaminobenzidine (DAB); 3-amino-9-ethylcarbazole (AEC); 4-chloro-1-naphthol (CN); 5-bromo-4-chloro-3-indolyl-phosphate (BCIP); ABTS®; BluoGal; iodonitrotetrazolium (INT); nitroblue tetrazolium chloride (NBT); phenazine methosulfate (PMS); phenolphthalein monophosphate (PMP); tetramethyl benzidine (TMB); tetranitroblue tetrazolium (TNBT); X-Gal; X-Gluc; and X-Glucoside.

Other substrates can be used to produce products for local deposition that are luminescent. For example, in the presence of hydrogen peroxide (H_2O_2), horseradish peroxidase (HRP) can catalyze the oxidation of cyclic diacylhydrazides, such as luminol. Immediately following the oxidation, the luminol is in an excited state (intermediate reaction product), which decays to the ground state by emitting light. Strong enhancement of the light emission is produced by enhancers, such as phenolic compounds. Advantages include high sensitivity, high resolution, and rapid detection without radioactivity and requiring only small amounts of antibody. See, e.g., Thorpe *et al.*, *Methods Enzymol.* 133: 331-53 (1986); Kricka *et al.*, *J. Immunoassay* 17(1): 67-83 (1996); and Lundqvist *et al.*, *J.*

Biolumin. Chemilumin. 10(6): 353-9 (1995). Kits for such enhanced chemiluminescent detection (ECL) are available commercially. The antibodies can also be labeled using colloidal gold.

As another example, when the antibodies of the present invention are used, *e.g.*, for flow cytometric detection, for scanning laser cytometric detection, or for fluorescent immunoassay, they can usefully be labeled with fluorophores. There are a wide variety of fluorophore labels that can usefully be attached to the antibodies of the present invention. For flow cytometric applications, both for extracellular detection and for intracellular detection, common useful fluorophores can be fluorescein isothiocyanate (FITC),
 5 allophycocyanin (APC), R-phycoerythrin (PE), peridinin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5, fluorescence resonance energy transfer fluorophores such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7.

Other fluorophores include, *inter alia*, Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa
 15 Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B,
 20 Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA), and Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, all of which are also useful for fluorescently labeling the antibodies of the present invention. For secondary detection using labeled avidin, streptavidin, captavidin or neutravidin, the
 25 antibodies of the present invention can usefully be labeled with biotin.

When the antibodies of the present invention are used, *e.g.*, for western blotting applications, they can usefully be labeled with radioisotopes, such as ^{33}P , ^{32}P , ^{35}S , ^3H , and ^{125}I . As another example, when the antibodies of the present invention are used for radioimmunotherapy, the label can usefully be ^{228}Th , ^{227}Ac , ^{225}Ac , ^{223}Ra , ^{213}Bi , ^{212}Pb ,
 30 ^{212}Bi , ^{211}At , ^{203}Pb , ^{194}Os , ^{188}Re , ^{186}Re , ^{153}Sm , ^{149}Tb , ^{131}I , ^{125}I , ^{111}In , ^{105}Rh , $^{99\text{m}}\text{Tc}$, ^{97}Ru , ^{90}Y , ^{90}Sr , ^{88}Y , ^{72}Se , ^{67}Cu , or ^{47}Sc .

As another example, when the antibodies of the present invention are to be used for *in vivo* diagnostic use, they can be rendered detectable by conjugation to MRI contrast

agents, such as gadolinium diethylenetriaminepentaacetic acid (DTPA), Lauffer *et al.*, *Radiology* 207(2): 529-38 (1998), or by radioisotopic labeling.

As would be understood, use of the labels described above is not restricted to the application as for which they were mentioned.

5 The antibodies of the present invention, including fragments and derivatives thereof, can also be conjugated to toxins, in order to target the toxin's ablative action to cells that display and/or express the polypeptides of the present invention. Commonly, the antibody in such immunotoxins is conjugated to Pseudomonas exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin. See Hall (ed.), Immunotoxin
10 Methods and Protocols (Methods in Molecular Biology, vol. 166), Humana Press (2000); and Frankel *et al.* (eds.), Clinical Applications of Immunotoxins, Springer-Verlag (1998).

The antibodies of the present invention can usefully be attached to a substrate, and it is, therefore, another aspect of the invention to provide antibodies that bind specifically to one or more of the polypeptides of the present invention, to one or more of the
15 polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, attached to a substrate. Substrates can be porous or nonporous, planar or nonplanar. For example, the antibodies of the present invention
20 can usefully be conjugated to filtration media, such as NHS-activated Sepharose or CNBr-activated Sepharose for purposes of immunoaffinity chromatography. For example, the antibodies of the present invention can usefully be attached to paramagnetic microspheres, typically by biotin-streptavidin interaction, which microsphere can then be used for isolation of cells that express or display the polypeptides of the present invention. As
25 another example, the antibodies of the present invention can usefully be attached to the surface of a microtiter plate for ELISA.

As noted above, the antibodies of the present invention can be produced in prokaryotic and eukaryotic cells. It is, therefore, another aspect of the present invention to provide cells that express the antibodies of the present invention, including hybridoma
30 cells, B cells, plasma cells, and host cells recombinantly modified to express the antibodies of the present invention.

In yet a further aspect, the present invention provides aptamers evolved to bind specifically to one or more of the OSPs of the present invention or to polypeptides encoded by the OSNAs of the invention.

In sum, one of skill in the art, provided with the teachings of this invention, has available a variety of methods which may be used to alter the biological properties of the antibodies of this invention including methods which would increase or decrease the stability or half-life, immunogenicity, toxicity, affinity or yield of a given antibody molecule, or to alter it in any other way that may render it more suitable for a particular application.

10 Transgenic Animals and Cells

In another aspect, the invention provides transgenic cells and non-human organisms comprising nucleic acid molecules of the invention. In a preferred embodiment, the transgenic cells and non-human organisms comprise a nucleic acid molecule encoding a OSP. In a preferred embodiment, the OSP comprises an amino acid sequence selected from SEQ ID NO: 249-396, or a fragment, mutein, homologous protein or allelic variant thereof. In another preferred embodiment, the transgenic cells and non-human organism comprise a OSNA of the invention, preferably a OSNA comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-248, or a part, substantially similar nucleic acid molecule, allelic variant or hybridizing nucleic acid molecule thereof.

In another embodiment, the transgenic cells and non-human organisms have a targeted disruption or replacement of the endogenous orthologue of the human OSG. The transgenic cells can be embryonic stem cells or somatic cells. The transgenic non-human organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric homozygotes. Methods of producing transgenic animals are well known in the art. *See, e.g., Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, 2d ed., Cold Spring Harbor Press (1999); Jackson et al., Mouse Genetics and Transgenics: A Practical Approach, Oxford University Press (2000); and Pinkert, Transgenic Animal Technology: A Laboratory Handbook, Academic Press (1999).*

Any technique known in the art may be used to introduce a nucleic acid molecule of the invention into an animal to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection. (*see, e.g., Paterson*

et al., *Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver *et al.*, *Biotechnology* 11: 1263-1270 (1993); Wright *et al.*, *Biotechnology* 9: 830-834 (1991); and U.S. Patent No. 4,873,191, herein incorporated by reference in its entirety); retrovirus-mediated gene transfer into germ lines, blastocysts or embryos (*see, e.g.*, Van der Putten *et al.*, *Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)); gene targeting in embryonic stem cells (*see, e.g.*, Thompson *et al.*, *Cell* 56: 313-321 (1989)); electroporation of cells or embryos (*see, e.g.*, Lo, 1983, *Mol. Cell. Biol.* 3: 1803-1814 (1983)); introduction using a gene gun (*see, e.g.*, Ulmer *et al.*, *Science* 259: 1745-49 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (*see, e.g.*, Lavitrano *et al.*, *Cell* 57: 717-723 (1989)).

Other techniques include, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (*see, e.g.*, Campbell *et al.*, *Nature* 380: 64-66 (1996); Wilmut *et al.*, *Nature* 385: 810-813 (1997)). The present invention provides for transgenic animals that carry the transgene (*i.e.*, a nucleic acid molecule of the invention) in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.* *e.*, mosaic animals or chimeric animals.

The transgene may be integrated as a single transgene or as multiple copies, such as in concatamers, *e. g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, *e.g.*, the teaching of Lasko *et al. et al.*, *Proc. Natl. Acad. Sci. USA* 89: 6232- 6236 (1992). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (RT-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Methods for creating a transgenic animal with a disruption of a targeted gene are also well known in the art. In general, a vector is designed to comprise some nucleotide sequences homologous to the endogenous targeted gene. The vector is introduced into a cell so that it may integrate, via homologous recombination with chromosomal sequences, into the endogenous gene, thereby disrupting the function of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type. See, e.g., Gu *et al.*, *Science* 265: 103-106 (1994). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. See, e.g., Smithies *et al.*, *Nature* 317: 230-234 (1985); Thomas *et al.*, *Cell* 51: 503-512 (1987); Thompson *et al.*, *Cell* 5: 313-321 (1989).

In one embodiment, a mutant, non-functional nucleic acid molecule of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous nucleic acid sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that

contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene. *See, e.g.,* Thomas, *supra* and Thompson, *supra*. However this approach can be
5 routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to
10 express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient in vivo. Such cells may be obtained from an animal or patient or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells
15 are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures,
20 including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered
25 cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.*, genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or
30 vascular graft. *See, e.g.,* U.S. Patent Nos. 5,399,349 and 5,460,959, each of which is incorporated by reference herein in its entirety.

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the

development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

5 Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

10 Computer Readable Means

A further aspect of the invention is a computer readable means for storing the nucleic acid and amino acid sequences of the instant invention. In a preferred embodiment, the invention provides a computer readable means for storing SEQ ID NO: 249-396 and SEQ ID NO: 1-248 as described herein, as the complete set of sequences or
15 in any combination. The records of the computer readable means can be accessed for reading and display and for interface with a computer system for the application of programs allowing for the location of data upon a query for data meeting certain criteria, the comparison of sequences, the alignment or ordering of sequences meeting a set of criteria, and the like.

20 The nucleic acid and amino acid sequences of the invention are particularly useful as components in databases useful for search analyses as well as in sequence analysis algorithms. As used herein, the terms "nucleic acid sequences of the invention" and "amino acid sequences of the invention" mean any detectable chemical or physical characteristic of a polynucleotide or polypeptide of the invention that is or may be reduced
25 to or stored in a computer readable form. These include, without limitation, chromatographic scan data or peak data, photographic data or scan data therefrom, and mass spectrographic data.

This invention provides computer readable media having stored thereon sequences of the invention. A computer readable medium may comprise one or more of the
30 following: a nucleic acid sequence comprising a sequence of a nucleic acid sequence of the invention; an amino acid sequence comprising an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises

the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of one or more nucleic acid sequences of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of a nucleic acid sequence of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention. The computer readable medium can be any composition of matter used to store information or data, including, for example, commercially available floppy disks, tapes, hard drives, compact disks, and video disks.

Also provided by the invention are methods for the analysis of character sequences, particularly genetic sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and similarity analysis, RNA structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, and sequencing chromatogram peak analysis.

A computer-based method is provided for performing nucleic acid sequence identity or similarity identification. This method comprises the steps of providing a nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and comparing said nucleic acid sequence to at least one nucleic acid or amino acid sequence to identify sequence identity or similarity.

A computer-based method is also provided for performing amino acid homology identification, said method comprising the steps of: providing an amino acid sequence comprising the sequence of an amino acid of the invention in a computer readable medium; and comparing said amino acid sequence to at least one nucleic acid or an amino acid sequence to identify homology.

A computer-based method is still further provided for assembly of overlapping nucleic acid sequences into a single nucleic acid sequence, said method comprising the steps of: providing a first nucleic acid sequence comprising the sequence of a nucleic acid

of the invention in a computer readable medium; and screening for at least one overlapping region between said first nucleic acid sequence and a second nucleic acid sequence. In addition, the invention includes a method of using patterns of expression associated with either the nucleic acids or proteins in a computer-based method to
5 diagnose disease.

Diagnostic Methods for ovarian Cancer

The present invention also relates to quantitative and qualitative diagnostic assays and methods for detecting, diagnosing, monitoring, staging and predicting cancers by comparing expression of a OSNA or a OSP in a human patient that has or may have
10 ovarian cancer, or who is at risk of developing ovarian cancer, with the expression of a OSNA or a OSP in a normal human control. For purposes of the present invention, “expression of a OSNA” or “OSNA expression” means the quantity of OSNA mRNA that can be measured by any method known in the art or the level of transcription that can be measured by any method known in the art in a cell, tissue, organ or whole patient.
15 Similarly, the term “expression of a OSP” or “OSP expression” means the amount of OSP that can be measured by any method known in the art or the level of translation of a OSNA that can be measured by any method known in the art.

The present invention provides methods for diagnosing ovarian cancer in a patient, by analyzing for changes in levels of OSNA or OSP in cells, tissues, organs or bodily
20 fluids compared with levels of OSNA or OSP in cells, tissues, organs or bodily fluids of preferably the same type from a normal human control, wherein an increase, or decrease in certain cases, in levels of a OSNA or OSP in the patient versus the normal human control is associated with the presence of ovarian cancer or with a predilection to the disease. In another preferred embodiment, the present invention provides methods for diagnosing
25 ovarian cancer in a patient by analyzing changes in the structure of the mRNA of a OSG compared to the mRNA from a normal control. These changes include, without limitation, aberrant splicing, alterations in polyadenylation and/or alterations in 5' nucleotide capping. In yet another preferred embodiment, the present invention provides methods for diagnosing ovarian cancer in a patient by analyzing changes in a OSP compared to a OSP
30 from a normal patient. These changes include, *e.g.*, alterations, including post translational modifications such as glycosylation and/or phosphorylation of the OSP or changes in the subcellular OSP localization.

For purposes of the present invention, diagnosing means that OSNA or OSP levels are used to determine the presence or absence of disease in a patient. As will be understood by those of skill in the art, measurement of other diagnostic parameters may be required for definitive diagnosis or determination of the appropriate treatment for the disease. The determination may be made by a clinician, a doctor, a testing laboratory, or a patient using an over the counter test. The patient may have symptoms of disease or may be asymptomatic. In addition, the OSNA or OSP levels of the present invention may be used as screening marker to determine whether further tests or biopsies are warranted. In addition, the OSNA or OSP levels may be used to determine the vulnerability or susceptibility to disease.

In a preferred embodiment, the expression of a OSNA is measured by determining the amount of a mRNA that encodes an amino acid sequence selected from SEQ ID NO: 249-396, a homolog, an allelic variant, or a fragment thereof. In a more preferred embodiment, the OSNA expression that is measured is the level of expression of a OSNA mRNA selected from SEQ ID NO: 1-248, or a hybridizing nucleic acid, homologous nucleic acid or allelic variant thereof, or a part of any of these nucleic acid molecules. OSNA expression may be measured by any method known in the art, such as those described *supra*, including measuring mRNA expression by Northern blot, quantitative or qualitative reverse transcriptase PCR (RT-PCR), microarray, dot or slot blots or *in situ* hybridization. See, e.g., Ausubel (1992), *supra*; Ausubel (1999), *supra*; Sambrook (1989), *supra*; and Sambrook (2001), *supra*. OSNA transcription may be measured by any method known in the art including using a reporter gene hooked up to the promoter of a OSG of interest or doing nuclear run-off assays. Alterations in mRNA structure, e.g., aberrant splicing variants, may be determined by any method known in the art, including RT-PCR followed by sequencing or restriction analysis. As necessary, OSNA expression may be compared to a known control, such as normal ovarian nucleic acid, to detect a change in expression.

In another preferred embodiment, the expression of a OSP is measured by determining the level of a OSP having an amino acid sequence selected from the group consisting of SEQ ID NO: 249-396, a homolog, an allelic variant, or a fragment thereof. Such levels are preferably determined in at least one of cells, tissues, organs and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over- or underexpression

of a OSNA or OSP compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of ovarian cancer. The expression level of a OSP may be determined by any method known in the art, such as those described *supra*. In a preferred embodiment, the OSP expression level may be determined by radioimmunoassays, competitive-binding assays, ELISA, Western blot, FACS, immunohistochemistry, immunoprecipitation, proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel-based approaches such as mass spectrometry or protein interaction profiling. *See, e.g.*, Harlow (1999), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. Alterations in the OSP structure may be determined by any method known in the art, including, *e.g.*, using antibodies that specifically recognize phosphoserine, phosphothreonine or phosphotyrosine residues, two-dimensional polyacrylamide gel electrophoresis (2D PAGE) and/or chemical analysis of amino acid residues of the protein. *Id.*

In a preferred embodiment, a radioimmunoassay (RIA) or an ELISA is used. An antibody specific to a OSP is prepared if one is not already available. In a preferred embodiment, the antibody is a monoclonal antibody. The anti-OSP antibody is bound to a solid support and any free protein binding sites on the solid support are blocked with a protein such as bovine serum albumin. A sample of interest is incubated with the antibody on the solid support under conditions in which the OSP will bind to the anti-OSP antibody. The sample is removed, the solid support is washed to remove unbound material, and an anti-OSP antibody that is linked to a detectable reagent (a radioactive substance for RIA and an enzyme for ELISA) is added to the solid support and incubated under conditions in which binding of the OSP to the labeled antibody will occur. After binding, the unbound labeled antibody is removed by washing. For an ELISA, one or more substrates are added to produce a colored reaction product that is based upon the amount of an OSP in the sample. For an RIA, the solid support is counted for radioactive decay signals by any method known in the art. Quantitative results for both RIA and ELISA typically are obtained by reference to a standard curve.

Other methods to measure OSP levels are known in the art. For instance, a competition assay may be employed wherein an anti-OSP antibody is attached to a solid support and an allocated amount of a labeled OSP and a sample of interest are incubated with the solid support. The amount of labeled OSP attached to the solid support can be correlated to the quantity of a OSP in the sample.

Of the proteomic approaches, 2D PAGE is a well known technique. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by isoelectric point and molecular weight. Typically, polypeptides are first separated by isoelectric point (the first dimension) and then separated by size using an electric current (the second dimension). In general, the second dimension is perpendicular to the first dimension. Because no two proteins with different sequences are identical on the basis of both size and charge, the result of 2D PAGE is a roughly square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

Expression levels of a OSNA can be determined by any method known in the art, including PCR and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASBA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction.

Hybridization to specific DNA molecules (*e.g.*, oligonucleotides) arrayed on a solid support can be used to both detect the expression of and quantitate the level of expression of one or more OSNAs of interest. In this approach, all or a portion of one or more OSNAs is fixed to a substrate. A sample of interest, which may comprise RNA, *e.g.*, total RNA or polyA-selected mRNA, or a complementary DNA (cDNA) copy of the RNA is incubated with the solid support under conditions in which hybridization will occur between the DNA on the solid support and the nucleic acid molecules in the sample of interest. Hybridization between the substrate-bound DNA and the nucleic acid molecules in the sample can be detected and quantitated by several means, including, without limitation, radioactive labeling or fluorescent labeling of the nucleic acid molecule or a secondary molecule designed to detect the hybrid.

The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a patient. Tissue extracts are obtained routinely from tissue biopsy and autopsy

material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. As used herein "blood" includes whole blood, plasma, serum, circulating epithelial cells, constituents, or any derivative of blood.

In addition to detection in bodily fluids, the proteins and nucleic acids of the invention are suitable to detection by cell capture technology. Whole cells may be captured by a variety of methods for example magnetic separation, U.S. Patent Nos. 5,200,084; 5,186,827; 5,108,933; 4,925,788, the disclosures of which are incorporated herein by reference in their entireties. Epithelial cells may be captured using such products as Dynabeads® or CELLection™ (DynaL Biotech, Oslo, Norway). Alternatively, fractions of blood may be captured, e.g., the buffy coat fraction (50mm cells isolated from 5ml of blood) containing epithelial cells. In addition, cancer cells may be captured using the techniques described in WO 00/47998, the disclosure of which is incorporated herein by reference in its entirety. Once the cells are captured or concentrated, the proteins or nucleic acids are detected by the means described in the subject application. Alternatively, nucleic acids may be captured directly from blood samples, see U.S. Patent Nos. 6,156,504, 5,501,963; or WO 01/42504, the disclosures of which are incorporated herein by reference in their entireties.

In a preferred embodiment, the specimen tested for expression of OSNA or OSP includes without limitation ovarian tissue, ovarian cells grown in cell culture, blood, serum, lymph node tissue, and lymphatic fluid. In another preferred embodiment, especially when metastasis of a primary ovarian cancer is known or suspected, specimens include, without limitation, tissues from brain, bone, bone marrow, liver, lungs, colon, and adrenal glands. In general, the tissues may be sampled by biopsy, including, without limitation, needle biopsy, e.g., transthoracic needle aspiration, cervical mediastinoscopy, endoscopic lymph node biopsy, video-assisted thoracoscopy, exploratory thoracotomy, bone marrow biopsy and bone marrow aspiration.

All the methods of the present invention may optionally include determining the expression levels of one or more other cancer markers in addition to determining the expression level of a OSNA or OSP. In many cases, the use of another cancer marker will decrease the likelihood of false positives or false negatives. In one embodiment, the one or more other cancer markers include other OSNA or OSPs as disclosed herein. Other cancer markers useful in the present invention will depend on the cancer being tested and are known to those of skill in the art. In a preferred embodiment, at least one other cancer

marker in addition to a particular OSNA or OSP is measured. In a more preferred embodiment, at least two other additional cancer markers are used. In an even more preferred embodiment, at least three, more preferably at least five, even more preferably at least ten additional cancer markers are used.

5 *Diagnosing*

In one aspect, the invention provides a method for determining the expression levels and/or structural alterations of one or more OSNA and/or OSP in a sample from a patient suspected of having ovarian cancer. In general, the method comprises the steps of obtaining the sample from the patient, determining the expression level or structural
10 alterations of a OSNA and/or OSP and then ascertaining whether the patient has ovarian cancer from the expression level of the OSNA or OSP. In general, if high expression relative to a control of a OSNA or OSP is indicative of ovarian cancer, a diagnostic assay is considered positive if the level of expression of the OSNA or OSP is at least one and a half times higher, and more preferably are at least two times higher, still more preferably
15 five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a OSNA or OSP is indicative of ovarian cancer, a diagnostic assay is considered positive if the level of expression of the OSNA or OSP is at least one and a half times lower, and more preferably are at least two times lower, still
20 more preferably five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

The present invention also provides a method of determining whether ovarian
25 cancer has metastasized in a patient. One may identify whether the ovarian cancer has metastasized by measuring the expression levels and/or structural alterations of one or more OSNAs and/or OSPs in a variety of tissues. The presence of a OSNA or OSP in a certain tissue at levels higher than that of corresponding noncancerous tissue (*e.g.*, the same tissue from another individual) is indicative of metastasis if high level expression of
30 a OSNA or OSP is associated with ovarian cancer. Similarly, the presence of a OSNA or OSP in a tissue at levels lower than that of corresponding noncancerous tissue is indicative of metastasis if low level expression of a OSNA or OSP is associated with ovarian cancer.

Further, the presence of a structurally altered OSNA or OSP that is associated with ovarian cancer is also indicative of metastasis.

In general, if high expression relative to a control of a OSNA or OSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the OSNA or OSP is at least one and a half times higher, and more preferably are at least two times higher, still more preferably five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a OSNA or OSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the OSNA or OSP is at least one and a half times lower, and more preferably are at least two times lower, still more preferably five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control.

Staging

The invention also provides a method of staging ovarian cancer in a human patient. The method comprises identifying a human patient having ovarian cancer and analyzing cells, tissues or bodily fluids from such human patient for expression levels and/or structural alterations of one or more OSNAs or OSPs. First, one or more tumors from a variety of patients are staged according to procedures well known in the art, and the expression levels of one or more OSNAs or OSPs is determined for each stage to obtain a standard expression level for each OSNA and OSP. Then, the OSNA or OSP expression levels of the OSNA or OSP are determined in a biological sample from a patient whose stage of cancer is not known. The OSNA or OSP expression levels from the patient are then compared to the standard expression level. By comparing the expression level of the OSNAs and OSPs from the patient to the standard expression levels, one may determine the stage of the tumor. The same procedure may be followed using structural alterations of a OSNA or OSP to determine the stage of a ovarian cancer.

Monitoring

Further provided is a method of monitoring ovarian cancer in a human patient. One may monitor a human patient to determine whether there has been metastasis and, if there has been, when metastasis began to occur. One may also monitor a human patient to determine whether a preneoplastic lesion has become cancerous. One may also monitor a

human patient to determine whether a therapy, *e.g.*, chemotherapy, radiotherapy or surgery, has decreased or eliminated the ovarian cancer. The monitoring may determine if there has been a reoccurrence and, if so, determine its nature. The method comprises identifying a human patient that one wants to monitor for ovarian cancer, periodically
5 analyzing cells, tissues or bodily fluids from such human patient for expression levels of one or more OSNAs or OSPs, and comparing the OSNA or OSP levels over time to those OSNA or OSP expression levels obtained previously. Patients may also be monitored by measuring one or more structural alterations in a OSNA or OSP that are associated with ovarian cancer.

10 If increased expression of a OSNA or OSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an increase in the expression level of a OSNA or OSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. One having ordinary skill in the art would recognize that if this were the case, then a decreased
15 expression level would be indicative of no metastasis, effective therapy or failure to progress to a neoplastic lesion. If decreased expression of a OSNA or OSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting a decrease in the expression level of a OSNA or OSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous,
20 respectively. In a preferred embodiment, the levels of OSNAs or OSPs are determined from the same cell type, tissue or bodily fluid as prior patient samples. Monitoring a patient for onset of ovarian cancer metastasis is periodic and preferably is done on a quarterly basis, but may be done more or less frequently.

The methods described herein can further be utilized as prognostic assays to
25 identify subjects having or at risk of developing a disease or disorder associated with increased or decreased expression levels of a OSNA and/or OSP. The present invention provides a method in which a test sample is obtained from a human patient and one or more OSNAs and/or OSPs are detected. The presence of higher (or lower) OSNA or OSP levels as compared to normal human controls is diagnostic for the human patient being at
30 risk for developing cancer, particularly ovarian cancer. The effectiveness of therapeutic agents to decrease (or increase) expression or activity of one or more OSNAs and/or OSPs of the invention can also be monitored by analyzing levels of expression of the OSNAs and/or OSPs in a human patient in clinical trials or in *in vitro* screening assays such as in

human cells. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the human patient or cells, as the case may be, to the agent being tested.

Detection of Genetic Lesions or Mutations

5 The methods of the present invention can also be used to detect genetic lesions or mutations in a OSG, thereby determining if a human with the genetic lesion is susceptible to developing ovarian cancer or to determine what genetic lesions are responsible, or are partly responsible, for a person's existing ovarian cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion, insertion and/or substitution of
10 one or more nucleotides from the OSGs of this invention, a chromosomal rearrangement of a OSG, an aberrant modification of a OSG (such as of the methylation pattern of the genomic DNA), or allelic loss of a OSG. Methods to detect such lesions in the OSG of this invention are known to those having ordinary skill in the art following the teachings of the specification.

15 Methods of Detecting Noncancerous ovarian Diseases

 The present invention also provides methods for determining the expression levels and/or structural alterations of one or more OSNAs and/or OSPs in a sample from a patient suspected of having or known to have a noncancerous ovarian disease. In general, the method comprises the steps of obtaining a sample from the patient, determining the
20 expression level or structural alterations of a OSNA and/or OSP, comparing the expression level or structural alteration of the OSNA or OSP to a normal ovarian control, and then ascertaining whether the patient has a noncancerous ovarian disease. In general, if high expression relative to a control of a OSNA or OSP is indicative of a particular noncancerous ovarian disease, a diagnostic assay is considered positive if the level of
25 expression of the OSNA or OSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a OSNA or OSP is indicative of a noncancerous ovarian disease, a diagnostic assay is considered positive if the level of expression of the OSNA or
30 OSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid

of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

One having ordinary skill in the art may determine whether a OSNA and/or OSP is associated with a particular noncancerous ovarian disease by obtaining ovarian tissue from a patient having a noncancerous ovarian disease of interest and determining which OSNAs and/or OSPs are expressed in the tissue at either a higher or a lower level than in normal ovarian tissue. In another embodiment, one may determine whether a OSNA or OSP exhibits structural alterations in a particular noncancerous ovarian disease state by obtaining ovarian tissue from a patient having a noncancerous ovarian disease of interest and determining the structural alterations in one or more OSNAs and/or OSPs relative to normal ovarian tissue.

Methods for Identifying ovarian Tissue

In another aspect, the invention provides methods for identifying ovarian tissue. These methods are particularly useful in, e.g., forensic science, ovarian cell differentiation and development, and in tissue engineering.

In one embodiment, the invention provides a method for determining whether a sample is ovarian tissue or has ovarian tissue-like characteristics. The method comprises the steps of providing a sample suspected of comprising ovarian tissue or having ovarian tissue-like characteristics, determining whether the sample expresses one or more OSNAs and/or OSPs, and, if the sample expresses one or more OSNAs and/or OSPs, concluding that the sample comprises ovarian tissue. In a preferred embodiment, the OSNA encodes a polypeptide having an amino acid sequence selected from SEQ ID NO: 249-396, or a homolog, allelic variant or fragment thereof. In a more preferred embodiment, the OSNA has a nucleotide sequence selected from SEQ ID NO: 1-248, or a hybridizing nucleic acid, an allelic variant or a part thereof. Determining whether a sample expresses a OSNA can be accomplished by any method known in the art. Preferred methods include hybridization to microarrays, Northern blot hybridization, and quantitative or qualitative RT-PCR. In another preferred embodiment, the method can be practiced by determining whether a OSP is expressed. Determining whether a sample expresses a OSP can be accomplished by any method known in the art. Preferred methods include Western blot, ELISA, RIA and 2D PAGE. In one embodiment, the OSP has an amino acid sequence selected from SEQ ID NO: 249-396, or a homolog, allelic variant or fragment thereof. In

another preferred embodiment, the expression of at least two OSNAs and/or OSPs is determined. In a more preferred embodiment, the expression of at least three, more preferably four and even more preferably five OSNAs and/or OSPs are determined.

5 In one embodiment, the method can be used to determine whether an unknown tissue is ovarian tissue. This is particularly useful in forensic science, in which small, damaged pieces of tissues that are not identifiable by microscopic or other means are recovered from a crime or accident scene. In another embodiment, the method can be used to determine whether a tissue is differentiating or developing into ovarian tissue. This is important in monitoring the effects of the addition of various agents to cell or
10 tissue culture, *e.g.*, in producing new ovarian tissue by tissue engineering. These agents include, *e.g.*, growth and differentiation factors, extracellular matrix proteins and culture medium. Other factors that may be measured for effects on tissue development and differentiation include gene transfer into the cells or tissues, alterations in pH, aqueous:air interface and various other culture conditions.

15 Methods for Producing and Modifying ovarian Tissue

In another aspect, the invention provides methods for producing engineered ovarian tissue or cells. In one embodiment, the method comprises the steps of providing cells, introducing a OSNA or a OSG into the cells, and growing the cells under conditions in which they exhibit one or more properties of ovarian tissue cells. In a preferred
20 embodiment, the cells are pluripotent. As is well known in the art, normal ovarian tissue comprises a large number of different cell types. Thus, in one embodiment, the engineered ovarian tissue or cells comprises one of these cell types. In another embodiment, the engineered ovarian tissue or cells comprises more than one ovarian cell type. Further, the culture conditions of the cells or tissue may require manipulation in
25 order to achieve full differentiation and development of the ovarian cell tissue. Methods for manipulating culture conditions are well known in the art.

Nucleic acid molecules encoding one or more OSPs are introduced into cells, preferably pluripotent cells. In a preferred embodiment, the nucleic acid molecules encode OSPs having amino acid sequences selected from SEQ ID NO: 249-396, or
30 homologous proteins, analogs, allelic variants or fragments thereof. In a more preferred embodiment, the nucleic acid molecules have a nucleotide sequence selected from SEQ ID NO: 1-248, or hybridizing nucleic acids, allelic variants or parts thereof. In another highly

preferred embodiment, a OSG is introduced into the cells. Expression vectors and methods of introducing nucleic acid molecules into cells are well known in the art and are described in detail, *supra*.

Artificial ovarian tissue may be used to treat patients who have lost some or all of their ovarian function.

Pharmaceutical Compositions

In another aspect, the invention provides pharmaceutical compositions comprising the nucleic acid molecules, polypeptides, fusion proteins, antibodies, antibody derivatives, antibody fragments, agonists, antagonists, or inhibitors of the present invention. In a preferred embodiment, the pharmaceutical composition comprises a OSNA or part thereof. In a more preferred embodiment, the OSNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-248, a nucleic acid that hybridizes thereto, an allelic variant thereof, or a nucleic acid that has substantial sequence identity thereto. In another preferred embodiment, the pharmaceutical composition comprises a OSP or fragment thereof. In a more preferred embodiment, the pharmaceutical composition comprises a OSP having an amino acid sequence that is selected from the group consisting of SEQ ID NO: 249-396, a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof. In another preferred embodiment, the pharmaceutical composition comprises an anti-OSP antibody, preferably an antibody that specifically binds to a OSP having an amino acid that is selected from the group consisting of SEQ ID NO: 249-396, or an antibody that binds to a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof.

Such a composition typically contains from about 0.1 to 90% by weight of a therapeutic agent of the invention formulated in and/or with a pharmaceutically acceptable carrier or excipient.

Pharmaceutical formulation is a well-established art that is further described in Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20th ed., Lippincott, Williams & Wilkins (2000); Ansel *et al.*, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed., Lippincott Williams & Wilkins (1999); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3rd ed. (2000) and thus need not be described in detail herein.

Briefly, formulation of the pharmaceutical compositions of the present invention will depend upon the route chosen for administration. The pharmaceutical compositions utilized in this invention can be administered by various routes including both enteral and parenteral routes, including oral, intravenous, intramuscular, subcutaneous, inhalation, topical, sublingual, rectal, intra-arterial, intramedullary, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine.

Oral dosage forms can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Solid formulations of the compositions for oral administration can contain suitable carriers or excipients, such as carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or microcrystalline cellulose; gums including arabic and tragacanth; proteins such as gelatin and collagen; inorganics, such as kaolin, calcium carbonate, dicalcium phosphate, sodium chloride; and other agents such as acacia and alginic acid.

Agents that facilitate disintegration and/or solubilization can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, microcrystalline cellulose, cornstarch, sodium starch glycolate, and alginic acid.

Tablet binders that can be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (PovidoneTM), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.

Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

Fillers, agents that facilitate disintegration and/or solubilization, tablet binders and lubricants, including the aforementioned, can be used singly or in combination.

Solid oral dosage forms need not be uniform throughout. For example, dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

Oral dosage forms of the present invention include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or

sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Additionally, dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Liquid formulations of the pharmaceutical compositions for oral (enteral) administration are prepared in water or other aqueous vehicles and can contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations can also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and flavoring agents.

The pharmaceutical compositions of the present invention can also be formulated for parenteral administration. Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.

For intravenous injection, water soluble versions of the compounds of the present invention are formulated in, or if provided as a lyophilate, mixed with, a physiologically acceptable fluid vehicle, such as 5% dextrose ("D5"), physiologically buffered saline, 0.9% saline, Hanks' solution, or Ringer's solution. Intravenous formulations may include carriers, excipients or stabilizers including, without limitation, calcium, human serum albumin, citrate, acetate, calcium chloride, carbonate, and other salts.

Intramuscular preparations, *e.g.* a sterile formulation of a suitable soluble salt form of the compounds of the present invention, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution. Alternatively, a suitable insoluble form of the compound can be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long chain fatty acid (*e.g.*, ethyl oleate), fatty oils such as sesame oil, triglycerides, or liposomes.

Parenteral formulations of the compositions can contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like).

Aqueous injection suspensions can also contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Non-lipid polycationic amino polymers can also be used for delivery. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical compositions of the present invention can also be formulated to permit injectable, long-term, deposition. Injectable depot forms may be made by forming microencapsulated matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in microemulsions that are compatible with body tissues.

The pharmaceutical compositions of the present invention can be administered topically. For topical use the compounds of the present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of lotions, creams, ointments, liquid sprays or inhalants, drops, tinctures, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration of the active ingredient. In other transdermal formulations, typically in patch-delivered formulations, the pharmaceutically active compound is formulated with one or more skin penetrants, such as 2-N-methyl-pyrrolidone (NMP) or Azone. A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, e.g., 5 to 10%, in a carrier such as a pharmaceutical cream base.

For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders.

For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as cocoa butter, wax or other glyceride.

Inhalation formulations can also readily be formulated. For inhalation, various powder and liquid formulations can be prepared. For aerosol preparations, a sterile formulation of the compound or salt form of the compound may be used in inhalers, such

as metered dose inhalers, and nebulizers. Aerosolized forms may be especially useful for treating respiratory disorders.

Alternatively, the compounds of the present invention can be in powder form for reconstitution in the appropriate pharmaceutically acceptable carrier at the time of
5 delivery.

The pharmaceutically active compound in the pharmaceutical compositions of the present invention can be provided as the salt of a variety of acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base
10 forms.

After pharmaceutical compositions have been prepared, they are packaged in an appropriate container and labeled for treatment of an indicated condition.

The active compound will be present in an amount effective to achieve the intended purpose. The determination of an effective dose is well within the capability of
15 those skilled in the art.

A "therapeutically effective dose" refers to that amount of active ingredient, for example OSP polypeptide, fusion protein, or fragments thereof, antibodies specific for OSP, agonists, antagonists or inhibitors of OSP, which ameliorates the signs or symptoms of the disease or prevent progression thereof; as would be understood in the medical arts, cure, although desired, is not required.
20

The therapeutically effective dose of the pharmaceutical agents of the present invention can be estimated initially by *in vitro* tests, such as cell culture assays, followed by assay in model animals, usually mice, rats, rabbits, dogs, or pigs. The animal model can also be used to determine an initial preferred concentration range and route of
25 administration.

For example, the ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) can be determined in one or more cell culture of animal model systems. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as LD50/ED50. Pharmaceutical
30 compositions that exhibit large therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies are used in formulating an initial dosage range for human use, and preferably provide a range of circulating concentrations that includes the ED50 with little or no toxicity. After

administration, or between successive administrations, the circulating concentration of active agent varies within this range depending upon pharmacokinetic factors well known in the art, such as the dosage form employed, sensitivity of the patient, and the route of administration.

5 The exact dosage will be determined by the practitioner, in light of factors specific to the subject requiring treatment. Factors that can be taken into account by the practitioner include the severity of the disease state, general health of the subject, age, weight, gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting
10 pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

 Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Where the therapeutic agent is a protein or antibody of the present invention, the therapeutic protein or antibody
15 agent typically is administered at a daily dosage of 0.01 mg to 30 mg/kg of body weight of the patient (*e.g.*, 1mg/kg to 5 mg/kg). The pharmaceutical formulation can be administered in multiple doses per day, if desired, to achieve the total desired daily dose.

 Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will
20 employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

 Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation(s) of the present invention to the
25 patient. The pharmaceutical compositions of the present invention can be administered alone, or in combination with other therapeutic agents or interventions.

Therapeutic Methods

 The present invention further provides methods of treating subjects having defects in a gene of the invention, *e.g.*, in expression, activity, distribution, localization, and/or
30 solubility, which can manifest as a disorder of ovarian function. As used herein, "treating" includes all medically-acceptable types of therapeutic intervention, including palliation and prophylaxis (prevention) of disease. The term "treating" encompasses any

improvement of a disease, including minor improvements. These methods are discussed below.

Gene Therapy and Vaccines

The isolated nucleic acids of the present invention can also be used to drive *in vivo* expression of the polypeptides of the present invention. *In vivo* expression can be driven from a vector, typically a viral vector, often a vector based upon a replication incompetent retrovirus, an adenovirus, or an adeno-associated virus (AAV), for the purpose of gene therapy. *In vivo* expression can also be driven from signals endogenous to the nucleic acid or from a vector, often a plasmid vector, such as pVAX1 (Invitrogen, Carlsbad, CA, USA), for purpose of “naked” nucleic acid vaccination, as further described in U.S. Patent Nos. 5,589,466; 5,679,647; 5,804,566; 5,830,877; 5,843,913; 5,880,104; 5,958,891; 5,985,847; 6,017,897; 6,110,898; 6,204,250, the disclosures of which are incorporated herein by reference in their entireties. For cancer therapy, it is preferred that the vector also be tumor-selective. *See, e.g.,* Doronin *et al.*, *J. Virol.* 75: 3314-24 (2001).

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a nucleic acid molecule of the present invention is administered. The nucleic acid molecule can be delivered in a vector that drives expression of a OSP, fusion protein, or fragment thereof, or without such vector. Nucleic acid compositions that can drive expression of a OSP are administered, for example, to complement a deficiency in the native OSP, or as DNA vaccines. Expression vectors derived from virus, replication deficient retroviruses, adenovirus, adeno-associated (AAV) virus, herpes virus, or vaccinia virus can be used as can plasmids. *See, e.g.,* Cid-Arregui, *supra*. In a preferred embodiment, the nucleic acid molecule encodes a OSP having the amino acid sequence of SEQ ID NO: 249-396, or a fragment, fusion protein, allelic variant or homolog thereof.

In still other therapeutic methods of the present invention, pharmaceutical compositions comprising host cells that express a OSP, fusions, or fragments thereof can be administered. In such cases, the cells are typically autologous, so as to circumvent xenogeneic or allotypic rejection, and are administered to complement defects in OSP production or activity. In a preferred embodiment, the nucleic acid molecules in the cells encode a OSP having the amino acid sequence of SEQ ID NO: 249-396, or a fragment, fusion protein, allelic variant or homolog thereof.

Antisense Administration

Antisense nucleic acid compositions, or vectors that drive expression of a OSG antisense nucleic acid, are administered to downregulate transcription and/or translation of a OSG in circumstances in which excessive production, or production of aberrant protein, is the pathophysiologic basis of disease.

Antisense compositions useful in therapy can have a sequence that is complementary to coding or to noncoding regions of a OSG. For example, oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred.

Catalytic antisense compositions, such as ribozymes, that are capable of sequence-specific hybridization to OSG transcripts, are also useful in therapy. *See, e.g.*, Phylactou, *Adv. Drug Deliv. Rev.* 44(2-3): 97-108 (2000); Phylactou *et al.*, *Hum. Mol. Genet.* 7(10): 1649-53 (1998); Rossi, *Ciba Found. Symp.* 209: 195-204 (1997); and Sigurdsson *et al.*, *Trends Biotechnol.* 13(8): 286-9 (1995).

Other nucleic acids useful in the therapeutic methods of the present invention are those that are capable of triplex helix formation in or near the OSG genomic locus. Such triplexing oligonucleotides are able to inhibit transcription. *See, e.g.*, Intody *et al.*, *Nucleic Acids Res.* 28(21): 4283-90 (2000); and McGuffie *et al.*, *Cancer Res.* 60(14): 3790-9 (2000). Pharmaceutical compositions comprising such triplex forming oligos (TFOs) are administered in circumstances in which excessive production, or production of aberrant protein, is a pathophysiologic basis of disease.

In a preferred embodiment, the antisense molecule is derived from a nucleic acid molecule encoding a OSP, preferably a OSP comprising an amino acid sequence of SEQ ID NO: 249-396, or a fragment, allelic variant or homolog thereof. In a more preferred embodiment, the antisense molecule is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-248, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

Polypeptide Administration

In one embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a OSP, a fusion protein, fragment, analog or derivative thereof is administered to a subject with a clinically-significant OSP defect.

Protein compositions are administered, for example, to complement a deficiency in native OSP. In other embodiments, protein compositions are administered as a vaccine to elicit a humoral and/or cellular immune response to OSP. The immune response can be used to modulate activity of OSP or, depending on the immunogen, to immunize against aberrant or aberrantly expressed forms, such as mutant or inappropriately expressed isoforms. In yet other embodiments, protein fusions having a toxic moiety are administered to ablate cells that aberrantly accumulate OSP.

In a preferred embodiment, the polypeptide administered is a OSP comprising an amino acid sequence of SEQ ID NO: 249-396, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the polypeptide is encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-248, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

Antibody, Agonist and Antagonist Administration

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an antibody (including fragment or derivative thereof) of the present invention is administered. As is well known, antibody compositions are administered, for example, to antagonize activity of OSP, or to target therapeutic agents to sites of OSP presence and/or accumulation. In a preferred embodiment, the antibody specifically binds to a OSP comprising an amino acid sequence of SEQ ID NO: 249-396, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antibody specifically binds to a OSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-248, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

The present invention also provides methods for identifying modulators which bind to a OSP or have a modulatory effect on the expression or activity of a OSP. Modulators which decrease the expression or activity of OSP (antagonists) are believed to be useful in treating ovarian cancer. Such screening assays are known to those of skill in the art and include, without limitation, cell-based assays and cell-free assays. Small molecules predicted via computer imaging to specifically bind to regions of a OSP can also be designed, synthesized and tested for use in the imaging and treatment of ovarian cancer. Further, libraries of molecules can be screened for potential anticancer agents by assessing the ability of the molecule to bind to the OSPs identified herein. Molecules

identified in the library as being capable of binding to a OSP are key candidates for further evaluation for use in the treatment of ovarian cancer. In a preferred embodiment, these molecules will downregulate expression and/or activity of a OSP in cells.

5 In another embodiment of the therapeutic methods of the present invention, a pharmaceutical composition comprising a non-antibody antagonist of OSP is administered. Antagonists of OSP can be produced using methods generally known in the art. In particular, purified OSP can be used to screen libraries of pharmaceutical agents, often combinatorial libraries of small molecules, to identify those that specifically bind and antagonize at least one activity of a OSP.

10 In other embodiments a pharmaceutical composition comprising an agonist of a OSP is administered. Agonists can be identified using methods analogous to those used to identify antagonists.

In a preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, a OSP comprising an amino acid sequence of SEQ
15 ID NO: 249-396, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, a OSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-248, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

20

Targeting ovarian Tissue

The invention also provides a method in which a polypeptide of the invention, or an antibody thereto, is linked to a therapeutic agent such that it can be delivered to the ovarian or to specific cells in the ovarian. In a preferred embodiment, an anti-OSP
25 antibody is linked to a therapeutic agent and is administered to a patient in need of such therapeutic agent. The therapeutic agent may be a toxin, if ovarian tissue needs to be selectively destroyed. This would be useful for targeting and killing ovarian cancer cells. In another embodiment, the therapeutic agent may be a growth or differentiation factor, which would be useful for promoting ovarian cell function.

30 In another embodiment, an anti-OSP antibody may be linked to an imaging agent that can be detected using, *e.g.*, magnetic resonance imaging, CT or PET. This would be useful for determining and monitoring ovarian function, identifying ovarian cancer tumors, and identifying noncancerous ovarian diseases.

EXAMPLES

Example 1a: Gene Expression Analysis

Identification of OSGs was carried out by a systematic analysis of gene expression data in the LIFESEQ® Gold database available from Incyte Genomics Inc, Palo Alto, CA, using the data mining software package CLASP™.

The CLASP target gene identification process is focused on, but not limited to, the following 5 CLASP profiles: tissue specific expression, cancer specific expression, differentially expressed in cancer, maximum tissue differential expression.

1. For these profiles: cDNA libraries were divided into 60 unique tissue organs. The genes were grouped into gene bins, each bin is a sequence based cluster grouped together with a common contig. The expression levels for each gene bin were calculated in each organ. Differential expression significance was calculated with rigorous statistical significant test considering the influence of sequence random fluctuations and sampling size of cDNA libraries from concept published by Audic S and Claverie JM (Genome Res 1997 7(10): 986-995: The significance of digital gene expression profiles).
2. Highly expressed organ specific genes were selected based on the percentage abundance level in the targeted organ versus all the other organs (organ-specificity).
3. The expression levels of each highly expressed organ-specific gene in the tumor tissue libraries were compared with normal tissue libraries and tissue libraries associated with tumor or disease (cancer-specificity) and analyzed for statistical significance.
4. Target genes exhibiting each CLASP profile criteria were selected.

CLASP 1 tissue specific expression profile: In order to meet the organ-specificity criteria, the expression level of the component clones which the gene is composed of must exhibit three or more occurrences regardless the total number of genes isolated for the target organ. The percentage abundance level in each organ was calculated to identify the organ with the highest expression percentage level.

CLASP 2 cancer specific expression profile: In order to fulfill the cancer specific criteria, genes must exhibit zero expression in normal libraries and measurable expression

in libraries associated with tumor and/or disease. The gene must also exhibit organ-specificity to be selected as a CLASP target for this profile.

CLASP 3 maximum tissue differential expression profile: CLASP targets were selected based on ratio of expression in tumor libraries compared to expression in normal libraries (including normal libraries associated with tumor or disease) for each organ regardless of whether the gene exhibited organ-specificity. This profile was divided into 2 sub-profiles, since the ratio of expression cannot be obtained if no expression is present in normal libraries (including normal libraries associated with tumor or disease). In this case, the maximum expression percentage of the gene was calculated by measuring the occurrence of the gene divided by the occurrence of all genes in the target organ. CLASP selects the top 50 targets for each sub-profile.

CLASP 4 maximum tissue differential expression profile with negligible expression in normal tissues: CLASP targets were selected based on ratio of expression in tumor libraries compared to expression in normal libraries (including normal libraries associated with tumor or disease) for each organ regardless of whether the gene exhibited organ-specificity.

CLASP 5 differentially expressed in cancer profile: Expression levels in tumor libraries in each organ and normal libraries (including normal libraries associated with cancer or disease) for all organs were obtained and statistically analyzed. If the gene exhibited 90% of confidence that it is over-expressed in tumor libraries in the target organ than normal libraries for all organs, it was selected as a CLASP target for this profile.

Accordingly, CLASP allows the identification of highly expressed organ and cancer specific genes based on the gene expression levels in each tissue organ. CLASP scores for a portion of the OSG of this invention are listed below.

25

DEX0337_X	CLASP
DEX0337_1	CLASP5 CLASP3
DEX0337_2	CLASP5 CLASP4
DEX0337_3	CLASP5 CLASP3
DEX0337_4	CLASP5 CLASP3
DEX0337_5	CLASP5
DEX0337_6	CLASP5
DEX0337_7	CLASP5
DEX0337_8	CLASP5
DEX0337_9	CLASP5
DEX0337_10	CLASP5
DEX0337_13	CLASP5
DEX0337_14	CLASP5

DEX0337_15	CLASP5
DEX0337_16	CLASP5
DEX0337_17	CLASP5
DEX0337_18	CLASP5
DEX0337_19	CLASP5
DEX0337_20	CLASP5
DEX0337_21	CLASP5
DEX0337_24	CLASP5
DEX0337_25	CLASP5
DEX0337_26	CLASP5 CLASP4 CLASP3
DEX0337_30	CLASP5
DEX0337_31	CLASP5
DEX0337_32	CLASP5 CLASP4
DEX0337_33	CLASP5
DEX0337_34	CLASP5 CLASP4
DEX0337_35	CLASP5 CLASP4
DEX0337_36	CLASP5 CLASP4
DEX0337_37	CLASP5 CLASP4
DEX0337_38	CLASP5 CLASP4
DEX0337_39	CLASP5 CLASP4
DEX0337_40	CLASP5
DEX0337_41	CLASP5
DEX0337_42	CLASP5 CLASP3
DEX0337_43	CLASP5
DEX0337_44	CLASP5
DEX0337_45	CLASP5 CLASP4
DEX0337_46	CLASP5 CLASP4
DEX0337_47	CLASP5 CLASP4
DEX0337_48	CLASP5 CLASP1 CLASP3 CLASP4
DEX0337_49	CLASP5 CLASP3 CLASP4
DEX0337_50	CLASP5 CLASP3 CLASP4
DEX0337_51	CLASP5
DEX0337_52	CLASP5
DEX0337_53	CLASP5
DEX0337_54	CLASP5
DEX0337_55	CLASP5
DEX0337_56	CLASP5
DEX0337_57	CLASP5
DEX0337_60	CLASP5
DEX0337_61	CLASP5
DEX0337_62	CLASP5
DEX0337_63	CLASP5
DEX0337_64	CLASP5
DEX0337_65	CLASP5 CLASP1 CLASP3 CLASP4
DEX0337_66	CLASP5
DEX0337_67	CLASP5
DEX0337_68	CLASP5
DEX0337_69	CLASP5 CLASP4
DEX0337_70	CLASP5
DEX0337_71	CLASP5
DEX0337_72	CLASP5 CLASP3
DEX0337_73	CLASP5 CLASP3
DEX0337_74	CLASP5 CLASP4
DEX0337_102	CLASP2
DEX0337_103	CLASP2
DEX0337_104	CLASP2
DEX0337_105	CLASP2

In addition the expression values for each organ in the format 9 - 0.9999 are listed. Each column first lists the given organ (ORG), a number representing the percentage of the expression (EXP) of the gene in the given organ.

5

DEX0337_X	Org	Exp	Org	Exp	Org	Exp	Org	Exp	Org	Exp
DEX0337_1	OVR	.2677	PIB	.0363	FAL	.0503	BMR	.0515	SPC	.06
DEX0337_2	OVR	.2339	MSL	.0845	SAG	.0988	BNC	.1085	UNC	.1236
DEX0337_3	OVR	.0021	BRN	.0013	UTR	.0013	BLD	.0016	BLV	.0016
DEX0337_4	OVR	.0021	BRN	.0013	UTR	.0013	BLD	.0016	BLV	.0016
DEX0337_5	OVR	.001								
DEX0337_6	OVR	.001								
DEX0337_7	OVR	.001	BRN	.0002						
DEX0337_8	OVR	.001	CON	.0011						
DEX0337_9	OVR	.001								
DEX0337_10	OVR	.001								
DEX0337_13	OVR	.001								
DEX0337_14	OVR	.001								
DEX0337_15	OVR	.001								
DEX0337_16	OVR	.001								
DEX0337_17	OVR	.001								
DEX0337_18	OVR	.001								
DEX0337_19	OVR	.001								
DEX0337_20	OVR	.001								
DEX0337_21	OVR	.001								
DEX0337_24	OVR	.0021	BRN	.0002						
DEX0337_25	OVR	.0021	BRN	.0002						
DEX0337_26	ESO	.0051	LIV	.0076	LMN	.0083	FAL	.0189		
DEX0337_27	ESO	.0051	LIV	.0076	LMN	.0083	FAL	.0189		
DEX0337_28	OVR	.0033	BRN	.0001	PRO	.0003	MAM	.0004	UTR	.0004
DEX0337_29	OVR	.0492	BRN	.0002	BRN	.0002	CON	.0034	CON	.0034
DEX0337_30	OVR	.001								
DEX0337_31	OVR	.001								
DEX0337_32	OVR	.0092	BLD	.0016	BLV	.0016	LIV	.0019	FTS	.002
DEX0337_33	THY	.006	UTR	.0069	KID	.0128	PRO	.0135		
DEX0337_34	OVR	.0133	MSL	.0053	SYN	.0056	NOS	.0073	UNC	.008
DEX0337_35	OVR	.8811	SAG	.316	NOS	.4326	FAL	.4399	PLE	.4486
DEX0337_36	OVR	.8811	SAG	.316	NOS	.4326	FAL	.4399	PLE	.4486
DEX0337_37	OVR	.0564	INT	.015	NOS	.0293	BMR	.0322	BLO	.036
DEX0337_38	OVR	.677	BMR	.1609	SAG	.1778	SPC	.1899	NOS	.198
DEX0337_39	OVR	.0092	PNS	.0023	LMN	.0028	THY	.004	PAN	.0047
DEX0337_40	CON	.0011								
DEX0337_41	OVR	.0636	BRN	.0082	LNG	.0207	GLB	.0231	BLD	.0273
DEX0337_42	OVR	.0144	BRN	.0029	BLV	.0033	BLO	.004	THY	.004
DEX0337_43	OVR	.0092	UNC	.004	BON	.0112				
DEX0337_44	OVR	.0072	FTS	.0018	PRO	.004	MAM	.0043	INL	.009
DEX0337_45	OVR	.0133	MSL	.0053	SYN	.0056	NOS	.0073	UNC	.008
DEX0337_46	OVR	.0103	BRN	.0006	BLV	.0016	INL	.0019	CRD	.0023
DEX0337_47	OVR	.0103	BRN	.0006	BLV	.0016	INL	.0019	CRD	.0023
DEX0337_48	OVR	.1908	SAG	.0593	SAG	.0593	SAG	.0593	INT	.0798
DEX0337_49	OVR	.1651	SPC	.02	SPC	.02	PIT	.0205	PIT	.0205
DEX0337_50	OVR	.1651	SPC	.02	SPC	.02	PIT	.0205	PIT	.0205
DEX0337_51	OVR	.0072	LNG	.0011	KID	.0026	BON	.0056		
DEX0337_52	BRN	.0199								

DEX0337_53	OVR .0031				
DEX0337_54	OVR .0031				
DEX0337_55	THY .006	UTR .0069	KID .0128	PRO .0135	
DEX0337_56	OVR .0051	ADR .003	CON .0045	BRN .0052	TON .0299
DEX0337_57	OVR .0698	BRN .03	FTS .0374	MAM .0397	PAN .0447
DEX0337_60	OVR .0031				
DEX0337_61	OVR .001				
DEX0337_62	OVR .001				
DEX0337_63	OVR .0062	FTS .0035	INS .0048	ADR .0089	BON .0112
DEX0337_64	OVR .0174	FTS .0023	PAN .0035	ESO .0051	
DEX0337_65	OVR .0328	TNS .0016	PNS .0022	PNS .0023	PNS .0023
DEX0337_66	OVR .0062	CRD .0023	UNC .004	STO .0041	PRO .0073
DEX0337_67	OVR .0318	UTR .0307	CON .034		
DEX0337_68	OVR .0195	LMN .0167	INL .0186	NOS .022	ESO .0256
DEX0337_69	OVR .8811	SAG .316	NOS .4326	FAL .4399	PLE .4486
DEX0337_70	OVR .0328				
DEX0337_71	OVR .0154	PNS .0047			
DEX0337_72	OVR .0174	BLO .004	ESO .0051	CON .0057	ADR .006
DEX0337_73	OVR .0174	BLO .004	ESO .0051	CON .0057	ADR .006
DEX0337_74	OVR .0154	LNG .0017	MSL .0026	TST .0027	ADR .003
DEX0337_102	OVR .0046				
DEX0337_103	OVR .0046				
DEX0337_104	OVR .0046				
DEX0337_105	OVR .0046				

Abbreviation for tissues:

5 ADR Adrenal Glands; BLD Bladder; BLO Blood; BLV Blood Vessels; BMR Bone Marrow; BNC Bronchi; BON Bones; BRN Brain; CON Connective Tissue; CRD Heart; ESO Esophagus; FAL Fallopian Tubes; FTS Fetus; GLB Gallbladder; INL Intestine, Large; INS Intestine, Small; INT Intestine; KID Kidney; LIV Liver; LMN Lymphoid Tissue; LNG Lung; MAM Breast; MSL Muscles; NOS Nose; OVR Ovary; PAN Pancreas; PIB Pineal Body; PIT Pituitary Gland; PLE Pleura; PNS Penis; PRO Prostate; SAG Salivary Glands; SPC Spinal Cord; 10 STO Stomach; SYN Synovial Membranes; THY Thymus Gland; TNS Tonsil/Adenoids; TON Tongue; TST Testis; UNC Mixed Tissues; UTR Uterus

Example 1b: Suppression Subtractive Hybridization (Clontech PCR-SELECT)

Clontech PCR-SELECT is a PCR based subtractive hybridization method designed to selectively enrich for cDNAs corresponding to mRNAs differentially expressed 15 between two mRNA populations (Diatchenko et al, Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 6025-6030, 1996). Clontech PCR-SELECT is a method for enrichment of differentially expressed mRNAs based on a selective amplification. cDNA is prepared from the two mRNA populations which are to be compared (Tester: cDNA population in which the differentially expressed messages are sought and Driver: cDNA population in 20 which the differentially expressed transcripts are absent or low). The tester sample is separated in two parts and different PCR adapters are ligated to the 5' ends. Each tester is separately annealed to excess driver (first annealing) and then pooled and again annealed (second annealing) to excess driver. During the first annealing sequences common to both populations anneal. Additionally the concentration of high and low abundance messages

are normalized since annealing is faster for abundant molecules due to the second order kinetics of hybridization. During the second annealing cDNAs unique or overabundant to the tester can anneal together. Such molecules have different adapters at their ends. The addition of additional driver during the second annealing enhances the enrichment of the desired differentially expressed sequences. During subsequent PCR, molecules that have different adapters at each end amplify exponentially. Molecules which have identical adapters, or adapters at only one end, or no adapters (driver sequences) either do not amplify or undergo linear amplification. The end result is enrichment for cDNAs corresponding to differentially expressed messages (unique to the tester or upregulated in the tester). This technique was used to identify transcripts unique to ovarian tissue or messages overexpressed in ovarian cancer. Pairs of matched samples isolated from the same patient, a cancer sample, and the “normal” adjacent tissue from the same tissue type were utilized. The mRNA from the cancer tissue is used as the “tester”, and the non-cancer mRNA as a “driver”. The non-cancer “driver” is from the same individual and tissue as the cancer sample (Matched). Alternatively, the “driver” can be from a different individual but the same tissue as the tumor sample (unmatched). In some cases mixtures of mRNAs derived from non-cancer tissues types different from the cancer tissue type are also used as “drivers”. The last approach allows the identification of transcripts whose expression is specific or upregulated in the cancer tissue type analyzed. Such transcripts may or may not be cancer specific in their expression.

Several subtracted libraries were generated for ovarian tissue. The product of the subtraction experiments was used to generate cDNA libraries. These cDNA libraries contain Expressed Sequence Tags (ESTs) from genes that are ovarian cancer specific, or upregulated in ovarian tissue. Randomized clones picked from each cDNA PCR Select library were sequenced and the genes identified by a systematic analysis of the sequence data against the LIFESEQ Gold database available from Incyte Pharmaceuticals, Palo Alto.

Descriptions of the sequences from subtractions are as follows:

DEX0337_X
DEX0337_75
DEX0337_76
DEX0337_77
DEX0337_78
DEX0337_79
DEX0337_80
DEX0337_81

DEX0337_82
DEX0337_83
DEX0337_84
DEX0337_85
DEX0337_86
DEX0337_87
DEX0337_88
DEX0337_89
DEX0337_90
DEX0337_91
DEX0337_92
DEX0337_93
DEX0337_94
DEX0337_95
DEX0337_96
DEX0337_97
DEX0337_98
DEX0337_99
DEX0337_100
DEX0337_101

The sequence identifications and predicted peptide sequences for each of the targets are listed below:

DEX0337_X	ID	Predicted Peptide
DEX0337_1	mry2111	
DEX0337_2	mry3521	DEX0337_106
DEX0337_3	mry4157	DEX0337_107
DEX0337_4	flex mry4157	DEX0337_108
DEX0337_5	mry15155	DEX0337_109
DEX0337_6	flex mry15155	
DEX0337_7	mry15229	DEX0337_110
DEX0337_8	mry15272	
DEX0337_9	mry15337	DEX0337_111
DEX0337_10	flex mry15337	
DEX0337_11	mry15382	DEX0337_112
DEX0337_12	flex mry15382	
DEX0337_13	mry15405	DEX0337_113
DEX0337_14	flex mry15405	
DEX0337_15	mry15451	
DEX0337_16	mry15467	
DEX0337_17	mry15525	
DEX0337_18	mry15565	
DEX0337_19	mry15600	
DEX0337_20	mry15613	
DEX0337_21	mry15622	
DEX0337_22	mry15630	
DEX0337_23	flex mry15630	
DEX0337_24	mry15658	DEX0337_114
DEX0337_25	flex mry15658	
DEX0337_26	mry15673	
DEX0337_27	flex mry15673	
DEX0337_28	mry15778	
DEX0337_29	mry15781	
DEX0337_30	mry15859	DEX0337_115
DEX0337_31	flex mry15859	
DEX0337_32	mry15867	DEX0337_116

DEX0337_33	mry15874	DEX0337_117
DEX0337_34	mry15985	DEX0337_118
DEX0337_35	mry15996	DEX0337_119
DEX0337_36	mry15998	DEX0337_120
DEX0337_37	mry16007	DEX0337_121
DEX0337_38	mry16160	DEX0337_122
DEX0337_39	mry16164	DEX0337_123
DEX0337_40	flex mry16164	DEX0337_124
DEX0337_41	mry16208	DEX0337_125
DEX0337_42	mry16281	DEX0337_126
DEX0337_43	mry16285	
DEX0337_44	mry16315	DEX0337_127
DEX0337_45	mry16528	
DEX0337_46	mry16562	DEX0337_128
DEX0337_47	flex mry16562	DEX0337_129
DEX0337_48	mry16608	DEX0337_130
DEX0337_49	mry16623	DEX0337_131
DEX0337_50	flex mry16623	
DEX0337_51	mry16637	
DEX0337_52	mry16662	
DEX0337_53	mry16664	DEX0337_132
DEX0337_54	flex mry16664	
DEX0337_55	mry16679	DEX0337_133
DEX0337_56	mry16737	DEX0337_134
DEX0337_57	mry16788	DEX0337_135
DEX0337_58	mry16796	DEX0337_136
DEX0337_59	flex mry16796	
DEX0337_60	mry16808	
DEX0337_61	mry16823	DEX0337_137
DEX0337_62	flex mry16823	
DEX0337_63	mry16840	
DEX0337_64	mry16866	DEX0337_138
DEX0337_65	mry16881	DEX0337_139
DEX0337_66	mry16899	DEX0337_140
DEX0337_67	mry16905	
DEX0337_68	mry16953	
DEX0337_69	mry16983	DEX0337_141
DEX0337_70	mry16999	DEX0337_142
DEX0337_71	mry17001	DEX0337_143
DEX0337_72	mry17002	DEX0337_144
DEX0337_73	flex mry17002	DEX0337_145
DEX0337_74	mry17010	
DEX0337_75	mry26089	
DEX0337_76	mry26204	
DEX0337_77	mry26237	
DEX0337_78	mry26278	
DEX0337_79	mry26393	
DEX0337_80	mry26505	
DEX0337_81	mry26515	
DEX0337_82	mry26743	
DEX0337_83	mry26768	
DEX0337_84	mry26994	
DEX0337_85	mry27242	
DEX0337_86	mry27281	
DEX0337_87	mry27330	
DEX0337_88	mry27363	
DEX0337_89	mry27399	

DEX0337_90	mry27436	
DEX0337_91	mry27438	
DEX0337_92	mry27510	
DEX0337_93	mry27564	
DEX0337_94	mry27609	
DEX0337_95	mry27635	
DEX0337_96	mry27636	
DEX0337_97	mry27664	
DEX0337_98	mry27774	
DEX0337_99	mry27818	
DEX0337_100	mry28002	
DEX0337_101	mry28011	
DEX0337_102	mry31791	
DEX0337_103	flex mry31791	
DEX0337_104	mry33414	
DEX0337_105	mry33868	

The source of the parent sequences are as follows:

DEX0337_X	Parent	Library
DEX0337_75	26089	PSovr003
DEX0337_75	26089	PSovr007
DEX0337_75	26089	PSovr008
DEX0337_75	26089	PSovr009
DEX0337_75	26089	PSovr011
DEX0337_76	26204	PSovr005
DEX0337_77	26237	PSovr003
DEX0337_78	26278	PSovr003
DEX0337_79	26393	PSovr005
DEX0337_80	26505	PSovr007
DEX0337_81	26515	PSovr007
DEX0337_82	26743	PSovr008
DEX0337_83	26768	PSovr008
DEX0337_84	26994	PSovr009
DEX0337_85	27242	PSovr010
DEX0337_86	27281	PSovr010
DEX0337_87	27330	PSovr010
DEX0337_88	27363	PSovr011
DEX0337_89	27399	PSovr011
DEX0337_90	27436	PSovr011
DEX0337_91	27438	PSovr011
DEX0337_92	27510	PSovr011
DEX0337_93	27564	PSovr011
DEX0337_94	27609	PSovr011
DEX0337_95	27635	PSovr012
DEX0337_96	27636	PSovr012
DEX0337_97	27664	PSovr012
DEX0337_98	27774	PSovr012
DEX0337_99	27818	PSovr012
DEX0337_100	28002	PSovr012
DEX0337_101	28011	PSovr012

The summary of samples for ovarian PCR Select cDNA subtraction are as follows:

library ID	Tester-Tissue I.D.	Driver Tissue
------------	--------------------	---------------

library ID	Tester-Tissue I.D.	Driver Tissue
PSovr003	Three ovarian tumor samples	Six normal tissues: kidney, pancreas, spleen, small intestine, heart, colon. All samples from Clontech, except for colon. Colon tissue ID: 9703C126RA
	1071C papillary cystadenocarcinoma	
	10050 papillary serous and endometrioid carcinoma	
	10400 papillary serous adenocarcinoma	
PSovr005	7070-97 cancer matching sample Papillary serous carcinoma	7060-97 NAT
PSovr007	Three ovarian tumor samples (papillary serous carcinoma)	From Clontech: pool of five normal ovaries.
	1071C papillary cystadenocarcinoma	
	10050 papillary serous and endometrioid carcinoma	
	10400 papillary serous adenocarcinoma	
PS.OVR008	2370V Invasive papillary serous adenocarcinoma	S9822105 papillary serous carcinoma of low malignant potential (LMP)
PS.OVR009	S9822105 papillary serous carcinoma of low malignant potential (LMP)	2370V Invasive papillary serous adenocarcinoma
PS.OVR010	VNM00329 mucinous cystadenocarcinoma	14638A1C mucinous cystic neoplasm of Low Malignant Potential
PS.OVR011	14638A1C mucinous cystic neoplasm of Low Malignant Potential	VNM00329 mucinous cystadenocarcinoma
PS.OVR012	Pool of three	Other female cancers: breast, endometrium, cervix and uterus. breast: 9703B011d; uterus: 850U; endometrium: 9901A185; cervix: VNM0056001
	1071C papillary cystadenocarcinoma	
	10400 papillary serous adenocarcinoma	
	2370V Invasive papillary serous adenocarcinoma	

Example 2: Gene Expression Analysis

Custom Microarray Experiment—Ovarian Cancer

The source of the parent sequences for microarray were as follows: Parent sequences DEX0337_5 - DEX0337_27 were obtained from CLASP mining of the LifeSeq Gold sequence database. Parent sequences DEX0337_75 - DEX0337_101 were obtained by the subtraction experiments experiments previously described. Parent sequences DEX0337_1 - DEX0337_4 and DEX0337_28 - DEX0337_74 were obtained by sequence assembly using ESTs from both the subtractions assembled with sequences from Incyte's LifeSeq Gold database.

Custom oligonucleotide microarrays were provided by Agilent Technologies, Inc. (Palo Alto, CA). The microarrays were fabricated by Agilent using their technology for the in-situ synthesis of 60mer oligonucleotides (Hughes, et al. 2001, Nature Biotechnology 19:342-347). The 60mer microarray probes were designed by Agilent, from gene
5 sequences provided by diaDexus, using Agilent proprietary algorithms. Whenever possible two different 60mers were designed for each gene of interest.

All microarray experiments were two-color experiments and were performed using Agilent-recommended protocols and reagents. Briefly, each microarray was hybridized with cRNAs synthesized from polyA+ RNA, isolated from cancer and normal tissues,
10 labeled with fluorescent dyes Cyanine3 and Cyanine5 (NEN Life Science Products, Inc., Boston, MA) using a linear amplification method (Agilent). In each experiment the experimental sample was polyA+ RNA isolated from cancer tissue from a single individual and the reference sample was a pool of polyA+ RNA isolated from normal tissues of the same organ as the cancerous tissue (i.e. normal ovarian tissue in experiments
15 with ovarian cancer samples). Tissue descriptions are listed in the following table. Hybridizations were carried out at 60°C, overnight using Agilent in-situ hybridization buffer. Following washing, arrays were scanned with a GenePix 4000B Microarray Scanner (Axon Instruments, Inc., Union City, CA). The resulting images were analyzed with GenePix Pro 3.0 Microarray Acquisition and Analysis Software (Axon). Two
20 different chip designs were evaluated with overlapping sets of a total of 19 samples, comparing the expression patterns of ovarian cancer derived polyA+ RNA to polyA+ RNA isolated from a pool of 9 normal ovarian tissues were analyzed. For Chip2 all 19 samples (14 invasive carcinomas (INV), 5 low malignant potential (LMP) samples) were analyzed and for Chip1 a subset of 17 of these samples (13 invasive carcinomas, 4 low
25 malignant potential samples) were assessed.

Data normalization and expression profiling were done with Expressionist software from GeneData Inc. (Daly City, CA/Basel, Switzerland). Gene expression analysis was performed using only experiments that meet certain quality criteria. The quality criteria that experiments must meet are a combination of evaluations performed by
30 the Expressionist software and evaluations performed manually using raw and normalized data. To evaluate raw data quality, detection limits (the mean signal for a replicated negative control + 2 Standard Deviations (SD)) for each channel were calculated. The detection limit is a measure of non-specific hybridization. Arrays with poor detection

limits were not analyzed and the experiments were repeated. To evaluate normalized data quality, positive control elements included in the array were utilized. These array features should have a mean ratio of 1 (no differential expression). If these features have a mean ratio of greater than 1.5-fold up or down, the experiments were not analyzed further and were repeated. In addition to traditional scatter plots demonstrating the distribution of signal in each experiment, the Expressionist software also has minimum thresholding criteria that employ user defined parameters to identify quality data. Only those features that meet the threshold criteria were included in the filtering and analyses carried out by Expressionist. The thresholding settings employed require a minimum area percentage of 60% $[(\% \text{ pixels} > \text{background} + 2\text{SD}) - (\% \text{ pixels saturated})]$, and a minimum signal to noise ratio of 2.0 in both channels. By these criteria, very low expressors and saturated features were not included in analysis.

Relative expression data was collected from Expressionist based on filtering and clustering analyses. Up- and down-regulated genes were identified using criteria for percentage of valid values obtained, and the percentage of experiments in which the gene is up- or down-regulated. These criteria were set independently for each data set, depending on the size and the nature of the data set. The results for the statistically significant upregulated and downregulated genes are shown in Table 1 and Table 2. The first three columns of each table contain information about the sequence itself (Oligo ID, Parent ID, and Patent#), the next 3 columns show the results obtained. '%valid' indicates the percentage of unique experiments total ($n=17$ for Chip1, $n=19$ for Chip2) in which a valid expression value was obtained, '%up' indicates the percentage of experiments in which up-regulation of at least 2-fold was observed, and '%down' indicates the percentage of the experiments in which down-regulation of at least 2-fold was observed. The last column in each table describes the location of the microarray probe (oligo) relative to the parent sequence. For genes that the parent sequence was extended using databases of public and proprietary sequences, the both the parent DEX number and the extended (FLEXS) DEX number are listed in the DEX ID column. In these cases, the site of the 60mer probe is listed in the last column.

Table 1. Sensitivity data for up-regulated genes.

DEX ID	Parent ID	OligoID	"%valid, n=17 *n=19"	"%up, n=17, *n=19"	"%up INV, n=13, *n=14"	"%up LMP, n=4, *n=5"	Start Pos. Par. Seq	Stop Pos. Par. Seq	Start Pos. FLEXS	Stop Pos. FLEXS
DEX0337_3 DEX0337_4	4157	5236	100*	31.6*	42.9*	0*	930	989	929	988

DEX ID	Parent ID	OligoID	"%valid, n=17 *n=19"	"%up , n=17, *n=19"	"%up INV, n=13, *n=14"	"%up LMP, n=4, *n=5"	Start Pos. Par. Seq	Stop Pos. Par. Seq	Start Pos. FLEXS	Stop Pos. FLEXS
DEX0337_5 DEX0337_6	15155	26294.01	100	41.2	46.2	25	1056	1115	1049	1108
DEX0337_5 DEX0337_6	15155	26294.02	94.1	35.3	38.5	25	1056	1115	1049	1108
DEX0337_8	15272	32650.01	94.1	41.2	46.2	25	406	465		
DEX0337_8	15272	32650.02	94.1	47.1	53.8	25	406	465		
DEX0337_13 DEX0337_14	15405	13911.01	100	23.5	30.8	0	203	262	70	11
DEX0337_13 DEX0337_14	15405	13911.02	88.2	29.4	30.8	25	203	262	70	11
DEX0337_16	15467	15613.01	100	35.3	46.2	0	516	575		
DEX0337_16	15467	15613.02	94.1	41.2	53.8	0	516	575		
DEX0337_22 DEX0337_23	15630	17604.01	52.9	23.5	30.8	0	885	944	947	1006
DEX0337_22 DEX0337_23	15630	17604.02	41.2	35.3	38.5	25	885	944	947	1006
DEX0337_24 DEX0337_25	15658	10312.01	88.2	29.4	38.5	0	505	564	637	696
DEX0337_24 DEX0337_25	15658	10312.02	88.2	29.4	30.8	25	505	564	637	696
DEX0337_26 DEX0337_27	15673	26480.01	88.2	0	0	0	430	489	630	689
DEX0337_26 DEX0337_27	15673	26480.02	82.4	23.5	30.8	0	430	489	630	689
DEX0337_29	15781	14712.01	64.7	41.2	30.8	75	91	150		
DEX0337_29	15781	14712.02	70.6	47.1	30.8	100	91	150		
DEX0337_32	15867	16318.01	100	23.5	30.8	0	172	231		
DEX0337_32	15867	16318.02	100	23.5	30.8	0	172	231		
DEX0337_33	15874	16374.01	100	23.5	30.8	0	1793	1852		
DEX0337_33	15874	16374.02	100	17.6	23.1	0	1793	1852		
DEX0337_34	15985	17430.01	100	23.5	30.8	0	833	892		
DEX0337_34	15985	17430.02	100	17.6	23.1	0	833	892		
DEX0337_35	15996	17482.01	100	35.3	30.8	50	179	238		
DEX0337_35	15996	17482.02	100	41.2	38.5	50	179	238		
DEX0337_36	15998	17490.01	100	52.9	53.8	50	469	528		
DEX0337_36	15998	17490.02	100	58.8	53.8	75	469	528		
DEX0337_37	16007	18044.01	100	58.8	76.9	0	220	279		
DEX0337_37	16007	18044.02	100	64.7	84.6	0	220	279		
DEX0337_42	16281	20773.01	100	17.6	23.1	0	2181	2240		
DEX0337_42	16281	20773.02	94.1	23.5	30.8	0	2181	2240		
DEX0337_43	16285	20785.01	70.6	17.6	7.7	50	347	406		
DEX0337_43	16285	20785.02	82.4	17.6	7.7	50	347	406		
DEX0337_44	16315	21433.01	100	64.7	61.5	75	1550	1609		
DEX0337_44	16315	21433.02	100	64.7	61.5	75	1550	1609		
DEX0337_45	16528	23466.01	88.2	17.6	23.1	0	1621	1680		
DEX0337_45	16528	23466.02	100	23.5	30.8	0	1621	1680		
DEX0337_46 DEX0337_47	16562	23690.01	100	23.5	23.1	25	495	554	496	555
DEX0337_46 DEX0337_47	16562	23690.02	100	29.4	30.8	25	495	554	496	555
DEX0337_48	16608	24524.01	100	70.6	69.2	75	967	1026		
DEX0337_48	16608	24524.02	100	70.6	69.2	75	967	1026		
DEX0337_55	16679	25036.01	100	29.4	23.1	50	2243	2302		
DEX0337_55	16679	25036.02	100	29.4	23.1	50	2243	2302		
DEX0337_56	16737	9720.01	100	47.1	38.5	75	2070	2129		
DEX0337_56	16737	9720.02	100	52.9	46.2	75	2070	2129		
DEX0337_58 DEX0337_59	16796	9958.01	100	47.1	46.2	50	1339	1398	193	134
DEX0337_58 DEX0337_59	16796	9958.02	100	47.1	46.2	50	1339	1398	193	134
DEX0337_60	16808	10394.01	76.5	23.5	7.7	75	459	518		
DEX0337_60	16808	10394.02	82.4	23.5	7.7	75	459	518		
DEX0337_61 DEX0337_62	16823	10460.01	35.3	5.9	0	25	1800	1859	1801	1860
DEX0337_61 DEX0337_62	16823	10460.02	88.2	23.5	15.4	50	1800	1859	1801	1860
DEX0337_63	16840	10528.01	100	35.3	38.5	25	2731	2790		

DEX ID	Parent ID	OligoID	%valid, n=17 *n=19"	%up , n=17, *n=19"	%up INV, n=13, *n=14"	%up LMP, n=4, *n=5"	Start Pos. Par. Seq	Stop Pos. Par. Seq	Start Pos. FLEXS	Stop Pos. FLEXS
DEX0337_1	2111	5022	100*	31.6*	35.7*	20*	84	143		
DEX0337_2	3521	2311	100*	21.1*	14.3*	40*	91	150		
DEX0337_7	15229	23094.01	88.2	41.2	46.2	25	505	564		
DEX0337_7	15229	23094.02	88.2	35.3	38.5	25	505	564		
DEX0337_9 DEX0337_10	15337	13065.01	76.5	29.4	30.8	25	640	699	223	164
DEX0337_9 DEX0337_10	15337	13065.02	76.5	17.6	15.4	25	640	699	223	164
DEX0337_11 DEX0337_12	15382	22211.01	100	47.1	38.5	75	1110	1169	141	82

DEX ID	Parent ID	OligoID	""%valid, n=17 *n=19"	""%up , n=17, *n=19"	""%up INV, n=13, *n=14"	""%up LMP, n=4, *n=5"	Start Pos. Par. Seq	Stop Pos. Par. Seq	Start Pos. FLEXS	Stop Pos. FLEXS
DEX0337_11 DEX0337_12	15382	22211.02	100	52.9	46.2	75	1110	1169	141	82
DEX0337_15	15451	9282.01	94.1	29.4	30.8	25	764	823		
DEX0337_15	15451	9282.02	88.2	29.4	30.8	25	764	823		
DEX0337_17	15525	9420.01	70.6	17.6	7.7	50	784	843		
DEX0337_17	15525	9420.02	82.4	17.6	15.4	25	784	843		
DEX0337_18	15565	40563.01	94.1	47.1	53.8	25	166	225		
DEX0337_18	15565	40563.02	82.4	23.5	23.1	25	166	225		
DEX0337_19	15600	9364.01	94.1	29.4	23.1	50	390	449		
DEX0337_19	15600	9364.02	94.1	29.4	23.1	50	390	449		
DEX0337_20	15613	33308.01	82.4	23.5	30.8	0	24	83		
DEX0337_20	15613	33308.02	76.5	17.6	23.1	0	24	83		
DEX0337_21	15622	37055.01	94.1	35.3	30.8	50	280	339		
DEX0337_21	15622	37055.02	100	35.3	30.8	50	280	339		
DEX0337_28	15778	14694.01	100	94.1	92.3	100	364	423		
DEX0337_28	15778	14694.02	100	94.1	92.3	100	364	423		
DEX0337_30	15859	16267.01	100	52.9	46.2	75	428	487		
DEX0337_30	15859	16267.02	94.1	23.5	15.4	50	428	487		
DEX0337_38	16160	19484.01	100	29.4	30.8	25	547	606		
DEX0337_38	16160	19484.02	100	29.4	30.8	25	547	606		
DEX0337_39 DEX0337_40	16164	19522.01	58.8	29.4	23.1	50	276	335	1079	1137
DEX0337_39 DEX0337_40	16164	19522.02	100	64.7	53.8	100	276	335	1079	1137
DEX0337_41	16208	20317.01	100	29.4	30.8	25	317	376		
DEX0337_41	16208	20317.02	100	29.4	30.8	25	317	376		
DEX0337_49 DEX0337_50	16623	24670.01	88.2	23.5	30.8	0	586	645	145	86
DEX0337_49 DEX0337_50	16623	24670.02	94.1	29.4	30.8	25	586	645	145	86
DEX0337_51	16637	24778.01	100	23.5	30.8	0	349	408		
DEX0337_51	16637	24778.02	94.1	11.8	15.4	0	349	408		
DEX0337_52	16662	24972.01	100	47.1	46.2	50	1960	2019		
DEX0337_52	16662	24972.02	100	41.2	46.2	25	1960	2019		
DEX0337_53 DEX0337_54	16664	24982.01	100	35.3	38.5	25	2863	2922	2861	2920
DEX0337_53 DEX0337_54	16664	24982.02	100	47.1	53.8	25	2863	2922	2861	2920
DEX0337_57	16788	9924.01	76.5	23.5	15.4	50	861	920		
DEX0337_57	16788	9924.02	64.7	17.6	23.1	0	861	920		
DEX0337_67	16905	11259.01	94.1	47.1	46.2	50	5362	5421		
DEX0337_67	16905	11259.02	88.2	29.4	30.8	25	5362	5421		
DEX0337_68	16953	11461.01	100	17.6	7.7	50	609	668		
DEX0337_68	16953	11461.02	100	17.6	7.7	50	609	668		
DEX0337_70	16999	11625.01	100	70.6	84.6	25	5360	5419		
DEX0337_70	16999	11625.02	100	70.6	84.6	25	5360	5419		
DEX0337_71	17001	12139.01	100	41.2	46.2	25	1917	1976		
DEX0337_71	17001	12139.02	100	41.2	46.2	25	1917	1976		
DEX0337_72 DEX0337_73	17002	12143.01	100	23.5	30.8	0	3910	3969	6228	6287
DEX0337_72 DEX0337_73	17002	12143.02	100	17.6	23.1	0	3910	3969	6228	6287
DEX0337_76	26204	57229.01	100	29.4	23.1	50	506	565		
DEX0337_76	26204	57229.02	94.1	23.5	15.4	50	506	565		
DEX0337_78	26278	57425.01	82.4	5.9	7.7	0	730	789		
DEX0337_78	26278	57425.02	100	17.6	7.7	50	730	789		
DEX0337_79	26393	57681.01	100	17.6	15.4	25	724	783		
DEX0337_79	26393	57681.02	100	17.6	7.7	50	724	783		
DEX0337_80	26505	57829.01	100	17.6	15.4	25	213	272		
DEX0337_80	26505	57829.02	100	23.5	15.4	50	213	272		
DEX0337_81	26515	57857.01	100	23.5	15.4	50	510	569		
DEX0337_81	26515	57857.02	94.1	11.8	7.7	25	510	569		
DEX0337_83	26768	58557.01	100	23.5	23.1	25	319	378		
DEX0337_83	26768	58557.02	100	23.5	15.4	50	319	378		
DEX0337_86	27281	70124.01	100	29.4	23.1	50	1169	1228		
DEX0337_86	27281	70124.02	88.2	11.8	7.7	25	1169	1228		
DEX0337_87	27330	70292.01	100	58.8	53.8	75	447	506		

DEX ID	Parent ID	OligoID	"%valid, n=17 *n=19"	"%up, n=17, *n=19"	"%up INV, n=13, *n=14"	"%up LMP, n=4, *n=5"	Start Pos. Par. Seq	Stop Pos. Par. Seq	Start Pos. FLEXS	Stop Pos. FLEXS
DEX0337 87	27330	70292.02	100	58.8	53.8	75	447	506		
DEX0337 88	27363	70408.01	94.1	5.9	0	25	833	892		
DEX0337 88	27363	70408.02	94.1	11.8	0	50	833	892		

Table 3. Microarray Tissue Descriptions

Samples	Tissue ID		age of patient	description of tumor	grade	stage
OV.L.MU.478A1B	17478A1B	LMP	33	benign mucinous cystadenoma with focal proliferation	n/a	no
OV.I.SE370V	2370V	INV	47	invasive papillary serous adenocarcinoma	1-2	IV
OV.L1.SE105	S9822105	LMP	29	papillary serous carcinoma LMP	0	IC
OV.L.SE604A2B	14604A2B	LMP	64	serous cystadenofibroma of low malignant potential(Patient w/transitional cell carcinoma, in-situ and invasive of the bladder grade III/III)	n/a	no
OV.I.EN360	9410C360	INV	52	Endometrioid Adenocarcinoma, Stage Tx, Grade I/III	1-3	IV
OV.I.SE/EN005O	1005O	INV	60	Papillary serous and endometrioid ovarian carcinoma. Metastatic breast cancer, probable ovarian cancer	3	IV
OV.INV.SE.1040O	1040O	INV	67	papillary serous adenocarcinoma (Stage IV)	2	IV
OV.INV.SE.1071C	1071C	INV	51	papillary cystadenocarcinoma (Stage IV)	2	IV
OV.INV.MU.009	9507H009	INV	87	mucinous cystadenoma, multiloculated	N/A	
OV.LMP.MU.084	9808A084	LMP	47	mucinous borderline (LMP)	GB	
OV.INV.SE.291D01	VNM00291D01	INV	28	serous cystadenocarcinoma (Stage II)	1	II
OV.I.MU329D01	VNM00329D01	INV	40	mucinous cystadenocarcinoma	3	n/a
OV.INV.MX.010SP 1	9803G010SP1	INV	71	poorly diff. clear cell, endometrioid & serous papillary types (Stage IV)	4	III
OV.I.EN/MU.608A	95017608A	INV	56	endometrioid and mucinous adenocarcinoma	2	IV
OV.I.SE814V	1814V	INV	66	Papillary serous adenocarcinoma,	3-4	IV
OV.L.MU638A1C	14638A1C	LMP	26	mucinous cystic neoplasm of low malignant potential.	n/a	no
OV.I.SE/EN471A1B	14471A1B	INV	56	poorly differentiated adenocarcinoma with serous and endometrioid features	3-4	IV
OV.INV.SE.693C	S995693A	INV	54	serous papillary carcinoma (Stage IV)	N/A	
OV.INV.SE.116D04	VNM00116D04	INV	47	cystadenocarcinoma	1	

Example 3a: Alternative Splice Variants

We identified gene transcripts associated with cancer disease, development, or progression using cloning experiments, the Gencarta™ tools software (Compugen Ltd., Tel Aviv, Israel), and a variety of public and proprietary databases. These splice variants are either novel sequences which differ from a previously defined sequence or new uses of known sequences. In general the previously defined sequence for a family is annotated as DEX0443_XXX.nt.1 and the novel variants are annotated as DEX0443_XXX.nt.2,

DEX0443_XXX.nt.3, etc. The novel variant DNA sequences encode novel proteins which differ from a previously defined protein sequence. In relation to the nucleotide sequence naming convention, the previously defined amino acid sequence is annotated DEX0443_XXX.aa.1 and the novel variants annotated as DEX0443_XXX.aa.2, etc.

- 5 The mapping of the nucleic acid (“NT”) SEQ ID NO; NT DEX ID; Parent NT ID, chromosomal location (if known); open reading frame (ORF) location; amino acid (“AA”) SEQ ID NO, AA DEX ID, and Parent AA ID are shown in the table below.

- 133 -

SEQ ID NO	NT DEX ID	Parent NT ID	Chromo Map	ORF Loc	SEQ ID NO	AA DEX ID	Parent AA ID
1	DEX0443_001.nt.1	DEX0337_13, DEX0337_14	7p11.2	-	249	DEX0443_001.aa.1	DEX0337_113
2	DEX0443_001.nt.2	DEX0337_13, DEX0337_14	7p11.2				
3	DEX0443_002.nt.1	DEX0337_11, DEX0337_12	2q13	-	250	DEX0443_002.aa.1	DEX0337_112
4	DEX0443_002.nt.2	DEX0337_11, DEX0337_12	2q13				
5	DEX0443_002.nt.3	DEX0337_11, DEX0337_12	2q13	274- 601	251	DEX0443_002.aa.3	
6	DEX0443_003.nt.1	DEX0337_35, DEX0337_36	*	-	252	DEX0443_003.aa.1	DEX0337_119
7	DEX0443_003.nt.2	DEX0337_35, DEX0337_36	*	-	253	DEX0443_003.aa.2	DEX0337_120
8	DEX0443_004.nt.1	DEX0337_34, DEX0337_45	9p24.3	-	254	DEX0443_004.aa.1	DEX0337_118
9	DEX0443_004.nt.2	DEX0337_34, DEX0337_45	9p24.3				
10	DEX0443_004.nt.3	DEX0337_34, DEX0337_45	9p24.3	2985- 5847	255	DEX0443_004.aa.3	
11	DEX0443_004.nt.4	DEX0337_34, DEX0337_45	9p24.3	2962- 5149	256	DEX0443_004.aa.4	
12	DEX0443_005.nt.1	DEX0337_60	2q24.3				
13	DEX0443_006.nt.1	DEX0337_58, DEX0337_59	*	-	257	DEX0443_006.aa.1	DEX0337_136
14	DEX0443_006.nt.2	DEX0337_58, DEX0337_59	*				
15	DEX0443_006.nt.3	DEX0337_58, DEX0337_59	*	295- 514	258	DEX0443_006.aa.3	
16	DEX0443_006.nt.4	DEX0337_58, DEX0337_59	*	1-360	259	DEX0443_006.aa.4	
17	DEX0443_006.nt.5	DEX0337_58, DEX0337_59	*	265- 649	260	DEX0443_006.aa.5	
18	DEX0443_006.nt.6	DEX0337_58, DEX0337_59	*	1-393	261	DEX0443_006.aa.6	
19	DEX0443_007.nt.1	DEX0337_7	4q28.1	-	262	DEX0443_007.aa.1	DEX0337_110
20	DEX0443_007.nt.2	DEX0337_7	4q28.1	1-584	263	DEX0443_007.aa.2	
21	DEX0443_008.nt.1	DEX0337_32	17p13.2	-	264	DEX0443_008.aa.1	DEX0337_116
22	DEX0443_009.nt.1	DEX0337_65	4q22.1	-	265	DEX0443_009.aa.1	DEX0337_139
23	DEX0443_010.nt.1	DEX0337_53, DEX0337_54	1p36.11	-	266	DEX0443_010.aa.1	DEX0337_132
24	DEX0443_010.nt.2	DEX0337_53, DEX0337_54	1p36.11				
25	DEX0443_011.nt.1	DEX0337_69	9q34.3	-	267	DEX0443_011.aa.1	DEX0337_141

- 134 -

SEQ ID NO	NT DEX ID	Parent NT ID	Chromo Map	ORF Loc	SEQ ID NO	AA DEX ID	Parent AA ID
26	DEX0443_011.nt.2	DEX0337_69	9q34.3	1-790	268	DEX0443_011.aa.2	
27	DEX0443_011.nt.3	DEX0337_69	9q34.3	1-1354	269	DEX0443_011.aa.3	
28	DEX0443_011.nt.4	DEX0337_69	9q34.3	1-1345	270	DEX0443_011.aa.4	
29	DEX0443_011.nt.5	DEX0337_69	9q34.3	2-410	271	DEX0443_011.aa.5	
30	DEX0443_011.nt.6	DEX0337_69	9q34.3	1-455	272	DEX0443_011.aa.6	
31	DEX0443_011.nt.7	DEX0337_69	9q34.3	1-685	273	DEX0443_011.aa.7	
32	DEX0443_012.nt.1	DEX0337_65	4q22.1	-	265	DEX0443_009.aa.1	DEX0337_139
33	DEX0443_012.nt.2	DEX0337_65	4q22.1	1-371	274	DEX0443_012.aa.2	
34	DEX0443_013.nt.1	DEX0337_8	12p13.2	-			
35	DEX0443_013.nt.2	DEX0337_8	12p13.2	-			
36	DEX0443_014.nt.1	DEX0337_33	7q11.21	-	275	DEX0443_014.aa.1	DEX0337_117
37	DEX0443_014.nt.2	DEX0337_33	7q11.21	608-959	276	DEX0443_014.aa.2	
38	DEX0443_014.nt.3	DEX0337_33	7q11.21	455-629	277	DEX0443_014.aa.3	
39	DEX0443_014.nt.4	DEX0337_33	7q11.21	1025-1460	278	DEX0443_014.aa.4	
40	DEX0443_015.nt.1	DEX0337_22, DEX0337_23	11p15.2				
41	DEX0443_015.nt.2	DEX0337_22, DEX0337_23	11p15.2				
42	DEX0443_015.nt.3	DEX0337_22, DEX0337_23	11p15.2	1-319	279	DEX0443_015.aa.3	
43	DEX0443_016.nt.1	DEX0337_71	1p21.3	-	280	DEX0443_016.aa.1	DEX0337_143
44	DEX0443_016.nt.2	DEX0337_71	1p21.3	215-419	281	DEX0443_016.aa.2	
45	DEX0443_016.nt.3	DEX0337_71	1p21.3	658-889	282	DEX0443_016.aa.3	
46	DEX0443_017.nt.1	DEX0337_18	21q21.1				
47	DEX0443_018.nt.1	DEX0337_20	3p14.1				
48	DEX0443_019.nt.1	DEX0337_21	6p22.3				
49	DEX0443_020.nt.1	DEX0337_61, DEX0337_62	*	-	283	DEX0443_020.aa.1	DEX0337_137
50	DEX0443_020.nt.2	DEX0337_61, DEX0337_62	*				
51	DEX0443_020.nt.3	DEX0337_61, DEX0337_62	*	243-633	284	DEX0443_020.aa.3	
52	DEX0443_020.nt.4	DEX0337_61, DEX0337_62	*	243-633	284	DEX0443_020.aa.3	
53	DEX0443_021.nt.1	DEX0337_49, DEX0337_50	2q32.2	-	285	DEX0443_021.aa.1	DEX0337_131
54	DEX0443_021.nt.2	DEX0337_49, DEX0337_50	2q32.2				

SEQ ID NO	NT DEX ID	Parent NT ID	Chromo Map	ORF Loc	SEQ ID NO	AA DEX ID	Parent AA ID
55	DEX0443_021.nt.3	DEX0337_49, DEX0337_50	2q32.2	609- 1653	286	DEX0443_021.aa.3	
56	DEX0443_021.nt.4	DEX0337_49, DEX0337_50	2q32.2	1212- 2256	286	DEX0443_021.aa.3	
57	DEX0443_021.nt.5	DEX0337_49, DEX0337_50	2q32.2	512- 1496	287	DEX0443_021.aa.5	
58	DEX0443_021.nt.6	DEX0337_49, DEX0337_50	2q32.2	Jan-10	288	DEX0443_021.aa.6	
59	DEX0443_022.nt.1	DEX0337_44	1p36.11				
60	DEX0443_022.nt.2	DEX0337_44	1p36.11	1-250	289	DEX0443_022.aa.2	
61	DEX0443_022.nt.3	DEX0337_44	1p36.11	189- 1272	290	DEX0443_022.aa.3	
62	DEX0443_022.nt.4	DEX0337_44	1p36.11	189- 1590	291	DEX0443_022.aa.4	
63	DEX0443_022.nt.5	DEX0337_44	1p36.11	189- 1176	292	DEX0443_022.aa.5	
64	DEX0443_022.nt.6	DEX0337_44	1p36.11	84-318	293	DEX0443_022.aa.6	
65	DEX0443_023.nt.1	DEX0337_56, DEX9000_058.nt.1, DEX9000_058.nt.2, DEX9000_058.nt.3	20p12.2	-	294	DEX0443_023.aa.1	DEX0337_134
66	DEX0443_023.nt.2	DEX0337_56, DEX9000_058.nt.1, DEX9000_058.nt.2, DEX9000_058.nt.3	20p12.2	-	295	DEX0443_023.aa.2	DEX9000_058.aa.1
67	DEX0443_023.nt.3	DEX0337_56, DEX9000_058.nt.1, DEX9000_058.nt.2, DEX9000_058.nt.3	20p12.2	-	296	DEX0443_023.aa.3	DEX9000_058.aa.2
68	DEX0443_023.nt.4	DEX0337_56, DEX9000_058.nt.1, DEX9000_058.nt.2, DEX9000_058.nt.3	20p12.2	-	297	DEX0443_023.aa.4	DEX9000_058.aa.4
69	DEX0443_023.nt.6	DEX0337_56, DEX9000_058.nt.1, DEX9000_058.nt.2, DEX9000_058.nt.3	20p12.2	604- 1570	298	DEX0443_023.aa.6	
70	DEX0443_023.nt.7	DEX0337_56, DEX9000_058.nt.1, DEX9000_058.nt.2, DEX9000_058.nt.3	20p12.2	1-1123	299	DEX0443_023.aa.7	
71	DEX0443_024.nt.1	DEX0337_17	7p14.2				
72	DEX0443_025.nt.1	DEX0337_64	*	-	300	DEX0443_025.aa.1	DEX0337_138
73	DEX0443_026.nt.1	DEX0337_63	1q32.3				

SEQ ID NO	NT DEX ID	Parent NT ID	Chromo Map	ORF Loc	SEQ ID NO	AA DEX ID	Parent AA ID
74	DEX0443_026.nt.2	DEX0337_63	1q32.3	-			
75	DEX0443_026.nt.3	DEX0337_63	1q32.3	512-1361	301	DEX0443_026.aa.3	
76	DEX0443_027.nt.1	DEX0337_37	2p25.1	-	302	DEX0443_027.aa.1	DEX0337_121
77	DEX0443_028.nt.1	DEX0337_30, DEX0337_31	11q13.3	-	303	DEX0443_028.aa.1	DEX0337_115
78	DEX0443_028.nt.2	DEX0337_30, DEX0337_31	11q13.3				
79	DEX0443_028.nt.3	DEX0337_30, DEX0337_31	11q13.3	1172-1631	304	DEX0443_028.aa.3	
80	DEX0443_028.nt.4	DEX0337_30, DEX0337_31	11q13.3	1046-1505	304	DEX0443_028.aa.3	
81	DEX0443_029.nt.1	DEX0337_16	3q22.1				
82	DEX0443_029.nt.2	DEX0337_16	3q22.1	-			
83	DEX0443_030.nt.1	DEX0337_39, DEX0337_40	12p12.3	-	305	DEX0443_030.aa.1	DEX0337_123
84	DEX0443_030.nt.2	DEX0337_39, DEX0337_40	12p12.3	-	306	DEX0443_030.aa.2	DEX0337_124
85	DEX0443_030.nt.3	DEX0337_39, DEX0337_40	12p12.3	1-441	307	DEX0443_030.aa.3	
86	DEX0443_030.nt.4	DEX0337_39, DEX0337_40	12p12.3	1-564	308	DEX0443_030.aa.4	
87	DEX0443_030.nt.5	DEX0337_39, DEX0337_40	12p12.3	1-349	309	DEX0443_030.aa.5	
88	DEX0443_030.nt.6	DEX0337_39, DEX0337_40	12p12.3	1-450	310	DEX0443_030.aa.6	
89	DEX0443_030.nt.7	DEX0337_39, DEX0337_40	12p12.3	1-261	311	DEX0443_030.aa.7	
90	DEX0443_030.nt.8	DEX0337_39, DEX0337_40	12p12.3	1-345	312	DEX0443_030.aa.8	
91	DEX0443_030.nt.9	DEX0337_39, DEX0337_40	12p12.3	1-440	313	DEX0443_030.aa.9	
92	DEX0443_031.nt.1	DEX0337_19	8q23.1				
93	DEX0443_032.nt.1	DEX0337_37	2p25.1	-	302	DEX0443_027.aa.1	DEX0337_121
94	DEX0443_032.nt.2	DEX0337_37	2p25.1	1-1595	314	DEX0443_032.aa.2	
95	DEX0443_033.nt.1	DEX0337_72, DEX0337_73	13q14.11	-	315	DEX0443_033.aa.1	DEX0337_144
96	DEX0443_033.nt.2	DEX0337_72, DEX0337_73	13q14.11	-	316	DEX0443_033.aa.2	DEX0337_145
97	DEX0443_033.nt.3	DEX0337_72, DEX0337_73	13q14.11	1-495	317	DEX0443_033.aa.3	
98	DEX0443_034.nt.1	DEX0337_52	17q21.33				

- 137 -

SEQ ID NO	NT DEX ID	Parent NT ID	Chromo Map	ORF Loc	SEQ ID NO	AA DEX ID	Parent AA ID
99	DEX0443_034.nt.2	DEX0337_52	17q21.33	197-1281	318	DEX0443_034.aa.2	
100	DEX0443_035.nt.1	DEX0337_66	1q25.3	-	319	DEX0443_035.aa.1	DEX0337_140
101	DEX0443_036.nt.1	DEX0337_5, DEX0337_6	6q27	-	320	DEX0443_036.aa.1	DEX0337_109
102	DEX0443_036.nt.2	DEX0337_5, DEX0337_6	6q27				
103	DEX0443_036.nt.3	DEX0337_5, DEX0337_6	6q27	-			
104	DEX0443_037.nt.1	DEX0337_41	19p13.12	-	321	DEX0443_037.aa.1	DEX0337_125
105	DEX0443_037.nt.2	DEX0337_41	19p13.12	108-645	322	DEX0443_037.aa.2	
106	DEX0443_037.nt.3	DEX0337_41	19p13.12	108-675	323	DEX0443_037.aa.3	
107	DEX0443_037.nt.4	DEX0337_41	19p13.12	1-327	324	DEX0443_037.aa.4	
108	DEX0443_038.nt.1	DEX0337_98	*				
109	DEX0443_039.nt.1	DEX0337_68	6p21.31				
110	DEX0443_039.nt.2	DEX0337_68	6p21.31	1-753	325	DEX0443_039.aa.2	
111	DEX0443_039.nt.3	DEX0337_68	6p21.31	1-207	326	DEX0443_039.aa.3	
112	DEX0443_039.nt.4	DEX0337_68	6p21.31	1039-1705	327	DEX0443_039.aa.4	
113	DEX0443_039.nt.5	DEX0337_68	6p21.31	1-753	325	DEX0443_039.aa.2	
114	DEX0443_040.nt.1	DEX0337_51	8p12				
115	DEX0443_041.nt.1	DEX0337_3, DEX0337_4	1q23.3				
116	DEX0443_041.nt.10	DEX0337_3, DEX0337_4	1q23.3	599-926	328	DEX0443_041.aa.8	
117	DEX0443_041.nt.11	DEX0337_3, DEX0337_4	1q23.3	1-520	329	DEX0443_041.aa.11	
118	DEX0443_041.nt.12	DEX0337_3, DEX0337_4	1q23.3	497-1505	330	DEX0443_041.aa.12	
119	DEX0443_041.nt.13	DEX0337_3, DEX0337_4	1q23.3	497-1553	331	DEX0443_041.aa.13	
120	DEX0443_041.nt.14	DEX0337_3, DEX0337_4	1q23.3	1-753	332	DEX0443_041.aa.14	
121	DEX0443_041.nt.2	DEX0337_3, DEX0337_4	1q23.3	-	333	DEX0443_041.aa.2	DEX0337_108
122	DEX0443_041.nt.3	DEX0337_3, DEX0337_4	1q23.3	1-342	334	DEX0443_041.aa.3	
123	DEX0443_041.nt.4	DEX0337_3, DEX0337_4	1q23.3	1-664	335	DEX0443_041.aa.4	
124	DEX0443_041.nt.5	DEX0337_3, DEX0337_4	1q23.3	1-601	336	DEX0443_041.aa.5	

SEQ ID NO	NT DEX ID	Parent NT ID	Chromo Map	ORF Loc	SEQ ID NO	AA DEX ID	Parent AA ID
125	DEX0443_041.nt.6	DEX0337_3, DEX0337_4	1q23.3	2-320	337	DEX0443_041.aa.6	
126	DEX0443_041.nt.7	DEX0337_3, DEX0337_4	1q23.3	454-850	338	DEX0443_041.aa.7	
127	DEX0443_041.nt.8	DEX0337_3, DEX0337_4	1q23.3	599-926	328	DEX0443_041.aa.8	
128	DEX0443_041.nt.9	DEX0337_3, DEX0337_4	1q23.3	998-1325	328	DEX0443_041.aa.8	
129	DEX0443_042.nt.1	DEX0337_46, DEX0337_47	9p13.3	-	339	DEX0443_042.aa.1	DEX0337_128
130	DEX0443_042.nt.2	DEX0337_46, DEX0337_47	9p13.3	-	340	DEX0443_042.aa.2	DEX0337_129
131	DEX0443_042.nt.3	DEX0337_46, DEX0337_47	9p13.3	1-1106	341	DEX0443_042.aa.3	
132	DEX0443_042.nt.4	DEX0337_46, DEX0337_47	9p13.3	1-645	342	DEX0443_042.aa.4	
133	DEX0443_043.nt.1	DEX0337_48	4p16.3	-	343	DEX0443_043.aa.1	DEX0337_130
134	DEX0443_044.nt.1	DEX0337_55	2q37.3	-	344	DEX0443_044.aa.1	DEX0337_133
135	DEX0443_044.nt.2	DEX0337_55	2q37.3	1-1354	345	DEX0443_044.aa.2	
136	DEX0443_044.nt.3	DEX0337_55	2q37.3	1-1101	346	DEX0443_044.aa.3	
137	DEX0443_044.nt.4	DEX0337_55	2q37.3	Jan-71	347	DEX0443_044.aa.4	
138	DEX0443_045.nt.1	DEX0337_24, DEX0337_25	12q15	-	348	DEX0443_045.aa.1	DEX0337_114
139	DEX0443_045.nt.2	DEX0337_24, DEX0337_25	12q15				
140	DEX0443_046.nt.1	DEX0337_64	*	-	300	DEX0443_025.aa.1	DEX0337_138
141	DEX0443_046.nt.2	DEX0337_64	*	6-702	349	DEX0443_046.aa.2	
142	DEX0443_047.nt.1	DEX0337_10, DEX0337_9	4q27				
143	DEX0443_047.nt.2	DEX0337_10, DEX0337_9	4q27	-	350	DEX0443_047.aa.2	DEX0337_111
144	DEX0443_048.nt.1	DEX0337_1	9q21.12				
145	DEX0443_049.nt.1	DEX0337_42, DEX9000_052.nt.1, DEX9000_052.nt.2, DEX9000_052.nt.3	12p13.31	-	351	DEX0443_049.aa.1	DEX0337_126
146	DEX0443_049.nt.2	DEX0337_42, DEX9000_052.nt.1, DEX9000_052.nt.2, DEX9000_052.nt.3	12p13.31	-	352	DEX0443_049.aa.2	DEX9000_052.aa.1
147	DEX0443_049.nt.3	DEX0337_42, DEX9000_052.nt.1, DEX9000_052.nt.2, DEX9000_052.nt.3	12p13.31	-	353	DEX0443_049.aa.3	DEX9000_052.aa.2

SEQ ID NO	NT DEX ID	Parent NT ID	Chromo Map	ORF LOC	SEQ ID NO	AA DEX ID	Parent AA ID
148	DEX0443_049.nt.4	DEX0337_42, DEX9000_052.nt.1, DEX9000_052.nt.2, DEX9000_052.nt.3	12p13.31	-	354	DEX0443_049.aa.4	DEX9000_052.aa.3
149	DEX0443_049.nt.5	DEX0337_42, DEX9000_052.nt.1, DEX9000_052.nt.2, DEX9000_052.nt.3	12p13.31	248- 2156	355	DEX0443_049.aa.5	
150	DEX0443_049.nt.6	DEX0337_42, DEX9000_052.nt.1, DEX9000_052.nt.2, DEX9000_052.nt.3	12p13.31	1-585	356	DEX0443_049.aa.6	
151	DEX0443_049.nt.7	DEX0337_42, DEX9000_052.nt.1, DEX9000_052.nt.2, DEX9000_052.nt.3	12p13.31	248- 1166	357	DEX0443_049.aa.7	
152	DEX0443_050.nt.1	DEX0337_28	1p13.3				
153	DEX0443_051.nt.1	DEX0337_26, DEX0337_27	15q15.3				
154	DEX0443_051.nt.2	DEX0337_26, DEX0337_27	15q15.3				
155	DEX0443_051.nt.3	DEX0337_26, DEX0337_27	15q15.3	126- 3510	358	DEX0443_051.aa.3	
156	DEX0443_051.nt.4	DEX0337_26, DEX0337_27	15q15.3	1-169	359	DEX0443_051.aa.4	
157	DEX0443_051.nt.5	DEX0337_26, DEX0337_27	15q15.3	1-221	360	DEX0443_051.aa.5	
158	DEX0443_052.nt.1	DEX0337_66	1q25.3	-	319	DEX0443_035.aa.1	DEX0337_140
159	DEX0443_053.nt.1	DEX0337_6	6q27				
160	DEX0443_054.nt.1	DEX0337_70	15q26.2	-	361	DEX0443_054.aa.1	DEX0337_142
161	DEX0443_055.nt.1	DEX0337_67	13q33.3				
162	DEX0443_055.nt.2	DEX0337_67	13q33.3	245- 1067	362	DEX0443_055.aa.2	
163	DEX0443_055.nt.3	DEX0337_67	13q33.3	224- 653	363	DEX0443_055.aa.3	
164	DEX0443_055.nt.4	DEX0337_67	13q33.3	245- 1067	362	DEX0443_055.aa.2	
165	DEX0443_055.nt.5	DEX0337_67	13q33.3	245- 1067	362	DEX0443_055.aa.2	
166	DEX0443_055.nt.6	DEX0337_67	13q33.3	245- 1067	362	DEX0443_055.aa.2	
167	DEX0443_056.nt.1	DEX0337_77	*				
168	DEX0443_056.nt.2	DEX0337_77	*				
169	DEX0443_057.nt.1	DEX0337_15	6p22.3	-			

- 140 -

SEQ ID NO	NT DEX ID	Parent NT ID	Chromo Map	ORF Loc	SEQ ID NO	AA DEX ID	Parent AA ID
170	DEX0443_057.nt.2	DEX0337_15	6p22.3	178-487	364	DEX0443_057.aa.2	
171	DEX0443_057.nt.3	DEX0337_15	6p22.3	1-279	365	DEX0443_057.aa.3	
172	DEX0443_057.nt.4	DEX0337_15	6p22.3	178-661	366	DEX0443_057.aa.4	
173	DEX0443_057.nt.5	DEX0337_15	6p22.3	1-279	365	DEX0443_057.aa.3	
174	DEX0443_058.nt.1	DEX0337_38	6p21.31	-	367	DEX0443_058.aa.1	DEX0337_122
175	DEX0443_058.nt.2	DEX0337_38	6p21.31	34-214	368	DEX0443_058.aa.2	
176	DEX0443_058.nt.3	DEX0337_38	6p21.31	114-447	369	DEX0443_058.aa.3	
177	DEX0443_058.nt.4	DEX0337_38	6p21.31	1-187	370	DEX0443_058.aa.4	
178	DEX0443_059.nt.1	DEX0337_2	1q22				
179	DEX0443_059.nt.2	DEX0337_2	1q22	151-1358	371	DEX0443_059.aa.2	
180	DEX0443_059.nt.3	DEX0337_2	1q22	863-1595	372	DEX0443_059.aa.3	
181	DEX0443_059.nt.4	DEX0337_2	1q22	863-1595	372	DEX0443_059.aa.3	
182	DEX0443_060.nt.1	DEX0337_74	17q25.1				
183	DEX0443_060.nt.2	DEX0337_74	17q25.1	474-1617	373	DEX0443_060.aa.2	
184	DEX0443_060.nt.3	DEX0337_74	17q25.1	474-2514	374	DEX0443_060.aa.3	
185	DEX0443_060.nt.4	DEX0337_74	17q25.1	474-1617	373	DEX0443_060.aa.2	
186	DEX0443_060.nt.5	DEX0337_74	17q25.1	474-1617	373	DEX0443_060.aa.2	
187	DEX0443_060.nt.6	DEX0337_74	17q25.1	176-548	375	DEX0443_060.aa.6	
188	DEX0443_060.nt.7	DEX0337_74	17q25.1	1-289	376	DEX0443_060.aa.7	
189	DEX0443_061.nt.1	DEX0337_43	9q22.32				
190	DEX0443_061.nt.2	DEX0337_43	9q22.32	838-1043	377	DEX0443_061.aa.2	
191	DEX0443_062.nt.1	DEX0337_57	*	-	378	DEX0443_062.aa.1	DEX0337_135
192	DEX0443_062.nt.2	DEX0337_57	*	1-212	379	DEX0443_062.aa.2	
193	DEX0443_063.nt.1	DEX0337_82					
194	DEX0443_064.nt.1	DEX0337_71		-	380	DEX0443_064.aa.1	DEX0337_143
195	DEX0443_065.nt.1	DEX0337_95					
196	DEX0443_066.nt.1	DEX0337_72		-	381	DEX0443_066.aa.1	DEX0337_144
197	DEX0443_066.nt.2	DEX0337_73		-	382	DEX0443_066.aa.2	DEX0337_145
198	DEX0443_067.nt.1	DEX0337_33		-	383	DEX0443_067.aa.1	DEX0337_117
199	DEX0443_068.nt.1	DEX0337_96					
200	DEX0443_069.nt.1	DEX0337_93					

SEQ ID NO	NT DEX ID	Parent NT ID	Chromo Map	ORF Loc	SEQ ID NO	AA DEX ID	Parent AA ID
201	DEX0443 070.nt.1	DEX0337 99					
202	DEX0443 071.nt.1	DEX0337 57		-	384	DEX0443 071.aa.1	DEX0337 135
203	DEX0443 072.nt.1	DEX0337 100					
204	DEX0443 073.nt.1	DEX0337 83					
205	DEX0443 074.nt.1	DEX0337 76					
206	DEX0443 075.nt.1	DEX0337 69		-	385	DEX0443 075.aa.1	DEX0337 141
207	DEX0443 076.nt.1	DEX0337 7		-	386	DEX0443 076.aa.1	DEX0337 110
208	DEX0443 077.nt.1	DEX0337 42		-	387	DEX0443 077.aa.1	DEX0337 126
209	DEX0443 078.nt.1	DEX0337 87					
210	DEX0443 079.nt.1	DEX0337 85					
211	DEX0443 080.nt.1	DEX0337 92					
212	DEX0443 081.nt.1	DEX0337 48		-	388	DEX0443 081.aa.1	DEX0337 130
213	DEX0443 082.nt.1	DEX0337 2					
214	DEX0443 083.nt.1	DEX0337 81					
215	DEX0443 084.nt.1	DEX0337 43					
216	DEX0443 085.nt.1	DEX0337 75					
217	DEX0443 086.nt.1	DEX0337 86					
218	DEX0443 087.nt.1	DEX0337 60					
219	DEX0443 088.nt.1	DEX0337 79					
220	DEX0443 089.nt.1	DEX0337 94					
221	DEX0443 090.nt.1	DEX0337 74					
222	DEX0443 091.nt.1	DEX0337 1					
223	DEX0443 092.nt.1	DEX0337 28					
224	DEX0443 093.nt.1	DEX0337 32		-	389	DEX0443 093.aa.1	DEX0337 116
225	DEX0443 094.nt.1	DEX0337 65		-	390	DEX0443 094.aa.1	DEX0337 139
226	DEX0443 095.nt.1	DEX0337 64		-	391	DEX0443 095.aa.1	DEX0337 138
227	DEX0443 096.nt.1	DEX0337 97					
228	DEX0443 097.nt.1	DEX0337 58		-	392	DEX0443 097.aa.1	DEX0337 136
229	DEX0443 097.nt.2	DEX0337 59					
230	DEX0443 098.nt.1	DEX0337 89					
231	DEX0443 099.nt.1	DEX0337 101					
232	DEX0443 100.nt.1	DEX0337 35		-	393	DEX0443 100.aa.1	DEX0337 119
233	DEX0443 101.nt.1	DEX0337 98					
234	DEX0443 102.nt.1	DEX0337 40		-	394	DEX0443 102.aa.1	DEX0337 124
235	DEX0443 102.nt.2	DEX0337 39		-	395	DEX0443 102.aa.2	DEX0337 123
236	DEX0443 103.nt.1	DEX0337 84					
237	DEX0443 104.nt.1	DEX0337 77					
238	DEX0443 105.nt.1	DEX0337 80					
239	DEX0443 106.nt.1	DEX0337 45					
240	DEX0443 107.nt.1	DEX0337 18					
241	DEX0443 108.nt.1	DEX0337 27					
242	DEX0443 109.nt.1	DEX0337 24		-	396	DEX0443 109.aa.1	DEX0337 114
243	DEX0443 109.nt.2	DEX0337 25					

SEQ ID NO	NT DEX ID	Parent NT ID	Chromo Map	ORF Loc	SEQ ID NO	AA DEX ID	Parent AA ID
244	DEX0443 110.nt.1	DEX0337 88					
245	DEX0443 111.nt.1	DEX0337 90					
246	DEX0443 112.nt.1	DEX0337 29					
247	DEX0443 113.nt.1	DEX0337 78					
248	DEX0443 114.nt.1	DEX0337 91					

EST Support

The alternative splice variants were predicted by computational analysis of Expressed Sequence Tags (ESTs) derived from public and proprietary cDNA libraries and genomic information.

5 *SAGE Support*

Serial Analysis of Gene Expression (SAGE) tag data analysis is performed on the splice variants. Gencarta™ tools (Compugen Ltd., Tel Aviv, Israel) report SAGE tag data for individual transcripts when available. SAGE data includes the SAGE tag sequence for the transcript, expression level (as a ratio) of the SAGE tag in tissue samples, the source or
10 tissue, state or disease condition of the tissue, tissue sample type, and a description of the tissue samples.

Sequence Alignment Support

Alignments of previously identified reference sequences and novel splice variant sequences are performed to confirm unique portions of splice variant nucleic acid and
15 amino acid sequences. The alignments are done using the Needle program in the European Molecular Biology Open Software Suite (EMBOSS) version 2.2.0 available at www.emboss.org from EMBnet (<http://www.embnet.org>). Default settings are used unless otherwise noted. The Needle program in EMBOSS implements the Needleman-Wunsch algorithm. Needleman, S. B., Wunsch, C. D., *J. Mol. Biol.* 48:443-453 (1970).

20 It is well known to those skilled in the art that implication of alignment algorithms by various programs may result in minor changes in the generated output. These changes include but are not limited to: alignment scores (percent identity, similarity, and gap), display of nonaligned flanking sequence regions, and number assignment to residues. These minor changes in the output of an alignment do not alter the physical characteristics
25 of the sequences or the differences between the sequences, e.g. regions of homology, insertions, or deletions. Descriptions of alignments are provided in each splice variant section below.

Splice Variant Polypeptide Annotation

The polypeptides of the present invention were analyzed and the following
30 attributes were identified; specifically, epitopes, post translational modifications, signal

peptides and transmembrane domains. Antigenicity (Epitope) prediction was performed through the antigenic module in the EMBOSS package. Rice, P., EMBOSS: The European Molecular Biology Open Software Suite, *Trends in Genetics* 16(6): 276-277 (2000). The antigenic module predicts potentially antigenic regions of a protein sequence, using the method of Kolaskar and Tongaonkar. Kolaskar, AS and Tongaonkar, PC., A semi-empirical method for prediction of antigenic determinants on protein antigens, *FEBS Letters* 276: 172-174 (1990). Examples of post-translational modifications (PTMs) and other motifs of the OSPs of this invention are listed below. In addition, antibodies that specifically bind such post-translational modifications may be useful as a diagnostic or as therapeutic. The PTMs and other motifs were predicted by using the ProSite Dictionary of Proteins Sites and Patterns (Bairoch *et al.*, *Nucleic Acids Res.* 25(1):217-221 (1997)), the following motifs, including PTMs, were predicted for the OSPs of the invention. The signal peptides were detected by using the SignalP 2.0, see Nielsen *et al.*, *Protein Engineering* 12, 3-9 (1999). Prediction of transmembrane helices in proteins was performed by the application TMHMM 2.0, "currently the best performing transmembrane prediction program", according to authors (Krogh *et al.*, *Journal of Molecular Biology*, 305(3):567-580, (2001); Moller *et al.*, *Bioinformatics*, 17(7):646-653, (2001); Sonnhammer, *et al.*, *A hidden Markov model for predicting transmembrane helices in protein sequences* in Glasgow, *et al.* Ed. Proceedings of the Sixth International Conference on Intelligent Systems for Molecular Biology, pages 175-182, Menlo Park, CA, 1998. AAAI Press. The PSORT II program may also be used to predict cellular localizations. Horton *et al.*, *Intelligent Systems for Molecular Biology* 5: 147-152 (1997). The table below includes the following sequence annotations: Signal peptide presence; TM (number of membrane domain, topology in orientation and position); Amino acid location and antigenic index (location, AI score, length); PTM and other motifs (type, amino acid residue locations); and functional domains.

AA SEQ ID	Sig P	TMHMM	Antigenicity	PTM	Domain
DEX0443_00 1.aa.1	Y	0 - o	4-25,1.252		
DEX0443_00 2.aa.1	y	0 - i	70-79,1.158; 94-105,1.153; 17-55,1.125; 59-67,1.082	Myristyl 62-67, 77-82, 87-92, 91-96, 94-99; Pkc_Phospho_Site 12-14; Prokar_Lipoprote in 68-78;	
DEX0443_00 2.aa.3	y	0 - i	70-79,1.158; 94-105,1.153; 17-55,1.125; 59-67,1.082	Myristyl 62-67, 77-82, 87-92, 91-96, 94-99; Pkc_Phospho_Site 12-14;	

				Prokar_Lipoprote in 68-78;	
DEX0443_00 3.aa.1	N	0 - o	51-60,1.178; 62-68,1.130; 30-45,1.109	Asn_Glycosylatio n 19-22; Ck2_Phospho_Site 60-63, 64-67; Myristyl 17-22, 41-46, 54-59; Pkc_Phospho_Site 47-49;	Lipocalin-related protein and Bos/Can/Equ allergen
DEX0443_00 3.aa.2	N	0 - o	4-15,1.178; 58-67,1.178; 69-81,1.149; 105-114,1.123; 94-100,1.080; 37-52,1.076	Asn_Glycosylatio n 26-29; Ck2_Phospho_Site 67-70, 71-74; Myristyl 24-29, 48-53, 61-66; Pkc_Phospho_Site 54-56, 89-91, 118-120;	Lipocalin-related protein and Bos/Can/Equ allergen
DEX0443_00 4.aa.1	N	0 - o	52-62,1.259; 16-24,1.148; 191-210,1.133; 151-159,1.116; 6-14,1.107; 33-39,1.106; 90-100,1.098; 161-166,1.073; 118-128,1.067; 104-110,1.059; 79-86,1.058; 225-231,1.043	Asn_Glycosylatio n 29-32, 144- 147, 171-174, 174-177, 207- 210; Ck2_Phospho_Site 35-38, 64-67, 100-103, 164- 167, 176-179; Glycosaminoglyca n 31-34; Myristyl 59-64; Pkc_Phospho_Site 21-23, 64-66, 223-225, 236- 238;	
DEX0443_00 4.aa.3	N	5 - i21- 43o56- 78i189- 211o266 - 288i295 -317o	141-213,1.251; 753-782,1.251; 570-587,1.245; 52-80,1.244; 655-680,1.230; 292-319,1.220; 21-46,1.201; 531-544,1.196; 624-652,1.188; 121-132,1.185; 884-898,1.185; 787-805,1.180; 818-881,1.176; 589-601,1.168; 348-380,1.166; 609-619,1.166; 721-739,1.162; 99-116,1.162; 512-524,1.154; 255-286,1.151; 321-340,1.148; 409-462,1.144; 492-507,1.141; 924-935,1.123; 243-252,1.116; 4-19,1.116; 84-92,1.108; 388-401,1.100; 551-568,1.095; 914-920,1.094; 691-697,1.081; 810-816,1.062; 700-708,1.061	Asn_Glycosylatio n 56-59, 233- 236, 746-749, 752-755, 787- 790; Ck2_Phospho_Site 508-511, 551- 554, 702-705, 719-722, 884- 887, 909-912, 939-942, 941- 944; Myristyl 135-140, 245- 250, 656-661, 700-705; Pkc_Phospho_Site 3-5, 144-146, 166-168, 235- 237, 264-266, 322-324, 337- 339, 356-358, 551-553, 627- 629, 721-723, 760-762, 789- 791, 813-815, 840-842, 884- 886, 909-911, 914-916, 917- 919, 943-945; Tyr_Phospho_Site 302-308; Prokar_Lipoprote in 664-674;	
DEX0443_00 4.aa.4	N	6 - o130- 149i169 - 191o206 - 228i340	292-364,1.251; 203-243,1.244; 126-152,1.243; 443-470,1.220; 172-197,1.201; 74-83,1.196; 9-27,1.196;	Asn_Glycosylatio n 125-128, 207- 210, 384-387; Ck2_Phospho_Site 37-40, 118-121, 659-662, 684- 687, 714-717,	

		- 3620417 - 4391446 -4680	250-283,1.185; 659-673,1.185; 94-120,1.182; 38-69,1.174; 499-531,1.166; 406-437,1.151; 472-491,1.148; 560-613,1.144; 699-710,1.123; 643-656,1.122; 394-403,1.116; 162-170,1.116; 538-552,1.100; 689-695,1.094; 154-160,1.051	716-719; Myristyl 286- 291, 396-401; Pkc_Phospho_Site 7-9, 95-97, 158- 160, 295-297, 317-319, 386- 388, 415-417, 473-475, 488- 490, 507-509, 659-661, 684- 686, 689-691, 692-694, 718- 720; Tyr_Phospho_Site 453-459;	
DEX0443_00 6.aa.1	N	0 - o	140-148,1.140; 4-21,1.126; 52-70,1.119; 37-46,1.108; 74-87,1.101; 111-121,1.089; 100-107,1.088; 93-98,1.082; 123-132,1.074	Amidation 140- 143; Asn_Glycosylatio n 34-37, 95-98; Ck2_Phospho_Site 64-67; Glycosaminoglyca n 53-56; Myristyl 44-49, 98-103, 137-142; Pkc_Phospho_Site 74-76, 133-135;	
DEX0443_00 6.aa.3	N	0 - o	36-61,1.137; 20-26,1.110	Asn_Glycosylatio n 70-73; Ck2_Phospho_Site 5-8, 9-12, 34- 37, 49-52, 66- 69;	
DEX0443_00 6.aa.4	N	0 - o	94-113,1.218; 38-54,1.123; 26-32,1.099; 71-78,1.079; 84-89,1.031	Asn_Glycosylatio n 39-42; Ck2_Phospho_Site 7-10, 13-16, 41- 44, 63-66, 74- 77; Pkc_Phospho_Site 74-76;	
DEX0443_00 6.aa.5	Y	0 - o	4-25,1.193; 77-90,1.180; 109-124,1.117; 43-58,1.096; 60-65,1.063; 28-36,1.061	Ck2_Phospho_Site 16-19, 82-85; Myristyl 116- 121;	
DEX0443_00 6.aa.6	N	0 - o	94-105,1.208; 28-46,1.188; 78-85,1.142; 117-127,1.097; 60-74,1.085	Amidation 9-12; Asn_Glycosylatio n 63-66; Ck2_Phospho_Site 61-64, 113-116; Pkc_Phospho_Site 52-54; Aa_Trna_Ligase_I i 1 27-49;	Aminoacyl-transfer RNA synthetases class-II
DEX0443_00 7.aa.1	N	0 - i	21-29,1.168; 63-80,1.159; 103-111,1.144; 82-96,1.123; 148-157,1.113; 54-60,1.086; 135-143,1.070; 125-133,1.062	Amidation 9-12; Camp_Phospho_Sit e 13-16; Ck2_Phospho_Site 149-152; Myristyl 79-84, 88-93; Pkc_Phospho_Site 20-22, 59-61, 67-69, 74-76, 149-151; Ribosomal_L21e 43-68;	Ribosomal protein L21E
DEX0443_00 7.aa.2	Y	1 - i30-520	146-164,1.228; 166-191,1.222; 39-67,1.208; 116-133,1.183; 75-85,1.175;	Asn_Glycosylatio n 93-96, 117- 120, 141-144; Ck2_Phospho_Site 58-61; Myristyl	

			9-34,1.171; 100-114,1.115	42-47, 138-143; Pkc_Phospho_Site 146-148, 176- 178;	
DEX0443_00 8.aa.1	N	0 - o	50-67,1.164; 35-48,1.140; 4-12,1.093; 16-22,1.087	Ck2_Phospho_Site 15-18;	
DEX0443_00 9.aa.1	N	0 - o	71-83,1.182; 90-97,1.134; 211-219,1.127; 130-141,1.117; 186-193,1.076; 59-65,1.067; 195-202,1.065; 226-240,1.059; 169-177,1.041	Asn_Glycosylatio n 13-16, 40-43; Ck2_Phospho_Site 119-122, 125- 128, 149-152, 162-165, 214- 217, 225-228; Myristyl 134- 139; Pkc_Phospho_Site 105-107, 173- 175; Rgd 93-95; Tyr_Phospho_Site 109-115;	Osteopontin; NULL
DEX0443_01 0.aa.1	Y	0 - o	4-37,1.173; 44-55,1.085	Ck2_Phospho_Site 15-18;	
DEX0443_01 1.aa.1	N	0 - o	23-35,1.178; 213-239,1.178; 140-168,1.155; 241-249,1.130; 290-299,1.123; 195-211,1.089; 279-285,1.080; 57-71,1.076; 100-106,1.070; 170-176,1.068; 79-89,1.060; 8-15,1.052; 261-266,1.025	Asn_Glycosylatio n 19-22, 46-49, 137-140; Ck2_Phospho_Site 77-80, 139-142, 239-242, 243- 246; Myristyl 15-20, 44-49, 68-73, 92-97, 97-102, 101-106, 115-120, 233- 238; Pkc_Phospho_Site 74-76, 77-79, 119-121, 188- 190, 212-214, 274-276, 303- 305;	Lipocalin-related protein and Bos/Can/Equ allergen; Lipocalin
DEX0443_01 1.aa.2	Y	0 - o	45-70,1.189; 97-109,1.178; 187-196,1.178; 15-38,1.169; 198-206,1.130; 247-256,1.123; 236-242,1.080; 131-145,1.076; 174-180,1.070; 6-12,1.064; 153-163,1.060; 82-89,1.052; 218-223,1.025	Asn_Glycosylatio n 93-96, 120- 123; Ck2_Phospho_Site 151-154, 196- 199, 200-203; Myristyl 89-94, 118-123, 142- 147, 166-171, 171-176, 175- 180, 186-191, 190-195; Pkc_Phospho_Site 7-9, 148-150, 151-153, 231- 233, 260-262; Lipocalin 75- 88;	Lipocalin-related protein and Bos/Can/Equ allergen
DEX0443_01 1.aa.3	N	0 - o	45-70,1.189; 320-332,1.178; 375-384,1.178; 15-38,1.169; 386-394,1.130; 435-444,1.123; 178-185,1.121; 132-150,1.107; 230-238,1.082; 424-430,1.080; 354-369,1.076; 108-114,1.075; 97-102,1.067; 268-277,1.065; 6-12,1.064;	Amidation 128- 131, 298-301; Asn_Glycosylatio n 268-271, 316- 319, 343-346; Ck2_Phospho_Site 219-222, 384- 387, 388-391; Glycosaminoglyca n 287-290; Myristyl 104- 109, 121-126, 196-201, 210- 215, 212-217, 213-218, 228-	Lipocalin-related protein and Bos/Can/Equ allergen; Lipocalin; Prostaglandin D synthase

			305-312,1.052; 255-261,1.049; 87-93,1.037; 166-172,1.033; 406-411,1.025	233, 232-237, 278-283, 298- 303, 312-317, 341-346, 365- 370, 378-383; Pkc_Phospho_Site 7-9, 88-90, 100- 102, 110-112, 125-127, 204- 206, 258-260, 371-373, 419- 421, 448-450; Lipocalin 298- 311, 299-311;	
DEX0443_01 1.aa.4	N	0 - o	418-433,1.295; 263-275,1.199; 45-70,1.189; 15-38,1.169; 200-209,1.156; 159-172,1.150; 407-413,1.106; 397-405,1.106; 382-388,1.103; 219-225,1.098; 436-444,1.088; 318-325,1.078; 108-114,1.075; 132-149,1.075; 345-354,1.074; 329-335,1.068; 97-102,1.067; 6-12,1.064; 237-242,1.056; 87-93,1.037; 246-252,1.033	Amidation 128- 131, 231-234, 327-330, 381- 384; Camp_Phospho_Sit e 233-236; Ck2_Phospho_Site 261-264; Myristyl 104- 109, 121-126, 190-195, 195- 200, 198-203, 200-205, 228- 233, 280-285, 288-293, 290- 295, 292-297, 293-298, 306- 311, 316-321, 324-329, 341- 346, 346-351, 360-365, 364- 369, 368-373, 372-377, 378- 383; Pkc_Phospho_Site 7-9, 88-90, 100- 102, 110-112, 125-127, 178- 180, 184-186, 220-222, 231- 233, 248-250;	NULL
DEX0443_01 1.aa.5	y	0 - o	46-89,1.223; 8-36,1.181; 120-129,1.123; 109-115,1.080; 38-44,1.052	Asn_Glycosylatio n 98-101; Myristyl 26-31, 59-64, 76-81; Pkc_Phospho_Site 104-106, 133- 135; Prokar_Lipoprote in 50-60;	Lipocalin-related protein and Bos/Can/Equ allergen
DEX0443_01 1.aa.6	N	0 - o	75-102,1.154; 11-27,1.137; 110-116,1.090; 38-45,1.081; 47-53,1.067; 137-147,1.065	Asn_Glycosylatio n 76-79; Ck2_Phospho_Site 51-54; Myristyl 56-61, 67-72, 70-75, 74-79, 79-84, 110-115, 120-125, 143- 148; Pkc_Phospho_Site 38-40, 121-123;	
DEX0443_01 1.aa.7	N	0 - o	45-70,1.189; 97-109,1.178; 152-161,1.178; 15-38,1.169; 163-171,1.130; 212-221,1.123; 201-207,1.080; 131-146,1.076; 6-12,1.064; 82-89,1.052;	Asn_Glycosylatio n 93-96, 120- 123; Ck2_Phospho_Site 161-164, 165- 168; Myristyl 89-94, 118-123, 142-147, 155- 160; Pkc Phospho Site	Lipocalin-related protein and Bos/Can/Equ allergen; Lipocalin; Prostaglandin D synthase

			183-188,1.025	7-9, 148-150, 196-198, 225- 227; Lipocalin 75-88;	
DEX0443_01 2.aa.2	N	0 - o	113-119,1.127; 32-43,1.117; 88-95,1.076; 97-104,1.065; 71-79,1.049	Ck2_Phospho_Site 5-8, 21-24, 27- 30, 51-54, 64- 67, 116-119; Myristyl 36-41; Pkc_phospho_Site 75-77;	
DEX0443_01 4.aa.1	N	0 - o	4-11,1.149; 45-54,1.095; 29-34,1.048	Asn_Glycosylatio n 24-27; Camp_Phospho_Sit e 42-45; Ck2_Phospho_Site 26-29, 54-57; Myristyl 19-24, 50-55;	Aminopeptidase N, APN (CD13)
DEX0443_01 4.aa.2	N	0 - o	69-80,1.147; 4-13,1.110; 27-37,1.085; 50-61,1.080; 82-89,1.049	Amidation 44- 47; Camp_Phospho_Sit e 53-56, 59-62; Ck2_Phospho_Site 41-44; Pkc_Phospho_Site 48-50, 52-54, 57-59, 62-64, 102-104, 106- 108;	
DEX0443_01 4.aa.3	N	0 - o	35-53,1.229; 9-19,1.088; 22-32,1.087	Asn_Glycosylatio n 56-59; Ck2_Phospho_Site 23-26; Tyr_Phospho_Site 32-40;	
DEX0443_01 4.aa.4	N	0 - o	87-110,1.192; 4-14,1.156; 53-64,1.118; 44-50,1.089; 76-82,1.081; 117-125,1.081; 67-74,1.056	Camp_Phospho_Sit e 22-25;	
DEX0443_01 5.aa.3	Y	0 - o	27-34,1.140; 4-11,1.096; 16-22,1.068; 38-44,1.033	Amidation 52- 55; Asn_Glycosylatio n 60-63; Camp_Phospho_Sit e 84-87; Ck2_Phospho_Site 87-90; Glycosaminoglyca n 42-45; Myristyl 43-48; Pkc_Phospho_Site 63-65;	
DEX0443_01 6.aa.1	Y	1 - o252- 274i	251-283,1.275; 216-228,1.194; 180-192,1.149; 61-71,1.145; 6-32,1.142; 96-114,1.119; 172-178,1.104; 142-160,1.096; 38-43,1.087; 236-242,1.071; 79-84,1.064; 88-94,1.049	Tissue_Factor 82-99; Amidation 200-203; Asn_Glycosylatio n 48-51, 161- 164, 174-177; Camp_Phospho_Sit e 237-240; Ck2_Phospho_Site 58-61, 90-93, 92-95, 125-128, 163-166, 179- 182, 242-245, 290-293; Myristyl 36-41, 39-44, 118-123, 157-162, 248- 253, 286-291; Pkc_Phospho_Site	Cytokine receptor class 2 family; Tissue Factor (TF)

				50-52, 76-78, 179-181, 200- 202, 204-206, 290-292;	
DEX0443_01 6.aa.2	Y	0 - o	52-64, 1.179; 42-49, 1.142; 6-33, 1.142	Glycosaminoglyca n 38-41; Myristyl 39-44, 43-48, 47-52;	
DEX0443_01 6.aa.3	Y	1 - i21-43o	4-44, 1.209; 61-73, 1.179; 51-58, 1.142	Myristyl 5-10, 39-44, 48-53, 52-57, 56-61; Pkc_Phospho_Site 13-15;	
DEX0443_02 0.aa.1	N	0 - o	14-47, 1.175; 76-98, 1.143; 119-126, 1.128; 49-57, 1.127; 109-116, 1.077; 101-107, 1.061; 6-12, 1.051; 66-73, 1.035	Myristyl 107- 112; Pkc_Phospho_Site 27-29, 51-53;	
DEX0443_02 0.aa.3	N	0 - o	14-47, 1.175; 76-98, 1.143; 119-126, 1.128; 49-57, 1.127; 109-116, 1.077; 101-107, 1.061; 6-12, 1.051; 66-73, 1.035	Myristyl 107- 112; Pkc_Phospho_Site 27-29, 51-53;	
DEX0443_02 1.aa.1	Y	0 - o	4-20, 1.253; 22-31, 1.067	Asn_Glycosylatio n 53-56; Ck2_Phospho_Site 23-26; Myristyl 51-56;	
DEX0443_02 1.aa.3	N	3 - o47- 69i215- 237o252 -270i	11-83, 1.303; 208-289, 1.280; 117-193, 1.233; 293-319, 1.228; 86-110, 1.216; 4-9, 1.137; 200-206, 1.064	Myristyl 136- 141;	NULL
DEX0443_02 1.aa.5	Y	0 - o	4-32, 1.295; 103-115, 1.061; 160-169, 1.056; 205-221, 1.055; 79-85, 1.048; 301-308, 1.028; 233-241, 1.010	Ck2_Phospho_Site 23-26, 174-177; Myristyl 101- 106, 119-124, 170-175, 182- 187, 194-199, 293-298; Pkc_Phospho_Site 148-150; Rgd 259-261;	Collagen triple helix repeat; Proline-rich region; NULL
DEX0443_02 1.aa.6	N	0 - o	646-660, 1.144; 628-641, 1.128; 544-554, 1.110; 692-699, 1.106; 605-617, 1.081; 569-594, 1.071; 255-261, 1.068; 486-496, 1.063; 202-211, 1.049; 45-60, 1.049; 436-445, 1.049; 151-159, 1.048; 112-118, 1.036; 670-676, 1.030; 375-381, 1.025; 682-689, 1.023; 174-187, 1.022; 12-27, 1.022; 535-540, 1.017; 133-139, 1.010; 511-520, 1.010; 327-333, 1.001	Ck2_Phospho_Site 275-278, 362- 365, 559-562, 612-615, 683- 686; Myristyl 118-123, 121- 126, 124-129, 127-132, 130- 135, 151-156, 163-168, 196- 201, 214-219, 232-237, 262- 267, 283-288, 349-354, 432- 437, 448-453, 453-458, 475- 480, 499-504, 511-516, 541- 546, 563-568; Pkc_Phospho_Site 39-41, 366-368, 546-548, 559- 561, 588-590,	Collagen triple helix repeat; Proline-rich region; Fibrillar collagen C-terminal domain; Gram-positive cocci surface protein 'anchoring' hexapeptide; NULL

				605-607, 612-614; Gram_Pos_Anchoring 449-454;	
DEX0443_02 2 .aa.2	N	0 - o	4-11,1.131; 15-23,1.096; 45-51,1.090	Glycosaminoglycan 81-84;	
DEX0443_02 2 .aa.3	N	0 - o	239-267,1.186; 13-34,1.181; 209-218,1.167; 309-318,1.162; 179-186,1.153; 73-108,1.131; 290-300,1.120; 121-147,1.118; 4-10,1.110; 193-199,1.098; 169-175,1.090; 112-119,1.083; 46-55,1.071; 341-347,1.071	Amidation 222-225, 330-333; Asn_Glycosylation 113-116; Camp_Phospho_Site 83-86; Ck2_Phospho_Site 23-26, 49-52; Myristyl 195-200, 208-213, 268-273; Pkc_Phospho_Site 53-55, 61-63;	NAD dependent epimerase/dehydratase family
DEX0443_02 2 .aa.4	N	0 - o	337-393,1.213; 239-267,1.186; 399-417,1.182; 13-34,1.181; 209-218,1.167; 309-318,1.162; 179-186,1.153; 422-434,1.145; 73-108,1.131; 290-300,1.120; 121-147,1.118; 4-10,1.110; 193-199,1.098; 169-175,1.090; 112-119,1.083; 46-55,1.071	Amidation 222-225, 330-333; Asn_Glycosylation 113-116; Camp_Phospho_Site 83-86; Ck2_Phospho_Site 23-26, 49-52; Glycosaminoglycan 465-468; Myristyl 195-200, 208-213, 268-273, 364-369; Pkc_Phospho_Site 53-55, 61-63, 351-353, 377-379, 404-406;	NAD dependent epimerase/dehydratase family
DEX0443_02 2 .aa.5	N	0 - o	239-267,1.186; 13-34,1.181; 209-218,1.167; 309-318,1.162; 179-186,1.153; 73-108,1.131; 290-300,1.120; 121-147,1.118; 4-10,1.110; 193-199,1.098; 169-175,1.090; 112-119,1.083; 46-55,1.071	Amidation 222-225; Asn_Glycosylation 113-116; Camp_Phospho_Site 83-86; Ck2_Phospho_Site 23-26, 49-52; Myristyl 195-200, 208-213, 268-273; Pkc_Phospho_Site 53-55, 61-63;	NAD dependent epimerase/dehydratase family
DEX0443_02 2 .aa.6	N	0 - o	59-74,1.132; 11-37,1.118		
DEX0443_02 3 .aa.1	N	1 - o236-258i	235-261,1.187; 165-177,1.167; 5-24,1.165; 196-228,1.160; 63-84,1.157; 138-147,1.152; 96-124,1.126; 46-52,1.097; 179-193,1.083; 154-160,1.064	Asn_Glycosylation 40-43, 58-61, 132-135; Ck2_Phospho_Site 46-49, 107-110; Myristyl 247-252; Pkc_Phospho_Site 140-142, 153-155; Lamp_1 61-75;	Lysosome-associated membrane glycoprotein (Lamp)/CD68
DEX0443_02 3 .aa.2	Y	0 - o	5-24,1.165; 63-84,1.157; 96-127,1.144; 139-145,1.100; 46-52,1.097; 156-162,1.056	Asn_Glycosylation 40-43, 58-61; Ck2_Phospho_Site 46-49, 107-110; Myristyl 137-142, 159-164; Pkc_Phospho_Site 169-171; Lamp_1 61-75;	Lysosome-associated membrane glycoprotein (Lamp)/CD68

DEX0443_02 3.aa.3	Y	0 - o	5-24,1.165; 58-87,1.147; 46-52,1.097	Asn_Glycosylation 40-43, 58-61; Ck2_Phospho_Site 46-49; Myristyl 75-80;	
DEX0443_02 3.aa.4	N	1 - o236- 258i	235-261,1.187; 165-177,1.167; 5-24,1.165; 196-228,1.160; 63-84,1.157; 138-147,1.152; 96-124,1.126; 46-52,1.097; 179-193,1.083; 154-160,1.064	Asn_Glycosylation 40-43, 58-61, 132-135; Ck2_Phospho_Site 46-49, 107-110; Myristyl 247- 252; Pkc_Phospho_Site 140-142, 153- 155; Lamp_1 61- 75;	Lysosome-associated membrane glycoprotein (Lamp)/CD68
DEX0443_02 3.aa.6	N	1 - o277- 299i	276-302,1.187; 206-218,1.167; 5-24,1.165; 237-269,1.160; 63-84,1.157; 179-188,1.152; 96-127,1.144; 139-145,1.100; 46-52,1.097; 220-234,1.083; 195-201,1.064	Asn_Glycosylation 40-43, 58-61, 173-176; Camp_Phospho_Site 162-165; Ck2_Phospho_Site 46-49, 107-110; Myristyl 137- 142, 288-293; Pkc_Phospho_Site 181-183, 194- 196; Lamp_1 61- 75;	Lysosome-associated membrane glycoprotein (Lamp)/CD68
DEX0443_02 3.aa.7	N	1 - o329- 351i	4-32,1.238; 328-354,1.187; 258-270,1.167; 289-321,1.160; 156-177,1.157; 38-61,1.154; 231-240,1.152; 73-122,1.145; 189-217,1.126; 139-145,1.097; 272-286,1.083; 247-253,1.064	Amidation 56- 59; Asn_Glycosylation 151-154, 225- 228; Ck2_Phospho_Site 139-142, 200- 203; Myristyl 37-42, 39-44, 88-93, 340-345; Pkc_Phospho_Site 7-9, 18-20, 233- 235, 246-248; Lamp_1 154-168;	Lysosome-associated membrane glycoprotein (Lamp)/CD68
DEX0443_02 5.aa.1	Y	0 - o	351-360,1.285; 4-15,1.269; 101-117,1.189; 150-164,1.148; 300-310,1.144; 264-294,1.134; 19-35,1.134; 184-200,1.124; 332-340,1.123; 207-220,1.112; 245-253,1.109; 312-319,1.085; 67-73,1.074; 119-138,1.065; 90-96,1.060; 238-243,1.051; 38-45,1.048; 229-235,1.042; 174-179,1.036	Asp_Protease 98-109; Asn_Glycosylation 95-98; Ck2_Phospho_Site 70-73, 173-176, 180-183, 226- 229, 302-305, 331-334, 345- 348, 353-356; Myristyl 137- 142, 147-152, 151-156, 167- 172, 230-235; Pkc_Phospho_Site 36-38, 70-72, 277-279, 353- 355, 365-367; Crystallin_Betagamma 238-253; Prokar_Lipoprotein 268-278;	Crystallin; Pepsin (A1) aspartic protease; Eukaryotic and viral aspartic protease active site
DEX0443_02 6.aa.3	Y	4 - i7- 29o44- 61i81- 98o113- 135i	10-59,1.254; 111-139,1.227; 80-104,1.210; 235-243,1.169; 212-228,1.151; 246-265,1.150; 267-275,1.083; 162-168,1.063; 174-180,1.045	Asn_Glycosylation 200-203; Glycosaminoglycan 149-152; Myristyl 86-91, 96-101, 123-128, 128-133, 226- 231, 233-238; Pkc_Phospho_Site 72-74, 172-174;	Cation efflux family; NULL

DEX0443_02 7.aa.1	N	0 - o	4-16,1.200; 118-136,1.135; 53-70,1.121; 84-100,1.118; 76-82,1.087; 163-172,1.086; 105-111,1.072; 18-35,1.070	Thioredoxin 91- 109; Ck2_Phospho_Site 157-160, 166- 169; Myristyl 16-21, 27-32, 42-47, 53-58; Pkc_Phospho_Site 37-39, 43-45, 148-150;	Thioredoxin
DEX0443_02 8.aa.1	N	0 - o	4-23,1.166; 53-62,1.137; 25-32,1.076	Camp_Phospho_Sit e 36-39; Myristyl 71-76;	
DEX0443_02 8.aa.3	N	0 - o	119-149,1.197; 32-87,1.174; 17-23,1.109; 89-95,1.106; 4-11,1.100; 104-110,1.031	Amidation 121- 124; Glycosaminoglyca n 15-18; Myristyl 16-21, 62-67, 93-98, 96-101, 114-119; Pkc_Phospho_Site 37-39; Prokar_Lipoprote in 73-83;	
DEX0443_03 0.aa.1	N	0 - i ~	9-21,1.314; 25-39,1.158	Ck2_Phospho_Site 40-43; Pkc_Phospho_Site 3-5;	
DEX0443_03 0.aa.2	N	1 - o15-37i	163-194,1.164; 148-161,1.149; 97-111,1.142; 69-86,1.136; 129-145,1.136; 34-54,1.104; 13-26,1.100	Ck2_Phospho_Site 87-90, 116-119, 148-151; Myristyl 142- 147, 191-196; Pkc_Phospho_Site 45-47;	Binding-protein- dependent transport systems inner membrane component; MAPEG (Membrane- associated proteins in eicosanoid and glutathione metabolism); NULL
DEX0443_03 0.aa.3	N	1 - i55-77o	109-126,1.136; 137-143,1.135; 9-16,1.114; 74-94,1.104; 53-66,1.100; 41-47,1.090; 24-36,1.061	Ck2_Phospho_Site 41-44, 127-130; Pkc_Phospho_Site 23-25, 85-87;	NULL
DEX0443_03 0.aa.4	N	1 - i55-77o	171-179,1.124; 9-16,1.114; 74-94,1.104; 148-154,1.101; 53-66,1.100; 41-47,1.090; 126-134,1.087; 24-36,1.061	Asn_Glycosylatio n 137-140; Ck2_Phospho_Site 41-44, 139-142; Myristyl 171- 176; Pkc_Phospho_Site 23-25, 85-87, 161-163, 164- 166;	NULL
DEX0443_03 0.aa.5	N	0 - o	4-87,1.251; 104-112,1.142; 96-102,1.056	Pkc_Phospho_Site 41-43;	Immunoglobulin and major histocompatibility complex domain
DEX0443_03 0.aa.6	N	1 - i55-77o	118-145,1.168; 9-16,1.114; 74-94,1.104; 53-66,1.100; 41-47,1.090; 109-115,1.089; 24-36,1.061	Ck2_Phospho_Site 41-44; Pkc_Phospho_Site 23-25, 85-87;	NULL
DEX0443_03 0.aa.7	N	1 - i55-77o	9-16,1.114; 53-66,1.100; 41-47,1.090; 24-36,1.061; 74-80,1.059	Ck2_Phospho_Site 41-44; Pkc_Phospho_Site 23-25, 85-87;	
DEX0443_03 0.aa.8	N	0 - o	60-111,1.149; 41-57,1.136; 9-16,1.114; 24-37,1.082	Ck2_Phospho_Site 60-63; Myristyl 54-59, 103-108; Pkc Phospho Site	MAPEG (Membrane- associated proteins in eicosanoid and glutathione

DEX0443_O3 0.aa.9	Y	0 - o	20-44,1.247; 91-142,1.149; 72-88,1.136; 10-17,1.098; 59-65,1.060	23-25; Ck2_Phospho_Site 91-94; Myristyl 26-31, 85-90, 134-139;	metabolism); NULL MAPEG (Membrane- associated proteins in eicosanoid and glutathione metabolism); NULL
DEX0443_O3 2.aa.2	N	1 - i38-60o	331-347,1.304; 38-70,1.234; 108-123,1.200; 470-502,1.191; 355-365,1.166; 504-520,1.149; 253-271,1.143; 77-100,1.134; 160-177,1.121; 219-235,1.118; 461-468,1.117; 298-308,1.100; 211-217,1.087; 314-320,1.087; 19-33,1.079; 442-448,1.077; 240-246,1.072; 125-142,1.070; 408-414,1.067; 198-204,1.052; 434-440,1.032	Thioredoxin 91- 109, 226-244; Ck2_Phospho_Site 66-69, 67-70, 202-205, 292- 295, 301-304, 334-337, 359- 362, 387-390, 419-422, 449- 452; Myristyl 20-25, 51-56, 63-68, 123-128, 134-139, 149- 154, 160-165, 184-189, 188- 193, 445-450, 466-471, 498- 503, 502-507; Pkc_Phospho_Site 37-39, 144-146, 150-152, 192- 194, 201-203, 202-204, 283- 285, 508-510; Prokar_Lipoprote in 45-55;	Thioredoxin
DEX0443_O3 3.aa.1	N	0 - o	9-21,1.183; 162-173,1.135; 135-147,1.124; 333-358,1.121; 307-315,1.097; 68-80,1.085; 196-208,1.074; 82-104,1.070; 319-325,1.056		RNA-binding protein C2H2 Zn-finger domain; WW / rsp5 / WWP domain; U1-like zinc finger
DEX0443_O3 3.aa.2	N	0 - o	356-398,1.245; 423-436,1.239; 26-43,1.189; 131-145,1.184; 589-599,1.174; 45-56,1.173; 210-228,1.167; 492-538,1.161; 438-455,1.150; 540-559,1.135; 237-249,1.127; 82-90,1.126; 282-289,1.113; 465-474,1.113; 4-17,1.107; 328-338,1.106; 268-280,1.098; 340-347,1.087; 412-421,1.071; 481-489,1.069; 63-71,1.063; 312-318,1.061; 153-159,1.060; 603-608,1.050	Amidation 181- 184; Asn_Glycosylatio n 198-201, 329- 332, 417-420, 522-525; Camp_Phospho_Sit e 576-579; Ck2_Phospho_Site 69-72, 93-96, 131-134, 132- 135, 172-175, 236-239, 311- 314, 410-413; Myristyl 341- 346, 344-349, 353-358, 497- 502, 555-560; Pkc_Phospho_Site 200-202, 236- 238, 326-328, 331-333, 422- 424, 437-439, 468-470, 493- 495, 543-545, 587-589; Tyr_Phospho_Site 259-266; Ets_Domain_1 215-223; Ets_Domain_2 261-276;	Ets-domain; HSF/ETS DNA-binding domain; NULL
DEX0443_O3 3.aa.3	Y	0 - o	96-115,1.189; 145-161,1.189;	Amidation 62- 65;	

			28-44,1.177; 9-18,1.140; 51-57,1.103; 63-71,1.086; 117-127,1.085	Ck2_Phospho_Site 147-150; Myristyl 35-40, 39-44, 72-77, 159-164; Pkc_Phospho_Site 25-27, 62-64;	
DEX0443_03 4.aa.2	N	0 - o	44-68,1.254; 140-149,1.164; 327-336,1.136; 353-358,1.128; 70-78,1.121; 5-11,1.110; 228-246,1.106; 164-172,1.079; 206-212,1.074; 24-30,1.067; 295-301,1.064; 274-283,1.059; 118-124,1.053; 261-267,1.047; 184-189,1.046; 155-160,1.034	Amidation 153- 156; Asn_Glycosylatio n 327-330, 345- 348; Ck2_Phospho_Site 92-95, 124-127, 175-178, 215- 218, 277-280; Myristyl 19-24, 22-27, 31-36, 288-293, 289- 294, 349-354; Pkc_Phospho_Site 26-28, 277-279;	NULL
DEX0443_03 5.aa.1	N	0 - o	92-109,1.185; 64-77,1.158; 23-36,1.141; 42-56,1.134	Asn_Glycosylatio n 60-63, 94-97; Ck2_Phospho_Site 42-45; Glycosaminoglyca n 62-65, 90-93; Myristyl 112- 117; Pkc_Phospho_Site 22-24;	
DEX0443_03 6.aa.1	Y	0 - o	29-48,1.173; 55-75,1.114; 18-27,1.048	Amidation 16- 19; Myristyl 7- 12, 21-26, 24- 29, 60-65; Pkc_Phospho_Site 64-66;	
DEX0443_03 7.aa.1	N	0 - o	72-89,1.221; 16-35,1.132; 43-63,1.080	Asn_Glycosylatio n 32-35, 59-62; Pkc_Phospho_Site 12-14;	
DEX0443_03 7.aa.2	Y	1 - i22-44o	19-46,1.260; 140-149,1.160; 54-73,1.132; 5-12,1.131; 81-101,1.080; 161-171,1.056; 151-157,1.051; 123-135,1.041	Amidation 178- 181; Asn_Glycosylatio n 70-73, 97- 100; Ck2_Phospho_Site 7-10, 161-164; Pkc_Phospho_Site 50-52, 150-152; Tyr_Phospho_Site 152-158;	NULL
DEX0443_03 7.aa.3	Y	1 - i22-44o	19-46,1.260; 169-185,1.221; 148-157,1.160; 131-144,1.136; 54-73,1.132; 5-12,1.131; 81-101,1.080; 113-128,1.071; 159-165,1.051	Asn_Glycosylatio n 70-73, 97- 100; Ck2_Phospho_Site 7-10, 169-172; Pkc_Phospho_Site 50-52, 158-160; Tyr_Phospho_Site 160-166;	NULL
DEX0443_03 7.aa.4	N	0 - o	78-105,1.202; 35-44,1.070	Amidation 18- 21, 26-29; Myristyl 41-46, 48-53, 49-54, 55-60, 62-67, 69-74, 74-79, 83-88; Pkc_Phospho_Site 18-20, 103-105;	NULL
DEX0443_03 9.aa.2	N	0 - o	38-51,1.199; 4-10,1.169;	Ck2_Phospho_Site 64-67, 213-216,	

			23-33, 1.156; 131-140, 1.101; 171-180, 1.098; 204-219, 1.095; 152-162, 1.088; 182-197, 1.081; 111-118, 1.062	225-228; Myristyl 23-28, 24-29, 27-32, 56-61, 60-65; Pkc_Phospho_Site 31-33, 37-39, 61-63, 100-102, 150-152; Tyr_Phospho_Site 151-159, 152- 159;	
DEX0443_03 9.aa.3	N	0 - o	21-36, 1.095	Ck2_Phospho_Site 30-33, 42-45;	
DEX0443_03 9.aa.4	N	0 - o	30-55, 1.226; 169-190, 1.183; 124-149, 1.183; 11-25, 1.145; 84-92, 1.128; 61-82, 1.107; 99-106, 1.075; 152-165, 1.075; 115-120, 1.042	Asn_Glycosylatio n 23-26, 45-48; Ck2_Phospho_Site 31-34, 158-161, 196-199; Myristyl 80-85, 115-120, 124- 129, 128-133, 173-178; Pkc_Phospho_Site 168-170;	
DEX0443_04 1.aa.8	N	0 - o	4-10, 1.234; 65-74, 1.192; 12-44, 1.117; 51-60, 1.101; 80-88, 1.081	Amidation 79- 82; Asn_Glycosylatio n 26-29; Ck2_Phospho_Site 44-47; Myristyl 13-18, 83-88; Pkc_Phospho_Site 28-30;	Rhodanese/cdc25 fold
DEX0443_04 1.aa.11	N	0 - o	129-138, 1.192; 24-44, 1.189; 51-62, 1.170; 4-17, 1.152; 64-71, 1.141; 86-97, 1.108; 115-124, 1.101; 144-152, 1.081; 102-108, 1.060	Amidation 143- 146; Ck2_Phospho_Site 66-69, 108-111; Myristyl 33-38, 147-152; Pkc_Phospho_Site 23-25, 59-61;	Rhodanese/cdc25 fold
DEX0443_04 1.aa.12	Y	2 - i12- 31o239- 261i	320-332, 1.259; 121-140, 1.247; 233-260, 1.240; 4-39, 1.236; 296-317, 1.216; 45-55, 1.173; 276-285, 1.160; 195-204, 1.131; 147-154, 1.129; 70-77, 1.128; 287-294, 1.100; 185-192, 1.094; 106-112, 1.087; 84-93, 1.069	Asn_Glycosylatio n 190-193; Ck2_Phospho_Site 39-42, 87-90, 105-108, 123- 126, 157-160, 159-162, 198- 201, 208-211, 299-302; Myristyl 110- 115, 121-126, 163-168, 224- 229, 242-247, 261-266, 294- 299, 314-319; Pkc_Phospho_Site 62-64, 74-76, 100-102, 184- 186, 274-276, 321-323;	Immunoglobulin and major histocompatibility complex domain; Immunoglobulin V- type; Immunoglobulin C-2 type; Immunoglobulin subtype
DEX0443_04 1.aa.13	Y	3 - i12- 31o76- 98i290- 312o	173-192, 1.247; 285-312, 1.240; 4-39, 1.236; 68-107, 1.236; 53-62, 1.136; 247-256, 1.131; 199-206, 1.129; 122-129, 1.128; 327-336, 1.114; 237-244, 1.094; 158-164, 1.087; 136-145, 1.069	Asn_Glycosylatio n 242-245; Camp_Phospho_Sit e 327-330; Ck2_Phospho_Site 39-42, 139-142, 157-160, 175- 178, 209-212, 211-214, 250- 253, 260-263, 344-347; Myristyl 54-59, 58-63, 162-167,	Immunoglobulin and major histocompatibility complex domain; Immunoglobulin V- type; Immunoglobulin C-2 type; Immunoglobulin subtype

				173-178, 215-220, 276-281, 294-299, 313-318; Pkc_Phospho_Site 63-65, 114-116, 126-128, 152-154, 236-238, 326-328, 331-333, 332-334, 341-343;	
DEX0443_04 1.aa.14	Y	0 - o	89-110, 1.236; 60-86, 1.225; 140-151, 1.160; 154-180, 1.149; 7-32, 1.128; 196-203, 1.118; 211-223, 1.090; 51-58, 1.073; 229-235, 1.035	Amidation 209-212; Myristyl 14-19, 192-197; Pkc_Phospho_Site 37-39, 65-67; Prokar_Lipoprote in 172-182;	
DEX0443_04 1.aa.2	N	0 - o	29-38, 1.192; 15-24, 1.101; 44-52, 1.081	Amidation 43-46; Ck2_Phospho_Site 5-8; Myristyl 47-52;	
DEX0443_04 1.aa.3	N	0 - o	35-59, 1.135; 83-96, 1.112; 15-23, 1.103; 66-74, 1.096	Ck2_Phospho_Site 99-102; Myristyl 19-24, 90-95, 96-101; Pkc_Phospho_Site 39-41, 44-46, 66-68, 75-77;	
DEX0443_04 1.aa.4	N	0 - o	177-186, 1.192; 24-44, 1.189; 51-62, 1.170; 4-17, 1.152; 64-71, 1.141; 86-97, 1.108; 103-126, 1.107; 163-172, 1.101; 140-156, 1.100; 192-200, 1.081	Amidation 191-194; Ck2_Phospho_Site 66-69, 118-121, 138-141, 156-159; Myristyl 33-38, 145-150, 195-200; Pkc_Phospho_Site 23-25, 59-61, 128-130;	Rhodanese/cdc25 fold
DEX0443_04 1.aa.5	N	0 - o	156-165, 1.192; 24-44, 1.189; 51-62, 1.170; 4-17, 1.152; 64-71, 1.141; 86-97, 1.108; 142-151, 1.101; 119-135, 1.100; 171-179, 1.081	Amidation 170-173; Ck2_Phospho_Site 66-69, 117-120, 135-138; Myristyl 33-38, 106-111, 124-129, 174-179; Pkc_Phospho_Site 23-25, 59-61;	Rhodanese/cdc25 fold
DEX0443_04 1.aa.6	N	0 - o	62-71, 1.192; 48-57, 1.101; 25-41, 1.100; 77-85, 1.081	Amidation 76-79; Ck2_Phospho_Site 23-26, 41-44; Myristyl 30-35, 80-85;	Rhodanese/cdc25 fold
DEX0443_04 1.aa.7	N	0 - o	88-97, 1.192; 4-37, 1.107; 74-83, 1.101; 51-67, 1.100; 103-111, 1.081	Amidation 102-105; Ck2_Phospho_Site 29-32, 49-52, 67-70; Myristyl 56-61, 106-111; Pkc_Phospho_Site 9-11, 39-41;	Rhodanese/cdc25 fold
DEX0443_04 2.aa.1	N	3 - i13- 35o50- 72i100- 122o	12-42, 1.290; 49-61, 1.272; 99-129, 1.187; 79-85, 1.072; 68-74, 1.055; 87-95, 1.041	Myristyl 65-70, 115-120; Prokar_Lipoprote in 119-129;	MIP family
DEX0443_04	Y	2 - i2-	4-22, 1.290;	Myristyl 45-50;	MIP family

2.aa.2		19029-51i	29-41,1.272; 59-65,1.072; 48-54,1.055; 67-73,1.035		
DEX0443_04 2.aa.3	N	6 - i54- 76o86- 108i129 - 151o232 - 254i267 - 289o317 -336i	242-260,1.290; 267-279,1.272; 44-78,1.213; 317-347,1.187; 126-171,1.159; 356-364,1.149; 86-124,1.139; 4-29,1.106; 33-42,1.102; 207-214,1.098; 190-199,1.079; 297-303,1.072; 220-228,1.065; 286-292,1.055; 182-187,1.042; 305-313,1.041	Asn_Glycosylation 221-224; Ck2_Phospho_Site 355-358; Myristyl 84-89, 87-92, 103-108, 108-113, 144- 149, 150-155, 154-159, 225- 230, 283-288, 333-338; Mip 114-122; Prokar_Lipoprotein 63-73, 337- 347;	MIP family
DEX0443_04 2.aa.4	Y	3 - o79- 101i114 - 136o164 -183i	89-107,1.290; 114-126,1.272; 164-194,1.187; 4-16,1.173; 203-211,1.149; 31-51,1.136; 54-61,1.098; 144-150,1.072; 67-75,1.065; 133-139,1.055; 152-160,1.041	Asn_Glycosylation 68-71; Ck2_Phospho_Site 202-205; Myristyl 72-77, 130-135, 180- 185; Prokar_Lipoprotein 184-194;	MIP family
DEX0443_04 3.aa.1	N	0 - o	13-24,1.138; 80-102,1.114	S100_Cabp 68- 89; Asn_Glycosylation 36-39; Ck2_Phospho_Site 11-14, 13-16, 40-43, 74-77; Myristyl 91-96; Pkc_Phospho_Site 15-17, 106-108; Ef_Hand 73-85; Prokar_Lipoprotein 86-96;	S-100/ICaBP type calcium binding protein; EF-hand
DEX0443_04 4.aa.1	N	0 - o	71-91,1.147; 100-110,1.136; 27-39,1.129; 131-153,1.127; 61-69,1.119; 199-206,1.110; 112-121,1.100; 159-174,1.094; 210-219,1.086; 41-54,1.068; 11-19,1.058	Asn_Glycosylation 14-17; Ck2_Phospho_Site 55-58, 94-97, 181-184, 200- 203, 219-222; Myristyl 28-33, 146-151, 178- 183; Pkc_Phospho_Site 219-221;	
DEX0443_04 4.aa.2	N	0 - o	169-184,1.231; 68-83,1.184; 200-219,1.173; 140-159,1.148; 28-66,1.147; 299-319,1.147; 5-20,1.136; 328-338,1.136; 255-267,1.129; 359-381,1.127; 289-297,1.119; 427-434,1.110; 221-229,1.103; 340-349,1.100; 190-198,1.098; 117-126,1.095; 387-402,1.094; 438-447,1.086; 269-282,1.062; 239-247,1.058;	Rnp_1 174-181; Asn_Glycosylation 96-99, 242- 245; Camp_Phospho_Site 114-117; Ck2_Phospho_Site 69-72, 98-101, 126-129, 283- 286, 322-325, 409-412, 428- 431, 447-450; Myristyl 12-17, 21-26, 91-96, 122-127, 160- 165, 256-261, 374-379, 406- 411; Pkc_Phospho_Site 447-449;	RNA-binding region RNP-1 (RNA recognition motif); Aminopeptidase N, APN (CD13)

DEX0443_04 4.aa.3	N	0 - o	101-106,1.048 85-100,1.231; 116-135,1.173; 62-75,1.153; 215-235,1.147; 244-254,1.136; 6-32,1.130; 171-183,1.129; 275-297,1.127; 205-213,1.119; 343-350,1.110; 137-145,1.103; 256-265,1.100; 106-114,1.098; 303-318,1.094; 37-54,1.090; 354-363,1.086; 185-198,1.062; 155-163,1.058	Rnp_1 90-97; Asn_Glycosylation 158-161; Ck2_Phospho_Site 199-202, 238-241, 325-328, 344-347, 363-366; Myristyl 71-76, 76-81, 172-177, 290-295, 322-327; Pkc_Phospho_Site 20-22, 27-29, 363-365;	RNA-binding region RNP-1 (RNA recognition motif)
DEX0443_04 4.aa.4	N	0 - o	355-370,1.231; 155-177,1.222; 416-488,1.204; 40-53,1.194; 96-144,1.189; 254-269,1.184; 506-525,1.173; 326-345,1.148; 225-252,1.147; 605-625,1.147; 189-219,1.145; 57-80,1.139; 634-644,1.136; 376-406,1.135; 561-573,1.129; 4-36,1.128; 665-687,1.127; 595-603,1.119; 733-740,1.110; 527-535,1.103; 646-655,1.100; 303-312,1.095; 693-708,1.094; 491-504,1.094; 744-753,1.086; 575-588,1.062; 545-553,1.058; 287-292,1.048	Rnp_1 360-367; Asn_Glycosylation 118-121, 282-285, 548-551; Camp_Phospho_Site 300-303; Ck2_Phospho_Site 86-89, 216-219, 255-258, 284-287, 312-315, 589-592, 628-631, 715-718, 734-737, 753-756; Myristyl 5-10, 43-48, 62-67, 277-282, 308-313, 346-351, 411-416, 415-420, 473-478, 562-567, 680-685, 712-717; Pkc_Phospho_Site 204-206, 416-418, 753-755;	RNA-binding region RNP-1 (RNA recognition motif); Proline-rich region; Aminopeptidase N, APN (CD13)
DEX0443_04 5.aa.1	N	0 - o	15-27,1.138		
DEX0443_04 6.aa.2	N	0 - o	155-180,1.130; 19-35,1.124; 101-118,1.114; 129-153,1.114; 42-55,1.112; 192-217,1.110; 80-88,1.109; 90-98,1.086; 182-190,1.072; 73-78,1.051; 64-70,1.042	Asp_Protease 118-129; Ck2_Phospho_Site 11-14, 61-64, 180-183, 220-223; Myristyl 65-70, 169-174, 187-192, 230-235; Pkc_Phospho_Site 131-133; Crystallin_Beta gamma 73-88;	Crystallin; Pepsin (A1) aspartic protease; Eukaryotic and viral aspartic protease active site
DEX0443_04 7.aa.2	N	0 - i	8-26,1.184	Amidation 36-39; Asn_Glycosylation 32-35; Camp_Phospho_Site 38-41; Pkc_Phospho_Site 31-33, 34-36, 41-43;	
DEX0443_04 9.aa.1	N	0 - o	72-88,1.205; 143-151,1.196; 29-64,1.191; 224-270,1.182;	Tnfr_Ngfr_1 26-63, 66-107; Asn_Glycosylation 23-26, 160-	Proline-rich region; TNFR/CD27/30/40/95 cysteine-rich region; NULL

			101-129,1.143; 159-167,1.132; 4-14,1.131; 302-314,1.094; 90-96,1.092; 189-195,1.087; 171-178,1.080; 280-285,1.067; 317-331,1.060; 338-344,1.040; 201-206,1.036; 214-219,1.034	163; Camp_Phospho_Site 102-105; Ck2_Phospho_Site 25-28, 65-68, 70-73, 123-126, 135-138, 172-175, 270-273; Myristyl 3-8, 48-53, 112-117, 146-151, 178-183, 185-190, 294-299, 299-304; Pkc_Phospho_Site 25-27, 52-54, 100-102, 101-103, 192-194; Tyr_Phospho_Site 27-33;	
DEX0443_04 9.aa.2	Y	0 - o	94-110,1.205; 165-173,1.196; 51-86,1.191; 246-292,1.182; 123-151,1.170; 9-36,1.166; 182-189,1.113; 324-336,1.094; 112-118,1.092; 211-217,1.087; 193-200,1.080; 302-307,1.067; 378-385,1.063; 339-353,1.060; 360-366,1.040; 223-228,1.036; 236-241,1.034	Tnfr_Ngfr_1 48-85, 88-129; Asn_Glycosylation 45-48, 182-185; Camp_Phospho_Site 124-127; Ck2_Phospho_Site 47-50, 87-90, 92-95, 145-148, 157-160, 194-197, 292-295; Myristyl 28-33, 70-75, 134-139, 168-173, 200-205, 207-212, 316-321, 321-326, 388-393; Pkc_Phospho_Site 47-49, 74-76, 122-124, 123-125, 187-189, 214-216, 392-394; Tyr_Phospho_Site 49-55;	Proline-rich region; TNFR/CD27/30/40/95 cysteine-rich region; NULL
DEX0443_04 9.aa.3	Y	1 - o226-248i	227-264,1.216; 94-110,1.205; 165-173,1.196; 51-86,1.191; 282-328,1.182; 123-151,1.170; 9-36,1.166; 182-189,1.113; 360-372,1.094; 112-118,1.092; 211-217,1.087; 193-200,1.080; 338-343,1.067; 414-421,1.063; 375-389,1.060; 396-402,1.040; 272-277,1.034	Tnfr_Ngfr_1 48-85, 88-129; Asn_Glycosylation 45-48, 182-185; Camp_Phospho_Site 124-127; Ck2_Phospho_Site 47-50, 87-90, 92-95, 145-148, 157-160, 194-197, 328-331; Myristyl 28-33, 70-75, 134-139, 168-173, 200-205, 207-212, 352-357, 357-362, 424-429; Pkc_Phospho_Site 47-49, 74-76, 122-124, 123-125, 187-189, 214-216, 428-430; Tyr_Phospho_Site 49-55; Prokar_Lipoprotein 241-251;	Proline-rich region; TNFR/CD27/30/40/95 cysteine-rich region; NULL
DEX0443_04	Y	1 -	227-264,1.216;	Tnfr_Ngfr_1 48-	Proline-rich region;

9.aa.4		o226-248i	94-110,1.205; 424-442,1.202; 165-173,1.196; 51-86,1.191; 282-328,1.182; 123-151,1.170; 9-36,1.166; 182-189,1.113; 360-372,1.094; 112-118,1.092; 211-217,1.087; 193-200,1.080; 338-343,1.067; 414-421,1.063; 375-389,1.060; 396-402,1.040; 272-277,1.034	85, 88-129; Asn_Glycosylation 45-48, 182-185; Camp_Phospho_Site 124-127; Ck2_Phospho_Site 47-50, 87-90, 92-95, 145-148, 157-160, 194-197, 328-331, 448-451, 450-453; Myristyl 28-33, 70-75, 134-139, 168-173, 200-205, 207-212, 352-357, 357-362, 424-429; Pkc_Phospho_Site 47-49, 74-76, 122-124, 123-125, 187-189, 214-216; Tyr_Phospho_Site 49-55; Prokar_Lipoprotein 241-251;	TNFR/CD27/30/40/95 cysteine-rich region; NULL
DEX0443_04 9.aa.5	y	1 - o426-448i	344-423,1.224; 427-464,1.216; 94-110,1.205; 165-173,1.196; 296-325,1.193; 51-86,1.191; 482-528,1.182; 268-294,1.175; 123-151,1.170; 9-36,1.166; 224-241,1.144; 247-265,1.134; 182-189,1.113; 560-572,1.094; 112-118,1.092; 211-217,1.087; 193-200,1.080; 538-543,1.067; 614-621,1.063; 575-589,1.060; 596-602,1.040; 472-477,1.034	Tnfr_Ngfr_1 48-85, 88-129; Amidation 387-390; Asn_Glycosylation 45-48, 182-185; Camp_Phospho_Site 124-127; Ck2_Phospho_Site 47-50, 87-90, 92-95, 145-148, 157-160, 194-197, 528-531; Myristyl 28-33, 70-75, 134-139, 168-173, 200-205, 207-212, 248-253, 291-296, 381-386, 401-406, 416-421, 552-557, 557-562, 624-629; Pkc_Phospho_Site 47-49, 74-76, 122-124, 123-125, 187-189, 214-216, 326-328, 336-338, 628-630; Tyr_Phospho_Site 49-55; Prokar_Lipoprotein 441-451;	Proline-rich region; TNFR/CD27/30/40/95 cysteine-rich region; NULL
DEX0443_04 9.aa.6	y	0 - o	13-25,1.182; 41-87,1.182; 119-131,1.094; 97-102,1.067; 173-180,1.063; 134-148,1.060; 155-161,1.040; 31-36,1.034	Camp_Phospho_Site 14-17; Ck2_Phospho_Site 87-90; Myristyl 111-116, 116-121, 183-188; Pkc_Phospho_Site 187-189;	Proline-rich region
DEX0443_04 9.aa.7	y	1 - o226-248i	227-265,1.216; 94-110,1.205; 165-173,1.196; 51-86,1.191;	Tnfr_Ngfr_1 48-85, 88-129; Asn_Glycosylation 45-48, 182-	TNFR/CD27/30/40/95 cysteine-rich region; NULL

			123-151,1.170; 9-36,1.166; 182-189,1.113; 112-118,1.092; 211-217,1.087; 193-200,1.080	185; Camp_Phospho_Site 124-127; Ck2_Phospho_Site 47-50, 87-90, 92-95, 145-148, 157-160, 194- 197, 293-296; Myristyl 28-33, 70-75, 134-139, 168-173, 200- 205, 207-212, 276-281, 289- 294; Pkc_Phospho_Site 47-49, 74-76, 122-124, 123- 125, 187-189, 214-216; Rgd 285-287; Tyr_Phospho_Site 49-55; Prokar_Lipoprote in 241-251;	
DEX0443_05 1.aa.3	N	1 - o1076- 1098i	75-97,1.213; 511-523,1.208; 101-127,1.205; 300-322,1.204; 830-853,1.199; 669-688,1.196; 785-803,1.189; 1067- 1094,1.185; 391-399,1.184; 327-340,1.179; 1105- 1124,1.175; 50-63,1.170; 757-776,1.166; 732-749,1.164; 183-214,1.156; 601-609,1.153; 159-167,1.149; 696-708,1.147; 257-270,1.146; 556-567,1.145; 488-500,1.135; 878-885,1.134; 624-642,1.127; 897-912,1.125; 1024- 1031,1.115; 811-828,1.115; 441-455,1.113; 865-875,1.108; 292-298,1.101; 470-480,1.099; 584-599,1.097; 362-370,1.093; 1046- 1054,1.091; 377-384,1.090; 138-143,1.090; 1096- 1102,1.088; 942-948,1.087; 1015- 1022,1.080; 346-352,1.078; 14-19,1.077; 413-423,1.077; 569-576,1.075; 229-238,1.074; 541-547,1.070; 919-925,1.063;	Asn_Glycosylatio n 689-692, 754- 757; Ck2_Phospho_Site 9-12, 12-15, 42- 45, 206-209, 303-306, 378- 381, 392-395, 480-483, 624- 627, 722-725, 784-787, 810- 813, 934-937; Myristyl 232- 237, 431-436, 503-508, 620- 625, 758-763, 921-926, 944- 949; Pkc_Phospho_Site 68-70, 224-226, 243-245, 347- 349, 409-411, 435-437, 472- 474, 572-574, 732-734, 997- 999; Tyr_Phospho_Site 702-709; His_Acid_Phospa t_1 396-410;	Histidine acid phosphatase

			275-281,1.062; 984-990,1.061; 998- 1004,1.059; 970-976,1.055; 650-656,1.047; 1034- 1041,1.034; 658-665,1.032		
DEX0443_05 1.aa.4	Y	0 - o	28-41,1.179; 4-23,1.161; 47-52,1.078	Pkc_Phospho_Site 48-50;	
DEX0443_05 1.aa.5	N	0 - o	40-69,1.205; 6-12,1.070; 15-38,1.069	Ck2_Phospho_Site 5-8; Myristyl 54-59; Prokar_Lipoprote in 59-69;	
DEX0443_05 4.aa.1	N	0 - o	41-70,1.189; 4-17,1.152; 19-32,1.139	Ck2_Phospho_Site 21-24, 61-64, 75-78; Myristyl 88-93; Pkc_Phospho_Site 54-56;	Ligand-binding domain of nuclear hormone receptor
DEX0443_05 5.aa.2	N	0 - o	206-216,1.161; 224-270,1.139; 134-141,1.105; 155-161,1.069; 170-176,1.057; 189-197,1.056; 181-187,1.046	Camp_Phospho_Sit e 27-30, 43-46, 56-59, 96-99; Ck2_Phospho_Site 71-74, 82-85, 98-101, 99-102; Pkc_Phospho_Site 14-16, 22-24, 51-53, 71-73, 95-97, 135-137, 235-237;	NULL
DEX0443_05 5.aa.3	N	0 - o	45-57,1.088; 131-139,1.087; 31-38,1.077; 82-99,1.054; 19-25,1.048; 121-127,1.043	Asn_Glycosylatio n 20-23, 30-33; Ck2_Phospho_Site 32-35, 65-68; Pkc_Phospho_Site 22-24, 32-34, 48-50, 142-144;	NULL
DEX0443_05 7.aa.2	N	0 - o	53-85,1.167; 23-46,1.136; 13-21,1.113	Amidation 14- 17; Pkc_Phospho_Site 3-5, 98-100;	
DEX0443_05 7.aa.3	N	0 - o	16-29,1.174; 4-14,1.170; 54-62,1.151; 37-43,1.094; 69-74,1.058	Myristyl 34-39, 56-61, 57-62; Pkc_Phospho_Site 28-30; Rgd 69- 71; Prokar_Lipoprote in 19-29, 54- 64;	
DEX0443_05 7.aa.4	N	0 - o	143-153,1.228; 53-85,1.167; 111-141,1.157; 23-46,1.136; 13-21,1.113; 94-109,1.111	Amidation 14- 17; Myristyl 150-155; Pkc_Phospho_Site 3-5, 98-100, 125-127;	
DEX0443_05 8.aa.1	N	0 - o	61-84,1.209; 28-40,1.130; 10-19,1.130; 97-116,1.105; 49-55,1.060	Camp_Phospho_Sit e 51-54; Ck2_Phospho_Site 13-16; Pkc_Phospho_Site 41-43, 56-58, 62-64; Tyr_Phospho_Site 5-12;	Ribosomal protein L1
DEX0443_05 8.aa.2	N	0 - o	30-42,1.130; 11-20,1.130; 51-56,1.091	Camp_Phospho_Sit e 53-56; Ck2_Phospho_Site 14-17; Pkc_Phospho_Site 3-5, 43-45, 58-	

				60; Tyr_Phospho_Site 7-14;	
DEXO443_05 8.aa.3	N	0 - i	4-50,1.172; 60-75,1.115; 81-89,1.094	Myristyl 43-48; Pkc_Phospho_Site 28-30, 71-73;	
DEXO443_05 8.aa.4	N	0 - o	6-19,1.134; 42-49,1.111; 22-32,1.100	Ck2_Phospho_Site 23-26;	
DEXO443_05 9.aa.2	N	0 - o	66-78,1.231; 115-126,1.181; 152-171,1.170; 4-29,1.161; 328-335,1.156; 380-399,1.130; 52-62,1.129; 342-355,1.121; 181-194,1.117; 99-112,1.116; 133-150,1.101; 304-320,1.087	Atp_Gtp_A 223- 230; Asn_Glycosylation 257-260, 268- 271; Ck2_Phospho_Site 63-66, 93-96, 101-104, 113- 116, 118-121, 177-180, 192- 195, 247-250, 273-276, 293- 296, 320-323, 375-378; Myristyl 28-33, 52-57, 106-111, 149-154, 182- 187, 265-270, 302-307, 361- 366; Pkc_Phospho_Site 32-34, 233-235, 244-246, 270- 272, 375-377;	Proline-rich region; ATP/GTP-binding site motif A (P-loop)
DEXO443_05 9.aa.3	Y	0 - o	201-235,1.223; 128-141,1.209; 5-21,1.185; 155-171,1.175; 33-54,1.174; 82-95,1.153; 60-66,1.125; 106-119,1.097; 181-194,1.090; 74-79,1.060	Camp_Phospho_Site 37-40; Ck2_Phospho_Site 101-104; Myristyl 127- 132; Pkc_Phospho_Site 35-37, 52-54, 70-72, 183-185; Tyr_Phospho_Site 116-123; Polyprenyl_Synthetase 172-186;	Polyprenyl synthetase
DEXO443_06 0.aa.2	N	0 - o	175-185,1.225; 124-165,1.203; 362-370,1.179; 25-49,1.169; 280-315,1.154; 73-90,1.133; 9-15,1.130; 111-121,1.127; 323-341,1.121; 95-102,1.121; 253-265,1.112; 201-211,1.092; 55-61,1.085; 350-357,1.074; 243-250,1.061; 269-278,1.061	Asn_Glycosylation 56-59, 349- 352; Ck2_Phospho_Site 123-126, 174- 177, 233-236, 235-238, 313- 316, 323-326, 357-360; Myristyl 60-65, 229-234, 362- 367; Pkc_Phospho_Site 73-75, 76-78, 301-303, 354- 356, 363-365; Tyr_Phospho_Site 303-309;	
DEXO443_06 0.aa.3	N	0 - o	175-185,1.225; 124-165,1.203; 473-482,1.179; 25-49,1.169; 578-589,1.155; 280-315,1.154; 394-416,1.152; 368-384,1.143; 424-465,1.143; 489-499,1.139; 73-90,1.133;	Asn_Glycosylation 56-59; Ck2_Phospho_Site 123-126, 174- 177, 233-236, 235-238, 313- 316, 323-326, 545-548, 645- 648, 658-661; Leucine_Zipper 458-479;	

			9-15,1.130; 111-121,1.127; 323-355,1.122; 95-102,1.121; 521-528,1.118; 253-265,1.112; 539-548,1.107; 601-618,1.106; 201-211,1.092; 623-630,1.089; 55-61,1.085; 655-665,1.082; 386-392,1.069; 557-564,1.066; 243-250,1.061; 269-278,1.061; 507-513,1.056; 633-639,1.052; 360-365,1.048	Myristyl 60-65, 229-234, 354- 359, 366-371, 512-517; Pkc_Phospho_Site 73-75, 76-78, 301-303, 518- 520, 531-533, 560-562, 593- 595, 636-638, 637-639, 657- 659; Tyr_Phospho_Site 303-309;	
DEX0443_06 0.aa.6	N	0 - o	4-25,1.169; 100-114,1.165; 49-66,1.133; 87-97,1.127; 71-78,1.121; 31-37,1.085	Asn_Glycosylatio n 32-35; Ck2_Phospho_Site 99-102; Myristyl 36-41; Pkc_Phospho_Site 49-51, 52-54;	
DEX0443_06 0.aa.7	N	0 - i	54-64,1.148; 42-50,1.103; 69-82,1.079; 28-33,1.073	Amidation 29- 32; Camp_Phospho_Sit e 42-45; Myristyl 33-38, 83-88; Pkc_Phospho_Site 56-58, 68-70, 78-80;	
DEX0443_06 1.aa.2	N	0 - o	4-16,1.105; 24-38,1.103; 41-50,1.071	Glycosaminoglyca n 59-62; Pkc_Phospho_Site 3-5, 53-55, 59- 61;	
DEX0443_06 2.aa.1	N	0 - o	41-51,1.181; 148-157,1.148; 173-180,1.141; 58-74,1.121; 22-38,1.115; 4-19,1.099; 77-88,1.088; 103-115,1.072; 117-129,1.064; 92-101,1.058	Ubiquitin_1 34- 59; Amidation 185-188; Camp_Phospho_Sit e 162-165; Ck2_Phospho_Site 25-28, 72-75; Glycosaminoglyca n 107-110; Pkc_Phospho_Site 99-101, 118-120, 165-167;	Ubiquitin domain
DEX0443_06 2.aa.2	N	0 - o	52-59,1.141; 12-20,1.088; 24-32,1.042	Amidation 64- 67; Camp_Phospho_Sit e 41-44; Pkc_Phospho_Site 31-33, 44-46;	
DEX0443_06 4.aa.1	Y	1 - o252- 274i	251-283,1.275; 216-228,1.194; 180-192,1.149; 61-71,1.145; 6-32,1.142; 96-114,1.119; 172-178,1.104; 142-160,1.096; 38-43,1.087; 236-242,1.071; 79-84,1.064; 88-94,1.049	Tissue_Factor 82-99; Amidation 200-203; Asn_Glycosylatio n 48-51, 161- 164, 174-177; Camp_Phospho_Sit e 237-240; Ck2_Phospho_Site 58-61, 90-93, 92-95, 125-128, 163-166, 179- 182, 242-245, 290-293; Myristyl 36-41, 39-44, 118-123, 157-162, 248-	Cytokine receptor class 2 family; Tissue Factor (TF)

				253, 286-291; Pkc_Phospho_Site 50-52, 76-78, 179-181, 200- 202, 204-206, 290-292;	
DEX0443_06 6.aa.1	N	0 - 0	9-21,1.183; 162-173,1.135; 135-147,1.124; 333-358,1.121; 307-315,1.097; 68-80,1.085; 196-208,1.074; 82-104,1.070; 319-325,1.056		RNA-binding protein C2H2 Zn-finger domain; WW / rsp5 / WWP domain; U1-like zinc finger
DEX0443_06 6.aa.2	N	0 - 0	356-398,1.245; 423-436,1.239; 26-43,1.189; 131-145,1.184; 589-599,1.174; 45-56,1.173; 210-228,1.167; 492-538,1.161; 438-455,1.150; 540-559,1.135; 237-249,1.127; 82-90,1.126; 282-289,1.113; 465-474,1.113; 4-17,1.107; 328-338,1.106; 268-280,1.098; 340-347,1.087; 412-421,1.071; 481-489,1.069; 63-71,1.063; 312-318,1.061; 153-159,1.060; 603-608,1.050	Amidation 181- 184; Asn_Glycosylatio n 198-201, 329- 332, 417-420, 522-525; Camp_Phospho_Sit e 576-579; Ck2_Phospho_Site 69-72, 93-96, 131-134, 132- 135, 172-175, 236-239, 311- 314, 410-413; Myristyl 341- 346, 344-349, 353-358, 497- 502, 555-560; Pkc_Phospho_Site 200-202, 236- 238, 326-328, 331-333, 422- 424, 437-439, 468-470, 493- 495, 543-545, 587-589; Tyr_Phospho_Site 259-266; Ets_Domain_1 215-223; Ets_Domain_2 261-276;	Ets-domain; HSF/ETS DNA-binding domain; NULL
DEX0443_06 7.aa.1	N	0 - 0	4-11,1.149; 45-54,1.095; 29-34,1.048	Asn_Glycosylatio n 24-27; Camp_Phospho_Sit e 42-45; Ck2_Phospho_Site 26-29, 54-57; Myristyl 19-24, 50-55;	Aminopeptidase N, APN (CD13)
DEX0443_07 1.aa.1	N	0 - 0	41-51,1.181; 148-157,1.148; 173-180,1.141; 58-74,1.121; 22-38,1.115; 4-19,1.099; 77-88,1.088; 103-115,1.072; 117-129,1.064; 92-101,1.058	Ubiquitin_1 34- 59; Amidation 185-188; Camp_Phospho_Sit e 162-165; Ck2_Phospho_Site 25-28, 72-75; Glycosaminoglyca n 107-110; Pkc_Phospho_Site 99-101, 118-120, 165-167;	Ubiquitin domain
DEX0443_07 5.aa.1	N	0 - 0	23-35,1.178; 213-239,1.178; 140-168,1.155; 241-249,1.130; 290-299,1.123; 195-211,1.089; 279-285,1.080; 57-71,1.076;	Asn_Glycosylatio n 19-22, 46-49, 137-140; Ck2_Phospho_Site 77-80, 139-142, 239-242, 243- 246; Myristyl 15-20, 44-49,	Lipocalin-related protein and Bos/Can/Equ allergen; Lipocalin

			100-106,1.070; 170-176,1.068; 79-89,1.060; 8-15,1.052; 261-266,1.025	68-73, 92-97, 97-102, 101-106, 115-120, 233- 238; Pkc_Phospho_Site 74-76, 77-79, 119-121, 188- 190, 212-214, 274-276, 303- 305;	
DEX0443_07 6.aa.1	N	0 - i	21-29,1.168; 63-80,1.159; 103-111,1.144; 82-96,1.123; 148-157,1.113; 54-60,1.086; 135-143,1.070; 125-133,1.062	Amidation 9-12; Camp_Phospho_Site 13-16; Ck2_Phospho_Site 149-152; Myristyl 79-84, 88-93; Pkc_Phospho_Site 20-22, 59-61, 67-69, 74-76, 149-151; Ribosomal_L21e 43-68;	Ribosomal protein L21E
DEX0443_07 7.aa.1	N	0 - o	72-88,1.205; 143-151,1.196; 29-64,1.191; 224-270,1.182; 101-129,1.143; 159-167,1.132; 4-14,1.131; 302-314,1.094; 90-96,1.092; 189-195,1.087; 171-178,1.080; 280-285,1.067; 317-331,1.060; 338-344,1.040; 201-206,1.036; 214-219,1.034	Tnfr_Ngfr_1 26- 63, 66-107; Asn_Glycosylation 23-26, 160- 163; Camp_Phospho_Site 102-105; Ck2_Phospho_Site 25-28, 65-68, 70-73, 123-126, 135-138, 172- 175, 270-273; Myristyl 3-8, 48-53, 112-117, 146-151, 178- 183, 185-190, 294-299, 299- 304; Pkc_Phospho_Site 25-27, 52-54, 100-102, 101- 103, 192-194; Tyr_Phospho_Site 27-33;	Proline-rich region; TNFR/CD27/30/40/95 cysteine-rich region; NULL
DEX0443_08 1.aa.1	N	0 - o	13-24,1.138; 80-102,1.114	S100_Cabp 68- 89; Asn_Glycosylation 36-39; Ck2_Phospho_Site 11-14, 13-16, 40-43, 74-77; Myristyl 91-96; Pkc_Phospho_Site 15-17, 106-108; Ef_Hand 73-85; Prokar_Lipoprote in 86-96;	S-100/ICaBP type calcium binding protein; EF-hand
DEX0443_09 3.aa.1	N	0 - o	50-67,1.164; 35-48,1.140; 4-12,1.093; 16-22,1.087	Ck2_Phospho_Site 15-18;	
DEX0443_09 4.aa.1	N	0 - o	71-83,1.182; 90-97,1.134; 211-219,1.127; 130-141,1.117; 186-193,1.076; 59-65,1.067; 195-202,1.065; 226-240,1.059; 169-177,1.041	Asn_Glycosylation 13-16, 40-43; Ck2_Phospho_Site 119-122, 125- 128, 149-152, 162-165, 214- 217, 225-228; Myristyl 134- 139; Pkc_Phospho_Site 105-107, 173-	Osteopontin; NULL

				175; Rgd 93-95; Tyr_Phospho_Site 109-115;	
DEX0443_09 5.aa.1	Y	0 - o	351-360,1.285; 4-15,1.269; 101-117,1.189; 150-164,1.148; 300-310,1.144; 264-294,1.134; 19-35,1.134; 184-200,1.124; 332-340,1.123; 207-220,1.112; 245-253,1.109; 312-319,1.085; 67-73,1.074; 119-138,1.065; 90-96,1.060; 238-243,1.051; 38-45,1.048; 229-235,1.042; 174-179,1.036	Asp_Protease 98-109; Asn_Glycosylatio n 95-98; Ck2_Phospho_Site 70-73, 173-176, 180-183, 226- 229, 302-305, 331-334, 345- 348, 353-356; Myristyl 137- 142, 147-152, 151-156, 167- 172, 230-235; Pkc_Phospho_Site 36-38, 70-72, 277-279, 353- 355, 365-367; Crystallin_Betag amma 238-253; Prokar_Lipoprote in 268-278;	Crystallin; Pepsin (A1) aspartic protease; Eukaryotic and viral aspartic protease active site
DEX0443_09 7.aa.1	N	0 - o	140-148,1.140; 4-21,1.126; 52-70,1.119; 37-46,1.108; 74-87,1.101; 111-121,1.089; 100-107,1.088; 93-98,1.082; 123-132,1.074	Amidation 140- 143; Asn_Glycosylatio n 34-37, 95-98; Ck2_Phospho_Site 64-67; Glycosaminoglyca n 53-56; Myristyl 44-49, 98-103, 137-142; Pkc_Phospho_Site 74-76, 133-135;	
DEX0443_10 0.aa.1	N	0 - o	51-60,1.178; 62-68,1.130; 30-45,1.109	Asn_Glycosylatio n 19-22; Ck2_Phospho_Site 60-63, 64-67; Myristyl 17-22, 41-46, 54-59; Pkc_Phospho_Site 47-49;	Lipocalin-related protein and Bos/Can/Equ allergen
DEX0443_10 2.aa.1	N	1 - o15-37i	163-194,1.164; 148-161,1.149; 97-111,1.142; 69-86,1.136; 129-145,1.136; 34-54,1.104; 13-26,1.100	Ck2_Phospho_Site 87-90, 116-119, 148-151; Myristyl 142- 147, 191-196; Pkc_Phospho_Site 45-47;	Binding-protein- dependent transport systems inner membrane component; MAPEG (Membrane- associated proteins in eicosanoid and glutathione metabolism); NULL
DEX0443_10 2.aa.2	N	0 - i	9-21,1.1314; 25-39,1.158	Ck2_Phospho_Site 40-43; Pkc_Phospho_Site 3-5;	
DEX0443_10 9.aa.1	N	0 - o	15-27,1.138		

Altogether, splice variant sequence analysis, EST support, SAGE tag data, and protein annotation are indicative of SEQ ID NO: 1-248 and encoded protein SEQ ID NO: 249-396 being a diagnostic marker and/or a therapeutic target for cancer.

Example 3b: RT-PCR Analysis

To detect the presence and tissue distribution of a particular splice variant Reverse Transcription-Polymerase Chain Reaction (RT-PCR) is performed using cDNA generated from a panel of tissue RNAs. *See, e.g.,* Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989) and; Kawasaki ES *et al.*, *PNAS* 85(15):5698 (1988). Total RNA is extracted from a variety of tissues and first strand cDNA is prepared with reverse transcriptase (RT). Each panel includes 23 cDNAs from five cancer types (lung, ovary, breast, colon, and prostate) and normal samples of testis, placenta and fetal brain. Each cancer set is composed of three cancer cDNAs from different donors and one normal pooled sample. Using a standard enzyme kit from BD Bioscience Clontech (Mountain View, CA), the target transcript is detected with sequence-specific primers designed to only amplify the particular splice variant. The PCR reaction is run on the GeneAmp PCR system 9700 (Applied Biosystem, Foster City, CA) thermocycler under optimal conditions. One of ordinary skill can design appropriate primers and determine optimal conditions. The amplified product is resolved on an agarose gel to detect a band of equivalent size to the predicted RT-PCR product. A band indicated the presence of the splice variant in a sample. The relation of the amplified product to the splice variant was subsequently confirmed by DNA sequencing.

After subcloning, all positively screened clones are sequence verified. The DNA sequence verification results show the splice variant contains the predicted sequence differences in comparison with the reference sequence.

RT-PCR results confirm the presence SEQ ID NO: 1-248 in biologic samples and distinguish between related transcripts.

Example 3c: Secretion Assay

To determine if a protein encoded by a splice variant is secreted from cells a secretion assay is preformed. A pcDNA3.1 clone containing the gene transcript which encodes the variant protein is transfected into 293T cells using the Superfect transfection reagent (Qiagen, Valencia CA). Transfected cells are incubated for 28 hours before the media is collected and immediately spun down to remove any detached cells. The adherent cells are solubilized with lysis buffer (1% NP40, 10mM sodium phosphate pH7.0, and 0.15M NaCl). The lysed cells are collected and spun down and the supernatant extracted as cell lysate. Western immunoblot is carried out in the following

manner: 15µl of the cell lysate and media are run on 4-12% NuPage Bis-Tris gel (Invitrogen, Carlsbad CA), and blotted onto a PVDF membrane (Invitrogen, Carlsbad CA). The blot is incubated with a polyclonal primary antibody which binds to the variant protein (Imgenex, San Diego CA) and polyclonal goat anti-rabbit-peroxidase secondary antibody (Sigma-Aldrich, St. Louis MO). The blot is developed with the ECL Plus chemiluminescent detection reagent (Amersham BioSciences, Piscataway NJ).

Secretion assay results are indicative of SEQ ID NO: 249-396 being a diagnostic marker and/or therapeutic target for cancer.

Example 2: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman[®] probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman[®]) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATPase, or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene are evaluated for every sample in normal and cancer tissues. Total RNA is extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA is prepared with reverse transcriptase and the polymerase chain reaction is done using primers and Taqman[®] probes specific to each target gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

One of ordinary skill can design appropriate primers. The relative levels of expression of the OSNA versus normal tissues and other cancer tissues can then be determined. All the values are compared to the calibrator. Normal RNA samples are commercially available pools, originated by pooling samples of a particular tissue from
5 different individuals.

The relative levels of expression of the OSNA in pairs of matched samples may also be determined. A matched pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. All the values are compared to the calibrator.

10 In the analysis of matching samples, the OSNAs that show a high degree of tissue specificity for the tissue of interest. These results confirm the tissue specificity results obtained with normal pooled samples. Further, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual are compared. This comparison provides an indication of specificity for the cancer state (*e.g.* higher
15 levels of mRNA expression in the cancer sample compared to the normal adjacent).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in matched samples tested are indicative of SEQ ID NO: 1-248 being a diagnostic marker and/or a therapeutic target for cancer.

Example 3: Protein Expression

20 The OSNA is amplified by polymerase chain reaction (PCR) and the amplified DNA fragment encoding the OSNA is subcloned in pET-21d for expression in *E. coli*. In addition to the OSNA coding sequence, codons for two amino acids, Met-Ala, flanking the NH₂-terminus of the coding sequence of OSNA, and six histidines, flanking the COOH-terminus of the coding sequence of OSNA, are incorporated to serve as initiating
25 Met/restriction site and purification tag, respectively.

An over-expressed protein band of the appropriate molecular weight may be observed on a Coomassie blue stained polyacrylamide gel. This protein band is confirmed by Western blot analysis using monoclonal antibody against 6X Histidine tag.

Large-scale purification of OSP is achieved using cell paste generated from 6-liter
30 bacterial cultures, and purified using immobilized metal affinity chromatography (IMAC). Soluble fractions that are separated from total cell lysate were incubated with a nickel

chelating resin. The column is packed and washed with five column volumes of wash buffer. OSP is eluted stepwise with various concentration imidazole buffers.

Example 4: Fusion Proteins

The human Fc portion of the IgG molecule can be PCR amplified, using primers
5 that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector. For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc
10 portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 2, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced. If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if
15 the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. *See, e.g.,* WO 96/34891.

Example 5: Production of an Antibody from a Polypeptide

In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such
20 cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100, µg/ml of streptomycin. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any
25 suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP20), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al.*, *Gastroenterology* 80: 225-232 (1981).

30 The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide. Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step

procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

10 **Example 6: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

RNA is isolated from individual patients or from a family of individuals that have a phenotype of interest. cDNA is then generated from these RNA samples using protocols known in the art. *See*, Sambrook (2001), *supra*. The cDNA is then used as a template for 15 PCR, employing primers surrounding regions of interest in SEQ ID NO: 1-248. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky *et al.*, *Science* 252(5006): 706-9 (1991). *See also* Sidransky *et al.*, *Science* 278(5340): 1054-9 (1997).

20 PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons are also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations are then cloned and sequenced to validate the results of the direct sequencing. PCR products is 25 cloned into T-tailed vectors as described in Holton *et al.*, *Nucleic Acids Res.*, 19: 1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements may also be determined. Genomic clones are nick-translated with digoxigenin deoxyuridine 5' triphosphate (Boehringer Mannheim), and 30 FISH is performed as described in Johnson *et al.*, *Methods Cell Biol.* 35: 73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C-and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. Johnson (1991). Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

10 **Example 7: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

Antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described above. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced. The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide. Next, 50 µl of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate. 75 µl of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution are added to each well and incubated 1 hour at room temperature.

25 The reaction is measured by a microtiter plate reader. A standard curve is prepared, using serial dilutions of a control sample, and polypeptide concentrations are plotted on the X-axis (log scale) and fluorescence or absorbance on the Y-axis (linear scale). The concentration of the polypeptide in the sample is calculated using the standard curve.

30 **Example 8: Formulating a Polypeptide**

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the

individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

5 As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1, $\mu\text{g/kg/day}$ to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given
10 continuously, the secreted polypeptide is typically administered at a dose rate of about 1 $\mu\text{g/kg/hour}$ to about 50 mg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the
15 desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid,
20 semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release
25 systems. Suitable examples of sustained-release compositions include semipermeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U. S. Pat. No.3,773,919, EP 58,481, the contents of which are hereby incorporated by reference herein in their entirety), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22: 547-556
30 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981), and R. Langer, Chem. Tech. 12: 98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the

secreted polypeptide are prepared by methods known per se: DE Epstein et al., Proc. Natl. Acad. Sci. USA 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324, the
5 contents of which are hereby incorporated by reference herein in their entirety. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is
10 formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and
15 other compounds that are known to be deleterious to polypeptides. Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably, the carrier is a parenteral carrier, more preferably, a solution that is isotonic with the blood of the recipient. Examples of such
20 carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the
25 dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e. g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid,
30 aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

5 Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

10 Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1 % (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized
15 polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container (s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or
20 biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 9: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or
25 normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the
30 activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is

in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided above.

Example 10: Method of Treating Increased Levels of the Polypeptide

Antisense or RNAi technology are used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided above.

Example 11: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e. g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks. pMV-7 (Kirschmeier, P. T. et al., DNA, 7: 219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 3. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and

the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB 101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector
5 has the gene of interest properly inserted.

The amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now
10 produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached
15 producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media.

If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector
20 that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 12: Method of Treatment Using Gene Therapy-In Vivo

25 Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide.

The polynucleotide of the present invention may be operatively linked to a
30 promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, Tabata H. *et al. Cardiovasc. Res.* 35 (3): 470-479 (1997); Chao J

et al. Pharmacol. Res. 35 (6): 517-522 (1997); Wolff J. A. *Neuromuscul. Disord.* 7 (5): 314-318 (1997), Schwartz B. *et al. Gene Ther.* 3 (5): 405-411 (1996); and Tsurumi Y. *et al. Circulation* 94 (12): 3281-3290 (1996); W0 90/11092, W0 98/11779; U. S. Patent No. 5,693,622; 5,705,151; 5,580,859, the contents of which are hereby incorporated by
5 reference herein in their entirety.

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, ovarian, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

10 The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P. L. *et al. Ann. NY Acad. Sci.* 772: 126-139 (1995) and Abdallah B. *et al. Biol. Cell* 85 (1): 1-7 (1995)) which
15 can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art
20 can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

25 The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, ovarian, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide
30 matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to

the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 $\mu\text{g/kg}$ body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to ovarians or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle in vivo is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.

The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

10 Example 13: Transgenic Animals

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e. g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (I. e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., *Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver et al., *Biotechnology* 11: 1263-1270 (1993); Wright et al., *Biotechnology* 9: 830-834 (1991); and U. S. Pat. No. 4,873,191, the contents of which is hereby incorporated by reference herein in its entirety); retrovirus mediated gene transfer into germ lines (Van der Putten et al., *Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., *Cell* 56: 313-321 (1989)); electroporation of cells or embryos (Lo, 1983, *Mol Cell. Biol.* 3: 1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e. g., Ulmer et al., *Science* 259: 1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm mediated gene transfer (Lavitrano et al., *Cell* 57: 717-723 (1989)). For a review of such techniques, see Gordon, "Transgenic Animals," *Intl. Rev. Cytol.* 115: 171-229 (1989).

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell *et al.*, *Nature* 380: 64-66 (1996); Wilmut *et al.*, *Nature* 385: 810813 (1997)).

5 The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, I. e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a
10 particular cell type by following, for example, the teaching of Lasko *et al.* (Lasko *et al.*, *Proc. Natl. Acad. Sci. USA* 89: 6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting
15 is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the
20 endogenous gene in only that cell type, by following, for example, the teaching of Gu *et al.* (Gu *et al.*, *Science* 265: 103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

 Once transgenic animals have been generated, the expression of the recombinant
25 gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained
30 from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 14: Knock-Out Animals

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E. g., see Smithies et al., *Nature* 317: 230-234 (1985); Thomas & Capecchi, *Cell* 51: 503-512 (1987); Thompson et al., *Cell* 5: 313-321 (1989)) Alternatively, RNAi technology may be used. For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e. g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However, this approach can be routinely adapted for

use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to
5 express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e. g., knockouts) are administered to a patient in vivo. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e. g., lymphocytes), adipocytes, muscle cells, endothelial
10 cells etc. The cells are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or
15 transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer, to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered
20 cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e. g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e. g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or
25 vascular graft. (See, for example, Anderson et al. U. S. Patent No. 5,399,349; and Mulligan & Wilson, U. S. Patent No. 5,460,959, the contents of which are hereby incorporated by reference herein in their entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the
30 development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such
5 conditions and/or disorders.

While preferred illustrative embodiments of the present invention are described, one skilled in the art will appreciate that the present invention can be practiced by other than the described embodiments, which are presented for purposes of illustration only and not by way of limitation. The present invention is limited only by the claims that follow.
10

We claim:

1. An isolated nucleic acid molecule comprising:
 - (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 249-396;
 - 5 (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-248;
 - (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b); or
 - (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (a) or (b).
- 10 2. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a cDNA.
- 15 3. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is genomic DNA.
4. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is an RNA.
- 20 5. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a mammalian nucleic acid molecule.
6. The nucleic acid molecule according to claim 5, wherein the nucleic acid molecule is a human nucleic acid molecule.
- 25 7. A method for determining the presence of a ovarian specific nucleic acid (OSNA) in a sample, comprising the steps of:
 - (a) contacting the sample with the nucleic acid molecule of SEQ ID NO: 1-248
 - 30 under conditions in which the nucleic acid molecule will selectively hybridize to a ovarian specific nucleic acid; and

(b) detecting hybridization of the nucleic acid molecule to a OSNA in the sample, wherein the detection of the hybridization indicates the presence of a OSNA in the sample.

5 8. A vector comprising the nucleic acid molecule of claim 1.

9. A host cell comprising the vector according to claim 8.

10. A method for producing a polypeptide encoded by the nucleic acid molecule according to claim 1, comprising the steps of:

(a) providing a host cell comprising the nucleic acid molecule operably linked to one or more expression control sequences, and

(b) incubating the host cell under conditions in which the polypeptide is produced.

15

11. A polypeptide encoded by the nucleic acid molecule according to claim 1.

12. An isolated polypeptide selected from the group consisting of:

20 (a) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 249-396 ; or

(b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-248.

25 13. An antibody or fragment thereof that specifically binds to:

(a) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 249-396 ; or

30 (b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-248.

14. A method for determining the presence of a ovarian specific protein in a sample, comprising the steps of:

- (a) contacting the sample with a suitable reagent under conditions in which the reagent will selectively interact with the ovarian specific protein comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 249-396; and
- 5 (b) detecting the interaction of the reagent with a ovarian specific protein in the sample, wherein the detection of binding indicates the presence of a ovarian specific protein in the sample.
15. A method for diagnosing or monitoring the presence and metastases of ovarian cancer in a patient, comprising the steps of:
- 10 (a) determining an amount of:
- (i) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 249-396;
- (ii) a nucleic acid molecule comprising a nucleic acid sequence of SEQ
- 15 ID NO: 1-248;
- (iii) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (i) or (ii);
- (iv) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (i) or (ii);
- 20 (v) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 249-396 ; or
- (vi) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-248
- 25 and;
- (b) comparing the amount of the determined nucleic acid molecule or the polypeptide in the sample of the patient to the amount of the ovarian specific marker in a normal control; wherein a difference in the amount of the nucleic acid molecule or the polypeptide in the sample compared to the amount of the nucleic acid molecule or the polypeptide in the normal control is associated with the
- 30 presence of ovarian cancer.

16. A kit for detecting a risk of cancer or presence of cancer in a patient, said kit comprising a means for determining the presence of:

- (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 249-396;
- 5 (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-248;
- (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b); or
- (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic
10 acid molecule of (a) or (b); or
- (e) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 249-396 ; or
- (f) a polypeptide comprising an amino acid sequence encoded by a nucleic
15 acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-248.

17. A method of treating a patient with ovarian cancer, comprising the step of administering a composition consisting of:

- (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an
20 amino acid sequence of SEQ ID NO: 249-396;
- (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-248;
- (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b);
- 25 (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (a) or (b);
- (e) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 249-396 ; or
- (f) a polypeptide comprising an amino acid sequence encoded by a nucleic
30 acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-248;

to a patient in need thereof, wherein said administration induces an immune response against the ovarian cancer cell expressing the nucleic acid molecule or polypeptide.

18. A vaccine comprising the polypeptide or the nucleic acid encoding the polypeptide of claim 12.

SEQUENCE LISTING

<110> diaDexus, Inc.
Macina, Roberto
Salceda, Susana
Liu, Chenghua
Sun, Yongming
Turner, Leah

<120> Compositions and Methods Relating to Ovarian Specific Genes and Proteins

<130> DEX-0443

<150> US 60/401,469

<151> 2002-08-06

<160> 396

<170> PatentIn version 3.1

<210> 1

<211> 272

<212> DNA

<213> Homo sapien

<400> 1

tgaatctcca	cacagtcaag	tctgatgtgt	ttgacagttc	ctgggatgtc	tctacagtag	60
ctcctcttga	aatctaaagc	aacatgtcca	cattgtaaac	cactttcaaa	gatagtaata	120
aaagttaaaa	agttggggga	ggtcagggaa	acagactaga	taagaaacag	caaggaaaca	180
aatacaaaaac	atggcagagg	aagatcatcc	acagtctata	ttatggcagt	gaagaggaat	240
gtgttaacac	tcctctgtaa	gaagaaaaag	at			272

<210> 2

<211> 288

<212> DNA

<213> Homo sapien

<400> 2

atctttttct	tcttacagag	gagtgttaac	acattcctct	tcactgccat	aatatagact	60
gtggatgatc	ttcctctgcc	atgttttggt	tttgtttcct	tgctgtttct	tatctagtct	120
gtttccctga	cctcccccaa	ctttttaact	tttattacta	tctttgaaag	tggtttacaa	180
tgtggacatg	ttgctttaga	tttcaagagg	agctactgta	gagacatccc	aggaactgtc	240
aaacacatca	gacttgactg	tgtggagatt	catcctcgtg	agcctcct		288

<210> 3

<211> 1182

<212> DNA

<213> Homo sapien

<400> 3

2

gtagcatttc cggcaggtgc ctgagggaaa gtgtggcagg gctcttctct ctgtctctct 60
 ttcccctctg agatatgcac ctgggtataa ttcttctctg tcttaatccc aattcaagct 120
 caggccgtcc agggccacag gcctctgtga tctggcagct acaatcagaa catctaacag 180
 tgccccacac tccccccgc cctcccctga gccatcagct ccacgactgg cccttgcttt 240
 gggctgtctt ctcttgggag ctgggaggggt cctaaagatg aggagatggg tctgggtctca 300
 aaagagatat cggcagacac aaattcttaa tggctttgct ttcttgagta tgacgtgttc 360
 tcaagcccct caaagccgc atggcctgcc ctgactctgg cccctccaac cgacactccc 420
 caaggctttc tgccctcgca gcccaggtgg aagtccggct ctccaagcct cacactctcc 480
 catggctggg ggatgttggt ggtcagctgt taagtggaaa ggaggaccga gaggaggtct 540
 gggctcagcc cctgggacca gggcagtggc actcactctc actaacctga gaagggtgcc 600
 atagggcagg gcagggccac ccctgtgccc actggacaga agtgacctag agggcagggc 660
 cctcccgag tcacatggat gcctttattg ggatgagtga cctcagctct tgcccagaga 720
 atcagaagtg gctgagattg cagagcagcc ctccctggcc ccagtcagg ctctcgacca 780
 cccccagctc acacaccct gcagtgggac atttcccaga ataaggggagc agagctcgcg 840
 agctggagtg acagtgcct cactgccag ggtggctctc aagccaggg acggcagtgg 900
 gccctgaga tgcggcccct tctgaattaa ttcttggcta tctgtgccag accctgctta 960
 ggagcccaaa gctggggaga aagcatgggg gttccaggac ttgcccatcc tgtggaaagg 1020
 tgggtgtggt gccttcagcc ccactcttgg tgtggagggc actgcaaggc actgaagagt 1080
 tggggctcca gacccactc agggagcctc cagatgagtg ttctagaaac ctgcttcac 1140
 tccagctaag cttgttttca ttacatatt cattatgtca tc 1182

<210> 4
 <211> 1249
 <212> DNA
 <213> Homo sapien

<400> 4
 acttgtcagt gtaattttta ttaaattagg tccatctcat tcagaaaggg tttgagcaaa 60
 ccataagtga tgacataatg aatatgtaaa tgaaaacaag cttagctgga gtggaagcag 120
 gtttctagaa cactcatctg gaggtccct gagtggggtc tggagcccca actcttcagt 180
 gccttgcaat gccctccaca ccaagagtgg ggctgaaggc accacacca cctttccaca 240
 ggatgggcaa gtccctggaac ccccatgctt tctcccagc tttgggctcc taagcagggt 300
 ctggcacaga tagccaagaa ttaattcaga aggggccgca tctcagggcc cactgccgtc 360
 cctgggcttg agagccacc tggcagtgga gggcactgtc actccagctc gcgagctctg 420

3

```

ctcccttatt ctgggaaatg tcccactgca ggggtgtgtg agctgggggt ggtcgagagc 480
ctgactgggg gccaggagg gctgctctgc aatctcagcc acttctgatt ctctgggcaa 540
gagctgaggt cactcatccc aataaaggca tccatgtgac tgcgggaggg ccctgccctc 600
taggtcactt ctgtccagtg ggcacagggg tggccctgcc ctgccctatg ggcaccttct 660
caggttagt agtatgagt ccactgccct ggtcccaggg gctgagccca gacctcctct 720
cggtcctcct ttccacttaa cagctgacca acaacatccc ccagccatgg gagagtgtga 780
ggcttggaga gccggacttc cacctgggct gcgagggcag aaagccttgg ggagtgtcgg 840
ttggaggggc cagatcgagg gcaggccatg cgggctttga ggggcttgag aacacgtcat 900
actcaagaaa gcaaagccat taagaatttg tgtctgccga tatctctttt gagaccagac 960
ccatctctc atcttttagga ccctcccagc tccaagaga agacagccca aagcaagggc 1020
cagtcgtgga gctgatggct caggggaggg cggggggtag tgtggggcac tgtagatgt 1080
tctgattgta gctgccagat cacagaggcc tgtggccctg gacggcctga gcttgaattg 1140
ggattaagac agagaagaat tataaccagg tgcatatctc agaggggaaa gagagacaga 1200
gagaagagcc ctgccacact ttcctcagg cacctgccgg aaatgctac 1249

```

```

<210> 5
<211> 1246
<212> DNA
<213> Homo sapien

```

```

<400> 5
gcatttccgg caggtgcctg agggaaagtg tggcagggt cttctctctg tctctctttc 60
ccctctgaga tatgcacctg gttataattc ttctctgtct taatcccaat tcaagctcag 120
gccgtccagg gccacaggcc tctgtgatct ggcagctaca atcagaacat ctaacagtgc 180
cccacactac ccccgccct ccctgagcc atcagctcca cgactggccc ttgctttggg 240
ctgtcttctc ttgggagctg ggagggtcct aaagatgagg agatgggtct ggtctcaaaa 300
gagatatcgg cagacacaaa ttcttaatgg ctttgctttc ttgagtatga cgtgttctca 360
agccctcaa agcccgcatg gcctgccctc gatctggccc ctccaaccga cactcccaa 420
ggctttctgc cctcgcagcc caggtggaag tccggctctc caagcctcac actctcccat 480
ggctggggga tggtgttgt cagctgttaa gtggaaagga ggaccgagag gaggtctggg 540
ctcagcccct gggaccaggg cagtggcact catactcact aacctgagaa ggtgcccata 600
gggcagggca gggccacccc tgtgccact ggacagaagt gacctagagg gcagggccct 660
cccgagtc aatggatgcc ttattggga tgagtgcct cagctcttgc ccagagaatc 720
agaagtggct gagattgcag agcagccctc cctggcccc agtcaggctc tcgaccaccc 780

```

4

```

ccagctcaca caccctgca gtgggacatt tcccagaata agggagcaga gctcgcgagc      840
tggagtgaca gtgccctcca ctgccagggg ggctctcaag cccagggacg gcagtgggcc      900
ctgagatgcg gccccttctg aattaattct tggctatctg tgccagaccc tgcttaggag      960
cccaaagctg gggagaaagc atggggggttc caggacttgc ccatcctgtg gaaaggtggg     1020
tgtggtgcct tcagccccac tcttggtgtg gagggcactg caaggcactg aagagttggg     1080
gctccagacc ccactcaggg agcctccaga tgagtgttct agaaacctgc ttccactcca     1140
gctaagcttg ttttcattta catattcatt atgtcatcac ttatgggttg ctcaaaccct     1200
ttctgaatga gatggaccta atttaataaaa aattacactg acaagt                      1246

```

```

<210> 6
<211> 250
<212> DNA
<213> Homo sapien

```

```

<400> 6
gtgcaagtct gtggtggccc ctgccacgga tgggtggcctc aacctgacct ccaccttct      60
caggaaaaac cagtgtgaga cccgaaccat gctgctgctg cccgcggggg cctcggctc     120
ctacagctac cggagtcccc actggggcag cacctactcc gtgtcagtgg tggagaccga     180
ctacgaccag tacgcgctgc tgtacagcca aggccaggg cttcacagag gataccattg     240
tcttcctgcc                                         250

```

```

<210> 7
<211> 530
<212> DNA
<213> Homo sapien

```

```

<400> 7
gaagaaggcg gcgttgtcca tgtgcaagtc tgtggtggcc cctgccacgg atggtggcct      60
caacctgacc tccaccttcc tcaggaaaaa ccagtgtgag accogaacca tgctgctgca     120
gccgcggggg tccctcggct cctacagcta ccggagtccc cactggggca gcacctactc     180
cgtgtcagtg gtggagaccg actacgacca gtacgcgctg ctgtacagcc accctctaca     240
gccgaacca gaccccccagg gctgagttaa aggagaaatt caccgccttc tgcaaggccc     300
agggcttcac agaggatacc attgtcttcc tgccccaaac cgataagtgc atgacggaac     360
aataggactc cccagggctg aagctgggat cccggccagc caggtgacct ccacgctctg     420
gatgtctctg ctctgttctt tccccgagcc cctgccccgg ctccccgcca aagcaccct     480
gccactcgg gcttcatcct gcacaataaa ctccggaagc aagtcagtaa                    530

```

```

<210> 8
<211> 968

```

5

<212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (952)..(952)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (958)..(958)
 <223> n=a, c, g or t

<400> 8
 tacttatatt atttaaaaaa caattaatca aataagttgg ttaggattag tttcagtggc 60
 ataaacagaa acttaaacaa tgtgaaagct tatttctgtc tccttctgcc aggtgaacac 120
 acagtgttca tcccctcagg aggacacagc ttttgaggta ccatccttgg aagcagagac 180
 cagccctcac tagacacaaa ctgtcctggc acctagattt tggacttcat agcctctaga 240
 actgtgctgg gaagacaaca cttctgaact atattttgac agagcaacat agtaaaagag 300
 tagcgggtcat tttaaataaa tctggggaag gaagtgcgct ggagaaatcc ttagctgtca 360
 ggccaagggtg gagagctcta tgaagagtgg ctggaactta gaaatgggtg cctctgctgt 420
 tcagtgaagg agcaatggcc ttagagctat tgagaatttg atgcaaaaga aggggaaatt 480
 tgatgacata ctgttagaga ccaactggatt agcagaccct ggtatcataa ctattgtgga 540
 ttcaaaatat ggattaaaag tgaaatacca ctaaaggcag aagagaatga aatcatccca 600
 cccactgacc cgttcccaat ctgagcatat ggatagggcc caaagcagca aagaattgga 660
 caacgttaaa atgacagctc tctattctga ggacttgaca cccgggctac tgacattgtt 720
 cttttcagtt ctacaaatgt gacagcattt aatgcaatag aagcaatgaa tgaagttacc 780
 cagagaagca tttaacagaa gagaaacctg atggccttat caatgaagct actaggcaag 840
 ttgctttggc agatatcatt ctcatataa aaacagactt ggtcccagaa gaagatgtaa 900
 agaaattaag aacgacactt agatccataa atggactagg acaaactcta gnaacacnaa 960
 gatcaagg 968

<210> 9
 <211> 1807
 <212> DNA
 <213> Homo sapien

<400> 9
 cccggccagg ccgggagtgg cgtgctgggc gtgcgcggct gcggttacgg cgtgttggtc 60
 ccaggcgggt caactgaagg ttaggaagtt ccgtaagccg ggaatggtaa ccggctgttg 120

6

gatcttgagg	atgaggagga	ggatcctggc	ggaggaggat	tgtcctagaa	ttgggtcccc	180
caatgggaga	cgacgcaaaa	gcgaggcagg	agggaaaagt	tcctggcctt	cgggcgccaa	240
gatcccagtt	cacaattatc	accgggtatt	taggttgctg	ggaaagggaac	aacacttctt	300
ggaactatat	ttttgacaga	gcaaccatag	ttaaaagagt	agccgggtcat	tttaaatgaa	360
tcctggggaa	ggaagtgccg	ctggagaaat	ccttaagctg	tcagccaagg	tggagagctc	420
tattgaagag	tggcttgga	cttagaaacg	gttgccctctg	cttgttcagt	tgaagtgagg	480
aatgtgttta	ctgtgtacat	ggtttactag	aaatgtttat	tgattatatt	tccatgcttt	540
aattttcttg	gagtaattta	actgaattta	cacagttttg	cttcattgta	ttttcaaaca	600
aatagaaaat	taaacttatt	aggaagcatt	ttcttaaagt	gtttcttgct	gtcttttcta	660
tctgctctaa	tgttttggtc	cttttattga	gtttttattg	cttttgatgt	cagggccttat	720
ttaatctcta	gtgcatgaaa	gtctcatatg	taaaaaatga	ttattctgaa	tttaatctgt	780
cattgggtcat	atctctaagt	gttcaacctt	ataaaaaaaaa	taaatgacta	tcataaaaaga	840
gaaaaacctt	acattatggt	ctactagtta	agttttcaag	gacagtgttc	actagtctac	900
catagaccct	agaagagtta	cccaacacat	agttagcact	caaataatttg	tttgaatgaa	960
ttataaaaaat	gactacttgt	actgttaatt	tgtggtaatc	taagggaatt	aaatctcttc	1020
ggcatcattt	actcccttag	gtatttgact	ttgtgtcaaa	tgttttggca	aggataaaaat	1080
tataacagac	tttcttgaac	aacaaaaata	taatctatta	aggattttcc	ttcacttttg	1140
ataaaaataag	aaaaaaggaa	attaaaccct	tgcacccctaa	tgtaaaaatag	aattatatgg	1200
tgtttaatat	cagtgtctaa	tatagctatt	atattgacct	cctatagtta	atacatttta	1260
tcattatttt	gatatgttgg	ttttaaaaaat	ttcataaagc	tataaaaaga	tacttggtca	1320
gataaagttt	cctctgcttt	taattttta	aaagtattat	tatgtatatg	atttcttttt	1380
acctattata	tatatgcac	tattgttttc	tcactggtaa	atatgggaca	gacattttgt	1440
tagaagggtta	gaagtgagtt	aaattttcac	attcctaagg	atacttttgt	ctcgggttgt	1500
tgaatacatt	ttaaagtgtt	tataataatc	acttcaaaat	atttaggtaa	tttaactgtaa	1560
attatgtttc	ggtatttctc	agggacaatg	gccttagagc	tattgagaat	ttgatgcaaa	1620
agaaggggaa	atgtgattac	atactgttag	agaccactgg	attagcagac	cctggtaaga	1680
agtgagatta	tttaataacca	gaatatagtt	ctgtgatata	ttgtaaatag	atgtattaga	1740
ggaatatcta	aatgagtat	taaagctttt	gttagtatta	aacaaaaaac	tttttttggt	1800
tttaaaag						1807

<210> 10
 <211> 6351

<212> DNA

<213> Homo sapien

<400> 10

aaaaagaaaa aattgtcact ggttatcctt caggtataaa aattacaatt aaaattgtaa	60
tgttataacc ttccattctt tcccctatga attaaaactt ttttttttaa cgagactaaa	120
aaatcaagtt gataaaatct atgccctgtg ggaactgggt aggtcaggct acccactcca	180
gatttccagc aggctggcct cagctctacc tacagccagt agcttattaa ggctctaggc	240
gccagtgaca ccttcagaca ggtgggttagt gcgccctaag gactctccgc agcgtcgcctc	300
aggttcacag aacacgcca ggggcgtgtc cagctgtcgt cggggagagc ccacctcccc	360
gggggggtgtg gctaaggga gaggcagttc tcgtccagag ccaggtaat ccgggcggga	420
tcagctagcg tcgcgatgtg atgacgtcag gccccggcca ggccgggagt ggcgtgctgg	480
gcgtgcgcgg ctgcggtacg gcgtgttggt ccagcgggt cagctgaggt agggacgtgc	540
tgtaggccgg aatgttaccg gctgttggtat ctgtggatga ggaagaggat cctgcggagg	600
aggattgtcc tgaattgggt ccattgaga cgacgcaaag cgaggaggag gaaaagtctg	660
gcctcggcgc caagatccca gtcacaatta tcaccgggta tttagggtgt gggaagacaa	720
cacttctgaa ctatatattg acagagcaac atagtaaaag agtagcggtc attttaaagt	780
aatctgggga aggaagtgcg ctggagaaat ccttagctgt cagccaaggt ggagagctct	840
atgaagagtg gctggaactt agaaacgggt gcctctgctg ttcagtgaag tgaggaatgt	900
gtttactgtg tacatgggtt actagaaatg tttattgatt atatttccag ctttaatttt	960
cttgagtaat ttaactgaat ttacacagtt tgcttcattg tattttcaaa caaatagaaa	1020
ataaacttat taggaagcat tttcttaaag tgtttcttgc tgtcttttct atctgctcta	1080
atgttttggt ccttttattg agtttttatt gcttttgatg tcagggctta tttaatctct	1140
agtgcattgaa agtctcatat gtaaaaaatg attattctga atttaatctg tcattgggtca	1200
tacttctaag tgttcaacct tataaaaaat aaatgactat caaaaaagaa aaaccttaca	1260
ttatgttcta gtagttaagt ttccaaggac agtgatcact agtctaccat agaccctaga	1320
agagttaccc aacacatagt agcactcaaa tatttggtga atgaattata aaaatgacta	1380
cttgtattgt taattttgtg tattctagtg aattaaatct ctccggcatc atttactccc	1440
ttaggtattt gactttgtgt caaatgtttt ggcaaggata aaattataac agactttctt	1500
gaacaaccaa aatgtaatct attaggaatt ttccttcact tttgataaaa taagaaaaaa	1560
ggaatttaaa accttgcac ctaatgtaaa atagaattat atgggtgttta atatcagtgt	1620
ccctttagct attatattaa actactatag ttaataaatt ttatcattat tttgtatgtt	1680
ggtttttaaa aatttcataa agctataaaa agatacttgg tcagataaag tttcctctgc	1740

ttttaatttt	aataaagtat	tattatgtat	atgatttctt	tttacctatt	atatatatgc	1800
atctattggt	ttctcactgg	taaatatggg	acagacattt	tgtagaagg	ttagaagtga	1860
gttaaatttt	cacattccta	aggatacttt	tgtctcgggt	tggtgaatac	attttaaagt	1920
gtttataata	atcacttcaa	aatatttagg	taattaactg	taaattatgt	tttggtattc	1980
tccagggaca	atggccttag	agctattgag	aatttgatgc	aaaagaaggg	gaaatttgat	2040
gacatactgt	tagagaccac	tggattagca	gaccctggta	tcataactat	tgtggattca	2100
aatatggat	taaaagtga	ataccactaa	aggcagaaga	gaatgaaatc	atcccacca	2160
ctgaccggt	ccaatctga	gcatatggat	agggcccaaa	gcagcaaaga	attggacaac	2220
ttaaaatgac	agctctctat	tctgaggact	tgacaccogg	gctactgaca	ttgttctttt	2280
cagttctaca	aatgtgacag	catttaatgc	aatagaagca	atgaatgaag	ttaccagag	2340
aagcatttaa	cagaagagaa	acctgatggc	cttatcaatg	aagctactag	gcaagttgct	2400
ttggcagata	tcattctcat	taataaaaca	gacttggttc	cagaagaaga	tgtaaagaaa	2460
ttaagaacga	cacttagatc	cataaatgga	ctaggacaaa	tcttagaaac	acaagatca	2520
aggctcagca	gctgatagac	tcagcaacag	gcagccagga	gctctgaggc	tcacagctgg	2580
cagtctagtt	ccactcagtc	tctacttgag	aaattctttc	tttggaaagta	cagcagaggc	2640
cttaggtgag	tggcttgtct	gctatggcag	agattagagg	tgctgacaga	ctgccataag	2700
tattaggcag	taacagcagc	agctgcttat	atgcatgtga	acagctgggg	aattaatttg	2760
gtatgcattc	tcaggagcca	ctcatctgct	ggcagaggta	gcagaagaat	gcccttagtg	2820
taagtcctct	acaaccatac	accaaattgt	ctccctgcgt	ttcaaattcc	attgtagaga	2880
gtctctgata	atctcactta	taccatgagc	cattcctcag	tatctgtcct	cttcctgtta	2940
gtgttctaca	attcctttct	ccttaatttt	tctccgcttt	acaaaatgtc	acacagacaa	3000
gtgcatgata	cttaacaag	cttttaaaaa	taatgctcat	aatagcttt	ggttctgtca	3060
taatattcgt	atttataaac	attttaagtc	aattctcttc	ttttattttc	atttcagaaa	3120
tatccatgtc	ctgaataaaa	gttgtgtctt	gattagttaa	ttatgtaaca	atttagtgtg	3180
tttgacattt	ctaactttta	tttctaacat	ttgctttatt	atagaacaat	aaacatgcag	3240
tgattgattt	ttcttacttc	aagtggatga	gtgagcaagt	gactaaaatc	ttctgtgaat	3300
tcttcagtgt	atgggtgctg	ccaatgcac	tgagaatcta	gggactttct	gaaatagtac	3360
ttccttgcta	tgaggactga	agttggatta	gaatcctttt	caatgaagat	cagatgtcct	3420
gagtagaatt	cttactattg	ggtcctgaat	cttatattaa	atattctctc	aaattccttg	3480
agccaccgcg	cccagcctgt	cctctgtgat	tttctgggct	tatgttaaaa	ttataactca	3540

atcaccagtc	tttataaatt	tgcctttttta	tattttaaacc	aaacctaattg	ctaattgtga	3600
tatgttat	attctcacct	gatttgaatc	attggattca	attaaatgag	tttaattatc	3660
attaaataat	tctaagagaa	ataatgtcta	ttcggatggg	gggaattttc	tttctacatg	3720
cagccccatt	ctgaatgaat	gaaatcaaat	cacgtgacga	tcaggggtcct	agagtaactt	3780
aatattttgt	acattgggta	tttgactcct	cattttttata	ttacatgtta	tatcaaggga	3840
gggggtataa	aagaaataca	aaaattgcag	aggtatctgg	aatgtacctt	tttggttaatt	3900
ctattttgtca	tttcttttgg	ttcatctttt	gagtaataag	ctgccttgga	aagtttctgt	3960
tcttttagctg	atttttttagc	tataaaaatg	tatttgaaaa	gctcataaat	ttcaggattg	4020
aaaagataat	tgaaagttaa	aaaaaacct	aattcattga	agtaataacc	aaataatttt	4080
caatcttgat	tcaactgtga	ttcaaactct	acaccatttg	cccacttcta	tgaattttat	4140
gtataaaatt	ttttaagagt	cagagttttt	ttttcttgat	taattggatg	tatttcacag	4200
aattttccaac	tgctcacgtt	agttttcttc	cttttagagt	tgatctctct	aatgtattag	4260
atcttcatgc	ctttgatagt	ctctctggaa	taagtttgca	gaaaaaactt	cagcatgtgc	4320
caggaacaca	acctcacctt	gatcagagta	ttgttacaat	cacatttgac	gtaccaggaa	4380
atgcaaagga	agaacatctt	aatatgttta	ttcagaatct	tctgtgggaa	aagaatgtga	4440
gaaacaagga	caatcactgc	atggagggtca	taaggctgaa	ggtacagttt	actgttgcag	4500
acttttggac	aaagtccttt	tcttggctgt	tataaaaact	atatttggtt	ttaaacagaa	4560
acactgggtt	tagtacaaat	catctttgtc	tacttttcatt	tttctttatt	attttcatga	4620
ctgaaaagga	gctttggaaa	tcactgcata	aggcttgatt	tatttgcaca	actttcttta	4680
gggttgcagc	tagaacaac	ctgtgtgctt	tgaaatgtta	ccttctgctc	tctgttccca	4740
agtacagaga	aataatgttg	caaactcac	ttctgctgaa	cattatgctt	cctgatgcat	4800
ttagcagaca	ctaaacattt	gttgtactct	aaacaaagtt	acaaaggact	agaagaattc	4860
ttgttctgta	tttagaaacc	cactcacatt	acttgatatt	tgggtattta	agtcatgaaa	4920
ggatatttct	ctaggaagca	gtgattctaa	agtgtatgct	taaccagtca	gttgagtgtc	4980
tactcttggtg	tgttcacaag	tgtgcacaaa	gtttttggta	aattaagaat	attatttcaa	5040
ataaattaat	ttcatcccca	taggagccag	tttatcagat	aattcgtttc	tcatttctgc	5100
aatcaatac	acaatgagct	catattccag	ataaatataa	tagtttttct	ttatttcaac	5160
attgttcatt	gattgcaacc	catttctaaa	acaaattatt	taatataacc	aaactccttt	5220
aacttctcaa	cttttcccac	taaaactgtg	aaacattata	taaaatcttt	aatcaatagg	5280
atatgataca	tatttcatca	ttttgtttca	ggttttgggt	gtgataaata	acactgaaaa	5340
accatcctaa	tatatgtatt	aactttatca	ttagaaaagg	ggattgttca	aaaaaaaaatc	5400

10

aatacacaga aacctttttt gaaaattaaa aacattaaga aacttcttgt aattcacaaa 5460
taattggaat taagtaattt tctcagctta agagtttgta ttttttaagt gaatatcagt 5520
aattaatcca ttaacattga tgctctattt ctgcttttaa gtttgaactg aggctgatta 5580
atgttcagtc aattctcctt tgagcaggat tgggtgtcaat caaagacaaa tcacaacaag 5640
tgattgtcca ggggtgtccat gagctctatg atctggagga gactccagtg agctggaagg 5700
atgacactga gagaacaaat cgattgggtc tcattggcag aaatttagat aaggatatcc 5760
ttaaacagct gtttatagct actgtgacag aaacagaaaa gcagtggaca acacatttca 5820
aagaagatca agtttgtaca taacactaga ggcatttctt atcaaaagga ttggataata 5880
aaaataagtt tctactgggt atatttcaag catttattta ttactttagt tacgaattcc 5940
aatatacttt aaaatgggtat ttgttttaca gcatacataa aatgtagcaa atcagtactg 6000
taaaacattt aacattcata caattatata taatatcctt ttttttaaag aatgggtattt 6060
cacaaaaata tcttttgaaa ttggctttgg agtttacata tactgaacat gaaagtttat 6120
aataatgatg atacaacttt caacattgtc attttttctt agaacttcag ctgattgcag 6180
agatataatg attacattgt tattaaattt ttttaacaca agtaagtgtc accattttat 6240
gacatgaaat aaaaggttat gactgttaaa aaaaaaatg gcctcttggc cctacggtgg 6300
gtctcggccc ttcctttatg ggggtattca tgaccctctc ctgccccgc a 6351

<210> 11
<211> 5654
<212> DNA
<213> Homo sapien

<400> 11
cgcaatcagt attttcatac atatttaaaa ttttccatcc atacaaagggt tgctaacata 60
tttatttaaa attttaaaaa taattttata tgccctcttgt aaccagtaat aggatgcaaa 120
gttttttttt aaggtaacat tgctcctctt ccccatattgt ctctgtcatc tatagtactc 180
cctgaggtag ttcattgttat tgcaaggggtg tgtatcatca caaacatatt gcttccacat 240
acatatatca gcatacatat atatatatga gcacatatta atatatgccc atgcacatac 300
aagcatgttt ttgttaattt ttactgaaat ggaatcatac tacatactta tgaacaaatt 360
gcttctttca ccttatatca cttataattg ttattctaca aatcagtaca tataaaaaat 420
acatatttac atatgtaata ctctatcttt ctgttataat tttctgcatg cacatgtatg 480
catatacata tattcataaa cataaaactt aatctaaacg ggattttttt ttgggggggg 540
gatatggttt ggctgtgtcc ccacccaaat ctcatcttga attcccatgt gttgtggggg 600
gacccggtgg gaggttaattg aattatgggg gcaggtcttt cctgtgctgt tcttgggata 660

gtgaaaaagt ctcacaagat ctgatggttt taaaaagggtg agtttccctg cataatctct	720
cttctcctgt ctggttccat gtgagatgtg ccttttgcct tccgccatga ttgtgaggcc	780
tccccagcca tgcggacccg cccatagggtg gaagggactt gccttgtctc ggatgagact	840
ttggactttg gactgtggac ttttgagtta acactgaaat gaattaatgc tgaaatgaat	900
taagactttg ggagacgggtt gagaagccat gactcatttt aaaatgtgag acatgccttt	960
caccttctgc catgattgtg aggcctctcc agccatgtgg aactgtgaac acacagtgtt	1020
catcccctca ggaggacaca gcttttgagg taccatcttg gaagcagaga ccagccctca	1080
ctagacacaa acttcctggc acgttgattt tggacttcat agcctctaga actgtgctgg	1140
gaagacaaca cttctgaact atatthttgac agagcaacat agtaaaagag tagcgggtcat	1200
tttaaagtga tctggggaag gaagtgcgct ggagaaatcc ttagctgtca gccaaagggtg	1260
agagctctat gaagagtggc tggaaacttag aaacgggttg ctctgctgtt cagtgaagt	1320
aggaatgtgt ttactgtgta catggtttac tagaaatgtt tattgattat atttccagct	1380
ttaattttct tgagtaattt aactgaattt acacagtthg cttcattgta ttttcaaaca	1440
aatagaaaat aaacttatta ggaagcattt tcttaaagtgt tttcttgctg tcttttctat	1500
ctgctctaata gttttgggtcc ttttattgag tttttattgc ttttgatgtc agggcttatt	1560
taatctctag tgcataaag tctcatatgt aaaaaatgat tattctgaat ttaatctgtc	1620
attggtcata cttctaagtgt ttcaacctta taaaaaataa atgactatca aaaaagaaaa	1680
accttacatt atgttctagt agttaagttt ccaaggacag tgatcactag tctaccatag	1740
accctagaag agttacccaa cacatagtag cactcaaata tttgttgaat gaattataaa	1800
aatgactact tgtattgtta attttgtgta ttctagtga ttaaactctct tcggcatcat	1860
ttactccctt aggtatttga ctttgtgtca aatgttttgg caaggataaa attataacag	1920
actttcttga acaacccaaa tgtaatctat taaggatttt ccttcacttt tgataaaata	1980
agaaaaaagg aatttaaaac cttgcatcct aatgtaaaat agaattatat ggtgtttaat	2040
atcagtgtcc ctttagctat tatattaaac tactatagtt aataaatttt atcattattt	2100
tgtatgttgg tttttaaaaa tttcataaag ctataaaaag atacttggtc agataaagtt	2160
tcctctgctt ttaattttta taaagtatta ttatgtatat gatttctttt tacctattat	2220
atatatgcat ctattgtttt ctactggta aatatgggac agacattttg ttagaagggt	2280
agaagtgagt taaattttca cattcctaag gatacttttg tctcgggttg ttgaatacat	2340
tttaaagtgt ttataataat cacttcaaaa tatttaggta attaactgta aattatgttt	2400
tggtattctc cagggacaat ggccttagag ctattgagaa tttgatgcaa aagaagggga	2460

12

aatttgatga	catactgtta	gagaccactg	gattagcaga	ccctgggtatc	ataactattg	2520
tggattcaaa	atatggatta	aaagtgaaat	accactaaag	gcagaagaga	atgaaatcat	2580
cccacccact	gacccgttcc	caatctgagc	atatggatag	ggcccaaagc	agcaaagaat	2640
tggacaactt	aaaatgacag	ctctctattc	tgaggacttg	acacccgggc	tactgacatt	2700
gttcttttca	gttctacaaa	tgtgacagca	tttaatgcaa	tagaagcaat	gaatgaagtt	2760
accagagaa	gcatttaaca	gaagagaaac	ctgatggcct	tatcaatgaa	gctactaggc	2820
aagttgcttt	ggcagatatc	attctcatta	ataaaacaga	cttgggtcca	gaagaagatg	2880
taaagaaatt	aagaacgaca	cttagatcca	taaatggact	aggacaaatc	ttagaaacac	2940
aaagatcaag	gctcagcagc	tgatagactc	agcaacaggc	agccaggagc	tctgaggctc	3000
acagctggca	gtctagttcc	actcagtctc	tacttgagaa	attctttctt	tgggaagtaca	3060
gcagaggcct	taggtgagtg	gcttgtctgc	tatggcagag	attagagggtg	ctgacagact	3120
gccataagta	ttaggcagta	acagcagcag	ctgcttatat	gcatgtgaac	agctggggaa	3180
ttaatttggg	atgcattctc	aggagccact	catctgctgg	cagaggtagc	agaagaatgc	3240
ccttagtgta	agtcctctac	aaccatacac	caaatgtgct	ccctgcgttt	caaattccat	3300
tgtagagagt	ctctgataat	ctcacttata	ccatgagcca	ttcctcagta	tctgtcctct	3360
tcctgttagt	gttctacaat	tcctttctcc	tttaatttttc	tcgcgtttac	aaaatgtcac	3420
acagacaagt	gcatgatact	taaacaagct	tttaaaaata	atgctcataa	atagctttgg	3480
ttctgtcata	atattcgtat	ttataaacat	tttaagtcaa	ttctcttctt	ttattttcat	3540
ttcagaaata	tccatgtcct	gaataaaaagt	tgtgtcttga	ttagtttatt	atgtaacaat	3600
ttagtgtgtt	tgacatttct	aacttttatt	tctaacattt	gctttattat	agaacaataa	3660
acatgcagtg	attgattttt	cttacttcaa	gtggatgagt	gagcaagtga	ctaaaatctt	3720
ctgtgaattc	ttcagtgtat	ggtgcttgcc	aatgcatctg	agaatctagg	gactttctga	3780
aatagtactt	ccttgctatg	aggactgaag	ttggattaga	atccttttca	atgaagatca	3840
gatgtcctga	gtagaattct	tactattggg	tcctgaatct	tatattaaat	attctctcaa	3900
attccttgag	ccaccgcgcc	cagcctgtcc	tctgtgattt	tctgggctta	tgttaaaatt	3960
ataactcaat	caccagtctt	tataaatttg	cttttttata	tttaaaccac	acctaagtct	4020
aattgtgata	tgttatttat	tctcacctga	tttgaatcat	tggattcaat	taaatgagtt	4080
taattatcat	taaataattc	taagagaaat	aatgtctatt	cggatgggtg	gaattttctt	4140
tctacatgca	gccccattct	gaatgaatga	aatcaaatca	cgtgacgata	agggtcctag	4200
agtaacttaa	tattttgtac	attgggttatt	tgactcctca	tttttatatt	acatgttata	4260
tcaagggagg	gggtataaaa	gaaatacaaa	aattgcagag	gtatctggaa	tgtacctatt	4320

13

```

tgtaattct atttgtcatt tctttggttt catcttttga gtaataagct gcttggaana 4380
gtttctgttc tttagctgat ttttttagcta taaaaatgta tttgaaaagc tcataaattt 4440
caggattgaa aagataattg aaagttttaa aaaaaccta ttcattgaag taataaccaa 4500
ataattttca atcttgattc aactgtgatt caaatcttac accatttgcc cacttctatg 4560
aattttatgt ataaaatttt ttaagagtca gagttttttt ttcttgatta attggatgta 4620
tttcacagaa tttccaactg ctacggttag ttttcttcct tttagagttg atctctctaa 4680
tgtattagat cttcatgcct ttgatagtct ctctggaata agtttgcaga aaaaacttca 4740
gcatgtgcca ggaacacaac ctacacttga tcagagtatt gttacaatca catttgacgt 4800
accaggaaat gcaaaggaag aacatcttaa tatgtttatt cagaatcttc tgtgggaaaa 4860
gaatgtgaga aacaaggaca atcactgcat ggaggtcata aggctgaagg gattgggtgc 4920
aatcaaagac aaatcacaac aagtgattgt ccagggtgtc catgagctct atgatctgga 4980
ggagactcca gtgagctgga aggatgacac tgagagaaca aatcgattgg tcctcattgg 5040
cagaaattta gataaggata tccttaaaca gctgtttata gctactgtga cagaaacaga 5100
aaagcagtgg acaacacatt tcaaagaaga tcaagtttgt acataacact agaggcattt 5160
cttatcaaaa ggattggata ataaaaataa gtttctactg ggtatatctc aagcatttat 5220
ttattacttt agttacgaat tccaatatac tttaaaatgg tatttgtttt acagcataca 5280
taaaatgtag caaatcagta ctgtaaaaca tttaacattc atacaattat atataatctc 5340
ctttttttta aagaatggta tttcacaaaa atatcttttg aaattggctt tggagtttac 5400
atatactgaa catgaaagtt tataataatg atgatacaac tttcaacatt gtcatttttt 5460
cttagaactt cagctgattg cagagatata atgattacat tgttattaaa tttttttaac 5520
acaagtaagt gtcaccattt tatgacatga aataaaaggt tatgactgtt aaaaaaaaaa 5580
atggcctctt ggccctacgg tgggtctcgg cccttccttt atgggggtat tcatgaccct 5640
ctccttgccc cgca 5654

```

```

<210> 12
<211> 534
<212> DNA
<213> Homo sapien

```

```

<400> 12
ataaatttga tcctggctgt ggtggacatg gtctacgagg aacagaatca ggccaccttg 60
gaagaagcag aacagaaaga ggccgaattt cagcagatga ttgaacagct taaaagcaa 120
caggaggcag ctacggcagc aacggcaact gcctcagaac attccagaga gccagtgca 180
gcaggcaggc tctcagacag ctcatctgaa gcctctaagt tgagttccaa gagtgctaag 240

```

14

```

gaaggaagaa atcggaggaa gaaaagaaaa cagaaagagc agtctggtgg ggaagagaaa      300
gatgaggatg aattccaaaa atctgaagct ggggacccac acggcagagc catggtactg      360
gaggagccat taacaaagct ttcaataaac ctctctttct tgaagttacc tgagaatgga      420
tccattccct gcaactgaag attctaagga actgggtttc tcagtataca atgggaatgg      480
ttgggaggag gtaaagagta gaagacagta tcaagaatcc agagcccagc acct          534

```

```

<210> 13
<211> 1457
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1024)..(1024)
<223> n=a, c, g or t

```

```

<220>
<221> misc_feature
<222> (1073)..(1073)
<223> n=a, c, g or t

```

```

<400> 13
ctgagtatgt ggttgctctg aatagccatc tcaaaattga ccacagaatc tgttttgggg      60
tggcatagat tagtctccca cacaggtcaa gccagggaac cccacccagt gcctccgtcc      120
ctcgttcagg cccagcctga gtgagccac cccagtggga ggagagggca tggccagggc      180
agggaggggg tctgagtgtc ctcttggtct ctgaaggcac cagtcagctg ccgctccagc      240
cactgcccc a gtggagttct ttggttccaa gccacagaa gaaggtggtg ggtgggcccag      300
tgtgccctga ggcttcttac tggggaggga gagagtcagg tcctccactg ttaggtggcc      360
aagcgcccaa acgcatctc cactctcacc ctggatgcaa gaagtgacct cggaggcctg      420
agtcctggcc ttggtctggt ttgatgccat ccaccgcaga ggctgttctg agggcaggctg      480
gtcagtgcag agtggcgcg c tttgtggatg gcagcctccc cccattacta ggaatctgac      540
tgccagccca gtagccctgg gctgcctgct caggcccccac cacctgtggg gcagggtgctt      600
tagtcccctt aagaggatga ggagggtgag gcatcagcag gcttgagcgc cttgctcagg      660
gcagttccgt gggaccctgc tgaacagcac gtggctgccc aacgcctgcc tggagcatcc      720
cctatcccca cccagcccaa cccatgttct cagcagcagg gatggttcta ggctggctga      780
atgagggacc agggcagaga ctgcaaaagc ttgagagcca aggggggcagc acagagcggg      840
gagggggctg ggcttgggct gtgctcctgt tgggtttcca ttaaccaggg gaccagctgg      900
gctgctgtga tttcactttc gcagaaaatg aaactgaagc cgtgggtcacg tgacaggaca      960

```

15

```

tgtagtatat agcaggctgc cagcgactcc tgctcttgct tctggatctg cagggcagtc 1020
gccngcagga ccccatggag tgccttcgt gccagcatgt ctccaagggg ggnaaccccc 1080
aagttctgca gccagtgcgg agagaggctg cctcctgcag ccccatagc agattctgag 1140
aacaataact ccacaatggc gtcggcctcg gagggtgaaa ctggagtgtg ggcaggagct 1200
gaaggaggaa gggggcccgt gcttgttccc gggctcagac agttggcaag aaaaccccga 1260
ggagccctgt tccaaagcct cctgggaccg tccaagaagg agctacatca gaggttttgg 1320
tagatgctgc thtagacctc atatccgatg aatgggaagc tgctaatgcc ataccagca 1380
agagaaggaa gcaggatgca gccccgcttg aggccgccag cgtgccttct gcagactgtg 1440
agcagagcaa aaaaaaa 1457

```

```

<210> 14
<211> 1527
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (457)..(457)
<223> n=a, c, g or t

```

```

<400> 14
gcgggggggg aaggtggtgg gggaggaggc aaaagaggag ggagagggga gggtagtggg 60
ggggggagga tttagagtgg accgctctgc tcacagtctg cagaaggcac gctggcggcc 120
tcaagcgggg ctgcatcctg cttccttctc ttgctgggta tggcattagc agcttcccat 180
tcatcggata tgaggtctac agcagcatct accaaaacct ctgatgtagc tccttcttgg 240
acggtccagg aggccttggg acagggctcc tcgggggttt cttgccaaact gtctgagccc 300
gggaacaagc acgggcccc ttctccttc agctcctgcc cacactccat ttcaccctcc 360
gaggccgacg ccattgtgga gttattgttc tcagaatctg ctatgggggc tgcaggaggc 420
agcctctctc cgcactggct gcagaacttg ggggttnccc cccttgagga catgctggca 480
cgaaggacac tccatgggtc ctgctgggac tgccctgcag atccagaagc aagagcagga 540
gtcgtggca gcctgctata tactacatgt cctgtcacgt gaccacggct tcagtttcat 600
tttctgcgaa agtgaaatca cagcagccca gctgggtccc tgggttaatgg aaacccaaca 660
ggagcacagc ccaagcccag cccctcccc gctctgtgct gccccttgg ctctcaagct 720
tttgagctct ctgccctggc ccctcattca gccagcctag aaccatccct gctgctgaga 780
acatgggttg ggctgggtgg ggatagggga tgctccaggc aggcgttggg cagccacgtg 840
ctgttcagca ggggtcccacg gaactgcct gagcaaggcg ctcaagcctg ctgatgcctc 900

```

16

```

accctcctca tcctcttaag gggactaaag cacctgcccc acaggtgatg gggcctgagc      960
aggcagccca gggctactgg gctggcagtc agattcctag taatgggggg aggctgccat    1020
ccacaaagcg cgccactctg cactgaccac ctgccctcag aacagcctct gcggtggatg    1080
gcatcaaacc agaccaaggc caggactcag gcctccgggg tcacttcttg catccagggt    1140
gagagtggag atggcgtttg ggcgcttggc cacctaacag tggaggacct gactctctcc    1200
ctccccagta agaagcctca gggcacactg gccacccac caccttcttc tgctggcttg    1260
gaaccaaaga actccactgg ggcagtggct ggagcggcag ctgactgggtg ccttcagcag    1320
ccaggaggac actcaggccc cctccctgcc ctggccctgc cctctcctcc cactggggtg    1380
ggctcactca ggctgggcct gaacgaggga cggaggcact ggggtggggtt ccctggcttg    1440
acctgtgtgg gagactaatc tatgccacc caaaacagat tctgtggtca attttgagat    1500
ggctattcag agcaaccaca tactcag                                     1527

```

```

<210> 15
<211> 601
<212> DNA
<213> Homo sapien

```

```

<400> 15
ctcgtgacat tgggaggaag aggctggatg ctaggacggc acagtctttc tgtctgaktc      60
acccttggtt gtgctgaarc tggggtycct ggttccctcc taccacctg gagcagaacc    120
cctaccctgc tcatgttagc aggcccaatg caggacctcg gagggagaac aggggtgaatc    180
tctccatgca ctcgtgggga ggatttctgt ttttccttcc taacactcgc ttctctctga    240
gatctgacct ttccttcata tgccgttaca gattctgaga acaataactc cacaatggcg    300
tcggcctcgg agggtgaaat ggagtgtggg caggagctga aggaggaagg gggcccgtgc    360
ttgttcccgg gctcagacag ttggcaagaa aaccccagag agccctgttc caaagcctcc    420
tggaaccgtc aagaagtgag tgcactgcct cggctcccct ccgccccgcg tcactctgcc    480
caggaaaatc tcactgcaca gctgcccagc tagccccga aaatgccacc atggcccagc    540
ccattgaacc tgcccacagg gcagcagcag agctgccctt tctgcacctg attcatctct    600
g                                                                    601

```

```

<210> 16
<211> 578
<212> DNA
<213> Homo sapien

```

```

<400> 16
aacggccgca gtgtgctgga atcggctttc gagcggcgcc cgggcaggta caaagcggat    60

```


17

ctgagcccgg aaaatgctaa gctcctcagc acattcctaa atcagactgg cctagacgcc 120
 ttcttgctag agctgcacga aatgataatc ttgaaactaa agaaccccca aacccaaacc 180
 gaggagcgct tccgccctca gtggagcctg agagacactc tcgtaagtta catgcaaact 240
 aaagaaagtg aaattcttcc tgaaatggca tctcagttcc cagaagagat actgctcgcc 300
 agctgtgtct cagtgtggaa aacagctgct gtgctgaaat ggaatcgaga aatgagatag 360
 aattatttcc tcagctatct ttggatgact ttggagagaa gactcctctc tcctcgtctg 420
 cggcgtggac ttgatcatgg actggtgcct ttgcattcag aaggagagct gtcagcgtag 480
 caccgaattc aagaccaagg cgtgctacct gagctgacag cttttttgaaa gccgagctgt 540
 ttctgaacca tgtacctcgg ccgcgaccac gctaagcc 578

<210> 17
 <211> 745
 <212> DNA
 <213> Homo sapien

<400> 17
 ttgctgagct acatagttag agatccgctg caagtctcag cccgctgcat cccatgacct 60
 gggctttcca ctcatctactg tggacgtcta ggatgtctgt ttgcacgggg ctggcctcag 120
 atgagaagtc agttggagga gtctggctgt cgtcagtggt tgggtttttg cttttccctt 180
 cctcccttcc tctgccccat ttactccata tctgtaccag tcgtgatcag ccttctaggc 240
 tagtgtctag gtctccaggg ttttgatggg cttaggtagg ctcttggttc ttctgtccct 300
 cttagactgg catcagtact atgacatagt ttatatgaag cctcatggga gactccagaa 360
 agtcatgaac cacatcacag acgggccgag gaaggacctg gtgaagggga agcagattgc 420
 cgctgcgctc atgctggaca gcaccttcag catcctgcag acctgggaca ccatcaacct 480
 gaacagcttc ttcacccagt tcgagcagtt ttgctttgtc ctgcaacagc ctatgattta 540
 tgaaggacag gcacagctgt ggaccgattt gcagtacagg gagaaagagg tatcaggctt 600
 gccaccagct gctctacctg ctgggcagga gccacacctg acctgctagt ggccggatga 660
 ccccttgact ctgtgggcca ggttgcaaata gggaatgtgt agaactttcc agccttttct 720
 cctaccactg tctcttgga tttct 745

<210> 18
 <211> 649
 <212> DNA
 <213> Homo sapien

<400> 18
 agtgtgctga agcctgggaa gcgtgggaga aggctctgca gcgagcagag cgggagccga 60
 ccacaggagg gagaagggca agatcctcgc tccaaccgtg gcccggtgtc tctccttttg 120

18

```

tccccatagt gtgactccgc caggaacttg gaatggctga agactgtgaa tgagagtcac 180
gggtctgtgg aacgctcatc cctgacctgg ccacggccat caaccaaaga ggcatctatg 240
tgatccaggc gcccaaaggt ggccaaaaga tttccccaga cacggttctg cacttgatcc 300
ttcctgagag ccctggcagc cacgaggagt cacgagagta ctctttagag aaagtcagca 360
gagtttccaa acaaaaccct ctgttgatgat ttttcctaaa cttctcttat tgtacttggg 420
gaccacagaa ggacactgag gacttggggac tccacagcca ttgcttccag cgtcaccccc 480
agaggggttct ctgcattggg gacctggcag aatgatggcg tctggtagag aggcaggcgg 540
gcggctgctc attcccctcc actcctccac agatgtaagt caagtgcccc catgtgccag 600
ctctgaaatc tgatgtctca atcacaaaga ccccttggc caggccagg 649

```

```

<210> 19
<211> 874
<212> DNA
<213> Homo sapien

```

```

<400> ' 19
gggaaacaag gcattccaag tacaggaaaa agcattttta aaggctcagg accttttggc 60
tggaacaacc atcttccagt aatttgccaa aatgacaaat acaaaggga agaggagatg 120
cacccaatat atgtcctcta ggccttttag aaaatatgga gttgttctt tggccacatg 180
gtacatgtga atctatgaga caggtgatac tgtagacatc aagggaatgg gtactgttca 240
aaaaggaatg tcccacaaat gttaccatgg caaaactgga agagtctacg gtattacca 300
acgtgctgtt ggcattgttg taaacaaata agttacaggc cagattcttg ccaagagaat 360
tgtgcctatt gagcacatta agcacactaa gagccaatag agcttcctga aatgtgtgaa 420
ggaaaatgat cagaaaaaga aagaagccaa agagaaaggt acctgggttc aaattaagcg 480
ccagcctgct ccaccagag aagcatatct tgtgagaacc agtgggaagg agcctgagct 540
gctggaacct attccctatg aattcatggc ataataggtg ttaaaaaaat aaaagacttc 600
tggaactgtta aaaaaaaaaa aaagggttaa taattttccc aaggtcacaa agctgttggg 660
taaaacagcg tattgtgttt tcccaagcct tgccttggtt cttcattcat ttttatttaa 720
caataatttc ttgagttatc taccacagac taagtgttat tctaaggcac ataagatttg 780
tccatgaaga aaacagaaaa aaacacattg tggcttcatg gagtttattt tcccacagac 840
aataagcaac aatttttata acagaaggaa gtga 874

```

```

<210> 20
<211> 584
<212> DNA
<213> Homo sapien

```

19

```

<400> 20
atggcgtagaa ttcacagggga ataggctcca gcaactcagg ctccctccca ctgggttctta      60
cacagtgtgc ttctctgggt gtagcaggct ggcgcttaat ttgaaccggg gtacctttct      120
ctctggcttc cttctttttac taaacatttt ccttcacaca tttcaggaag ctctattggc      180
tcttagtgtg cttaatgtgc tcaataggca caattctctt ggcaagaatc tggcctgtaa      240
cttatttggt tacaacaatg ccaacagcac gttgggtaat accgtagact cttccagttt      300
tgccatggta acatttggtg gacattcctt tttgaacagt acccattccc ttgatgtcta      360
cagtatcacc tgtctcatag attcacatgt accatgtggc caaaggaaca actccatatt      420
ttctaaaagg cctagaggac atatattggg tgcattctct ctttcccttt gtatttgtca      480
ttttggcaaa ttactggaag atggttggtc cagccaaaag gtccctgagcc ttttaaaatg      540
ctttttcctg tacttggaat gccttggttc ccgatttcg tttta      584

```

```

<210> 21
<211> 314
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (307)..(307)
<223> n=a, c, g or t

```

```

<400> 21
gtgccaatgg cccgctatga ggaggtgagc gtgtccggct tcgaggagtt ccaccggggc      60
gtggaacagc acaatggttg aaagatccaa ataatgactt cagaaaaaac ttgaaagtaa      120
cagcagtgcc tacactactt aagtatggaa cacctcaaaa actggtagaa tctgagtgtc      180
ttcaggccaa cctgggtggaa atggtgttct ctgaagatta agattttagg atggcaatca      240
tgtcttgatg tcctgatttg ttctagtatc aataaactgt atacttgctt tgaattcatg      300
ttagcantaa atga      314

```

```

<210> 22
<211> 2528
<212> DNA
<213> Homo sapien

```

```

<400> 22
gtccgggtga ctatatgctt ccatcaagac tagtgaagaa tgggtgtttt ttccattcat      60
ccctacatct cttttttttaa taatgataaa catgcaactt ttttgtagct ttacaacaaa      120
taccagatg ctgtggccac atggctaaac cctgacctat ctgagaagca gaatctcta      180
gccccacagg tattttttaa cttctcataa ttaaactaca gtgatgaaag atagccacac      240

```

tcaggccatt tgggctgctc agatgaatcc tgccctgacctg ctggcaaaca tgtgcttagg 300
acattgactg atctgccatg ttggcttctc tctgtgttaa gccatccaca gatgaggctg 360
aaaaataaaa actgcttttg attaaaaagg ttaacttttg aataaaaaag ctaggcatgt 420
gtgatgcgca ctaacacgtg ccattccttc ttcagaatgc tgtgtcctct gaagaaacca 480
atgactttta acaagaggta agttctcatt ttcaatcaga ggcccatcat gccttgaaga 540
gatgaaagaa ggcatcgctt ggattctctt ctgatgaaat ttcattagca agt tttccag 600
ctaattggca gtctaaaact tgctcataaa taaaacatgt atttactaaa tatcagaaat 660
actagggttc ctccgataag tttagcatta cagaagatgt ttattaatgc ctgttatttg 720
aaacattaat ctgcttgcaa tttattttaag gtattttgta gatatcta atctaataag 780
catctaatta atgcgtatca aagctaagat tttgccttta ggaaagt ttt cttccta at 840
aaaatagttt atttgacaac tattcttttt attaggatca ttcatatatt tgctaagcaa 900
agagtaaatt tattttcctt aagattcaat ttgaatatac taagaatatt aaagcaagtt 960
agataaatta cccaatatat ttgtcaattt gaaatttgat agacattagt tgtttaattc 1020
aatgggcagt tttgagctgc agtttataca cacatgcata acagagtcac ctttcaatta 1080
tccatgttaa taggaaagtg gttatagatt ttagtacaca cattaaaata tggatactct 1140
tctcttttga taaatctcat ttcaaataaa aaaaccagtc tcataattat gtatctgtat 1200
ctattacatc attgaattta gtaaataatg tttaatatgt ataaggaaaa acaatgttat 1260
tgacatgaag attataactca catatttggc ttgaaaatat ctataaaaaat aatttctgtt 1320
gcaaagtaag aaatgttctt cagaatgtta ttaatccctg tgttaaaaga gaaattggaa 1380
gatgctcact ttagctccta aaagccatgg tatgtactgt gaatgcaaag attctgaaac 1440
taaataaaaa gaaagatagt aaaagactaa tgtgctataa aggctaaggg aaaataaaaa 1500
cccatatatt aattttcccg gccatcttaa ttttcagacc cttccaagta agtccaacga 1560
aagccatgac cacatggatg atatggatga tgaagatgat gatgacctg tggacagcca 1620
ggactccatt gactcgaacg actctgatga tgtagatgac actgatgatt ctcaccagtc 1680
tgatgagtct caccattctg atgaatctga tgaactggtc actgattttc ccaaggacct 1740
gccagcaacc gaagttttca ctccagttgt cccacagta gacacatatg atggccgagg 1800
tgatagtgtg gtttatggac tgagggtcaaa atctaagaag tttcgcagac ctgacatcca 1860
gtaccctgat gctacagacg aggacatcac ctcacacatg gaaagcgagg agt tgaatgg 1920
tgcatacaag gccatccccg ttgcccagga cctgaacgcg ccttctgatt gggacagccg 1980
tggaaggac agttatgaaa cgagtcagct ggatgaccag agtgctgaaa cccacagcca 2040

21

```

caggcagtc agattatata agcggaaagc caatgatgag agcaatgagc attccgatgt 2100
gattgatagt caggaacttt ccaaagtcag ccgtgaattc cacagccatg aatttcacag 2160
ccatgaagat atgctgggtg tagaccccaa aagtaaggaa gaagataaac acctgaaatt 2220
tcgtatttct catgaattag atagtgcac ttctgaggtc aattaaaagg agaaaaaata 2280
caatttctca ctttgcattt agtcaaaaga aaaaatgctt tatagcaaaa tgaaagagaa 2340
catgaaatgc ttctttctca gtttattggt tgaatgtgta tctatttgag tctggaaata 2400
actgatgtgt ttgataatta gtttagtttg tggctcatgg aaactccctg taaactaaaa 2460
gcttcagggt tatgtctatg ttcattctat agaagaaatg caaactatca ctgtatttta 2520
atatttgt 2528

```

```

<210> 23
<211> 3220
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (2015)..(2015)
<223> n=a, c, g or t

```

```

<400> 23
ttaggtacaa attatgagt taaggaattg ggttacctgc tctcctgtct ttccatcttt 60
ttgggtcccc aagctaattg attgggcttc atttatgagc ctgttacagt aaagtgtgtg 120
tggggaaata tattgaggta tagagctatt ctttgtaggt accctgggtga gaccgataca 180
aatatgcccc tccccataat ggaataactaa tttttatttg atcactcatt tatagcagtt 240
gcttgaaatg tatgtattta tatgaaggta ttttaatttt taagagcaaa aaagttctaa 300
taagttgcc aatttctaataaatgcagggt ttatttggtg aaaagataag gaaaatgagt 360
tatgattctg tagttttttt aaaatgagtt cagcataatt gtttttccagg tttttttagt 420
tactgggggtt attctgcata agaaagccca atgctttctg atagtaggag ataatttttc 480
tctcttttga ctttgaaatc tgacttagga gatgaattct ttttaaaaag gtcagcatgc 540
aaaaaaataa attatatatt ttaaattcta aaagagaagg gacataaaat ttcactccta 600
gcataaagcc atataatatt attcttgaaa ctcatcacat catttgctc ctgcccattt 660
gaatataatc atacctacgt ttattaatt gtgcatttgt aaaaccaaac ccttccagta 720
aatacttgct ataaggctat tgcttgtcaa ttatcaaggc ttctaaatat gttaaaactt 780
gtcattttga tttttcaaag ataattttat tatactgagc taccaatatt cttaagaaa 840
actaaccaaa gttaatatta gtgtagtcca ttattatgtg gacaattatt atgtggaatc 900

```


tcttaagtga gcaactaaga aaaagcctta tagaaagact acactggatt tataagtgtg	960
tttatgtttc tctaagaatg ggagcttctg ttaacttagg ggtggagttg ttctgaggaa	1020
accagtagat tggatgactg actggagaat ccagaataac aaatccatta gccagacatg	1080
tttactttta tattagaagt ttgttgatta ggtcttaatt ttcaaacgca aacaccaagc	1140
tttaaaataa ttgcatatac aatgtattgg tcagcaattt aataatattt aatttgaagt	1200
taattattgt taatccttct agaaaagttt tttttcttta aataaaagta catatatata	1260
cttttttatt tagaggttac cagaagctct ggttttgttt ttttttgttt tgtttttttg	1320
tttttttaat cattttcaga tgttatccag aaatctgcaa gtgtactttt cctgttttaa	1380
ctccttcctt ttatcacctg actatcaggg aagcgagggt gaggctgccc tgacctgaca	1440
tgtcatgatg tcgacttgct aggtgggggt cgctggggac gataaccagt ggaattggtg	1500
gtaagaactt ttttttccta ttttttttta tatcagtagt ggggcattaa gtgtgggaga	1560
atgccccatat cctataagtg ggcaattatg tcagccttgt agaaaaatag gactttaata	1620
ttaaattatt ttgttcttaa taggaacata taataacact tcacttactt ttaaattggt	1680
agcagatcag caggaaaggc ctgcaagtat gaagtaatga aatactcagg gtatatttta	1740
agtgagcaaa atagacacct tataatctta aaaagtctgt tggagagaca ataaatttgc	1800
tttaactgtc atttcagtct agtattatat tttctatatt ttgttgata gattaacata	1860
taatgcatct taaagagata ttattgcac actaatttta gtgaaaacaa gaagacattg	1920
atagaatgga gggcttaaac accaaagata ctatttttta aaatcttcca aagtaatctt	1980
aacactgtaa aatgaaactt taaaaagttt tagcngtttg acaataatgg cctcaattta	2040
gagatatgtt gagacaatga ctttgggtca agaggatatt acatagctga aatattaaga	2100
ccttgaacat agcagaaaca taaacctatg aacaacttgt gttttgtgtg aaagctaggg	2160
tagctgatag gattagcaga tattggtaga attaagagtc aatattttaa ttattgctaa	2220
agattaaaat ccctcatctt atagtttgta ggggattcca tgatggtaag gtatagattg	2280
aaattaaatt tagtaactag gcatttctga ccataccata taaaaaataa ttgtaatatg	2340
gtataaacac tgattaaaag taattatgga ttttcatgcc tgaagaacct tctcagtatt	2400
cttacagcac tgtatcttct ttattggttg agaatatcag tctagaaaga ctttcctaga	2460
tgttaaagt gctagtcagt gtcatgaata taaaccctta cttgtaagtt tgctatagac	2520
tagttgtaca acactagaat gaaattatgt aatactttta agaattgtag tgattgcagg	2580
gttggtgttaa ggtaacattt tatgcatgtg tcagtgacag aaaggatcag ggtataaaac	2640
ttagcactaa atagcatgct ccttaggaag ttttaaggta agcagtagga atattcatgt	2700
aattctgatg agtttatgta agttaaggaa aatgcaatgc cagtttggtg actttaaaca	2760

ctaaaaacaa aatacatttt gtggaaccaa caaaggagac attctgggga aaaacttaaa 2820
 ttgctcaaat tttaaataagg gctctcactt tatatagtag atttgtcagg atcccatgaa 2880
 cattgctttt cttgatttct cacatatgag ggttgggcaa aagggaacttc tctagcctct 2940
 tcgataatgt aggtagactt gtacttagtg aatcccatta taatgtagg tactatgttc 3000
 taagactatt tctataattg gactgaaggc tcctgcaaac ataaattgct gatatggata 3060
 tagtaacata agaaatacca aatagggac atttgcaaga ccttttccat ttaatcatca 3120
 gtttaataaa aatcatgctt ttggtacagt gttcatgtac cataactgta ttggaatatt 3180
 tgtacgatgt taaatatatt taataaaatt taacatgttc 3220

<210> 24
 <211> 3224
 <212> DNA
 <213> Homo sapien

<400> 24
 ttaggtacaa attatgagtg taaggaattg gggtacctgc tctcctgtct ttccatcttt 60
 ttgggttccc aagctaattg attgggcttc atttatgagc ctgttacagt aaagtgtgtg 120
 tggggaaata tattgaggta tagagctatt ctttgtagg accctgggtga gaccgataca 180
 aatatgcccc tcccataat ggaatactaa tttttatttg atcactcatt tatagcagtt 240
 gcttgaaatg tatgtattta tatgaaggta ttttaatttt taagagcaaa aaagttctaa 300
 taagttgcca gatttctaata aatgcaggt ttatttggtg aaaagataag gaaaatgagt 360
 tatgattctg tagttttttt aaaatgagtt cagcataatt gtttttcagg tttttttagt 420
 tactgggggtt attctgcata agaaagccca atgctttctg atagtaggag ataatttttc 480
 tctcttttga ctttgaaatc tgacttagga gatgaattct ttttaaaaag gtcagcatgc 540
 aaaaaataa attatatatt ttaaattcta aaagagaagg gacataaaat ttcactccta 600
 gcataaagcc atataatatt attcctgaaa ctcatcatc catttgcctc ctgcccattt 660
 gaatataatc atacctacgt ttatttaatt gtgcatttgt aaaaccaaac ccttccagta 720
 aatacttgct ataaggctat tgcttgtcaa ttatcaaggc ttctaaatat gttaaaactt 780
 gtcattttga tttttcaaag ataattttat tatactgagc taccaatatt cttaaagaaa 840
 actaaccaaa gttaatatga gtgtagtcca ttattatgtg gacaattatt atgtggaatc 900
 tcttaagtga gcaactaaga aaaagcctta tagaaagact aactggatt tataagtgtg 960
 tttatgtttc tctaagaatg ggagcttctg ttaacttagg ggtggagttg ttctgaggaa 1020
 accagtagat tggatgactg actggagaat ccagaataac aaatccatta gccagacatg 1080
 tttactttta tattagaagt ttgttgatta ggtcttaatt ttcaaacgca aacaccaagc 1140

24

tttaaaaata	ttgcatatac	aatgtattgg	tcagcaattt	aataatattt	aatttgaagt	1200
taattattgt	taatccttct	agaaaagttt	tttttcttta	aataaaagta	catatatata	1260
cttttttatt	tagagggtac	cagaagctct	ggttttgttt	tgttttgttt	tgtttttttg	1320
tttttttaat	cattttcaga	tgttatccag	aaatctgcaa	gtgtactttt	cctgttttaa	1380
ctccttcctt	ttatcacctg	actatcaggg	aagcgagggt	gaggctgccc	tgacctgaca	1440
tgatcatgat	tcgacttgct	aggtgggggt	cgctggggac	gataaccagt	ggaattgttg	1500
gtaagaactt	ttttttccta	tttttttttt	tatcagtagt	ggggcattaa	gtgtgggaga	1560
atgcccatat	cctataagtg	ggcaattatg	tcagccttgt	agaaaaatag	gactttaata	1620
ttaaattatt	ttgttcttaa	taggaacata	taataacact	tcacttactt	ttaaattggg	1680
agcagatcag	caggaaaggc	ctgcaagtat	gaagtaatga	aatactcagg	gtatatttta	1740
agtgagcaaa	atagacacct	tataatctta	aaaagtctgt	tggagagaca	ataaatttgc	1800
tttaactgtc	atttcagtct	agtactatat	ttcttatatt	ttgttggata	gattaacata	1860
taatgcatct	taaagagata	tttattgcac	actaatttta	gtgaaaacaa	gaagacattg	1920
atagaatgga	gggcttaaac	accaaagata	ctatttttaa	aatcttcca	aagtaatctt	1980
aacactgtaa	aatgaaactt	taaaaagttt	tagcagtttg	acaataatgg	cctcaattta	2040
gagatatgtt	gagacaatga	ctttgggtca	agaggaaatt	acatagctga	aatattaaga	2100
ccttgaacat	agcagaaaca	taaacctatg	aacaacttgt	gttttgtgtg	aaagctaggg	2160
tagctgatag	gattagcaga	tattggtaga	attaagtcaa	tatttaaatt	attgctaaag	2220
attaaaatcc	ctcatcttat	agtttgtagg	ggattccatg	atggtaagg	atagattgaa	2280
attaaattta	gtaactaggc	atttctgacc	ataccatata	aaaaataatt	gtaatattgg	2340
ataaacactg	attaaaagta	attatggatt	ttcatgcctg	aagaaccttc	tcagtattct	2400
tacagcactg	tatcttcttt	attggttgag	aatactcagtc	tagaaagact	ttcctagatg	2460
ttaaatgtgc	tagtcagtgt	catgaatata	aacccttact	tgtaagtttg	ctatagacta	2520
gttgtaaca	actagaatga	aattatgtaa	tacttttaag	aattgtagt	attgcagggt	2580
tgtgttaagg	taacatttta	tgcatgtgtc	agtgcacagaa	aggatcaggg	tataaaactt	2640
agcactaaat	agcatgctcc	ttaggaagtt	ttaaggtaag	cagtaggaat	attcatgtaa	2700
ttctgatgag	tttatgtaag	ttaaggaaaa	tgcaatgcca	gtttgttgac	tttaaact	2760
aaaaacaaaa	tacattttgt	ggaaccaaca	aaggagacat	tctggggaaa	aacttaaatt	2820
gctcaaattt	aaataagggc	tctcacttta	tatagtagat	ttgtcaggat	cccatgaaca	2880
ttgcttttct	tgatttctca	catatgaggg	ttgggcaaaa	gggacttctc	tagcctcttc	2940

25

gataatgtag	gtagacttgt	acttagtgaa	tcccattata	atgttaggta	ctatgttcta	3000
agactatttc	tataattgga	ctgaaggctc	ctgcaaacat	aaattgctga	tatggatata	3060
gtaacataag	aaataccaaa	atagggacat	ttgcaagacc	ttttccattt	aatcatcagt	3120
ttaataaaaa	tcatgctttt	ggtagagtgt	tcatgtacca	taactgtatt	ggaatatttg	3180
tacgatgtta	aatattttta	ataaaattta	acatgttcaa	aaaa		3224

<210> 25
 <211> 1851
 <212> DNA
 <213> Homo sapien

<400> 25

gggcggggcc	acctcccggg	gcggggccgg	ggcctgatgg	gcgtgggtcag	ctcctggggc	60
ggggacgtga	ggggcggggg	cagctccctag	gggggcatgg	ggcgtgaggg	gcgcgggtcag	120
ttccctgggt	gtggacatga	agggcggggc	cagctcctgg	ggcgggggtcg	tgaggggctg	180
ggtcagctcc	tggggcgggg	atgtgagggg	cgggggtcatc	tcctggggcg	gggatgtgag	240
gggcgtgggc	agctcctggg	gcggagatgt	gaggggcggg	gtcatctcct	ggggcgggga	300
ttgaggggcg	ggggtcagtt	cctggggcgg	ggcgtgaggg	gcgtgggtgc	tcgggggatt	360
gggcgtgggg	gcggggccgg	gttgagagacc	ggaggagtag	acggcagagg	cgcccccgca	420
ggtaggcgca	ggtgggtccg	gagggctctg	gccgacgcgg	gtgggggtcg	ctcgccgcag	480
ttcctggggc	gctgggttcag	cgcgggcctc	gcctccaact	cgagctggct	ccgggagaag	540
aaggcggcgt	tgtccatgtg	caagtctgtg	gtggcccctg	ccacggatgg	tggcctcaac	600
ctgacctcca	ccttcctcag	gaaaaaccag	tgtgagaccc	gaacctatgt	gctgcagccc	660
gcgggggtccc	tcggctccta	cagctaccgg	agtccccgtg	agtggggcct	ccaccggccc	720
cctggggcca	gcctgggggg	gacacttgcc	gggacgactc	tggggccagcc	ccctgccgcg	780
gagatccatg	gggtgggagg	tgatggctgc	cccaccagcg	tcagaggcaa	aggccaggcc	840
tgggcgtgac	tacctatgca	caagtgttag	ggacagagag	acccttcctc	caggggggtg	900
gatcctctct	ggagcccacc	attgtcttgt	caggccccct	ccctgccctc	tggagttttc	960
cccacataag	cagcccccca	aggcccctcc	atatgcctcc	tcccaattct	cctccccagg	1020
accaggggt	ttcctcactc	ccacctgggg	aatggctccc	acggggaaac	ctcttcactt	1080
ccggttctgg	cagcgacttc	tgcggttgca	ccaggaatcc	tggttttctg	agcctggctc	1140
ccccagattc	tggtttgggg	acaggggtca	caggctgtgc	aggcgagagc	agggcactgg	1200
ctggagagca	gccgggtggg	ggagcatccc	gggccagccg	aggggctgag	tgcccccaaa	1260
gccacaggt	gcaccccttc	cctgaagcag	aggtgaggtt	tggggggctg	agtccccgac	1320

26

```

agggttgtct cttgggttcc cagactgggg cagcacctac tccgtgtcag tgggtggagac 1380
cgactacgac cagtacgcgc tgctgtacag ccagggcagc aagggccctg gcgaggactt 1440
ccgcatggcc accctctaca gccgaacca gacccccagg gctgagttaa aggagaaatt 1500
caccgccttc tgcaaggccc agggcttcac agaggatacc attgtcttcc tgccccaaac 1560
cgataagtgc atgacggaac aataggactc cccagggctg aagctgggat cccggccagc 1620
caggtgaccc ccacgctctg gatgtctctg ctctgttctt tccccgagcc cctgccccgg 1680
ctccccgcca aagcaaccct gccactcgg gcttcatcct gcacaataaa ctccggaagc 1740
aagtcagtag agctggctcc tggctgtctg cgctgtcatc acccgtcctg ggccctggccc 1800
tggccacccg gacctcccc tctaaaatct cagcctgacg tcaacaaagg a 1851

```

<210> 26
 <211> 954
 <212> DNA
 <213> Homo sapien

```

<400> 26
gcggcggcac agctcccga gctcctgctc tggtcgcct cggcccggac acctccctcg 60
ctctcccaca cactggcac caggccccgg acaccgctc tgctgcagga gaatggctac 120
tcatcacacg ctgtggatgg gactggccct gctgggggtg ctgggcgacc tgcaggcagc 180
accggaggcc caggtctccg tgcagcccaa cttccagcag gacaagttcc tggggcgctg 240
gttcagcgcg ggctcgcct ccaactcgag ctggctccgg gagaagaagg cggcgttgtc 300
catgtgcaag tctgtggtgg cccctgccac ggatggtggc ctcaacctga cctccacctt 360
cctcaggaaa aaccagtgtg agaccgaac catgctgctg cagcccgcg ggctccctcg 420
ctcctacagc taccggagtc cccgtgagtg gggcctccac cggccccctg ggcccagcct 480
gggggcgaca cttgccggga cgactctggg ccagccccct gccgcggaga tccatgggggt 540
gggaggtgac tggggcagca cctactccgt gtcagtgggt gagaccgact acgaccagta 600
cgcgctgctg tacagccagg gcagcaaggg ccctggcgag gacttccgca tggccaccct 660
ctacagccga acccagaccc ccagggctga gttaaaggag aaattcaccg ccttctgcaa 720
ggcccagggc ttcacagagg ataccattgt ctctctgccc caaaccgata agtgcattgac 780
ggaacaatag gactccccag ggctgaagct gggatcccgg ccagccaggt gacccccacg 840
ctctggatgt ctctgctctg ttccttcccc gagccccctg cccggctccc cgccaaagca 900
cccctgccc ctcgggcttc atcctgcaca ataaactccg gaagcaagtc agta 954

```

<210> 27
 <211> 1519
 <212> DNA

27

<213> Homo sapien

<400> 27

```

gcgggcggcac agctcccgca gctcctgctc tgggtccgcct cggccccggac acctccctcg      60
ctctcccaca ccactggcac caggcccccg acaccccgctc tgctgcagga gaatggctac      120
tcatcacacg ctgtggatgg gactggccct gctgggggtg ctggggcgacc tgcaggcagc      180
accggaggcc caggtctccg tgcagcccaa cttccagcag gacaaggtga ggggctttcc      240
tgcgtcatcc ccaagggcta caggacctg tcaggggaag ggcactttcc ggctgggtct      300
tccccctggg aggagtgagc gaagtcccg agtgccgggc agtgccggcc agggactgag      360
cgggcgcgca ggaaggaggc tgggtagccg cccgaggagg ctgccccgca gaagccctcc      420
ctgggcaccg cgtcccgtct cccctgatgg gccacgcaga caccgggcca cacacgcgcc      480
cacgccagcc agacacgtcc acccctgtgg gcacgcgacc cccagaggac acacgagcgc      540
acgttccaca cctgggtgcc aggacacggg cgggtggggc acagggatgg cgacaaacac      600
tccgtgcgcg gtgggggttg ggagggacgc gcaccgcaca gacagccggc gacgcgcgct      660
ctcgccccgg agctgctcgg ggaagcgccg gagcgcgggc ccccgcgccg cgcgccctc      720
cctggcgtcg aggagaacct cagcgggtccg cagagctgag ccgaagacct gccccgatcc      780
ccgccaggaa tgcgacgtcc tctgccgcc gctgtatggg ccaggcgctc agccagggca      840
cagaatcggg accgggggcg gaggggcccga agctggctgg tgggcggcgt gcgaggttcc      900
tggggcgctg gttcagcgcg ggcctcgct ccaactcgag ctggctccgg gagaagaagg      960
cggcgttgct catgtgcaag tctgtggtgg cccctgccac ggatgggtgg ctcaacctga     1020
cctccacctt cctcaggaaa aaccagtgtg agacccgaac catgctgctg cagcccgcgg     1080
ggcctcctcg ctctacagc taccggagtc cccactgggg cagcacctac tccgtgtcag     1140
tgggtggagac cgactacgac cagtacgcgc tgctgtacag ccaggggcagc aagggccctg     1200
gcgaggactt ccgcatggcc accctctaca gccgaacca gacccccagg gctgagttaa     1260
aggagaaatt caccgccttc tgcaaggccc agggcttcac agaggatacc attgtcttcc     1320
tgccccaaac cgataagtgc atgacggaac aataggactc cccagggctg aagctgggat     1380
cccggccagc caggtgacct ccacgctctg gatgtctctg ctctgttct tccccgagcc     1440
cctgccccgg ctccccgcca aagcaccct gccactcgg gcttcactct gcacaataaa     1500
ctccggaagc aagtcagta                                     1519

```

<210> 28

<211> 2459

<212> DNA

<213> Homo sapien

28

<400> 28
 gcggcgccac agctcccga gctcctgctc tggtcgcct cggcccggac acctccctcg 60
 ctctcccaca ccactggcac caggccccgg acaccgcctc tgctgcagga gaatggctac 120
 tcatcacacg ctgtggatgg gactggccct gctgggggtg ctgggcgacc tgcaggcagc 180
 accggaggcc caggtctccg tgcagccaa cttccagcag gacaaggatga ggggctttcc 240
 tgcgtcatcc ccaagggtta caggaccctg tcagggaag ggcactttcc ggctgggtct 300
 tccccctggg aggagtgagc gaagtccgc agtgccgggc agtgccggcc agggactgag 360
 cgggcgcgca ggaaggaggc tgggtagccg cccgaggagg ctgcccgcga gaagccctcc 420
 ctgggcaccg cgtcccgtct cccctgatgg gccacgcaga caccgggcca cacacgcgc 480
 cacgccagcc agacacgtcc acccctgtgg gcacgcgacc cccagaggac acacgagcgc 540
 acgttccaca cctgggtgcc aggacacggg cgggtggggc acagggatgg cgacaaacac 600
 tccgtgcgcg gtgggggttg ggaggacgc gcaccgcaca gacagccggc gacgcgcgct 660
 ctgcgccggg agctgctcgg ggaagcgcg gagcgcgggt cccgcgcg ccgcgccctc 720
 cctggcgtcg aggagaacc cagcgggtccg cagagctgag ccgaagacc gccccgatcc 780
 ccgccaggaa tgcgacgtcc tctgccgcc gctgtatggg ccaggcgctc agccagggca 840
 cagaatcggg accgggggcg gaggggccga agctggctgg tgggcggcgt gcgagggtga 900
 gggactgtcc tcgggagggg cgtggccaga cgggggtgct ggggtgtcagg ggcgtggcca 960
 gctcctgggg cggagatgtg aggggcgggg tcatctcctg gggcggggat tgaggggcgg 1020
 gggtcagttc ctggggcggg gcgtgagggg cgtggctgct cgggggattg ggcgtggggg 1080
 cggggccggg ttggagaccg gaggagtaga cggcagaggc gccccgcag gtaggcgcag 1140
 gtgggtccgg agggtcctgg ccgacgcggg tgggggtcgc tcgccgcagt ttcttggggc 1200
 gctgggttcag cgcgggcctc gcctccaact cgagctggct ccgggagaag aaggcggcgt 1260
 tgtccatgtg caagtctgtg gtggcccctg ccacggatgg tggcctcaac ctgacctcca 1320
 ccttcctcag gaaaaaccag tgtgagacc gaacctatgct gctgcagccc gcgggggtccc 1380
 tcggctccta cagctaccgg agtcccctg agtggggcct ccaccggccc cctgggcca 1440
 gcctgggggc gacacttgcc gggacgactc tgggccagcc ccctgccgcg gagatccatg 1500
 ggggtgggagg tgatggctgc cccaccagcg tcagaggcaa aggccaggcc tgggcgtgac 1560
 taccatgca caagtgttag ggacagagag acccttcctc caggggggttg gatcctctct 1620
 ggagcccacc attgtcttgt caggcccctt ccctgccctc tggagttttc cccacataag 1680
 cagcccccca agggccctcc atatgcctcc tccaattct cctcccagc acccaggggt 1740
 ttctcactc ccacctgggg aatggctccc acggggaaac ctcttcactt ccggttctgg 1800

29

cagcgacttc	tgcggctgca	ccaggaatcc	tggttttctg	agcctggctc	ccccagattc	1860
tggtttgggg	acagggttca	caggctgtgc	aggcgagagc	agggcactgg	ctggagagca	1920
gccgggtggg	ggagcatccc	gggccagccg	aggggctgag	tgcccccaaa	gcccacaggt	1980
gcaccccttc	cctgaagcag	aggtgaggtt	tggggggctg	agtccccgac	agggttgtct	2040
cttgggttcc	cagactgggg	cagcacctac	tccgtgtcag	tggtaggagac	cgactacgac	2100
cagtacgcgc	tgctgtacag	ccagggcagc	aagggccctg	gcgaggactt	ccgcatggcc	2160
accctctaca	gccgaaccca	gacccccagg	gctgagttaa	aggagaaatt	caccgccttc	2220
tgcaaggccc	agggtttcac	agaggatacc	attgtcttcc	tgccccaaac	cgataagtgc	2280
atgacggaac	aataggactc	cccagggctg	aagctgggat	cccggccagc	caggtgaccc	2340
ccacgctctg	gatgtctctg	ctctgttcct	tccccgagcc	cctgccccgg	ctccccgcca	2400
aagcaccctt	gccactcgg	gcttcctcct	gcacaataaa	ctccggaagc	aagtcagta	2459

<210> 29
 <211> 575
 <212> DNA
 <213> Homo sapien

<400> 29						
caatggcagc	cgccccaatg	gcagccgtag	ccgtgcgggc	cgcacgcgtt	agtcgccctg	60
gccggcctcg	tcacagggat	acccacccac	catcccaggg	tctacaacat	ccacagccgg	120
accgtcaccc	gctatcctgc	caactctatc	gtggtcgtag	gaggctgtcc	tgtctgcagg	180
gttgggggtgc	tggaggactg	cttcaccttc	ctgggcatct	tcctggccat	catcctcttc	240
cgcattgggc	cggctgccat	tgggcaatgg	cagccgcca	atggcagccg	aaccagacc	300
cccagggctg	agttaaagga	gaaattcacc	gccttctgca	aggcccaggg	cttcacagag	360
gataccattg	tcttcctgcc	ccaaaccgat	aagtgcattga	cggacaata	ggactcccca	420
gggctgaagc	tgggatcccc	gccagccagg	tgacccccac	gctctggatg	tctctgctct	480
gttccttccc	cgagcccctg	cccgggtccc	ccgccaagc	acccctgccc	actcgggctt	540
catcctgcac	aataaactcc	ggaagcaagt	cagta			575

<210> 30
 <211> 638
 <212> DNA
 <213> Homo sapien

<400> 30						
ccgccctgct	cgaggcctgg	gccagggaca	gaggggtgag	tgttcaagtc	agaacctccc	60
tcccgcagcc	ccttcattgag	gagccccctc	catgggggac	atggagacca	ggcgcccact	120
ctgtgccagg	cccagcagc	tcccaggatg	tggggcttca	gcctgggtggg	gggcataggg	180

30

```

tagaggggtgc ccatggggga tacaggggaa ccaaccatac tgggctcagg cacagcctcc 240
taggggtgga cagcctgctc ttggcagagg tggagaaaga ccctctcttt gtttccagtg 300
cccagggaga ggtgggaggt gatgggggat ctgtgcagtt tgggggctca gtcaagacga 360
gctctgcggt acgggaggaa caggaagccc agtgggaaaa ttggcctaag tctgggggttc 420
tgacgacagc ccctggcttc tttcttggca gataagtgc tgacggaaca ataggactcc 480
ccagggctga agctgggatc ccggccagcc aggtgacccc cacgctctgg atgtctctgc 540
tctgttcctt ccccgagccc ctgccccggc tccccgcaa agcaccctg ccactcggg 600
cttcctcctg cacaataaac tccggaagca agtcagta 638

```

```

<210> 31
<211> 745
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (718)..(718)
<223> n=a, c, g or t

```

```

<400> 31
gcggcgccac agctcccga gctcctgctc tggctcgcct cggcccggac acctccctcg 60
ctctcccaca cactggcac caggccccgg acaccgctc tgctgcagga gaatggctac 120
tcatcacacg ctgtggatgg gactggccct gctgggggtg ctgggcgacc tgcaggcagc 180
accggaggcc caggtctccg tgcagccaa cttccagcag gacaagtcc tggggcgctg 240
gttcagcgcg ggctcgcct ccaactcgag ctggctccgg gagaagaagg cggcggtgtc 300
catgtgcaag tctgtggtgg ccctgccac ggatggtggc ctcaacctga cctccacctt 360
cctcaggaaa aaccagtgtg agaccgaac catgctgctg cagcccgcg ggtccctcgg 420
ctcctacagc taccggagtc cccactgggg cagcacctac tccgtgtcag tgggtggagac 480
cgactacgac cagtacgagc tgctgtacag ccagggcagc aagggccctg gcgaggactt 540
ccgcatggcc accctctaca gccgaacca gacccccagg gctgagttaa aggagaaatt 600
caccgccttc tgcaaggccc agggcttcac agaggatacc attgtcttcc tgccccaaac 660
cgwtaagtgc atgacggrac awtaggayty cccaggggtk wagttgggtt ccggccanca 720
gtgaccccag gtttggtgtt tttgt 745

```

```

<210> 32
<211> 2528
<212> DNA
<213> Homo sapien

```

<400> 32
gtccgggtga ctatatgctt ccatcaagac tagtgaagaa tggttgtttt ttccattcat 60
ccctacattt ctttttttaa taatgataaa catgcaactt ttttgtagct ttacaacaaa 120
taccagatg ctgtggccac atggctaaac cctgacccat ctgagaagca gaatctccta 180
gccccacagg tattttttaa cttctcataa ttaaactaca gtgatgaaag atagccacac 240
tcaggccatt tgggctgctc agatgaatcc tgcttgctg ctggcaaaca tgtgcttagg 300
acattgactg atctgccatg ttggcttctc tctgtgttaa gccatccaca gatgaggctg 360
aaaaataaaa actgcttttg attaaaaagg ttaacttttg aataaaaaag ctaggcatgt 420
gtgatgcgca ctaacacgtg ccattccttc ttcagaatgc tgtgtcctct gaagaaacca 480
atgactttta acaagaggta agttctcatt ttcaatcaga ggcccatcat gccttgaaga 540
gatgaaagaa ggcattgcct ggattctctt ctgatgaaat ttcattagca agttttccag 600
ctaattggca gtctaaaact tgctcataaa taaaacatgt atttactaaa tatcagaaat 660
actaggtttc ctgggataag tttagcatta cagaagatgt ttattaatgc ctgttatttg 720
aaacattaat ctgcttgcaa tttattttaag gtatttttga gatatcta atctaataag 780
catctaatta atgcgtatca aagctaagat tttgccttta ggaaagtttt ctttccta at 840
aaaatagttt atttgacaac tattcttttt attaggatca ttcatatatt tgctaagcaa 900
agagtaaatt tatttttcctt aagattcaat ttgaatatac taagaatatt aaagcaagtt 960
agataaatta cccaatatat ttgtcaattt gaaatttgat agacattagt tgtttaattc 1020
aatgggcagt tttgagctgc agtttataca cacatgcata acagagtcac ctttcaatta 1080
tccatgttaa taggaaagtg gttatagatt ttagtacaca cattaaaata tggatactct 1140
tctcttttga taaatctcat ttcaaataaa aaaaccagtc tcataattat gtatctgtat 1200
ctattacatc attgaattta gtaaataatg tttaatatgt ataaggaaaa acaatgttat 1260
tgacatgaag attataactca catatttggc ttgaaaatat ctataaaaaat aatttctggt 1320
gcaaagtaag aaatgttctt cagaatgtta ttaatccctg tgttaaaaaga gaaattggaa 1380
gatgctcact ttagctccta aaagccatgg tatgtactgt gaatgcaaag attctgaaac 1440
taaataaaaa gaaagatagt aaaagactaa tgtgctataa aggctaaggg aaaataaaaa 1500
cccatatatt aattttcccg gccatcttaa ttttcagacc cttccaagta agtccaacga 1560
aagccatgac cacatggatg atatggatga tgaagatgat gatgaccatg tggacagcca 1620
ggactccatt gactcgaacg actctgatga tgtagatgac actgatgatt ctaccagtc 1680
tgatgagtct caccattctg atgaatctga tgaactggtc actgattttc ccacggacct 1740
gccagcaacc gaagttttca ctccagttgt cccacagta gacacatatg atggccgagg 1800

32

tgatagtgtg gtttatggac tgaggtcaaa atctaagaag ttctgcagac ctgacatcca	1860
gtaccctgat gctacagacg aggacatcac ctcacacatg gaaagcgagg agttgaatgg	1920
tgcatacaag gccatccccg ttgcccagga cctgaacgcg ccttctgatt gggacagccg	1980
tgggaaggac agttatgaaa cgagtcagct ggatgaccag agtgctgaaa cccacagcca	2040
caggcagtcc agattatata agcggaaagc caatgatgag agcaatgagc attccgatgt	2100
gattgatagt caggaacttt ccaaagtcag ccgtgaattc cacagccatg aatttcacag	2160
ccatgaagat atgctggttg tagaccccaa aagtaaggaa gaagataaac acctgaaatt	2220
tcgtatctct catgaattag atagtgcac ttctgaggtc aattaaaagg agaaaaaata	2280
caatttctca ctttgcattt agtcaaaaga aaaaatgctt tatagcaaaa tgaaagagaa	2340
catgaaatgc ttctttctca gtttattggg tgaatgtgta tctatctgag tctggaaata	2400
actgatgtgt ttgataatta gtttagtttg tggctcatgg aaactccctg taaactaaaa	2460
gcttcagggt tatgtctatg ttcattctat agaagaaatg caaactatca ctgtatttta	2520
atatttgt	2528

<210> 33
 <211> 917
 <212> DNA
 <213> Homo sapien

<400> 33	
agcggcgcag tgtgatggat gtcgcggccg aggtaccctg atgctacaga cgaggacatc	60
acctcacaca tggaaagcga ggagttgaat ggtgcataca aggccatccc cgttgccag	120
gacctgaacg cgccttctga ttgggacagc cgtgggaagg acagttatga aacgagtcag	180
ctggatgacc agagtgctga aaccacagc cacaagcagt ccagattata taagcggaaa	240
gcyaatgatg agagcaatga gcattccgat gtgattgata gtcaggaact ttccaaagtc	300
agcgtgaat tccacagcca tgaatttcac agccatgaag atatgctggg tgtagacccc	360
caaaagtaag gaagaagata aacacctgaa atttcgtatt tctcatgaat tagatagtgc	420
atcttctgag gtcaattaaa aggagaaaaa atacaatttc tcactttgca tttagtcaaa	480
agaaaaaatg ctttatagca aaatgaaaga gaacatgaaa tgcttctttc tcagtttatt	540
ggttgaatgt gtatctatct gagtctggaa ataactaatg tgtttgataa ttagtttagt	600
ttgtggcttc atggaaactc cctgtaaact aaaagcttca gcggtaaact catgggcca	660
ttagcctgtt tttccctggg tgtggaaaat tggtttaact cgctccaaca aattccaccc	720
atttcggacg ccgaacaaac acacttaggg ttaccgcctg ggggccacag caatagaaac	780
acccccaata tgctgacaaa ggcccaccat tcgacagaga aaaaatccac gatgataaaa	840

33

acagcaaccc gagagaaagc ggtagaaaac cgcgaacagc cacgcccaga atagcacact 900
tcctggcgag aagaaaa 917

<210> 34
<211> 482
<212> DNA
<213> Homo sapien

<400> 34
ctttccta at cagtactcct gatgctgctg aggaagagtc gaactataga ggtcacacat 60
tggttttcctt gtttttggat gcagttttgt tttctgtgat aatcataaat tgaggattta 120
tgacagccga tttctctctg ttatttttggc cacaatttca caatgtgacc tttggaagta 180
agggctttga gttccttaaa atagctaaat tgagaggata aaggaaaact gactcaaact 240
agagaatttg catcagggtt ctgtagggtt cttataataa tcaacaagta tttagcaatt 300
cttttttcac ataaatagaa gagcccaaga gaagaacagc gtcttttgacc tgatgggtgt 360
aagcctgcaa tctgggtaaa aaggaatttg cggaacactc tggatctgat actgaaaagt 420
tgaagaaagc aacatcttgc ttattaccct tgtgtttaag accatttggg gccgggagcg 480
gt 482

<210> 35
<211> 483
<212> DNA
<213> Homo sapien

<400> 35
ctttccta at cagtactccc tgatgctgct gaggaagagt cgaacttata gaggtcacac 60
attgttttcc ttgttttttg atgcagtttt gttttctttg ataatacataa attgaggatt 120
tatgacagcc gatttctctc tgttattttg gtcacaattt cacaatgtga cctttggaag 180
taagggtctt gagttcctta aaatagctaa attgagagga taaaggaaaa ctgactcaa 240
tcagagaatt tgcacaggt ttctgtaggc ttcttataat aatcaacaag tatttagcaa 300
ttcttttttc acataaatag aagagccaag agaagaacag cgtctttgac ctgatgggtgt 360
taagcctgca atctgggtaa aaaggaattt gcggaacact ctggatctga tactgaaaag 420
ttgaagaaag caacatcttg cttattaccct ttgtgtttaa gaccatttgg ggccgggagc 480
ggt 483

<210> 36
<211> 1853
<212> DNA
<213> Homo sapien

<220>
 <221> misc_feature
 <222> (502)..(502)
 <223> n=a, c, g or t

<400> 36
 gtcacgcatg tcatccacga ggtggcccac agttgggttcg gcaacgctgt caccaacgcc 60
 acgtgggaag agatgtggct gagcgagggc ctggccacct tatgcccagc gccgtatcac 120
 caccgagacc tacggtgctg ccttcacctg cctggagact gccttccgcc tggacgccct 180
 gcaccggcag tcgagtacct acccgaaacg accgcgggcg agcggggcctt tggtagccg 240
 gtggagacgc aggcgaggac tccagcggga ggaagaagag gcctttgccca gcagtcagag 300
 cagccaaggg gcccaatccc tcatattctc caagtttgaa ggaaagaaaa ccaacaagaa 360
 gacccgcaag gttaccacag tgaagaaatc ttcagtagct cttccagggc tcggatcaaa 420
 gaaggatatt gaaatggatt ccaggcgtgt gcctcgagac aagctggcct gcatcaccaa 480
 gtgcagcaag cacatcttgc gntgccatca agatcaccta gaacgagctg gcgtcagcag 540
 atgacttccc tccccaccct catctacatt gttttgaagg gcaacccccca tgccttcagt 600
 ctaatatcca gtatatcacg cgcttctgca atccaagccg acggcatgac tggagaggat 660
 ggctactatt tcaccaatct ggtgagtaaa gtgagttctt ggcggtgtgg agaacggact 720
 aggaagggtg tggttttggg gatgtgatag gtcactcagg ccccatgaca ggtgaatgct 780
 tctgtgtgag aaggcagcac ggctgaggaa gctcactttg catcagggag cacaaggacc 840
 caggccgtac agacactccg cctcccagca cttagatcaga gattgtgttt atcctacaga 900
 aacagatgac atgtgttggg catcactccc ccacggctcct gggtaggaaa gaggtccttc 960
 cacttggcag ggctttttca accaatgaat aaggcaaatt atatataagg taattaatgc 1020
 ccatttcgaa ccgagacaga tggcagctag aatgaagctt taatgtaaga gtaaagtaga 1080
 agcaatgagt gctggggccc tttttattgg gtactggcat tctactttcg accacaaaag 1140
 acgaagtgac cccaactttc aaggaaacag ctgttgagat ggaaggaaaag aaacaggagc 1200
 tttgctcaag gaggagagct gggctttccc aagttacctg accttaaaga tgctgaagct 1260
 gttccagaag tttctttcct tgaaggaaat acagcttggg gaagagttac tagctgcaag 1320
 gtgaatatga gaaggggctg agacccatct gacaaatggg aattgctgtg tgtggacagc 1380
 ccacagccag tttactgcag ggccttacag caaactcttc ccaccactag tgttcccaga 1440
 tgcttttgac taagctccca acaattagag aattctaagt gctcagagct tggctgaaga 1500
 tgatgtggaa tgagaaacaa atgttaacat aataaaatct cagttaaaaa tatttaaaaa 1560
 attcttggtg gcttgagcag ctctggggga ataagggcaa atatgcttgt tatgaactac 1620

35

actgaaatct	accaaagtta	atgtttactt	tgtgtagatc	catttgtcta	ttttatztat	1680
ttttcccagt	gaaaagtgtg	ttttgataga	gaacttttca	ttcatataaa	tacactatga	1740
gttactgaaa	attcatatca	tggatttcat	ttattcctga	aacatagtta	aaatgtacat	1800
atgacatggc	ttatgttaaa	aatacccagt	gctcaagttt	tgaaagatag	gca	1853

<210> 37

<211> 2184

<212> DNA

<213> Homo sapien

<400> 37

aggcagacgg	gaacctgaga	ctttgtccaa	acctcggctg	gaaggctggg	cttggcactc	60
ggcgtcttag	ctagtggatt	tatcgcatta	agactgtact	tgggcctttt	tcatgatgac	120
ttgggtctca	atccttggag	cagctgaaag	aacagctcgg	gccacctgtg	gatgcaccca	180
caatgaaatc	agaggccacg	tgaggtttgc	aaggcagagt	ggcctgcagt	tttaactcgg	240
gcactatggc	aatgcagacc	caaaccaatt	gtgccagttc	tttgctgggt	ggcaaagtgt	300
tttcaggcct	gtggtcactc	ctgatttctg	tttggaagca	cagttctctc	tctaaggaga	360
atggaaactt	ggaaaggcct	gtaaaatcgg	aaagcctgta	aaaggccgta	gagtggagat	420
gtataaaaaat	gtacggtcac	ccatgtttta	ggggttgacc	gggagcgggg	cgaggaggag	480
ggtgggtatg	aggcggtagc	ggaccgcgga	gtcgagacct	accggaacga	cgcgggcgag	540
cggggccttg	gacgccggtg	gagacgcagg	cgagggtctg	tgtaaaatat	tacaggcata	600
ctttggagat	gttatgggtt	tggttccaca	tcactgcaat	aaaactccag	cgggaggaag	660
aagaggcctt	tgccagcagt	cagagcagcc	aaggggcca	atccctcata	ttctccaagt	720
ttgaaggaaa	gaaaaccaac	aagaagaccc	gcaaggttac	cacagtgaag	aaatcttcag	780
tacgtcttcc	agggtcggat	caaagaagga	tattgaaatg	gattccaggc	gtgtgcctcg	840
agacaagctg	gcctgcatca	ccaagtgcag	caagcacatc	ttcgatgcca	tcaagatcac	900
ctagaacgag	ctggcgtcag	cagatgactt	cctccccacc	ctcatctaca	ttgttttgaa	960
gggcaacccc	catgccttca	gtctaataatc	cagtatatca	cgcgcttctg	caatccaagc	1020
cgactgatga	ctggagagga	tggctactat	ttcaccaatc	tggtgagtaa	gtgagttctt	1080
ggcgttgtgg	agaaggacta	ggaagggtgg	ggttttgggg	atgtgatagg	tcactcaggc	1140
ccatgacagg	tgaatgcttc	tgtgtgagaa	ggcagcacgg	ctgaggaagc	tcactttgca	1200
tcagggagca	caaggaccag	gccgtacaga	cactccgcct	ccccgcactt	gatcagagat	1260
tgtgtttatc	ctacagaaac	agatgacatg	tgttgggcat	cactccccac	ggtcctgggt	1320
agaagagtcc	ttcacttggc	agggtttttt	caaccaatga	ataaggcaaa	ttatatataa	1380

36

```

gttaataatg ccatttcgaa ccgagacaga tggcagctaa atgaagttta attaaagaat 1440
gagcgcgggg cccttttcat tgggtactgc atctacttcg accgcaaaag acgaagtgac 1500
cccaacttca agaacaggct tcgagaacga agaaagaaac agaagcttgc caaggagaga 1560
gctgggcttt ccaagttacc tgaccttaaa gatgctgaag ctgttcagaa gttcttcctt 1620
gaagaaatac agcttggtga agagttacta gctcaagggtg aatatgagaa gggcgtagac 1680
catctgacaa atggaattgc tgtgtgtgga cagccacagc agttactgca ggccttacag 1740
caaactcttc caccactagt gttccagatg cttttgacta agctcccaac aattagagaa 1800
ttctaagtgc tcagagcttg gctgaagatg atgtggaatg agaaacaaat gttaacataa 1860
taaaatctca gttaaaaata tttaaaaaat tcttggtagt tgagcagctc tgggggaata 1920
agggcaaata tccttggtat gaactacact gaaatctacc aaagttaatg tttactttgt 1980
gtaggtccat ttgtctatct tatttatctt tcccagtga aagtgtatct tgatagagaa 2040
cttttcattt tataaataca ctatgagtta ctgaaaattc atatcatgga tttcatttat 2100
tcctgaaaca tagttaaaat gtacatatga catggcttat gttaaaaata cccagtgtc 2160
agttttgaaa gataggcaca aaaa 2184

```

```

<210> 38
<211> 906
<212> DNA
<213> Homo sapien

```

```

<400> 38
agtaggtggg gttacaggca cgcgccacct ttggatccac acctcctccc gtccctgagcc 60
aaaggccacg gaagtgacgt ttgcacgcgc tgcgtaacgt gcattctggc ggtgcgggga 120
gcggggcgag gaggaggggtg ggtatgaggc ggtagcggac cgcggagtcg agacctaccc 180
gaacgacgcg ggcgagcggg gctttggacg ccggtggaga cgcaggcgag actccagcgg 240
gaggaagaag aggcctttgc cagcagtcag agcagccaag gggcccaatc cctcatattc 300
tccaagtttg aaggaaagaa aaccaacaag aagacccgca aggttaccac agtgaagaaa 360
tcttcagtac gtcttccagg gtcggatcaa agaaggctga aattcaggaa gcaaaagctc 420
ccagtccttc cataaaccgg caaaccagca ttgaaatgga tagagtgtct aaggagtcca 480
tagaatttct caagaccttc tgcaagacag gccagaat ctataaactg accaagctgt 540
ttttggaagg gatgcattac aaaactctat gtttctatgt gattattctc aacctaccct 600
tttgtaatgc atcccttcca aaagggtagg ttgagaataa tcacatagaa acatagagtt 660
ttggtttgag gaaagggtctt agagataata tagtgcaacc ttgtcatctt atgcctgaga 720
aatcaagac caagagatgt taaattactt acctaagaaa agcctctgaa tcaagctaaa 780

```


37

agccaactct taggctagta cttttccact gcaactcagt ggtgtttgaa tcatctttgt 840
 gtggaaattc tgaccttgaa gccacttgaa ttatgtgctt tagtacaggc ctaaaagact 900
 tgtgac 906

<210> 39
 <211> 2318
 <212> DNA
 <213> Homo sapien

<400> 39
 agtaggtggg gttacaggca cgcgccacct ttggatccac acctcctccc gtccctgagcc 60
 aaaggccacg gaagtgacgt ttgcacgccg tgcgtaacgt gcattctggc ggtgccggga 120
 gcggggcgag gaggaggggtg ggtatgaggc ggtagcggac cgcggagtcg agacctaccc 180
 gaacgacgcg ggcgagcggg gctttggacg ccggtggaga cgcaggcgag actccagcgg 240
 gaggaagaag aggcctttgc cagcagtcag agcagccaag gggcccaatc cctcatattc 300
 tccaagtttg aaggaaagaa aaccaacaag aagacccgca aggttaccac agtgaagaaa 360
 tcttcagtac gtcttccagg gtcggatcaa agaaggatat tgaaatggat tccaggcgtg 420
 tgccctcgaga caagctggcc tgcatacca agtgcagcaa gcacatcttc gatgccatca 480
 agatcaccta gaacgagctg gcgtcagcag atgacttcct cccaccctc atctacattg 540
 ttttgaaggg caacccccat gccttcagtc taatatccag tatatcacgc gcttctgcaa 600
 tccaagccga ctgatgactg gagaggatgg ctactatttc accaatctgg tgagtaagtg 660
 agttcttggc gttgtggaga aggactagga aggtggtggg tttggggatg tgatagggtca 720
 ctcaggccca tgacagggtga atgcttctgt gtgagaaggc agcacggctg aggaagctca 780
 ctttgcata gggagcacia ggaccaggcc gtacagacac tccgcctccc cgcacttgat 840
 cagagattgt gtttatccta cagaaacaga tgacatgtgt tgggcatcac tccccacggt 900
 cctgggtaga agagtccttc acttggcagg gctttttcaa ccaatgaata aggcaaatta 960
 tatataagtt aataatgcca tttcgaaccg agacagatgg cagctaaatg aagtttaatt 1020
 aaagaatgag cgcggggccc ttttcattgg gtactgcatc tacttcgacc gcaaaagacg 1080
 aagtgacccc aacttcaaga acaggcttcg agaacgaaga aagaaacaga agcttgccaa 1140
 ggagagagct gggctttcca agttacctga ccttaaagat gctgaagctg ttcagaagtt 1200
 cttccttgaa gaaatacagc ttggtgaaga gtactagct caagaggctg ggcactcact 1260
 gcagctggct aatgatgacc atgtggacat gctttcgggc cttcaggatc ttctccagcc 1320
 agtggatgtc gtacgtgttg gggttccgga aagggatgtc aggtggtggc tcacacctgc 1380
 gatcccagca ctttgggagg ccaaggcggg tggatcgctt gagcccagaa gatcaagacc 1440

38

```

agtctgggca acatggtgaa acctcgtctc tactaaaaat agaaaaatta gccgggagtg 1500
gtggcgcacg cttgtagtcc cagctacttg agaggctggg gcaggaggat tgcctaagcc 1560
catgaggtgg aggctgcagt gagcagacat tgcaccactg tactccagcc tgggcaacag 1620
agtgagacgc tgtttaaaaa aaaaaaaga aaatcaacat acacaaaatg tgggtcatgg 1680
gcagagcagc catgtcccca gggagcaggc aggccagctg ggggctcctg aaggctaggg 1740
tggctgcaga gggagggagg gcctccccct ttccccggga ggagggcttg gtgtgctgac 1800
cctgaccaca gacactgact gtatttctcg ttgaagagtt ccttcacctg ctctgcagg 1860
atcacctccc caagtctgtt ggtatcatct tcatctaaag aggaagacaa gggggcctga 1920
gagttggcac tggcttggcc accagacctg ctgcttctcc caccaggcat ccctgacctg 1980
ccaaaacatt ctctgcaggc cctgcctact ccatttgctg gagtgcagag ggcgatctc 2040
agcttactgc aacctccacc tcccagggtc aagtgattct cctgcgtcag cccccaagt 2100
agctggaatc acaggcaccg caccaccatg cctagctaata ttttgtaatt tttagtagag 2160
acgggttttc atcatgttgc tcaggctggg ctcaaactct tgggctcagg tgatccaccc 2220
gccttggcct cccaaagtgt tgggattaca ggcgtgagcc actgtgcctg gctgtagctg 2280
gtttctagcc ccagttgttg gtctgtccat ccattccat 2318

```

```

<210> 40
<211> 1017
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (418)..(418)
<223> n=a, c, g or t

```

```

<220>
<221> misc_feature
<222> (422)..(422)
<223> n=a, c, g or t

```

```

<220>
<221> misc_feature
<222> (826)..(826)
<223> n=a, c, g or t

```

```

<400> 40
gctccggctg ggcagcagcg ctctgcgcag cctcgcgctc atctggctcc ggggtgagtg 60
cagagcaggg tgagggtaga agaagtagga tcctcaatac aagctcatta aagagagggg 120
aggagggagg aggcaagaac cccctatact ggaaaacaaa caaccaagg aaattgacgt 180

```

39

ggtccgagcc catTTTtcaaa gtaaggaagt ataatggaga tttcgctact cttctgtatg 240
 ggaaggactg atggcagcta gaactttagt ttgtggatatg aagtgcTTta aaagaaacac 300
 ttggatgaaa aggaaattcc ttgaatgtta attgtgactg taaacgtgtt aaaactagcc 360
 aaagaggacg cactgggtgtc ggtctctgcc tttcttacct ctttggataa aacccatnag 420
 gncaccaaaa tcttggctgt ttacatttct gcagatttgg gaattaceca tctgctaaat 480
 catttgtctt ttattttctt ttcaaaggct aaaactgtat cgaagtctaa ccctgtattt 540
 cctcctagta aacacaatag atgttaaaag ggaattcttt tcccaaaaat aaccttttat 600
 tattacaaaa gccaaacata atcatttgag atataaaatc ctggcaaaca taatcgtggt 660
 taaaatttaa tctgggccct ttgggatctg tcccttcaaa ggcagggtgag ttgcccttta 720
 attcgtattg ccacttcatt gactcaatca ctgttatttc agaaaaaat aaaaggaagt 780
 agcagaattc aagttacgca aaacaaaact tgctgtctaa caagcncctt ttgaaagcaa 840
 agatgtttta gtgttcagct tttaaattga gctatgtgat taaaaccaac catgacctta 900
 acggatttta cccaaactcg tctaacttca gtatgttttg tcagagatta atcagttact 960
 tgttcaaact taaattgaga tagtgtaa atcaggggtt cctagataag gacagaa 1017

<210> 41

<211> 1079

<212> DNA

<213> Homo sapien

<400> 41

ttttttcttg cagaatgcag tgggccagcc ggctcgcgga cttgaaacca ggctgttgcg 60
 agcccagagc tccggctggg cagcagcgct ctgcgcagcc tcgcgctcat ctggctccgg 120
 ggtgagtgca gagcaggggtg agggtagaag aagtaggata ctcaatacaa gctcattaaa 180
 gagagggaag gagggaggag gcaagaaccc cctatactgg aaaacaaaca acccaaggaa 240
 attgacgtgg tccgagccca ttttcaaagt aaggaagtat aatggagatt tcgctactct 300
 tctgtatggg aaggactgat ggcagctaga actttagttt gtggatatgaa gtgctttaaa 360
 agaaacactt ggatgaaaag gaaattcctt gaatgttaat tgtgactgta aacgtgttaa 420
 aactagccaa agaggacgca ctgggtgtcg tctctgcctt tcttacctct ttgataaaac 480
 ccataggcac caaaatcctg gctgtttaca tttctgcaga tttgggaatt acccatctgc 540
 taaatcattt gtcttttatt ttctttcaaa ggctaaactg tatcgaagtc taaccctgta 600
 tttcctccta gtaaacacaa tagatgttaa aagggaattc ttttcccaaa ataacctttt 660
 attattacaa aagccaaaca taatcatttg agatataaaa tcttggcaaa cataatcgtg 720
 gttaaaattt aatctgggcc ctttgggatc tgtcccttca aaggcagggt agttgccctt 780

40

taattcgtat	tgccacttca	ttgactcaat	cactgttatt	tcagaaaaaa	ataaaaggaa	840
gtagcagaat	tcaagttacg	caaaacaaaa	cttgctgtct	aacaagcact	ctttgaaagc	900
aaagatgttt	tagtgttcag	cttttaaatt	gagctatgtg	attaaaacca	accatgacct	960
taacggattt	tacccaaact	cgtctaactt	cagtatgttt	tgtcagagat	taatcagtta	1020
cttggttcaaa	cttaaattga	gatagtgtaa	atatcagggt	ttcctagata	aggacagaa	1079

<210> 42
 <211> 1076
 <212> DNA
 <213> Homo sapien

<400> 42	
ttttttcttg	cagaatgcag tgggccagcc ggctcgcgga cttgaaacca ggctgttgcg 60
agccagagc	tccggctggg cagcagcgt ctgcgcagcc tcgcgctcat ctggctccgg 120
ggcgagtga	gagcagggtg agggtagaag aagtaggac ctcaatacaa gctcattaaa 180
gagagggaag	gagggaggag gcaagaaccc cctatactgg aaaacaaaca acccaaggaa 240
attgacgtgg	tccgagccca ttttcaaagt aaggaagtat aatggagatt tcgctactct 300
tctgtatggg	aaggactgat ggcagctaga actttagttt gtggtatgaa gtgctttaa 360
agaaacactt	ggatgaaaag gaaattcctt gaatgttaat tgtgactgta aacgtgttaa 420
aaactagccaa	agaggacgca ctggtgtcgg tctctgcctt tcttacctct ttgataaaac 480
ccatagggcac	caaaatcctg gctgtttaca tttctgcaga tttgggaatt acccatctgc 540
taaatcattt	gtcttttatt ttctttcaaa ggctaaactg tatcgaagtc taaccctgta 600
tttcctccta	gtaaacacaa tagatgttaa aagggaattc ttttcccaa ataacctttt 660
attattacaa	aagccaaaca taatcatttg agatataaaa tcctggcaaa cataatcgtg 720
gttaaaat	aatctggggc ctttgggatc tgtcccttca aaggcagggt agttgcctt 780
taattcgtat	tgccacttca ttgactcaat cactgttatt tcagaaaaaa ataaaaggaa 840
gtagcagaat	tcaagttacg caaaacaaaa cttgctgtct aacaagcact ctttgaaagc 900
aaagatgttt	tagtgttcag cttttaaatt gagctatgtg attaaaacca accatgacct 960
taacggattt	tacccaaact cgtctaactt cagtatgttt tgtcagagat taatcagtta 1020
cttggttcaaa	cttaaattga gatagtgtaa atatcagggt ttcctagata aggaca 1076

<210> 43
 <211> 2206
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature

41

<222> (1423)..(1725)
<223> n=a, c, g or t

<400> 43
ggagagcgcg ccgcggccct ttatagcgcg cggggcaccg gctccccaag actgcgagct 60
ccccgcaccc cctcgcactc cctctggccg gccagggggc gccttcagcc caacctcccc 120
agccccacgg gcgccacgga acccgctcga tctcgccgcc aactggtaga catggagacc 180
cctgcctggc cccgggtccc gcgccccgag accgcccgtc ctcggacgct cctgctcggc 240
tggtgtcttcg ccaggtggc cggcgcttca ggcactacaa atactgtggc agcatataat 300
ttaacttgga aatcaactaa tttcaagaca attttggagt gggaacccaa acccgctcaat 360
caagtctaca ctgtgtcaaa taagcactaa gtcaggagat tggaaaagca aatgctttta 420
cacaacagac acagagtgtg acctcaccga cgagattgtg aaggatgtga agcagacgta 480
cttggcacgg gtcttctcct acccggcagg gaatgtggag agcaccggtt ctgctgggga 540
gcctctgtat gagaactccc cagagttcac accttacctg gagacaaacc tcggacagcc 600
aacaattcag agttttgaac aggtgggaac aaaagtgaat gtgaccgtag aagatgaacg 660
gacttttagtc agaaggaaca acactttcct aagcctccgg gatgtttttg gcaaggactg 720
aatttataca ctttattatt ggaaatcttc aagttcagga aagaaaacag ccaaaacaaa 780
cactaatgag tttttgattg atgtggataa aggagaaaac tactgtttca gtgttcaagc 840
agtgattccc tcccgaacag ttaaccggaa gagtacagac agcccggtag agtgtatggg 900
ccaggagaaa ggggaattca gagaaatatt ctacatcatt ggagctgtgg tatttgtggt 960
catcatcctt gtcatcatcc tggctatatc tctacacaag tgtagaaagg caggagtggg 1020
gcagagctgg aaggagaact cccactgaa tgtttcataa aggaagcact gttggagcta 1080
ctgcaaattgc tatattgcac tgtgaccgag aacttttaag aggatagaat acatggaaac 1140
gcaaattgagt atttcggagc atgaagacc tggagttcaa aaaactcttg atatgacctg 1200
ttattaccat tagcattctg gttttgacat cagcattagt cactttgaaa tgtaacgaat 1260
ggtactacaa ccaattccaa gttttaattt ttaacaccat ggcacctttt gcacataaca 1320
tgcttttagat tatatatcc gcactcaagg agtaaccagg tcgtccaagc aaaaacaaat 1380
gggaaaatgt cttaaaaaat cctgggtgga cttttgaaaa gcnnnnnnnnn nnnnnnnnnn 1440
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1500
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1560
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1620
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1680

42

```

nnnnnnnnnnnn nnnnnnnnnnnn nnnnnnnnnnnn nnnnnnnnnnnn nnnnnngaaaa gcttttgagg 1740
ggctgacttc aatccatgta ggaaagtaaa atggaaggaa attgggtgca tttctaggac 1800
ttttctaaaca tatgtctata atatagtgtt taggttcttt tttttttcag gaatacattt 1860
ggaaattcaa aacaattggc aaactttgta ttaatgtgtt aagtgcagga gacattggta 1920
ttctgggcac ctctctaata tgctttacaa tctgcacttt aactgactta agtggcatta 1980
aacatttgag agctaactat atttttataa gactactata caaactacag agtttatgat 2040
ttaagggtact taaagcttct atgggtgaca ttgtatatat aattttttta aaagggtttc 2100
tatatgggga ttttctattt atgtaggtaa tattgttcta tttgtatata ttgagataat 2160
ttatttaata tacttttaaat aaagggtgact gggaattgtt aaaaaa 2206

```

```

<210> 44
<211> 2939
<212> DNA
<213> Homo sapien

```

```

<400> 44
gggagggagcg gcggggggcgg gcgccggggg cgggcagagg cgcgggagag cgcgccgccg 60
gccctttata gcgcgcgggg caccggctcc ccaagactgc gagctccccg caccctctcg 120
cactccctct ggccggccca gggcgcttc agcccaacct cccagcccc acgggcgcca 180
cggaacccgc tcgatctcgc cgccaactgg tagacatgga gaccctgcc tggccccggg 240
tcccgcgccc cgagaccgcc gtcgctcgga cgctcctgct cggctgggtc ttcgcccagg 300
tggccggcgc ttcaggtttg ggtagaggca atccaaaagg gctggattgc tgcttagatt 360
ggagcaggta caacgttgtg catgccccgt atttctacga ggtgttcggg acggcgtaga 420
gactgggacc tgctgcgtac tggcaaagca gaccttcata agaaataatc ctgatccaat 480
acagccgacg gtgtgacagg ccacacgtcc ccgtgggtct ctgtggaagt ttcagtgtag 540
cgacatttca gataaaagtg gaaaaagtga agtttggtt ttttcatttg tatgcagtcc 600
taactcttgt cacacgtgtg ggatttatct ttttccataa ctactgaaa acccttctg 660
gcgggctgaa cctgactctt cctgagctga gtcctggact ggcacactga tggctctggg 720
ctcttcccg tcaagttata acaaggcttt gcccatgaat aatttcaaac gaaaatgtca 780
agatccttgc cgggtgtcctg ggattacaag gtgaatcttg tcatgaagaa attctaggtc 840
tagaaaaaat ttgaagattc tttttctctt gataattcac taatgaagct tttgtggttg 900
aaaaataaaa agtgaggttt atgggtgatgt cagggtgggaa ggtgttttat acatcaatac 960
attcgagtgc tctgaagtgc atgtaataat agctgtttct ctgttggtta aaggcactac 1020
aaatactgtg gcagcatata atttaacttg gaaatcaact aatttcaaga caattttgga 1080

```

gtgggaaccc	aaacccgtca	atcaagtcta	cactgttcaa	ataagcacta	agtcaggaga	1140
ttggaaaagc	aaatgctttt	acacaacaga	cacagagtgt	gacctcaccg	acgagattgt	1200
gaaggatgtg	aagcagacgt	acttggcacg	ggctcttctc	taccgggcag	ggaatgtgga	1260
gagcaccggt	tctgctgggg	agcctctgta	tgagaactcc	ccagagttca	caccttacct	1320
ggagacaaac	ctcggacagc	caacaattca	gagttttgaa	caggtgggaa	caaaagtgaa	1380
tgtgaccgta	gaagatgaac	ggacttttagt	cagaaggaa	aacactttcc	taagcctccg	1440
ggatgttttt	ggcaaggact	taattttatac	actttattat	tggaaatctt	caagttcagg	1500
aaagaaaaca	gccaaaacaa	acactaatga	gttttttgatt	gatgtggata	aaggagaaaa	1560
ctactgtttc	agtgttcaag	cagtgattcc	ctcccgaaca	gttaaccgga	agagtacaga	1620
cagcccggta	gagtgtatgg	gccaggagaa	aggggaattc	agagaaatat	tctacatcat	1680
tggagctgtg	gtatttgtgg	tcatcatcct	tgtcatcatc	ctggctatat	ctctacacaa	1740
gtgtagaaag	gcaggagtgg	ggcagagctg	gaaggagaa	tcccactga	atgtttcata	1800
aaggaagcac	tgttggagct	actgcaaagt	ctatattgca	ctgtgaccga	gaacttttaa	1860
gaggatagaa	tacatggaaa	cgcaaagtga	tatttcggag	catgaagacc	ctggagttca	1920
aaaaactctt	gatatgacct	gttattacca	ttagcattct	ggttttgaca	tcagcattag	1980
tcactttgaa	atgtaacgaa	tgggtactaca	accaattcca	agtttttaatt	tttaacacca	2040
tggcaccttt	tgcacataac	atgcttttaga	ttatatattc	cgcactcaag	gagtaaccag	2100
gtcgtccaag	caaaaacaaa	tgggaaaatg	tcttaaaaaa	tcctgggtgg	acttttgaaa	2160
agcttttttt	tttttttttt	tttgagacgg	agtcttgctc	tggtgcccag	gctggagtgc	2220
agtagcacga	tctcggtcca	ctgcaccctc	cgtctctcgg	gttcaagcaa	ttgtctgcct	2280
cagcctcccg	agtagctggg	attacaggtg	cgcactacca	caccaagcta	atttttgtat	2340
tttttagtag	agatgggggt	tcaccatctt	ggccaggctg	gtcttgaatt	cctgacctca	2400
gttgatccac	ccaccttggc	ctcccaaagt	gctagtatta	tgggcgtgaa	ccaccatgcc	2460
cagccgaaaa	gcttttgagg	ggctgacttc	aatccatgta	ggaaagtaaa	atggaaggaa	2520
attgggtgca	tttctaggac	ttttctaaca	tatgtctata	atatagtgtt	taggttcttt	2580
tttttttcag	gaatacatct	ggaaattcaa	aacaattggc	aaactttgta	ttaatgtgtt	2640
aagtgcagga	gacattggta	ttctgggcac	cttcctaata	tgctttacaa	tctgcacttt	2700
aactgactta	agtggcatta	aacatttgag	agctaactat	atttttataa	gactactata	2760
caaactacag	agtttatgat	ttaagggtact	taaagcttct	atgggtgaca	ttgtatatat	2820
aattttttta	aaagggtttc	tatatgggga	ttttctatct	atgtaggtaa	tattgttcta	2880
tttgtatata	ttgagataat	ttatttaata	tactttaaat	aaagggtgact	gggaattgt	2939

<210> 45
 <211> 2242
 <212> DNA
 <213> Homo sapien

<400> 45
 gggaggagcg gcggggggcgg gcgccggggg cgggcagagg cgcgggagag cgcgccgccg 60
 gccctttata gcgcgcgggg caccggctcc ccaagactgc gagctccccg caccctctcg 120
 cactccctct ggccggccca gggcgccttc agcccaacct cccagcccc acggggcgcca 180
 cggaaccgcg tcgatctcgc cgccaactgg tagacatgga gaccctgcc tggccccggg 240
 tcccgcgccc cgagaccgcc gtcgctcgga cgctcctgct cggctgggtc ttcgcccagg 300
 tggccggcgc ttcaggtgag tggcaccagc ccctggaagc ccggggcgcg ccacacgcag 360
 gagggaggcg acagtcctgg ctggcagcgg gctcgccctg gttccccggg gcgcccattgt 420
 tgtccccgcg gcctacggga ctcggtcgcg ctcaccagc ccggcttgaa tgaaccgagt 480
 ccgtcggggc ccggcgggag ttgcaggagg ggagttggcg cccagaccc cgctgcccct 540
 tccgctggag agttttgctc ggggtgtccg agtaattgga ctgttggtgc ataagcggac 600
 ttttagctcc cgctttaact ctggggaaag ggcttcccag tgagttgcga ccttcaatat 660
 gataggactt gtgcctgcgt ctgcacgtgt tggcgtgcag aggtttggat attatctttc 720
 attatatgtg catcttccct taataaagag cgctccctgg cttttcctgg ccatctttgt 780
 tctaggtttg ggtagaggca atccaaaagg gctggattgc tgcttagatt ggagcaggta 840
 caacgttggt catgccccgt atttctacga ggtgttcggg acggcgtaga gactgggacc 900
 tgctgcgtac tggcaaagca gaccttcata agaaataatc ctgatccaat acagccgacg 960
 gtgtgacagg ccacacgtcc ccgtgggtct ctgtggaagt ttcagtgtag cgacatttca 1020
 gataaaagtg gaaaaagtga agtttggctt ttttcatttg tatgcagtcc taactcttgt 1080
 cacacgtgtg ggatttatct ttttcataa cttactgaaa acccttcctg gcgggctgaa 1140
 cctgactctt cctgagctga gtcctggact ggcacactga tggctctggg ctcttcccgg 1200
 tcaagttata acaaggcttt gccatgaat aatttcaaac gaaaatgtca agatccttgc 1260
 cgggtgcctg ggattacaag gtgaatcttg tcatgaagaa attctaggtc tagaaaaaat 1320
 ttgaagattc tttttctctt gataattcac taatgaagct tttgtggttg aaaaataaaa 1380
 agtgaggttt atggtgatgt cagggtgggaa ggtgttttat acatcaatac attcgagtgc 1440
 tctgaagtgc atgtaataat agctgtttct ctgttggtta aaggcactac aaatactgtg 1500
 gcagcatata atttaacttg gaaatcaact aatttcaaga caattttgga gtgggaaccc 1560
 aaaccgcgtc atcaagtcta cactgttcaa ataaggtaag ctgggtacag aaaaagaaaa 1620

45

ttaaggtcctt	tgatgtttct	actgtcctat	gctgaacaag	aatgtcttta	aagctgatta	1680
ctggatgaaa	ttatttaaca	gatgacgaag	aagaagggat	tcttggcaat	tcgctggccg	1740
gtgtcatact	ctattaggcc	tgcaacattt	ccagacctta	aactgataga	acattttaat	1800
tgttttaatt	gtttttggaa	atgatgggag	agttcctaag	tggagtataa	actgtggaga	1860
gatgaaccat	cttgagtagg	cactgaagtg	tgctttgggt	catgatagat	taattaatct	1920
catctaaaca	ttgatgtcct	tttctgttgc	tgtctagact	gtgaacaatg	tctaacacct	1980
tagggaagag	gtggggagga	atcccaatgt	atacattgcc	cttaagcagt	gtttgattca	2040
ttcatctttg	gactccatga	atcgaaatct	ggtagaatac	atgatcttag	tggaggaggc	2100
caaatgcgtg	actcactgag	cctggcagag	cagaaatact	ctgctgtctg	caccctctgg	2160
gtctgggtgtg	gctctgcttc	ttgggtgcttc	aactctgact	ggcagctgtc	cccaggaggc	2220
gataattcag	catgttcaat	ct				2242

<210> 46
 <211> 376
 <212> DNA
 <213> Homo sapien

<400> 46						
gcaaccttgt	gttaggtaat	agcattacca	ttctgtagag	gagtaaactg	agacgcagca	60
agattaagtt	atatgtgcaa	ggataaatag	ggagtaatgg	aagagccgga	gtttgaatct	120
gaataatcca	acttcaaagt	gttaatcacc	actccaggct	gcctctcagc	cagttgaacc	180
tcataaaaatt	caagactata	ataagtggtc	aaaaacctaa	gacgaaactc	tgcttacatg	240
gttattttaat	atgttgattga	caatgaaaaa	taattttaat	gcataaagtc	atgttgaatg	300
taactacaat	attaaagatc	ataaagagta	aagtaagtaa	aatagaaaaa	tcaaaataaa	360
ataaaaataa	ttatgt					376

<210> 47
 <211> 187
 <212> DNA
 <213> Homo sapien

<400> 47						
aggacctgac	atccaaaaca	agatggattt	ctacacagag	ttgctaaaga	taccataaag	60
aaccaagaag	gaataagaag	gggaaggtag	aggtcagaga	tgtacacagg	atctggccag	120
aaagaggctt	ctgggtgggg	ctggaagatg	caggggctta	gaaaaagcag	gggcggccag	180
gtgcggt						187

<210> 48

46

<211> 380
 <212> DNA
 <213> Homo sapien

<400> 48
 caggcatgag ccaccgtgct cttggcctta attgttctga ttttaataat ggcatgatac 60
 ccctgtaccc caagttatac agatgagaga ttttggctct ggtatctctg tctctatcct 120
 gggtaagggtt tctcagggtt gtaggccagt ctctttgtca ggaagagagc tagtagttaa 180
 actgaaacaa aggtccgaca gtctttatatt tgcattttta ggtacctgtt gaaaatgact 240
 aaacgtaaaa tgggactttt gttaattcag tagctgttac tgaagcatta gattgattca 300
 cctgttttaa agtagttatg aaagacaaca gagaacagct ttctatttgt cgtaacttac 360
 taatagatag ccaagtctgc 380

<210> 49
 <211> 1903
 <212> DNA
 <213> Homo sapien

<400> 49
 ttttccccca aggaagagag tagggcaggg aggtgaagag gaatggaaac tccaccactc 60
 caccgccgcta tactagatga agcagctgtg tctcagaaac agggcactca ggctctctgg 120
 cttccaggga ttagagaaca aggcacagat cagcccctcc ccagaaatca caggaccgcc 180
 aacttggcag atgcatccaa gggcaccttg actcctctgc cacatggatt gtaggtccca 240
 gcgatgagca gcccaattaa cagtgatgtc agactgtttg ggtccagatc attcctgagc 300
 catgaaacag ttaagaaata tcctgccccca ctggctgccg tgctcataaa ggtagacca 360
 cgtgtacttc cctgtggctc caagaagcgc cagctcgctc atttgctcac acccagcagg 420
 cagagaaggc agcagcaggc aggaccgcca ccctcccatg caaatcacc cggggagtgc 480
 agctgggctc ctcccgtcc tcctaggcaa tgctcctggg gagtctgtgg ggaagatgcc 540
 atccagggtg ctgtgcgctc ttctcatcc tcgcctcct gctggacgcg gtcggcctgg 600
 tccttttgct gctggggatc ttggccccc tgagttcctg ggacttcttc atctacacag 660
 gtgcctgat cctggctctc agcctactgc tctggatcat ctggtattcc ctcaacattg 720
 aggtgtctcc tgaaaaactg gacctgtaat ttggccatgg gaagaggaga agagacgcag 780
 gtgctgtatg cagacatgtc tgtgaacctg gggctcttgg gcagcaacac gttgcagctt 840
 ccacctagca agccacgccg ggaccaggtc ccatctgatg gaggagaatc aattcaagga 900
 gatgcccttc ctttacagaa caccctttaa cagcatccag gaggaacgag aggctgcaat 960
 actgaggctt tcaaagtact cacgaggatg tccgagaatg gctgtgatgc caggcttctg 1020
 gcaggttcca gactccatca caagcccagc atccctgcac cagatctgac atcgctgctg 1080

ttgtgccagc	tgtttatgaa	gggcctgagt	agctagcagg	tttttatcag	gagccctgct	1140
gggggcttag	acaccaaag	agaagtctca	tcctctgtag	ttcttcttgt	gaatgtcctt	1200
ttagaaaaac	aattagaacc	aaccacaagc	accaaagtcc	taatgggatc	tcctgcgagc	1260
acatatcaag	caggattgtt	gctattttctc	ctcactggct	ctttggacag	actgtgtgag	1320
ctcctggagg	gttccactgt	atctaccctt	tgacactgac	cagttggcac	atggtgactt	1380
attccaatgt	gttgattgca	aatgtgaacg	tacagccagt	gctgtgtgcg	ggaggactct	1440
ctcctcctca	gtggggccac	accgtgcact	attaatggag	ccccactcct	ttgcacagcc	1500
tggccatgca	gtggctcata	ttgaggtttt	agccaactga	aatctcccgt	gcatttttct	1560
gacaagccag	ctaggcctct	gctatgctgt	ccttgtgtct	ttcatttgat	gaccttaagg	1620
gtgggactgt	tttatcttaa	gttacagggtg	gtcaagtcca	gccaaggac	agcaactctg	1680
aggggtcaagc	ctcataggct	aactggatag	atgttctctg	ctttgccacc	cactggagcc	1740
cgacctgccc	cactaattta	tatttccctg	gtctcatttt	gtacttttta	tttataattc	1800
acccttaaag	tgtatgtgtc	tcttataagc	tgccctccgat	ctttcatggg	atgaggtggg	1860
tacctaaata	aagaaggaga	tttggccttt	gtttttatgt	aaa		1903

<210> 50
 <211> 1911
 <212> DNA
 <213> Homo sapien

<400> 50	
ttttccccca	aggaagagag tagggcaggg aggtgaagag gaatggaaac tccaccactc 60
caccccgcta	tactagatga agcagctgtg tctcagaaac agggcactca ggctctctgg 120
cttccaggga	ttagagaaca aggcacagat cagccccctcc cccagaatca caggaccgcc 180
aacttggcag	atgcatccaa gggcaccctg actcctctgc cacatggatt gtaggtccca 240
gcgatgagca	gcccaattaa cagtgatgtc agactgtttg ggtccagatc attcctgagc 300
catgaaacag	ttaagaaata tcctgccccca ctggctgccg tgctcataaa ggtagaccca 360
cgtgtacttc	cctgtggctc caagaagcgc cagctcgctc atttgctcac acccagcagg 420
cagagaaggc	agcagcaggc aggaccgcca ccctcccatg caaatcacc cggggagtgc 480
agctgggctc	ctcccgtcc tcctaggcaa tgctcctggg gagtctgtgg ggaagatgcc 540
atccagggcg	ctgtgcgctc ttctcatcc tcgccctcct gctggacgcg gtcggcctgg 600
tccttttgct	gctggggatc ttggccccc tgagttcctg ggacttcttc atctacacag 660
gtgccctgat	cctggctctc agcctactgc tctggatcat ctggtattcc ctcaacattg 720
aggtgtctcc	tgaaaaactg gacctgtaat ttggccatgg gaagaggaga agagacgcag 780

48

```

gtgctgtatg cagacatgtc tgtgaacctg gggctcttgg gcagcaacac gttgcagctt      840
ccacctagca agccacgccg ggaccagggtc ccatctgatg gaggagaatc aattcaagga      900
gatgcccttc ctttacagaa caccctttaa cagcatccag gaggaacgag aggctgcaat      960
actgaggctt tcaaagtact cagcaggatg tccgagaatg gctgtgatgc caggcttctg     1020
gcaggttcca gactccatca caagcccagc atccctgcac cagatctgac atcgctgctg     1080
ttgtgccagc tgtttatgaa gggcctgagt agctagcagg tttttatcag gagccctgct     1140
gggggcttag acaccaaaag agaagtctca tcctctgtag ttcttcttgt gaatgtcctt     1200
ttagaaaaac aattagaacc aaccacaagc accaaagtcc taatgggatc tcctgcgagc     1260
acatatcaag caggattggt gctatttctc ctactgggt ctttggacag actgtgtgag     1320
ctcctggagg gttccactgt atctaccctt tgacactgac cagttggcac atggtgactt     1380
attccaatgt gttgattgaa aatgtgaacg tacagccagt gctgtgtgcg ggaggactct     1440
ctcctcctca gtggggccac accgtgcact attaatggag cccactcct ttgcacagcc     1500
tggccatgca gtggctcata ttgaggtttt agccaactga aatctcccgt gcatttttct     1560
gacaagccag ctaggcctct gctatgctgt ccttgtgtct ttcatttgat gaccttaagg     1620
gtgggactgt tttatcttaa gttacagggt gtcaagtcca gcccaaggac agcaactctg     1680
aggggtcaagc ctcatagggt aactggatag atgttctctg ctttggcacc cactggagcc     1740
cgacctgcc cactaattta tatttccct ggtctcattt tgtacttttt atttataatt     1800
cacccttaaa gtgtatgtgt ctcttataag ctgcctccga tctttcatgg tatgaggtgg     1860
ttacctaaat aaagaaggag atttggcctt tgtttttatg taaaaaaaaa a             1911

```

```

<210> 51
<211> 2672
<212> DNA
<213> Homo sapien

```

```

<400> 51
ttttcccca aggaagagag tagggcaggg aggtgaagag gaatggaaac tccaccactc      60
caccocgcta tactagatga agcagctgtg tctcagaaac agggcactca ggctctctgg     120
cttccaggga ttagagaaca aggcacagat cagccccctc ccagaatca caggaccgcc     180
aacttggcag atgcatccaa gggcaccctg actcctctgc cacatggatt gtaggtccca     240
gcgatgagca gcccaattaa cagtgatgtc agactgtttg ggtccagatc attcctgagc     300
catgaaacag ttaagaaata tcctgccccca ctggctgccg tgctcataaa ggtagacca     360
cgtgtacttc cctgtggctc caagaagcgc cagctcgctc atttgctcac acccagcagg     420
cagagaaggc agcagcaggc aggaccgcca ccctcccatg caaatcacc cggggagtgc     480

```

agctgggctc	ctcccgcctc	tcctaggcaa	tgctcctggg	gagtctgtgg	ggaagatgcc	540
atccaggggtg	ctgtgcgctc	ttcctcatcc	tgcacctcct	gctggacgcg	gtcggcctgg	600
tcctttttgct	gctgggggatc	ttggccccc	tgagttcctg	ggacttcttc	atctacacag	660
gtgccctgat	cctggctctc	agcctactgc	tctggatcat	ctggtattcc	ctcaacattg	720
aggtgtctcc	tgaaaaactg	gacctgtaat	ttggccatgg	gaagaggaga	agagacgcag	780
gtgctgtatg	cagacatgtc	tgtgaacctg	gggctcttgg	gcagcaacac	gttgcagctt	840
ccacctagca	agccacgccg	ggaccaggtg	agtgcacaca	agacctacct	ggcaggggtgg	900
ccagagagggc	ttggacaagc	aggggcaaga	ccaggcctcc	tgaggctgca	taagcaaata	960
gccagacact	gcaccctgac	tggggatcct	gtggccctgg	cctcaggtcc	tgctgggggtg	1020
gccagccaag	aggacgtggg	gcaggtgttt	tctcctccgg	gcccttttcc	tcgcagagggc	1080
tggaaagaga	gtctcaacag	ccccttccac	ccctgatata	ccacgaatga	tcctggcttc	1140
tgggcacaat	gggaagttat	ccctttacct	cggaacttgg	ggacaaaaag	accccatctg	1200
cattctctgt	tgggaagaat	ctctgctggg	gagaaaagtc	tttagcacag	gagaggacgg	1260
aaagttcccc	aatgactctt	gtgcccttgc	atacatgaag	gggtgtgaac	tggggccacgg	1320
taaaagcaaa	cagagcagaa	ccaccagaa	cggccctct	cgttacttc	ctccctgcac	1380
ctgcccagat	gggatacaag	aagcggggta	gggactactc	gcctccatgc	ccactcagtg	1440
cacacacctc	ctctctctgc	agtattccca	ccccaccctc	actcacactc	acacgcagcc	1500
aacacatgtg	cccagccagt	ctccaaggcc	cagaagtcaa	gacagtttgg	cttcatggat	1560
ttcatccgct	gagttgcatg	tcacagctca	gtctatcgcg	tgcaaccaa	gaggcagaga	1620
gttgtaagat	tttttcacat	caagacagag	tcccagagat	agagtggctc	ggtccttaca	1680
accctgaatt	agagatggac	agctgtctcc	aggggactga	agtcagagcc	acggtccatt	1740
gggcagccat	accctcctcc	ccaggtgggc	ccaacctgca	cgcaggtgta	tccaggcact	1800
cccgtttctt	actcccttac	cagaagtaag	agcaaaggtc	gttgctgagt	tgaaagaagg	1860
aaataataat	tgtgtctttt	gtgggggatt	acacctgact	ctcagaactc	agagaaaaga	1920
gaagcaaaat	gaagaggtct	cagtagagta	aggtaagccc	atacctagga	aatgatgtag	1980
aaagagatga	gaagtcagtc	ccactctgat	cttcagcact	tgtagctgg	gtgtttttgg	2040
ccaggttgca	cactctgagc	ctcaggattc	tcctctgtaa	gatgaagaga	atatttctgg	2100
cccttattgc	tgcaaggatc	gaaaagagat	aaggcagggg	aaggctgtac	aattgatgtg	2160
gttcttacac	cagatgtcaa	gcatacaaaa	cacataatct	gggatgagtt	aactgacca	2220
aagtccaaat	gtgaagtacc	ttggtgtctc	tcaaattggg	agtgatgggg	gtcaactcac	2280

50

actttgcatc	aggaaacttc	rgagcaaaaa	gggtccctga	tttgtgtgct	ggtatggttg	2340
aatgtgtcag	gcactgtgca	agacactggg	gataagaaat	gagacacatg	gaccaggcac	2400
agtgactcat	gcctgtaatc	ccagcacttt	gggaggccga	ggcgggcaga	tcacttgagg	2460
tcaggagttc	aagaccagcc	ttggcaacat	ggtgaaacct	catctccacc	aaaaatacaa	2520
aaaattagcc	acgcatgggtg	atgcacacct	gtaatcccag	ctattcagga	ggttgaggca	2580
gaaggattgc	tggagcccag	gaggcacagg	ctgcagtgag	cagagattgc	accactgcat	2640
tccaacctgg	gcggcagagt	gagacctgtc	tc			2672

<210> 52

<211> 1495

<212> DNA

<213> Homo sapien

<400> 52

ttttcccca	aggaagagag	tagggcaggg	aggtgaagag	gaatggaaac	tccaccactc	60
caccccgcta	tactagatga	agcagctgtg	tctcagaaac	agggcactca	ggctctcttg	120
cttccaggga	ttagagaaca	aggcacagat	cagcccctcc	cccagaatca	caggaccgcc	180
aacttggcag	atgcatccaa	gggcaccctg	actcctctgc	cacatggatt	gtaggtccca	240
gcgatgagca	gccaattaa	cagtgatgtc	agactgtttg	ggtccagatc	attcctgagc	300
catgaaacag	ttaagaaata	tccctgcccc	ctggctgccg	tgctcataaa	ggtagacca	360
cgtgtacttc	cctgtggctc	caagaagcgc	cagctcgctc	atltgctcac	accagcagg	420
cagagaaggc	agcagcaggc	aggaccgcca	ccctcccattg	caaatacccc	ccgggagtg	480
agctgggctc	ctcccgtctc	tcctaggcaa	tgctcctggg	gagctctgtg	ggaagatgcc	540
atccagggtg	ctgtgcgctc	ttcctcatcc	tcgcccctct	gctggacgcg	gtcggcctgg	600
tccttttgct	gctggggatc	ttggccccc	tgagttcctg	ggacttcttc	atctacacag	660
gtgccctgat	cctggctctc	agcctactgc	tctggatcat	ctggtattcc	ctcaacattg	720
aggtgtctcc	tgaaaaactg	gacctgtaat	ttggccatgg	gaagaggaga	agagacgcag	780
gtgctgtatg	cagacatgtc	tgtgaacctg	gggctcttgg	gcagcaacac	gttgcagctt	840
ccacctagca	agccacgcgc	ggaccagggtg	agtgcacaca	agacctacct	ggcagggtgg	900
ccagagaggc	ttggacaagc	aggggcaaga	ccaggcctcc	tgaggctgca	taagcaaata	960
gccagacact	gcaccctgac	tggggatcct	gtggccctgg	cctcaggctc	tgctgggggtg	1020
gccagccaag	aggacgtggg	gcagggtgtt	tctcctccgg	gcccttttcc	tcgcagaggc	1080
tggaaagaga	gtctcaacag	ccccttccac	ccctgatata	ccacgaatga	tcctggcttc	1140
tgggcacaat	gggaagttat	ccctttacct	cgggaacttg	ggacaaaaag	accccatctg	1200

51

```

cattctctgt tgggaagaat ctctgctggg gagaaaagtc tttagcacag gagaggacgg 1260
aaagtcccc aatgactctt gtgcccttgc atacatgaag ggggtgtgaac tgggccacgg 1320
taaaagcaaa cagagcagaa ccacccagaa cggccctct cgttcacttc ctccctgcac 1380
ctgcccagat gggatacaag aagcggggta gggactactc gcctccatgc ccactcagtg 1440
cacacacctc ctctctcaac agccccttcc accctgatat accacgaatg atcct 1495

```

```

<210> 53
<211> 692
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (83)..(83)
<223> n=a, c, g or t

```

```

<400> 53
gatagcatgt catagtgtca agaataaat ctttatatga atatagtcca agtatgaatc 60
tcagcaccag caatctaaaa gtnattttta cctcttcata gagttcctgg ttttcaaagg 120
cttaatgctt ttcccaaatt ttgatttttg tgctattctt acataatttc ctccatttc 180
atatagggtc ctcttggtcc ccaagggtgc aaagggtgaac gtggcagtcc tgggtggacct 240
gtaagtattg atcctcttaa ctattattga aaagcattaa ttgatataca cctgtataaa 300
agctgcattg agacactagt tccataaaga gaatgtaaaa attgtaatcg ctcatcaca 360
catgagttat atgtaaattc caaggggaaa cacaaaccat aaatgacttt cagggtacaat 420
gcagatcatg ccacacatta tacttttttt ttgttgtaca gttatttggt ctacttttga 480
aattcaaaaa tatattacca ttccacaggg tgctgctggc ttccctgggt ctcggtggtct 540
tcctggctct cctggtagta atgtaagtaa ttgttaaagt cttttctcat catacacttc 600
agaaagagca ttcattgtat tataggatga gaaacttaca cattgctact tatttctcta 660
gtaagtctca aataaaaatta tttgaagtaa gt 692

```

```

<210> 54
<211> 731
<212> DNA
<213> Homo sapien

```

```

<400> 54
gaccgcttaa ttaaagatct tttttttttt ttttttttac ttacttcaaa taattttatt 60
tgagacttac tagagaaata agtagcaatg tgtaagtttc tcctcctata catacatgaa 120
tgctctttct gaagtgtatg atgagaaaag actttaacaa ttacttacat tactaccagg 180
aggaccagga agaccacgag caccagggaa gccagcagca ccctgtgaaa tggtaatata 240

```


52

```

tttttgaatt tcaaaagtag aacaaataac tatacaacaa acaaaaagta taatgtgtgg 300
tatgatctgc attgtacctg aaagtcattt atggtttgtg tttccccttg gaatttacat 360
ataactcatg tatgaatgag cgattacaat ttttacattc tctttatgga actagtgtct 420
caaatgcagc ttttatacag gttgatatca attaattgctt ttcaataata gttaagagga 480
tcaatactta caggtccacc aggactgcc a gttcacctt tgacaccttg gggaccagga 540
ggaccctata tgaaatggaa ggaaattatg taagaatagc accaaaatca aaatttggga 600
aaagcattaa gcctttgaaa accaggaact ctatgaagag gttaaaataa ctttttagatt 660
gctggtgctg agattcatac ttggactata ttcataataa gattatattc ttgacactat 720
gacatgctat c 731

```

```

<210> 55
<211> 1779
<212> DNA
<213> Homo sapien

```

```

<400> 55
gttaaatttc ttaaattctaa cattcacagg agaccatttt aaatcaggat ttctttccta 60
aataactctg gaaaaaatat atgaattgca caagtagtac atgtttgtaa ttaggtatct 120
cttaagccta tagaatcttt gcctgagact ccttctagat ttaaaagtct tgaccttcag 180
gatttaagac tctggaaaga tatttagtaa atggttttta aaaataaatc agttaatttt 240
tcagttaagc ttctaccata tattgaaata cataaatatc tatatatata aatgtgttaa 300
atactttaaa attctcaaac tatttttctt gcaaataata tcacagtagg aggcagaagg 360
aatcaatggg tctgggtatct tccactccta attttattga gaagtggcaa agtcttcaga 420
agtttatcgg ctactctgca catttcctgc ttaaaggaaa gaaaagataa gatgataaga 480
tgacatttcc tgcctaaagg agatgacgca cacttcactg tgactaagga ggatattttt 540
ctcttcaggg tgagagaggt gaaactggcc ctccaggacc tgctgggttc cctgggtgctc 600
ctggacagaa tgggtgaacct ggtggtaaag gagaaagagg ggctccgggt gagaaagggtg 660
aaggaggccc tcctggaggt gcaggacccc ctggagggtc tggacctgct ggtcctcctg 720
gtccccaagg tgtcaaagggt gaacgtggca gtccctgggtg acctgggtgct gctggcttcc 780
ctgggtgctc tggtcttctt ggtcctcctg gtagtaatgg taaccagga ccccagggtc 840
ccagcgggtc tccaggcaag gatgggcccc caggctcctgc gggtaacact ggtgctcctg 900
gcagccctgg agtgtctgga ccaaagggtg atgctggcca accaggagag aagggatcgc 960
ctgggtgccca gggcccacca ggagctccag gccacttggt gattgctggg atcactggag 1020
cacgggggtc tgcaggacca ccaggcatgc caggctcctag gggaagccct ggccctcagg 1080

```

53

```

gtgtcaaggg tgaaagtggg aaaccaggag ctaacgggtct cagtggagaa cgtgggtcccc 1140
ctggacccca gggctcttct ggtctggctg gtacagctgg tgaacctgga agagatggaa 1200
accctggatc agatgggtctt ccaggccgag atggatctcc tgggtggcaag ggtgatcgtg 1260
gtgaaaatgg ctctcctggg gccctggcg ctcttgggtca tccaggccca cctgggtcctg 1320
tcgggtccagc tggaaagagt ggtgacagag gagaaagtgg ccctgctggc cctgctgggtg 1380
ctcccgggtcc tgctgggttcc cgagggtgtc ctgggtcctca aggccacgt ggtgacaaag 1440
gtgaaacagg tgaacgtgga gctgctggca tcaaaggaca tcgaggattc cctggtaatc 1500
cagggtcccc aggttctcca ggcctgctg gtcagcaggg tgcaatcggc agtccaggac 1560
ctgcaggccc cagaggaccc tgttggaccc atgtggactc ctgggaagga tggacctgtg 1620
ggctcccgtc cttggaccac gggctcttgag tgaccggggg gagacgggtg ggggtcccag 1680
ggcctggcg caagcctctt gcctctgtgc ctgggtctgt gtgtttggcc gctgtgggtg 1740
tggtactcgt ttccgtttgg gactgttaaa ccggttttc 1779

```

```

<210> 56
<211> 2382
<212> DNA
<213> Homo sapien

```

```

<400> 56
gttaaatttc ttaaactctaa cattcacagg agaccatttt aaatcaggat ttcttttcta 60
aataactttg gaaaaaatac atgaattgca caagtagtac atgtttgtaa ttaggtattt 120
cttaagccta tagaatcttt gcctgagact ccttctagat taaaagtct tgaccttcag 180
gatttaagac tctggaaaga tatttagtaa atggttttta aaaataaatc agttaatttt 240
tcagttaagc ttctaccata tattgaaata cataaatatc tatatatata aatgtgttaa 300
atactttaaa attctcaaac tatttttctt gcaaataata tcacagtagg aggcagaagg 360
aatcaatggg tctgggtattt tccactccta attttattga gaagtggcaa agtcttcaga 420
agtttattgg ctactctgca catttcctgc ttaaaggaaa gaaaagataa gatgataaga 480
tgacatttcc tgctaaagg agatgacgca cacttcactg tgactaagga ggatattttt 540
ctcttcaggg tgagagaggt gaaactggcc ctccaggacc tgctggtttc cctgggtgctc 600
ctgtaagtgt gaatatttat acatacatgt cccatagccc aggatctcta tcttgctgaa 660
aaattacaaa agtatagtca agtttggttt ctagtctcat ttagctgct cattccctat 720
aggattattg taccctatt ttgttttact ttaccctat tgcgctctt tgaaagatgg 780
aaataaaaac acctgtcctg cttttatgac tgggtaatga actaaagcag tatcatggat 840
ttaaagcac tctgaatttt tgtaaattct tccattataa gatggtacta attaaaattt 900

```

tctcttaa at cccgtcttcc tcaaaaaaat ttactgggtgc tgattttcaa atgtttta atc 960
 cttagagaca cttcctccct cccta atggc aaata atgca cagtttatgc tttcttggtc 1020
 atgttctttg atcatgaaaa tatttttgatt ggcttcattt tgc atgtct tca gaaagcc 1080
 ttgtttttta attttatttc aactccttcc atctgaagaa ttctatatcc tgaagagaaa 1140
 taataataag ccaattgtat cataaagagt gtcagctgag agattgctgt tgttggtgca 1200
 tgtagggaca gaatggtgaa cctgggtggta aaggagaaag aggggctccg ggtgagaaag 1260
 gtgaaggagg ccctcctgga gttgcaggac ccctggagg ttctggacct gctggctcctc 1320
 ctgggtccca aggtgtcaaa ggtgaacgtg gcagtcctgg tggacctggg gctgctggct 1380
 tccctgggtgc tegtgggtctt cctgggtcctc ctggtagtaa tggtaacca ggacccccag 1440
 gtcccagcgg ttctccaggc aaggatgggc cccaggtcc tgcgggtaac actgggtgctc 1500
 ctggcagccc tggagtgtct ggaccaaag gtgatgctgg ccaaccagga gagaagggat 1560
 cgcctgggtgc ccagggccca ccaggagctc caggccact tgggattgct gggatcactg 1620
 gagcacgggg tcttgcagga ccaccaggca tgccaggtcc taggggaagc cctggccctc 1680
 aggggtgtcaa gggtgaaagt gggaaaccag gagctaacgg tctcagtgga gaacgtggtc 1740
 ccctggacc ccaggggtctt cctgggtctgg ctgggtacagc tgggtgaacct ggaagagatg 1800
 gaaaccctgg atcagatggg cttccaggcc gagatggatc tcctgggtggc aagggtgatc 1860
 gtgggtgaaaa tggctctcct ggtgccctg gcgctcctgg tcatccaggc ccacctgggtc 1920
 ctgtcgggtcc agctggaaag agtgggtgaca gaggagaaag tggccctgct ggcctgctg 1980
 gtgctcccgg tcctgctggg tcccagggtg ctctgggtcc tcaaggccca cgtgggtgaca 2040
 aagggtgaaac aggtgaacgt ggagctgctg gcatcaaagg acatcgagga ttccttggtgta 2100
 atccaggtgc cccaggttct ccaggccctg ctgggtcagca ggggtgcaatc ggcagtccag 2160
 gacctgcagg cccagagga cctgttgga ccatgtgga ctctgggaa ggtatggacct 2220
 gtgggctccc gtccttgga caggggtctt gaggaccgg ggtgagacgg ttgggggtcc 2280
 cagggccctg gcgcaagcct cttgcctctg tgctgggtct gttgtggtt ggcgctgtgg 2340
 tgggtgtact cgtttccgtt tgggactgtt aaacgggtt tc 2382

<210> 57

<211> 1623

<212> DNA

<213> Homo sapien

<400> 57

tccctctctc tctccctctc cccctctgt aagtcctaag tgttcta atg gaaaaacatg 60

gaggtttatc agtaatttaa tattttatac tgagatagca tgc atagt tcaagaatat 120

55

```

aatctttata tgaatatagt ccaagtatga atctcagcac cagcaatcta aaagttatTT 180
taacctcttc atagagttcc tggttttcaa aggcttaatg cttttcccaa attttgattt 240
tggtgctatt cttacataat ttccttccat ttcatatagg gtccctcctgg tccccaaaggT 300
gtcaaaggTg aacgtggcag tcctggTgga cctgtaagta ttgatcctct taactattat 360
tgaaaagcat taattgatat caacctgtat aaaagctgca tttgagacac tagttccata 420
aagagaatgt aaaaattgta atcgctcatt catacatgag ttatatgtaa attccaaggG 480
gaaacacaaa ccataaatga ctttcaggta caatgcagat catgccacac attatacttt 540
ttgtttgttg tacagttatt tgttctactt ttgaaattca aaaatatatt accatttcac 600
agggacctgg tgctgctggc ttccctggTg ctcgTggTct tcctggTcct cctggtagta 660
atggtaaccc aggaccccca ggtcccagcg gttctccagg caaggatggg ccccaggtc 720
ctgcgggtaa cactggTgct cctggcagcc ctggagtgtc tggaccaaaa ggtgatgctg 780
gccaaccagg agagaaggga tcgcctggTg cccaggggccc accaggagct ccaggccac 840
ttgggattgc tgggatcact ggagcacggg gtcttgcagg accaccaggc atgccaggtc 900
ctaggggaag ccctggccct cagggtgtca agggTgaaag tgggaaacca ggagctaacg 960
gtctcagTgg agaacgtggT cccctggac cccagggtct tcctggTctg gctggTacag 1020
ctggTgaacc tggaaagagat ggaaacctg gatcagatgg tcttccaggc cgagatggat 1080
ctcctggTgg caagggtgat cgtggTgaaa atggctctcc tggTgcccct ggcgctcctg 1140
gtcatccagg cccacctggT cctgtcggTc cagctggaaa gagtggTgac agaggagaaa 1200
gtggccctgc tggccctgct ggtgctcccG gtccTgctgg tccccaggT gctcctggTc 1260
ctcaaggccc acgtggTgac aaaggTgaaa caggTgaacg tggagctgct ggcatacaaag 1320
gacatcgagg attccctggT aatccaggTg ccccaggTtc tccaggccct gctggTcagc 1380
agggtgcaat cggcagTcca ggacctgcag gccccagagg acctgttgG acccatgtgg 1440
actcctggga aggatggacc tgtgggctcc cgtccttgga ccacgggtct tgagtgaccg 1500
gggtgagacg gttgggggtc ccagggccct ggcgcaagcc tcttgccctct gtgcctggTc 1560
tgttgtgttt ggccgctgtg gtggTggTac tcgtttccgt ttgggactgt taaaccggTt 1620
ttc 1623

```

<210> 58
<211> 2110
<212> DNA
<213> Homo sapien

<400> 58
caaggacccc ctggTgaacc tgggcaagct ggtccttcag gccctccagg acctcctggT 60

gctataggtc	catctggtcc	tgctggaaaa	gatggagaat	caggtagacc	cggacgacct	120
ggagagcgag	gattgcctgg	acctccaggt	atcaaaggtc	cagctgggat	acctggattc	180
cctgggtatga	aaggacacag	aggcttcgat	ggacgaaatg	gagaaaaggg	tgaaacaggt	240
gctcctggat	taaagggtga	aaatggtctt	ccaggcgaaa	atggagctcc	tggacccatg	300
ggtccaagag	gggctcctgg	tgagcgagga	cggccaggac	ttcctggggc	tgcagggtgct	360
cggggtaatg	acggtgctcg	aggcagtgat	ggtcaaccag	gccctcctgg	tcctcctgga	420
actgccggat	tccttggtac	ccctgggtgct	aagggtgaag	ttggacctgc	agggtctcct	480
ggttcaaata	gtgcccctgg	acaaagagga	gaacctggac	ctcagggaca	cgctgggtgct	540
caaggctctc	ctggccctcc	tgggattaat	ggtagtcctg	gtggtaaagg	cgaaatgggt	600
cccgtggca	ttcctggagc	tcctggactg	atgggagccc	ggggtcctcc	aggaccagcc	660
ggtgctaata	gtgctcctgg	actgagaggt	ggtgcagggt	agcctggtaa	gaatgggtgcc	720
aaaggagagc	ccggaccacg	tggatgaacg	ggtgaggctg	gtattccagg	tgttccagga	780
gctaaaggcg	aagatggcaa	ggatggatca	cctggagAAC	ctgggtgcaaa	tgggcttcca	840
ggagctgcag	gagaaagggg	tgcccctggg	ttccgaggac	ctgctggacc	aaatggcatc	900
ccaggagaaa	agggtcctgc	tggagagcgt	ggtgctccag	gccctgcagg	gcccagagga	960
gctgctggag	aacctggcag	agatggcgtc	cctggaggtc	caggaatgag	gggcatgccc	1020
ggaagtccag	gaggaccagg	aagtgatggg	aaaccagggc	ctcccgggaag	tcaaggagaa	1080
agtggtcgac	caggctcctcc	tgggccatct	ggtccccgag	gtcagcctgg	tgtcatgggc	1140
ttccccggtc	ctaaaggaaa	tgatgggtgct	cctggtaaga	atggagaacg	agggtggcct	1200
ggaggacctg	gccctcaggg	tcctcctgga	aagaatggtg	aaactggacc	tcagggaccc	1260
ccagggccta	ctgggcctgg	tggtgacaaa	ggagacacag	gacccctggg	tccacaagga	1320
ttacaaggct	tgcttggtac	agggtggtcct	ccaggagaaa	atggaaaacc	tggggaacca	1380
ggtccaaagg	gtgatgccgg	tgacacctga	gctccaggag	gcaagggtga	tgctgggtgcc	1440
cctgggtgaac	gtggacctcc	tggattggca	ggggccccag	gacttagagg	tggagctggt	1500
ccccctggtc	ccgaaggagg	aaagggtgct	gctggtcctc	ctgggccacc	tggtgctgct	1560
ggtactcctg	gtctgcaagg	aatgcctgga	gaaagaggag	gtcttggaag	tccttggtcc	1620
tcccagcgct	ggtttcgact	tcagcttcct	gccccagcca	cctcaagaga	aggctcacga	1680
tgggtggccgc	tactaccggg	ctgatgatgc	caatgtggtt	cgtgaccgtg	acctcgaggt	1740
ggacaccacc	ctcaagagcc	tgagccagca	gatcgagaac	atccggagcc	cagagggcag	1800
ccgcaagaac	cccgcccgca	cctgccgtga	cctcaagatg	tgccactctg	actggaagag	1860

57

tggagagtac tggattgacc ccaaccaagg ctgcaacctg gatgccatca aagtcttctg 1920
 caacatggag actggtgaga cctgcgtgta cccactcag ccagtggtg cccagaagaa 1980
 ctggtacatc aacaagaacc ccaaggacaa gaggcattgc tggttcggcg agagcatgac 2040
 cgatggaatt ccatttccag tttggcgggc agggcttcga cccttccgat gtggccatcc 2100
 agctgacctt 2110

<210> 59
 <211> 1639
 <212> DNA
 <213> Homo sapien

<400> 59
 gggccgccta gagcaggagg tattagtcac tgcgccagg agccagttta cacctagcga 60
 aggcggaggc attggacaag cctgggtctg agcagacaga accccttcct gcgaccctgg 120
 agtcccaatc gtgctgccat tttccttctg ccaggactc tccagtcctc agtcaccttg 180
 gacaaagaag tgtggatcct cagattccat cttttccaac tccaagggtgc catggcagag 240
 aaggctgctg taacagggtg ggctggctac attggcagcc acacgggtgct ggagctgctg 300
 gaggctggct acttgctgt ggtcatcgat aacttccata atgccttccg tggagggggc 360
 tccctgcctg agagcctgcg gcgggtccag gagctgacag gccgctctgt ggagtttgag 420
 gagatggaca ttttggacca gggagcccta cagcgtctct tcaaaaagta cagctttatg 480
 gcggtcatcc actttgcggg gctcaaggcc gtgggcgagt cggtgcagaa gcctctggat 540
 tattacagag ttaacctgac cgggaccatc cagcttcttg agatcatgaa ggcccacggg 600
 gtgaagaacc tgggtgttcag cagctcagcc actgtgtacg ggaacccccca gtacctgccc 660
 cttgatgagg cccacccac ggggtggttg accaaccctt acggcaagtc caagttcttc 720
 atcgaggaaa tgatccggga cctgtgccag gcagacaaga cttggaacgc agtgctgct 780
 gcgctatttc aacccacag gtggcccatg cctctggctg cattgggtgag gatccccagg 840
 gcatacccaa caacctcatg ccttatgtct ccaggtggc gatcgggcga cgggaggccc 900
 tgaatgtctt tggcaatgac tatgacacag aggatggcac aggtgtccgg gattacatcc 960
 atgtcgtgga tctggccaag ggccacattg cagccttaag gaagctgaaa gaacagtgtg 1020
 gctgccggat ctacaacctg ggcacgggca caggctattc agtgctgcag atgggtccagg 1080
 ctatggagaa ggcctctggg aagaagatcc cgtacaaggt ggtggcacgg cgggaagggtg 1140
 atgtggcagc ctgttacgcc aacccacagc tggcccaaga ggagctgggg tggacagcag 1200
 ccttagggct ggacaggatg tgtgaggatc tctggcgtg gcagaagcag aatccttcag 1260
 gctttggcac gcaagcctga ggaccctccc ctaccaagga ccaggaaaag cagcagctgc 1320

58

ctgctctcca	gcctctggca	ggaactcagg	gccctggagc	tgctggggcc	aagccaaggc	1380
ctccccctacc	tcaaacccca	gctggggccc	cttagccac	caggcatgag	gccaagggct	1440
ccactgacca	ggaggccgag	gtctctaact	cttatcttcc	acagggcca	agagttcatc	1500
aggaccccca	agagtgagt	agggggcaag	gctctggcac	aaaacctcct	cctcccaggc	1560
actcatttat	attgctctga	aagagctttc	caaagtattt	aaaaatagaa	acaagttttc	1620
ttacactggg	aaaaaaaaa					1639

<210> 60
 <211> 598
 <212> DNA
 <213> Homo sapien

<400> 60	
acaggtgccc	atgcctctgg ctgcattggt gaggatcccc agggcatacc ctgccccttg 60
atgaggccca	ccccacgggt ggttgtagca acccttacgg caagtccaag ttcttcatcg 120
aggaaatgat	cggggacctg tgccaggcag acaaggggtg gacagcagcc ttagggctgg 180
acaggatgtg	tgaggatctc tggcgctggc agaagcagaa tccttcaggc tttggcacgc 240
aagcctgagg	accctcccct accaaggacc aggaaaagca gcagctgcct gctctccagc 300
ctctggcagg	aactcagggc cctggagctg ctggggccaa gccaaggcct cccctacctc 360
aaaccccagc	tgggcccgcct tagccaccca ggcatgaggc caagggctcc actgaccagg 420
aggccgaggt	ctctaactct tatcttccac agggccaag agttcatcag gacccccaa 480
agtgagtgag	ggggcaaggc tctggcacia aacctcctcc tcccaggcac tcatttatat 540
tgctctgaaa	gagctttcca aagtatttaa aaataaaaac aagttttctt acactggg 598

<210> 61
 <211> 1696
 <212> DNA
 <213> Homo sapien

<400> 61	
cgtggagggg	cggggctcggg gccggagtgg gccgtcagca cttaaagggc ccgaggctcg 60
ggcgtaggag	gcggtgcctc tgcagcaagc gtggggcgcg ggaacccgag caggactctc 120
cagtcctcag	tcaccttgga caaagaagtg tggatcctca gattccatct tttccaactc 180
caaggcgcca	tggcagagaa ggtgctggta acagggtggg ctggctacat tggcagccac 240
acgggtgctg	agctgctgga ggctggctac ttgcctgtgg tcatcgataa cttccataat 300
gccttccgtg	gaggggggctc cctgcctgag agcctgcggc ggggccagga gctgacaggc 360
cgctctgtgg	agtttgagga gatggacatt ttggaccagg gagccctaca gcgtctcttc 420
aaaaagtaca	gctttatggc ggtcatccac tttgcggggc tcaaggccgt gggcgagtcg 480

```

gtgcagaagc ctctggatta ttacagagtt aacctgaccg ggaccatcca gcttctggag 540
atcatgaagg cccacggggg gaagaacctg gtgttcagca gctcagccac tgtgtacggg 600
aaccctcagt acctgccctt tgatgaggcc caccctcagg gtggttgtag caacccttac 660
ggcaagtcca agttcttcat cgaggaaatg atccgggacc tgtgccaggc agacaagact 720
tggaacgcag tgctgctgcg ctatttcaac cccacagggtg cccatgcctc tggctgcatt 780
ggtgaggatc cccagggcat acccaacaac ctcatgcctt atgtctccca ggtggcgatc 840
gggcgaaggg aggccttgaa tgtctttggc aatgactatg acacagagga tggcacaggc 900
gtccgggatt acatccatgt cgtggatctg gccaaaggcc acattgcagc cttaaggaag 960
ctgaaagAAC agtgtggctg ccgggtagga agagaaggga gaagtgaggg aggggaggga 1020
ccagatccag gcagagcggc ccagaggcgt ggtcagtcca gcccgctcca taaacctgt 1080
tctccgtggg ccagatctac aacctgggca cgggcacagg ctattcagtg ctgcagatgg 1140
tccaggctat ggagaaggcc tctgggaaga agatcccgta caagggtggg gcacggcggg 1200
aaggatgatgt ggcagcctgt tacgccaacc ccagcctggc ccaagaggag ctgggggtgga 1260
cagcagcctt agggctggac aggatgtgtg aggatctctg gcgctggcag aagcagaatc 1320
cttcaggctt tggcacgcaa gcctgaggac cctcccctac caaggaccag gaaaagcagc 1380
agctgcctgc tctccagcct ctggcaggaa ctcaaggccc tggagctgct ggggccaagc 1440
caaggcctcc cctacctcaa accccagctg ggcccgttta gccaccagg catgaggcca 1500
agggctccac tgaccaggag gccgaggtct ctaactctta tcttccacag ggtccaagag 1560
ttcatcagga cccccaagag tgagtgaggg ggcaaggctc tggcacaaaa cctcctcctc 1620
ccaggcactc atttatattg ctctgaaaga gctttccaaa gtatttataaa ataaaaacaa 1680
gttttcttac actggg 1696

```

```

<210> 62
<211> 1939
<212> DNA
<213> Homo sapien

```

```

<400> 62
cgtggaaggg cggggtcggg gccggagtgg gccgtcagca cttaaagggc ccgcggctcg 60
ggcgtaggag gcggtgcctc tgcagcaagc gtggggcgcg ggaacccgag caggactctc 120
cagtcctcag tcaccttggc caaagaagtg tggatcctca gattccatct tttccaactc 180
caaggtagcca tggcagagaa ggtgctggta acaggtaggg ctggctacat tggcagccac 240
acggtagctg agctgctgga ggctggctac ttgcctgtgg tcatcgataa cttccataat 300
gccttcagtg gagggggctc cctgcctgag agcctgcggc ggggtccagga gctgacaggc 360

```

60

cgctctgtgg agtttgagga gatggacatt ttggaccagg gagccctaca gcgtctcttc 420
 aaaaagtaca gctttatggc ggtcatccac ttgcggggc tcaaggccgt gggcgagtcg 480
 gtgcagaagc ctctggatta ttacagagtt aacctgaccg ggaccatcca gcttctggag 540
 atcatgaagg cccacgggggt gaagaacctg gtgttcagca gctcagccac tgtgtacggg 600
 aacccccagt acctgcccct tgatgaggcc cccccacgg gtggttgtac caacccttac 660
 ggcaagtcca agttcttcat cgaggaaatg atccgggacc tgtgccaggc agacaagact 720
 tggaacgcag tgctgctgcg ctatttcaac cccacagggtg cccatgcctc tggctgcatt 780
 ggtgaggatc cccagggcat acccaacaac ctcatgcctt atgtctccca ggtggcgatc 840
 gggcgacggg aggccttgaa tgtctttggc aatgactatg acacagagga tggcacaggc 900
 gtccgggatt acatccatgt cgtggatctg gccaaaggcc acattgcagc cttaaggaag 960
 ctgaaagaac agtgtggctg ccgggtagga agagaaggga gaagtgaggg aggggaggga 1020
 ccagatccag gcagagcggc ccagaggcgt ggtcagtcca gcccgctcca taaaccctgt 1080
 tctccgtggg ccagatctac aacctgggca cgggcacagg ctattcagtg ctgcagatgg 1140
 tccaggctat ggagaaggcc tctgggaaga aggtaggccc cccacccca cccacctcac 1200
 ccacctcacc ccaccagct ctgagcaaca gagcagcttt ggcccttccc actcacctct 1260
 ctggagggtg cctggcactg cccagtctcc tcagcctgcc tagcaccggg tgcctgcggg 1320
 ccagccgctg ctctgcactt ctgcttctta aagacctggc cagcagctgg gccagggccg 1380
 gctcagctaa gctccaacta cctcctgtct tgcagatccc gtacaagggtg gtggcacggc 1440
 gggaagggtg tgtggcagcc tgttacgcca accccagcct ggcccaagag gagctgggggt 1500
 ggacagcagc cttagggctg gacaggatgt gtgaggatct ctggcgctgg cagaagcaga 1560
 atccttcagg ctttggcacg caagcctgag gacctcccc taccaaggac caggaaaagc 1620
 agcagctgcc tgctctccag cctctggcag gaactcaggg ccctggagct gctggggcca 1680
 agccaaggcc tcccctacct caaaccccag ctgggcccgc ttagcccacc aggcattgagg 1740
 ccaagggtc cactgaccag gaggccgagg tctctaactc ttatcttcca cagggtccaa 1800
 gagttcatca ggacccccaa gaggagtgga gggggcaagg ctctggcaca aaacctctc 1860
 ctcccaggca ctcatttata ttgctctgaa agagctttcc aaagtattta aaaataaaaa 1920
 caagttttct tacactggg 1939

<210> 63
 <211> 2082
 <212> DNA
 <213> Homo sapien

61

<400> 63

cgtggagggg	cgggggtcggg	gccgggagtgg	gccgtcagca	cttaaagggc	ccgcggctcg	60
ggcgtaggag	gcggtgcctc	tgcagcaagc	gtggggcgcg	ggaacccgag	caggactctc	120
cagtcctcag	tcaccttgga	caaagaagtg	tggatcctca	gattccatct	tttccaactc	180
caaggtgcca	tggcagagaa	ggtgctggta	acaggtgggg	ctggctacat	tggcagccac	240
acggtgctgg	agctgctgga	ggctggctac	ttgcctgtgg	tcatcgataa	cttccataat	300
gccttccgtg	gagggggctc	cctgcctgag	agcctgcggc	gggtccagga	gctgacaggc	360
cgctctgtgg	agtttgagga	gatggacatt	ttggaccagg	gagccctaca	gcgtctcttc	420
aaaaagtaca	gctttatggc	ggtcatccac	tttgcggggc	tcaaggccgt	gggcgagtcg	480
gtgcagaagc	ctctggatta	ttacagagtt	aacctgaccg	ggaccatcca	gcttctggag	540
atcatgaagg	cccacggggg	gaagaacctg	gtgttcagca	gctcagccac	tgtgtacggg	600
aacccccagt	acctgcccct	tgatgaggcc	cacccacagg	gtggttgtac	caacccttac	660
ggcaagtcca	agttcttcat	cgaggaaatg	atccgggacc	tgtgccaggc	agacaagact	720
tggaacgcag	tgctgctgcg	ctatttcaac	cccacagggt	cccatgcctc	tggctgcatt	780
ggtgaggatc	cccagggcat	acccaacaac	ctcatgcctt	atgtctccca	ggtggcgatc	840
gggcgacggg	aggccctgaa	tgtctttggc	aatgactatg	acacagagga	tggcacaggc	900
gtccgggatt	acatccatgt	cgtggatctg	gccaagggcc	acattgcagc	cttaaggaag	960
ctgaaagaac	agtgtggctg	ccgggtagga	agagaaggga	gaagtgaggg	aggggagggg	1020
ccagatccag	gcagagcggc	ccagaggcgt	ggtcagtcca	gcccgcctcca	taaaccctgt	1080
tctccgtggg	ccagatctac	aacctgggca	cgggcacagg	ctattcagtg	ctgcagatgg	1140
tccaggctat	ggagaaggcc	tctgggaaga	aggtaggccc	ccccaccca	cccacctcac	1200
ccacctcacc	ccaccagct	ctcagcaaca	gagcagcttt	ggcccttccc	actcacctct	1260
ctggagggta	cctggcactg	cccagtctcc	tcagcctgcc	tagcaccogg	tgctgcggg	1320
ccagccgctg	ctctgcactt	ctgcttctta	aagacctggc	cagcagctgg	gccagggccg	1380
gctcagctaa	gctccaacta	cctcctgtct	tgcagatccc	gtacaagggt	gtggcacggc	1440
gggaagggtga	tgtggcagcc	tgttacgcca	accccagcct	ggcccaagag	gagctggggg	1500
ggacagcagc	cttagggctg	gacaggatgt	gtgagtgtct	gcctgacccc	tgcatgttagg	1560
ggccagggag	gggctaaatc	agatctgggc	atgccacccc	agggcgggct	gtgggggtggg	1620
ggaggctctg	cattccaccg	tgggcccctga	gcacacacct	cgccgtgttg	cagggtgagga	1680
tctctggcgc	tggcagaagc	agaatccttc	aggctttggc	acgcaagcct	gaggaccctc	1740
ccctaccaag	gaccaggaaa	agcagcagct	gcctgctctc	cagcctctgg	caggaactca	1800

62

gggccctgga gctgctgggg ccaagccaag gcctccccta cctcaaacc cagctgggcc 1860
 cgcttagccc accaggcatg aggccaaggg ctccactgac caggaggccg aggtctctaa 1920
 ctcttatctt ccacagggtc caagagttca tcaggacccc caagagttag tgagggggca 1980
 aggctctggc acaaaacctc ctccctcccag gcactcattt atattgctct gaaagagctt 2040
 tccaaagtat ttaaaaataa aaacaagttt tcttacactg gg 2082

<210> 64
 <211> 457
 <212> DNA
 <213> Homo sapien

<400> 64
 taaatgagag tgctcatcac ctccagccca ttctcctgtg gaggagtaac aggggtgggag 60
 taatgtgtga ggcagaggtc actgatgcca tctctccacg gccagatcat gaaggccac 120
 ggggtgaaga acctggtgtt cagcagctca gccactgtgt acgggaacc ccagtacctg 180
 ccccttgatg agggccacc caccgggtgt tgtaccaacc cttacggcaa gtccaagttc 240
 ttcatcgagg aaatgatccg ggacctgtgc caggcagaca aggtgagggc ccccttgaca 300
 gtgccctggc tccactgatc gatggactcc tcagggccca ccctgagccc aggggtggga 360
 ttccgaacac cccactaag gaggaagcta aggtcaggc agttgcagtg gagggcccca 420
 tcccctgctt gtttctaaag ataataaata gacaact 457

<210> 65
 <211> 2160
 <212> DNA
 <213> Homo sapien

<400> 65
 tccaaattca ggaaactgtt gccatagcat ttcccttct ctattcctgc atagccctcc 60
 tccccgaat cagcaacaat ttttgctcca ccgttttctt tcgggaacca gatgcgtttt 120
 cagaagacag tactccagtg ataaggtatc tacaccactt aataactgta cctggtaagg 180
 agatttaata aggctgaggg tggatattaag tttctcagaa cagactcatc tttgcggatg 240
 cagttgcaga acaggaaaca gaccagggga gaagtttagt cccccagat ctcataggcc 300
 ctccgcacaa gccagccac agccactcct gccacacaaat cggattgctt tcagcactcg 360
 cagccgtgga ccgccgtgcg gtcctttcct ccgcagttag ccgatttgct ctgccagcag 420
 ctgtcgggtg ccgcctcgac accgagtcct agctaggcgc tcacagaata ccgcctccct 480
 ccctccccct tctctgtccc ccgcctctcg ctaccaccgg cccactccag cggcgacttt 540
 gagggattcc ctctctggcg gcctctgcag cagcacagcc ggccctcattc ggggcactgc 600
 gagtatggat ctccaaggaa gaggggtccc cagcatcgac agacttcgag ttctcctgat 660

63

```

gttggtccat acaatggctc aaatcatggc agaacaagaa gtggaaaatc tctcaggcct 720
ttccactaac cctgaaaaag atatatattgt ggtgcgggaa aatgggacga cgtgtctcat 780
ggcagagttt gcagccaaat ttattgtacc ttatgatgtg tgggccagca actacgtaga 840
tctgatcaca gaacaggccg atatcgcat gacccgggga gctgaggtga agggccgctg 900
tggccacagc cagtcggagc tgcaagtgtt ctgggtggat cgcgcatatg cactcaaaat 960
gctctttgta aaggaaagcc acaacatgtc caagggacct gaggcgactt ggaggctgag 1020
caaagtgcag tttgtctacg actcctcgga gaaaaccac ttcaaagacg cagtcagtgc 1080
tgggaagcac acagccaact cgcaccacct ctctgccttg gtcacccccg ctgggaagtc 1140
ctatgagtgt caagctcaac aaaccatttc actggcctct agtgatccgc agaagacggt 1200
caccatgatc ctgtctgcgg tccacatcca accttttgac attatctcag attttgtctt 1260
cagtgaagag cataaatgcc cagtggatga gcgggagcaa ctggaagaaa ccttgcccct 1320
gattttgggg ctcatcttgg gcctcgtcat catggtaaca ctgcgattt accacgtcca 1380
ccacaaaatg actgccaacc aggtgcagat ccctcgggac agatcccagt ataagcacat 1440
gggctagagg ccgttaggca ggcaccccct attcctgctc ccccaactgg atcaggtaga 1500
acaacaaaag cactttttcca tcttgtacac gagatacacc aacatagcta caatcaaaca 1560
ggcctgggta tctgaggctt gcttggcttg tgtccatgct taaaccacg gaagggggag 1620
actctttcgg atttgtaggg tgaaatggca attattctct ccatgctggg gagggagggg 1680
ggagggtctc agacagcttt cgtgctcatg gtggcttggc tttgactctc caaagagcaa 1740
taaatgccac ttggagctgt atctggcccc aaagttagg gattgaaaac atgcttcttt 1800
gaggaggaaa ccccttttagg ttcagaagaa tatggggtgc tttgctccct tggacacagc 1860
tggcttatcc tatacagttg tcaatgcaca cagaatacaa cctcatgctc cctgcagcaa 1920
gaccctgaa agtgattcat gcttctggct ggcatctgc atgttttagtg attgtcttgg 1980
gaatgtttca ctgctaccg catccagcga ctgcagcacc agaaaacgac taatgtaact 2040
atgcagagtt gtttggactt cttcctgtgc cagggtccaag tcggggggacc tgaagaatca 2100
atctgtgtga gtctgttttt caaatgaaa taaaacacac tattctctgg caaaaaaaaa 2160

```

```

<210> 66
<211> 2275
<212> DNA
<213> Homo sapien

```

```

<400> 66
tccaaattca ggaaactggt gccatagcat ttcccttct ctattcctgc atagccctcc 60
tccccgaat cagcaacaat ttttgctcca ccgttttctt tcgggaacca gatgcgtttt 120

```

cagaagacag tactccagtg ataaggtatc tacaccactt aataactgta cctggtaagg	180
agattttaata aggctgaggg tggtattaag tttctcagaa cagactcatc tttgcggatg	240
cagttgcaga acaggaaaca gaccagggga gaagtttagt ccccccagat ctcataggcc	300
ctccgcacaa gccaagccac agccactcct gccacacaat cggattgctt tcagcactcg	360
cagccgtgga ccgccgtgcg gtccttttct ctgcagtgag ccgatttgct ctgccagcag	420
ctgtcgggtgc cgcgctcgac accgagtcct agctaggcgc tcacagaata cgcgctccct	480
ccctccccct tctctgtccc ccgcctctcg ctcaccccg cccactccag cggcgacttt	540
gagggattcc ctctctggcg gcctctgcag cagcacagcc ggcctcattc ggggcactgc	600
gagtatggat ctccaaggaa gaggggtccc cagcatcgac agacttcgag ttctcctgat	660
gttggtccat acaatggctc aaatcatggc agaacaagaa gtggaaaatc tctcaggcct	720
ttccactaac cctgaaaaag atatatttgt ggtgcgggaa aatgggacga cgtgtctcat	780
ggcagagttt gcagccaaat ttattgtacc ttatgatgtg tgggccagca actacgtaga	840
tctgatcaca gaacaggccg atatcgcat t gaccggggga gctgaggtga agggccgctg	900
tggccacagc cagtcggagc tgcaagtgtt ctgggtggat cgcgcataatg cactcaaaat	960
gctctttgta aaggtaactc cgagcccagc gggcagaggg gccgcaggct ccgcgtgggt	1020
gtgggaagtg gcggcccta ggtttaagaa ccagacgct gcggggacga ttgaagcgca	1080
cctccccggc tcaacaggaa agccacaaca tgtccaaggg acctgaggcg acttggaggc	1140
tgagcaaagt gcagtttgtc tacgactcct cggagaaaac ccacttcaaa gacgcagtca	1200
gtgctgggaa gcacacagcc aactcgcacc acctctctgc cttggtcacc cccgctggga	1260
agtcctatga gtgtcaagct caacaaacca tttcactggc ctctagtgat ccgcagaaga	1320
cggtcaccat gatcctgtct gcggtccaca tccaaccttt tgacattatc tcagattttg	1380
tcttcagtga agagcataaa tgcccagtgg atgagcggga gcaactggaa gaaaccttgc	1440
ccctgatttt ggggctcatc ttgggcctcg tcatcatggg aacactcgcg atttaccacg	1500
tccaccacaa aatgactgcc aaccagggtgc agatccctcg ggacagatcc cagtataagc	1560
acatgggcta gaggcggtta ggcaggcacc ccctattcct gctcccccaa ctggatcagg	1620
tagaacaaca aaagcacttt tccatcttgt acacgagata caccaacata gctacaatca	1680
aacaggcctg ggtatctgag gcttgcttgg cttgtgtcca tgcttaaacc cacggaaggg	1740
ggagactctt tcggatttgt aggggtgaaat ggcaattatt ctctccatgc tggggaggag	1800
gggaggaggg tctcagacag ctttcgtgct catgggtggct tggctttgac tctccaaaga	1860
gcaataaatg ccacttggag ctgtatctgg ccccaaagtt tagggattga aaacatgctt	1920

65

ctttgaggag gaaacccctt taggttcaga agaatatggg gtgctttgct cccttggaca	1980
cagctggctt atcctataca gttgtcaatg cacacagaat acaacctcat gctccctgca	2040
gcaagacccc tgaaagtgat tcatgcttct ggctggcatt ctgcatgttt agtgattgtc	2100
ttgggaatgt ttactgcta cccgcatcca gcgactgcag caccagaaaa cgactaatgt	2160
aactatgcag agttgttttg acttcttcct gtgccaggtc caagtcgggg gacctgaaga	2220
atcaatctgt gtgagtctgt ttttcaaaat gaaataaaac acactattct ctggc	2275

<210> 67
 <211> 2026
 <212> DNA
 <213> Homo sapien

<400> 67	
tccaaattca ggaaactgtt gccatagcat tttcccttct ctattcctgc atagccctcc	60
tccccgaat cagcaacaat ttttgctcca ccgttttctt tcgggaacca gatgcgtttt	120
cagaagacag tactccagtg ataaggtatc tacaccactt aataactgta cctggtaagg	180
agatttaata aggctgaggg tggatttaag tttctcagaa cagactcatc tttgcggatg	240
cagttgcaga acaggaaaca gaccagggga gaagtttagt ccccccagat ctcatggcc	300
ctccgcacaa gccaagccac agccactcct gccacacaat cggattgctt tcagcactcg	360
cagccgtgga ccgccgtgcg gtcctttcct ctgcagtgag ccgatttgct ctgccagcag	420
ctgtcgggtgc cgcgctcgac accgagtcct agctaggcgc tcacagaata cgcgctccct	480
ccctccccct tctctgtccc ccgcctctcg ctcaccccgg cccactccag cggcgacttt	540
gagggattcc ctctctggcg gcctctgcag cagcacagcc ggcctcatte ggggcactgc	600
gagtatggat ctccaaggaa gaggggtccc cagcatcgac agacttcgag ttctcctgat	660
gttgttccat acaatggctc aaatcatggc agaacaagaa gtggaaaatc tctcaggcct	720
ttccactaac cctgaaaaag atatatattgt ggtgcgggaa aatgggacga cgctgtggcc	780
acagccagtc ggagctgcaa gtgttctggg tggatcgcg atatgcactc aaaatgctct	840
ttgtaaagga aagccacaac atgtccaagg gacctgaggc gacttggagg ctgagcaaag	900
tgcagtttgt ctacgactcc tcggagaaaa cccacttcaa agacgcagtc agtgctggga	960
agcacacagc caactcgcac cacctctctg ccttgggtcac ccccgctggg aagtcctatg	1020
agtgtcaagc tcaacaaacc atttcaactgg cctctagtga tccgcagaag acggtcacca	1080
tgatcctgtc tgcgggtccac atccaacctt ttgacattat ctgagatttt gtcttcagtg	1140
aagagcataa atgcccagtg gatgagcggg agcaactgga agaaaccttg cccctgattt	1200
tggggctcat cttgggcctc gtcatcatgg taacactcgc gatttaccac gtccaccaca	1260

66

```

aatgactgc caaccaggtg cagatccctc gggacagatc ccagtataag cacatgggct 1320
agaggccgtt aggcaggcac cccctattcc tgctcccca actggatcag gtagaacaac 1380
aaaagcactt ttccatcttg tacacgagat acaccaacat agctacaatc aaacaggcct 1440
gggtatctga ggcttgcttg gcttgtgtcc atgcttaaac ccacggaagg gggagactct 1500
ttcggatttg tagggtgaaa tggcaattat tctctccatg ctggggagga ggggaggagg 1560
gtctcagaca gctttcgtgc tcatgggtggc ttggctttga ctctccaaag agcaataaat 1620
gccacttgga gctgtatctg gcccacaaagt ttagggattg aaaacatgct tctttgagga 1680
ggaaacccct ttaggttcag aagaatatgg ggtgctttgc tcccttggac acagctggct 1740
tatcctatac agttgtcaat gcacacagaa tacaacctca tgctccctgc agcaagaccc 1800
ctgaaagtga ttcatgcttc tggctggcat tctgcatgtt tagtgattgt cttgggaatg 1860
tttcaactgt acccgcatcc agcgactgca gcaccagaaa acgactaatg taactatgca 1920
gagttgtttg gacttcttcc tgtgccaggt ccaagtcggg ggacctgaag aatcaatctg 1980
tgtgagtctg tttttcaaaa tgaaataaaa cacactattc tctggc 2026

```

```

<210> 68
<211> 1062
<212> DNA
<213> Homo sapien

```

```

<400> 68
tccaaattca ggaaactggt gccatagcat tttcccttct ctattcctgc atagccctcc 60
tccccgaat cagcaacaat ttttgctcca ccgttttctt tcgggaacca gatgcgtttt 120
cagaagacag tactccagtg ataaggatc tacaccactt aataactgta cctggtaagg 180
agatttaata aggctgaggg tggatattaag tttctcagaa cagactcatc tttgcggatg 240
cagttgcaga acaggaaaca gaccagggga gaagttagt cccccagat ctcatggcc 300
ctccgcacaa gccaagccac agccactcct gccacacaat cggattgctt tcagcactcg 360
cagccgtgga ccgccgtgcg gtccttttct ctgcagtgag ccgatttgct ctgccagcag 420
ctgtcgggtg cgcgctcgac accgagtcct agctaggcgc tcacagaata cgcgctccct 480
ccctccccct tctctgtccc ccgcctctcg ctacccccgg cccactccag cggcgacttt 540
gagggattcc ctctctggcg gcctctgcag cagcacagcc ggcctcatc ggggcactgc 600
gagtatggat ctccaaggaa gaggggtccc cagcatcgac agacttcgag ttctcctgat 660
gttgttccat acaatggctc aaatcatggc agaacaagaa gtggaaaatc tctcaggcct 720
ttccactaac cctgaaaaag atatatattgt ggtgcgggaa aatgggacga cgtgtctcat 780
ggcagagttt gcagccaaat ttattgtacc ttatgatgtg tgggccagca actacgtaga 840

```


67

tgtaaggaat ctttcccccc cctcagcttg ctcctagggc tccagggcga agggcacccct 900
 tcctcaaggc tcttcgaaga cctgggttgc ccgccttctt tcccacaccc cggcaggctg 960
 ctcccgaatg ctgcatgggg attccagctt gtaatgcctt ctgttcccct gcctgctttg 1020
 aaagtaaacc cccttctctc cgcttcccta tcgggggctgc ac 1062

<210> 69

<211> 2275

<212> DNA

<213> Homo sapien

<400> 69

tccaaattca ggaaactggt gccatagcat tttcccttct ctattcctgc atagccctcc 60
 tccccgaat cagcaacaat ttttgctcca ccgttttctt tcgggaacca gatgcgtttt 120
 cagaagacag tactccagtg ataaggtatc tacaccactt aataactgta cctggtaagg 180
 agatttaata aggctgaggg tggattaag tttctcagaa cagactcatc tttgcggatg 240
 cagttgcaga acaggaaaca gaccagggga gaagttagt cccccagat ctcatggcc 300
 ctccgcacaa gccaagccac agccactcct gccacacaat cggattgctt tcagcactcg 360
 cagccgtgga ccgcgtgcg gtcctttcct ctgcagtgag ccgatttgct ctgccagcag 420
 ctgtcgggtgc cgcgctcgac accgagtcct agctaggcgc tcacagaata cgcgctccct 480
 ccctccccct tctctgtccc ccgcctctcg ctcaccccg g cccactccag cggcgacttt 540
 gagggattcc ctctctggcg gcctctgcag cagcacagcc ggcctcattc ggggcactgc 600
 gagtatggat ctccaaggaa gaggggtccc cagcatcgac agacttcgag ttctcctgat 660
 gttgttccat acaatggctc aaatcatggc agaacaagaa gtggaaaatc tctcaggcct 720
 ttccactaac cctgaaaaag atatatattgt ggtgcgggaa aatgggacga cgtgtctcat 780
 ggcagagttt gcagccaaat ttattgtacc ttatgatgtg tgggccagca actacgtaga 840
 tctgatcaca gaacaggccg atatcgcat gaccggggga gctgaggtga agggccgctg 900
 tggccacagc cagtcggagc tgcaagtgtt ctgggtggat cgcgcatatg cactcaaaat 960
 gctctttgta aaggtaactc cgagcccagc gggcagaggg gccgcaggct ccgcgtgggt 1020
 gtgggaagtg gcggccccta ggtttaagaa cccagacgct gcggggacga ttgaagcgca 1080
 cctccccggc tcaacaggaa agccacaaca tgtccaaggg acctgaggcg acttggaggc 1140
 tgagcaaagt gcagtttgct tacgactcct cggagaaaac ccacttcaaa gacgcagtca 1200
 gtgctgggaa gcacacagcc aactcgcacc acctctctgc cttggtcacc cccgctggga 1260
 agtcctatga gtgtcaagct caacaaacca tttcactggc ctctagtgat ccgcagaaga 1320
 cggtcaccat gatcctgtct gcggtccaca tccaaccttt tgacattatc tcagattttg 1380

68

tcttcagtga	agagcataaa	tgcccagtg	atgagcggga	gcaactggaa	gaaaccttgc	1440
ccctgatttt	ggggctcatc	ttgggcctcg	tcatcatggt	aacactcgcg	atttaccacg	1500
tccaccacaa	aatgactgcc	aaccaggtgc	agatccctcg	ggacagatcc	cagtataagc	1560
acatgggcta	gaggccgtta	ggcaggcacc	ccctattcct	gctcccccaa	ctggatcagg	1620
tagaacaaca	aaagcacttt	tccatcttgt	acacgagata	caccaacata	gctacaatca	1680
aacaggcctg	ggtatctgag	gcttgcttgg	cttgtgtcca	tgcttaaacc	cacggaaggg	1740
ggagactctt	tcggatttgt	agggtgaaat	ggcaattatt	ctctccatgc	tggggaggag	1800
gggaggaggg	tctcagacag	ctttcgtgct	catggtggct	tggctttgac	tctccaaaga	1860
gcaataaatg	ccacttggag	ctgtatctgg	ccccaaagtt	tagggattga	aaacatgctt	1920
ctttgaggag	gaaacccctt	taggttcaga	agaatatggg	gtgctttgct	cccttggaca	1980
cagctggctt	atcctataca	gttgtcaatg	cacacagaat	acaacctcat	gctccctgca	2040
gcaagacccc	tgaaagtgat	tcatgcttct	ggctggcatt	ctgcatgttt	agtgattgtc	2100
ttgggaatgt	ttcactgcta	cccgcatcca	gcgactgcag	caccagaaaa	cgactaatgt	2160
aactatgcag	agttgtttgg	acttcttcct	gtgccaggtc	caagtcgggg	gacctgaaga	2220
atcaatctgt	gtgagtctgt	ttttcaaaat	gaaataaaac	acactattct	ctggc	2275

<210> 70

<211> 1826

<212> DNA

<213> Homo sapien

<400> 70

tcgaaymgta	accgttcgta	cgagaatcgc	tgtcctctcc	ttgcggccgc	agtgtggtgg	60
aattcttttc	cgacacgtag	tagtactgac	gcttgggaac	ggcctgggcc	agaatctcga	120
tctggcgagc	gttcaggccc	atgcggcggt	acagggccgc	cgtgtcctca	tccctggcgt	180
aaatattcgg	caggaaaatc	ttggtcgcgg	tcgattccac	gatcacgtcc	aggatgccgc	240
tgttggcggc	gtcggacagg	ctctgcgttg	ccatcagcac	aaggcagttg	gccttacgca	300
gcaccttgag	ccattccctg	atcttcgcgc	ggaatgccgg	gtggccgagc	atcaaccagg	360
cttcgtccag	gatgatgacg	gccgccagtg	tggtggaatt	ctaaccctga	aaaagatata	420
tttgtggtgc	gggaaaatgg	gacgacgtgt	ctcatggcag	agtttgcagc	caaatttatt	480
gtaccttatg	atgtgtgggc	cagcaactac	gtagatctga	tcacagaaca	ggccgatatc	540
gcattgaccc	ggggagctga	ggtgaagggc	cgctgtggcc	acagccagtc	ggagctgcaa	600
gtgttctggg	tggatcgcg	atatgcactc	aaaatgctct	ttgtaaagga	aagccacaac	660
atgtccaagg	gacctgaggg	gacttggagg	ctgagcaaag	tgcagtttgt	ctacgactcc	720

69

toggagaaaa	cccacttcaa	agacgcagtc	agtgcctggga	agcacacagc	caactcgcac	780
cacctctctg	ccttggtcac	ccccgctggg	aagtcctatg	agtgtcaagc	tcaacaaacc	840
atttcactgg	cctctagtga	tccgcagaag	acggtcacca	tgatcctgtc	tgcgggtccac	900
atccaacctt	ttgacattat	ctcagatttt	gtcttcagtg	aagagcataa	atgcccagtg	960
gatgagcggg	agcaactgga	agaaaccttg	cccctgattt	tggggctcat	cttgggcctc	1020
gtcatcatgg	taacactcgc	gatttaccac	gtccaccaca	aaatgactgc	caaccagggtg	1080
cagatccctc	gggacagatc	ccagtataag	cacatgggct	agaggccggt	aggcaggcac	1140
cccctattcc	tgctcccca	actggatcag	gtagaacaac	aaaagcactt	ttccatcttg	1200
tacacgagat	acaccaacat	agctacaatc	aaacaggcct	gggtatctga	ggcttgcttg	1260
gcttgtgtcc	atgcttaaac	ccacggaagg	gggagactct	ttcggatttg	tagggtgaaa	1320
tggcaattat	tctctccatg	ctggggagga	ggggaggagg	gtctcagaca	gctttcgtgc	1380
tcatgggtgg	ttggctttga	ctctccaaag	agcaataaat	gccacttgga	gctgtatctg	1440
gccccaaagt	ttagggattg	aaaacatgct	tctttgagga	ggaaaccctt	ttaggttcag	1500
aagaatatgg	ggtgctttgc	tcccttggac	acagctggct	tatcctatac	agttgtcaat	1560
gcacacagaa	tacaacctca	tgctccctgc	agcaagacct	ctgaaagtga	ttcatgcttc	1620
tggctggcat	tctgcatgtt	tagtgattgt	cttgggaatg	tttactgct	acccgcattc	1680
agcgactgca	gcaccagaaa	acgactaatg	taactatgca	gagttgtttg	gacttcttcc	1740
tgtgccagggt	ccaagtcggg	ggacctgaag	aatcaatctg	tgtgagtctg	tttttcaaaa	1800
tgaaataaaa	cacactattc	tctggc				1826

<210> 71
 <211> 879
 <212> DNA
 <213> Homo sapien

<400> 71	
ctgttcatca	ccagggtgcct gaatccctac cagaaactcc tattggtggt acctatccag 60
gacacggatt	tctcttgctc ctttcctttc tctgtccttt ctctccctga atctgagctg 120
ctttctggaa	gtggtcagca gcaccctccc tttgccagaa gtgcaaagtt tggccaacac 180
tccccctagt	ggcaatttaa cagactcctg aactgaccaa cccaaaagcc aaggacgagc 240
actgatgcca	cgtggtggtta gctggggcac ttgttaatta aagacatata actgggacct 300
acctcaggag	tgtggcccag aaatagggtat tcttttttaa caagcatctc aagcatgggt 360
ttttgtccca	tttgtaccct tcctttgtca tttttatgga atacatagtg attgggattc 420
agttttttat	agaaacttga ttccaatttt tagtactgaa tgtgaaaaaa aacattcaag 480

70

cttcaa atcg attggcctag agcatgtatt tcttatat ttt tagagaagag gcaataggat 540
 aagagagaag ctcttgtaaa ctaaataatac atttctaaaa agaatagaga ccagaggcgt 600
 ttgttataat gtcctccagt gaacacttgt gaaaagacta gctgctactt tattctacct 660
 gcagctatgt cagtgtataa attacaacca agcacgttat accttggcac tgttgctttc 720
 ttattctcca tgtctatttc taaacatccc ctatacgtga aatttgttct ccagtggcca 780
 gcgagccagc ctctttggag cagcctgctg atttaataca catgctgctt atcatgtttt 840
 ccagatgggt aatgcatctc ttaaataaaa ctggcccag 879

<210> 72
 <211> 2734
 <212> DNA
 <213> Homo sapien

<400> 72
 ggagggggca agggagaagc tgctggtcgg actcacaatg aaaacgctcc ttcttttgct 60
 gctggtgctc ctggagctgg gagaggccca aggatccctt cacagggtgc ccctcaggag 120
 gcatccgtcc ctcaagaaga agctgcgggc acggagccag ctctctgagt tctggaaatc 180
 ccataatttg gacatgatcc agttcaccga gtcctgctca atggaccaga gtgccaagga 240
 accctcatc aactacttgg atatggaata cttcggcact atctccattg gctccccacc 300
 acagaaactt actgtcatct tcgacactgg ctctccaac ctctgggtcc cctctgtgta 360
 ctgcactagc ccagcctgca agacgcacag caggttccag ccttcccagt ccagcacata 420
 cagccagcca ggtcaatctt tctccattca gtatggaacc gggagcttgt ccgggatcat 480
 tggagccgac caagtctctg tggaaggact aaccgtgggt ggccagcagt ttggagaaag 540
 tgtcacagag ccaggccaga cctttgtgga tgcagagttt gatggaattc tgggcctggg 600
 atacccttcc ttggctgtgg gaggagtgc tccagtat ttt gacaacatga tggctcagaa 660
 cctggtggac ttgccgatgt tttctgtcta catgagcagt aaccagaag gtggtgccgg 720
 gagcgagctg attttcggag gctacgacca ctcccatttc tctgggagcc tgaattgggt 780
 ccagtcacc aagcaagctt actggcagat tgcactggat aatatgctgt ggagtgtgcc 840
 aacctaacg tcatgccgga tgtcaccttc accattaacg gagtccccta taccctcagc 900
 ccaactgcct acaccctact ggacttcgtg gatggaatgc agttctgcag cagtggcttt 960
 caaggacttg acatccaccc tccagctggg cccctctgga tcctggggga tgtcttcatt 1020
 cgacagtttt actcagtctt tgaccgtggg aataaccgtg tgggactggc ccagcagtc 1080
 ccctaaggag gggccttgtg tctgtgcctg cctgtctgac agaccttgaa tatgttaggc 1140
 tggggcattc ttacaccta caaaaagtta ttttccagag aatgtagctg tttccagggt 1200

71

```

tgcaacttga  attaagacca  aacagaacat  gagaatacac  acacacacac  acatatacac  1260
acacacacac  ttcacacata  cacaccactc  ccaccaccgt  catgatggag  gaattacggt  1320
atacattcat  attttgtatt  gatttttgat  tatgaaaatc  aaaaattttc  acatttgatt  1380
atgaaaatct  ccaaacatat  gcacaagcag  agatcatggg  ataataaatc  cctttgcaac  1440
tccactcagc  cctgacaacc  catccacaca  cggccaggcc  tgtttatcta  cactgctgcc  1500
cactcctctc  tccagctcca  catgctgtac  ctggatcatt  ctgaagcaaa  ttccgagcat  1560
tacatcattt  tgtccataaa  tatttctaac  atccttaaata  atacaatcgg  aattcaagca  1620
tctcccattg  tcccacaaat  gtttggctgt  ttttgtagtt  ggattgtttg  tattaggatt  1680
caagcaaggc  ccatatattg  catttatatt  aaatgtctgt  aagtctcttt  ccatctacag  1740
agtttagcac  atttgaacgt  tgctgggtga  aatcccaggg  tgtcatttga  catggttctc  1800
tgaacttata  tttcctataa  aatggtagtt  agatctggag  gtctgatttt  gtggcaaaaa  1860
tacttcctag  gtggtgctgg  gtacttcttg  ttgcatcctg  tcaggaggca  gataatgctg  1920
gtgcctctct  attggtaatg  ttaagactgc  tgggtgggtt  tggagttctt  ggctttaata  1980
attcattaca  aagttcagca  ttttacctga  tcgtttcagt  ggtcattgat  gatcattgct  2040
gagatccaca  ctataattag  gggcggcaga  acagggtgtt  ttctaattct  gctatccctt  2100
tggcatttgt  tagttggaat  tcttctataa  aaaacatagg  ccgggtacag  tggctcacgc  2160
ctgtaatcct  agcactttcg  gaggccaaag  caggcagatc  acgagggtca  gagatggaga  2220
ctatcctggc  caacatgggt  aaacccttc  tctactaaaa  gtacaaaaat  tagccaggca  2280
tgggtggcaca  cccctgtagt  cccagctacc  caggaagctg  aggaggaga  atcgcatgaa  2340
cccaggagac  agaggctgca  gtgagccaag  atcacgccac  tgcactccag  actggcaaca  2400
gagcgagact  ccttctcaaa  ataaaaacaa  aaataataat  ctttggctgg  gccacgatgg  2460
ctcacgtctg  tcccagcact  ctgggaaccc  aaggaaggag  gattgcttga  cccagggtg  2520
tcaaagttgc  agtgatctat  gaccttgcca  ctgtactcca  atctgggtga  tagagcaaga  2580
ccttgtcttg  aaaacaagat  aaaacaagat  aaaacctttc  cctcatcaac  catttgccca  2640
ggaaagaaga  caattacttg  gggttttgtt  tcctttgttt  accagttttc  agaattgagt  2700
ggtactatat  taaacaccaa  agaattttta  acat  2734

```

<210> 73
<211> 3012
<212> DNA
<213> Homo sapien

<400> 73
atttacaaaa tatataagta tttttaagga tgttgacacc taataattac atgctaaacg 60

caaacgatta atgtaatctt ttaaaccggg cgtttgaaaa aaaattttca aggtcatttc	120
atgataacca atcatgaatg gatttaaagt gagctttttg tgcacaacca gcaatgtttg	180
tgctttctaa gagtcactga cttgagagga aagaaaacca gaaggttaat gcagtttgga	240
tattaaattc ttagcaaaat taataattaa agcaaaatta attaagattt tgtaagtcac	300
cctgtcttca catactcaga tcttccaata gtggcttatt ttgcaagatg ccacaatatc	360
tacacagaaa attgtggcta tttcattatt gctatagatt tcaaatacaa cacaaatatt	420
taagggtgtt taagttatat ttttcttgat agagggtatg ctttgtgaca aaattagatt	480
tttgtccttg aaaggattaa tattagcatc agttatgtat agctctattt ttctagaaac	540
aaggtattct gactactttt atagctgact acttttggga tggctacgtt ttgggattta	600
aaatagttca ttgtttaatg ggttgtaaga ggaaaaagtg ttaggatttg acagttactt	660
tttaaaggga tgatcttttg tgggtgtgtg ttttcctagt ataagcctat tgctggcgat	720
gggcctattt aagaacagct gattttttcc agtgaaaata tggtaatttt aggaacacag	780
tttgtaagtt cacatttact ataatgggcc aaaaccataa cctgccagtt tgcaatacat	840
cttgatcttt taatattctt atctgatatt gtgtaattca attcctaaac tgatagttac	900
cttgaatttt gcgaaaagggt ttgggtgggt ttttttaaac atgaaattga gggatctcat	960
ctgggcgaac aagaagagaa agctgtgaat tgtactgtat catgtacatt cctgatttaa	1020
tactttacag aacattttat tcagatatca atttgttaca taaacatttc agcaatgata	1080
caaagataac tgataaaaata tattacattc aatgagggtt tctttacaaa tgctctactt	1140
gaggtctgtg tcttaaagat ggcattgacac ctaagtacaa gacatcaact gaatgaggat	1200
tttaaaaaat ggtatataag cataggacaa gggctatgtt tgtttgtttt tcaaaagtgc	1260
tttgaagata acagccttta ggtttgagtt atttcacttt tcataatttt taagtagctt	1320
atatataatg gtggtaccat aggattttct tttttcaaat gactgtcggc agaaacagtg	1380
ggcactgact caccttttga gtttttagcag agaattattt atttctttac aatgcacttt	1440
ctaaccatt gtagctatat tagcattatc ttttaaaaaa gacatgcttt tgtatttaaa	1500
tattgtagga ttttaagtgc tttctcaaaa tagcttattc ctttctgaaa gaaaatgagg	1560
gaaatactct gaattattag gagacttaaa cccaatattt aaatatgcta ttttataaca	1620
ctgcatcagt tttaggagtt gcatctctcc tgctggctct tttatatattg agcaagatca	1680
gtgtagaata tgtgtttaga aacttgtctg ttgtctcagt ttagtgaaaa ggagggtgctg	1740
catgtgcctg aattaaaacc aagaaatttt tccaagccaa atgcagcctt agtgatgaga	1800
gatttaattc tccattgtca ccttttagct tttatgattg cttagttttt tctgaaggat	1860
gtctgcattg taaaactatg gactaaaacc taaaaaacag aatcctcaaa aactttgctg	1920

```

tatgtgtttt aacatttttag agaacagtat gttgaataac taaggatatgt aacttgaata 1980
ggaaaaatgt ccatcaaattg caccttggaa aatcacagta ggtagaaggc tgtgttaacc 2040
gtttgtgtct tattaacatc cttaagttaa ttttgaattt ttgacagttt tgagggaaaa 2100
gacctatgga acctaattgtg aagtatttcg tatgttaact ggtgttgagt tgaagatttt 2160
tactgtgtat aagcagatat catttgaatg ataaaaatgt cattaacctg ctgtcttaag 2220
atgttcacac aaatatggag agtaattcta caatataaaa atatttatatt taatactgag 2280
tttcagttaa gtcataaaca gtgttaaaac tcttgggaag gtgtaggggt tttttgtttg 2340
tcatttttaa aattgaaact gtgtcataca gtgtttcacg tctctgaaat tgggattata 2400
atagcactat tttgatgtag ctctaccgat actatgtggt aatgctattt tgttttacta 2460
acaagctctg gaatatattag cagtcatttt cactggcaca agagcctttt gtatgttatt 2520
caatttaaac ttttaaacca aaaattttat ggtccagtgt ctttggcaaa aagatgctgg 2580
agggaatgta acatacaatt aatatgtggt tatatatata tataaaaaga cacaaattgc 2640
catgttatgg ttctgccttg aaacagcaca atgaagtgta tcagtatatt ctgtgattat 2700
gaaacttata tgttgtgttg ttttgtgtct tctgttgctt gtcctttggg ccagatgtgg 2760
cccagttaaa tgcagttatc atctcattaa atacagatgc agataaaata tcttttagtgc 2820
tgcaacattt tacctaactt tttgtatgtt ttcattgactg tgtgttattt tccaaagctg 2880
ttcctacctc accatgaggc tttatggatt gttatgtatt ataatgttc tatatgagac 2940
agactactgt gtttcttctc atttattaaa agttaagtag aaaaataaac taattttaat 3000
atctaaaaaa aa 3012

```

```

<210> 74
<211> 2969
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (24)..(24)
<223> n=a, c, g or t

```

```

<400> 74
ccagtctggt ccgccccggg gtanggcata tagtcggacc cacgccctcg cccatgcgtc 60
aggagagaaat ttcaatgtca tttcatgata accaatcatg aatggattta aatggagctt 120
tttgagcaca accagcaatg tttgtgcttt ctaagagtca ctgacttgag aggaaagaaa 180
accagaaggt taatgcagtt tggatattaa attcttagca aaattaataa ttaaagcaaa 240
attaattaag attttgtaag tcattctgtc ttcacatact cagatcttcc aatagtggct 300

```

tattttgcaa gatgccacaa tatctacaca gaaaattgtg gctatttcat tattgctata	360
gatttcaaat ccaacacaaa tatttaaggg tgtttaagtt atatTTTTct tgatagaggg	420
tatgctttgt gacaaaatta gatttttgtc cttgaaagga ttaatatag catcagttat	480
gtatagctct atTTTTctag aaacaaggta ttctgactac ttttatagct gactactttt	540
gggatggcta cgttttggga tttaaaatag ttcatgttt aatgggtgt aagaggaaaa	600
agtgttagga ttgacagtt actttttaaa gggatgatct tttgtggtgt gtgtttttcc	660
tagtataagc ctattgctgg cgatgggcct atttaagaac agctgatttt ttccagtga	720
aatatggtaa ttttaggaac acagtttgta agttcacatt tactataatg ggccaaaacc	780
ataacctgcc agtttgcaat acatcttgat cttttaatat tcttatctga tattgtgtaa	840
ttcaattcct aaactgatag ttaccttgaa ttttgcgaaa aggtttgggt ggtttttttt	900
aaacatgaaa ttgagggatc tcatctgggc gaacaagaag agaaagctgt gaattgtact	960
gtatcatgta cattcctgat ttaatacttt acagaacatt ttattcagat atcaatttgt	1020
tacataaaca tttcagcaat gatacaaaga taactgataa aatatattac attcaatgag	1080
gttttcttta caaatgctct acttgaggtc tgtgtcttaa agatggcatg acacctaagt	1140
acaagacatc aactgaatga ggattttaaa aatgggtata taagcatagg acaagggcta	1200
tgtttgtttg tttttcaaaa gtgctttgaa gataacagcc tttaggtttg agttatttca	1260
cttttcataa tttttaagta gcttatatat aatgggtggt ccataggatt ttcttttttc	1320
aaatgactgt cggcagaaac agtgggcact gactcacctt ttgagtttta gcagagaatt	1380
atttatttct ttacaatgca ctttctaacc cattgtagct atattagcat tatcttttaa	1440
aaaagacatg cttttgtatt taaatatgtt aggatttaag tgtctttctc aaaatagctt	1500
attcctttct gaaagaaaat gagggaaata ctctgaatta ttaggagact taaaccaat	1560
atttaaatat gctattttat aacactgcat cagttttagg agttgcatct ctctgctgg	1620
ctcttttata tttgagcaag atcagtgtag aatatgtgtt tagaaacttg tctgttgtct	1680
cagt ttagtg aaaaggaggt gctgcatgtg cctgaattaa aaccaagaaa tttttccaag	1740
ccaaatgcag ccttagtgat gagagattta attctccatt gtcacctttt agcttttatg	1800
attgcttagt tttttctgaa ggatgtctgc attgtaaaac tatggactaa aacctaaaaa	1860
acagaatcct caaaaacttt gctgtatgtg ttttaacatt ttagagaaca gtatgttgaa	1920
taactaaggt atgtaacttg aataggaaaa atgtccatca aatgcacctt ggaaaatcac	1980
agtaggtaga aggctgtgtt aaccgtttgt gtcttattaa catccttaag ttaattttga	2040
attt ttgaca gttttgaggg aaaagaccta tggaacctaa tgtgaagtat ttcgatatgt	2100

75

```

aactggtggt gagttgaaga tttttactgt gtataagcag atatcatttg aatgataaaa 2160
atgtcattaa cctgctgtct taagatgttc acacaaatat ggagagtaat tctacaatat 2220
aaaaatatat attttaatac tgagtttcag ttaagtcata aacagtgtta aaactcttgg 2280
gaagggtgtag ggggttttttg tttgtcattt ttaaaattga aactgtgtca tacagtgttt 2340
cacgtctctg aaattgggat tataatagca ctattttgat gtagctctac cgatactatg 2400
tggtaatgct attttggttt actaacaagc tctggaatat ttagcagtca ttttcactgg 2460
cacaagagcc ttttgtatgt tattcaattt aaacttttaa accaaaaatt ttatgggtcca 2520
gtgtcttttg caaaaagatg ctggagggaa tgtaacatac aattaatatg tggttatata 2580
tatatataaa aagacacaaa ttgccatggt atggttctgc cttgaaacag cacaatgaag 2640
tgtatcagta tattctgtga ttatgaaact tatatgttgt gttgttttgt gtcttctggt 2700
gcctgtcctt tgggccagat gtgggccagt taaatgcagt tatcatctca ttaaatacag 2760
atgcagataa aatatcttta gtgctgcaac attttaccta actttttgta tgttttcatg 2820
actgtgtggt attttccaaa gctgttccta cctcaccatg aggctttatg gattgttatg 2880
tattataaat gttctatatg agacagacta ctgtgtttct tctcatttat taaaagttaa 2940
gtagaaaaat aaactaattt taatatcta 2969

```

```

<210> 75
<211> 1608
<212> DNA
<213> Homo sapien

```

```

<400> 75
gtggccgccc cctctctagc tcctcagcca tccgctcctc agtccagccg ccgcagagga 60
gaccagcaag cagagccctc agatgctcgg agctttctcg gcgcgaagct gcccgtcgcc 120
ctctcctgcc gccctcgccc gccgcccctc tgctcctgct ccggctgcgg ctcttggtac 180
cccggctccg ggagcccagc tccccgccac cgccgccgcc tgggtgtggg ggctgctgag 240
gctgagccgg gcctcggcgc cggctctgag gacggacgcc tgaggagctg cgcggcgcgg 300
cgccgcgggc tggcggagaa cgcccacagg cgcggggctc ggccggcttg cccgggcttg 360
tccccgtgcg gccgcggggg cccctcagcg gtttcccgaa cggcccgaact cgggcgctcc 420
tccgtgtcgc ggtcgccgac cctccgcgtc ccgccaacgc cgcgctgca ccagtctccg 480
ggccgggctc ggccggcccc gcagccgcag ccatgggggtg ttggggtcgg aaccggggcc 540
ggctgctgtg catgctggcg ctgaccttca tgttcattgt gctggagggt gtggtgagcc 600
gggtgacctc gtcgctggcg atgctctccg actccttcca catgctgtcg gacgtgctgg 660
cgctggtggt ggcgctgggt gccgagcgtc tcgcccggcg gaccacgcc acccagaaga 720

```

76

acacgttcgg ctggatccga gccgaggtaa tgggggctct ggtgaacgcc atcttcctga 780
 ctggcctctg ttctgccatc ctgctggagg ccatcgagcg cttcatcgag ccgcacgaga 840
 tgcagcagcc gctgggtggc cttggggctg gcgtggccgg gctgctggtc aacgtgctgg 900
 ggctctgcct ctccaccat cacagcggct tcagccagga ctccggccac ggccactcgc 960
 acgggggtca cggccacggc cacggcctcc ccaaggggcc tcgcgttaag agcaccgcc 1020
 ccgggagcag cgacatcaac gtggccccgg gcgagcaggg tcccgaccag gaggagacca 1080
 acaccctggg ggccaatacc agcaactcca acgggctgaa attggacccc gcaggtgagc 1140
 cgggaaagtc gctgccgcag gtggttgggt ttggggtgcc cagagcctcg cctggccttc 1200
 ggcgggggtg cccgcacgcc cctgctgcc cgagcgggcc tgcgcgcgc cgcctctgcc 1260
 tgctccctcc ccgtcctgca cacgccccgc tgctgctcca ggaaatcaga acccctcag 1320
 tcgggtgcaa ggagccggcg acgcgtctgg catatttgta ggtgggggct gtgggtcaga 1380
 ccctaagaaa aagggtcagg aggtgatcat catcccgctg cagtccacac ccgcacttgg 1440
 ctgtctttac aggctgcagc aactttgctg gagacttgtc tggttatggt tataacagcg 1500
 tcagaaatgc ttcccaattc aattccttgg ccctcttggg aaacggagag aatccccaat 1560
 tcgtccccag tagttgggtg ctggaaacct tgctctgcca aagtagtt 1608

<210> 76
 <211> 535
 <212> DNA
 <213> Homo sapien

<400> 76
 agcaactgca ttaaaagatg ttgtcaaagt tgggtgcagtt gatgcagata agcatcattc 60
 cctaggaggt cagtatgggtg ttcagggatt tcctaccatt aagatttttg gatccaacaa 120
 aaacagacca gaagattacc aagggtggcag aactggtgaa gccattttag atgctgcgct 180
 gagtgctctg cgccagctcg tgaaggatcg cctcggggga cgaagcgaag gatgttctgg 240
 acagtgaaga tgtttggatg gttgagttct atgctccttg gtgtggacac tgcaaaaacc 300
 tagagccaga gtgggctgcc gcagcttcag aagtaaaaga gcagacgaaa ggaagagtga 360
 aactggcagc tgtggatgct acagtcaatc aggttctggc ctcccgatac gggattagag 420
 gatttcctac aatcaagata ttccagaaag gcgagctctc tgtggattat gacggtgggc 480
 ggacaagatc cgacatcgtg tcccgggccc ttgattgggt ttctgataac gcccc 535

<210> 77
 <211> 527
 <212> DNA
 <213> Homo sapien

77

<400> 77
 ccgaacttcc cccatggcca ccacctcccc cttccctctc cccagaccgc ctgggggtggg 60
 ccgctgggag gaagcccatc tctgacgtgg accccgcata caggaggctc tgggcctgtc 120
 agatagggtc acccgaatca agggatgatg taaaagctgt cctccaaat taggccagag 180
 cccccggagc cccgctgatt acagcctgtg caccgaggac aaagggtccc tctaggggtca 240
 ttaatatgga ttgaggccca ttgttttctc aaattaggcc acagggagcg cttcttgggg 300
 aagcacatag cgggtgaggg ttcttcgaga atgttctgga gaaatacaag gatccctctg 360
 agtacctgct gggactgagt gagcattctt aacttacaca gaggggtctt ctgtctgcaa 420
 agcgttatag attctcaatg cctttcaacc tccagcacct tgggaattcc actccaatac 480
 ttaggtgtgg gacagtgagg ctccgaaagg tccaaaggct gtctcgc 527

<210> 78
 <211> 658
 <212> DNA
 <213> Homo sapien

<400> 78
 ccgaacttcc cccatggcca ccacctcccc cttccctctc cccagccgc tgggggtgggc 60
 cgctgggagg aagcccatct ctgacgtgga ccccgcatc aggggggtcgt gggcctgtca 120
 gattgggtca cccgaatcaa gggatgatg aaaacctgtc cctccaaatt aggccagagc 180
 cccacggagc cccgctgatt acagcctgtg caccgaggac aaagggtccc tctaggggtca 240
 ttaatatgga ttgaggccca ttgttttctc aaattaggcc acagggagcg cttcttgggg 300
 aagcacatag cgggtgaggg ttcttcgaga atgttctgga gaaataaaag gatccctctg 360
 agtacctgct gggactgagt gagcattctt aacttacaca gaggggtctt ctgtctgcaa 420
 agcgttttag attctcaatg cctttcaacc tccagcacct tgggaattcc actccaattc 480
 ttagtgtggg aaagtgaggg tccgaaagg ccaaaggctg tctcgctggt tcgcaagcct 540
 gaatgcaggt gccctcctt cagctcgtga catgccaatc accgtgggga ctactgacc 600
 gcgtcaagaa caggatggcc agatacatcg atgcacacgt cacgtgacga cagcatgg 658

<210> 79
 <211> 1885
 <212> DNA
 <213> Homo sapien

<400> 79
 aggcggcagg aaggtgggggt ctctccagcc agggcttcct gaaagagctg cttcttgagc 60
 agggccccca ggctaggaag atgtgcacct gccgagctgg gcaggagagg gtggcccagt 120
 ggaggaccca gcatgggcag aggtttggag gtggcaggtc ctgagggaag cggaaggcag 180

78

```

ccaggttgtg acagcctgtg aggacctctt ggctcccgga gccttctctc tcctggaata 240
gagatgacac cgtgctgcca ttgaactcaa cccgaaaaaa tgatctgttg caaagctcac 300
aggaaataat ggagcaatgt tacacgataa actgtaaagt gtggtgagca tgtgaacaag 360
cgtccaggac ccagcgaagc cccaggcta c tgggctaggc gtcagatgag aagaggcaga 420
gggcaacctc ctgtaggac t gaggacct c atgtgctcag cccatggctg tcgtcacggc 480
gacgtgtgca tgcgatgtat ctgggcca c cttgttcttg aacgcgggca gtgagtccca 540
cggatgatgtg gcatgtcacg agctgaagga ggggcacctg cattcaggct tgcgaaccag 600
cgagacagcc tttggacctt tcggagcct c actttccac actaagaatt ggagtggaat 660
tccaagggtg ctggagggtg aaaggcatt g agaatctaaa acgctttgca gacagcaaga 720
ccctctgtgt aagttaagaa tgctcactca gtcccagcag gtactcagag ggatcctttt 780
atttctccag aacattctgc aggtgagct g gggagacca ctggccctgg cctcaccccc 840
gagcccagac cttcagcctg ggaatggct c ggctcttcc ttgctggctc tccagcctgg 900
cctcgcagga ccctgggcgg gaccccagga accctcacc gctatgtgct tccccagaa 960
gcgctccctg tggcctaatt tgagaaaaca atgggcctca atccatatta atgaccctag 1020
agggaccctt tgcctcggc gcacaggct g taatcagcgg ggctccgggg gctctggcct 1080
aatttggagg gacagggttt atcatcacc c ttgattcggg tgacccaatc tgacaggccc 1140
acgacccct gtatgcgggg tccacgtcag agatgggctt cctcccagcg gccacccca 1200
gcgggctggg gagagggag ggggaggtg tggccatggg ggaagttcgg ggtgaagaag 1260
gggtcacagc cagaccccca ctgggatggg cctgtgatcg ggttctcggg aggagcagga 1320
tattgattag atcagtgaat ggtgtggagg cagctctccc caggcacgtg ctcccagca 1380
cccaccagca agcgtctgtt gcctgcgggt gccagggctg ggtggggact ctgggacagg 1440
ccggctgcct' aggagggggc aggcaggag c caaggggctg gctccaggga ctgccaggag 1500
ggccccaggg aaggggagcc gggagcgt t ttggctgcct ccggcgtgaa gtcgtggaaa 1560
cgtgtttgca ggttagggcc gtggcatcct cgttgacca tttagagcgc tatgggggtgc 1620
cagatacatg acaaagggcc acctcattta atgcttccct caaccttccc agggcccgat 1680
cccatgttc tgggtcagga ggccattc g aggtcaagg gtgggcgaag gctgacgaga 1740
caaaccaggg gactagctcc tgagtccca aacctgtcct caccaccca ggggtcccct 1800
gcacgctctc cagggtgtgc ggtgcgtgg c tgctgggttt ggggtgatta gagcctgagg 1860
caagggcttg agtctgaatt ctgcg 1885

```

<210> 80

<211> 1759

<212> DNA

<213> Homo sapien

<400> 80

aggcggcagg aaggtggggt ctctccagcc agggcttcct gaaagagctg ccttctgagc	60
aggcccccca ggctaggaag atgtgcacct gccgagctgg gcaggagagg gtggcccagt	120
ggaggaccca gcatgggcag aggttttgag gtggcaggtc ctgagggaag cggaaggcag	180
ccaggttgtg acagcctgtg aggacctctt ggctcccgga gccttctctc tcctggaata	240
gagatgacac cgtgctgcca ttgaactcaa cccgaaaaaa tgatctgttg caaagctcac	300
aggaaataat ggagcaatgt tacacgataa actgtaaagt gtggtgagca tgtgaacaag	360
cgtccaggac ccagcgaagc cccaggctac tgggctaggc gtcagatgag aagaggcaga	420
gggcaacctc ctgtaggata tgaggccttc atgtgctcag cccatggctg tcgtcacggt	480
gacgtgtgca tgcgatgtat ctggggccatc cttgttcttg aacgcgggca gtgagtcca	540
cggatgatgtg gcatgtcacg agctgaagga ggggcacctg cattcaggct tgcgaaccag	600
cgagacagcc tttggacctt tcggagcctc actttccac actaagaatt ggagtggaat	660
tccaagggtg ctggagggtg aaaggcattg agaatctaaa acgctttgca gacagcaaga	720
ccctctgtgt aagttaagaa tgctcactca gtcccagcag gtactcagag ggatcctttt	780
atttctccag aacattctgc aggaacctc acccgctatg tgcttccca agaagcgctc	840
cctgtggcct aatttgagaa aacaatgggc ctcaatccat attaataacc ctagagggac	900
cctttgtcct cgggtgcacag gctgtaatca gcggggctcc gggggctctg gcctaatttg	960
gagggacagg ttttatcatc acccttgatt cgggtgacct aatctgacag gccacgacc	1020
ccctgtatgc ggggtccacg tcagagatgg gcttctccc agcggcccac cccagcgggc	1080
tggggagagg gaagggggag gtgggtggcca tgggggaagt tcggggtgaa gaaggggtca	1140
cagccagacc ccacttgga tgggcctgtg atcgggttct cgggaggagc aggatattga	1200
ttagatcagt gaatggtgtg gaggcagctc tcccaggca cgtgctccc accaccacc	1260
agcaagcgtc tgttgctgc cgggtgccagg gctgggtggg gactctggga caggccggct	1320
gcctaggagg ggccaggcag gagccaaggg gctgggtcca gggactgcca ggaggggccc	1380
agggaagggg agccgggaag cgttttggt gcctccggcg tgaagtcgtg gaaacgtgtt	1440
tgcagggttag ggccgtggca tcctcgttgc accatttgag cgcctatggg gtgccagata	1500
catgacaaag ggccacctca tttaatgctt ccctcaacct tcccaggccc cgatccccat	1560
gttctgggtc aggaggcca ttcgagggtc aggggtgggc gaaggctgac gagacaaacc	1620
cagggactag ctctgagtc ccaaaacctg tcctcacca cccaggggtc ccctgcacgc	1680
tctccagggt gtgcggtgcg tggctgctgg gtttgggtgc attagagcct gaggcaaggg	1740

cttgagtctg aattctcgc

1759

<210> 81
 <211> 604
 <212> DNA
 <213> Homo sapien

 <220>
 <221> misc_feature
 <222> (581)..(581)
 <223> n=a, c, g or t

<400> 81
 aacttttttct tttttccttt ttctttcctc tgttctcttg caccatgaac ctcaagcagt 60
 cctgcagtga cagcagattg ggtctagca agagcttaaa actctgattt tagggaacca 120
 ttctcagatc agtggagctg tggttacaag aggggtggaat gagtctcaat tgcttttttt 180
 ctctctcctt catctgcttg cttccaaaca aaggcactat tatggaaatt gtatggctga 240
 gcagagtaaa taacatacca gctttctgac taggtaatga gaaaggggaa tccattgac 300
 ctagaaagta ctgggagatt ataagatatt tgaaaataaa ctcttttaaat ttattatga 360
 atttttgagc ttattcatgc agtctgcatg cagaaatctg accccaaaca gtatacctag 420
 actttgagaa atgaagtagg ggtagacca ttgccaaagtc ccagactggc aacaggggtgg 480
 gtggtgcac tgtgggacag atccaaaaag cactgcaaag actttgaaaa cttaactgac 540
 attggagttc tggctgggga acagtgcaag gatgtcctct ntggcaattt ctattggtat 600
 tgaa 604

<210> 82
 <211> 598
 <212> DNA
 <213> Homo sapien

<400> 82
 acttttttctt ttttcctttt tctttcctct gttctcttgc accatgaacc tcaagcagtc 60
 ctgcagtgac agcagattgg ggtctagcaa gagcttaaaa ctctgatttt agggaaccat 120
 tctcagatca gtggagctgt ggttacaaga ggggtggaatg agtctcaatt gctttttttc 180
 tctctccttc atctgcttgc ttccaaacaa aggcactatt atggaaattg tatggctgag 240
 cagagtaaat aacataccag ctttctgact aggtaatgag aaagggggaat ccattgacc 300
 tagaaagtac tgggagatta taagatatat gaaaataaac tcttttaaatt ttattatgaa 360
 tttttgagct tattcatgca gtctgcatgc agaaatctga ccccaaacag tatacctaga 420
 ctttgagaaa tgaagtaggg gtagaccat tgccaagtcc cagactggca acaggggtggg 480

81

tggtgcatct gtgggacaga tccaaaaagc actgcaaaga ctttgaaaac ttaactgaca 540
 ttggagttct ggctggggaa cagtgcaagg atgtcctctc tggcaatttc tattggta 598

<210> 83
 <211> 351
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (274)..(274)
 <223> n=a, c, g or t

<400> 83
 cgcgcgaccc ggcggcggga caggcttgct gcttcctcct cctcggcctc accgtttttg 60
 ccaatccaga agactgtgta gcatttggca aaggagaaaa tgccaagaag tatcttcgaa 120
 cagatgacag agtagaacgt gtacgcagtt cattgtaaag ctgttacgat tagtcatatt 180
 tgaacggcag agccagaatg gggctacaaa tgaagtgaaa agtatgcttt accgtgtgca 240
 acaattgtga aagttaatac atacacatat gganacaatt aactaaagac ttaagagccc 300
 acctgaatga cctgaaaata ttattccatt tctgggaatt ggcctcctgt a 351

<210> 84
 <211> 1536
 <212> DNA
 <213> Homo sapien

<400> 84
 ctgatgtcta tttaggaaga aacaaactgg tgtatatattg cttgtttcta cattttctag 60
 gcactgcttt gttatctgtg gtggcttttc ccttggaaga tttctatctg ggcacttacc 120
 atgcagttaa caacatacca aaaacagagc agcacaggct gttttatgta gcactgctga 180
 ccatttgcct tggcattgga ggcgtaagag ccacgctctg tccactgggt gcttttggcc 240
 ttcaggagta tggatcacia aaaacgatgt ctttttttaa ctgattcctt caggatatta 300
 tctgcaaact atgaattcca acctgaattt ggatggattt cttctgccga ttgcagtaat 360
 gaatgccatc agcagcctac cattactaat tctggctcct tttctggagt atttcagcac 420
 ctgcctgttt ccctctaaga gagttggatc atttctgtca acatgcatca ttgctggaaa 480
 tctttttgct gcattgtctg tgatgatagc tggcttcttt gaaatacacc gaaaacattt 540
 ccctgcagtg gagcagcccc tttcaggaaa agttctcact gtttcctcca tgccctgttt 600
 ctacctgatt cttcagtatg ttttacttgg agtggcggaa acactggtaa acccagcccg 660
 aggggacatc gtgacaaagc aaattgtctg gtatcatgaa tttggaacac cattccagac 720
 caaaattgaa aaaatgggtg acctcaccca ggtaatggat gatgaagtat tcatggcttt 780

82

tgcatcctat gcaacaatta ttctttcaaa aatgatgctt atgagtactg caactgcatt 840
 ctatagattg acaagaaagg tttttgccaa tccagaagac tgtgtagcat ttggcaaagg 900
 agaaaatgcc aagaagtatc ttccgaacaga tgacagagta gaacgtgtac gcagtcattg 960
 taaagctgtt acgattagca tatttgaacg gcagagccag aatggggcta caaatgaagt 1020
 gaaaagtatg ctttaccgtg tgcaacaatt gtgaaagtta atacatacac atatggaaca 1080
 attaaactaaa gacttaagag cccacctgaa tgaccttgaa aatattatc catttcttgg 1140
 aatgggcctc ctgtattcct tgagtggctc cgacctctc acagccatcc tgcacttcag 1200
 actatttgtc ggagacacgg atctaccaca ccattgcata tttgacaacc cccttgccgc 1260
 agcaaataag agcttgagtt tttgttgat atgggagtta ctctttccat ggcttacagg 1320
 ttgctgaaag taacatgtcc tgtacaggaa ttatacactc agcatccagt ggtctaagaa 1380
 tcggattcat tatatgcata tctctggatt aggagggggg ccgagattga agggtaacct 1440
 gataagtgca cacgttccgt taatgttgag acaacattat gtgtaaacct taaggagtgt 1500
 aacccctga aaacgaaatc cgacgaaaaa atcgtc 1536

<210> 85
 <211> 1101
 <212> DNA
 <213> Homo sapien

<400> 85
 gggcgggtgcc tgcgtccggc ccgcgcgggc acagtccctg cattgcgcgc gaccgggcgg 60
 cgggacaggc ttgctgcttc ctctcctcg gcctcaccat tccagaccaa aattgaaaaa 120
 atgggttgacc tcacccaggc aatggatgat gaagtattca tggcttttgc atcctatgca 180
 acaattattc tttcaaaaat gatgcttatg agtactgcaa ctgcattcta tagattgaca 240
 agaaagggtt ttgccaatcc agaagactgt gtagcatttg gcaaaggaga aaatgccaag 300
 aagtatcttc gaacagatga cagagtagaa cgtgtacgca gtcattgtaa agctgttacg 360
 attagcatat ttgaacggca gagccagaat ggggctacaa atgaagtgaa aagtatgctt 420
 taccgtgtgc aacaattgtg aaagttaata catacacata tggaacaatt aactaaaaac 480
 ttaagagccc acctgaatga ccttgaaaat attattccat ttcttggaat tggcctcctg 540
 tatccttgga gtggtcccga cccctctaca gccatcctgc acttcagact atttgtcggg 600
 gcaaggatct accacaccat tgcataattg acacctctc ccagccaaa tagagctttg 660
 agtctttttg ttggatatgg agttactctt tccatggctt acaggttgct gaaaagtaaa 720
 ttgtacctgt aaagaaaatc atacaactca gcatccagtt ggctttttta gaattctgta 780
 cttccaattt ataatgaata ctttcttaga ttttaggtag gaggggagca gaggaattat 840

83

```

gaactggggt aaacccattt tgaatattag cattgccaat atcctgtatt cttgtttttac 900
atttggatta gaaatttaac atagtaattc ttaagtcttt tgtctgattt ttaaagtact 960
ttcttataaa tttggatcat gttatgattt gtaacattca cacaacacct cactttttgaa 1020
tctataaaag aattgcacgt atgagaaacc tatatttcaa tactgctgaa acagacatga 1080
aataaagaat ttaaagaatg a 1101

```

```

<210> 86
<211> 951
<212> DNA
<213> Homo sapien

```

```

<400> 86
gggcgggtgcc tgcgtccggc ccgcgcggcc acagtccctg cattgcgcgc gacccggcgg 60
cgggacaggc ttgctgcttc ctctcctcg gcctcaccat tccagaccaa aattgaaaaa 120
atggttgacc tcacccaggc aatggatgat gaagtattca tggcttttgc atcctatgca 180
acaattatcc tttcaaaaat gatgcttatg agtactgcaa ctgcattcta tagattgaca 240
agaaagggtt ttgccaatcc agaagactgt gtagcatttg gcaaaggaga aaatgccaag 300
aagtatcttc gaacagatga cagagtagaa cgtgtacgca gggcacagga gatcttaggc 360
ccagaaaggc agattcagaa gaacctacat gtaaatgaga ctggagtgga aatgagaatg 420
gcaggaaatg catggaaaca gacttgtaac tgtctcatgg cctggtcgtc caaatcccag 480
aggatggagt gcaatggcat gatctcagct caccgcaacc tctgcctccc ggattcaagt 540
gattctcctg cctcagcctc ttgagtagct gggattacag gtgctgcaga agtcaagagc 600
taaccaagaa gacaaggaat gtaacatatt tatcaaatac cacatcatct ctattataag 660
acagtgggtt ttaatactat cactgacaga tatttcgatt tttaacacca gcaaatatta 720
gtcagatcag cactttcttt agatcaggtc aatgtctgct gggcagaggt cccgtgtcga 780
attggtcccc atcaccggca aaacctccga gacaggggcc gggcatttta caaaacccca 840
tggccaagta tcaccgctca ggcacctcca aggtgggtgtg aaaacaaccc cccctcaat 900
attatacggt tacatgatga tactttactt aatataaatt aattatattg g 951

```

```

<210> 87
<211> 1803
<212> DNA
<213> Homo sapien

```

```

<400> 87
ttacagctgt gtagtattcc atggtgtata cgtaccacat tgtctttatc caattcatat 60
tgatggacac ctaggttgca ttagcccttt tttgattctc tgtgaaagtc tgaagcccct 120

```

84

```

ccaagattt ctgcagattc ccttatggca tatcatctcc aggttaactc tggatctggg 180
ttcctgcctc tatgcatggt tccatattct gcaattgggt atgctggatg ttaatccagc 240
cctttcatca gttcccttca aaaatgaact aaaaaaatg tggctaaaaa tagacttgag 300
taagtggaag tgcagaggcg ttacactgt ggcagcacia acattttaag ttgtatgtta 360
tttctctgtc agacaatggc cttcagcatc ctctctttgc agaataatgcc ccgtacctgt 420
acctccttca cgcaagcaat gccagtggt acaccatttt tgaggctctc ctctagcccc 480
acagactctt caaccttttc agcactaaaa ttaaaagtac cttcttgctc atgcaaaaca 540
attctacccc caagctattc atcaagcaag aatgtttctc ttctaagaag aagtctgtgc 600
agatacttag cacaaaattt caccttctat ctacttagt tatatacttc ttaattcagc 660
agccctgctg agtaaatacag tgagtcttga gaatgggttg tgtcaagaat atggatataa 720
aatagtttca ggacaaagaa tcactgtgga aatttcaaac agcagaacia tatcaaagga 780
aaaattatgt gttagacgaa aaaaaataaa aaaaagtgag tgaagcttaa gttttcaaaa 840
ccactgaaga gacatgaaaa cttttaaaagc cttgtctggg cctttatgca cttccccttt 900
tagagcaggc agccgcctgc atgatgctag tcatggcct gtatttataa aattgcccag 960
aactggaaag tgatcagaag caattagacc ctcatagta ttagtaagac tgaaatgaaa 1020
atccaagtaa gtctcctgtg tgaaagcgta acaaaagata ttttatttgg ggattttaga 1080
ttcctcccta ctattctttc cgacctcca cccttactcc ctgcccgtgg gattgtactt 1140
ttagaggaaa acgacgttat ctaaattgat ccgctagtca gggtgcaaat gaatgttaga 1200
aagaacaatt gaccccagtt ctgtaaaggt tccgagtcct ggaggagggt cagcgactgt 1260
gtgcacagcg cccctgggtg atgagacact ggcttttccg catactgaga gaagagcgtc 1320
tccaacagag cggagtttcc agttgtataa tgctttttga gacagtacct gtttcatcga 1380
aaaagtgcct aataacacac ttttggagac acttttcaga cagagcgttt ccagcatctt 1440
ccctttccac ttttaagtta agactttttt tttttcacct ctctcgttac ttcagtcatt 1500
gtaaagctgt tacgattagc atatttgaac ggcagagcca gaatgggggt acaaatgaag 1560
tgaaaagtat gctttaccgt gtgcaacaat tgtgaaagtt aatacataca catatggaac 1620
aattaactaa aaacttaagg taatatgtgt tgaaatacca agatatgtga cttaaagtca 1680
gttatttgag ttctggaaag acagaaacca gtgatgggtta gaaagcactt gacatattta 1740
tttatttatt taataccatc ttagcttgtc taggaagcat tcaagaccat atacattcaa 1800
cac 1803

```

<210> 88

<211> 898

85

<212> DNA

<213> Homo sapien

<400> 88

gggcgggtgcc	tgcgtccggc	ccgcgcggcc	acagtccctg	cattgcgcgc	gaccgcggcgg	60
cgggacaggc	ttgctgcttc	ctcctcctcg	gcctcaccat	tccagaccaa	aattgaaaaa	120
atggttgacc	tcacccaggc	aatggatgat	gaagtattca	tggcttttgc	atcctatgca	180
acaattattc	tttcaaaaat	gatgcttatg	agtactgcaa	ctgcattcta	tagattgaca	240
agaaagggtt	ttgccaatcc	agaagactgt	gtagcatttg	gcaaaggaga	aaatgccaa	300
aagtatcttc	gaacagatga	cagagtagaa	cgtgtacgca	gccttgagt	gtcccgaccc	360
ctctacagcc	atcctgcact	tcagactatt	tgtcggagca	cggatctacc	acaccattgc	420
atatttgaca	ccccttcccc	agccaaatag	agctttgagt	ttttttgttg	gatattggagt	480
tactctttcc	atggcttaca	ggttgctgaa	aagtaaattg	tacctgtaaa	gaaaatcata	540
caactcagca	tccagttggc	tttttaagaa	ttctgtactt	ccaatttata	atgaatactt	600
tcttagat	taggtaggag	gggagcagag	gaattatgaa	ctggggtaaa	cccattttga	660
atattagcat	tgccaatatc	ctgtattctt	gttttacatt	tggattagaa	atttaacata	720
gtaattctta	agtcttttgt	ctgattttta	aagtactttc	ttataaattt	ggatcatgtt	780
atgatttgta	acattcacac	aacacctcac	ttttgaatct	ataaaagaat	tgcacgtatg	840
agaaacctat	atttcaatac	tgctgaaaca	gacatgaaat	aaagaattta	aagaatga	898

<210> 89

<211> 862

<212> DNA

<213> Homo sapien

<400> 89

gggcgggtgcc	tgcgtccggc	ccgcgcggcc	acagtccctg	cattgcgcgc	gaccgcggcgg	60
cgggacaggc	ttgctgcttc	ctcctcctcg	gcctcaccat	tccagaccaa	aattgaaaaa	120
atggttgacc	tcacccaggc	aatggatgat	gaagtattca	tggcttttgc	atcctatgca	180
acaattattc	tttcaaaaat	gatgcttatg	agtactgcaa	ctgcattcta	tagattgaca	240
agaaagagcc	cacctgaatg	accttgaaaa	tattattcca	tttcttgga	ttggcctcct	300
gtattccttg	agtgggtccc	accctctac	agccatcctg	cacttcagac	tatttgtcgg	360
agcacggatc	taccacacca	ttgcatat	gacacccctt	ccccagccaa	atagagcttt	420
gagttttttt	gttggatatg	gagttactct	ttccatggct	tacaggttgc	tgaaaagtaa	480
attgtacctg	taaagaaaat	catacaactc	agcatccagt	tggcttttta	agaattctgt	540
acttccaatt	tataatgaat	actttcttag	atttttaggta	ggagggggagc	agaggaatta	600

86

tgaactgggg taaacccatt ttgaatatta gcattgccaa tatcctgtat tcttgtttta 660
 catttggatt agaaatttaa catagtaatt cttaagtctt ttgtctgatt tttaaagtac 720
 tttcttataa atttggatca tgttatgatt tgtaacattc acacaacacc tcacttttga 780
 atctataaaa gaattgcacg tatgagaaac ctatatattca atactgctga aacagacatg 840
 aaataaagaa tttaaagaat ga 862

<210> 90
 <211> 714
 <212> DNA
 <213> Homo sapien

<400> 90
 gggcggtgcc tgcgtccggc ccgcgcggcc acagtccctg cattgcgcgc gaccgcgcgc 60
 cgggacaggc ttgctgcttc ctctcctcg gcctcaccag cccacctgaa tgaccttgaa 120
 aatattattc catttcttgg aattggcctc ctgtattcct tgagtgggcc cgacctctct 180
 acagccatcc tgcacttcag actatttgtc ggagcacgga tctaccacac cattgcatat 240
 ttgacacccc ttccccagcc aaatagagct ttgagttttt ttgttgata tggagttact 300
 ctttccatgg cttacagggt gctgaaaagt aaattgtacc tgtaaagaaa atcatacaac 360
 tcagcatcca gttggctttt taagaattct gtacttccaa ttataaatga atactttctt 420
 agattttagg taggagggga gcagaggaat tatgaactgg ggtaaaccac ttttgaatat 480
 tagcattgcc aatatcctgt attcttggtt tacatttgga ttagaaattt aacatagtaa 540
 ttcttaagtc ttttgtctga tttttaaagt actttcttat aaatttggat catgttatga 600
 tttgtaacat tcacacaaca cctcactttt gaatctataa aagaattgca cgtatgagaa 660
 acctatattt caatactgct gaaacagaca tgaaataaag aatttaaaga atga 714

<210> 91
 <211> 809
 <212> DNA
 <213> Homo sapien

<400> 91
 gggcggtgcc tgcgtccggc ccgcgcggcc acagtccctg cattgcgcgc gaccgcgcgc 60
 cgggacaggc ttgctgcttc ctctcctcg gcctcaccgt ttttgccaat ccagaagact 120
 gtgtagcatt tggcaaagga gaaaatgcc aagaagtatct tcgaacagat gacagagtag 180
 aacgtgtacg cagagccac ctgaatgacc ttgaaaatat tattccattt cttggaattg 240
 gcctcctgta ttcttgagt ggtcccgacc cctctacagc catcctgcac ttcagactat 300
 ttgtcggagc acggatctac cacaccattg catatttgac accccttccc cagccaaata 360
 gagctttgag tttttttgtt ggatatggag ttactcttct catggcttac aggttgctga 420

aaagtaaatt gtacctgtaa agaaaatcat acaactcagc atccagttgg cttttttaaga 480
 attctgtact tccaatttat aatgaatact ttcttagatt ttaggtagga ggggagcaga 540
 ggaattatga actggggtaa acccattttg aatattagca ttgccaatat cctgtattct 600
 tgttttacat ttggattaga aatttaacat agtaattctt aagtcttttg tctgattttt 660
 aaagtacttt cttataaatt tggatcatgt tatgatttgt aacattcaca caacacctca 720
 cttttgaatc tataaaagaa ttgcacgtat gagaaacctt tatttcaata ctgctgaaac 780
 agacatgaaa taaagaattt aaagaatga 809

<210> 92
 <211> 516
 <212> DNA
 <213> Homo sapien

<400> 92
 gctcaaaaat acaaacctga tttattttcta cctttacaaa ctgtggttatg gttatgtagg 60
 aaattcaaaa tggattacaa gagactgcat ggccaggaaa agattaaatg tgtctcaaat 120
 aattaaataa aaataatgat aactgatact agaaactaaa ctacgattaa aatatttgga 180
 tggatgggta gtgatagctc cacagcagtg gcaaacttga agtcagattg taacgaatgt 240
 ttgttaccgc attaaacaat aacacatcct tcctgggaaa actaaaatga caggtgtagc 300
 cattgatgct ttaagcatat actctgacct catgactcac aatctgctgc agcctgtgga 360
 acacatactg tggagtcaga attatgctta gggaaagaag ggctagaaaa tgtagtgtag 420
 gaacttcac ttatttactg caaaatatgt ttttcaatgt cttattgaga taacatttta 480
 aaaataaaca tgaaaatgaa catctccctg actgct 516

<210> 93
 <211> 535
 <212> DNA
 <213> Homo sapien

<400> 93
 agcaactgca ttaaaagatg ttgtcaaagt tgggtgcagtt gatgcagata agcatcatc 60
 cctaggagggt cagtatgggtg ttcagggatt tcctaccatt aagatttttg gatccaacaa 120
 aaacagacca gaagattacc aagggtggcag aactgggtgaa gccattgtag atgctgcgct 180
 gagtgctctg cgccagctcg tgaaggatcg cctcggggga cgaagcgaag gatgttctgg 240
 acagtgaaga tgtttggtatg gttgagttct atgctccttg gtgtggacac tgcaaaaacc 300
 tagagccaga gtgggctgcc gcagcttcag aagtaaaaga gcagacgaaa ggaagagtga 360
 aactggcagc tgtggatgct acagtcaatc aggttctggc ctcccgatac gggattagag 420

88

gatttcctac aatcaagata tttcagaaag gcgagtctcc tgtggattat gacggtgggc 480
 ggacaagatc cgacatcgtg tcccggggccc ttgattgggtt ttctgataac gcccc 535

<210> 94
 <211> 1835
 <212> DNA
 <213> Homo sapien

<400> 94
 gccctcgga ccaccggact ggcctggggc gggacgtggg cgcgggggcg cggcgtgcgg 60
 cacgctgcag ggctgaagcg gcggcggcgg tggggactgc acgtagcccc gcgctcggca 120
 tggctctcct ggtgctcggg ctggtgagct gtaccttctt tctggcagtg aatgggtctgt 180
 attcctctag tgatgatgtg atcgaattaa ctccatcgaa tttcaaccga gaagttattc 240
 agagtgatag tttgtggctt gtagaattct atgctccatg gtgtgggtcac tgtcaaagat 300
 taacaccaga atggaagaaa gcagcaactg cattaaaaga tgttgtcaaa gttgggtgcag 360
 ttgatgcaga taagcatcat tccctaggag gtcagtatgg tgttcaggga tttcctacca 420
 ttaagatttt tggatccaac aaaaacagac cagaagatta ccaaggtggc agaactgggtg 480
 aagccattgt agatgctgcg ctgagtgctc tgcgccagct cgtgaaggat cgcctcgggg 540
 gacggagcgg aggatacagt tctggaaaac aaggcagaag tgatagttca agtaagaagg 600
 atgtgattga gctgacagac gacagctttg ataagaatgt tctggacagt gaagatgttt 660
 ggatggttga gttctatgct ccttgggtgtg gacactgcaa aaacctagag ccagagtggg 720
 ctgccgcagc ttcagaagta aaagagcaga cgaaaggaaa agtgaaactg gcagctgtgg 780
 atgctacagt caatcagggt ctggcctccc gatacgggat tagaggattt cctacaatca 840
 agatatttca gaaaggcgag tctcctgtgg attatgacgg tgggcggaca agatccgaca 900
 tcgtgtcccg ggcccttgat ttgttttctg ataacgcccc acctcctgag ctgcttgaga 960
 ttatcaacga ggacattgcc aagaggacgt gtgaggagca ccagctctgt gttgtggctg 1020
 tgctgcccc aatccttgat actggagctg caggcagaaa ttcttatctg gaagttcttc 1080
 tgaagtggc agacaaatac aaaaagaaaa tgtgggggtg gctgtggaca gaagctggag 1140
 ccagctctga acttgagacc gcgttgggga ttggagggtt tgggtacccc gccatggccg 1200
 ccatcaatgc acgcaagatg aaatttgctc tgctaaaagg ctcttctcagt gagcaaggca 1260
 tcaacgagtt tctcagggag ctctcttttg ggcgtggctc cacggcacct gtaggaggcg 1320
 gggctttccc taccatcgtt gagagagagc cttgggacgg cagggatggc gaggagtgcc 1380
 cgggagggaa gctgtgcggg cagcagtcct ggtttactct cttgagcctg tgcattctctg 1440
 cacctggagt caagtccttc ccatcagacc tcagccctgg tgcacccgtg ggccttttaa 1500

89

```

gaggttcttc tctgaagacc cttcatcttc cttatcaciaa gtttaagtgc tgcattggcat 1560
ttgatactct tgacagccaa gatacatttc agtagtaagg ttgctttcct gattattacc 1620
ttaaagtga cttttaacct ggaattcatt tactttatct tagaaaaata gaaatgata 1680
gctttgaaat tagcacttat ttctgtactg ttgtgtccca ccctcctcaa aaggacacgt 1740
tcaagtggct tccagtgtta aaatgggtgag tgatgtgatg ttgaaatgtt tcacctgagt 1800
tctgagcttt tccatccgta taatcatagg tacga 1835

```

```

<210> 95
<211> 4213
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (1239)..(1239)
<223> n=a, c, g or t

```

```

<220>
<221> misc_feature
<222> (1253)..(1253)
<223> n=a, c, g or t

```

```

<220>
<221> misc_feature
<222> (1259)..(1259)
<223> n=a, c, g or t

```

```

<400> 95
gaagactcta tgctggaact tggatcctca tcatttatat atataagatc ttttggcatt 60
tcttttaaact gatacaccaa gcgctgacct tccacttttg ccagaatacc cctttggtta 120
tagtacctga gtgctcttcc catgggtctca taattcatat caggtttggt tttgtgcttc 180
ccccacaacc tggacactgc tttagaatcc accaatttaa aaatgccttt ctctcgctgg 240
gtccacttga tgtatttagg acaagtagcc ttgtcctgga gcagtgccag taaaaactcc 300
caaagataaa ttgtgtttcc ctttccgtct ttgtttttct tcttcacaga tatatttggc 360
gtagtggctg gggaaatctgg tcgtgggtgt ttagtttttc ttcccttttt cctcttaggc 420
tgttctgggt atgaggctcc cggtgagtct gcatattttt cttgcacctg ctgtgtttcc 480
atcacttcag gaatcccatc taatgtgacg gacacatggg tgactggggc aacaacctg 540
tcatcttcag gtgaactaaa tatattatta tttattcgtt tttcatccag catagggcca 600
ggggaatcca tattgaggag tgcctcagca gcctcaatag tttcaattgt ttcattcccc 660
tcatgacaag aagcttcaac tgtaagggtg atgtcatcat catcatcgtc tatgatttct 720

```

tcttcagcaa catccagtga actctcagta atcatgtcac tgggctcttc cacacaggct	780
agaccggcat aactattgag aatatcagca ccaggaacat gtccacaat tacggcagga	840
aaaatagctg gatcaccaag ctgtcgttca tctccatga cgttactagc aaattcaa	900
actaggctcgt tctgttggac aacagcagcc ataataaagc attcccctta gatccacatg	960
agaaaaattc caagaagatt cacgtatcag gcagcaaaat ccagtgactg atttgggtaa	1020
aaaaccctca gctctgtctg tggagtaatt gtatacccaa gttttcttta gggaagggtgc	1080
ttcagttttc ctgggttcatt gatattctag tcaaattgag acaatttttc tgaaattttt	1140
cttctctcaa gcttcttggc ctgacaagca taagtgcctc tgcctccttc gccgcacctc	1200
tgcacaacgc cgctctgcg ctactgaagc tgctgcttnt tgccgccgcc gcngccgcng	1260
ccgccgctgc tgccacacg ctcccgagct aggaacaag ccccatccga gcgcgtgggc	1320
gtcgtagggg agaggagggg cggggccgct ccgctgcaac agcaaagttt gaggcgaagc	1380
ctagcgactc gcagcgccgg tcccgagctt tcacctcttt tttttttaac tccgccagag	1440
gaccccgacc cacaggctcc ggttgctccg ctggtcaaag tgcgtgcgga gtagttggca	1500
aagttgagag cggagacgtc tctgggaaca gctgtttgcg ttccgggagg aggcggcgcg	1560
ctgagctcct tggccttgag ccagcgagcc tagaaggagg atggaggttt tgggccccag	1620
gggaggacac agagacggcg ggatggcgca gggacttgag gcttgagatc ccgtccttca	1680
gctcagggtcc cgtcgcgctt ttacccttcc ccggtgacct caacccttt ataccgacct	1740
cacctctttg gagccgggag taccggcctt gtagggggag gggagaggag gcgatttcga	1800
acgcggattg gatcgtctgg gcaccgtag ttgggaacag cggaacgctg gtcccgggga	1860
ctgagt aagg tgtctggatc ggaggagggt tcgggtgggc atcgggcggc tggaagagct	1920
cgactcgtcc cgctgggaaa gcgcgagctt gagtggaaac ctggacgact tgcagagcgg	1980
ctggcgcagt catggcggac tactggaagt cacagccaaa gaaattctgt gattactgca	2040
agtgtc ggat agcagacaat aggcctagtg ttgaatttca tgaaagagga aagaatcata	2100
aggaaaatgt ggcaaaaagg atcagtgaga ttaaacagaa aagcctggat aaggcaaagg	2160
aagaagaaaa ggcatacaag gagtttgctg caatggaggc agctgccctg aaagcatacc	2220
aagaggatctt gaaaagactt ggcttagagt cagaaatttt ggagccaagc ataacaccag	2280
taaccagcac tatccacct acctcgacat caaatcaaca gaaagaaaag aaagacaaga	2340
agaaaagaca aaaagatcct tcaaaaggca gatgggtaga aggcataacc tctgagggtt	2400
accattacta ttatgatctt atctcaggag catctcagtg ggagaaacct gaaggatttc	2460
aaggagactt aaaaagaca gcagtgaaga ccgtttgggt agaaggttta agtgaagatg	2520
gttttaccta ttactataat acagaaacag gagaatccag atgggagaaa cctgatgatt	2580

tcattccaca	cactagtgat	ctgccttcta	gtaagggtcaa	tgaaaattca	cttggcaccc	2640
tagatgaatc	caaatcatca	gattcgcata	gtgattctga	tggggaacag	gaagcagaag	2700
aaggaggggt	ctctacagag	acagaaaagc	caaaaataaa	gtttcaggaa	aaaaataaaa	2760
atagtgatgg	aggaagtgac	ccagaaacac	agaaagaaaa	aagtattcag	aaacagaatt	2820
cattaggttc	aatgaagaa	aatcgaaaa	ctcttaagaa	atcaaacc	tatggagaat	2880
ggcaagaaat	taaacaagag	gttgagtctc	atgaggaggt	agatttggaa	cttccaagca	2940
ctgaaaatga	gtatgtatca	acttcagaag	ctgatgggtg	cggagaaccc	aaagtgggtat	3000
ttaaagaaaa	aacagtcact	tctcttggag	ttatggcaga	tggagtggcc	ccagtcttca	3060
aaaagagaag	aactgaaaat	ggaaaatcta	gaaatttaag	gcaacgaggt	gatgatcaat	3120
agttgcagga	gagctttttg	tacatgcttt	taggacagaa	tggagactta	tacacccaaa	3180
gtttatctgt	gtttgtttgt	aagtattatg	atgctaataa	tttagattta	ttctaaatgt	3240
atttgatgtg	aattaaaata	aatatttttt	catgtgaaat	ttatttttgt	tcctaaaatg	3300
gaagcctacc	acattgcatt	gtaatacagt	gtattatgtt	cagtgtctaa	aaactgctaa	3360
ttaagtcata	atttaagatg	ctatgtatct	gttatttaaa	acatggagaa	acagggcctt	3420
tattccattc	atattcataa	gagcatattt	atcctgcatt	gaaaatgcat	tacttttgca	3480
cattgatatt	aactgttgtc	caacaaataa	gtatcggagt	acgtgagaat	attcccagcc	3540
cagtgatgat	ttggttctga	ggctgatgtg	agaaagctga	tgtaaaaaat	gtatgcatat	3600
tggcttacct	tactcaatth	aaagtcaaaa	gccaacagcc	aggagcagct	caggtacttc	3660
agatgtgctt	aatatggagt	gaaaactgga	ccagaggtgg	aaagatgtat	ttgccccagt	3720
tcacttcaaa	gcagcaaacg	ttgtttaagc	atthttagth	gaaccaggca	ttgtgttagg	3780
aatccaggga	taaagatgaa	tgaaatgtat	ttctgttctt	caggagttca	cattctagca	3840
tatgccttht	ttcccccagt	catgcactct	thtttagcagt	cttatatgta	ctagaaaaga	3900
thttthtaag	thttatthaaa	gctgtgtaga	tgaaggcttg	atctaaaata	gtataaggtc	3960
tccagcttca	gtaaaagtht	ttagtgthta	cttaaaattag	taatthctca	ctthctgtct	4020
ggttaaaatg	tcttaaaaag	tagaaththt	thctthtaatc	cgtthtagtag	ttacctccct	4080
thtactthth	aaattcacaa	aattacathh	ctcataaatt	gtatagtatt	taacttataa	4140
tagthtaatat	thgtctthth	aagatgactg	tacatgtaag	aaaaaagctt	attaaaaact	4200
tgatcaaaga	ata					4213

<210> 96
 <211> 6537
 <212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (3557)..(3557)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (3571)..(3571)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (3577)..(3577)

<223> n=a, c, g or t

<400> 96

tttttatatg atttattttaa taataaacca attaaagata caaaaatggt tagaggattc	60
caaaatttaa atttttgttt aaatacaaat tcactctgta atatgaaaac atagcattag	120
acctctaaac ataatgattt ttttcatcta caaaaatttc tggtatacta gaaaatttgc	180
agaagacatt tttttcttgt gacattaaat gtacattatt tacagttgaa aagtaatcta	240
aaaacatttc atttcagaaa gttggatata tatgttatct ttgatatgca accccccaa	300
gtccgcccc agtaaaaaat gatccaaaat ataaagcaat tatgctttta taactgacta	360
ctcagccaga ttagcccaag gctcaagttg ctttcttggc ccttaagaaa gagtcttgac	420
tctctcaaaa tagcagtatt ctgttttagca cttagcaaca caagtttact aatggaccgc	480
aaagcacagt ggcctaaaga gttagtaaac aaattattta ggaagaattt atggcagatc	540
ttgaccata acagatgaat aaattttggt gggtcactta tttctctgca acatttttagc	600
tatcttacat taggaaataa cctgataatg atttaattga cataacttga aaatataggt	660
attagaatta aaaaaattag aactagaaga gaaagtgggt atcatctagt ctaatccaat	720
acatctcttc cttttatgag aggaactaaa gcccaaagag gtcaagatta catagctagt	780
tagtgggagt gccattctta ggctgatgct tttatactat cctgcttctg aaacagggtc	840
agccatacca ccagcacctc caatttttca tggtattcta catattcata gttctatatt	900
atatagtgca gtcaactaaa gtcaatctaa gtgacaccat aattttaaca aagcataaaa	960
taggtttttt gcatttgaaa gagtcaagac ttaacttaca caagtggaat gaaaatagtt	1020
cctatataaa tttcctgttg ctttctattt aagttctgta ttacaaaag aatcagaaaa	1080
tctaatacaa tgtaaaatta gaaaagaaac tttaaaaatg cttatgatat agcaactgaa	1140
ataaaaatct caaaagaatg tcttcatagt gtaaaatgcc tgttccttca cgattgaatt	1200

ctgaaacatt tagataacaa agagaaacag ttgagttttc ctccctcatc taacaaagtc	1260
aaaattaact ctattttttaa caattacaaa attagaaacc tccttagaat ttatcttaga	1320
atcagtcagt ctgcatataa ttgaaaatgt tcaattaaca aacaattatt cataagcttt	1380
ggtatattaa ctaaaaagag ttgggttcca gcagttcgtt ttgtttcata gctacctgag	1440
aagtaaatac attggaactg gacactacca tcacataagg ctgtggctgc tgctccgttt	1500
tctcagtggt ctctttcaaa tgatcttcag attccttttt ctctacttcc tgtgtaagag	1560
tttttgtttc ttgagttttg ataactgaag tgattacagt gccagggtggg tgagcaacca	1620
gctgtgaact gcgaggagaa aaggtcacca caggtgcagt agcactgaag gatggagagg	1680
aagccacact gacgggtcca ttgcaaatgg tctgaacatt gctagtaagg acctgctgaa	1740
cctgggcagg gcccaagaca attgaaggag gagagcccgc cttt tgtgac tgcagcatga	1800
cattttcttt cagtactgtc atgggctgtg atgatggaat ggcttgtaaa ataaacttct	1860
gagatccagt acctgctgat ggatctgtgc tggctataac tgttgtgagt ggcactgttt	1920
ggagtgttac tgtatgcaac tgctgattcc taggagacac aaccactgga acttgggttg	1980
gagcctgtat agtcctaata ctctgaacgg aagaatttaa tgttctcatc tgcattgtac	2040
tggttctagc tgcttctccc tctgggacag cctgtactgg ctgtactaca tgaacagtcc	2100
ggaagagctg ggtaggatat ggagactgcg tgggctgcac tgtcctcaaa acttctgatg	2160
gttgtgcaac ttccacagga tctttgggtt ttgcagcttt agaattccct ggttttagaa	2220
ctgaagtggc tcctcctttt acccctggac ttgaagatac tctcgaccgg ctggtttgat	2280
tcctatttga agtggctgat gaagatagcg atggatctga agactctatg ctggaacttg	2340
gatcctcatc atttatatat ataagatctt ttggcatttc tttaaactga tacaccaagc	2400
gctgaccttc cacttttgcc agaatacccc ttggttaata gtacctgagt gctcttccca	2460
tggtctcata attcatatca ggtttgtttt tgtgcttccc ccacaacctg gacactgctt	2520
tagaatccac caatttaaaa atgcctttct ctgctgggt ccacttgatg tatttaggac	2580
aagtagcctt gtcctggagc agtgccagta aaaactccca aagataaatt gtgtttccct	2640
ttccgtcttt gtttttcttc ttcacagata tatttggcgt agtggctggg gaatctggtc	2700
gtggtgggtt agtttttctt ccttttttcc tcttaggctg ttctgggtgat gaggctcccg	2760
gtgagtctgc atatttttct tgcacctgct gtgtttccat cacttcagga atcccatcta	2820
atgtgacgga cacatgggtg actggggcaa caaccatgtc atcttcaggt gaactaaata	2880
tattattatt tattcgtttt tcatccagca tagggccagg ggaatccata ttgaggagtg	2940
cctcagcagc ctcaatagtt tcaattgttt catccccgtc atgacaagaa gcttcaactg	3000
taagggtgat gtcattcatc tcatcgtcta tgatttcttc ttcagcaaca tccagtgaac	3060

tctcagtaat	catgtcactg	ggctcttcca	cacaggctag	accggcataa	ctattgagaa	3120
tatcagcacc	aggaacatgt	tccacaatta	cggcaggaaa	aatagctgga	tcaccaagct	3180
gtcgttcac	ctccatgacg	ttactagcaa	attcaaatac	taggtcgttc	tgttggacaa	3240
cagcagccat	aataaagcat	tccccttaga	tccacatgag	aaaaattcca	agaagattca	3300
cgtatcaggc	agcaaaatcc	agtgactgat	ttgggtaaaa	aaccctcagc	tctgtctgtg	3360
gagtaattgt	atacccaagt	tttcttttagg	gaagggtgctt	cagttttcct	ggttcattga	3420
tattctagtc	aaattgagac	aatttttctg	aaatttttct	tctctcaagc	ttcttggcct	3480
gacaagcata	agtgcctctg	cctccttcgc	cgcacctctc	gccaccgccg	cctctgcgct	3540
actgaagctg	ctgcttnttg	ccgccgccgc	ngccgcngcc	gccgctgctg	cccacacgct	3600
cccagagctag	ggaacaagcc	ccatccgagc	gcgtgggcgt	cgtaggggag	aggaggggag	3660
gggccgctcc	gctgcaacag	caaagtttga	ggcgaagcct	agcgactcgc	agcgccggtc	3720
ccgcagtttc	acctcttttt	tttttaactc	cgccagagga	ccccgacca	caggtcccgg	3780
ttgctccgct	ggtcaaagtg	cgtgcggagt	agttggcaaa	gttgagagcg	gagacgtctc	3840
tgggaacagc	tgtttgcggt	ccgggcggag	gcggcgcgct	gagctccttg	gccttgagcc	3900
agcgagccta	gaaggaggat	ggaggttttg	ggccccaggg	gaggacacag	agacggcggg	3960
atggcgagc	gacttgaggc	ttgagatccc	gtccttcagc	tcagggtccc	tcgcgctttt	4020
accccttccc	ggtgacctca	acccctttat	accgacccca	cctcttttga	gccgggagta	4080
ccggccctgt	agggggaggg	gagaggaggc	gatttcgaac	gcggattgga	tcgtctgggc	4140
acccgtagtt	gggaacagcg	gaacgctggt	cccggggact	gagtaagggt	tctggatcgg	4200
agggagggtc	gggtgggcat	cgggcggctg	gaagagctcg	actcgtccc	ctgggaaagc	4260
gcgagtctga	gtggaaccct	ggacgacttg	cagagcggct	ggcgcagtca	tggcggacta	4320
ctggaagtca	cagccaaaga	aattctgtga	ttactgcaag	tgctggatag	cagacaatag	4380
gcctagtgtt	gaatttcatg	aaagaggaaa	gaatcataag	gaaaatgtgg	caaaaaggat	4440
cagtgagatt	aaacagaaaa	gcctggataa	ggcaaaggaa	gaagaaaagg	catcaaagga	4500
gtttgctgca	atggaggcag	ctgccctgaa	agcataccaa	gaggatttga	aaagacttgg	4560
cttagagtca	gaaatttggg	agccaagcat	aacaccagta	accagcacta	tcccacctac	4620
ctcgacatca	aatcaacaga	aagaaaagaa	agaaaagaag	aaaagaaaaa	aagatccttc	4680
aaagggcaga	tgggtagaag	gcataacctc	tgagggttac	cattactatt	atgatcttat	4740
ctcaggagca	tctcagtggg	agaaacctga	aggatttcaa	ggagacttaa	aaaagacagc	4800
agtgaagacc	gtttgggtag	aaggtttaag	tgaagatggt	tttacctatt	actataatac	4860

95

```

agaaacagga gaatccagat gggagaaacc tgatgatctt attccacaca ctagtgatct 4920
gccttctagt aagggtcaatg aaaattcact tggcacccta gatgaatcca aatcatcaga 4980
ttcgcatagt gattctgatg gggaacagga agcagaagaa ggaggggtct ctacagagac 5040
agaaaagcca aaaataaagt ttaaggaaaa aaataaaaaat agtgatggag gaagtgaccc 5100
agaaacacag aaagaaaaaa gtattcagaa acagaattca ttaggttcaa atgaagaaaa 5160
atcgaaaact ctttaagaaat caaacccata tggagaatgg caagaaatta aacaagaggt 5220
tgagtctcat gaggaggtag atttggaact tccaagcact gaaaatgagt atgtatcaac 5280
ttcagaagct gatggtggcg gagaacccaa agtggtatct aaagaaaaaa cagtcacttc 5340
tcttgaggtt atggcagatg gagtggcccc agtcttcaaa aagagaagaa ctgaaaatgg 5400
aaaatctaga aatttaaggc aacgaggtga tgatcaatag ttgcaggaga gctttttgta 5460
catgctttta ggacagaatg gagacttata cacccaaagt ttatctgtgt ttgtttgtaa 5520
gtattatgat gctaaaaatt tagatttatt ctaaattgat ttgatgtgaa ttaaaataaa 5580
tattttttca tgtgaaatct attttgggtc ctaaaatgga agcctaccac attgcattgt 5640
aatacagtgt attatgttca gtgtctaaaa actgctaatt aagtcataat ttaagatgct 5700
atgtatctgt tattttaaagc atggagaaac agggccttta ttccattcat attcataaga 5760
gcatatttat cctgcattga aaatgcatta cttttgcaca ttgatattaa ctgttgtcca 5820
acaaataagt atcggagtac gtgagaatat tcccagccca gtgatgattt ggttctgagg 5880
ctgatgtgag aaagctgatg taaaaaatgt atgcatattg gcttacctta ctcaatttaa 5940
agtcaaaagc caacagccag gagcagctca ggtacttcag atgtgcttaa tatggagtga 6000
aaactggacc agaggtggaa agatgtatct gcccaggtc acttcaaagc agcaaacgtt 6060
gtttaagcat tttagtttga accaggcatt gtgttaggaa tccagggata aagatgaatg 6120
aaatgtatct ctgttcttca ggagtccaca ttctagcata tgcctttttt ccccagtc 6180
tgcactcttt ttagcagtct tataatgtact agaaaagatt ttttaaagtt tatttaaagc 6240
tgtgtagatg aaggcttgat ctaaaatagt ataaggcttc cagcttcagt aaaagttttt 6300
agtgtttact taaattagta atttctcact ttctgtctgg ttaaaatgtc ttaaaaagta 6360
gaattttctt ctttaatccg tttagtagtt acctcccttt tacttttcaa attcacaaaa 6420
ttacatttct cataaattgt atagtattta acttataata gttaatatct gtctttttta 6480
gatgactgta catgtaagaa aaaagcttat taaaaacttg atcaaagaaa aaaaaaa 6537

```

```

<210> 97
<211> 1630
<212> DNA
<213> Homo sapien

```

<400> 97
cgaagcctag cgactcgcag cgccgggtccc gcagttttcac ctctttttttt ttttaactcc 60
gccagaggac cccgacccac aggtcccggg tgctccgctg gtcaaagtgc gtgcggagta 120
gttggcaaag ttgagagcgg agacgtctct gggaacagct gtttgcgcttc cgggcggagg 180
cggcgcgctg agctccttgg ccttgagcca gcgagcctag aaggaggatg gaggttttgg 240
gccccagggg aggacacaga gacggcgggg tggcgcaggg acttgaggct tgagatcccg 300
tccttcagct caggtcccgt cgcgctttta ccccttcccg gtgacctcaa cccctttata 360
ccgacccac ctctttggag cggggagtac cgcccctgta gggggagggg agaggaggcg 420
atttcgaacg cggattggat cgtctgggca ccgtagttg ggaacagcgg aacgctggtc 480
ccggggactg agtaaggtgt ctggatcgga gggaggttcg ggtgggcatc gggcggctgg 540
aagagctcga ctcgtcccgc tgggaaagcg cgagtctgag tggaaacctg gacgacttgc 600
agagcggctg gcgcagtcac ggcggactac tggaaagtcac agccaaagaa attctgtgat 660
tactgcaagt gctggatagc agacaatagg cctgtatgat aattccgctg ttagagattc 720
taataataat tgtgttgaat gaagtgcctc tttttgatgt aaactcagtt taaaagcac 780
ttttatgtac attgctcttg catthttcaa acatcagaag atttctgtct tctcagtccc 840
ctatgaaagc tgtgagcctt cttccttttc atcaacctga ctttgattat atattaaatt 900
atttctctgt ggccttttgg gaaatgggca atgagttggg catatcatc atgttatgaa 960
gcacctatat tataatgggt gtgttcataa tactgtcata cccaaagaat tgtggaaagc 1020
ccttaaaaaa taaaagcaac atgttttagtt tttcttgtat attttgtggg ctagaaataa 1080
tcaagtgtat ttaatgcaga gctgtgtatc tttagatgct taaatttgaa agaacaccat 1140
tatttccttt ctcatgaaac aaagtaacaa ctctgttagg tatgttggtta gtctgtctca 1200
tagttgagat ccagttttga agatgtaaag caaaaagcac accgctgatt tttctcccct 1260
cttgcagtgc aaaatactat gtacatacca cataaacact agggatatctg ttaaataatat 1320
tttatgttga taccgttttt acttggcaaa gttggatgca caaagaatag tagtctcata 1380
ttttaacaat gctgtggatt tcttctgtag acatttatth cctgttacct gcaagggtgtt 1440
taggatttgg attttttttt gatgttttgg tcttttttgg tagttgctaa agttcttcac 1500
tattttacct aggcatacct tataaataaa taccatgaat ttttaaaacc acacaggtca 1560
cttaaagtct ctctttcttg gaggtaccta ggctgtaaaa tgaattttgt gagttatcta 1620
gagtaagtaa 1630

<210> 98
<211> 2177

<212> DNA

<213> Homo sapien

<400> 98

ccgaagtgct tgaattacag gcgtgagccc cgcgccggtc cgaagcaaag ctaaattgtaa	60
ttttatgtac tgtttttaaca gtataaacct atgggataaa ggcccccaat catcagaagg	120
actactgaaa agaaaagaaa gcaaacgtag atgtcaaatt gtctaaacat tcttaagtac	180
cactgatttt tttttttctg gactattata caaagatgtc tgtaaaaagt ataccagtgg	240
cttttatgca tatacacgat taggctagat tgtgaagtac atggggatttc atgagccaga	300
ggaggcattt ggatccattg ggccacatgt gactataagc acatttgtga cacaataaaa	360
ttgtagccac tcatgtatta aaactgtttt ggtaaaagct gtattaaaag aataattttt	420
tgcttgagct acttagtcac ttttttgcag ggcacccaaa tgtaggctac ttttccatag	480
cttgtttgct atgtttttat ttcatcttaa atctgagcca tttttggcaa tatcttttaa	540
aaaatcatta ttaaacattt attggaaatg ttgtatagat tcacaagaaa gagacaccaa	600
agtgtttggg aatttttaatc ccaagaagta aacatcccag agtcagatcc catttgctgt	660
tgttcagcca tgtttgtatg actgaatgta atttaggaaa tcaggagtta gagatgaaa	720
atacaaacat gtcaaattgt tgtaattgct ttttttgaac ttactggctt taacttaagt	780
aatataggtg tgtagttgtt ttatctaaag atgtcagatt atctgtggcc ctgttaatta	840
actgcaggga ccagagagag gacaaaaatg cctgtataat ttgcttttaa ggcttgtcct	900
tatgtttgta atttcagtta aatatcttct acagattgct tcacttcccc tttcccccaa	960
taacaagttc atattcttgt aatgtttact ttgggtcaacg tggtaatttt tgggaagaaa	1020
tgccaaaatg taagcttctc acaagcagca aaggaatgta actgcctgta gctaccacat	1080
caagggagag aagaggcttg cgtacttttg gttgatctca ctgtacaaaa aaagtgtacc	1140
cctattggaa gaaataagga atacttgaag gtttctcctt tttttacact tgagtcatgt	1200
gcaaggttga accatatgaa attgccagtg ttcaaccatt gctgatctgc aaaagcgaca	1260
atatcatatg cctcaacctt acacttactc ttaaattgcag gttaaaatct ctgtgaggca	1320
aagggataat attctctagg aactcacttt tgagagtatt tttctctaac ccatgtggat	1380
ctaaatttta aaaataggaa tgaatctctt aattgcagct tgtggagagt ataaaacatt	1440
ttgagcacia tatgcagcac ataacttttc agatttgtgt tgcatagaaa aggttaaaat	1500
caattctttc agttactgta ttgttcattt cttgtaaagg tcttcctaca tttgagacga	1560
gaccctttaa cataggctgc cttagtaaca aaataaaaca gatgtgtcat aatattaact	1620
gtcctaaaga acatgtgtct tgcaaatgcc atggaactga atatttattt ccttgtgagt	1680
attatgaccg ttaccaaagg actcaaccag atttagggct cttcttaatt gatcatgttc	1740

agaaagggac tcatttggtc ccactttgta acatgggaag agtagaagag aaaattaaat 1800
 gtggaaatca taaatgcttt tctaacaggg ttatgctatt ctgtaacact aaatgtctgt 1860
 cttttctctt aaaagattaa gttttattaa ttttgtcata cttttctcta tttgaatata 1920
 tcttaaccat tttatgttcc aaattcgttt tttgtccaag acattctatc agaattttac 1980
 ttgcctctat aatctgaaaa atgggttcta gaatgtccca cttgctgtct cttagaggct 2040
 gagcttcatt tctatgagca aagagctcat ttagcaatgt agttatttca gtattttattt 2100
 ctattatgga atccctgggg ttcagaatgt aactttgtac atgagatata tataaatatg 2160
 tatatgaaca tgtatga 2177

<210> 99
 <211> 1281
 <212> DNA
 <213> Homo sapien

<400> 99
 ggcggttggg gtgagagcgc ctacgccacc cctcccctcc tccggccccg gccccacccc 60
 cgccggggccc agccccagcc ccggccccggg ctccagccct agtaccggtc ccagccccgag 120
 tcgggtccgt cccgtgcggg caggtgccgc ccctctgccg gcgacgcccc gggccgcccc 180
 cccgtccgct tgccaccatg gagctggagg acggtgtggt gtatcaggag gagccccggc 240
 gctccggggc cgtgatgtcg gagcgggtgt ccggcctggc cggctccatc taccgcgagt 300
 tcgagcggct tatcgggcgc tatgacgagg aggtgggtcaa agagctgatg ccgctggtgg 360
 tggctgtgct ggagaacctg gactcgggtgt tcgcgcagga ccaggagcac caggtggagc 420
 tggagctgct gcgggacgac aacgagcagc tcatcaccca gtacgagcgg gagaaggcgc 480
 tgcgcaagca cgctgaggag aaattcattg aatttgaaga ctctcaagaa caggaaaaaa 540
 aggacttaca gacccgagtg gaatcttttag aatctcaaac aagacaactt gagctgaaag 600
 cgaaaaacta tgctgaccag agcctatcag cagtctgatg gggcagaaga caacagagat 660
 ggaagggtgtt ccaaacttgg caaaggccat caatctcagg agttagcaga cttgaagaaa 720
 gagaagcaga actgaagaag gaatataatg cattacatca aagacacact gagatgatcc 780
 ataattatat ggaacattta gaaagaacaa aacttcatca gctctcaggg agtgatcaac 840
 tagaatccac agctcatagt agaattagaa aagaacgccc tatatcatta ggaattttcc 900
 cattacctgc tggagatgga ttgcttacac ctgatgctca gaaaggagga gagaccctg 960
 gatctgagca atggaaattt caggaattaa gtcaaccacg ttctcatacc agcctgaagg 1020
 atgagctttc tgatgttagc caaggcggat ctaaagctac cactccagca tcaacagcta 1080
 attcagatgt ggcaacaatt cctactgata ctcccttaaa ggaagaaaac gaaggatttg 1140

tgaagggttac agatgcgcca aataaatcag agataagcaa acacattgaa gtacaggtag 1200
 cccaggaaac tagaaatgta tctactggct ctgctgaaaa tgaagaaaag tcagtagata 1260
 catttctagt ttcctgggct g 1281

<210> 100
 <211> 3665
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1543)..(1565)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (2711)..(2744)
 <223> n=a, c, g or t

<400> 100
 aaaattctct aaattctcac ccagaatcat tatctctagc agatatggac aatgctgcaa 60
 gcatttcccc ttctgaacag acttctaata ccacagaaaa ccatgagact acaaattctta 120
 atgggtgaatg tacagattta gataaccagc ttcaagaaca atcagaaact gaggaagatt 180
 ccaatcctaa tgttagctgg ggtaaaaagg tccagcctat agactccata ttagcagact 240
 ggaatgaaga tatagaagca tttgaaatga tggagaagga tgagctatga cttgctaaac 300
 aatctgttgg taggtattta aaaagaaaag gtaaactgtg tgtggttaat agacatccta 360
 atactaagca ggcttttctaa tgggaggcct taagtatggg gatgaacaac cacgttctga 420
 ctggcgtagt tatcgtagga atctggagca tgctgtgtta gaattgacct tgtttaaaac 480
 tgtcccatca aaaatggaaa tccacagttc ccccttcaaa tgcagcactg caccaccctg 540
 caacacctca ggccagggaa agattactga gcattcctgc gaaccagatt tctgttgtct 600
 ctggatagac aagaaacaaa attcatttag tagtggagtg gggaaatagga gtttggatag 660
 ccttctaatt aaaggaagct cgcctttctt ggttttgggg gttagaggct cttttgggaa 720
 gatgcatccg agtatttgtg cattctgatt atgctgcctt cacaaaacac tctaagtgac 780
 ctaagtgggt atgaagcaaa tgcatttatg gtgaaaacag tctttgctca ttgctttctc 840
 ttgtttcatt tagtgacaaa tgatcaagat gacttgattt tttttccttc ttaacaatgt 900
 cttttttatt taaaccaaag gtgaagccag tgtactttct cagtgaagttc tctgcataaa 960
 gactaatcag tgggaccagg taaaaaggtc atataatata ttgtggagat tgcttactta 1020
 atacttctga aaaatggagt aaggagagaa ctgtaatgtt gcaatatgaa cctccattg 1080

ggccttccat agggaaagct gtgactactc tgaaatggaa cctagcatta tateccttgta 1140
gggtagatta taaatcattt ccagttcatt tctcttagag gtgattacct ctagccatca 1200
gccttactcc atcccatggt tggtagtcaa tttgagccac aaggctcgta tcgccaacag 1260
ctatatacat tttgttccat ttttctgtct tacagagcca tgataaaact gtgggttagtg 1320
agttaaaatt cctggagtaa ctactgtttt tctcctttga aacttagggt tctaaagttg 1380
cacctaagga atctgtcaca ttttctgttg aatcatgggt tttgtttttg tttttaacag 1440
atattccttc tgatacggac ttgaaaatta gtgtatgggt acctgtgttt aaaaaaaaaa 1500
gtacaataca actacatata gctatatagc ttaatgagac ttnnnnnnnn nnnnnnnnnn 1560
nnnnnggttt gttgttggtg tagtagtctg gtgctggcca catttaagtc ttaaaaattt 1620
ttaaatTTTTg ttgttgatgt ttgtagacag cctgttggt gaaatcatgg ctttattcat 1680
tttattttatt ttttaaactt gcctgaattt gttctaaagg aatatttaag agacataatt 1740
ttcttctctt taccataaca ttacacaaaa ctttttccta aaacacgggt gtgaggtact 1800
gatgaggtgt aagtggagct gttaaaaaca gcagtgtgt attgcagtta tgtatatctg 1860
tgtacagtat gtttagatcc caggtaaaca tattcttttc tgagaggata aatacctgca 1920
ttcagatatt ccaggtaaatt ataattgagt caggtagtag taaatctgat ggagaattca 1980
ctttggggag gggaaaaaga atagtatgca agacccttat tggcttttaa ttatacctga 2040
aaccaaaatg gatattttta gtctctctgc atgtgagatt tgggtgtaaca agatagaact 2100
ataatatata cagtatatgg aaggatagat atagtgtctt gttcatttta attgcaaagc 2160
tgccaaaata gttgaagctt aattacttga cttgccttga tttataggac tggggccttg 2220
agaaaatgag cagatgttcc tctaagacat cgattacaga agccttatat acatggattt 2280
gattttgtat ttgtagctga aagtcactgt tgtctaaaac taacttttct aagttatcaa 2340
aacaacctaa tttcttttcc aacaaggaga acttaatggc atgaaggatt gtgtgacaca 2400
ttggaaaagc cagcttactg ccactctctt cctttggcca ttagagggag gtgttgctt 2460
tcattgacgc ttagaagcaa attgttcact tgtaagaaa agtaaatcct taaaaaaga 2520
aaaggaaaaa atttaaccaa tttttcttaa taccagaag gaattatct caatatttcc 2580
ctagttaaga aaagaggaga taatgttcgt ctaaaaaact ccaacgttgt aattacaact 2640
ctacattcat ttacttactt gacatactgc cacaaagtag ttttgagtt cattaaaaat 2700
tccaaaggca nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnttagtt aacttttata 2760
gacattttag taacttgcta aagattcagg ggattctatg aaaccccgaa tttagaaaca 2820
tctgggtctac ctcagttaaa tgttgactgc ttagaaatat agctgaagtg atcaccacag 2880

101

```

ccataaaatt gtttaagaaa gatttatata atgtttacaa atctggaatc aaggatttta 2940
gctgaaatcc ttttaagagat attagagcaa gtatttaatt caggatatttt caagttttta 3000
aacttaacct gtttacctac taaaaataaa atagctagtt tttttctgca tataaaagtt 3060
cattgaaatg atatgccctt atttgcaata cttttcccat aaagttttta gtgtgaaaga 3120
attgtaattt actagatatg tttgggatgg gatattttgt taggcaagtt ttcttttttc 3180
ttcttaaatt gcaataggct tccaaaaaga gtataattgt ttcagaacaa attaactctt 3240
ggcattatac gtctcccttt ttctttacag tattagtaaa aagaaaaatt gtacactttc 3300
tgattttaac ttcactaatg taattactct ctcaagaagc ttttaaaatt taaattacca 3360
tcacacaacc ttttttatag taaagccaac atttgttctc tcaccaaac ccattgcaaa 3420
ttcatcatga agaaagctca gcataagtaa ttcaaatact gcttataatt ttagaggggg 3480
gtagaattta gtaaataatc cagccggctg ttttatgac aaggcttcag tcagaacata 3540
gaaaaaaaaa acattctgtg aatgaaatat tgtatgttca gattttataa aagacttttt 3600
aaaagcccaa tttacagccg tatattttct tatggatgta atttatgaaa aagatgtctg 3660
tacta 3665

```

```

<210> 101
<211> 1168
<212> DNA
<213> Homo sapien

```

```

<400> 101
gttatgttca tcctgtaacc ttatttttaa tgctcttctt acctgggggt ttaagagtgt 60
ggaggtggaa gtaggggggt tccaagatca agtgtccac tcttccagtt aaaagaagta 120
tcttgtagta caaaactatt tgtttcctat agattcaagt ctaatttact tctgcattcc 180
agtctttcca gagtttttgg tattctcttt cgcattgaatt tcccggatgt ataaaggaac 240
cagcattacc ttacagcagg gcagaaggag cggagctctg ggttcacttg gcactttctc 300
acctctgct ggggtggcctc tgcgcctctg gttgttgtgt actctgaatt ttgacctctg 360
tccttgccag ggtgacaggg ggcaattagg acaacaagcc agcttgaaag tcacacctga 420
gcctctgttc agttttactg tggcaatgca ggcaagaggc tgagggacaa ggtgccagcc 480
ccagtttgtc aggtgacagt cagatgatgc ccagatgagg agaatcctct cacttcaagg 540
aggagctcca gaaggaagat tctgccagtt atgaacctgg gaggggaagag gggaaggagt 600
gcaaaagggtg tcacggaaca agtgcctcag ctacagacgt caggcacggg tgcagagccc 660
taggagtgcc cgactgtgcc tgagtccagg gagcccatgc tgcttgaatg ggctccaccc 720
ggcctctgcc catttgtgca tccatgctgc tgcccacac tgtctttgct tcttggtttt 780

```


102

```

agatccttgc acttggtcac ctcttccaca cccagcctct gctaaccct aatcccctct 840
tctgtggggt gtgaagtccc ctgagctgct gtatgtcctc tttgcatttg ctcttacaca 900
aggaagcctc agaagaaaca cagccttctc tctgtatctt caatggaaag taattttgtc 960
ataaaaataa ctgactctgg aatctttgct attacgaaaa tatttgtcat gtgtgggtgaa 1020
aaggtagagt aggtatcagt gtagtacaat tactggcttc cgtgagtcta atgtgattta 1080
ggagtctgca ggggttagct tcagggtata ttgtaatttc aagactaggt tctttgtact 1140
tttactagta ttagaataaa cttagtat 1168

```

```

<210> 102
<211> 1269
<212> DNA
<213> Homo sapien

```

```

<400> 102
gttatgttca tcctgtaacc ttattttaaa tgctcttctt acctgggggtt ttaagagtgt 60
ggaggtggaa gtatgggggt tccaagatca gtgtccacct cttccagtta aaagaagtat 120
cttgcagtac aaaactatctt gtttcctata gattcaagtc taatttactt ctgcattcag 180
tctttcagag tttttgggtat tctctttcgc atgatttccg gatgtataaa ggaaccagca 240
ttaccttaca gcagggcaga aggagcggag ctctgggttc acttggcact ttctcaccct 300
ctgctgggtg gcctctgcgc ctctgggttg tgtgtactct gaattttgac ctctgtcctt 360
gccaggggtga cagggggcaa ttaggacaac aagccagctt gaaagtcaca cctgagcctc 420
tgttcagttt tactgtggca atgcaggcaa gaggtgagg gacaagggtgc cagccccagt 480
ttgtcaggtg acagtcagat gatgccaga tgaggagaat cctctcactt caaggaggag 540
ctccagaagg aagattctgc cagttatgaa cctgggaggg aagaggggaa ggagtgcaaa 600
aggtgtcagg aaaagtgcct cagctcagac gctcaggcac ggggtgcagag ccctaggagt 660
gcccagactgt gcctgagtcc agggagccca tgctgcttga atgggctcca cccggcctct 720
gcccatttgt gcatccatgc tgctgccac acctgtcttt gcttcttgtt tttagatcct 780
tgcacttggt cacctcttcc acaccagcc tctgctaata cctaataccc tcttctgtgg 840
gggtgtgaagt cccctgagct gctgtatgtc ctctttgcat ttgctcttac acaaggaagc 900
ctcagaagaa acacagcctt ctctctgtat cttcaatgga aagtaatttt gtcataaaaa 960
taactgactc tggaatcttt gctattacga aaatatctgt catgtgtggg gaaaaggtag 1020
agtaggtatc agtgtagtac aattactggc ttccgtgagt ctaatgtgat ttaggagtct 1080
gcaggggtta gcttcagggt atattgtaat ttcaagacta gggtctttgt acttttacta 1140
gtattagaat aaacttagta tgaaagtggg gtctaatagt taaaataata tttcagaaag 1200

```

103

actattactg cctatcgtgt gaaaagtaga gtgtaaattt tcacttttaa actttaaatc 1260
 tccagcatt 1269

<210> 103
 <211> 1264
 <212> DNA
 <213> Homo sapien

<400> 103
 gttatgttca tcctgtaacc ttatttttaa tgctcttctt acctgggggt ttaagagtgt 60
 ggaggtggaa gtagggggct tccaagatca gtgtccacct cttccagtta aaagaagtat 120
 cttgcagtac aaaactattt gtttcctata gattcaagtc taatttactt ctgcattcag 180
 tctttcagag tttttggtat tctctttcgc atgatttccg gatgtataaa ggaaccagca 240
 ttaccttaca gcagggcaga aggagcggag ctctgggttc acttggcact ttctcaccct 300
 ctgctgggtg gcctctggcc tctgggtgtt tgtctctgaa ttttgacctc tgtccttgcc 360
 agggtgacag ggggcaatta ggacaacaag ccagcttgaa agtcacacct gagcctctgt 420
 tcagttttac tgtggcaatg caggcaagag gctgaggggac aagggtgccag ccccagtgtc 480
 aggtgacagt cagatgatgc ccagatgagg agaatcctct cacttcaagg aggagctcca 540
 gaaggaagat tctgccagtt atgaacctgg gaggggaagag gggaaggagt gcaaaagggtg 600
 tcaggaaaag tgcctcagct cagacgctca ggcacgggtg cagagcccta ggagtgcccg 660
 actgtgcctg agtccaggga gcccatgctg cttgaatggg ctccaccggg cctctgccca 720
 tttgtgcac ccatgctgctg cccacacctg tctttgcttc ttgttttttag atccttgcac 780
 ttggtcacct cttccacacc cagcctctgc taatccctaa tcccctcttc tgtgggggtgt 840
 gaagtcccct gagctgctgt atgtcctctt tgcatttgct cttacacaag gaagcctcag 900
 aagaaacaca gccttctctc tgtatcttca atggaaagta attttgtcat aaaaataact 960
 gactctggaa tctttgctat tacgaaaata tttgtcatgt gtgggtgaaaa ggtacagtag 1020
 gtatcagtgt agtacaatta ctggcttccg tgagtctaag gtgatttagg agtctgcagg 1080
 ggtagcttc agggatatatt gtaatttcaa gactagggtc tttgtacttt tactagtatt 1140
 agaataaact tagtatgaaa gtgggtgtcta atagttaaaa taatatttca gaaagactat 1200
 tactgcctat cgtgtgaaaa gtagagtgtg aatttttact tttaaacttt aaatctccag 1260
 catt 1264

<210> 104
 <211> 534
 <212> DNA
 <213> Homo sapien

104

<400> 104
 gtgcccttga ttatcttcac catcaaggcc aacagcgagg cctgccggga cggccttcgg 60
 gcagtgatgg agtgtcgcaa tgtcacccat ctcttgcaac aagagctgac cgaggcccag 120
 aagggttttc aggatgtgga ggcccaggcc gccacctgca accacactgt gatggcccta 180
 atggcttccc tggatgcaga gaaggcccag gactccagct ccgctgcggc gcccagctg 240
 ctgattgtgc tgctgggcct cagcgctctg ctgcagtgag atcccaggaa gctggcacat 300
 cttggaaggc cgcctctgct cggcttttcg cttgaacatt cccttgatct catcagttct 360
 gagcgggtca tggggcaaca cggttagcgg ggagagcacg gggtagccgg agaagggcct 420
 ctggagcagg tctggagggg ccatggggca gtctgggtg tggggacaca gtcgggttga 480
 cccagggtg tctccctcc agagcctccc tccggacaat gagtcccccc tctt 534

<210> 105
 <211> 1081
 <212> DNA
 <213> Homo sapien

<400> 105
 ctattggtca ggacgtttcc tatgctaata aaggggtggc ccgtagaaga ttccagcacc 60
 ctcccctaac tccaggccag actcctttca gctaaagggg agatctggat ggcattctact 120
 tcgtatgact attgcagagt gcccatggaa gacggggata agcgtgtaa gcttctgctg 180
 gggataggaa ttctggtgct cctgatcatc gtgattctgg ggggtgccctt gattatcttc 240
 accatcaagg ccaacagcga ggctgcccgg gacggccttc gggcagtgat ggagtgtcgc 300
 aatgtcacc atctcctgca acaagagctg accgaggccc agaagggtt tcaggatgtg 360
 gagggcccag ccgccacctg caaccacact gtgatggccc taatggcttc cctggatgca 420
 gagaaggccc aaggacaaaa gaaagtggag gagcttgagg gagagatcac tacattaaac 480
 cataagcttc aggacgcgtc tgcagaggtg gagcgactga gaagagaaaa ccaggcttta 540
 agcgtgagaa tcgcggacaa gaagtactac ccagctccc aggactccag ctccgctgcg 600
 gcgccccagc agcacaatca gcagctgggg cgccgcagct gctgattgtg ctgctgggcc 660
 tcagcgctct gctgcagtga gatcccagga agctggcaca tcttggaagg tccgtcctgc 720
 tcggcttttc gcttgaacat tcccttgatc tcatcagttc tgagcgggtc atggggcaac 780
 acggttagcg gggagagcac ggggtagccg gagaagggcc tctggagcag gtctggaggg 840
 gccatggggc agtcctgggt gtggggacac agtcgggttg acccagggt gtctccctcc 900
 agagcctccc tccggacaat gagtcccccc tcttgtctcc caccctgaga ttgggcatgg 960
 ggtgcggtgt ggggggcatg tgctgcctgt tgttatgggt tttttttgcg ggggggggtg 1020
 cttttttctg gggcttttga gctccaaaaa ataaacactt cctttgaggg agagcacacc 1080

105

t

1081

<210> 106
<211> 1075
<212> DNA
<213> Homo sapien

<400> 106
ctattggtca ggacgtttcc tatgctaata aaggggtggc ccgtagaaga ttccagcacc 60
ctcccctaac tccaggccag actcctttca gctaaagggg agatctggat ggcatctact 120
tcgtatgact attgcagagt gcccatggaa gacggggata agcgctgtaa gcttctgctg 180
gggataggaa ttctggtgct cctgatcatc gtgattctgg gggtgccctt gattatcttc 240
accatcaagg ccaacagcga ggcctgccgg gacggccttc gggcagtgat ggagtgtcgc 300
aatgtcaccc atctcctgca acaagagctg accgaggccc agaagggctt tcaggatgtg 360
gaggcccagg ccgccacctg caaccacact gtgatggccc taatggcttc cctggatgca 420
gagaaggccc aaggacaaaa gaaagtggag gagcttgagg tcactacatt aaaccataag 480
cttcaggacg ctttaagacct ggTTTTctct tctcagtcgc tccacctctg cagacgcgtc 540
tgagaagaga aaaccaggtc ttaagcgtga gaatcgcgga caagaagtac taccacagct 600
cccaggactc cagctccgct gcggcgcccc agctgctgat tgtgctgctg ggcctcagcg 660
ctctgctgca gtgagatccc aggaagctgg cacatcttgg aaggTccgtc ctgctcggct 720
tttcgcttga acattccctt gatctcatca gttctgagcg ggtcatgggg caacacgggt 780
agcggggaga gcacggggta gccggagaag ggcctctgga gcagggtctgg agggggccatg 840
gggcagtcct ggggtgtgggg acacagtcgg gttgacccag ggctgtctcc ctccagagcc 900
tccctccgga caatgagtcc cccctcttgt ctcccaccct gagattgggg atgggggtgcg 960
gtgtgggggg catgtgctgc ctgttggtat gggTTTTTTT tgcggggggg gttgctTTTT 1020
tctgggggtct ttgagctcca aaaaataaac acttcctttg agggagagca cacct 1075

<210> 107
<211> 672
<212> DNA
<213> Homo sapien

<400> 107
ctccgaagtc tagagagaga ggctgcaggg gaagggaactg ggcgcagagg tgaggggcct 60
tggggaagga gggagaatcc agtgagaagg atgccctgga tcggggggcg gctgatagct 120
gtatggggcg gggctatcaa tggggggcggg tctatcgatg gaggggaggg gcttatggat 180
gggtggggcg ggtctagcga tggggggcggg gcttggggcc gggcttgagg cggggccagt 240

106

gcctgctgcc tccagtctgc cctgagtccc tcttctggtc ctttaggcac atcttggaag 300
gtccgtectg ctgggctttt cgcttgaaca ttcccttgat ctcatcagtt ctgagcgggt 360
catggggcaa cacggtttagc ggggagagca cggggtagcc ggagaagggc ctctggagca 420
ggtctggagg ggccatgggg cagtcctggg tgtggggaca cagtcgggtt gacccagggc 480
tgtctccctc cagagcctcc ctccggacaa tgagtcccc ctcttgctc ccaccctgag 540
attgggcatg ggggtgcggtg tggggggcat gtgctgcctg ttgttatggg ttttttttgc 600
gggggggggtt gcttttttct ggggtctttg agctccaaaa aataaacact tcctttgagg 660
gagagcacac ct 672

<210> 108
<211> 438
<212> DNA
<213> Homo sapien

<400> 108
ggggaggacg gagactttga tcgactccat atggagaggc aaccatgtct ggaagttgac 60
tatagcctgg agtcccaggc gtgcggggca ggtggaggac atacatttca cagatgagag 120
acaggcagat tccccacaat tctgcatgct ttggagacct gtacaatgag aagccattgg 180
tatgtcccat gctcttgctg tagtggggaa ccttgagcgt gctctgtttc aagtctctc 240
agatcatcaa gtagtatcct gggggaaaaa cagagcgtgg tagacattga agaggagcg 300
aattgagtgt ggggatggca ttttgtgact ttgcactgag aaattcggag atacatttgt 360
catcactcca cttgtatatt ggttccggat gacgctcccc gacaagagaa taagataaat 420
aaattattgg gctgcttt 438

<210> 109
<211> 674
<212> DNA
<213> Homo sapien

<400> 109
gattaattga tctgattttt ctgtaggttg gggagttgat gaggcagagc tatgcctcca 60
aaaagtagtt tctaatagca gagctgtagt ccaggtttgc ttcccgca ga gtggagaagc 120
cagtgcctagc tgcaggcctg cttcatgtga acgctttatt aagtatggc tttcctcaag 180
gtacagacac tgtgggaggc aggactcctt tgctcacctc ctttgggatt ctttgctttt 240
caggttgcag agcctgaggc ctgtgatcag atgtacgaga gcttagcgcg actccattca 300
aactactgac aaaccacaag gtgagtgggc cacagtcttt tatataccca gctttctgac 360
gggacaacta ataagaatga gtgaaaatct gattaggtaa tgttttgtaa agacttggct 420
ttgctgcgtt caaatgaaac cagtaatttc aaccaagcca acagaggtgc ctggtagagg 480

107

cttttaggcc acctaaataa aagctattta aaattgtgaa tataggggaag aaacaaaacc 540
aattatgaat agaagccatg tatttgatat gccagtgtgt gctcctggga atgtctgaca 600
gccattggat ttatacctat tttcccatcc actctgacgg aactgacacc tccccacatt 660
ctggtgataa agat 674

<210> 110
<211> 1099
<212> DNA
<213> Homo sapien

<400> 110
catccagtaa cctgtattta catgcaaata tattggttta tgcaaaacag cggaggcctc 60
gggggagggg ttttttagtct caagcttgtg cagtcattga aaaagagacg caaagctgtc 120
tctgggggtac tccacgtccg ccttgcccct gggagctggg ccggttccag gaggacgaag 180
actgaattag ctcggttgc agagaaaggc gagcagcgcc cctacacgga gagtagcggc 240
gcgctacaa agtcgcgcat gccactccg gcctcccgct ccactcctaa ggcaggcggc 300
gaggcttagt gcgcaagcgc cattcgctcg cgccgactcc tcccgctaag gcgggaacac 360
gcggggccca agatggcggc cagccggtac cggcgttttc ttaagctctg tgaggaatgg 420
ccagtggacg agaccaaacg gggccgggac ttgggcgctt acctgcgaca gcgggtagca 480
caggcctttc gggagggaga gaatacccag gttgcagagc ctgaggcctg tgatcagatg 540
tacgagagct tagcgcgact ccattcaaac tactacaaac acaagtaccc tcgccccaga 600
gacaccagct tcagtggcct gtcgttgga gagtacaagc tgatcctgtc cacagacacc 660
ttggaagagc ttaaggaaat agataaaggc atgtggaaga aactgcagga gaagtttgcc 720
cccaagggtc ctgaggagga tcataaggcc tgagctcagg ccttacctcg tgcacatacc 780
taggtgtgga gtcttgtaca ttgccatcgt caataaaact gccccagttt ccccttaaaa 840
aaaaaaacaa cacagaacac aaacactgtt tgtggccgcc ctgccccag aaaaagggtt 900
ataaaccatt cgtgtgtggg cggccgcgca tagtgtcggc taaccgtgcg ccacgctggc 960
cccaaggaaa accggggcca gaactcagtg gtgtgggtccc caccaataaa aacgccgcg 1020
gaccggggt cggacaatcc aagtggctgg agccataccg gctacacagc gccaggact 1080
gatatcccgg gaggggaca 1099

<210> 111
<211> 289
<212> DNA
<213> Homo sapien

<220>

108

<221> misc_feature
 <222> (2)..(2)
 <223> n=a, c, g or t

<400> 111
 gntctagatc gcgagcagcc gctcggatct agaactagta ccctcgcccc agagacacca 60
 gcttcagtgg cctgtcgttg gaagagtaca agctgacctt gtccacagac accttggaag 120
 agcttaagga aatagataaa ggcatgtgga agaaactgca ggagaagttt gcccccaagg 180
 gtcctgagga ggatcataag gcctgagctc aggccttacc tcgtgcacat acctaggtgt 240
 ggagtcttgt acattgccat cgtcaataaa actgccccag ttccccctt 289

<210> 112
 <211> 2770
 <212> DNA
 <213> Homo sapien

<400> 112
 ggcagcaacg aaggctggga gatagtcccg ccattgggtcc gcgctgcagc ttgttctggc 60
 agcgagttta gttcaggaaa tttgctgaga atttgttttc acagcaagcc tcatattttt 120
 gttgcaaatt gtgtggcgta acttaccaaa tgtttcctct gacaggacaa gaaaagacct 180
 gcagcacctt gtagtgagag gctttgaggg cctggcaagt ctgaaatgtg ctgtgttctg 240
 ggttatgtgt gtgtccaccc tgggattggg gtcattggaaa gcgcctaagg gaggcctcag 300
 tgtccacctg gacactggaa acatggactt ctggaaaagc tccagagcag gggctttttt 360
 ctgttacctt ttttggtcag aaaagatact ctttttttct ccagtagttt tgttaacgtg 420
 aaaatttagg ctggtaaagc aaaacaatat tataagaata tctaaaattt aacatgcacg 480
 taaaattaga tttcatggaa cattagccct agagacttta gacaaatggc tccgtactgg 540
 ggggatgggt ttgcccccca ggggacatgt ggcaatgtct ggagacattt ttagttgtca 600
 caactgggtg tgcgggcagc ggtgctactg gcattagtgg gtagaggcca ggatgctttg 660
 aaacagcctt cagtgatgca caggccagcc cacgacgaaa aattatctgg cccaaagtgt 720
 tggtagtgcc aaggccaaga aacctgctt tggttcctgg gtgtagggac gtgtatgttc 780
 ttaaacaaga gcccctccc cctgcattgt ggtggatgat ggctgccttt tcattgagtg 840
 cgggctgtgt gccaaagcag ttacctccat gcttttcttt aatccttaca acttttgagg 900
 tacgtgtggt tttttttttt ttactttttt acctctcccc aagttgtctg cagatgtgtg 960
 ttttttatctt cattttacag atgaggaacc cgaagcgtag aggggttaagt aatttgcttg 1020
 aggggaccca gagtgggaga tgatgggctc ggattcaggc ccaaggccat ccccctcca 1080
 gtgcctgctc aactccacag catgtgctga gtccacacac caggattcaa atccctgctc 1140

109

cacttcccag ctgtgcaacc tgagcaagtt acttcactgc ctccctgcctc agttttccaca 1200
cctgaaaact ggggacagga agggctgtgt ggagcaggcc aaatttttgcg atgaagcatc 1260
tgggtctgtg ggttgccacag cggacagcgc agggccattt ctttgcctc atacggagca 1320
gggcaacgag cagcacatcc cgctttgatg ccgaggggtga ggagagggca ggagaccact 1380
gacagcgtgc tgggcacaga gtctggcaca cagtgtcag tccccgcaag cggtcacttc 1440
tgttacctgt ttgatctgct cttcaggagc tgggtctcca cctttttcag gaacacactg 1500
tgtgaaaagc aagccatgct tgtgtcggga aagcccagtg ggtccaatct atgtcatcaa 1560
gttttagact tcagtcctc tctctttttg tcttccctt ttgcagacac cttggaagag 1620
cttaaggaaa tagataaagg catgtggaag aaactgcagg agaagtttgc cccaagggt 1680
cctgaggagg atcataaggc ctgagctcag gccttacctc gtgcacatac ctaggtgtgg 1740
agtcttgtag attgccatcg tcaataaaac tgccccagtt tccccttgac cttacggttt 1800
gggaatctcc tctagctttc ccagaaagga agcccttgct gctctaaaga aagtttcagc 1860
ctgagaaggg atggtgattg agctatctgc tgtgactgct gctcagggtg gggaaatctc 1920
ctggggagag gaaatgcagg tttccctctg ggcctgatga gggtaatggg gcctcggcac 1980
aaggtgcttc ctgcattgcc acgggagccc ccgcccctct ggcacgggtc tgggtgtctcc 2040
tggcaagata ctcaggctcc cttttgttgt aggagctcct gggaggaagc caaaaatagc 2100
agtaaatact gaaaagggca tcctgttgca aagagaaagc agtagggagg tgtgaggccg 2160
agagaggcaa aaagcctgct tggccctcat cccactgac tcagagaagg atggacctta 2220
ggcctctatc cctgaccttg caaaaaccca cattgcccag ttggcttaag ggacagggaa 2280
gctatagaca ggccttggcc aagcggggcc tcagctgcag ttggcttcag cactgtgggc 2340
aggttctgta ggtggccaca agtcagaggc cctgctggct gaggacacac acagggtcac 2400
ctcattattc catggaacct tggctcttac tgatattgag catccttctc tctggaaccg 2460
tgagggacag ggctgggccc acagcggccc tgggtgggtac aaagtggaag tgggttctta 2520
acctcgtctg tgtctagact cctcaggatg ttctgaaatg cataaaataa aatcgacagg 2580
actgccgtag aaaccagtta tgccgaaatg cagttctggg taggcaaatc tcaggggagg 2640
acccttgaga caggatgtca ctcagcgtat ctccctgagag cctgagaggc caggccagca 2700
gggaggggct cttgttcctg tcttctgcca gtgtgtcctg ttaatcccca cagcccccg 2760
gggagtgcag 2770

<210> 113
<211> 1819
<212> DNA
<213> Homo sapien

<400> 113
 catccagtaa cctgtattta catgcaaata tattggttta tgcaaaacag cggaggcctc 60
 gggggaggggt ttttttagtct caagcttgtg cagtcattga aaaagagacg caaagctgtc 120
 tctgggggtac tccacgtccg ccttgccccct gggagctggg ccggttccag gaggacgaag 180
 actgaattag ctgggcttgc agagaaaggc gagcagcgcc cctacacgga gagtagcggg 240
 gcgcctacaa agtcgcgcat gccactccg gcctcccgt cactcctaa ggcaggcggc 300
 gaggcttagt gcgcaagcgc cattcgtcgg cgcgactcc tcccgctaag gcgggaacac 360
 gcggggccca agatggcggc cagccgggtac cggcgttttc ttaagctctg tgaggaatgg 420
 ccagtggacg agaccaaacg gggccgggac ttgggcgctt acctgcgaca gcgggtagca 480
 caggcctttc gggagggaga gaatacccag gttgcagagc ctgaggcctg tgatcagatg 540
 tacgagagct tagcgcgact ccattcaaac tactacaaac acaagtacc tcgccccaga 600
 gacaccagct tcagtggcct gtcgttggaa gagtacaagc tgatcctgtc cacagacacc 660
 ttggaagagc ttaaggaaat agataaaggc atgtggaaga aactgcagga gaagtttgcc 720
 cccaagggtc ctgaggagga tcataaggcc tgagctcagg ccttacctcg tgcacatacc 780
 taggtgtgga gtcttgtaca ttgccatcgt caataaaact gcccagttt ccccttgacc 840
 ttacggtttg ggaatctcct ctagctttcc cagaaaggaa gcccttgctg ctctaaagaa 900
 agtttcagcc tgagaaggga tgggtattga gctatctgct gtgactgctg ctcagggtag 960
 ggaaatctcc tggggagagg aaatgcaggt ttccctctgg gcctgatgag ggtaatgggg 1020
 cctcggcaca aggtgcttcc tgcattgcca cgggagcccc cgccctctg gcacgggtct 1080
 ggtgtctcct ggcaagatac tcaggctccc ttttgttgta ggagctcctg ggaggaagcc 1140
 aaaaatagca gtaaatactg aaaagggcat cctgttgcaa agagaaagca gtagggaggt 1200
 gtgaggccga gagaggcaaa aagcctgctt ggccctcatc ccactgact cagagaagga 1260
 tggaccttag gcctctatcc ctgaccttgc aaaaaccac attgcccagt tggcttaagg 1320
 gacaggggaag ctatagacag gccttggcca agcggggcct cagctgcagt tggcttcagc 1380
 actgtgggca ggttctgtag gtggccacaa gtcagaggcc ctgctggctg aggacacaca 1440
 cagggtcacc tcattattcc atggaacctt ggctcttact gatattgagc atccttctct 1500
 ctggaaccgt gagggacagg gctgggcca cagcggccct ggtgggtaca aagtggaagt 1560
 gggttcttaa cctcgtctgt gtctagactc ctcaggatgt tctgaaatgc ataaaataaa 1620
 atcgacagga ctgccgtaga aaccagttat gccgaaatgc agttctgggt aggcaaactc 1680
 caggggagga cccttgagac aggatgtcac tcagcgtatc tcctgagagc ctgagaggcc 1740
 aggccagcag ggaggggctc ttgttcctgt cttctgccag tgtgtcctgt taatccccac 1800

111

agcccccggg ggagtgcag

1819

<210> 114

<211> 415

<212> DNA

<213> Homo sapien

<400> 114

gtcagaggcag ccccttaggg ggcttaggcc tgccctgtgg agcatccctg cggggaactc 60

ccgccagctt gagcgacgcg gatcctgcga gcgctcctgg gtaggcaatt gccccggtgg 120

aacgcctagt cagagcagtg cgtggcaggc ccccggtggag tatcaacgca gtggctgaac 180

accgggaagg aacaggcact tggagtccgg acatttgaaa cttggaatgt tgcatagaac 240

gaccgcctct tgggtgcgt ggcttcggag cagctttgac tacaactccc agactgcac 300

gcccctgccc cccacttcc ggagctgact tcacttcgag gaaccttttc cctccaggaa 360

tcaaggatth tcttttgctt tgtggccgga ttttgctact gcttgctctt cttac 415

<210> 115

<211> 1314

<212> DNA

<213> Homo sapien

<400> 115

gggaacggga gatgttgcag gcgccgagag ggcgggccag ggccgcactc cggagactcg 60

gcggttgcta cgcgcaccat ggctggaggt acctgcgggg gattcctggg gccgcggttc 120

tcttggtcct ctgggttgag gcgtggcagg gagtgggggtg gcggagcgaa ggggcgtggc 180

tgaggggtct tcgtgcacac cctaccggga ggggcgctgc caggtgaggg gatgccatgg 240

cggccgtgac tcctaggccc cctcttcctg aaggctgtcg cgcctcttc tcagcgccca 300

cggctctcgt tcctgaactc cgttcactcc tagcctccgg acgggcccgg ctcttcgacg 360

tgcgctctcg cgaggaggcg gcagctggga ccatcccagg ggcgctcaac atcccgggta 420

taggggtggag aggggacgcc caggtggtgg aatagagacc gttcaggagg ttctttgcca 480

atgggacctc atttaggatg gaatggggaa ggcaactgatt atgggggtcc tgcattcccg 540

ggagccagcc ctacgcttcc gtaggaagga ctgatggggg gcggatcttg gcatcggaac 600

tggcccatcc agtttgagaa gacagcaggc ggagaggaga ggggcagacc agcttctctt 660

gacctcccca aatctggacg cctgaggggg catcccgcc cgcctcctca cagcttaggg 720

agtggcttgc attcaaaagt tgtcgggtttc tgctccttga aattgggggtg ggggtagggg 780

atggttatca tatgttgttt gggggccccc aggaccagc ccttccaggc ccagcttccg 840

aacctgagtg ccaaattgct ggctttccct tctaccctct ccactcctcc agtgtccgag 900

112

ttggagagtg ctctgcagat ggagccagct gccttccagg ctttatattc tgctgagaag 960
ccaaagctgg aagatgagca tctcgttttc ttctgtcaga tgggcaagcg gggcctccag 1020
gccacgcagc tggcccggag tcttggatac actgggtacg gggaggtgtg gctgctagct 1080
gggaggtgat ggggactgcc tgtcattcct gtcagtctct cacgcttctt tgtctccaca 1140
gggctcgcaa ctacgctgga gcctatagag aatgggttga gaaagagagt taggcaggag 1200
gcagcttact gattgccacc cctggcccct taatggccac cttaactaag ggtgtgaacg 1260
ggctgacttg gtgaattggg caactcctta tagtggtgtg cacacaaaag catc 1314

<210> 116
<211> 1067
<212> DNA
<213> Homo sapien

<400> 116
ttccggatcc ggtctcagct ctgggagggga acgggagatg ttgcaggcgc cgagagggcg 60
ggccaggggc gcactccgga gactcgcggt tgctacgcgc accatggctg gagcgcccac 120
ggtctcgctt cctgaactcc gttcactcct agcctccgga cgggcccggc tcttcgacgt 180
gcgctctcgc gaggagggcg cagctgggac catcccaggg gcgctcaaca tcccgggtat 240
aggggtggaga ggggacgccc aggtgggtga atagagaccg ttcaggaggt tctttgccaa 300
tgggacctca tttaggatgg aatggggaag gcactgatta tgggggtcct gcattcccgg 360
gagccagccc tcagcttccg taggaaggac tgatgggggg cggatcttgg catcggaact 420
ggcccatcca gtttgagaag acagcaggcg gagaggagag gggcagacca gcttctcttg 480
acctccccaa atctggacgc ctgagggggc atcccgcccc gcctcctcac agcttaggga 540
gtggcttgca ttcaaaagtt gtcggtttct gttccttgaa attgggggtg gggtagggga 600
tggttatcat atgttgtttg ggggccccca ggaccagcc cttccaggcc cagcttccga 660
acctgagtgc caaattgctg gctttccctt ctaccctctc cactcctcca gtgtccgagt 720
tggagagtgc tctgcagatg gagccagctg ccttccaggc tttatattct gctgagaagc 780
caaagctgga agatgagcat ctcgttttct tctgtcagat gggcaagcg ggcctccagg 840
ccacgcagct ggcccggagt cttggataca ctggggctcg caactacgct ggagcctata 900
gagaatgggt ggagaaagag agttaggcag gaggcagctt actgattgcc accccctggc 960
cccttaatgg ccaccttaac taaggggtgt aacgggctga cttggtgaat tgggcaactc 1020
cttatagtgt tgtgcacaca tcgcaacggt ascgagctcg atgtacc 1067

<210> 117
<211> 742
<212> DNA

113

<213> Homo sapien

<400> 117

```

gggaaaagct ctgtgccatc ctcaaattgc aatggcccag gtcccaccag ggacacctag      60
acgtgggctc cccagacatc agggcctggg tcatgccacc cacctccacc aagctgtctt      120
ctgctgggtg gccgagggca tgagggcaga caccacgtgt agccctaggg tggcagtggg      180
cactgcagca gaggggctgt tgctcagagt ccacatgtgg gggaaggag atgttgcagg      240
cgccgagagg gcggggccagg gccgcactcc ggagactcgc gggtgctacg cgcaccatgg      300
ctggagtgtc cgagttggag agtgctctgc agatggagcc agctgccttc caggctttat      360
attctgctga gaagccaaag ctggaagatg agcatctcgt tttcttctgt cagatgggca      420
agcggggcct ccaggccacg cagctggccc ggagtcttgg atacactggg gctcgcaact      480
acgctggagc ctatagagaa tggttggaga aagagagtta ggcaggaggc agcttactga      540
ttgccacccc ctggcccctt aatggccacc ttaactaagg gtgtgaacgg gctgacttgg      600
tgaattgggc aactccttat agtgttgtgc acacaaaagc atcaaataaa gaacatttaa      660
tcaaaaaaaaa agagtagaaa aagagaaaaa actttggggg gggcgttggg cccttggaag      720
aagtttttaa gaccattggt gg                                         742

```

<210> 118

<211> 4633

<212> DNA

<213> Homo sapien

<400> 118

```

gggaaaagct ctgtgccatc ctcaaattgc aatggcccag gtcccaccag ggacacctag      60
acgtgggctc cccagacatc agggcctggg tcatgccacc cacctccacc aagctgtctt      120
ctgctgggtg gccgagggca tgagggcaga caccacgtgt agccctaggg tggcagtggg      180
cactgcagca gaggggctgt tgctcagagt ccacatgtgg gggaaggag atgttgcagg      240
cgccgagagg gcggggccagg gccgcactcc ggagactcgc gggtgctacg cgcaccatgg      300
ctggagaggt acttctcagc cctctagctc caactgagaa cccagccagt caggaagtgc      360
ctacttcggg aacaccaacc aatcaggggg ccgtcacctg ctgaagggtt ggctctcagt      420
cccctcgctg tagtcgcgga gctgtgtctg ttcccaggag tccttcggcg gctgttgtgt      480
cagtggcctg atcgcgatgg ggacaaaggc gcaagtcgag aggaaactgt tgtgcctctt      540
catattggcg atcctgttgt gctccctggc attgggcagt gttacagtgc actcttctga      600
acctgaagtc agaattcctg agaataatcc tgtgaagttg tcctgtgcct actcgggctt      660
ttcttctccc cgtgtggagt ggaagtthga ccaaggagac accaccagac tcgtttgcta      720
taataacaag atcacagctt cctatgagga ccgggtgacc ttcttgccaa ctggtatcac      780

```

cttcaagtcc gtgacacggg aagacactgg gacatacact tgtatgggtct ctgaggaagg	840
cggcaacagc tatggggagg tcaaggtcaa gctcatcgtg cttgtgcctc catccaagcc	900
tacagttaac atccccctct ctgccaccat tgggaaccgg gcagtgcctga catgctcaga	960
acaagatggg tccccacctt ctgaatacac ctgggttcaaa gatgggatag tgatgcctac	1020
gaatcccaaa agcaccctgt ccttcagcaa ctcttcctat gtccctgaatc ccacaacagg	1080
agagctgggc tttgatcccc tgtcagcctc tgatactgga gaatacagct gtgaggcacg	1140
gaatgggtat gggacaccca tgacttcaaa tgctgtgcgc atggaagctg tggagcggaa	1200
tgtgggggtc atcgtggcag ccgtccttgt aacctgatt ctccctggga tcttggtttt	1260
tggcatctgg tttgcctata gccgaggcca ctttgacaga acaaagaaat ctgccccag	1320
aggctctcct ttgtactgcc cccatcccag ggcttggcat ggggtgtcatc tgagtactga	1380
ccctgatact gtgctcatgt gtgtgggtgt tgtcccctgg ggaacactga tcacccatct	1440
aacaccaaga gctggggggc tgcccctcca tcttcccaag ccatgctgtc ttctgtcctg	1500
ctgacactca tgatcccatt tcttctcttt caggaacaaa gaaaggggtga gtgaggtgct	1560
gtcctggggg tctccaagtt tgagagcatg gatgcatgtg gtttgaagct gaagtgggcc	1620
taggggaatg ggttgaaggc agaagcaacc agtttggagg gaaggcattt ggatatccag	1680
ccctttctct gtggccttgg ccctgggtct gtccctgttac cccacccata cctgtctgct	1740
gcgcacatct gtgcttctgt agcattctcg cttctggcct ttaaagttgg caaggggagg	1800
ttaataagca cctaggtggc tgagtgtctc tgtcttctgg cttgttcaca gggacttcga	1860
gtaagaaggt gatttacagc cagcctagtg cccgaagtga aggagaattc aaacagacct	1920
cgtcattcct ggtgtgagcc tggtcggctc accgcctatc atctgcattt gccttactca	1980
ggtgctaccg gactctggcc cctgatgtct gtagtttcac aggatgcctt atttgtcttc	2040
tacacccac agggccccct acttcttcgg atgtgttttt aataatgtca gctatgtgcc	2100
ccatcctcct tcatgccctc cctcccttcc ctaccactgc tgagtggcct ggaacttggt	2160
taaagtgttt attccccatt tctttgaggg atcaggaagg aatcctgggt atgccattga	2220
cttcccttct aagtagacag caaaaatggc gggggtcgca ggaatctgca ctcaactgcc	2280
cacctggctg gcagggatct ttgaataggt atcttgagct tgggtctggg ctctttcctt	2340
gtgtactgac gaccagggcc agctgttcta gagcgggaat tagaggctag agcggctgaa	2400
atgggtgttt ggtgatgaca ctggggtcct tccatctctg gggccactc tcttctgtct	2460
tcccatggga agtgccactg ggatccctct gccctgtcct cctgaataca agctgactga	2520
cattgactgt gtctgtggaa aatgggagct cttgttgtgg agagcatagt aaattttcag	2580

115

agaacttgaa	gccaaaagga	tttaaaaccg	ctgctctaaa	gaaaagaaaa	ctggaggctg	2640
ggcgcagtgg	ctcacgccta	taatcccaga	ggctgaggca	ggcggatcac	ctgaggtcag	2700
gagttcaaga	tcagcctgac	caacatggag	aaaccctact	gaaaatacaa	agttagccag	2760
gcatggtggt	gcatgcctgt	aatcccagct	gctcaggagc	ctggcaacaa	gagcaaaact	2820
ccagctcaaa	aaaaaaaaag	aaagaaaaga	aagctggagc	tggtggctta	ggccatcacc	2880
cttcccttgg	ctggaactac	tggacagacc	cttttgagat	gtgcctgtgg	tgctgtggag	2940
atgtgtgtag	tggtcttagc	tctttgttga	gcttgtgtgt	gtgttgtgta	gtcttagctg	3000
tatgctgaaa	ttgggcgtgt	gttggagggc	ttcttagctc	tttggtgaga	ttgtatttct	3060
atgtgtttgt	atcagctgaa	tgttgctgga	aataaaacct	tggtttgtca	aggctctttt	3120
ttgtgggaag	taagtagggg	aaaaggctct	tgagggttcc	taggctcctt	tgtacaacag	3180
gaaaatgcct	caaagccttg	cttcccagca	acctggggct	ggttcccagt	gcctggctct	3240
gccccttcct	ggttcttata	tcaaggcaga	gcttctgaat	ttcaggcctt	cattccagag	3300
ccctcttgtg	gccaggcctt	cctttgctgg	aggaaggtag	acagggtgaa	gctgatgctg	3360
tacttggggg	atctccttgg	cctgttccac	caagttagag	aaggtagtta	ctcttgtacc	3420
tcctgttcag	ccagggtgat	taacagacct	ccctacagct	gtaggaacta	ctgtcccaga	3480
gctgaggcaa	ggggatttct	caggctcattt	ggagaacaag	tgctttagta	gtagttttaa	3540
gtagtaactg	ctactgtatt	tagtgggggtg	gaattcagaa	gaaatttgaa	gaccagatca	3600
tgggtggtct	gcatgtgaat	gaacaggaat	gagcgggaca	gcctggctgt	cattgctttc	3660
ttcctcccca	tttggaccct	tctctgccct	tacatttttg	tttctccatc	taccaccatc	3720
caccagtcta	tttattaact	tagcaagagg	acaagtaaag	ggccctcttg	gcttgatttt	3780
gcttctttct	ttctgtggag	gatatactaa	gtgcgacttt	gccctatcct	atttggaat	3840
ccctaacaga	attgagtttt	ctattaagga	tccaaaaaga	aaaacaaaat	gctaataaag	3900
ccatcagtca	agggtcacat	gccataaac	aataaatttt	ccagaagaaa	tgaaatccaa	3960
ctagacaaat	aaagtagagc	ttatgaaatg	gttcagtaaa	gatgagtttg	ttgttttttg	4020
ttttgttttg	ttttgttttt	ttaaagacgg	agtctcgctc	tgtaaccacg	gctggagtgc	4080
agtggtagat	tcttgggtca	ctgtaacctc	cgcctcccgg	gttcaagcca	ttctcctgcc	4140
tcagtctcct	gagtagctgg	gattgcgggt	gcgtgccacc	atgcctggct	aatttttgtg	4200
tttttagtag	agacagggtt	tcaccatggt	ggcggggctg	gtctcagact	cctgacctct	4260
tgatccgcct	gccttggcct	cccaaagtga	tgggattaca	gatgtgagcc	accgtgccta	4320
gccaaggatg	agatttttaa	agtatgtttc	agttctgtgt	catggttgga	agacagagta	4380
ggaaggatat	ggaaaaggtc	atgggggaagc	agaggtagatt	catggctctg	tgaatttgag	4440

116

gtgaatgggt ccttattgtc tagggcactt gtgaagaata tgagtcagtt attgccagcc 4500
 ttggaattta cttctctagc ttacaatgga ccttttgaac tggaaaacac cttgtctgca 4560
 ttcactttta aatgtcaaaa ctaattttta taataaatgt ttattttcac attgagtttg 4620
 tttaaatacct gaa 4633

<210> 119
 <211> 4249
 <212> DNA
 <213> Homo sapien

<400> 119
 gggaaaagct ctgtgccatc ctcaaattgc aatggcccag gtcccaccag ggacacctag 60
 acgtgggctc ccagacatc agggcctggg tcatgccacc cacctccacc aagctgtctt 120
 ctgctgggtg gccgagggca tgagggcaga caccacgtgt agccctaggg tggcagtggg 180
 cactgcagca gaggggctgt tgctcagagt ccacatgtgg gggaaggag atgttgcagg 240
 cgccgagagg gcgggcccagg gccgcactcc ggagactcgc ggttgctacg cgcaccatgg 300
 ctggagaggt acttctcagc cctctagctc caactgagaa ccagccagt caggaagtcc 360
 ctacttcggg aacaccaacc aatcaggggg ccgtcacctg ctgaagggtt ggctctcagt 420
 cccctcgctg tagtcgcgga gctgtgtctg ttcccaggag tccttcggcg gctgttgtgt 480
 cagtggcctg atcgcgatgg ggacaaaggc gcaagtcgag aggaaactgt tgtgcctctt 540
 catattggcg atcctgttgt gctcctggc attgggcagt gttacagtgc actcttctga 600
 acctgaagtc agaattcctg agaataatcg tgagttggga ggggccatgg aggggtgtgag 660
 ggtgagcagt tgccggccgc ctggggatct agagagcacc cagcccagcc tgcagtttgg 720
 ggctgttccc catctcgtgt atttgctgct gcttcttctt tcggctcatt ttgacctgt 780
 ctgcagctgt gaagttgtcc tgtgcctact cgggcttttc ttctccccgt gtggagtggg 840
 agtttgacca aggagacacc accagactcg tttgctataa taacaagatc acagcttcct 900
 atgaggaccg ggtgaccttc ttgccaaactg gtatcacctt caagtccgtg acacgggaag 960
 aactgggac atacacttgt atggtctctg aggaaggcgg caacagctat ggggaggtca 1020
 aggtcaagct catcgtgctt gtgcctccat ccaagcctac agttaacatc ccctcctctg 1080
 ccaccattgg gaaccgggca gtgctgacat gctcagaaca agatgggttcc ccaccttctg 1140
 aatacacctg gttcaaagat gggatagtga tgcctacgaa tcccaaaagc acccgtgcct 1200
 tcagcaactc ttctatgtc ctgaatccca caacaggaga gctgggtctt gatccctgt 1260
 cagcctctga tactggagaa tacagctgtg aggcacggaa tgggtatggg acacccatga 1320
 cttcaaattg tgtgcgcatg gaagctgtgg agcggaatgt gggggtcatc gtggcagccg 1380

tccttgtaac	cctgattctc	ctgggaatct	tggttttttg	catctgggtt	gcctatagcc	1440
gaggccactt	tgacagaaca	aagaaagga	cttcgagtaa	gaagggtgatt	tacagccagc	1500
ctagtgcctg	aagtgaagga	gaattcaaac	agacctcgtc	attcctgggtg	tgagcctggg	1560
cggctcaccg	cctatcatct	gcatttgcct	tactcaggtg	ctaccggact	ctggcccctg	1620
atgtctgtag	tttcacagga	tgcccttattt	gtcttctaca	ccccacaggg	ccccctactt	1680
cttcggatgt	gtttttaata	atgtcagcta	tgtgccccat	cctccttcat	gccctccctc	1740
cctttcctac	cactgctgag	tggcctggaa	cttgtttaaa	gtgtttattc	cccatttctt	1800
tgagggatca	ggaaggaatc	ctgggtatgc	cattgacttc	ccttctaagt	agacagcaaa	1860
aatggcgggg	gtcgcaggaa	tctgcactca	actgcccacc	tggctggcag	ggatctttga	1920
ataggtatct	tgagcttggg	tctgggctct	ttccttgtgt	actgacgacc	agggccagct	1980
gttctagagc	gggaattaga	ggctagagcg	gctgaaatgg	ttgtttgggtg	atgacactgg	2040
ggtccttcca	tctctggggc	ccactctctt	ctgtcttccc	atgggaagtg	ccactgggat	2100
ccctctgccc	tgtcctcctg	aatacaagct	gactgacatt	gactgtgtct	gtggaaaatg	2160
ggagctcttg	ttgtggagag	catagtaa	tttcagagaa	cttgaagcca	aaaggattta	2220
aaaccgctgc	tctaaagaaa	agaaaactgg	aggctgggcg	cagtggctca	cgcctataat	2280
cccagaggct	gaggcaggcg	gatcacctga	ggtcaggagt	tcaagatcag	cctgaccaac	2340
atggagaaaac	cctactgaaa	atacaaagtt	agccaggcat	ggtgggtgcat	gcctgtaatc	2400
ccagctgctc	aggagcctgg	caacaagagc	aaaactccag	ctcaaaaaaa	aaaaagaaag	2460
aaaagaaagc	tggagctggg	ggccttaggcc	atcacccctc	ccttggctgg	aactactgga	2520
cagacccttt	tgagatgtgc	ctgtgggtgct	gtggagatgt	gtgtagtggt	cttagctctt	2580
tgttgagctt	gtgtgtgtgt	tgtgtagtct	tagctgtatg	ctgaaattgg	gcgtgtgttg	2640
gagggcttct	tagctctttg	gtgagattgt	atttctatgt	gtttgtatca	gctgaatggt	2700
gctggaaata	aaaccttggg	ttgtcaaggc	tcttttttgt	gggaagtaag	taggggaaaa	2760
ggtctttgag	ggttcctagg	ctcctttgta	caacaggaaa	atgcctcaaa	gccttgcttc	2820
ccagcaacct	ggggctgggt	cccagtgcct	ggtcctgccc	cttcctgggt	cttatctcaa	2880
ggcagagctt	ctgaatttca	ggccttcatt	ccagagccct	cttgtggcca	ggccttcctt	2940
tgctggagga	aggtacacag	ggtgaagctg	atgctgtact	tgggggatct	ccttggcctg	3000
ttccaccaag	tgagagaagg	tacttactct	tgtacctcct	gttcagccag	gtgcattaac	3060
agacctccct	acagctgtag	gaactactgt	cccagagctg	aggcaagggg	atttctcagg	3120
tcatttggag	aacaagtgc	ttagtagtag	tttaaagtag	taactgctac	tgtatttagt	3180

118

```

ggggtggaat tcagaagaaa tttgaagacc agatcatggg tggctctgcat gtgaatgaac 3240
aggaatgagc cggacagcct ggctgtcatt gctttcttcc tccccatttg gacccttctc 3300
tgcccttaca tttttgtttc tccatctacc accatccacc agtctattta ttaacttagc 3360
aagaggacaa gtaaagggcc ctcttggtt gattttgtct ctttctttct gtggaggata 3420
tactaagtgc gactttgccc tatcctatct ggaaatccct aacagaattg agttttctat 3480
taaggatcca aaaagaaaaa caaatgcta atgaagccat cagtcaaggg tcacatgcca 3540
ataaacaata aattttccag aagaaatgaa atccaactag acaaataaag tagagcttat 3600
gaaatggttc agtaaagatg agtttggtgt tttttgtttt gttttgtttt gtttttttaa 3660
agacggagtc tcgctctgtc acccaggctg gagtgcagtg gtatgatctt ggctcactgt 3720
aacctccgcc tcccgggttc aagccattct cctgcctcag tctcctgagt agctgggatt 3780
gcgggtgcgt gccaccatgc ctggctaatt tttgtgtttt tagtagagac agggtttcac 3840
catgttggtc gggctgggtc cagactcctg acctcttgat ccgcctgcct tggcctccca 3900
aagtgatggg attacagatg tgagccaccg tgcctagcca aggatgagat ttttaaagta 3960
tgtttcagtt ctgtgtcatg gttggaagac agagtaggaa ggatatggaa aaggatcatg 4020
ggaagcagag gtgattcatg gctctgtgaa tttgaggtga atgggttcctt attgtctagg 4080
ccacttgtga agaatatgag tcagttattg ccagccttgg aatttacttc tctagcttac 4140
aatggacctt ttgaactgga aaacaccttg tctgcattca ctttaaaatg tcaaaactaa 4200
tttttataat aaatgtttat tttcacattg agtttgttta aatcctgaa 4249

```

```

<210> 120
<211> 901
<212> DNA
<213> Homo sapien

```

```

<400> 120
aaaggcgcca gtgcgccgag gcggggagtg gcggcggggt tccacctggc ggctggctct 60
cagttctgaa gagcagcggg tccttacacc aatcggaacg tgcaggggtg gggagctggc 120
caatcaggcg cggagggcgg ggccgggagg ggtccacct ggcggtggc tctcagtccc 180
ctcgctgtag tcgcggagct gtgtctgttc ccaggagtcc ttcggcggct gttgtgtcag 240
tggcctgatc gcgatgggga caaaggcgca agtcgagagg aaactgttgt gcctcttcat 300
attggcgatc ctgttgtgta agttcccaga gtttcgggag gaatcgggtg gtcgggtcag 360
aggttggagg aaggctctcc ccacgcccct agcccgcggg aggggaggag ctcaaaaacc 420
ttcctatata gttctgcgaa ttatcttttc caccctggc tggccctctt ttcaccactc 480
tcacagctgg gtgagtggct ggctcccctc cccacactg gtgagttgtg accgcacccc 540

```

119

tcacggccac	caggagggag	ctgacccatc	tgcacacacc	agaggtaca	tcctcgtcct	600
cactggagag	ggccgtcggg	ccaaggaccc	ttccacactc	atctacccag	cgcgcgctcc	660
acacgcacct	gggaagggcc	agcctgcccc	tccaacggcc	acccagcatc	cacgaacccc	720
gctgcgcagc	cgggagcctt	ggctccttta	acggtcttcg	aagaaaatca	aatggaggtg	780
gtctgggggtg	gaagtctctt	cccctagctt	ttgctgaagg	agtctctggc	tcttctgaat	840
ctttgaattg	cggcggttgc	tctgggaaaa	tgtctgggtg	cacagtctaa	agaggaaatg	900
c						901

<210> 121

<211> 1339

<212> DNA

<213> Homo sapien

<400> 121

gggaacggga	gatgttgag	gcgcagagag	ggcggggccag	ggccgcactc	cggagactcg	60
cggttgctac	gcgcaccatg	gctggaggta	cctgcggggg	attcctgggg	ccgcggttct	120
cttggtcctc	tgggttgagg	cgtggcaggg	agtgggggtg	cggagcgaag	gggcgtggct	180
gaggggtctt	cgtgcacacc	ctaccgggag	gggcgctgcc	aggtgagggg	atgccatggc	240
ggcgtgact	cctaggcccc	ctcttcctga	aggctgtcgc	gcccttctct	cagcgcccac	300
ggtctcgctt	cctgaactcc	gttcactcct	agcctccgga	cgggcccggc	tcttcgacgt	360
gcgctctcgc	gaggaggcgg	cagctgggac	catcccaggg	gcgctcaaca	tcccgggtat	420
aggggtggaga	ggggacgccc	aggtgggtgga	atagagaccg	ttcaggagggt	tctttgccaa	480
tgggacctca	tttaggatgg	aatggggaag	gcactgatta	tgggggtcct	gcattcccgg	540
gagccagccc	tcagcttccg	taggaaggac	tgatgggggg	cggatcttgg	catcggaact	600
ggcccatcca	gtttgagaag	acagcaggcg	gagaggagag	gggcagacca	gcttctcttg	660
acctccccaa	atctggacgc	ctgagggggc	atcccgcgcc	gcctcctcac	agcttagggga	720
gtggcttgca	ttcaaaagtt	gtcggtttct	gttccttgaa	attgggggtg	gggtagggga	780
tggttatcat	atgttgtttg	ggggccccca	ggaccagcc	cttccaggcc	cagcttccga	840
acctgagtgc	caaattgctg	gctttccctt	ctaccctctc	cactcctcca	gtgtccgagt	900
tggagagtgc	tctgcagatg	gagccagctg	ccttccaggc	tttatattct	gctgagaagc	960
caaagctgga	agatgagcat	ctcgttttct	tctgtcagat	gggcaagcgg	ggcctccagg	1020
ccacgcagct	ggcccggagt	cttgataca	ctgggtacgg	ggaggtgtgg	ctgctagctg	1080
ggaggtgatg	gggactgcct	gtcattcctg	tcagtctctc	acgcttcttt	gtctccacag	1140
ggctcgcaac	tacgctggag	cctatagaga	atggttggag	aaagagagtt	aggcaggagg	1200

120

cagcttactg attgccaccc cctggcccct taatggccac cttaactaag ggtgtgaacg 1260
 ggctgacttg gtgaattggg caactcctta tagtggtgtg cacacaaaag catcaaataa 1320
 agaacattta atcaaaaaa 1339

<210> 122
 <211> 464
 <212> DNA
 <213> Homo sapien

<400> 122
 ggtgactctg aggatccccg attcgatccg gacgggcccg gctcttcgac gtgcgctctc 60
 gcgaggaggc ggcagctggg accatcccag gggcgctcaa catcccgggtg tccgagttgg 120
 agagtgcctc gcagatggag ccagctgcct tccaggcttt atattctgct gagaagccaa 180
 agctggaaga tgagcatctc gttttcttct gtcagatggg caagcggggc ctccaggcca 240
 cgcagctggc ccggagtctt ggatacactg gggctcgcaa ctacgctgga gcctatagag 300
 aatggttgga gaaagagagt taggcaggag gcagcttact gattgccacc ccctggcccc 360
 ttaatggcca ccttaactaa ggggtgtgaac gggctgactt ggtgaattgg gcaactcctt 420
 atagtgttgt gcacacatcg catacgggga ctctctatg agtc 464

<210> 123
 <211> 806
 <212> DNA
 <213> Homo sapien

<400> 123
 gggaaaagct ctgtgccatc ctcaaattgc aatggcccag gtcccaccag ggacacctag 60
 acgtgggctc ccagacatc agggcctggg tcatgccacc cacctccacc aagctgtctt 120
 ctgctgggtg gccgagggca tgagggcaga caccacgtgt agccctaggg tggcagtggg 180
 cactgcagca gaggggctgt tgctcagagt ccacatgtgg gggaaggag atgttgcagg 240
 cgccgagagg gcgggcccagg gccgcactcc ggagactcgc ggttgctacg cgacccatgg 300
 ctggaggctg tcgcgcccct tcctcagcgc ccacggctct gcttcctgaa ctccgttcac 360
 tcctagcctc cggacggggc cggctcttcg acgtgcgctc tcgcgaggag gcggcagctg 420
 ggaccatccc aggggcgctc aacatcccgg tgtccgagtt ggagagtgt ctgcagatgg 480
 agccagctgc cttccaggct ttatattctg ctgagaagcc aaagctggaa gatgagcatc 540
 tcgttttctt ctgtcagatg ggcaagcggg gcctccaggc cacgcagctg gcccgagtc 600
 ttggatacac tggggctcgc aactacgctg gagcctatag agaatggttg gagaaagaga 660
 gttaggcagg aggcagctta ctgattgcca cccctggcc ccttaatggc caccttaact 720
 aaggggtgtga acgggctgac ttggtgaatt gggcaactcc ttatagtgt gtgcacacat 780

121

cgcatacggg gactcctcta tgagtc

806

<210> 124

<211> 743

<212> DNA

<213> Homo sapien

<400> 124

gggaaaagct ctgtgccatc ctcaaattgc aatggcccag gtcccaccag ggacacctag 60

acgtgggctc cccagacatc agggcctggg tcatgccacc cacctccacc aagctgtctt 120

ctgctgggtg gccgagggca tgagggcaga caccacgtgt agccctaggg tggcagtggg 180

cactgcagca gaggggctgt tgctcagagt ccacatgtgg gggaaggag atgttgcagg 240

cgccgagagg gcggggccagg gccgcactcc ggagactcgc ggttgctacg cgcaccatgg 300

ctggagccgg acggggccgg ctcttcgacg tgcgctctcg cgaggaggcg gcagctggga 360

ccatcccagg ggcgctcaac atcccgggtgt ccgagttgga gagtgcctctg cagatggagc 420

cagctgcctt ccaggcttta tattctgctg agaagccaaa gctggaagat gagcatctcg 480

ttttcttctg tcagatgggc aagcggggcc tccaggccac gcagctggcc cggagtcttg 540

gatacactgg ggctcgcaac tacgctggag cctatagaga atggttggag aaagagagtt 600

aggcaggagg cagcttactg attgccaccc cctggccctt taatggccac cttaactaag 660

gggtgtgaacg ggctgacttg gtgaattggg caactcctta tagtgttgtg cacacatcgc 720

atacggggac tcctctatga gtc 743

<210> 125

<211> 461

<212> DNA

<213> Homo sapien

<400> 125

agatgttgca ggcgccgaga ggaccocggac gggcccggct cttcgacgtg cgctctcgcg 60

aggaggcggc agctgggacc atcccagggg cgctcaacat cccgggtgtcc gagttggaga 120

gtgctctgca gatggagcca gctgccttcc aggctttata ttctgctgag aagccaaagc 180

tggaagatga gcatctcggt ttcttctgtc agatgggcaa gcggggcctc caggccacgc 240

agctggcccg gagtcttggg tacactgggg ctgcgaacta cgctggagcc tatagagaat 300

ggttggagaa agagagttag gcaggaggca gcttactgat tgccaccccc tggcccctta 360

atggccacct taactaaggg tgtgaacggg ctgacttggt gaattgggca actccttata 420

gtgttggtgca cacatcgcat acggggactc ctctatgagt c 461

•

<210> 126

122

<211> 993
 <212> DNA
 <213> Homo sapien

<400> 126
 gggaaaagct ctgtgccatc ctcaaattgc aatggcccag gtcccaccag ggacacctag 60
 acgtgggctc cccagacatc agggcctggg tcatgccacc cacctccacc aagctgtctt 120
 ctgctgggtg gccgagggca tgagggcaga caccacgtgt agccctaggg tggcagtggg 180
 cactgcagca gaggggctgt tgctcagagt ccacatgtgg gggaaggag atgttgcagg 240
 cgccgagagg gcggggccagg gccgcactcc ggagactcgc ggttgctacg cgcaccatgg 300
 ctggaggtac ctgcggggga ttcttggggc cgcggttctc ttgggtcctct gggttgaggc 360
 gtggcagggg gtgggggtggc ggacgaaggg gcgtggctga ggggtcttcg tgcacaccct 420
 accgggaggg gcgctgccag gtgaggggat gccatggcgg ccgtgactcc tagggcccct 480
 cttcctgaag gctgtcgcgc ccttctctca gcgccacgg tctcgcttcc tgaactccgt 540
 tcactcctag cctccggacg ggcccggctc ttcgacgtgc gctctcgcga ggaggcggca 600
 gctgggacca tcccaggggc gctcaacatc ccggtgtccg agttggagag tgctctgcag 660
 atggagccag ctgccttcca ggctttatat tctgctgaga agccaaagct ggaagatgag 720
 catctcgttt tcttctgtca gatgggcaag cggggcctcc aggccacgca gctggcccgg 780
 agtcttggat aactggggc tcgcaactac gctggagcct atagagaatg gttggagaaa 840
 gagagttagg caggaggcag cttactgatt gccaccccct ggccccttaa tggccacctt 900
 aactaagggt gtgaacgggc tgacttgggtg aattgggcaa ctcttatag tgttgtgcac 960
 acaaaagcat caaataaaga acatttaatc aaa 993

<210> 127
 <211> 1070
 <212> DNA
 <213> Homo sapien

<400> 127
 ttccggatcc ggtctcagct ctgggagggg acgggagatg ttgcaggcgc cgagagggcg 60
 ggccagggcc gcactccgga gactcgcggt tgctacgcgc accatggctg gagcgcccac 120
 ggtctcgctt cctgaactcc gttcactcct agcctccgga cgggcccggc tcttcgacgt 180
 gcgctctcgc gaggaggcgg cagctgggac catcccaggg gcgctcaaca tcccgggtat 240
 aggggtggaga ggggacgccc aggtggtgga atagagaccg ttcaggaggt tctttgccaa 300
 tgggacctca tttaggatgg aatggggaag gcactgatta tgggggtcct gcattcccgg 360
 gagccagccc tcagcttccg taggaaggac tgatgggggg cggatcttgg catcggaact 420
 ggcccatcca gtttgagaag acagcaggcg gagaggagag gggcagacca gcttctcttg 480

123

```

acctcccaa atctggacgc ctgagggggc atcccgcccc gcctcctcac agcttaggga      540
gtggcttgca ttcaaaagtt gtcggtttct gttccttgaa attgggggtgg gggtagggga      600
tggttatcat atgttgtttg ggggccccca ggacccagcc cttccaggcc cagcttccga      660
acctgagtgc caaattgctg gctttccctt ctaccctctc cactcctcca gtgtccgagt      720
tggagagtgc tctgcagatg gagccagctg ccttccaggc tttatattct gctgagaagc      780
caaagctgga agatgagcat ctcgttttct tctgtcagat gggcaagcgg ggcctccagg      840
ccacgcagct ggcccggagt cttggataca ctgggggctcg caactacgct ggagcctata      900
gagaatgggt ggagaaagag agttaggcag gaggcagctt actgattgcc accccctggc      960
cccttaatgg ccaccttaac taaggggtgt aacgggctga cttgggtgaat tgggcaactc     1020
cttatagtgt tgtgcacaca aaagcatcaa ataaagaaca tttaatcaaa      1070

```

```

<210> 128
<211> 1468
<212> DNA
<213> Homo sapien

```

```

<400> 128
gggaaaagct ctgtgccatc ctcaaattgc aatggcccag gtcccaccag ggacacctag      60
acgtgggctc ccagacatc agggcctggg tcatgccacc cacctccacc aagctgtctt     120
ctgctgggtg gccgagggca tgagggcaga caccacgtgt agccctaggg tggcagtggg     180
cactgcagca gaggggctgt tgctcagagt ccacatgtgg gggaaggag atgttgcagg     240
cgccgagagg gcgggccagg gccgcactcc ggagactcgc ggttgctacg cgcaccatgg     300
ctggaggtac ctgcggggga ttcctggggc cgcggttctc ttgggtcctct gggttgaggc     360
gtggcagggg gtgggggtggc ggacgaaggg gcgtggctga ggggtcttcg tgcacaccct     420
accgggaggg gcgctgccag gtgaggggat gccatggcgg ccgtgactcc taggccccct     480
cttcctgaag gctgtcgcgc cccttctca gcgccacgg tctcgcttcc tgaactccgt     540
tcactcctag cctccggacg ggcccggctc ttcgacgtgc gctctcgcga ggaggcggca     600
gctgggacca tcccaggggc gctcaacatc ccgggtatag ggtggagagg ggacgcccag     660
gtggtggaat agagaccgtt caggaggttc tttgccaatg ggacctcatt taggatggaa     720
tggggaaggc actgattatg ggggtcctgc attcccggga gccagccctc agcttccgta     780
ggaaggactg atggggggcg gatcttggca tcggaactgg cccatccagt ttgagaagac     840
agcaggcgga gaggagaggg gcagaccagc ttctcttgac ctccccaaat ctggacgcct     900
gagggggcat cccgccccgc ctctcacag cttagggagt ggcttgcatt caaaagttgt     960
cggtttctgt tccttgaaat tgggggtgggg gtaggggatg gttatcatat gttgtttggg     1020

```

124

ggccccccagg acccagccct tccaggccca gcttccgaac ctgagtgcc aattgctggc 1080
 tttcccttctt accctctcca ctctccagc gtccgagttg gagagtgtc tgcagatgga 1140
 gccagctgcc ttccaggctt tatattctgc tgagaagcca aagctggaag atgagcatct 1200
 cgttttcttc tgtcagatgg gcaagcgggg cctccaggcc acgcagctgg cccggagtct 1260
 tggatacact ggggctcgca actacgctgg agcctataga gaatggttgg agaaagagag 1320
 ttaggcagga ggcagcttac tgattgccac cccctggccc cttaatggcc accttaacta 1380
 aggggtgtgaa cgggctgact tgggtgaattg ggcaactcct tatagtgttg tgcacacaaa 1440
 agcatcaaat aaagaacatt taatcaaa 1468

<210> 129
 <211> 841
 <212> DNA
 <213> Homo sapien

<400> 129
 tgggctcagg cctctcccct gactcactgt gtgtctaata tgtcaccaga tgcaatctgg 60
 cacttcgccg acaaccagct ttttgtttcg ggcccgaatg gcacagccgg catctttgct 120
 acctaccct ctggacactt ggatatgatc aatggcttct ttgaccaggt atgggctggg 180
 gacgtgtgag gggaacgcag ggaggggacc gagttgcctt ggtagctcat gggctgggtg 240
 ggggacagga ctctcgact gtagcagggt ttctccaata tgtggggtaa ccgcatcag 300
 aacatgggtg caagtactta caaaacatgc ggctctccag cgggttcttg tcacgcagac 360
 attctagcac cattgcttct aggagaagag catgggcggg cgctgacaag agtttaagag 420
 ctagagggaa gacgggggat ggaaggagg gtcagagaaa gggagggagc tgcagctcac 480
 cctgttctcc cactcccca gttcataggc acagcctccc ttatcgtgtg tgtgctggcc 540
 attgttgacc cctacaacaa ccccgctccc cgaggcctgg aggccttcac cgtgggcctg 600
 gtggtcctgg tcattggcac ctccatgggc ttcaactccg gctatgccgt caaccctgcc 660
 cgggactttg gccccgcct ttttacagcc ctgcgggct ggggctctgc agtcttcacg 720
 accggccagc attgggtggg ggtgcccac gtgtccccac tcctgggctc cattgcgggt 780
 gtcttcgtgt accagctgat gatcggctgc cacctggagc agccccacc ctccaacgag 840
 a 841

<210> 130
 <211> 1000
 <212> DNA
 <213> Homo sapien

<400> 130

125

```

tgggctcagg cctctcccct gactcactgt gtgtctaata tgtcaccaga tgcaatctgg      60
cacttcgccg acaaccagct ttttgtttcg ggccccaatg gcacagccgg catcttttgc      120
acctacccct ctggacactt ggatatgata aatggcttct ttgaccaggt atgggctggg      180
gacgtgtgag gggaacgcag ggaggggacc gagttgcctt gtgtagctca tgggctgggt      240
gggggacagg actcctcgac tgtagcaggg tttctccaat ctgtggggta acccgcatca      300
gaacatgggtg gcaagtactt acaaaacatg cggctctcca gcgggttctt gtcacgcaga      360
cattctagca ccattgcttt caggagaaga gcatggggcg gcgctgacaa gagtttaaga      420
gctagagggga agacggggga tggaaggagg ggtcagagaa agggaggag ctgcagctca      480
ccctgttctc ccactcccc agttcatagg cacagcctcc cttatcgtgt gtgtgctggc      540
cattgttgac ccctacaaca accccgtccc ccgaggcctg gaggccttca ccgtgggcct      600
ggtggctcctg gtcattggca cctccatggg cttcaactcc ggctatgccg tcaaccctgc      660
ccgggacttt ggcccccgcc tttttacagc ccttgccggc tggggctctg cagtcttcac      720
gtgaggtaca gggcagggca acaaagatac acaggcaagc catgccgtca tccagcatga      780
ccagagagcc acgcaatggc gcaatgacta atgaagagtg tactggagac caccacaacg      840
agaacacgac acaaccacaa tcaggtagaa aagaagtgcc acacatcaac gaaaacaaaa      900
actaccagga gagaaccaca agaacagatg aagaagagta gtacagcagc cgaacagacc      960
gaggtagaac acacgagagg agacaaaaaa accacgcaaa      1000

```

```

<210> 131
<211> 1990
<212> DNA
<213> Homo sapien

```

```

<400> 131
agccaccagc gctggaggcc gctgctcgct gcgccaccgc ctcccgccac ccctgcccgc      60
ccgacagcgc cgccgcctgc ccgcctatgg gtcgacagaa ggagctgggtg tcccgcctgcg      120
gggagatgct ccacatccgc taccggctgc tccgacaggc gctggccgag tgcctggggga      180
ccctcatcct cgtgatgttt ggctgtggct ccgtggccca ggttgtgctc agccggggca      240
cccacgggtgg tttcctcacc atcaacctgg cctttggctt tgctgtcact ctgggcatcc      300
tcatcgctgg ccaggtctct ggggcccacc tgaaccctgc cgtgaccttt gccatgtgct      360
tcctggctcg tgagccctgg atcaagctgc ccatctacac cctggcacag acgctgggag      420
ccttcttggg tgctggaata gtttttgggc tgtattatgg taagcattcc ccaccctgtc      480
ctcctccact acccccgctc ctctgttcag gacctgctgg caccaggcct tttgatgaca      540
gacggctagg acctgcccag gccccgggct catgactcac tcattcacgc acagggtcaa      600

```

126

gatgcaatct ggcacttcgc cgacaaccag ctttttgttt cgggcccacaa tggcacagcc 660
 ggcatctttg ctacctaccc ctctggacac ttggatatga tcaatggctt ctttgaccag 720
 ttcataaggca cagcctccct tatcgtgtgt gtgctggcca ttgttgaccc ctacaacaac 780
 cccgtccccc gaggcctgga ggccttcacc gtgggcctgg tggtcctggt cattggcacc 840
 tccatgggct tcaactccgg ctatgccgtc aacctgccc gggacttttg cccccgcctt 900
 ttacagccc ttgcgggctg gggctctgca gtcttcacga ccggccagca ttggtggtgg 960
 gtgcccacg tgtccccact cctgggctcc attgcgggtg tcttcgtgta ccagctgatg 1020
 atcggctgcc acctggagca gccccaccc tccaacgagg aagagaatgt gaagctggcc 1080
 catgtgaagc acaaggagca gatctgagtg ggcaggggccc atctccccac tccgctgccc 1140
 tggccttgag catccactga ctgtccaagg gccactccca agaagcccc ttcacgatcc 1200
 accctttcag gctaaggagc tccctatcta cctcacccc acgagacagc cccttcagga 1260
 tttccactgg accttgccca aatagcacct tagggcactg ccctaagct ggggtggaac 1320
 cggaatattg gtcaatacat ctttttgtct cccaaggga gagaatgggc agcaggtatg 1380
 tgtgtgtgtg catgtgtgtg catgtgtgtg catgtgtgtg caggggtgtg tgtgtgtggg 1440
 gggggttccc agatattcag ggcaaggagc cagtcggaag ggattctggc tattggggga 1500
 gccagagac aggggaaggc agcctgtcca tctgtgcata aggagaggaa agttccaggg 1560
 tgtgtatgtt tcaggggctt cacatggagg agctgcagat agatatgtgt ttctgtgtat 1620
 gtgtatgtct gccttttttt ctaagtgggg gcttctacag gcttttgga agtaggggtg 1680
 atgtgggtag ggctgggagg agggggccac agcttaggtt tggagctctg gatgtacata 1740
 cataagtagg agcagtggga cgtgtttctg tcataatgca ggcatgaagg gtggagtga 1800
 gtcaggatcat aagtttcatg tttgcttttg ttttgttttg tttttaatgt atgtagcaga 1860
 tgttacagtc ttagggatcc gggatgggag accccacttt agaaagggtc gtcactcctt 1920
 taatcctcta ctcaacaatg tactctttta cttttatatt aaaaaaata aaataaatat 1980
 gtgcctaaaa 1990

<210> 132
 <211> 1528
 <212> DNA
 <213> Homo sapien

<400> 132
 gccaccccct ctgcctgctg caatacagca gtattgctac ttaccataa ctcatgggag 60
 ggtggggagg gcacacctga gaggggaagtc tgggctcagg cctctcccc gactcactgt 120
 gtgtctaata tgtcaccaga tgcaatctgg cacttcgccg acaaccagct ttttgtttcg 180

127

```

ggccccaatg gcacagccgg catctttgct acctaccct ctggacactt ggatatgac 240
aatggcttct ttgaccagtt cataggcaca gcctccctta tcgtgtgtgt gctggccatt 300
gttgaccctt acaacaaccc cgtcccccca ggccctggagg ccttcaccgt gggcctgggtg 360
gtcctgggtca ttggcacctc catgggcttc aactccggct atgccgtcaa cctgcccgg 420
gactttggcc cccgcctttt tacagccctt gcgggctggg gctctgcagt cttcacgacc 480
ggccagcatt ggtgggtgggt gcccatcgtg tccccactcc tgggctccat tgcgggtgtc 540
ttcgtgtacc agctgatgat cggctgccac ctggagcagc cccaccctc caacgaggaa 600
gagaatgtga agctggccca tgtgaagcac aaggagcaga tctgagtggg caggggccat 660
ctccccactc cgctgccctg gccttgagca tccactgact gtccaagggc cactcccaag 720
aagccccctt cagatccac cctttcaggc taaggagctc cctatctacc ctcacccac 780
gagacagccc cttcaggatt tccactggac cttgccccaa tagcacctta ggccactgcc 840
cctaagctgg ggtggaaccg gaatttgggt caatacatcc ttttgtctcc caaggaaga 900
gaatgggcag caggtatgtg tgtgtgtgca tgtgtgtgca tgtgtgtgca tgtgtgtgca 960
ggggtgtgtg tgtgtggggg gggttcccag atattcaggg caagggacca gtcggaagg 1020
attctggcta ttgggggagc ccagagacag gggaaggcag cctgtccatc tgtgcataag 1080
gagaggaaag ttccagggtg tgtatgtttc aggggcttca catggaggag ctgcagatag 1140
atatgtgttt ctgtgtatgt gtatgtctgc ctttttttct aagtgggggc ttctacaggc 1200
ttttgggaag tagggtggat gtgggtaggg ctgggaggag ggggccacag cttaggtttg 1260
gagctctgga tgtacataca taagtaggag cagtgggacg tgtttctgtc ataatgcagg 1320
catgaagggt ggagtgaagt caggtcataa gtttcatgtt tgcttttgtt ttgttttgtt 1380
tttaatgtat gtagcagatg ttacagtctt agggatccgg gatgggagac cccactttag 1440
aaagggtcgt cactccttta atcctctact caacaatgta ctcttttact tttatatata 1500
aaaaaataaa ataaatatgt gcctaaaa 1528

```

```

<210> 133
<211> 1052
<212> DNA
<213> Homo sapien

```

```

<400> 133
tttactgctg tattccaagc agaaagggtg gcatacagga gacctcaaaa atacgctact 60
ttgatcttga ggagagtga aaatcttact cattttatgt acaaagcaca gatgtgcata 120
cattatataa aaagaaatag ttacgtatg gcattaagat ttcatagaaga ttagaaaaac 180
aatgtttaca aaaggctcctt acaaaggtag taattcaaga aaagatcaat aaacgatgtg 240

```

128

```

ttaaagtaag attttttgga gctcaaattc aggcaataca aaagccagca atatatcttg 300
ctactcgaat gcctctattt cacctcaaac tcacagataa aactgaaccc aatatgtcct 360
tgtccattaa aaagcaaata accaagaaag ctaacaaaag attcccttca atgtctcttt 420
tattgacagt ggtcccaaaa ctcttggtca atgaattcaa aacccaaatc ttgcaggtag 480
gacttaacct catctgctgc caaatagctg gctatgtgac cttgggcaga gccacagcct 540
cccgcgctc gctcagctcc aacatggcaa aaatctccag ccctacagag actgagcggc 600
gcatcgagtc cctgattgct gtcttccaga agtatgctgg aaaggatggc tataactaca 660
ctctctccaa gacagagttc ctaagcttca tgaatacaga actagctgcc ttcacaaaga 720
accagaagga ccctgggtgc cttgaccgca tgatgaagaa actggacacc aacagtgatg 780
gtcagctaga tttctcagaa tttcttaata tgattggcgg cctagctatg gcttgccatg 840
actccttctt caaggctgct ccttcccaga agcggacctg aggacccctt ggccctggcc 900
ttcaaaccac ccccttttcc ttccagcctt tctgtcatca tctccacagc ccacccatcc 960
cctgagcaca ctaaccacct catgcaggcc ccacctgcca atagtaataa agcaatgtca 1020
ctttttttaa acatgaaaaa aaacaaaaaa gg 1052

```

```

<210> 134
<211> 2307
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (2155)..(2155)
<223> n=a, c, g or t

```

```

<400> 134
cctccctggg gccggtggca caggctaagc aggccaaagtc aggcactccc aggaagcggg 60
ccatggaaac caggtgtgca aagggcctgg tgcaggaagg gcgggtgacg ggggtgtcct 120
ggagctggag aacagcagcc agccctgttt atgtgtcact tgtaaaggctg tccctgaggg 180
tctgagggct tggggcccag gaaggcactg caggggttcag acattgaggg agaggccaga 240
attgctggag ggtgggtgagg tgccactggg agggctgtgc atggtgacac caagtttttg 300
aaggtacagc aagtgcatac agagcttttt ggtgggtagg gaatgggcac tgccctttaa 360
gagcaggaat atcatcttaa cagcctgttg ccccatccc gccctgcgt ggttcattgg 420
gcaggtgggc tccaccagca ctgagggttg gtttagacta cttcattgtc ttccaccag 480
gagaggcgtg gagtgggtgc gagatccctt ggtcaccaac ccaagtctct gcttccctgt 540
acccttcac agaagccctt tcagtggctt caagtggcag tgctggctgg agctgactcc 600

```

129

gccttcctga acagcccacg tccctggaac aggccacctg cctggaacac actcagggtc 660
 tgggggtctcc tgggcagatt gctcaggcag ccccttccta gcctgggcag ggaccccaag 720
 gttaattctt ccccttcaag ggctggaatt cgagcgctgg ctcaatgcca caggcccgcc 780
 ggctggctga gcccggacct gtctcaggga tccagcctga cccgggcccg tggaggccct 840
 tttcccagct gtggaccgca gaacctctgg accacggcag ctgcctcggc cagcgccatt 900
 gacatctcca agctggagga ccttcagac agcactcttc ctgggaccgg ctccctggatg 960
 ggtccccgct gccgcaggag gtggtgatga gcctgtccaa gtgctactcc tccctgctgg 1020
 actcgatgaa cgctgagatc cgcattccgct ggctgcagat tgtgggtccgc aacgactact 1080
 atcctgacct ccacaggggtg cggcgcttcc tggagagcca gatgtcacgc atgtacacca 1140
 tcccgtgta acgaggacct ctgcaccggt gccctcaagt ccttcgcgct ggaggctctc 1200
 taccagacgc agggccggct gcaccccaac ctgcgcagag ccatccagca gatcctgttc 1260
 ccagggcctg ggctccagca cagagcccgc ctgagagccc agcactggag ctgggcaagg 1320
 ctgaagcaga cacagactcg gacgcacagg ccctgctgct tggggacgag gccccagca 1380
 gtgccatctc ctctcaggga cgtcaatgtg tctgcctagc cctgttggcg ggctgacct 1440
 cgacctcca gacaccacaa ttgtgccttc tgtgggcccag gcctgccatg actgcgtctc 1500
 ggctctggcc atgagctctg cccaggccca caagcccctc ccctgggctc tcccaggcag 1560
 ggagaatggg gagagggacc tcctttgtgt cttggcagag acctgtggac tttggcctcc 1620
 ccgactcca gcttctcctt gcactcgcag gtccctggggg ccagcccgc cacaccatgc 1680
 cctcctgtct caaacactga cagctgtgcc tagccccgga ttgccagcac ctgtccaggt 1740
 gccgccccgg ggcaaagggc cccagcagcc ctatggtgac cgccacaact gtgcctttaa 1800
 tgtctgccgg gggcccagtg ctgtgcttgt acctgcagc acgctctcct tgcagggatt 1860
 ctgagccacc ctgccccgca catggcctct gccaccccgc ccctaggggtt ggcagcctca 1920
 gttggccctt ggcagaggaa caaggacaca gacattccct cagtgtgggg ggcagggcac 1980
 accagggaga ggatggttgt ccctggggag ggcctcttg cccagggcta actcttagcc 2040
 ccctcagaac caggggagtcc caggaccag ggagagtgtg gggacaggac agcctgtact 2100
 cttgtagctt ctctgggggtg ggaggcatca ggggcaaagc aattaccca ggganaagtg 2160
 ggaggtggtg ctggtgcgtc tctgcaggcc caccatgtct gggagaggcg gccagagcct 2220
 gggggcctcc agcctgggac tgcttgtgat ggggtatcac ggtgatggtc ccattaaact 2280
 taccactctg caaacctgaa aaaaaa 2307

<210> 135
 <211> 2194

130

<212> DNA

<213> Homo sapien

<400> 135

ggagctcacc	gcaggggctg	ggctgatccc	tgctgggtgg	aaggtggggg	gcgggtgtgc	60
aggggtgggag	tctgagcccc	gaggtctgcc	accctcaccg	ccctcccggg	gcaggtacga	120
cattgtcttc	ctgccaccct	ccttccccat	cgtggccatg	gagaacccct	gcctcacctt	180
catcatctcc	tccatcctgg	agagcgatga	gttcctgggtc	atcgatgtca	tccacgaggt	240
ggcccacagt	tgggtcggca	acgctgtcac	caacgccacg	tgggaagaga	tgtggctgag	300
cgagggcctg	gccacctatg	cccagcgccg	tatcaccacc	gagacctacg	gtgctgcctt	360
cacctgcctg	gagactgcct	tccgcctgga	cgccctgcac	cggcagatga	agcttctggg	420
agaggacagc	ccggtcagca	aactgcaggt	caagctggag	ccaggagtga	atcccagcca	480
cctgatgaac	ctgttcacct	acgagaaggg	ctactgcttc	gtgtactacc	tgtcccagct	540
ctgcggagac	ccacagcgct	ttgatgactt	tctccgagcc	tatgtggaga	agtacaagtt	600
caccagcgtg	gtggcccagg	acctgctgga	ctccttcctg	agcttcttcc	cggagctgaa	660
ggagcagagc	gtggactgcc	gggcagggct	ggaattcgag	cgtctggctca	atgccacagg	720
cccgccgctg	gctgagccgg	acctgtctca	gggatccagc	ctgaccgggc	ccgtggaggc	780
ccttttccag	ctgtggaccg	cagaacctct	ggaccaggca	gctgcctcgg	ccagcgccat	840
tgacatctcc	aagtggagga	ccttccagac	agcactcttc	ctggaccggc	tcctggatgg	900
gtccccgctg	ccgcaggagg	tggatgatgag	cctgtccaag	tgctactcct	ccctgctgga	960
ctcgatgaac	gctgagatcc	gcatccgctg	gctgcagatt	gtggtccgca	acgactacta	1020
tcctgacctc	cacaggggtgc	ggcgcttcct	ggagagccag	atgtcacgca	tgtacaccat	1080
cccgtgttac	gaggacctct	gcaccgggtgc	cctcaagtcc	ttcgcgctgg	aggtcttcta	1140
ccagacgcag	ggccggctgc	acccaacct	gcgcagagcc	atccagcaga	tcctgtccca	1200
gggcctgggc	tccagcacag	agcccgcttc	agagcccagc	acggagctgg	gcaaggctga	1260
agcagacaca	gactcggacg	cacaggccct	gctgcttggg	gacgaggccc	ccagcagtgc	1320
catctctctc	agggacgtca	atgtgtctgc	ctagccctgt	tggcgggctg	accctcgacc	1380
tcccagacac	cacaattgtg	ccttctgtgg	gccaggcctg	ccatgactgc	gtctcggctc	1440
tggccatgag	ctctgcccag	gccacaagc	ccctccctg	ggctctccca	ggcagggaga	1500
atggggagag	ggacctcctt	gtgtctggca	gagacctgtg	gacctggcct	ccccactccc	1560
agctctcttg	cactgcaggc	cctggggcca	gcccgcacac	accatgcctc	ctgtctcaac	1620
actgacagct	gtgcctagcc	ccggatgcca	gcacctgcca	ggtgccgccc	cggggcaagg	1680
gccccagcag	ccctatgggtg	acgcgcacac	tgtgccttaa	tgtctgccgg	gggcccaggc	1740

131

tgtgctgtcc ctgcagcacg cctccttgca gggatctgag ccaccctccc cgcacagccc 1800
 tgcacccccg ccctaggggtt ggcagcctca gttggcccct ggcagaggaa caaggaca ca 1860
 gacattccct cagtgtgggg ggcaggggac acagggagag gatgggtgtc cctggggagg 1920
 gccctctggc ccagggaac cttagcccct cagaacaggg agtcccagga cccaggga ga 1980
 gtgtggggac aggacagcct gtctcttgta gcttcctggg gtgggaggca caggggca aa 2040
 gcaatacccc agggaaagtg ggaggtggtg ctggtgctct ctccaggccc accatgct gg 2100
 gagaggcggc cagagcctgg ggcctccagc ctgggactgc tgtgatgggg tatcacggtg 2160
 atggtcccat taaacttcca ctctgcaaac ctga 2194

<210> 136
 <211> 1941
 <212> DNA
 <213> Homo sapien

<400> 136
 ggctctgagc agcagtcaca gtggtgtgtg agtcctcagt ctccccgag gccctgccgc 60
 tgcacgcccc gggcatcagt acacatctgg acatgtgagg gacagtggcg cttggccctt 120
 gctgctcctc ggagcctgac cactgcccct ccctattcca cgggacactg gtggtttcgg 180
 acgccagccc aggtgggtgt tcaccttgca ggagtgaatc ccagccacct gatgaacctg 240
 ttcacctacg agaagggcta ctgcttcgtg tactacctgt ccagctctg cggagacc ca 300
 cagcgctttg atgactttct ccgagcctat gtggagaagt acaagttcac cagcgtggtg 360
 gcccaggacc tgctggactc ctctctgagc ttcttcccgg agctgaagga gcagagcgtg 420
 gactgccggg cagggctgga attcgagcgc tggctcaatg ccacaggccc gccgctggct 480
 gagccggacc tgtctcaggg atccagcctg acccggcccg tggaggccct tttccagctg 540
 tggaccgcag aacctctgga ccaggcagct gcctcggcca gcgccattga catctcca ag 600
 tggaggacct tccagacagc actcttctg gaccggctcc tggatgggtc cccgctgc cg 660
 caggaggtgg tgatgagcct gtccaagtgc tactcctccc tgctggactc gatgaacgct 720
 gagatccgca tccgctggct gcagattgtg gtccgcaacg actactatcc tgacctccac 780
 aggggtgcggc gcttcctgga gagccagatg tcacgcatgt acaccatccc gctgtacgag 840
 gacctctgca ccggtgccct caagtccctc gcgctggagg tcttctacca gacgcagggc 900
 cggctgcacc ccaacctgcg cagagccatc cagcagatcc tgtcccaggg cctgggct cc 960
 agcacagagc ccgcctcaga gcccagcacg gagctgggca aggctgaagc agacacagac 1020
 tcggacgcac aggccttgct gcttggggac gaggccccca gcagtgccat ctctctcagg 1080
 gacgtcaatg tgtctgccta gccctggtgg cgggctgacc ctcgacctcc cagacaccac 1140

132

aattgtgcct tctgtgggcc aggcctgccca tgactgcgtc tcggctctgg ccatgagctc 1200
tgcccaggcc cacaagcccc tcccctgggc tctcccaggc agggagaatg gggagaggga 1260
cctccttgtg tctggcagag acctgtggac ctggcctccc cactcccagc tctcttgcac 1320
tgcaggccct ggggccagcc cgcacacacc atgcctcctg tctcaacact gacagctgtg 1380
cctagccccg gatgccagca cctgccaggt gccgccccgg ggcaagggcc ccagcagccc 1440
tatggtgacc gccacactgt gccttaatgt ctgccggggg cccaggctgt gctgtccctg 1500
cagcacgcct ccttgcaggg atctgagcca cctccccgc acagccctgc accccgcccc 1560
tagggttggc agcctcagtt ggcccctggc agaggaacaa ggacacagac attccctcag 1620
tgtggggggc aggggacaca gggagaggat ggttgtccct ggggagggcc ctctggcccc 1680
aggcaacctt agcccctcag aacagggagt cccaggacct agggagagtg tggggacagg 1740
acagcctgtc tcttgtagct tcttgggggt ggaggcacag gggcaaagca ataccccagg 1800
gaaagtggga ggtggtgctg gtgctctctc caggcccacc atgctgggag aggcggccag 1860
agcctggggc ctccagcctg ggactgctgt gatgggggat cacggtgatg gtcccattaa 1920
acttccactc tgcaaacctg a 1941

<210> 137
<211> 3110
<212> DNA
<213> Homo sapien

<400> 137
gtagcgggcg tcccgccctgc cgcgcgcgag acgcccctggc ccttcgcctt ctccgcccc 60
gggcccggggc ccgcgcgcgc gcccccgcctg cccgccttcc ccgaggcgcc cggctccgag 120
cccgcctgct gtccgctggc cttcaggggtg gaccgcgttca ccgactacgg ctccctcgctc 180
accgtcacgc tgccgcccga gctgcaggcg caccagccct tccagggtcat cctgcggtac 240
acctcgaccg acgccccgc catctgggtg ctggaccag agctgacctt tggctgcgcc 300
aagcccttcg tcttcaccca gggccactcc gtgtgcaacc gctccttctt cccgtgcttc 360
gacacacctg ccgtgaagtg cacctactct gccgtcgtca aggcgcctat ggggggtgcag 420
gtgctgatga gtgccaccgc gactgcatac atggaggaag aaggcgtctt ccacttccac 480
atggagcacc ccgtgccgc ctacctcgtg gccctgggtg ccggagacct caagccggca 540
gacatcgggc ccaggagccg cgtgtgggccc gagccatgcc tcttgcaccac ggccaccagc 600
aagctgtcgg gcgcagtgga gcagtggctg agtgcagctg agcggctgta tgggcccctac 660
atgtggggca ggtacgacat tgtcttcctg ccaccctcct tcccctcgt ggccatggag 720
aaccctgcc tcaccttcat catctcctcc atcctggaga gcgatgagtt cctgggtcatc 780

133

gatgtcatcc acgaggtggc ccacagttgg ttcggcaacg ctgtcaccaa cgccacgtgg	840
gaagagatgt ggctgagcga gggcctggcc acctatgccc agcgccgtat caccaccgag	900
acctacggtg ctgccttcac ctgcctggag actgccttcc gcctggacgc cctgcaccgg	960
cagatgaagc ttctgggaga ggacagcccg gtcagcaaac tgcaggtcaa gctggagcca	1020
ggagtgaatc ccagccacct gatgaacctg ttcacctacg agaagggcta ctgcttcgtg	1080
tactacctgt cccagctctg cggagaccca cagcgctttg atgactttct ccgagtgagc	1140
agccccctgc ccgggacggc cctgctgcca tctgccccca gccctcccc ggctcacagg	1200
gctgcctgct cttgcggcag ttgggggtgga actggcaggg gcctgtgagc ctggctggga	1260
cctagtctgc ctttctttgt ggggagtgcc tgggttgcca cctccccttc tgccaccctg	1320
tttgctccct tggcagggcc tgcgtgccaa gtgctggctc cgcagtgcc actagctgcc	1380
cctgtgcccc gcacgtacct tggcgcacgc cctgcagtgc cctgcaggcc tctgggtggg	1440
ctgcctgtgc cccacccttc caggcctgct gaggccccac ctctgccaca caggcctatg	1500
tggagaagta caagttcacc agcgtggtgg cccaggacct gctggactcc ttcctgagct	1560
tcttcccgga gctgaaggag cagagcgtgg actgccgggc agggctggaa ttcgagcgct	1620
ggctcaatgc cacaggcccg ccgctggctg agccggacct gtctcaggga tccagcctga	1680
cccggcccgt ggaggccctt ttccagctgt ggaccgcaga acctctggac caggcagctg	1740
cctcggccag cgccattgac atctccaagt ggaggacctt ccagacagca ctcttcctgg	1800
accggctcct ggatgggtcc ccgctgccgc aggaggtggt gatgagcctg tccaagtgct	1860
actcctccct gctggactcg atgaacgctg agatccgcat ccgctggctg cagattgtgg	1920
tccgcaacga ctactatcct gacctcaca ggggtgcggcg cttcctggag agccagatgt	1980
cacgcatgta caccatcccc ctgtacgagg acctctgcac cgggtgccctc aagtccttcg	2040
cgctggaggt cttctaccag acgcagggcc ggctgcaccc caacctgcgc agagccatcc	2100
agcagatcct gtcccagggc ctgggctcca gcacagagcc cgcctcagag cccagcacgg	2160
agctgggcaa ggctgaagca gacacagact cggacgcaca ggccctgctg cttggggacg	2220
aggccccag cagtgccatc tctctcaggg acgtcaatgt gtctgcctag ccctgttggc	2280
gggctgaccc tcgacctccc agacaccaca attgtgcctt ctgtgggcca ggctgcca	2340
gactgcgtct cggctctggc catgagctct gccagggccc acaagcccct cccctgggct	2400
ctcccaggca gggagaatgg ggagagggac ctcttgtgt ctggcagaga cctgtggacc	2460
tggcctcccc actcccagct ctcttgcact gcaggccctg gggccagccc gcacacacca	2520
tgccctcctgt ctcaaacctg acagctgtgc ctagccccgg atgccagcac ctgccaggtg	2580

134

```

ccgccccggg gcaagggccc cagcagccct atggtgaccg ccacactgtg ccttaatgtc 2640
tgccggggggc ccaggctgtg ctgtccctgc agcacgcctc cttgcaggga tctgagccac 2700
cctccccgca cagccctgca ccccgcccct agggttggca gcctcagttg gcccctggca 2760
gaggaacaag gacacagaca ttccctcagt gtgggggggca ggggacacag ggagaggatg 2820
gttgtccctg gggagggccc tctggcccca ggcaacctta gcccctcaga acagggagtc 2880
ccaggaccca gggagagtgt ggggacagga cagcctgtct cttgtagctt cctggggtgg 2940
gaggcacagg ggcaaagcaa taccacaggg aaagtgggag gtgggtgctgg tgctctctcc 3000
aggcccacca tgctgggaga ggcggccaga gcctggggcc tccagcctgg gactgctgtg 3060
atgggggtatc acggtgatgg tccattaaa ctccactct gcaaacctga 3110

```

```

<210> 138
<211> 695
<212> DNA
<213> Homo sapien

```

```

<400> 138
tatgattcag atgaaagaga atgtcagatc agtgaaacag aataaatgaa cccagaccag 60
aatctcgtac atgcgggagc aagacaggaa gggcagaggt gtctagggca gaggtggaac 120
tagaacaat ggtagttact tggggaaaag gtgaagttag atctgtacct tatgccaaaa 180
tgaatttcaa atgagtttaa aagttaaatg aaaaatagaa tacaacatat ttgaaagata 240
gtcactttta atttgactgt taatatctgt attacataaa aagtcttccc aaagtcaata 300
aggaaaacat taaaaacttc aaatagcaaa aagggcagac agttcacaaa aatttctcac 360
agtaaatacg aatgactaat aaatatgggg agaggggtgaa ttttggtgat ttttagcttt 420
acagatagta aaaaatgcc aagggtgtc cttttgatct atcaaattag taaaaataaa 480
atttttactc atccttactc atcagtgtc ataacttgtg tattagcact gataaactgt 540
tggtctgtaa attggtaaaa gtgggtaaaa attgattaaa tttttcggat tataaaaaag 600
cttagatggc ggcgggtggc acaccgttaa tcccagcact tggaaggccg aagcgggtga 660
ttttcgaaat ctgactcaag tgatccactg cctga 695

```

```

<210> 139
<211> 733
<212> DNA
<213> Homo sapien

```

```

<400> 139
tgccaaaggc gtataccaaa aaaaaaagag agagagagaa aatagttgac agagagaaaa 60
tagttgagaa cagttagtag acatagtaga cgaaaaggct gttgcctgag gaagtcgcag 120
taactaagac cgtatgattc agatgaaaga gaatgtcaga tcagtgaaac agaataaatg 180

```

135

aaccagacc agaattctgt acatgcgggc agaagacagg aagggcagag gtgtctaggg 240
 cagagggtgga actagaacaa atggtagtta cttggggaaa aggtgaagtt agatctgtac 300
 cttatgccaa aatgaatttc aaatgagttt aaaagttaaa tgaaaaatag aatacaacat 360
 atttgaaaga tagtcacttt aaatttgact gttaatatct gtattacata aaaagtcttc 420
 ccaaagtcaa taaggaaaac attgaaaact tcaaataagca aaaagggcag acagttcaca 480
 aaaatttctc acagtaaata cgaatgacta ataaatatgg ggagaggggtg aattttgggtg 540
 attttttagct ttacagatag taaaaaatgc caaaaggggtg tccttttgat ctatcaaatt 600
 agtaaaaata aaattttttac tcattccttac tcattcagtgc taataacttg tgtattagca 660
 ctgataaact gttgggtctgt aaattggtaa aagtgggtaa aaattgatta aatttttcgg 720
 attataaaaa agc 733

<210> 140
 <211> 2734
 <212> DNA
 <213> Homo sapien

<400> 140
 ggaggggggca agggagaagc tgctgggtcgg actcacaatg aaaacgctcc ttcttttgct 60
 gctgggtgctc ctggagctgg gagaggccca aggatccctt cacaggggtgc ccctcaggag 120
 gcatccgtcc ctcaagaaga agctgcgggc acggagccag ctctctgagt tctggaaatc 180
 ccataatttg gacatgatcc agttcaccga gtctgtctca atggaccaga gtgccaagga 240
 accctcatc aactacttgg atatggaata ctccggcact atctccattg gctccccacc 300
 acagaaattc actgtcatct tcgacactgg ctccctccaac ctctgggtcc cctctgtgta 360
 ctgcactagc ccagcctgca agacgcacag caggttccag ccttcccagt ccagcacata 420
 cagccagcca ggtcaatctt tctccattca gtatggaacc gggagcttgt ccgggatcat 480
 tggagccgac caagtctctg tggaaggact aaccgtgggt ggccagcagt ttggagaaag 540
 tgtcacagag ccaggccaga cctttgtgga tgcagagttt gatggaattc tgggcctggg 600
 ataccctctc ttgggtgtgg gaggagtgc tccagtattt gacaacatga tggctcagaa 660
 cctgggtggac ttgccgatgt tttctgtcta catgagcagt aaccagaag gtggtgccgg 720
 gagcgagctg attttcggag gctacgacca ctcccatctc tctgggagcc tgaattgggt 780
 cccagt cacc aagcaagctt actggcagat tgcactggat aatatgctgt ggagtgtgcc 840
 aacctaacg tcattgccga tgtcaccttc accattaacg gaggcccta taccctcagc 900
 ccaactgcct acaccctact ggacttcgtg gatggaatgc agttctgcag cagtggcttt 960
 caaggacttg acatccacc tccagctggg cccctctgga tcctggggga tgtcttcatt 1020

136

cgacagtttt actcagtctt tgaccgtggg aataaccgtg tgggactggc cccagcagtc 1080
 ccctaaggag gggccttggtg tctgtgcctg cctgtctgac agaccttgaa tatgttaggc 1140
 tggggcattc ttacaccta caaaaagtta ttttccagag aatgtagctg tttccagggt 1200
 tgcaacttga attaagacca aacagaacat gagaatacac acacacacac acatatacac 1260
 acacacacac ttcacacata cacaccactc ccaccaccgt catgatggag gaattacgtt 1320
 atacattcat attttgtatt gatttttgat tatgaaaatc aaaaattttc acatttgatt 1380
 atgaaaatct ccaaacatat gcacaagcag agatcatggg ataataaatc cctttgcaac 1440
 tccactcagc cctgacaacc catccacaca cggccaggcc tgtttatcta cactgctgcc 1500
 cactcctctc tccagctcca catgctgtac ctggatcatt ctgaagcaaa ttccgagcat 1560
 tacatcattt tgtccataaa tatttctaac atccttaa atacaatcgg aattcaagca 1620
 tctccattg tcccacaaat gtttggctgt ttttgtagtt ggattgtttg tattaggatt 1680
 caagcaaggc ccatatattg catttatttg aaatgtctgt aagtctcttt ccatctacag 1740
 agtttagcac atttgaacgt tgctgggtga aatcccaggg tgtcatttga catggttctc 1800
 tgaacttata tttcctataa aatggtagtt agatctggag gtctgatttt gtggcaaaaa 1860
 tacttcctag gtggtgctgg gtacttcttg ttgcatcctg tcaggaggca gataatgctg 1920
 gtgcctctct attggtaatg ttaagactgc tgggtgggtt tggagtcttt ggctttaatc 1980
 attcattaca aagttcagca ttttacctga tcgtttcagt ggtcattgat gatcattgct 2040
 gagatccaca ctataattag gggcggcaga acagggtgtt ttctaattct gctatccctt 2100
 tggcatttgt tagttggaat tcttctataa aaaacatagg ccgggtacag tggctcacgc 2160
 ctgtaatcct agcactttcg gaggccaaagg caggcagatc acgagggtcaa gagatggaga 2220
 ctatcctggc caacatgggt aaacccttc tctactaaaa gtacaaaaat tagccaggca 2280
 tgggtggcaca cccctgtagt cccagctacc caggaagctg aggaggaga atcgcatgaa 2340
 cccaggagac agaggctgca gtgagccaag atcacgccac tgcactccag actggcaaca 2400
 gagcgagact ccttctcaaa ataaaaacaa aaataataat ctttggctgg gccacgatgg 2460
 ctacgtctg tccagcact ctgggaacc aaggaaggag gattgcttga cccagggtg 2520
 tcaaagttgc agtgatctat gaccttgcca ctgtactcca atctgggtga tagagcaaga 2580
 ccttgtcttg aaaacaagat aaaacaagat aaaacctttc cctcatcaac catttgccca 2640
 ggaaagaaga caattacttg gggttttgtt tcctttgttt accagttttc agaatgagtt 2700
 ggtactatat taaacaccaa agaattttta acat 2734

<210> 141

137

<211> 1192

<212> DNA

<213> Homo sapien

<400> 141

```

agatgctgtc gagcggcgca gtgtgatgga tcggcgcccc ggcagagagt ttgatggaat      60
tctgggcctg ggataccctt ccttggctgt gggaggagtg actccagtat ttgacaacat      120
gatggctcag aacctggtgg acttgccgat gttttctgtc tacatgagca gtaaccaga      180
aggtggtgcg gggagcgagc tgatTTTTTgg aggctacgac cactccatt tctctgggag      240
cctgaattgg gtcccagtca ccaagcaagc ttactggcag attgcactgg ataacatcca      300
gggaggaggc actgttatgt tctgctccga gggctgccag gccattgtgg acacagggac      360
ttccctcatc actggccctt ccgacaagat taagcagctg caaaacgcca ttggggcagc      420
ccccgtggat ggagaatatg ctgtggagtg tgccaacctt aacgtcatgc cggatgtcac      480
cttcaccatt aacggagtcc cctataccct cagcccaact gcctacacc tactggactt      540
cgtggatgga atgcagttct gcagcagtgg ctttcaagga cttgacatcc accctccagc      600
tgggcccttc tggatcctgg gggatgtctt cattcgacag ttttactcag tctttgaccg      660
tggaataaac cgtgtgggac tggccccagc agtcccctaa ggaggggcct tgtgtctgtg      720
cctgcctgtc tgacagacct tgaatatgtt aggctggggc attctttaca cctacaaaaa      780
gttatTTTcc agagaatgta gctgtttcca gggttgcaac ttgaattaag accaaacaga      840
acatgagaat acacacacac acacacatat acacacacac acacttcaca catacacacc      900
actcccacca ccgtcatgat ggaggaatta cgttatacat tcataTTTTg tattgatttt      960
tgattatgaa aatcaaaaat tttcacattt gattatgaaa atctccaaac atatgcacaa     1020
gcagagatca tgggtataata aatccctttg caactccact cagccctgac aacccatcca     1080
cacacggcca ggctgttta tctacactgc tgcccactcc tctctccagc tccacatgct     1140
gtacctgccc gggcgggcga tccatcacac tgcgcgctc gacatgcatt ag              1192

```

<210> 142

<211> 862

<212> DNA

<213> Homo sapien

<400> 142

```

TTTTTTTTTT ttggtagtga tttatatata tttattatag atttataata aaataaaaaa      60
tgctattgga attctatatt tacacatgct ccatttatat acacgcaaac aaatgtcaat      120
atcaatggta aaattttagg attttaaaga ggcacatttc ctctaccta cccacttcca      180
catattcatt actctaagat gagttttcat aagcaacatt tagatttTgt aaggaaaaaa      240
atgaatatTT ctagtactta tcctctttcc tttcatgctt ttgtttgaga aaggaagcag      300

```

138

```

cacataaaat ctaaaacaga aactaaggct gtaagacctt ctgtaataca tgttcacact      360
catgcatgag ttgactgtaa taggtcagaa gatatttgag caaagtaatg cacttacatg      420
tatatgcact gcatataagt gatactcttc agacacacac acacagacac acacactcat      480
gtttcttgaa aataacatgt taactatact atgtaacccc aagaatttat caccaagaat      540
acttccatgg tgcaactgct gattataatt taccaataaa tgcctctata tagccaacaa      600
cacaccatga aaaggaaaac aaaagccagt tattgtgaaa caaaggcaaa ttaaagatac      660
acaaacatct tgagtgttaa tataactaaga agacagttat tataaaaggg tatctgaacc      720
cacctacatt attgaacgtc tcttaaattt acttagccaa tttctaagtc tcaattactt      780
agactttata ggcacctaag ggtctgggtct tttcccaaga aaatacccca gccaaaatct      840
ttcacagcag gaaacagaag ac                                             862

```

```

<210> 143
<211> 848
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (384)..(413)
<223> n=a, c, g or t

```

```

<400> 143
gtcttctgtt tcctgctgtg aaagattttg gctggggtat tttcttgga aaagaccaga      60
cccttaggtg cctataaagt ctaagtaatt gagacttaga aattggctaa gttaaatttaa      120
gagacgttca ataatgtagg tgggttcaga taccctttta taataactgt cttcttagta      180
tattaacact caagatgttt gtgtatcttt aatttgcctt tgtttcacia taactggctt      240
ttgttttcct tttcatgggtg tgttggtggc tatatagagg catttattgg taaattataa      300
tcagcagttg caccatggaa gtattcttgg tgataaatc ttgggggttac atagtatagt      360
taacatgtta ttttcaagaa acannnnnnn nnnnnnnnnn nnnnnnnnnn nnaagagta      420
tcacttatat gcagtgcata tacatgtaag tgcattactt tgctcaaata tcttctgacc      480
tattacagtc aactcatgca tgagtgtgaa catgtattac agaaggctctt acagccttag      540
tttctgtttt agattttatg tgctgcttcc tttctcaaac aaaagcatga aaggaaagag      600
gataagtact agaaatatc atttttttcc ttcacaaatc taaatgttgc ttatgaaaac      660
tcatcttaga gtaatgaata tgtggaagtg gtaggtagg aggaaatgtg cctctttaa      720
atcctaaaat tttaccattg atattgacat ttgtttgcgt gtatataaat ggagcatgtg      780
taaatataga attccaatag cattttttat tttattataa atctataata aatatatata      840

```

139

aatcacta

848

<210> 144
<211> 284
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (162)..(162)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (172)..(172)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (230)..(230)
<223> n=a, c, g or t

<400> 144
cttttgtctt tccgtggagc tgtcgccatg aaggtcgagc tgtgcagttt tagcgggtac 60
aagatctacc ccggacacgg gaggcgctac gccagggacc gacgggaagg ttttcccagt 120
ttcttaatgc gaaatgcgga gttcggcttt tccttttcca angagggaat tncctcggca 180
agattaaact tgggacttgt ccctcttacc aggaagggaa ggcaccaaen aaaggggacc 240
agttcgggaa aggaaaattt tcaaaaaagg aaaaaaggaa cccc 284

<210> 145
<211> 2244
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (962)..(962)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (980)..(980)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (984)..(984)
<223> n=a, c, g or t

140

<400> 145

gctctgtgaa ggcacgggat gaggctagag gagccctggg tctgccttta cttacccggg	60
tctgctctag ccctagccct cgggagtcag ggaaggggaa ttgcctaagt aacaaagggg	120
gcttttgggt ggggtttccc acccaagttc aagaggagga gcagacatct gtctctgccc	180
ccttcctttg gtcttcttcc tccaggatct gtgtctcagc tcttgcctct cactccctct	240
ctatctgcct tctgtttctc tttgggtctc tctgtctctc ctctttcttg cctgcctcct	300
ctctctaate ctgcctctct tctctctccc cccttgcctt gccccctctc actctaggcc	360
ctcagctcca gcctctggcc ctgacctga gctgtgtcct gattctgtct ctgccccagg	420
actgcagggc tccaggaggt ctgggctgcc tccagcttcc cactcccagg ttgcggctgg	480
actgggactg gttcctttcc agttgaatct ggcagccaaa cctctcctcc ccctcacctg	540
acaggtgcag cggcctggct ggggagcccc cccgccggcc ggccagggat ggaagcgaca	600
ggaatctcat tagcatctca attaaaggtg cctccatatg cgtcggagaa ccagacctgc	660
agggaccagg aaaaggaata ctatgagccc cagcacccga tctgtctgctc ccgctgcccc	720
ccaggcacct atgtctcagc taaatgtagc cgcattccggg acacagtttg tgccacatgt	780
gccgagaatt cctacaacga gcaactggaac tacctgacca tctgccagct gtgccgcccc	840
tgtgaccag tgatgggcct cgaggagatt gccccctgca caagcaaacg gaagaccag	900
tgccgctgcc agccgggaat gttctgtgct gcctgggccc tcgagtgtac aactgctgag	960
cnactttctg actgccccgn tggnaactgaa gccgagctca aagatgaagt tgggaaggg	1020
aacaaccact gcgtcccctg caaggcaggg cacttccaga atacctcctc cccagcgcc	1080
ctgctgccag cccacacca ggtgtgagaa ccaaggtctg gtggaggcag ctccaggcac	1140
tgcccagtcc gacacaacct gcaaaaaatcc attagagcca ctgccccag agatgtcagg	1200
atcgtctgctc aagaggcgtc cgcagggaga gggacccaat cctgtagctg gaagctggga	1260
gcctccgaag gccatccat acttccctga cttggtacag ccactgctac ccatttctgg	1320
agatgtttcc ccagtatcca ctgggctccc cgcagcccca gttttggagg caggggtgcc	1380
gcaacagcag agtctctctg acctgaccag ggagccgcag ttggaacccg gggagcagag	1440
ccaggtggcc cacggtacca atggcattca tgtcaccggc ggggtctatga ctatcactgg	1500
caacatctac atctacaatg gaccagtact ggggggacca ccgggtcctg gagacctccc	1560
agctaccccc gaacctccat accccattcc cgaagagggg gaccctggcc ctcccgggct	1620
ctctacaccc caccaggaag atggcaaggc ttggcaccta gcggagacag agcactgtgg	1680
tgccacaccc tctaacaggg gcccaaggaa ccaatttatc acccatgact gactgagtct	1740
gagaaaaggc agaagaaggg gggcacaagg gcaccttctc ccttgaggct gccctgcca	1800

141

cgtgggattc acaggggcct gagtagggcc cggggaagca gagccctaag ggattaaggc 1860
 tcagacacct ctgagagcag gtgggcactg gctgggtacg gtgccctcca caggactctc 1920
 cctactgcct gagcaaacct gagggcacac ggtcacctgc aaggacgtca cgggccctc 1980
 taaaggattc gtggtgctca tccccaaagct tcagagaccc tttgggggttc cacacttcac 2040
 gtggactgag gtagaccctg catgaagatg aaattatagg gaggacgtc cttccctccc 2100
 ctcctagagg agaggaaagg gagtcattaa caactagggg gttgggtagg attcctaggt 2160
 atggggaaga gttttggaag gggaggaaaa tggcaagtgt atttatattg taaccacatg 2220
 caaataaaaa gaatgggacc taga 2244

<210> 146
 <211> 2077
 <212> DNA
 <213> Homo sapien

<400> 146
 ccggcctggc tcccagcgct ccctgtcccc gcccgcggc cagctcgctc cactcccact 60
 tcctgagctc cgccgtggga gccctggagg cccggcctgg ccgctcccgg ccctgggggtg 120
 cacatcggcc ctgagtcctg tcccaggctc tgggctcggg cagccgccc caccgctgcc 180
 caggacgtcg ggctcctgc cttcctccca ggccccacg ttgctggccg cctggccgag 240
 tggccgccat gctcctgcct tgggccacct ctgcccccg cctggcctgg gggcctctgg 300
 tgctgggcct cttcgggctc ctggcagcat cgcagcccca ggcggtgcct ccatatgcgt 360
 cggagaacca gacctgcagg gaccaggaaa aggaatacta tgagccccag caccgcatct 420
 gctgctcccg ctgcccccca ggcacctatg tctcagctaa atgtagccgc atccgggaca 480
 cagtttgtgc cacatgtgcc gagaattcct acaacgagca ctggaactac ctgaccatct 540
 gccagctgtg ccgcccctgt gaccagtgga tgggcctcga ggagattgcc ccctgcacaa 600
 gcaaacggaa gaccagtgct cgctgccagc cgggaatgtt ctgtgctgcc tgggccctcg 660
 agtgtacaca ctgagagcta ctttctgact gccgcctgg cactgaagcc gagctcaaag 720
 atgaagttgg gaagggtaac aaccactgcg tcccctgcaa ggcagggcac ttccagaata 780
 cctcctcccc cagcggcccg tgccagcccc acaccaggtg tgagaaccaa ggtctggtgg 840
 aggcagctcc aggcactgcc cagtccgaca caacctgcaa aaatccatta gagccactgc 900
 cccagagat gtcaggatcg ctgctcaaga ggcgtccgca gggagaggga cccaatcctg 960
 tagctggaag ctgggagcct ccgaaggccc atccatactt ccctgacttg gtacagccac 1020
 tgctacccat ttctggagat gtttccccag tatccactgg gctccccgca gcccagttt 1080
 tggaggcagg ggtgccgcaa cagcagagtc ctctggacct gaccaggag ccgcagttgg 1140

142

```

aaccgcggga gcagagccag gtggcccacg gtaccaatgg cat tcatgtc accggcgggt 1200
ctatgactat cactggcaac atctacatct acaatggacc agt actgggg ggaccaccgg 1260
gtcctggaga cctcccagct acccccgaac ctccataccc cat tcccgaag gaggggggacc 1320
ctggccctcc cgggctctct acaccccacc aggaagatgg caaggccttg cacctagcgg 1380
agacagagca ctgtggtgcc acaccctcta acagggggccc aaggaaccaa tttatcacc 1440
atgactgacg gagtctgaga aaaggcagaa gaagggggggc acaaggggcac cttctccctt 1500
gaggctgccc tgcccacgtg ggattcacag gggcctgagt agggcccggg gaagcagagc 1560
cctaagggat taaggctcag acacctctga gagcagggtg gca ctggctg ggtacggtgc 1620
cctccacagg actctcccta ctgcctgagc aaacctgagg cct cccggca gaccaccca 1680
ccccctgggg ctgctcagcc tcaggcacgg acagggcaca tgataccaac tgctgcccac 1740
tacggcacgc cgcaccggag cacggcacgg agggagccgc cacacgggtc cctgcaagga 1800
cgtcacgggc cctctaaag gattcgtggt gctcatcccc aagcttcaga gaccctttgg 1860
ggttccacac ttcacgtgga ctgaggtaga cctgcatga agatgaaatt atagggagga 1920
cgctccttcc ctcccctcct agaggagagg aaagggagtc attaacaact aggggggttg 1980
gtaggattcc taggtatggg gaagagtttt ggaaggggag gaaaatggca agtgtattta 2040
tattgtaacc acatgcaaat aaaaagaatg ggaccta 2077

```

```

<210> 147
<211> 2048
<212> DNA
<213> Homo sapien

```

```

<400> 147
ccggcctggc tcccagcgct cctgtcccc gcccgcggc cagctcgctc cactcccact 60
tcctgagctc cgcctgggga gccctggagg cccggcctgg ccgctcccgg cctgggggtg 120
cacatcggcc ctgagtcccg tcccaggctc tgggctcggg cagccggcgc caccgctgcc 180
caggacgtcg ggctcctgc ctctctccca ggccccacg ttgctggccg cctggccgag 240
tggccgccat gctcctgcct tgggccacct ctgcccccg cctggcctgg gggcctctgg 300
tgctgggcct ctccgggctc ctggcagcat cgcagcccca ggcgggtgcct ccatatgcgt 360
cggagaacca gacctgcagg gaccaggaaa aggaatacta tgagccccag caccgcatct 420
gctgctcccg ctgcccggca ggcacctatg tctcagctaa atgtagccgc atccgggaca 480
cagtttgtgc cacatgtgcc gagaattcct acaacgagca ctggaactac ctgacctct 540
gccagctgtg cggccctgt gaccagtgga tgggcctcga ggagattgcc cctgcacaa 600
gcaaacggaa gaccagtgcc cgctgccagc cgggaatgtt ctgtgctgcc tgggcctcgg 660

```

143 .

```

agtgtacaca ctgcgagcta ctttctgact gcccgcctgg cactgaagcc gagctcaaag 720
atgaagt tgg gaagggtaac aaccactgcg tcccctgcaa ggcagggcac ttccagaata 780
cctcctcccc cagcgcccg cgcagcccc acaccaggtg tgagaaccaa ggtctggtgg 840
aggcagctcc aggcactgcc cagtccgaca caacctgcaa aaatccatta gagccactgc 900
ccccagagat gtcaggaacc atgctgatgc tggccgttct gctgccactg gccttctttc 960
tgctcct tgc caccgtcttc tcctgcatct ggaagagcca cccttctctc tgcaggaaac 1020
tgggatc gct gctcaagagg cgtccgcagg gagagggacc caatcctgta gctggaagct 1080
gggagcctcc gaaggcccat ccatacttcc ctgacttggg acagccactg ctacccattt 1140
ctggagatgt ttccccagta tccactgggc tccccgcagc ccagttttg gaggcagggg 1200
tgccgcaaca gcagagtcct ctggacctga ccaggagacc gcagttggaa cccggggagc 1260
agagccagggt ggcccacggg accaatggca ttcatgtcac cggcgggtct atgactatca 1320
ctggcaacat ctacatctac aatggaccag tactgggggg accaccgggt cctggagacc 1380
tcccagctac cccgaacct ccatacccca tccccgaaga gggggaccct ggccctcccg 1440
ggctctctac accccaccag gaagatggca aggcttggca cctagcggag acagagcact 1500
gtggtgccac accctctaac aggggcccac ggaaccaatt tatcaccat gactgacgga 1560
gtctgagaaa aggcagaaga agggggggcac aagggcacct tctcccttga ggctgccctg 1620
cccacgtggg attcacaggg gcctgagtag ggcccgggga agcagagccc taagggatta 1680
aggctcagac acctctgaga gcagggtgggc actggctggg tacgggtgcc tccacaggac 1740
tctccctact gcctgaggtc acctgcaagg acgtcacggg cccctctaaa ggattcgtgg 1800
tgctcatccc caagcttcag agaccctttg gggttccaca cttcacgtgg actgaggtag 1860
acctgcatg aagatgaaat tatagggagg acgtccttc cctccctcc tagaggagag 1920
gaaagggagt cattaacaac taggggggtt ggtaggattc ctaggtatgg ggaagagttt 1980
tggaagggga ggaaaatggc aagtgtattt atattgtaac cacatgcaaa taaaaagaat 2040
gggacct a 2048

```

<210> 148
 <211> 1778
 <212> DNA
 <213> Homo sapien

```

<400> 148
ccggcctggc tcccagcgct ccctgtcccc gcccgcgggc cagctcgctc cactcccact 60
tcctgagctc cgcctgggga gccctggagg cccggcctgg ccgctcccg ccctgggggtg 120
cacatcggcc ctgagtcctg tcccaggctc tgggctcggg cagccgccc caccgctgcc 180

```

144

caggacgtcg ggcctcctgc cttcctccca ggccccacg ttgctggccg cctggccgag	240
tggccgcat gctcctgcct tgggccacct ctgcccccg cctggcctgg gggcctctgg	300
tgctgggcct cttcgggctc ctggcagcat cgcagcccca ggcgggtgcct ccatatgogt	360
cggagaacca gacctgcagg gaccaggaaa aggaatacta tgagccccag caccgcatct	420
gctgctcccg ctgcccgcga ggcacctatg tctcagctaa atgtagccgc atccgggaca	480
cagtttgtgc cacatgtgcc gagaattcct acaacgagca ctggaactac ctgaccatct	540
gccagctgtg ccgcccctgt gaccagtgga tgggcctcga ggagattgcc ccctgcacaa	600
gcaaacggaa gaccagtgcc cgctgccagc cgggaatgtt ctgtgctgcc tgggccctcg	660
agtgtacaca ctgagagcta ctttctgact gcccgctgg cactgaagcc gagctcaaag	720
atgaagttgg gaagggtaac aaccactgcg tcccctgcaa ggcagggcac ttccagaata	780
cctcctcccc cagcgcccg tgccagcccc acaccaggtg tgagaaccaa ggtctggtgg	840
aggcagctcc aggcactgcc cagtccgaca caacctgcaa aaatccatta gagccactgc	900
cccagagat gtcaggaacc atgctgatgc tggccgttct gctgccactg gccttctttc	960
tgctccttgc caccgtcttc tcttgcctct ggaagagcca cccttctctc tgcaggaaac	1020
tgggatcgct gctcaagagg cgtccgcagg gagagggacc caatcctgta gctggaagct	1080
gggagcctcc gaaggcccat ccatacttcc ctgacttggg acagccactg ctaccatttt	1140
ctggagatgt tccccagta tccactgggc tccccgcagc ccagtttttg gaggcagggg	1200
tgccgcaaca gcagagtcct ctggacctga ccagggagcc gcagttggaa cccggggagc	1260
agagccaggt ggcccacggg accaatggca ttcatgtcac cggcgggtct atgactatca	1320
ctggcaacat ctacatctac aatggaccag tactgggggg accaccgggt cctggagacc	1380
tcccagctac cccgaacct ccatacccca tccccgaaga gggggaccct ggccctcccg	1440
ggctctctac accccaccag gaagatggca aggcttggca cctagcggag acagagcact	1500
gtggtgccac accctctaaa ggattcgtgg tgctcatccc caagcttcag agaccctttg	1560
gggttccaca cttcacgtgg actgaggtag accctgcatg aagatgaaat tatagggagg	1620
acgctccttc cctcccctcc tagaggagag gaaagggagt cattaacaac taggggggtg	1680
ggtaggattc ctaggtatgg ggaagagttt tggaagggga ggaaaatggc aagtgtattt	1740
atattgtaac cacatgcaaa taaaaagaat gggaccta	1778

<210> 149
 <211> 2785
 <212> DNA
 <213> Homo sapien

145

<400> 149
 ccggcctggc tcccagcgct ccctgtcccc gccccgcggc cagctcgctc cactcccact 60
 tcctgagctc cgccgtggga gccctggagg cccggcctgg ccgctcccgg ccctgggggtg 120
 cacatcggcc ctgagtcccc tcccaggctc tgggctcggg cagccgccgc caccgctgcc 180
 caggacgtcg ggcctcctgc cttcctccca gggccccacg ttgctggccg cctggccgag 240
 tggccgccat gctcctgcct tgggccacct ctgcccccg cctggcctgg gggcctctgg 300
 tgctgggcct cttcgggctc ctggcagcat cgcagcccca ggcggtgcct ccataatgcgt 360
 cggagaacca gacctgcagg gaccaggaaa aggaatacta tgagcccag caccgcatct 420
 gctgctcccg ctgcccgcc ggcacctatg tctcagctaa atgtagccgc atccgggaca 480
 cagtttgtgc cacatgtgcc gagaattcct acaacgagca ctggaactac ctgaccatct 540
 gccagctgtg ccgcccctgt gaccagtgga tgggcctcga ggagattgcc ccctgcacaa 600
 gcaaacggaa gaccagtgcc cgctgccagc cgggaatgtt ctgtgctgcc tgggccctcg 660
 agtgtacaca ctgagagcta ctttctgact gccgcctgg cactgaagcc gagctcaaag 720
 atgaagttgg gaagggtaac aaccactgcg tcccctgcaa ggcagggcac ttccagaata 780
 cctcctcccc cagcgcccg cgcagcccc acaccaggtg tgagaaccaa ggtctggtgg 840
 aggcagctcc aggcactgcc cagtccgaca caacctgcaa aaatccatta gagccactgc 900
 ccccagagat gtcagaacct gccctgagca aggggggtgga gaacttgcaa gccctgctct 960
 accaggcggc cacaggcagt tccgaagcaa gtttccctac tctctcacc cttgtaaacac 1020
 ccccacaggt acaggtacag cagggcaacc ctagctcctc tacagcagcc cctctgtaca 1080
 atggctgagg ccacagaaat gtggctctag cctgtgtctg ttacaaactc caagtccac 1140
 ccttccctac tgtctcccaa tcccacttcc agacctgaa aatcaactgc ctaagctccc 1200
 atcctgcaca cacaagcctg cccaatcctg gtctctgagc aggagggcac ccacaccacc 1260
 cccaaacatg cccatccatg atacagtctc tcctggctgc caagaggtcc tcaagtccaa 1320
 cttagtcccc cttctctata acccaaggga agtttctctc attctgcctt taggagctgc 1380
 attgtgtcta gaaggaaaa agctgctccc ttttctctgt ctgggttgcc cagggatctg 1440
 gaaagctctt ccttctcctc ctcccctctg cccttcttgg ggctgtgatc accctcctgt 1500
 ctgctgtcct ggcaggaacc atgctgatgc tggccgttct gctgccactg gccttctttc 1560
 tgctccttgc caccgtcttc tcctgcatct ggaagagcca cccttctctc tgcaggaaac 1620
 tgggatcgct gctcaagagg cgtccgcagg gagagggacc caatcctgta gctggaagct 1680
 gggagcctcc gaaggcccat ccatacttcc ctgacttggg acagccactg ctaccatttt 1740
 ctggagatgt ttcccagta tccactgggc tcccgcagc cccagttttg gaggcagggg 1800

146

tgccgcaaca gcagagtcct ctggacctga ccagggagcc gcagttggaa cccggggagc 1860
 agagccaggt ggcccacggt accaatggca ttcatgtcac cggcgggtct atgactatca 1920
 ctggcaacat ctacatctac aatggaccag tactgggggg accaccgggt cctggagacc 1980
 tcccagctac ccccgaacct ccatacccca ttcccgaaga gggggaccct ggccctcccg 2040
 ggctctctac accccaccag gaagatggca aggcttggca cctagcggag acagagcact 2100
 gtggtgccac accctctaac aggggcccac ggaaccaatt tatcaccat gactgacgga 2160
 gtctgagaaa aggcagaaga agggggggcac aagggcacct tctcccttga ggctgccctg 2220
 cccacgtggg attcacaggg gcctgagtag ggcccgggga agcagagccc taagggatta 2280
 aggctcagac acctctgaga gcaggtgggc actggctggg tacggtgccc tccacaggac 2340
 tctccctact gcctgagcaa acctgaggcc tcccggcaga cccacccacc ccctggggct 2400
 gctcagcctc aggcacggac agggcacatg ataccaactg ctgccacta cggcacgccc 2460
 caccggagca cggcacccgag ggagccgcca cacggtcacc tgcaaggacg tcacgggccc 2520
 ctctaaagga ttctgtgtgc tcatcccca gcttcagaga ccctttgggg ttccacactt 2580
 cacgtggact gaggtagacc ctgcatgaag atgaaattat agggaggacg ctccctccct 2640
 cccctcctag aggagaggaa agggagtcac taacaactag ggggttgggt aggattccta 2700
 ggtatgggga agagttttgg aaggggagga aaatggcaag tgtatttata ttgtaaccac 2760
 atgcaaataa aaagaatggg accta 2785

<210> 150
 <211> 1214
 <212> DNA
 <213> Homo sapien

<400> 150
 aagaagaggg agggagggag agagaaaaaa gggctctgggg ccctcatcat tgtttgggtc 60
 tccatctctt tcctgcaggg agagggaccc aatcctgtag ctggaagctg ggagcctccg 120
 aaggcccatc catacttccc tgacttggtc cagccactgc taccatttc tggagatgtt 180
 tccccagtat ccactgggct ccccgagcc ccagttttgg aggcaggggt gccgcaacag 240
 cagagtcctc tggacctgac caggagaccg cagttggaac ccggggagca gagccaggtg 300
 gcccacggta ccaatggcat tcatgtcacc ggcgggtcta tgactatcac tggcaacatc 360
 tacatctaca atggaccagt actgggggga ccaccgggtc ctggagacct cccagctacc 420
 cccgaacctc catacccat tcccgaagag ggggacctg gccctcccg gctctctaca 480
 ccccaccagg aagatggcaa ggcttggcac ctagcggaga cagagcactg tggtgccaca 540
 ccctctaaca ggggcccag gaaccaattt atcaccatg actgacggag tctgagaaaa 600

147

```

ggcagaagaa ggggggcaca agggcacctt ctcccttgag gctgccctgc ccacgtggga 660
ttcacagggg cctgagtagg gcccggggaa gcagagccct aagggattaa ggctcagaca 720
cctctgagag caggtgggca ctggctgggt acggtgccct ccacaggact ctccctactg 780
cctgagcaaa cctgaggcct cccggcagac ccacccaccc cctggggctg ctcagcctca 840
ggcacggaca gggcacatga taccaactgc tgcccactac ggcacgccgc accggagcac 900
ggcaccgagg gagccgccac acggtcacct gcaaggacgt cacgggcccc tctaaaggat 960
tcgtggtgct catccccaag cttcagagac cctttggggg tccacacttc acgtggactg 1020
aggtagacct tgcataaga tgaaattata gggaggacgc tccttcctc ccctcctaga 1080
ggagaggaaa gggagtcatt aacaactagg ggggttgggt ggattcctag gtatggggaa 1140
gagttttgga aggggaggaa aatggcaagt gtatttatat tgtaaccaca tgcaaataaa 1200
aagaatggga ccta 1214

```

<210> 151
<211> 1276
<212> DNA
<213> Homo sapien

```

<400> 151
ccggcctggc tcccagcgt cctgtcccc gccccgggc cagctcgct cactccact 60
tcctgagctc cgccgtggga gccctggagg cccggcctgg ccgctcccg cctgggggtg 120
cacatcggcc ctgagtcccg tcccaggctc tgggctcggg cagccgccgc caccgctgcc 180
caggacgtcg ggcctcctgc cttcctccca ggcacccacg ttgctggccg cctggccgag 240
tggccgccat gctcctgcct tgggccacct ctgcccccg cctggcctgg gggcctctgg 300
tgctgggcct cttcgggctc ctggcagcat cgcagcccca ggcggtgcct ccatatgcgt 360
cggagaacca gacctgcagg gaccaggaaa aggaatacta tgagccccag caccgcatct 420
gctgctcccg ctgcccgcc ggcacctatg tctcagctaa atgtagccgc atccgggaca 480
cagtttgtgc cacatgtgcc gagaattcct acaacgagca ctggaactac ctgaccatct 540
gccagctgtg ccgcccctgt gaccagtgga tgggcctcga ggagattgcc ccctgcacaa 600
gcaaacggaa gaccagtgcc cgctgccagc cgggaatgtt ctgtgctgcc tgggccctcg 660
agtgtacaca ctgcgagcta ctttctgact gcccgccctgg cactgaagcc gagctcaaag 720
atgaagttgg gaagggtaac aaccactgcg tccctgcaa ggcagggcac ttccagaata 780
cctcctcccc cagcgcccg tgccagcccc acaaccagggtg tgagaaccaa ggtctggtgg 840
aggcagctcc aggcactgcc cagtccgaca caacctgcaa aaatccatta gagccactgc 900
ccccagagat gtcaggaacc atgctgatgc tggccgttct gctgccactg gccttctttc 960

```

148

tgctccttgc caccgtcttc tcctgcatct ggaagagcca cccttctctc tgcaggaaac 1020
 tgggatcgct gctcaagagg cgtccgcagg taatggcggg ggctgagaag gcagcaagaa 1080
 ggggaagagg tgatgagggt acaagggtga gcagacagga agagagtatg caggctgact 1140
 ccacactcat tcattcattc aactgatgat ttactgaaca tgccacgtac caggcactgt 1200
 cctaggcact gggcgtacag cagtgaagcaa aacacagtac ctcatcttct ggagttcaca 1260
 tgcccatgga gcaaga 1276

<210> 152
 <211> 424
 <212> DNA
 <213> Homo sapien

<400> 152
 gaggtctgtg aggaccaatt tgtgggtagt tcattcttccc tcgattgggt aactccttag 60
 tttcagacca cagactcaag attggctctt ccagaggggc agcagacagt caccccaagg 120
 caggtgtagg gagcccaggg aggccaatca gcccctgaa gactctgggt ccagtcagcc 180
 tgtggcttgt ggcctgtgac ctgtgacct ctgccagaat tgtcatgcct ctgaggcccc 240
 ctcttaccac actttaccag ttaaccactg aagcccccaa tccccacagc ttttccatta 300
 aaatgcaa at ggtgggtgggt caatctaata tgatattgac atattagaag gcaattaggg 360
 tgtttcctta agcaactaca caccaacctg ctggcttttag aataaaagcc ccaactgaac 420
 tgag 424

<210> 153
 <211> 541
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (242)..(242)
 <223> n=a, c, g or t

<400> 153
 gggggattgc caggtgagct tgactgggct gttgggtggag atcagcctag tttggcccaac 60
 atctgacatg agagttatgg cctctagagc atgaccttcc tcttgatggt gctgctcatc 120
 ttcttctaca tttttgctgt gactgggtgtc tacgtcttct cagagtacac ccgttcacct 180
 cgtcaggacc tggagtagca tgtgttcttc tcgtaagcag agctgagtga cagctgggtg 240
 angggagaaa atttggctaa gagaccagga agcttgtcca aagtatagta atataaaaag 300
 tgcagtctat tccaagaaac tgaaatagaa cacaataggg agagggaag agaaagcaaa 360
 agaatagtga atgggtattag ctctgatctt gaggttaggg cagctagttc catgtttatt 420

149

ctggggttttg caaattcaaa ccacactgtc atcaggcatc tttaaatagc agtacactcc 480
 agtggttaag cttgggtttct gtgactcagt tacctctttt gaaaaatggg ggcagggcgc 540
 g 541

<210> 154
 <211> 739
 <212> DNA
 <213> Homo sapien

<400> 154
 ctaagatctt ttcactattg ttcctcttac acccctctcc acatggcttt gactgccttc 60
 aacctttttgt agctgaatta catcatccac aaagtttgcc aaatagcccg tccagagctg 120
 ctggatgacc agcaccctgt ggtccgggtg ctgcgcagtt tttcctctga ctgtacaggg 180
 ggccgggccag tctccttgga tgccacgctg gcgcacacc tgcaccagtg ctctaccac 240
 ctgcgcctct tccggaactg gatctgacat gagagttatg gcctctagag catgaccttc 300
 ctcttgatgt tgctgctcat cttcttctac atttttgctg tgactggtgt ctacgtcttc 360
 tcagagtaca cccgttcacc tcgtcaggac ctggagtacc atgtgttctt ctcgtaagca 420
 gagctgggga cagctgggtg aggggagaaa atttggctaa gagaccagga agcttgtcca 480
 aagtatagta atataaaaag tgcagtctat tccaagaaac tgaaatagaa cacaataggg 540
 agaggggaaag agaaagcaaa agaatagtga atggtattag ctctgatctt gaggttaggg 600
 cagctagttc catgtttatt ctggggttttg caaattcaaa ccacactgtc atcaggcatc 660
 tttaaatagc agtacactcc agtggttaag cttgggtttct gtgactcagt tacctctttt 720
 gaaaaatggg ggcagggcgc 739

<210> 155
 <211> 6308
 <212> DNA
 <213> Homo sapien

<400> 155
 gcgggactca agagtagcct tcctcgagga cctgcctttc ccatttgctg cctgaagtta 60
 atgtttcttg ctggccaaat cagggacatg ccggcattag cgggatgagt ggggtgtccg 120
 gcagggatgt ggtcattgac ggccagtgag ggcgagagta ccacggccca cttcttcttt 180
 ggagctggag atgaggggct gggcaccctg ggaataggca tgaggccaga agagagtgac 240
 agcgagctcc ttgaggatga ggaggatgaa gtgcctcctg aacctcagat cattgttggc 300
 atctgtgcca tgaccaagaa atccaagtcc aagccaatga ctcaaatact agagcgactc 360
 tgcagatttg actacctgac tgttgtcatt ctgggagaag atgtaatact taatgaacct 420

150

gtggaaaact ggccatcctg ccactgcctc atctctttcc actccaaagg ctttcctctg	480
gacaaagctg ttgcttactc caagcttcga aacccttttc ttatcaatga tctggccatg	540
cagtattaca tccaagatag gagggaggtg taccggatcc tgcaggaaga gggatttgat	600
ctgcctcgat atgctgtgct caaccgtgat cctgcccggc ctgaggaatg caacctgata	660
gaaggtgaag accaagtaga ggtcaatgga gctgtctttc ccaagccctt tgtggagaag	720
ccagtgaagt cagaagacca caatgtttac atctactacc ccagctcagc tggaggagga	780
agccagcgtc tctttcgtaa gattggcagc cgaagcagtg tttactctcc tgagagcagc	840
gtccgaaaga cggggtcgta catctatgag gagtttatgc caacagatgg cacagatgtc	900
aaggtgtata cagtggggcc agattatgcc catgctgaag ctagaaaatc tccagctttg	960
gatgggaagg ttgaacgaga cagtgagggg aaagagattc gatatccagt catgctgact	1020
gccatggaaa agctgggtggc caggaaagtc tgcgtagctt tcaagcaaac agtttgtgga	1080
tttgaccttc ttcgtgccaa tggtcattcc tttgtgtgtg atgtcaatgg ctttagtttt	1140
gtcaagaact cgatgaaata ctacgatgac tgtgccaaga ttctggggaa caccataatg	1200
cgggagcttg cccacagtt ccagattcca tgggtccatcc ccacggaggc tgaggacatt	1260
cccattgttc ccaccacatc tggcactatg atggaacttc gttgtgtcat tgcaattatt	1320
cgtcatgggg atcgtactcc caagcagaag atgaagatgg aagtgaaca cccaaggttt	1380
tttgctctgt ttgaaaaaca tgggtggctac aagacaggga aattaaaact caagcgacct	1440
gagcagctcc aggaggtgct ggatatcaca aggctgttgt tggctgaact ggagaaagaa	1500
ccaggtggtg agatcgagga gaagactgga aaactagagc agctgaagtc tgtactggag	1560
atgtatggtc acttctcagg tataaaccgg aaggtacaat tgacttacta ccctcatgga	1620
gtaaaagctt ctaatgaggg gcaagatcca cagagggaaa ctctggcccc atctctgttg	1680
ctggtaactga agtgggggtgg agaactgact cctgctggcc gtgttcaggc tgaggagctg	1740
gggcgagctt ttcgctgcat gtaccctgga ggacaggggtg actatgctgg cttccctggc	1800
tgtgggctgc ttcgctctca tagcactttc cgccacgata tcaagatcta tgctctgat	1860
gagggctgtg ttcagatgac tgctgctgcc ttcgccaagg gccttctggc tctagaaggg	1920
gagctgacac ccattttggc gcaaatgggtg aagagtgcc aatgaatgg gctactggac	1980
agcgatgggg attccttgag cagctgccag caccgggtga aggctcggct gcaccatatt	2040
ctacagcagg atgcaccctt tggccctgag gactacgata agctggctcc caccagaagt	2100
acttccctgc tcaactccat gactatcaca cagaatcctg tgaaggctct tgatcaggta	2160
tttgccctga tcgaaaacct caccaccag atccgggaac gaatgcagga cccaggtct	2220
gtagacctgc agctctacca cagtgagaca ctagagctaa tgctacagcg ttggagcaag	2280

ctggagcgtg acttttcgaca gaagagtggg cgctatgata tcagtaagat ccctgacatc	2340
tatgactgtg tcaagtatga tgtgcagcac aatgggagtc tgggacttca aggcacagca	2400
gagttgctcc gtctctctaa ggcactggct gatgtggcca tccccagga gtacgggatc	2460
agtcgggagg agaaactgga aattgctgtg ggcttctgtc ttccactggt gcggaagata	2520
ctacttgacc tgcagagaac ccacgaggat gagtctgtca acaagctgca tcccctgtac	2580
tcccgaggcg tgctctcccc aggtcgccac gttcgaacgc gtctctatct caccagtgtg	2640
agccatgtcc actccctgct cagtgtcttc cgttatggag gacttcttga tgagaccag	2700
gatgcacaat ggcagcgagc tttggattat cttagtgtca tctcagagct taactacatg	2760
accagattg tcatcatgct ttatgaggac aacacacagg atcccttctc agaggaacgg	2820
ttccatgtgg agctacactt cagccccgga gtgaaagggt ttgaggaaga aggcagtgtc	2880
ccggctggct gtggattccg tccagcctct tctgagaatg aggagatgaa aaccaaccaa	2940
ggcagtatgg agaacctgtg tccaggaaag gcatcagatg aaccagaccg ggcattgcag	3000
acttcacccc agcctcctga gggccctggc ctcccagga gatcacccct cattcgtaac	3060
cgaaaagctg gttccatgga ggtactttct gagacttcat cctcgaggcc tgggtggctac	3120
cggctctttt catcttcacg gccaccacaa gaaatgaagc agagtggcct aggctcacag	3180
tgcacagggc tgttcagcac cacagtgtgt ggtggctcct ccagtgtccc gaatcttcag	3240
gactacgccc gcagccatgg caaaaagcta ccacctgtca gtctgaagca ccgagatgaa	3300
ttgctggaat ccacaaatac caaactatgg ccattgaagc tgaccttga ggtggcagct	3360
tggtttatct tgcttatctt catcctggag atccttctta agtggctatc caacttttct	3420
gttttctgga agagtgcctg gaatgtcttt gactttgttg ttaccatgtt ggtaaggata	3480
gagatcctga gggttcgttt agtgggatga agaattgtgc taggtgaatc gaaagaacaa	3540
gttaacatct acttaacttc tttcttttga ttttttttcc ctaaaactaa acatcaatca	3600
ttgcaggagt tgttggtatt aggagcaaag tagactaact acaacatcaa tgccaacaag	3660
agcatctgcc ggttactgag cacttactaa gtgccaagca ttattttaag tgttttcctt	3720
acattatctc atttatgtct cacaacaacc caattaaata accatgaatt ttatccccct	3780
ttttatatct gaacaagttt aagtatagt ttttaagcaac ttaatataga aaggctgaat	3840
agtaagcact tctcagagaa tgctattcaa gggataacgc ccagggaaca atgaagagga	3900
taagatgaag aagctgcaat tctgcctggg tgccttgggg tgtattttac ttataacctg	3960
tgtgttttcc acagtccctg ctccccgagg ttgtggtatt ggtaggggta acaggccaat	4020
cgggtgtggct tcagcttctg aggatctgcc ggggtgctgag gtctctcaaa ctccctgcac	4080

152

aattccgtca aattcaaatt attatTTTTgg tcctgggtcag ggccctcaag agcatgacct	4140
tcctcttgat gttgctgctc atcttcttct acatttttgc tgtgactggg gtctacgtct	4200
tctcagagta cacccgttca cctcgtcagg acctggagta ccatgtgttc ttctcggacc	4260
tcccgaattc cctggtaaca gtgttcattc tcttcacctt ggatcattgg tatgcactgc	4320
ttcaggacgt ctggaagggtg cctgaagtca gtgcgcatct cagcagcatc tatttcatcc	4380
tttggttggt gcttggctcc attatcttct gaagtatcat agtagccatg atgggtaagc	4440
atagaggagg tgaaacttgt ttgggaagtg tggttgggaa aaagtatttc tgaaagctgg	4500
gattggtggc ttatgggtat aaagaacctc gtgtagcagg aaggcttggg ttctggattg	4560
gatatttcac ttggattctc cccacccaag ccctcttccc aagtctagtc attaccatct	4620
cccagctcct aatggccctt tggggcagtt actaactttc agaatatcag gaaagagctg	4680
aatgaggaga tggcgcgtcg ggaggttcag ctcaaagctg acatgttcaa gcggcagatc	4740
atccagagggt ctgcttctcc cttttcaacc ccaactttcc ttctcaagggt ttctctgagc	4800
tcatttcttg ttctacttc tcgacccac ttttcccttt gtgacagtag atttgcccc	4860
aaggataaga attctccagc tctagaatat tgcttgattc ttcattccact gtggggtgtc	4920
ctccattttt ttcacccctt gactacaatt tgttctcccc aattagtttt cttcactttc	4980
tgatatgaac tttttttttc ttaccacact tttgcttgaa tataactgtc ttgctcttt	5040
tttttttttg ctctgcagga gaaaaaacat gtcacatgaa gcactgacgt caagccatag	5100
caaaatagag gacagcagggt taggagtatg tatgtgaact gggatagaaa cacatgaagg	5160
aggagagggt ggaaaactaa agatgaagat tggctttgag agataattca ttcatttaat	5220
aactgcatat tgtagtaggt tgactagtggt cacccgaaat aatatgtcca tgtctttgct	5280
ccctggaacc tgtgaatgtg acctattttg gaaaaaaaaa aagatcctaa gttaaggatc	5340
ttgagatgag atcatcctag attatccagc aagaggagct agtcaacaaa gggaaagttt	5400
ggacttatca gaagtgtctg aagtagagtc taattatgggt gccactgaag aggatttaat	5460
aacatctgca tcaaaaacag aagagacctt gtcaaaaaag agagagtacc agtcttctc	5520
ctgtgtctcc tccacatcct cttcctattc ttctcttct gaatccagat ttctgaatc	5580
tattggtgag ccgaagaact ataataatga gttttttcca ttgaattca gactcctct	5640
taagacatct tagtcttaac aggagctctc ctagtatatc tcctttccaa ttctctggtc	5700
ttaattactt tgtttttgct tcttaatttc ccctgtactt cttcttcact tcgggtaagt	5760
gtggctgtgg ccctctttgc tcgttgtaaa aagtggtttc ttactgatgc accctttccc	5820
tccttgcttc ctgttacctc ttccacccc acctttccac ccacaccata ggatttacca	5880
gctcttacct aacttttaca aatctagacg tgcttttctg aagcattcct ccctgcaggt	5940

153

cgtttggact gggagactct tgtgcacgaa aatctgcccg ggctaattgga aatggatcag 6000
gatgaccgtg tttggcccag agactcactc ttccgatatt ttgagttgct agaaaagctt 6060
cagtataacc tagaggaacg taagaagtta caagagtttg cagtgcaggc actgatgaac 6120
ttggaagaca agtaaagcaa tggatggctt caatatcctt gggcccagca aaagataatg 6180
aagggaattg ttggaaatag agaattgaaa atataaacat tcagatagaa caatgtctgt 6240
tcattaaaat taaaaagtat aagtgtctag gccaggcgtg gtgaaaccct gtctctacta 6300
aaaataca 6308

<210> 156
<211> 271
<212> DNA
<213> Homo sapien

<400> 156
aagagtaact gtcttgttct catctttctt cttttccttg cagcaaacag tttgtggatt 60
tgaccttctt cgtgccaatg gtcattcctt tgtgtgtgat gtcaatggct ttagttttgt 120
caagaactcg atgaaatact acgatgactg tgccaagatt ctggggtaag agacatagtg 180
gtctgcgctg gggagaatgg gcttacagaa gaatatttga aagtttttgc tttattttaa 240
atatcacaaa tatgatttaa aagtgaaaaa g 271

<210> 157
<211> 424
<212> DNA
<213> Homo sapien

<400> 157
aaaaaggcac aggtcatgaa catgcagtgc acgggggaacc tggacctcat ccccttgcgg 60
ggacggcgct gcaggaggtc gggagactcc cccagccttc cctagccatt ggcctacagc 120
cccgggctgt gtccaccact cacctggcat cctgcacaca ggtgtccctc cctacctcac 180
cttcctgtct tgccttctgt ctttgccttt tgggatctag gggctcagac actatctggg 240
tgggatgtgt gtgttttggg ggttgtgtga ttgggccctt gtgggcattg taaaaattct 300
gtttcatgtt tctaggggtg agacagtgga ggggtgggct tcttggttct aacaaggaat 360
gtagtatggt tgcagtagcc acagctctcc catgcaaaga agagaggggtg gccagactct 420
tatc 424

<210> 158
<211> 3665
<212> DNA
<213> Homo sapien

154

<220>
 <221> misc_feature
 <222> (1543)..(1565)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (2711)..(2744)
 <223> n=a, c, g or t

<400> 158
 aaaattctct aaattctcac ccagaatcat tatctctagc agatatggac aatgctgcaa 60
 gcatttcccc ttctgaacag acttctaata ccacagaaaa ccatgagact acaaatttta 120
 atggtgaatg tacagattta gataaccagc ttcaagaaca atcagaaact gaggaagatt 180
 ccaatcctaa tgtagctgg ggtaaaaagg tccagcctat agactccata ttagcagact 240
 ggaatgaaga tatagaagca tttgaaatga tggagaagga tgagctatga cttgctaaac 300
 aatctgttgg taggtattta aaaagaaaag gtaaaactgtg tgtggttaat agacatccta 360
 atactaagca ggctttctaa tgggaggctt taagtatggg gatgaacaac cacgttctga 420
 ctggcgtagt tatcgtagga atctggagca tgctgtgtta gaattgacct tgtttaaaac 480
 tgtcccatca aaaatggaaa tccacagttc ccccttcaaa tgcagcactg caccaccctg 540
 caacacctca ggccaggga agattactga gcattcctgc gaaccagatt tctgttgtct 600
 ctggatagac aagaaacaaa attcatttag tagtggagtg gggaatagga gtttggatag 660
 ccttctaatt aaaggaagct cgcctttctt ggttttgggg gttagaggct cttttgggaa 720
 gatgcacccg agtattgtgg cattctgatt atgctgcctt cacaaaacac tctaagtgac 780
 ctaagtgggt atgaagcaaa tgcatttatg gtgaaaacag tctttgctca ttgctttctc 840
 ttgtttcat t tagtgacaaa tgatcaagat gacttgattt tttttccttc ttaacaatgt 900
 cttttttatt taaaccaaag gtgaagccag tgtactttct cagtgagttc tctgcataaa 960
 gactaatcag tgggaccagg taaaaaggtc atataatata ttgtggagat tgcttactta 1020
 atacttctga aaaatggagt aaggagagaaa ctgtaatggt gcaatatgaa cctccatttg 1080
 ggcttccat agggaaagct gtgactactc tgaaatggaa cctagcatta tatccttgta 1140
 gggtagatta taaatcattt ccagttcatt tctcttagag gtgattacct ctagccatca 1200
 gccttactcc atcccatggt tggatgcaa tttgagccac aaggctcgta tcgccaacag 1260
 ctatatacat tttgttccat ttttctgtct tacagagcca tgataaaact gtggttagtg 1320
 agttaaaatt cctggagtaa ctactgtttt tctcctttga aacttaggtt tctaaagttg 1380
 cacctaagga atctgtcaca ttttctgttg aatcatgggt tttgtttttg tttttaacag 1440

155

atattccttc tgatacggac ttgaaaatta gtgtatgggtg acctgtgttt aaaaaaaaaa	1500
gtacaataca actacatata gctatatagc ttaatgagac ttnnnnnnnnn nnnnnnnnnnn	1560
nnnnngggtt gttgttggtg tagtagtctg gtgctggcca catttaagtc ttaaaaattt	1620
ttaaattttg ttgttgatgt ttgtagacag ccctgttggt gaaatcatgg ctttattcat	1680
tttattttatt ttttaaactt gcctgaattt gttctaaagg aatatttaag agacataatt	1740
ttcttctctt taccataaca ttacacaaaa ctttttccta aaacacgggt gtgaggtact	1800
gatgaggtgt aagtggagct gttaaaaaca gcagtgtgt attgcagtta tgtatatctg	1860
tgtacagtat gtttagatcc caggtaaaca tattcttttc tgagaggata aatacctgca	1920
ttcagatatt ccaggtaaata ataattgagt caggtagtag taaatctgat ggagaattca	1980
ctttggggag gggaaaaaga atagtatgca agacccttat tggcttttaa ttatacctga	2040
aaccaaagt gatattttta gtctctctgc atgtgagatt tgggtgaaca agatagaact	2100
ataatatata cagtatatgg aaggatagat atagtgttt gttcatttta attgcaaagc	2160
tgccaaaata gttgaagctt aattacttga cttgccttga tttataggac tggggcttgg	2220
agaaaatgag cagatgttcc tctaagacat cgattacaga agccttatat acatggattt	2280
gattttgtat ttgtagctga aagtcactgt tgtctaaaac taacttttct aagttatcaa	2340
aacaacctaa tttcttttcc aacaaggaga acttaatggc atgaaggatt gtgtgacaca	2400
ttggaaaagc cagcttactg ccactctctt cctttggcca ttagaggag gtgttgcctt	2460
tcattgacgc ttagaagcaa attgttact tgttaagaaa agtaaatacct taaaaaaga	2520
aaaggaaaaa atttaaccaa tttttcttaa taccagaag gaattatact caatatttcc	2580
ctagttaaga aaagaggaga taatgttcgt ctaaaaaact ccaacgttgt aattacaact	2640
ctacattcat ttacttactt gacatactgc cacaaagtag tttttgagtt cattaaaaat	2700
tccaaaggca nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnttagtt aacttttata	2760
gacatttttag taacttgcta aagattcagg ggattctatg aaaccccgaa tttagaaaca	2820
tctgggtctac ctcagttaaa tgttgactgc ttagaaatat agctgaagtg atcaccacag	2880
ccataaaatt gttaagaaa gatttatata atgtttacaa atctggaatc aaggatttta	2940
gctgaaatcc ttttaagagat attagagcaa gtatttaatt caggatattt caagttttta	3000
aacttaacct gtttacctac taaaaataaa atagctagtt ttttctgca tataaaagtt	3060
cattgaaatg atatgccctt atttgcaata cttttcccat aaagttttta gtgtgaaaga	3120
attgtaattt actagatatg tttgggtatgg gatattttgt taggcaagtt ttcttttttc	3180
ttcttaaatt gcaataggct tccaaaaaga gtataattgt ttcagaacaa attaactctt	3240
ggcattatac gtctcccttt ttctttacag tattagtaaa aagaaaaatt gtacactttc	3300

156

tgatTTTtaac tTcactaatg taattactct ctcaagaagc tTTTaaaatt taaattacca 3360
 tcacacaacc tTTTTtatag taaagccaac atttgTtctc tcaccaaacc ccatgccaaa 3420
 tTcatcatga agaaagctca gcataagtaa tTcaaatact gcttataatt ttagaggggg 3480
 gtagaattta gtaaataattc cagccgggtcg tTTtatgcac aaggcttcag tcagaacata 3540
 gaaaaaaaaa acattctgtg aatgaaatat tgtatgttca gattttataa aagactTTTT 3600
 aaaagcccaa tttacagccg tatatTTTct tatggatgta atttatgaaa aagatgtctg 3660
 tacta 3665

<210> 159
 <211> 1269
 <212> DNA
 <213> Homo sapien

<400> 159
 gttatgttca tCctgtaacc ttatTTTtaa tgctcttctt acctgggggtt ttaagagtgt 60
 ggaggtggaa gtatggggct tccaagatca gtgtccacct cttccagtta aaagaagtat 120
 cttgcagtac aaaactatTT gTTtCctata gattcaagtc taatttactt ctgcattcag 180
 tctttcagag tTTttggat tctctttcgc atgatttccg gatgtataaa ggaaccagca 240
 ttaccttaca gcagggcaga aggagcggag ctctgggttc acttggcact ttctcaccct 300
 ctgctgggtg gcctctgcgc ctctgggtgt tgtgtactct gaattttgac ctctgtcctt 360
 gccaggggtga cagggggcaa ttaggacaac aagccagctt gaaagtcaca cctgagcctc 420
 tgttcagttt tactgtggca atgcaggcaa gaggtgagg gacaagggtgc cagccccagt 480
 ttgtcaggtg acagtcagat gatgccaga tgaggagaat cctctcactt caaggaggag 540
 ctccagaagg aagattctgc cagttatgaa cctgggaggg aagaggggaa ggagtgcaaa 600
 aggtgtcagg aaaagtgcct cagctcagac gctcaggcac ggggtgcagag ccctaggagt 660
 gcccgactgt gcctgagtcc agggagccca tgctgcttga atgggctcca ccgggcctct 720
 gcccatTTgt gcatccatgc tgctgccac acctgtcttt gcttcttggt tttagatcct 780
 tgcacttggT cacctcttcc acaCCcagcc tctgctaatt cctaattccc tcttctgtgg 840
 ggtgtgaagt cccctgagct gctgtatgtc ctctttgcat ttgctcttac acaaggaagc 900
 ctCagaagaa acacagcctt ctctctgtat cttcaatgga aagtaatttt gtcataaaaa 960
 taactgactc tggaatcttt gctattacga aaatatttgt catgtgtggT gaaaaggTac 1020
 agtaggtatc agtgtagTac aattactggc ttccgtgagt ctaatgtgat ttaggagtct 1080
 gcaggggtta gcttcagggt atattgtaat ttcaagacta ggTtcttTgt acttttacta 1140
 gtattagaat aaacttagta tgaaagtggT gtctaatagt taaaataata tttcagaaag 1200

157

actattactg cctatcgtgt gaaaagtaga gtgtaaattt tcacttttaa acttttaaattc 1260
tccagcatt 1269

<210> 160
<211> 5517
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (2543)..(2594)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (2874)..(2896)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (4157)..(4157)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (4217)..(4218)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (4246)..(4246)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (4911)..(4911)
<223> n=a, c, g or t

<400> 160
cttttttatag ctgctgggca ctaccaggcc tgcctctgggg agaggagagg aaggctggat 60
tgcaggaagg atgcttcaga tagattcccc acatgggcca tagggcagcc tctgctgcct 120
gtttccccca cctgcagtat ccagattggg atgccctctc ctgctccctt tcttgagccc 180
aggccccccg ggctgctgg gccccaggga atctcctcaa gccctcgggtt ttctctagcg 240
ccctggctgg gcctccagga gatgccctgg gcagtggagc agccctgaca ttgtctctgc 300
agggaaaagt ttgcctgcta actcaatagg agttggagct ccaggcaaatt ccaacctgag 360
ggcagcaatt ttcaaaatca cattcttact ggaataatgc agactgccag gagaggcgaa 420

aagatgtgtc aggatggggc aacaggagga aagggacogt cataactcct cagaatgtct	480
gcaggagggtt gaagactctg gcctcttgct tcccctgccc caagcaaaca cttaggcaa	540
ttttcaaaca acccaaagtg tatgccaaact tgggctggat atggatgttg ctagagatat	600
aaaaccatca ttgactgcat tatgcaatct aattagtttg catgtagttt aacctgtgtg	660
agtaatagag ctgatactaa ttaacttgag gcaaaatgat ttttgaagggt gtctggcttt	720
ccattttggg ccacacctga gctttttggc tgcctccagg ctgagttcag catagcccag	780
gtggatggaa atcaccaacc ccctttcaca ttcttgact aagttgtcag ctgatccttt	840
tgtcatggct gagaggggaa aggggttccc gattaagaat acaaacatc tggacgttag	900
cagggttg aacctagtca ccactacaa ttttttaagc ttgttaacag gaaacgagga	960
gagatgtgta gtttatgttg caaacataaa ggaggccac aatctcttcc ttattgttcg	1020
aaagaagtct ggggaactaa gtcattagct gaacagcttg cagcttctta gtcctcaaac	1080
tgtgtcttg tacattgctg ctttccacat aaaacctccc agcacagcca ccccaaattc	1140
tgcctttgga agtccttagg taatcaatta aaggccagtg tctgggcagg gaagctgttt	1200
gcagggttt ggatagggat tatttttctc gagtgccct catacctaga acgtttgcct	1260
gctgcagata tacagacaag atatctccct acctcatagc caccctcacc cctgtcccac	1320
aaccaaacac ccagcccacc ttcttgagc atggaggtag tcgttaattt cttggtatca	1380
ttgctagctc ttagccttac ccttggtctt tcaagaaaaa aaaaatgcct gatactgtcg	1440
ttaacagttt aatttatgac tattttgcaa atgtggaggc ctgtgtggag aatgcaaatc	1500
gcctcacaaa gagataaagg ttctgttat ctgattcaga gggagacaca cagttccgag	1560
gatgccgagg gaaggagtcc tgtgcaaaca gatcttttag ttctgtcca cagacacctc	1620
tacattctgt agacatgcag agtcctagat atacatatga ggagggttgca tgtgtgtctg	1680
gttcttgggg tggagggtgt ggtggagatt ttcgaaatc tgttttaatg actcacaata	1740
tgcatatgtt aaccccagtc ttgtatgggg agccctgaaa ggtcaggtca caacctgaac	1800
cgctttacc aagaagcttc tcatttcaaa ggcacttact gtattttcac gtatcaaaaa	1860
agaaaagtgt tttcctgaag ataacaggga ggggggatgc ttctcggagg gacctgggtt	1920
ttaaaaaata aaggggggta ggagaaaaag ggagagagaa gaaaaagggg gaaaagaaac	1980
agctcaaagt aacagagaga tcacggtttg catggctgcc cttcaatagg ctaaactgac	2040
aagatcagtt ttaaagggcc acttaaataca gtttcaaaga ctggagaaaa atgagtcgcc	2100
ctctttgggg ggaatctgag gctggatcgt ggacgccatt actcgggact gggccaggct	2160
gtccaccccc aacccccaac ccctatataa ttataagcca aactattatt tacagaggag	2220

159

gaggggagag	agtgctggta	gttttggttt	cttctgttta	ctgacttggg	ccagacagac	2280
ccaatgcact	tttgcttggg	cctctcaatg	acccaggcta	aggactcggg	cagtgaagc	2340
ctgtagcaca	ctgagctatg	ttttatttta	aagcaaacac	ttcctcagga	ccatctcttg	2400
ctctttcttc	ccccaccccg	cctccccccc	ttaagttttc	agtacataga	catttgctcc	2460
aactccgggt	ggggcagttt	gacagagctc	tgtgcacaca	cctcatgtga	ccaattcaa	2520
acctcttaat	ctgatgactg	aannnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	2580
nnnnnnnnnn	nnnnaaactt	tcttccagat	gcctgtggtc	tctctgatgt	agcccatgtg	2640
gaaagcttgc	aggaaaagtc	tcagtgtgct	ttggaagaat	acgttaggag	ccagtacccc	2700
aaccagccga	cgagattcgg	aaagcttttg	cttcgcctcc	cttccctccg	caccgtctcc	2760
tcctcagtca	tagagcaatt	gtttttcgtc	cgtttggtag	gtaaaacccc	catcgaaacc	2820
ctcatccggg	atatgttact	gtccggcagc	agttttaact	ggccgtatat	ggcnnnnnnn	2880
nnnnnnnnnn	nnnnnngaag	ggggagtga	acagagaaag	aaaaggcaaa	agactggttt	2940
gtttgcttaa	tttccttctg	ttaagaaagg	atataaaagg	atgttacaag	tttgctaaaa	3000
gaagagaggg	gaagaattta	atggactgtg	aatttcaaaa	aaaaaaaaaa	gactgtcaaa	3060
tgaactttta	cagaatgcat	taaaaaaaaa	aaaactcctg	tgtcggtcag	aacaacttgc	3120
tacttatcat	ttttgtataa	aaaggaaatt	agtctttttc	tttttttggt	aaatttttga	3180
aaaatattgc	taaaagtgca	tttaaggaga	ttgggagaca	attagcagaa	tggagaaagt	3240
aagtcttttt	ttttcccaaa	ttattaattg	tcctgtgtct	atgtacctct	agcaacatgt	3300
tcttttttgt	acttttctgg	ttccaaacca	gtttattctg	tggttctata	ataagttttg	3360
atataatctt	ggcttcttaa	aaactgtgta	tcattaaaat	atatgttctg	caagaattaa	3420
aactgagtcc	atgaaaatac	cataggaaga	cataaaactt	taaaaggcaa	ctcaaagatg	3480
atggaaacgc	acttacaagt	ggtgaccaa	attttttaggt	gaagtcgagc	actctaatta	3540
gagaactgga	ggaaccacat	ataacactta	acttccccta	ccctgcccct	ccccaaaaga	3600
aaccatgaca	aacctagctt	ttaaaaaata	ttttaagaaa	gagaatgaac	tgtggaattt	3660
attggcagcc	aaggaatgtg	tccaagacac	atgctgaggt	tttgaataaa	aagtgaactt	3720
ttgtaatttg	aattgggtcc	cgcttagttc	ttgaattggt	atgaaaatcc	tatatctgtt	3780
tgtatatattg	caaacccttt	gtattataat	tgttgatatt	ttcccttttt	aaaaaaatac	3840
cattgaaatc	agcatgacaa	aaataacact	gttggcactt	ataggtaacg	tgattgattc	3900
agtatcttag	agtttacagt	ttgtgtttta	aaaaaactga	aggttttttt	ttttaagtgc	3960
aacatttctg	tatactgtaa	aagttataat	aactgaactg	tttggtcgag	tctttgtgtg	4020
ttatatcca	aggaaaattg	aaagtattca	gaaattaaaa	tattatttga	tatctgaaac	4080

160

ctggctgtcc ccactcactg tctttacatc tagaagagcc cctgtgagct ctcgcttagc 4140
 tggccgggcg ggggggtnggt gggggggcat ttgcttactc ccctcagtca gtttgttcaa 4200
 aggtggacta ctgtatnngc ctgtttaatt tgggtgtgtg tgtgtngggg ggggagctga 4260
 agttaatggt ttatctatgg tttaggaagt gccatactga tatagtaaac cccccccatt 4320
 cacctaatac tccttttaat taaaaatgga ttttccagga aaaaaaaaaa ggcccttata 4380
 tttgtcacac ttaagtgcct gcttagggaa ggtattgtga aaaagtatta gaatatctga 4440
 gatcagtatc tattttatga tcagaaaaaa atactctttt gtacatttct gacagttact 4500
 cagaagatcg ttcaagcaag ctaatcacag cattgtaact agaggacagt tgtttgcagt 4560
 gagtttttcc ttaagtaggt acgatttttt aaaatatctt gtgattctac tctagcgtgg 4620
 ttgttgagag agtttcaa atcagtgtac aggttctaag actgaaagggt ctacttttaa 4680
 tgtatatatg ataacttgcg gttgggtttc ctctccctc cccccctta ccttcagtct 4740
 gtgagagcat gaccacaggg tcaagggaat cttttccatt ggagttatgt acataaaaac 4800
 acatcgacat tttgacattt cagattgtgt ggctacaatc tgtactgctc ttgggaccc 4860
 ttgtccttag aagccaaatt aaggaagaga aagcaggaca gagaaaaaga nagatggaag 4920
 gagggaaact ttacaggggtg tgctgatttg gaagtagtaa ctatttcttt tggagtcttt 4980
 ttttcathtt tcctctttct cttttcctgg tttggaggaa gctcgggtgct gggagcttgc 5040
 aattttgttc ttattcaagg ttccaaccc accccccccac cgccagtact tcatcatgtt 5100
 gtggttta at tctaattggt gggggggggg gaggactagt gagggaggtg aaagaacagg 5160
 gataattttg taaagtgtat taaacgttaa tattcagatc cagtcaatac atgcagacca 5220
 gtaaaatctg atttgtgcag agttctccat ctgactctca cttatttctg tagatatata 5280
 catatataaa tacaagtatg ttcttacggc acagtattgc tgaccttag ttcgaggttt 5340
 tgtcggttgt tggtgatttt ctctctcttg caagtgtat ccattgtgagt gtgtgaagtt 5400
 tctctaataa gtaaaacaca ggcccttttc cttgtttgtt ttgtgttagt ttattgtaaa 5460
 cagccatttg ttgtaaatta ttattggcat taaattataa tttatgattt tcaaagc 5517

<210> 161
 <211> 5688
 <212> DNA
 <213> Homo sapien

<400> 161
 gggcggccgg tgcagccgca gctgccatct taggggagcc tggcgctacg gggttctcgt 60
 tggaggcggc cttcgtggca gctgtagacg ccgggaaaag gcataaagtc cgttggccga 120
 cacctttctt tcctccggcc tcggtagaac cgccagcccg cgtccgaagg cggaggcgag 180

161

gggaactggc	cgcgtgaggg	gcctgagggc	agcggttaga	gcgtctcccg	gaaggatggg	240
ccggtctcgg	agccggagct	cgtcccgcct	caagcacacc	aagagcagca	agcacaacaa	300
gaagcgcagc	cgggtcccgg	cgcgatcccg	ggacaaggag	cgcgtgcgga	agcgttccaa	360
atctcgggaa	agtaaacgga	accggcggcg	ggagtcgcgg	tcccgttcgc	gctccaccaa	420
cacggccgtg	tcccggcgcg	agcgggaccg	ggagcgcgcc	tcgtccccgc	ccgaccgcat	480
cgacatcttc	gggcgcacgg	tgagcaagcg	cagcagcctg	gacgagaagc	agaagcgaga	540
ggaggaggag	aagaaagcgg	agttcgagcg	gcagcgaaaa	attcgacagc	aagaaataga	600
agaaaaactc	atcgaggaag	aaacagcacg	aagagtagaa	gaattggtag	caaaaaaggg	660
tggaggaaga	actggagaaa	aggaaggatg	aaattgaacg	agaagtcttc	cgaaggggtg	720
aggaagccaa	acgcatcatg	gaaaagcagt	tgctcgaaga	actcgagcga	cagagacaag	780
ctgagcttgc	cgcacaaaaa	gctagagagg	taacgcctcg	tcgttttgaa	agtagagaca	840
gtccatggca	aaactttcag	tgttgggttc	tgctcctgc	tcagttcaga	aagagatgga	900
atacagacta	tctaattcct	ttctcgtcta	aacttaacat	tgctgcgaaa	gttaattttt	960
tagcctattc	agaagtgctg	actgataact	taaaagttgg	aagcttttat	aaaacatatt	1020
caaggatact	ttttgattta	atggaactgg	ctatttgaga	agtgtttgaa	acttttgcca	1080
tggctgcagg	acttacattc	ttttttggga	ggacgggtggg	gagacagggg	gtggtaaagg	1140
gaaaagggtta	aaaatccacc	tgtggttgta	tattcttcta	ttctgtcact	ctgttaccta	1200
gactgtgaga	ggcttttgcc	ttcagtcaga	ttaaaaagag	cagggcctaa	cattgagtga	1260
tagcacctgc	tttgataaat	aggttttctc	actcttcttt	ttttccttct	tttatccctc	1320
actccctccc	ctaaaccctg	cttcagcaca	atggactaat	tctagcattc	tgatcataag	1380
gccctccatt	ttcctaattg	gtttcaaggga	atcttttttag	gaaaaatatc	cagattattc	1440
atccactttt	tttagtatct	actaacaact	cctttttttc	tctagagagt	tatgaaggaa	1500
caggttgtcc	ttgtctggag	tcaagctaaa	cacatgattt	gttttatcag	cagctggagc	1560
agaagttgaa	aatgtctttc	tgtgagacag	taatttgcta	ctgaagcttt	atggcttggt	1620
tgcactgatt	actccaggat	ccaaaaactt	ggtgaaagtc	actgaaacac	tcaaggcaaa	1680
ttactttaca	gccctgagtg	tctgtcacca	tagtttgcat	aatgaatatg	aatcccattg	1740
gtgtgtgatg	taggaaatcc	tgtagttgta	ttttcttgaa	ctgaaatatt	tgactcaaaa	1800
taattaagac	tcattgtcat	ttttcatctt	ggcattattg	tggacaagtt	gacatattaa	1860
atctctttgc	tttctggtaa	gcttagcttt	taaaatgcat	tttccttgt	cctgtcttta	1920
actagatata	catgcttata	tttatagtgg	gtttcacaga	ctataaaaatt	gaatgtatga	1980

162

aatttttatt	tatatcagtg	cttttaataa	tgaagatatt	tttggagtaa	tggtgctgtc	2040
ttgtagcgag	ttattaatca	tagtaagatt	tttttctctt	catttgcttt	ttttgtttca	2100
tattaacaat	ttttttttta	cacggacaca	accctctgac	agtctttcca	aatattaaaa	2160
tcatttgaat	atgtatgctg	tgatctgaac	actgctcaag	ccatcaagca	gtcttcatac	2220
agtttgcat	ataaaatctc	attaaattct	ccaagaaaaa	ataagttgaa	gaattttatt	2280
tcctgaccat	gcatcccctg	gatttctgag	tttcagttca	gattgtagat	gacaatataa	2340
gctgccttcc	gaaattgtca	acatctgaat	gttaagtcca	ttttcccat	ggaagaagcc	2400
cgtagttcca	tgaagtatgg	attaccattt	gtatttttca	ctaacagtaa	atgtattttt	2460
cttattaatt	gtttgcctta	ggaatgatga	attacatttt	ttgttccttc	ttaccataaa	2520
catctgcatt	cctcagctca	gccttccttg	tatgttggtt	ctttataaat	ggttgagctg	2580
ctgatgcagg	tattgccaag	ctaacagtac	aatcattttt	aaagaggaag	ctggcgcgta	2640
tggcagccga	ggagcacact	ctgcaggaca	ctggacaaga	cagtaaata	tcaactttta	2700
atgctgatta	aaggagtata	ggtaaagaat	acgtaggtat	acataattgg	tgagacaaat	2760
attcacttta	tttatatttt	atatattatt	tttttaattt	ggtaaatact	atccagtttt	2820
gtagttgtcc	ttgttgattt	gtgtgatatt	aaagtattag	taataattgc	caggaaacta	2880
tcattagggg	gggtttagtt	ggttgctggt	tggactggga	gggatgattt	aaatttagtg	2940
ctagaaacca	attttagtga	ctgcacagtt	tatcatttgt	cagacagaag	gtagctataa	3000
agctaccctg	taagtcatat	caaaaaagtt	cagaggaaga	ttagtaaata	tttatcaata	3060
aaaataaaca	ttttgttttt	ctaatatctt	aacatatcct	cccctttagg	aggaagaacg	3120
tgcaaaacgt	gaggagctag	agcgaatact	ggaagagaat	aaccgaaaaa	ttgcagaagc	3180
acaagccaaa	ctggccgaag	aacagttgag	aattgttgaa	gaacaaagaa	agattcatga	3240
ggaaaggatg	aaactagaac	aagaacgaca	acgtcaacaa	aaagaagaac	aaaaaattat	3300
cctgggcaag	gggaagtcca	ggccaaaact	gtccttctca	ttaaaaaccc	aggattaaat	3360
tgcaaaactc	gaacttttta	caaagaaaaa	tggaaaaact	ttgtatggta	gcttcattgt	3420
gaagtgggtt	tttggttttg	tttttggttt	tttaatttgt	aaaatctgga	aagttagctt	3480
gttctaatag	gggctatgct	ctgcaattcc	cttttttttt	tttttttctt	tccactaagt	3540
caaatcctta	tcagatcatt	gttgtaattc	aaggagtgac	gtatttttca	cctgtttgga	3600
ttctatat	gtggtctgag	gaagagcaga	tcacattgta	aaactatgga	tggtctgata	3660
aggcttttac	tgacccact	gacttcagag	ttatactctg	tttgctacat	cataatgctg	3720
gttttgctga	ctttttgttt	ttttatatat	ttataaaaaa	agaaaaagtt	ggtgattgca	3780
ttgggaaatt	cccagggtat	tactggacct	atgtggtgta	ttgttaaacc	agtgtccttg	3840

tgatactgtt	gctcttgatg	ttcctgatac	aggtaaggaa	acagttggtc	aactctgata	3900
caaagtatat	atacagttca	gtattgtctc	tgttcatttt	gtttttat	cattgacaaa	3960
atcaaaccag	cattcccat	tgtgtaaata	aatgattttg	ctgaataaag	taaagtctta	4020
aattcatatg	ttgaagcaat	ttttttta	gttatgttaa	gtcttaaaga	gggtggttca	4080
ctttttgatg	gtcaaccatt	tagaagtctt	agaactatat	ttcctcttgt	ttatactttt	4140
aacatagggg	ttatatgtac	attaaatata	cttgtgaatt	agtatttta	ggctattttt	4200
acaaatatca	actttatgct	gatagagcaa	atggcatcag	tgttaccttt	aagaaagact	4260
aacaacatcc	agaagattta	aattctcaaa	cctgtgcctc	tgtttttagg	tataagtatt	4320
atcacaaagt	atacttaata	aaggctagaa	aaatgctttt	aaattatgga	atctgagatc	4380
gttttcagag	tgggccatca	gaaagaactt	agctttatac	tgtcaaaaaa	aggctaagat	4440
ggtcgagtca	ttttcattgt	gtagtgtact	tgcacgttta	tttttaggac	aaacacattt	4500
gaactttatg	aatttttttt	ttttattttg	gcatgtgaaa	tcttatgaat	ggctttcatt	4560
ttatacacta	gaatctgcct	catttactct	taacatatgt	ttaagtatac	tggtattaaa	4620
acattcaaga	aaaggatatt	gatctaaaat	gtacctgag	atgcataaac	atgtcatcaa	4680
gtagagaaaa	tattttttatt	tttgcccaat	attttttaga	cagtttgatt	attcttaaaa	4740
attgaaaaca	taagctaaag	agatgactaa	atggtagatt	attttgtgtg	tgcattgctag	4800
gaaaaatgct	gttgcttttag	ttttgagctc	ttcaatgagt	ctaattgtgg	taaggaacaa	4860
tataaaatca	gtttaaagat	ctttaaagg	agaattttta	ataggcatga	aatatagtga	4920
gaacttttag	taaacatact	acttactcta	aaatcaaaca	ttttattttc	ctaaagaata	4980
taggttgcca	aaaaatat	tatctctaaa	tatagggttag	ctgtaattat	ttcatgaatt	5040
tttttttttt	ttcaatgtaa	cttttttttg	tgaagattca	tggttcctaa	gttctgtatt	5100
caagtttttg	gaaatgttta	tttaaaaact	gttctataca	agtgttcaaa	acattgtatc	5160
taaagagagt	agcctggact	taaaatat	gaaatcagct	tatgcgtgcc	ttttaatttt	5220
ttttttaagt	ttcttactgc	cacatatgg	gtgaagtgac	agtaagtgtc	ttaatgacat	5280
cctgcagtat	ctgcttgctt	ttggagactc	cagtgagatg	ttgaaattgt	tcctgtgctt	5340
ggtaactact	ttcctctgcc	aggctatggg	aaagaggatg	taattgtgaa	taatatacac	5400
catccagtct	ttaatgtgct	gcaacaatgt	agtaatttgt	ttttttcatt	tgttccact	5460
gccttttgtg	acatagaaaa	cttaaaaatt	tccccagtc	tattagaagt	taagatgttc	5520
cctaatttat	taaatatgcc	tttattcaca	atttgttttt	ttaggttatt	cttaatgcat	5580
tatagaatta	agtatgactt	tgtttat	tattacagta	tgtagttatt	gacatattgt	5640

164

ggtttgcaga attatcaatt gtataaacta aaccttttaa ttaaaaaa 5688

<210> 162

<211> 4257

<212> DNA

<213> Homo sapien

<400> 162

attgtgggaa gggcggccgg tgcagccgca gctgccatct taggggcgcc tggcgctacg 60
ggtttctcgt tggaggcggc cttegtggca gctgtagacg ccgggaaaag gcataaagtc 120
cgttggccga cacctttctt tcctccggcc tcggtagaac cgccagcccc cgtccgaagg 180
cggaggcgag gggaaactggc cgcgtgaggg gcctgaggcg agcgggttaga gcgtctcccc 240
gaaggatggg ccggtctcgg agccggagct cgtcccgcct caagcacacc aagagcagca 300
agcacaacaa gaagcgcagc cgggtcccggc cgcgatcccc ggacaaggag cgcgtgcgga 360
agcgttccaa atctcgggaa agtaaacgga accggcggcg ggagtcgcgg tcccgttcgc 420
gctccaccaa cacggccgtg tcccggcgcg agcgggaccg ggagcgcgcc tcgtccccgc 480
ccgaccgcat cgacatcttc gggcgcacgg tgagcaagcg cagcagcctg gacgagaagc 540
agaagcgaga ggaggaggag aagaaagcgg agttcgagcg gcagcgaaaa attcgacagc 600
aagaaataga agaaaaactc atcgaggaag aaacagcacg aagagtagaa gaattggtag 660
caaaaagggg ggaggaagaa ctggagaaaa ggaaggatga aattgaacga gaagttctcc 720
gaaggggtgga ggaagccaaa cgcacatcgg aaaagcagtt gctcgaagaa ctcgagcgac 780
agagacaagc tgagcttgcc gcacaaaaag ctagagaggt aacgctcggc cgtttggaaa 840
gtagagacag tccatggcaa aactttcagt gttgggttct gcctcctgct cagttcagaa 900
agagatggaa tacagactat ctaattcctt tctcgtctaa acttaacatt gctgcgaaag 960
ttaatttttt agcctattca gaagtgctga ctgataactt aaaagttgga agcttttata 1020
aaacatatct aaggatactt tttgatttaa tggaactggc tatcttgagaa gtgtttgaaa 1080
cttttgccat ggctgcagga cttacattct tttttgggag gacgggtgggg agacagggag 1140
tggtaaaggg aaaagggttaa aaatccacct gtgggttgat attcttctat tctgtcactc 1200
tgttacctag actgtgagag gcttttgcct tcagtcagat taaaaagagc agggcctaac 1260
attgagtgat agcacctgct ttgataaata ggttttctca ctcttctttt tttccttctt 1320
ttatccctca ctccctcccc taaacctgc ttcagcaciaa tggactaatt ctagcattct 1380
gatcataagg ccctccattt tcctaattgtg tttcaaggaa tcttttttagg aaaaatatcc 1440
agattattca tccacttttt ttagtatcta ctaacaactc ctttttttct ctagagagtt 1500
atgaaggaac aggttgctct tgtctggagt caagctaaac acatgatattg ttttatcagc 1560

165

agctggagca	gaagttgaaa	atgtctttct	gtgagacagt	aatttgctac	tgaagcttta	1620
tggcttggtt	gcactgatta	ctccaggatc	caaaaacttg	gtgaaagtca	ctgaaacact	1680
caaggcaa	tactttacag	ccctgagtgt	ctgtcaccat	agtttgcata	atgaatatga	1740
atcccatgg	tgtgtgatgt	aggaaatcct	gtagttgtat	tttcttgaac	tgaaatat	1800
gactcaaa	aattaagact	cattgtcatt	tttcatcttg	gcattattgt	ggacaagttg	1860
acataaaaa	tctctttgct	ttctggtaag	cttagctttt	aaaatgcatt	ttcccttgct	1920
ctgtctttaa	ctagatatac	atgcttatat	ttatagtggg	tttcacagac	tataaaattg	1980
aatgtatgaa	atTTTTat	atatcagtgc	ttttaataat	gaagatat	ttggagtaat	2040
gggtgctgtc	tgtagcgagt	tattaatcat	agtaagattt	tttctcttc	atTTgctttt	2100
tttgtttcat	attaacaatt	ttttttttac	acggacacaa	ccctctgaca	gtctttccaa	2160
atattaaa	catttgaata	tgtatgctgt	gatctgaaca	ctgctcaagc	catcaagcag	2220
tcttcataca	gtttgcat	taaaatctca	ttaaattctc	caagaaaaaa	taagttgaag	2280
aattttat	cctgaccatg	catccctgg	atTTctgagt	ttcagttcag	attgtagatg	2340
acaatataag	ctgccttccg	aaattgtcaa	catctgaatg	ttaagtccat	tttcccatg	2400
gaagaagccc	gtagttccat	gaagtatgga	ttaccatttg	tatttttcac	taacagtaaa	2460
tgtatttttc	ttattaattg	tttgccttag	gaatgatgaa	ttacattttt	tgttccttct	2520
taccataaac	atctgcattc	ctcagctcag	ccttccttgt	atgTTgtttc	tttataaatg	2580
gttgagctgc	tgatgcaggt	attgccaagc	taacagtaca	aatcatttta	aagaggaagc	2640
tggcgcgtat	ggcagccgag	gagcacactc	tgcaggacac	tggacaagac	agtaaata	2700
caacttttaa	tgctgattaa	aggagtatag	gtaaagaata	cgtaggtata	cataattggt	2760
gagacaaata	ttcactttat	ttatatTTta	tatattat	ttttaatttg	gtaaatacta	2820
tccagttttg	tagttgtcct	tgttgatttg	tgtgatatta	aagtattagt	aataattgcc	2880
aggaaactat	cattagggag	ggttttagttg	gttgctgttt	ggactgggag	ggatgattta	2940
aatttagtgc	tagaaaccaa	tttttagtgac	tgcacagttt	atcatttgtc	agacagaagg	3000
tagctataaa	gttaccctgt	aagtcata	aaaaaaagt	agaggaagat	tagtaaatat	3060
ttatcaataa	aaataaacat	tttgTTTTtc	taatatttta	acatatcctc	cccttttagga	3120
ggaagaacgt	gcaaaacgtg	aggagctaga	gcgaatactg	gaagagaata	accgaaaaat	3180
tgcagaagca	caagccaaac	tggccgaaga	acagttgaga	attgTTgaag	aacaaagaaa	3240
gattcatgag	gaaaggatga	aactagaaca	agaacgacaa	cgtcaacaaa	aagaagaaca	3300
aaaaattatc	ctgggcaagg	ggaagtccag	gccaaaactg	tccttctcat	taaaaacca	3360
ggattaaatt	gcaaaactctg	aactTTTTac	aaagaaaaat	ggaaaaactt	tgtatggtag	3420

166

```

cttcatgttg aagtggtttt ttgtttttgt ttttgttttt ttaatttgta aaatctggaa 3480
agttagcttg ttctaatagg ggctatgctc tgcaattccc tttttttttt ttttttcctt 3540
ccactaagtc aaatccttat cagatcattg ttgtattcta aggagtgacg tattttttcac 3600
ctgtttggat tctatatattg tgggtctgagg aagagcagat cacattgtaa aactatggat 3660
ggctctgataa ggcttttact gacccactg acttcagagt tatactctgt ttgctacatc 3720
ataatgctgg ttttgctgac tttttgtttt tttatatatt tataaaaaaa gaaaaagttg 3780
gtgattgcat tgggaaattc ccaggggtatt actggaccta tgtgggtgtat tgtaaacca 3840
gtgtccttgt gatactgttg ctcttgatgt tcttgataca ggtaaggaaa cagttgggtca 3900
actctgatac aaagtatata tacagttcag tattgtctct gttcattttg tttttatttc 3960
attgacaaaa tcaaaccagc attccccatt gtgtaaataa atgattttgc tgaataaagt 4020
aaagtcttaa attcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4080
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaactta agggaccgg gatccaaaaa 4140
gcttgatatt gaaattctcg ccccggggaa aataatccag ggcttggggc ccccttttag 4200
ggctttttcc caaaaggtaa ttttggtatgc cctaattaac ctaagggtct catggct 4257

```

```

<210> 163
<211> 1321
<212> DNA
<213> Homo sapien

```

```

<400> 163
gactccttag cagcggagca gccacggcc tgctgtact gcctgttaca tgggccctct 60
ggtttgatgt catcagtgga aatagaagca gggaactgac attctgattt ggcatttgct 120
tcgacagcaa gaaatagaag aaaaactcat cgaggaagaa acagcacgaa gagtagaaga 180
attggtagca aaaaggggtg aggaagaact ggagaaaagg aaggatgaaa ttgaacgaga 240
agttctccga aggggtggagg aagccaaacg catcatggaa aagcagttgc tcgaagaact 300
cgagcgacag agacaagctg agcttgccgc acaaaaagct agagagagga agctggcgcg 360
tatggcagcc gaggagcaca ctctgcagga cactggacaa gacagaggaa gaacgtgcaa 420
aacgtgagga gctagagcga atactggaag agaataaccg aaaaattgca gaagcacaag 480
ccaaactggc cgaagaacag ttgagaattg ttgaagaaca aagaaagatt catgaggaaa 540
ggatgaaact agaacaagaa cgacaacgtc aacaaaaaga agaacaaaaa attatcctgg 600
gcaaggggaa gtccaggcca aaactgtcct tctcattaaa aaccaggat taaattgcaa 660
actctgaact ttttaciaag aaaaatggaa aaactttgta tggtagcttc atgttgaagt 720
ggttttttgt ttttgttttt gtttttttaa tttgtaaaat ctggaaagtt agcttgttct 780

```


167

```

aataggggct atgctctgca attccctttt tttttttttt ttccttccac taagtcaaat      840
ccttatcaga tcattgttgt attctaagga gtgacgtatt tttcacctgt ttggattcta      900
tattagtggc ctgaggaaga gcagatcaca ttgtaaaact atggatgggc tgataaggct      960
tttactgacc ccactgactt cagagttata ctctgtttgc tacatcataa tgctggtttt      1020
gctgactttt tgttttttta tatatttata aaaaaagaaa aagttgggtga ttgcattggg      1080
aaattcccag ggtattactg gacctatgtg gtgtattgtt aaaccagtgt ccttgtgata      1140
ctgttgctct tgatgttcct gatacaggta aggaaacagt tggccaactc tgatacaaag      1200
tatatataca gttcagtatt gtctctgttc attttgtttt tatttcattg acaaaatcaa      1260
accagcattc cccattgtgt aaataaatga ttttgctgaa taaagtaaag tcttaaattc      1320
a                                                                                   1321

```

```

<210> 164
<211> 3982
<212> DNA
<213> Homo sapien

```

```

<400> 164
attgtgggaa gggcgggccg tgcagccgca gctgccatct taggggcgcc tggcgctacg      60
ggtttctcgt tggaggcggc cttcgtggca gctgtagacg ccgggaaaag gcataaagtc      120
cgttggccga cacctttctt tcctccggcc tcggtagaac cgccagcccg cgtccgaagg      180
cggaggcgag gggaaactggc cgcgtgaggg gcctgaggcg agcgggttaga gcgtctcccg      240
gaaggatggg ccggtctcgg agccggagct cgtcccgcct caagcacacc aagagcagca      300
agcacaacaa gaagcgcagc cgggtcccgt cgcgatcccg ggacaaggag cgcgtgcgga      360
agcgttccaa atctcgggaa agtaaacgga accggcgggc ggagtcgcgg tcccgttcgc      420
gctccaccaa cacggccgtg tcccggcgcg agcgggaccg ggagcgcgcc tcgtccccgc      480
ccgaccgcat cgacatcttc gggcgcacgg tgagcaagcg cagcagcctg gacgagaagc      540
agaagcgaga ggaggaggag aagaaagcgg agttcgcgag gcagcgaaaa attcgacagc      600
aagaaataga agaaaaactc atcgaggaag aaacagcacg aagagtagaa gaattggtag      660
caaaaagggg ggaggaagaa ctggagaaaa ggaaggatga aattgaacga gaagttctcc      720
gaagggtgga ggaagccaaa cgcacatggg aaaagcagtt gctcgaagaa ctcgagcgac      780
agagacaagc tgagcttgcc gcacaaaaag ctagagaggt aacgctcggc cgtttggaaa      840
gtagagacag tccatggcaa aactttcagt gttgggttct gcctcctgct cagttcagaa      900
agagatggaa tacagactat ctaattcctt tctcgtctaa acttaacatt gctgcgaaag      960
ttaatttttt agcctattca gaagtgcgta ctgataactt aaaagttgga agcttttata      1020

```

aaacatatcc aaggatactt ttgattttaa tgggaactggc tatttgagaa gtgtttgaaa	1080
cttttgccat ggctgcagga cttacattct tttttgggag gacgggtgggg agacagggag	1140
tggtaaaggg aaaagggttaa aaatccacct gtgggttgat attcttctat tctgtcactc	1200
tgttacctag actgtgagag gcttttgcct tcagtcagat taaaaagagc agggcctaac	1260
attgagtgat agcacctgct ttgataaata ggttttctca ctcttctttt ttctctctct	1320
ttatccctca ctccctcccc taaaccctgc ttcagcacia tggactaatt ctagcattct	1380
gatcataagg ccctccattt tcctaattgt tttcaaggaa tcttttttagg aaaaatatcc	1440
agattattca tccacttttt ttagtatcta ctaacaactc ctttttttct ctagagagtt	1500
atgaaggaac aggttgctct tgtctggagt caagctaaac acatgatttg ttttatcagc	1560
agctggagca gaagttgaaa atgtctttct gtgagacagt aatttgctac tgaagcttta	1620
tggcttggtt gcactgatta ctccaggatc caaaaacttg gtgaaagtca ctgaaacact	1680
caaggcaaat tactttacag ccctgagtggt ctgtcaccat agtttgcata atgaatatga	1740
atcccatagg tgtgtgatgt aggaaatcct gtagttgtat tttcttgaac tgaaatatct	1800
gactcaaaat aattaagact cattgtcatt tttcatcttg gcattattgt ggacaagttg	1860
acatattaaa tctctttgct ttctggtaag cttagctttt aaaatgcatt ttcccttgctc	1920
ctgtctttta ctagatatac atgcttatat ttatagtggg tttcacagac tataaaattg	1980
aatgtatgaa atttttattt atatcagtgc ttttaataat gaagatatct ttggagtaat	2040
gggtgctgtct tgtagcgagt tattaatcat agtaagattt ttttctcttc atttgctttt	2100
tttgtttcat attaacaatt ttttttttac acggacacia ccctctgaca gtctttccaa	2160
atattaaaat cttttgaata tgtatgctgt gatctgaaca ctgctcaagc catcaagcag	2220
tcttcataca gtttgcatta taaaatctca ttaaattctc caagaatttc agttcagatt	2280
gtagatgaca atataagctg ccttccgaaa ttgtcaacat ctgaatgtta agtccatttt	2340
cccatggaa gaagcccgtg gttccatgaa gtatggatta ccatttgtat ttttactaa	2400
cagtaaattgt atttttctta ttaattgttt gccttaggaa tgatgaatta cttttttgt	2460
tccttcttac cataaacatc tgcattcttc agctcagcct tccttgtatg ttgtttcttt	2520
ataaatgggt gagctgctga tgcaggtatt gccaaagctaa cagtacaaat cattttaag	2580
aggaagctgg cgcgtatggc agccgaggag cacactctgc aggacactgg acaagacagt	2640
aaatattcaa cttttaatgc tgattaaagg agtataggta aagaatacgt aggtatacat	2700
aattgggtgag acaaatattc actttattta ttttttatat attatttttt taatttggt	2760
aatactatcc agttttgtag ttgtccttgt tgatttgtgt gatattaaag tattagtaat	2820

169

```

aattgccagg aaactatcat tagggagggg ttagttgggt gctgtttgga ctgggagggg 2880
tgattttaa ttagtgctag aaaccaattt tagtgactgc acagtttatc atttgtcaga 2940
cagaaggtag ctataaagct accctgtaag tcatatcaaa aaagttcaga ggaagattag 3000
taaatattta tcaataaaaa taaacatttt gtttttctaa tatcttaaca tctctcccc 3060
tttaggagga agaacgtgca aaacgtgagg agctagagcg aatactggaa gagaataacc 3120
gaaaaattgc agaagcacia gccaaactgg ccgaagaaca gttgagaatt gttgaagaac 3180
aaagaaagat tcatgaggaa aggatgaaac tagaacaaga acgacaacgt caacaaaaag 3240
aagaacaaaa aattatcctg ggcaagggga agtccaggcc aaaactgtcc ttctcatata 3300
aaaccagga ttaaattgca aaactctgaac tttttacaaa gaaaaatgga aaaactttgt 3360
atggtagctt catgttgaag tgggttttttg tttttgtttt tgttttttta atttgtaaaa 3420
tctggaaagt tagcttggtc taataggggc tatgctctgc aattcccttt tttttttttt 3480
tttcttcca ctaagtcaaa tcttctatcag atcattgttg tattctaagg agtgacgtat 3540
ttttcacctg tttggattct atattagtgg tctgaggaag agcagatcac attgtaaaac 3600
tatggatggg ctgataaggc ttttactgac cccactgact tcagagttat actctgtttg 3660
ctacatcata atgctgggtt tgcctgacttt ttgttttttt atatatttat aaaaaagaa 3720
aaagttgggt attgcattgg gaaattccca gggattact ggacctatgt ggtgtattgt 3780
taaaccagtg tccttgtgat actgttgctc ttgatgttcc tgatacagg aaggaaacag 3840
ttgggtcaact ctgatacaaa gtatatatac agttcagtat tgtctctgtt cattttgttt 3900
ttatttcatt gacaaaatca aaccagcatt cccattgtg taaataaatg attttgctga 3960
ataaagtaaa gtcttaaatt ca 3982

```

```

<210> 165
<211> 4055
<212> DNA
<213> Homo sapien

```

```

<400> 165
attgtgggaa gggcggccgg tgcagccgca gctgccatct taggggccc tggcgctacg 60
ggtttctcgt tggaggcggc ctctcgtggca gctgtagacg ccgggaaaag gcataaagtc 120
cgttggccga cacctttctt tctctcggcc tcggtagaac cgcagccc cgtccgaagg 180
cggaggcgag gggaactggc cgcgtgaggg gctgagggc agcggttaga gcgtctccc 240
gaaggatggg ccggtctcgg agccggagct cgtcccgtc caagcacacc aagagcagca 300
agcacaacaa gaagcgcagc cgggtcccgg cgcgatccc ggacaaggag cgcgtgcgga 360
agcgttccaa atctcgggaa agtaaacgga accggcggcg ggagtcgcgg tcccgttcgc 420

```

170

gctccaccaa	cacggccgtg	tcccggcgcg	agcgggaccg	ggagcgcgcc	tcgtccccgc	480
ccgaccgcat	cgacatcttc	gggcgcacgg	tgagcaagcg	cagcagcctg	gacgagaagc	540
agaagcgaga	ggaggaggag	aagaaagcgg	agttcgagcg	gcagcgaaaa	attcgacagc	600
aagaaataga	agaaaaactc	atcgaggaag	aaacagcacg	aagagtagaa	gaattggtag	660
caaaaagggg	ggaggaagaa	ctggagaaaa	ggaaggatga	aattgaacga	gaagttctcc	720
gaaggggtga	ggaagccaaa	cgcattcatg	aaaagcagtt	gctcgaagaa	ctcgagcgcg	780
agagacaagc	tgagcttgcc	gcacaaaaag	ctagagaggt	aacgctcggg	cgttttgaaa	840
gtagagacag	tccatggcaa	aactttcagt	gttgggttct	gcctcctgct	cagttcagaa	900
agagatggaa	tacagactat	ctaattcctt	tctcgtctaa	acttaacatt	gctgcgaaag	960
ttaatttttt	agcctattca	gaagtgcgtg	ctgataactt	aaaagttgga	agctttttata	1020
aaacatattc	aaggataact	tttgatttaa	tggaactggc	tatttgagaa	gtgtttgaaa	1080
cttttgccat	ggctgcagga	cttacattct	tttttgggag	gacgggtggg	agacagggag	1140
tggtaaaggg	aaaagggtta	aatccacct	gtgggtgtat	attcttctat	tctgtcactc	1200
tggtacctag	actgtgagag	gcttttgcct	tcagtcagat	taaaaagagc	agggcctaac	1260
attgagtgat	agcacctgct	ttgataaata	ggttttctca	ctcttctttt	tttccttctt	1320
ttatccctca	ctccctcccc	taaaccctgc	ttcagcacia	tggaactaatt	ctagcattct	1380
gatcataagg	ccctccattt	tcctaattgt	tttcaaggaa	tcttttttagg	aaaaatatcc	1440
agattattca	tccacttttt	ttagtatcta	ctaacaactc	ctttttttct	ctagagagtt	1500
atgaaggaac	aggttgtcct	tgtctggagt	caagctaaac	acatgatttg	ttttatcagc	1560
agctggagca	gaagttgaaa	atgtctttct	gtgagacagt	aatttgctac	tgaagcttta	1620
tggcttggtt	gcactgatta	ctccaggatc	caaaaacttg	gtgaaagtca	ctgaaacact	1680
caaggcaaat	tactttacag	ccctgagtg	ctgtcaccat	agtttgcata	atgaatatga	1740
atcccatggg	tgtgtgatgt	aggaaatcct	gtagttgtat	tttcttgaac	tgaaatatat	1800
gactcaaaat	aattaagact	cattgtcatt	tttcatcttg	gcattattgt	ggacaagttg	1860
acatatataa	tctctttgct	ttctggtaag	cttagctttt	aaaatgcatt	ttcccttgct	1920
ctgtctttta	ctagatatac	atgcttatat	ttatagtggg	tttcacagac	tataaaattg	1980
aatgtatgaa	atttttat	atatcagtg	ttttaataat	gaagatat	ttggagtaat	2040
ggtgctgtct	tgtagcgagt	tattaatcat	agtaagattt	ttttctcttc	atgtgctttt	2100
tttgtttcat	attaacaatt	ttttttttac	acggacacaa	ccctctgaca	gtctttccaa	2160
atattaaaat	catttgaata	tgtatgctgt	gatctgaaca	ctgctcaagc	catcaagcag	2220
tcttcataca	gtttgcatta	taaaatctca	ttaaattctc	caagaaaaaa	taagttgaag	2280

aatatttattt cctgaccatg catccccctgg atttctgagt ttcagttcag attgtagatg	2340
acaatataag ctgccttccg aaattgtcaa catctgaatg ttaagtccat tttccccatg	2400
gaagaagccc gtagttccat gaagtatgga ttaccatttg tattttttcac taacagtaaa	2460
tgtatttttc ttattaattg tttgccttag gaatgatgaa ttacattttt tgttccttct	2520
taccataaac atctgcattc ctcagctcag ccttccttgt atgttggttc tttataaatg	2580
gttgagctgc tgatgcagggt attgccaagc taacagtaca aatcatttta aagaggaagc	2640
tggcgcgat ggagccgag gagcacactc tgcaggacac tggacaagac agtaaataatt	2700
caacttttaa tgctgattaa aggagtatag gtaaagaata cgtaggtata cataattggt	2760
gagacaaata ttcactttat ttatatatta tatattattt ttttaatttg gtaaatacta	2820
tccagttttg tagttgtcct tgttgatttg tgtgatatta aagtattagt aataattgcc	2880
aggaaactat cattagggag ggtttagttg gttgctgttt ggactgggag ggatgattta	2940
aatttagtgc tagaaaccaa ttttagtgac tgcacagttt atcatttgtc agacagaagg	3000
tagctataaa gctaccctgt aagtcatatc aaaaaagttc agaggaagat tagtaaatat	3060
ttatcaataa aaataaacat tttgtttttc taatatctta acatatcctc cccttttagga	3120
ggaagaacgt gcaaaacgtg aggagctaga gcgaatactg gaagagaata accgaaaaat	3180
tgcagaagca caagccaaac tggccgaaga acagttgaga attggttgag aacaaagaaa	3240
gattcatgag gaaaggatga aactagaaca agaacgacaa cgtcaacaaa aagaagaaca	3300
aaaaattatc ctgggcaagg ggaagtccag gccaaaactg tccttctcat taaaaacca	3360
ggattaaatt gcaaactctg aactttttac aaagaaaaat ggaaaaactt tgtatggtag	3420
cttcatgttg aagtggtttt ttgtttttgt ttttgttttt ttaatttgta aaatctggaa	3480
agttagcttg ttctaataagg ggctatgctc tgcaattccc tttttttttt ttttttcctt	3540
ccactaagtc aaatccttat cagatcattg ttgtattcta aggagtgacg tattttttcac	3600
ctgtttggat tctatattag tggctctgagg aagagcagat cacattgtaa aactatggat	3660
ggtctgataa ggctttttact gacccactg acttcagagt tatactctgt ttgctacatc	3720
ataatgctgg ttttgctgac tttttgtttt tttatatatt tataaaaaaa gaaaaagttg	3780
gtgattgcat tgggaaattc ccagggtatt actggacctt tgtggtgtat tgttaaacca	3840
gtgtccttgt gatactgttg ctcttgatgt tcctgatata ggtaaggaaa cagttggtca	3900
actctgatac aaagtatata tacagttcag tattgtctct gtccattttg tttttatttc	3960
attgacaaaa tcaaaccagc attccccatt gtgtaaataa atgattttgc tgaataaagt	4020
aaagtcttaa attcaaaaaa aaaaaaagg aaacc	4055

172

<210> 166
 <211> 5688
 <212> DNA
 <213> Homo sapien

<400> 166

```

attgtgggaa gggcggccgg tgcagccgca gctgccatct taggggcgcc tggcgctacg      60
ggtttctcgt tggaggcggc cttcgtggca gctgtagacg ccgggaaaag gcataaagtc      120
cgttggccga cacctttctt tcctccggcc tcggtagaac cgccagcccc cgtccgaagg      180
cggaggcgag gggaaactggc cgcgtgaggg gcctgaggcg agcggttaga gcgtctcccg      240
gaaggatggg ccggtctcgg agccggagct cgtcccgcctc caagcacacc aagagcagca      300
agcacaacaa gaagcgcagc cgggtcccggc cgcgatcccc ggacaaggag cgcgtgcgga      360
agcgttccaa atctcgggaa agtaaacgga accggcggcg ggagtcgcgg tcccgttcgc      420
gctccaccaa cacggccgtg tcccggcgcg agcgggaccg ggagcgcgcc tcgtccccgc      480
ccgaccgcat cgacatcttc gggcgcacgg tgagcaagcg cagcagcctg gacgagaagc      540
agaagcgaga ggaggaggag aagaaagcgg agttcgagcg gcagcgaaaa attcgacagc      600
aagaaataga agaaaaactc atcgaggaag aaacagcacg aagagtagaa gaattggtag      660
caaaaagggt ggaggaagaa ctggagaaaa ggaaggatga aattgaacga gaagttctcc      720
gaaggggtgga ggaagccaaa cgcattcatg aaaagcagtt gctcgaagaa ctcgagcgac      780
agagacaagc tgagcttgcc gcacaaaaag ctagagaggt aacgctcggc cgttttgaaa      840
gtagagacag tccatggcaa aactttcagt gttgggttct gcctcctgct cagttcagaa      900
agagatggaa tacagactat ctaattcctt tctcgtctaa acttaacatt gctgcgaaag      960
ttaatttttt agcctattca gaagtgtga ctgataactt aaaagttgga agctttttata     1020
aaacatatct aaggatactt tttagattta tggaaactggc tatttgagaa gtgttttgaaa     1080
cttttgccat ggctgcagga cttacattct tttttgggag gacgggtgggg agacagggag     1140
tggtaaaggg aaaagggttaa aaatccacct gtgggttgat attcttctat tctgtcactc     1200
tgttacctag actgtgagag gcttttgcct tcagtcagat taaaaagagc agggcctaac     1260
attgagtgat agcacctgct ttgataaata ggttttctca ctcttctttt tttccttctt     1320
ttatccctca ctccctcccc taaacctgc ttcagcacia tggactaatt ctagcattct     1380
gatcataagg ccctccattt tcctaattgtg tttcaaggaa tcttttttagg aaaaatatcc     1440
agattattca tccacttttt ttagtatcta ctaacaactc ctttttttct ctagagagtt     1500
atgaaggaac aggttgctct tgtctggagt caagctaaac acatgatttg ttttatcagc     1560
agctggagca gaagttgaaa atgtctttct gtgagacagt aatttgctac tgaagcttta     1620

```

173

tggcttggtt	gcactgatta	ctccaggatc	caaaaacttg	gtgaaagtca	ctgaaacact	1680
caaggcaaat	tactttacag	ccctgagtgt	ctgtcaccat	agtttgcata	atgaatatga	1740
atcccatgg	tgtgtgatgt	aggaaatcct	gtagtgtat	tttcttgaac	tgaaatat	1800
gactcaaaat	aattaagact	cattgtcatt	tttcatcttg	gcattattgt	ggacaagttg	1860
acataattaa	tctctttgct	ttctggtaag	cttagctttt	aaaatgcatt	ttcccttgtc	1920
ctgtctttta	ctagatatat	atgcttatat	ttatagtggg	tttcacagac	tataaaattg	1980
aatgtatgaa	atgtttat	atatcagtgc	ttttaataat	gaagatat	ttggagtaat	2040
ggtgctgtct	tgtagcgagt	tattaatcat	agtaagattt	ttttctcttc	atttgctttt	2100
tttgtttcat	attaacaatt	ttttttttac	acggacacaa	ccctctgaca	gtctttccaa	2160
atattaaaat	catttgaata	tgtatgctgt	gatctgaaca	ctgctcaagc	catcaagcag	2220
tcttcataca	gtttgcatta	taaaatctca	ttaaattctc	caagaaaaaa	taagttgaag	2280
aattttat	cctgaccatg	catccctgg	atttctgagt	ttcagttcag	attgtagatg	2340
acaatataag	ctgccttccg	aaattgtcaa	catctgaatg	ttaagtccat	tttcccatg	2400
gaagaagccc	gtagttccat	gaagtatgga	ttaccatttg	tattttttcac	taacagtaaa	2460
tgtatttttc	ttattaattg	tttgcccttag	gaatgatgaa	ttacattttt	tgttccttct	2520
taccataaac	atctgcattc	ctcagctcag	ccttccttgt	atgttggttc	tttataaatg	2580
gttgagctgc	tgatgcaggt	attgccaagc	taacagtaca	aatcatttta	aagaggaagc	2640
tggcgcgtat	ggcagccgag	gagcacactc	tgcaggacac	tggacaagac	agtaaata	2700
caacttttaa	tgctgattaa	aggagtatat	gtaaagaata	cgtaggtata	cataattggt	2760
gagacaaata	ttcactttat	ttatatttta	tatattat	ttttaatttg	gtaaatacta	2820
tccagttttg	tagttgtcct	tgttgatttg	tgtgatatta	aagtattagt	aataattgcc	2880
aggaaactat	cattagggag	ggttttagttg	gttgctgttt	ggactgggag	ggatgattta	2940
aatttagtgc	tagaaaccaa	ttttagtgac	tgcacagttt	atcatttgtc	agacagaagg	3000
tagctataaa	gctaccctgt	aagtcatatc	aaaaaagttc	agaggaagat	tagtaaata	3060
ttatcaataa	aaataaacat	tttgtttttc	taatatctta	acatatcctc	cccttttagga	3120
ggaagaacgt	gcaaaacgtg	aggagctaga	gcgaatactg	gaagagaata	accgaaaaat	3180
tgcagaagca	caagccaaac	tggccgaaga	acagttgaga	attggttgaag	aacaaagaaa	3240
gattcatgag	gaaaggatga	aactagaaca	agaacgacaa	cgtcaacaaa	aagaagaaca	3300
aaaaattatc	ctgggcaagg	ggaagtccag	gccaaaactg	tccttctcat	taaaaacca	3360
ggattaaatt	gcaaaactctg	aactttttac	aaagaaaaat	ggaaaaactt	tgtatggtag	3420
cttcatgttg	aagtggtttt	ttgtttttgt	ttttgttttt	ttaatttgta	aaatctggaa	3480

agttagcttg ttctaataagg ggctatgctc tgcaattccc tttttttttt ttttttcctt 3540
ccactaagtc aaatccttat cagatcattg ttgtattcta aggagtgacg tttttttcac 3600
ctgtttggat tctatattag tggctctgagg aagagcagat cacattgtaa aactatggat 3660
ggctctgataa ggcttttact gacccactg acttcagagt tatactctgt ttgctacatc 3720
ataatgctgg ttttgctgac tttttgtttt tttatatatt tataaaaaa gaaaaagttg 3780
gtgattgcat tgggaaattc ccagggattt actggaccta tgtgggtgtat tgttaaacca 3840
gtgtccttgt gatactgttg ctcttgatgt tcctgatata ggtaaggaaa cagttgggtca 3900
actctgatac aaagtatata tacagttcag tattgtctct gtccattttg tttttatttc 3960
attgacaaaa tcaaaccagc attccccatt gtgtaaataa atgattttgc tgaataaagt 4020
aaagtcttaa attcatatgt tgaagcaatt ttttttaattg ttatgttaag tcttaaagag 4080
gggtggttcac tttttgatgg tcaaccattt agaagtctta gaactatatt tcctcttggt 4140
tatactttta acataggggt tatatgtaca ttaaataatac ttgtgaatta gtatttaattg 4200
gctattttta caaatatcaa ctttatgctg atagagcaaa tggcatcagt gttaccttta 4260
agaaagacta acaacatcca gaagatttaa attctcaaac ctgtgcctct gttttaggat 4320
ataagtatta tcacaaagta tacttaataa aggctagaaa aatgctttta aattatggaa 4380
tctgagatcg ttttcagagt gggccatcag aaagaactta gctttatact gtcaaaaaaa 4440
ggctaagatg gtcgagtcac tttcattgtg tagtgtactt gcacgtttat ttttaggaca 4500
aacacatttg aactttatga attttttttt ttttttgcac gtgaaatctt atgaatggct 4560
ttcattttat acactagaat ctgcctcatt tactcttaac atatgtttta gtatactggc 4620
attaaaacat tcaagaaaag gatattgatc taaaatgcta cctgagatgc ataaacatgt 4680
catcaagtag agaaaatatt tttatttttg cccaatattt ttttagacagt ttgattattc 4740
ttaaaaattg aaaacataag ctaaagagat gactaaatgg tagattattt tgtgtgtgca 4800
tgctaggaaa aatgctgttg ctttagtttt gagctcttca atgagtctaa ttgtggtaag 4860
gaacaatata aaatcagttt aaagatcttt aaaggtagaa ttttaaataag gcatgaaata 4920
tagtgagaac ttttagtaaa catactactt actctaaaat caaacatttt attttcctaa 4980
agaatatagg ttgccaaaaa atattttatc tctaaatata ggtagctgt aattatttca 5040
tgaatttttt tttttttcaa tgtaactttt tttgggtgaag attcatgggt cctaagttct 5100
gtattcaagt ttttggaat gtttatttaa aaactgttct atacaagtgt tcaaaacatt 5160
gtatctaaag agagtagcct ggacttaaaa tatttgaaat cagcttatgc gtgcctttta 5220
attttttttt taagtttctt actgccacat atgggtgtgaa gtgacagtaa gttgcttaat 5280

175

gacatcctgc agtatctgct tgcttttggga gactccagtg agatgttgaa attgttcctg 5340
 tgcttggttaa ctactttcct ctgccaggct atgggaaaga ggatgtaatt gtgaataata 5400
 tacaccatcc agtctttaat gtgctgcaac aatgtagtaa tttgtttttt tcatttggtc 5460
 ccactgcctt tgtgtacata gaaaacttaa aaatttcccc cagtctatta gaagttaaga 5520
 tgttccttaa tttattaaat atgcctttat tcacaatttg ttttttttagg ttattcttaa 5580
 tgcattatag aattaagtat gactttgttt atttttatta cagtatgtag ttattgacat 5640
 attgtgggtt gcagaattat caattgtata aactaaacct ttaaatta 5688

<210> 167
 <211> 194
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (92)..(92)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (99)..(99)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (160)..(160)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (179)..(179)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (168)..(168)
 <223> n=a, c, g or t

<400> 167
 actcctccaa gaggcgacaa gttcaaagct gagtaaaggg gggaaatgaa ggaaacttct 60
 tgcacaagga gcttgcccaa gctttttgtg gngggggang aaaagtggat tgaagggagg 120
 ggggcttgta aggaaagcct tgatggggcc agcccttggn attgaagnaa ccaaggtgna 180
 ccccaggcca aggg 194

<210> 168

176

<211> 153
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (92)..(92)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (99)..(99)
 <223> n=a, c, g or t

<400> 168
 actcctccaa gaggcgacaa gttcaaagct gagtaaaggg gggaaatgaa ggaaacttct 60
 tgcacaagga gcttgcccaa gctttttgtg gngggggang aaaagtggat tgaagggagg 120
 ggggcttgta aggaaagcct tgatgggggcc agc 153

<210> 169
 <211> 936
 <212> DNA
 <213> Homo sapien

<400> 169
 ttttacactt caaggttcta tacaaatgta aaatatcatt ctattactta tttataatgc 60
 tgattattct ttaaatgact ttaaaatggt aatctctgct tgagcctacg gagaagtatg 120
 taacaaattt gtgaaggatt ggcattaaag atagtcaaaa taaaacatag aaattatggg 180
 aaataattta actggtaaaa taatctaagt ggtagttctc aggtaagtgg aaattcgatt 240
 agctgattgt ttaggattct tggttataag tgacagagac ctgactaaaa gtacatgaag 300
 cacataactg agaaggctgt ggtatggctc agcagaaatg ggaaaatctt gggactgggt 360
 cgtgttttat ttacattatc tttgttccca ggcagtctct gcatgtaagt ggcaaagatg 420
 actgtctgaa aatatatacc tactttttta aagggtatc tcaagccatt ctggagaagc 480
 accaaaagcc actttgctta tactgggaga atagtttgct ttccctaatt tgtgatgagt 540
 gaaacactga acagagacat agaataatat tctgtagttc aggggttggt gtaatatggc 600
 cagtgggcgg aatctgggtc tcagactgat ttgcaaata atcttataga aacacagcaa 660
 caccattca ttacatgttg tttatgggtg ctttgggggtt acaatggcag agttgagtag 720
 ttgtgacaga gatcactagg ctaccacat ctgagatatg tactgactga ccctgtacag 780
 aaagtttgct gctcttagag gaatgtgtgt ttctagtgtc agcaataaac ttcttggatt 840
 tgttttggtt tctcatcttt acatgatagt tgcagactag ttgatccttg tgacctgttt 900
 ttgaatgcca ctgtgtattc tgtcagggcc ctctga 936

177

<210> 170
 <211> 914
 <212> DNA
 <213> Homo sapien

<400> 170
 gccgcctcctt tgtctgctcc gggacttgga acaaaagggg gaactctgat gaactctctt 60
 tcctcccctc tcccccgga ggcggggtat ctccctctcg caactttgcc gccccgactt 120
 tctctgctgt caggccggga aaaagtgtcc gaacgcctcg tggactgcag cgggggaaat 180
 gtcccttaaa agtgcgacga agtggggaag aaggtgtaat tactattatc agcatctaga 240
 aagcatcatg aatttgctgg agtacttcct agcactgacc tccttcattc tgcgttggtc 300
 ttactggatc ttccatcag ccaacaatat ggaagtacca atacaaggtc aaatcattcc 360
 tggattcatc tggagttgct taaaagttaa atcattggaa tttttgatga taccttttct 420
 atatggatta caatttgatc gctgggaatt ctccacctta aagaaggta ttaacggaaa 480
 aatgtagtct atgatgcagc agagctctgc cctttttatt ttaatacatt ttaaataatat 540
 cacaattgtc tgcactctga taaaagaatg tagagctgga attttaattt gattatcatc 600
 cccaatcttc ccaggcttcc gcagactcct ttgctatctg gaaacccatg tccacctctg 660
 acttccactc aaaattgctt tcctcacagt ctgactgcga gagttgtgaa aaattgggat 720
 gtgcttctga ggtgggctgt ggaatgccat acagaatctc gaagtcttgg agtctcactc 780
 tgttgcccag gctggagtac agagggtgca gtgaactgag atcgtgccac tgaactccag 840
 cctgggagac agggtgagac tccgtctcaa aaaataaata aataaaaata aaaataaata 900
 cactgagtct catg 914

<210> 171
 <211> 5047
 <212> DNA
 <213> Homo sapien

<400> 171
 ctttcctcac agctccacgg ctgcatctcc gtgggcacgc aagcttcccc tggttacctg 60
 agctgctcct gcgctctccc gcctgggctt cgccgtgggtg caccgatcc cggaatcgtg 120
 cgtctgcgcc ctgcgaaaga aggacctgct ggcggagctc cggccgggggt ctctgcctc 180
 gcagctgggc gaggggactt ggaggacagg gtgaagctgc agaagacctg ggggtgggatg 240
 gctagagagg acgccaagga ctggggaagg ggaagttagg aataccttac atccaatgcc 300
 caccgtgct ccgcagggca agggcagccg tcgcctcggc cgcgtgcacc cagctcaggc 360
 tgttcccagg gatttagtct ggggggacaa cccatggcga gatgtggtgg cattttacct 420

178

cagagtggag	ctgaagatgg	ataaacaagg	tatctgatgt	atctgcctga	gaaggcagag	480
ctggagaaag	gcggagcgag	ggagcgcgtg	aaaagaaaga	gatgccgaat	gccgggtgat	540
tgtctgccgc	ttgctgtgca	ttctcattct	agggaggatg	gcataattta	taaccagca	600
catggataga	ggaactgtaa	attgtagtct	ggatgtcccc	ggcgctgtcg	acgaaggaaac	660
tgatgggcta	ggtgactgta	ccagtgtccc	cagagaaaat	cgcagcctcg	cagcatggat	720
ttaaatgcat	gtgcatgcat	gtagagacat	gaaaaaagg	ttctgaccat	tttacacagg	780
aagtctgtca	ctttgctgga	tcgggcttga	ttgcagcttg	tgttttcagc	tccagttcaa	840
cacccatttc	ctgactagt	agacagcatg	gccaaagcag	ctgcatgcag	aattttcttt	900
ttactgtgaa	agcaagcccc	ctctgtttta	actccttcca	gttctgaatg	ctctgtgctt	960
tgctaggacc	gattgtgggg	ttttgttttc	ttcttctaca	aatccctgta	aacacagctg	1020
tattcagtaa	tggcaaaaaa	attctatcct	gtaaatagaa	atctgatcaa	tttaatcaaa	1080
ataaatgtat	cccagatgac	tttgagacca	gctggctacc	acaggcttca	gatgctaaat	1140
gctcagtgga	gatgaataca	gtgttatatt	tacatgtttc	agagtgccgg	gatcagccta	1200
taatttgcaa	aaagaaatta	ttttctaaag	acgagaggtg	gtcctaccag	ctcacagctg	1260
atgggttaggt	acaggtgtaa	atgctgttca	tgtgatttgg	agatttgcag	tgttgcattt	1320
caaaaggcat	gtgccatgag	gcagagtatg	gctgttggtta	gtatggagaa	tgcttgcttc	1380
taacttgctg	ttatggagag	ccgaatgcc	tctgaatagc	ttctagttag	gttgagggca	1440
ggcacttgag	gcttggtgta	gattcagatg	tgagagctgg	ggttctccaa	ccccagctca	1500
gtggagtcag	ctcaaccctg	ggggtgagga	ggtttcccag	ttgtcatggg	gagctcttct	1560
gggacgcctg	tctggccctt	ccactgtttg	ttactaattc	tacaaaggca	gctctgtgtg	1620
ttggattatg	tttggccagc	tgttgatgca	ttcctgcgga	tggggctggg	tgaggatctt	1680
attactgtac	tttcaaactg	tagatctgtg	tgcagggata	gtacagaagg	aaaggaaaag	1740
caataagtta	cagaatctga	tcattcttac	ctctttctcc	agatagtcct	agagtgaatc	1800
cagaaaggct	ttaaagttaa	aagaggaaag	agagagtaag	tgattggggg	tgggtggcat	1860
gaggagaaga	gaatgaaaca	gagcaagcgc	acaagagaaa	aacagcctta	gaacttcaaa	1920
gctgcataga	caagcagaat	gtcaccagct	tgtaattagc	ggttcatggg	tgcgtcagt	1980
actgtatcta	tccaagaata	actatgtgat	atgtgccaca	aagtgaagaa	gatagtcata	2040
actaagttat	caaaccagct	tcaaacaagg	gcaaattggat	taagaaattt	tctgtttgta	2100
aatcaaatac	tgatggatta	cacagataag	acttaactga	attctgcgta	attgaaggct	2160
gaattatcaa	tttgtcaggg	gggatatggt	cattaaatga	aactgtgaac	gcttaaacat	2220
gcaaattaat	catgcgagaa	aatatcagtg	caagctctat	caatacaaga	tgttttacta	2280

aatagccaaa aatggcactg ccagtctcct atctctgtat ccacacataa atttttttgt	2340
ttgtttttgt gcatttcaat agagagaagt caaaagttac attcgagtaa atagggtaaa	2400
ttaaattcta aaattcccac tttagaattt aaaaaacaac taaggagttt tgatttttgg	2460
tgatctcccg agtttaaacc ttgaaggagc ttttgctgtc ttgaagccaa acagcagcta	2520
gtcagtaatc gttatgggaa gtcagggtac cacagttggt gagatttcaa ggccacgttc	2580
acttccctcc cttgtctctt gtgcttggag atttgggtgc tactacagcc tccacaaaga	2640
gacagtggga ggagctgatt ggtccgtagg cttagaatgt ttactcttat ttgttttcag	2700
tgctcctcca tggcattcat tttctgtttg tatttgtgtt catgctgcac aattactcct	2760
gacctgcttt gtttctctgc ccaaagagaa gtcaatttta gttcagctct gtgtgtttag	2820
cttgctgggt aatatgtgca tatgtattgc attacccatg tatgcatttt tcttttttta	2880
aatgtggat tagggaaaat tgtagcatgg aaagctgcat atattaaatc aatagctttt	2940
tgaatcacat gtaatataat ttaaataatac tcactttgag gttgccaaaa ctgacattgt	3000
ctgagcccg ttaatttaca tcttcgattt agtcaagaag cggaacctgc cagatcagaa	3060
tagtgtattc tgtgcacca acaggggtgga agacattatt ttgtttgtgt tagttcaaac	3120
agctggatcat taatgcagtc cccatttcta gagcgaagtg ctgctggaca tgaatgcccg	3180
cctgattaat gctgcccctc cgagggctct tcaccagca gtcattgctc cagcagaata	3240
atgtagcatg atgtgattgc actctaacag gatagtatgt cattgtgtca ccaagcaatt	3300
gaggttatta tggggcaggg cagacagacg ggacagtggg gttactagac cgtagcattt	3360
ttagaaatac aggctgacc tacttagagt tattctctct ggctggcagc tgcattggtac	3420
ataaagtctc ctgataggct gagtctgttg ctagggggaa ttagcatgaa tttttccaca	3480
cacagactca gtggctgaat gataaaagct gactggaatt aaagagattt ggtttagtat	3540
tatacagatt tatgtgcctc cttttctttc tcaagtgcag agaaagagtg caaaacacag	3600
attttgtttc catttgttct ttgaccttct tgttctctcc ccctcccctc aagatgcatg	3660
aggggaggag ggcagggcag ttatgaaatt ttggttaatc tctcactgtt ggggtcactg	3720
aaacgatgtc gcaaattgca agatatttaa gcttaaaaac tgttgggaat gactaacaga	3780
aggttagatt atttttcctc ttctgtgcac taagctgttt tgaagtggg catgcatctt	3840
tcatgcactg tatatttaaa ctctctttcc cttttgggct tgaacaaaac atttatataa	3900
attcttttct atccaaacag attgaagctt gcaatctctg tcttgtttta aacaagggtg	3960
tcaggattcc agatttagat aggaaaaata tatatatacc atttttgtta ttacaaaata	4020
ttattttctg gggattgtg ggtttggctc ctttttcaaa aaccagcctg atgtggatgc	4080

180

ttatggatga aactgaactg ctcctaccct accctgttgg cttcacaatg tataggaaaa	4140
catagggtttt tctccagaag aaaatctgcc tgcagaatgt atctggaggt tgttttcctt	4200
gttgctgaca tatgcactgc atgtagacaa ctcacataat caactgtata agatgaccca	4260
tttttttcct tctcatggat ctccaagtgt ctgtggcctt taatagatct tttctagagg	4320
aggagtcttg atagatcttt ttaaggtaat ctgaaaagcc atcaggagaa aaattaaagc	4380
aacacatatt taagaatact ttaatttttc ttgttcttaa ttatatgcta actgtgctta	4440
aactgcaatt tctttctgtt accttttact gctgaaagta gtgattatcc ttgcctttta	4500
gatttgaaat taattttcgt gagaacaccc tgggatatca caagtaaaaa agaaactggg	4560
ctacataaag gaaaagaata atagagattc ttgtaaactt gtcacattag ttttttttgc	4620
ccacgtgaaa aaggcaagag aaaatttagg tgtagatttt tcttttcatt tacattttta	4680
aaaatatttg gaactattta gatacataat gctttaaaac agtgattcct acttatagcg	4740
gagactacag tcaaaacaaa ataaaacaaa tcctctaattg ctatcagagc caagaaatct	4800
atcaatcata tatacatttt ttaaattccag gagtgtttac atttcagcat ataaatctta	4860
tcaagctaaa atagagtata tattctgatg ttgtaattga tagatcatac cctcactggc	4920
tttgagagtc cccaaacatt tattgtaaag gtttccaact acactagcaa tcttttgtaa	4980
ttgaataaaa tgccaattta tatttggtga ataaaagatt atctggggta ctgctccttc	5040
cgaaatg	5047

<210> 172
 <211> 756
 <212> DNA
 <213> Homo sapien

<400> 172	
gccgcctctt tgtctgctcc gggacttgga acaaaagggg gaactctgat gaactctctt	60
tcctcccctc tcccccgga cccgggggtat ctccctctcg caactttgcc gccccgactt	120
tctctgctgt caggccggga aaaagtgtcc gaacgcctcg tggactgcag cgggggaaat	180
gtcccttaaa agtgcgacga agtggggaag aaggtgtaat tactattatc agcatctaga	240
aagcatcatg aatttgctgg agtacttcct agcactgacc tccttcattc tgcgttgctc	300
ttactggatc tttccatcag ccaacaatat ggaagtacca atacaaggtc aaatcattcc	360
tggattcatc tggagttgct taaaagttaa atcattggaa tttttgatga taccttttct	420
atatggatta caatttgatc gctgggaatt ctccacctta aagaagactc ttttgctatc	480
tggaaacca tgtccacctc tgacttcac tcaaaattgc tttcctcaca gtctgactgc	540
gagagttgtg aaaaattggg atgtgcttct gaggtgggct gtggaatgcc atacagaatc	600

181

tcgaagtctt ggagtctcac tctgttgccc aggctggagt acagagggttg cagtgaactg 660
 agatcgtgcc actgaactcc agcctgggcg acaggggtgag actccgtctc aaaaaataaa 720
 taaataaaaa taaaaataaa tacactgagt ctcatg 756

<210> 173
 <211> 2868
 <212> DNA
 <213> Homo sapien

<400> 173
 ctttcctcac agctccacgg ctgcattctcc gtgggcacgc aagcttcccc tggttacctg 60
 agctgctcct gccgtctccc gcctgggctt cgcctggtg caccgatcc cggaatcgtg 120
 cgtctgcgcc ctgcgaaaga aggacctgct ggaggagctc cggccgggggt ctctgcctc 180
 gcagctgggc gaggggactt ggaggacagg gtgaagctgc agaagacctg gggtaggatg 240
 gctagagagg acgccaagga ctggggaagg ggaagttagg aataccttac atccaatgcc 300
 caccgatgct ccgcagggca agggcagccg tcgcctcggc cgcgtgcacc cagctcaggc 360
 tgttcccagg gatttagtct ggggggacaa cccatggcga gatgtggtgg cattttacct 420
 cagagtggag ctgaagatgg ataaacaagg tatctgatgt atctgcctga gaaggcagag 480
 ctggagaaag gcggagcgag ggagcgcgtg aaaagaaaga gatgccgaat gccgggtgat 540
 tgtctgccgc ttgctgtgca ttctcattct agggaggatg gcataattta taaccagca 600
 catggataga ggaactgtaa attgtagtct ggatgtcccc ggcgtgtcg acgaaggaaac 660
 tgatgggcta ggctcacagg cagaaggaat tttccttgtc ttggatgaga cttttgactt 720
 ggacttttgg gttaagttct ggagaccaga aggccaaaat caaaagtatg ggcaggcttg 780
 atttcttttag aagactccag cggagaactg tgtctccttg cttctgattc tacatctcca 840
 tccatgggcc actgtttcag caacctcagc cagtgcaca caacctcagc caagaagagt 900
 atgcagagaa aggagtcccc tacctgccac aaaactgttg tctgaaaact gtctcatatt 960
 gtctcaagtt gtcattcatt gtgaattaga cctgtttaac atgtaatctg caacatgctt 1020
 cactgtctaa ttttccagag cccctcatat aaggaactgt attattggta taatcatcat 1080
 ggtgaagaag ttggtatgtg ggggagagat gacagaaaca gagagtaagt cagagctggc 1140
 tgcctgacag ataaaaagga aatgaccaa aaaaaaaaaa aagacacaga agaatacttt 1200
 gttgtccaca cagaaaaggg aagtgtaggt aagacagcag tagactaaga ttcttaagac 1260
 tcaagttcta gtcttattta ttagctatgg gaggccttga gggagttcta gaattaagtg 1320
 atctctcttt ataaaatagg aacagtaata acttcctggc taactccctg gctgtctcac 1380
 aatgctgtag tagtaagaaa taattttata attaaagact attttagggc tgattacatt 1440

182

```

tttgggcagt ggctcataca tgtaatttca acattttggg aggccaaggt gggcggattg 1500
cttgagccca ggaattcaag accaggctgg gcaacacaga ccttgctact acaaaagaaa 1560
aaaacattag ctaggcgtgg tgatgtatgc ctgtgggtccc agctactcag gaagctgaga 1620
caggaggatc acctgagcct gggagggtcga ggctacagtg agccatgatc acactactgc 1680
actccagcct gggaaacaga gtgagactct gtctcaaaaa aaaaaaagga atatttttaca 1740
cttcaagggt ctatacaaat gtaaaatatc attctattac ttattttataa tgctgattat 1800
tctttaaatg actttaaaat gttaatctct gcttgagcct acggagaagt atgtaacaaa 1860
tttgtgaagg attggcatta aagatagtca aaataaaaca tagaaattat ggtaaataat 1920
ttaactggta aaataatcta agtggtagt ctccaggtaag tggaaattcg attagctgat 1980
tgtttaggat tcttggttat aagtgcacaga gacctgacta aaagtacatg aagcacataa 2040
ctgagaaggc tgtgggtatgg ctccagcagaa atgggaaaat cttgggactg gttcgtgttt 2100
tattttacatt atctttgttc ccaggcagtc tctgcatgta agtggcaaag atgactgtct 2160
gaaaatatat acctactttt ttaaagggtc atctcaagcc attctggaga agcaccaaaa 2220
gccactttgc ttatactggg agaatagttt gctttcccta atttgtgatg agtgaaacac 2280
tgaacagaga catagaataa tattctgtag ttcaggggtt ggtgtaatat ggccagtggg 2340
cggaatctgg tcctcagact gattttgcaa ataatcttat agaaacacag caacacccat 2400
tcattacatg ttgtttatgg ttgctttggg gttacaatgg cagagttgag tagttgtgac 2460
agagatcact aggctcacca catctgagat atgtactgac tgaccctgta cagaaagttt 2520
gctgctctta gaggaatgtg tgtttctagt gtcagcaata aacttcttgg atttgttttg 2580
ttttctcatc ttacatgat agttgcagac tagttgatcc ttgtgacctg tttttgaatg 2640
ccactgtgta ttctgtcagg gccctctgat tctgtttctt atgggtgctga atgcacaatt 2700
taatgccctg gaatttcctt ctgtcttctg ctaaactcat gcctcttcag atagttaaaa 2760
tcctgttcta ccttagaagt ctccagagtt attttcctaa attaagaaga actggctttg 2820
aagttactca ttatgccaca cacaatgggt gaaaagagca tctcttat 2868

```

```

<210> 174
<211> 606
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (61)..(61)
<223> n=a, c, g or t

```

```

<400> 174

```

183

```

gccctatccg cgttcatccg cgccttcagg tgccccgcgc agggttcgga tcctgtaggc      60
nagccgcgga cccttgcgcc acctgcgcgc cggggcattt ctcaaggcgg gtcggcctgc      120
gggtcggcct tcctaccagg tccgatcact gagagcctcc ctcttccacc ggggcttggg      180
tctgggtctg agctcccgtc gctctacttg gtgtccgcgg ccctgagcgc cctgtcgctt      240
ctctcccgca gcagcaaagt ctctcgcgac accctgtacg aggcggtgcg ggaagtcctg      300
cacgggaacc agcgcaacgc cgcaagttcc tggagacggt ggagttgcag atcagcttga      360
agaactatga tccccagaag gacaagcgct tctcgggcac cgttcaggct taagtccact      420
ccccgcccta agttctctgt gtgtgtcctg ggggaccagc agcactgtga cgaggctaag      480
gccgtggata tccccacat ggacatcgag gcgctgaaaa aactcaacaa gaataaaaaa      540
ctggtcaaga agctggccaa gaagtatgat gcgttttttg cctcagagtc tctgatcaag      600
cagatt                                                                 606

```

<210> 175
 <211> 735
 <212> DNA
 <213> Homo sapien

```

<400> 175
caagcttggg aacacagggc gggcgtgaga agccatgagc agcaaagtct ctcgcgacac      60
cctgtacgag gcggtgcggg aagtcctgca cgggaaccag cgcaacgcgc caagttcctg      120
gagacggtgg agttgcagat cagcttgaag aactatgatc ccagaagga caagcgcttc      180
tcgggcaccg tcaggttggc accgttctga tcccaccag ccctcagtgc ccccgctgctt      240
gcccctcccc tgcaggctcc cgctgagccg gaggggggca cgtcgggtact gatgtgctag      300
ggtagttcag accctctgct ccgggcaggc gcggctggac ggacccccac cctgggtctt      360
aaaacatgag gggaggcgtg ggtaggcctc ggccgagccc gccggccagc ctgagaagcc      420
aggctggctg ctggtgaatg tgaacgctcc gggtaaggct cggtggctgc tgcggtccca      480
gacccttcac cggcccttgg gaccagggc taggcgtaac ctgttggtgc tgtcccccaa      540
aacgcaggct taagtccact ccccgcccta agttctctgt gtgtgtcctg ggggaccagc      600
agcactgtga cgaggctaag gccgtggata tccccacat ggacatcgag gcgctgaaaa      660
aactcaacaa gaataaaaaa ctggtcaaga agctgggtga gtccggccgc tgtggttttg      720
catgtgagat gtgtg                                                                 735

```

<210> 176
 <211> 943
 <212> DNA
 <213> Homo sapien

184

<400> 176

```

aatgatgag gggcctagaa tagcaaagga tcggcggtgg ttgcctagct tgccctgagtg      60
ctgtttttagc tttgggggtgg tttgatgttt gtattgctat gaggattcca gttgatgagg      120
gaggccaggc attgtaagtt gaccagccag gtgctggtga actatgattt ggaaatcttt      180
acgctgcgtt gtttaggcag tggcattaga ctgcttttac aggtaggaag cagacattcc      240
cagttgtcac gtgtccaggg tccacagcta agaaataggc agaattcgag cccaggcagt      300
cttgaccaga gcatccgttg tacagcggtt atgccatgga tcatgggtca gcctggtttt      360
ctgagagcat gttttgggac cagtgaaggt ccagaggact ttctggaaac cgtttgggct      420
agggaaaaga ctgaggcggg gtcttagaga ggggtgctgct tggaggtcac ttacatgatt      480
gattcaagtg cgtttctggc ctgccacatt tgagggtgtgc cttggtgacc aggttctaag      540
caatgccaat ggcttcctct ctctatcagc caagaagtat gatgcgtttt tggcctcaga      600
gtctctgatc aagcagattc cacgaatcct cggcccagggt ttaaataagg caggaaagtt      660
cccttccttg ctcacacaca acgaaaacat ggtggccaaa gtggatgagg tgaagtccac      720
aatcaagttc caaatgaaga aggtgttatg tctggctgta gctgttggtc acgtgaagat      780
gacagacgat gagcttgtgt ataacattca cctggctgtc aacttcttgg tgtcattgct      840
caagaaaaac tggcagaatg tccgggcctt atatatcaag agcaccatgg gcaagcccca      900
gcgcctatat taaggcacat ttgaataaat tctattacca gtt                               943

```

<210> 177

<211> 742

<212> DNA

<213> Homo sapien

<400> 177

```

aaagggacca actggagctc cccgcgtgcg cccctactat acggtcctaa gtagcgacca      60
tgagcagcaa agtctctcgc gacaccctgt acgaggcggt gcgggaagtc ctgcacggga      120
accagcgcaa cgccgcaagt tcctggagac ggtggagttg cagatcagct tgaagaacta      180
tgatccccag aaggacaagc gcttctcggg caccgtcagg cttaagtcca ctccccgccc      240
taagttctct gtgtgtgtcc tgggggacca gcagcactgt gacgaggcta aggccgtgga      300
tatcccccac atggacatcg aggcgctgaa aaaactcaac aagaataaaa aactgggtcaa      360
gaagctggcc aagaagtatg atgcgttttt ggccctcagag tctctgatca agcagattcc      420
acgaatcctc ggcccagggt taaataaggc aggaaagttc ccttcctctg tcacacacaa      480
cgaaaacatg gtggccaaag tggatgaggt gaagtccaca atcaagttcc aaatgaagaa      540
gggtgttatgt ctggctgtag ctgttggtca cgtgaagatg acagacgatg agcttgtgta      600
taacattcac ctggctgtca acttcttgggt gtcattgctc aagaaaaact ggcagaatgt      660

```

185

ccgggcctta tatatcaaga gcaccatggg caagccccag cgcctatatt aaggcacatt 720
tgaataaatt ctattaccag tt 742

<210> 178
<211> 199
<212> DNA
<213> Homo sapien

<400> 178
ggccactcca gaacagtacc agatcctgaa gaaggaggct gagaaagtgg cccgggtgaa 60
ggcgctatat gaggagctgg atctgccagc agtgttcttg caatatgagg aagacagtta 120
cagccacatt atggctctca ttgaacagta cgcagcacc ctgccccag ccgtctttct 180
ggggcttgcg cgcaaaatc 199

<210> 179
<211> 1358
<212> DNA
<213> Homo sapien

<400> 179
cgccgggcgg ggaccgtggg ggccgcggac aagcccaagg ccggagcggg tccaggagga 60
ccctgggtctg cacctgtggt tgccaggtag gtggatgtga gagaccctac ctttctgggt 120
ctctagaagc catcccatcg ccgctagcat catgctgtcc cctcagagag ctttactctg 180
caacctcaac cacatccacc tccagcacgt ctccctgggc ctgcacttgt cccgccgtcc 240
tgagctacag gaggggcctt tgagcacacc ccctcctcca ggagacactg ggggcaagga 300
gagcaggggc ccctgcagtg gcaccctggg ggacgcctaat tccaacagcc cagctgtgcc 360
ctgccggtgc tgccaggagc acggtccggg cctagaaaac cggcaggacc cgtcacagga 420
ggaagagggg gctgcctctc cctcagaccc aggtctgtcc tcctcactca gctcctgctc 480
agatcttagc ccgatgagt ccctgtctc agtctacttg cgggacctcc ctgggtgatga 540
ggatgcccac cctcagccca gtatcatccc cctggagcag ggctccccac tggcttcagc 600
aggccctggc acctgctcac cggacagctt ctgctgctct cctgattcct gctccggagc 660
ttcttcttca cccgatcctg gcctggactc gaactgcaac gccctgacca cctgccagga 720
cgtcccttcc ccaggcttgg aggaagagga cgagagggcg gagcaggatc tccctacctc 780
tgagctctta gaggcggatg atgggaaaat cgacgctggg aaaacggagc ccagttggaa 840
gattaacca atttgaaaaa ttgacacaga gaaaactaaa gctgaatgga aaaccactga 900
aaacaataac actggttgga aaaacaacgg gaatgttaac tctagctgga aaagtgaacc 960
tgaaaaattc gactctgggt ggaaaaccaa cacaagaata actgattctg gctcgaaaac 1020

186

agatgcaggg aaaattgatg gaggatggag aagtgacgtc agcgaggagc cgggtgcccc 1080
 ccggacaatc acgtccttcc acgagctggc ccagaagcgc aagcggggcc cagggctgcc 1140
 ccttgtcccg caggcgaaga aagatcgagc tgactggctc atagtcttct cgcccgacac 1200
 cgagctcccc ccctcggggc cgccggggcg ctccctcgga cctcctcggg aagtcaccac 1260
 cttcaaggaa ctccgggtccc gaagccgggc ccagcccccg ccagtcccgc ctcgagaccc 1320
 ccagttggc tgggctttgg tcccgccccg gccccac 1358

<210> 180
 <211> 2761
 <212> DNA
 <213> Homo sapien

<400> 180
 aaaggctagg tacgaggctg ggtgttgaat cggccgaggg tgagagagga tgtgtgctgg 60
 gccttggagg aagggggccg agaccgggccc ttacttctgt aacgatactg tgaggcatcg 120
 gaaggccagc ctgttgtgtc cgttttgaag gtcggtgggc tagactggct ggccttctag 180
 ggggtgtggag acttcccaac tctgcccttg tgctttcctg gaatccccaa tatgcccga 240
 ccccggttta ctcccttgct gcgagccctt ctctcccgtc cagagttgct ccgagcctat 300
 ctgctcagtc ctagcgattc ctgtggggct tgggacgcgc ggttcaagca ccccgga 360
 tatggatgca gcacccatgg gttctcgctc caatgcttct ttccctcctg gggcgtaact 420
 cagaccctgg gcacccctct cactgcccga ggggagacct gggttctaga tttggctctg 480
 cctctactat cttcctacct cctagagcct cagtttggct tgtgtaaaat aggatgactt 540
 aagggtcctt tcagccccta atcctggggc actttactct gtaccgcctc cttaccagc 600
 cttgtgcacg ccatcttgaa ggcactgagt tctagcctgt ttattgtaag tggtgattag 660
 ttgggtctca gtcacccagc catacttttt tgttccctgc gtatccttcc tgtaattgtc 720
 cccaagcaca ttccacaaga gggaggggca ctctgggcta aggctggggg gggagttatc 780
 tggggagctg ccaccatgcc tctgcctttg gtgcttgccc ctgcaggag tgcttagtgc 840
 cccctcccta tgccactccc aggatgatgc ccctgtcccg ctgggttgaga tctgtggggg 900
 tcttcctgct gccagcccc tactgggcac ccgggagag gtggctgggt tccctacggc 960
 ggccctccct ggtgcacggg taccagtc tggcctggca cagtgcgcgc tgctgggtgc 1020
 aagcgtggac agaggaacct cgagcccttt gctcctccct cagaatgaac ggagaccaga 1080
 attcagatgt ttatgcccc gaaaagcagg atttcgttca gcacttctcc cagatcgta 1140
 ggggtgctgac tgaggatgag atggggcacc cagagatagg agatgctatt gcccggtca 1200
 aggaggtcct ggagtacaat gccattggag gcaagtataa ccgggggtttg acggtggtag 1260

187

tagcattccg	ggagctggtg	gagccaagga	aacaggatgc	tgatagtctc	cagcgggcct	1320
ggactgtggg	ctggtgtgtg	gaactgctgc	aagctttctt	cctggtggca	gatgacatca	1380
tggattcatc	ccttaccgcg	cggggacaga	tctgctggta	tcagaagccg	ggcgtggggt	1440
tggatgccat	caatgatgct	aacctcctgg	aagcatgtat	ctaccgcctg	ctgaagctct	1500
attgccggga	gcagccctat	tacctgaacc	tgatcgagct	cttcctgcag	gtgtattgca	1560
gacagggccc	gatgcccaga	gggtgcccac	ggtagccttg	gcctctatag	gacatgctca	1620
tctagctggt	ttcaggggtac	aggattgcag	cgtgcctgga	agggaaagaa	agcgaggaag	1680
ggtgttggga	agtgggggtg	tggtagtggc	aagaaagggc	ttctctgtcc	tgtgtaattg	1740
gaagaaaggg	tgataaagga	ctgtgtgtat	gaatatgggc	cttaagtttt	ggggctttct	1800
ccccttctgt	tgcccttctg	attctgccc	gttgtcagct	ggtatgggat	gttgggcttg	1860
ggataccagg	gtttcgcata	tctggagaaa	gcctggctca	tggaccgtct	ttgtcttgct	1920
tagagttcct	atcagactga	gattgggcag	accctggacc	tcctcacagc	cccccagggc	1980
aatgtggatc	ttgtcagatt	cactgaaaag	agggtgaggg	gaggtgaggg	acagcgcgaa	2040
ccatgtctgg	acagcgaggg	agggtcagg	atgtgcattg	ccctcctgag	gagtttctct	2100
tctcccctta	ctcaggtaca	aatctattgt	caagtacaag	acagctttct	actccttcta	2160
ccttcctata	gctgcagcca	tgtacatggc	aggaattgat	ggcgagaagg	agcacgccaa	2220
tgccaagaag	atcctgctgg	agatggggga	gttctttcag	attcaggatg	attaccttga	2280
cctctttggg	gaccccagtg	tgaccggcaa	aattggcact	gacatccagg	acaacaaatg	2340
cagctggctg	gtggttcagt	gtctgcaacg	ggccactcca	gaacagtacc	agatcctgaa	2400
ggaaaattac	gggcagaagg	aggctgagaa	agtggcccgg	gtgaaggcgc	tatatgagga	2460
gctggatctg	ccagcagtgt	tcttgcaata	tgaggaagac	agttacagcc	acattatggc	2520
tctcattgaa	cagtacgcag	caccocctgc	cccagccgtc	tttctggggc	ttgcgcgcaa	2580
aatctacaag	cggagaaagt	gacctagaga	ttgcaagggc	ggggagagga	ggctctcaat	2640
aaataatcgt	gtaaccttaa	aaaaaaaaaa	tcgggattct	ttggggggga	aaaagttgaa	2700
ggcacggcta	ctgttctgcc	cttttgacag	gggaatcgcc	caagagctat	cgaccgacta	2760
g						2761

<210> 181
 <211> 2371
 <212> DNA
 <213> Homo sapien

<400> 181
 aaaggctagg tacgaggctg ggtgttgaat cggccgaggg tgagagagga t g t g t g c t g g 60

188

gccttggagg aaggggggccc agaccggggc ttacttctgt aacgatactg tgaggcatcg	120
gaaggccagc ctgttgtgtc cgttttgaag gtcgggtgggc tagactggct ggccttctag	180
gggtgtggag acttcccaac tctgcccttg tgctttcctg gaatccccaa tatgcccgga	240
ccccggttta ctcccttgct gcgagccctt ctctcccgtc cagagttgct ccgagcctat	300
ctgctcagtc ctagcgattc ctgtgggggt tgggacgcgc ggttcaagca ccccggaaca	360
tatggatgca gcacccatgg gttctcgctc caatgcttct ttccctcctg gggcgtaact	420
cagaccctgg gcacccctct ccactgcccc ggggagacct gggttctaga tttggctctg	480
cctctactat cttcctacct cctagagcct cagtttggct tgtgtaaaat aggatgactt	540
aagggtcctt tcagccccta atcctgggggt actttactct gtaccgcctc cttaccacgc	600
cttgtgcacg ccatcttgaa ggcactgagt tctagcctgt ttattgtaag tggtgattag	660
ttgggtctca gtcaccacgc cataacttttt tgttccctgc gtatccttcc tgtaattgtc	720
ccaagcaca ttccacaaga gggaggggca ctctgggcta aggctgggggt gggagttatc	780
tggggagctg ccacccatgcc tctgcctttg gtgcttgccc ctgcaggag tgcttagtgc	840
cccctcccta tgccactccc aggatgatgc ccctgtcccg ctgggttgaga tctgtggggg	900
tcttctgct gccagccccc tactgggcac cccgggagag gtggctgggt tccctacggc	960
ggccctccct ggtgcacggg taccagtcct tggcctggca cagtgcgcgc tgctggtgcc	1020
aagcgtggac agaggaacct cgagcccttt gctcctccct cagaatgaac ggagaccaga	1080
attcagatgt ttatgcccga gaaaagcagg atttcgttca gcacttctcc cagatcgtta	1140
gggtgctgac tgaggatgag atggggcacc cagagatagg agatgctatt gcccggctca	1200
aggaggctct ggagtacaat gccattggag gcaagtataa ccgggggtttg acgggtggtag	1260
tagcattccg ggagctggtg gagccaagga aacaggatgc tgatagtctc cagcgggcct	1320
ggactgtggg ctggtgtgtg gaactgctgc aagctttctt cctgggtggca gatgacatca	1380
tggattcatc ccttaccgcg cggggacaga tctgctggta tcagaagccg ggcgtggggt	1440
tggatgccat caatgatgct aacctcctgg aagcatgtat ctaccgcctg ctgaagctct	1500
attgccggga gcagccctat tacctgaacc tgatcgagct cttcctgcag gtgtattgca	1560
gacagggccc gatgccca gaaggcccat ggtagccttg gcctctatag gacatgctca	1620
tctagctggt ttcaggagtt cctatcagac tgagattggg cagaccctgg acctcctcac	1680
agccccccag ggcaatgtgg atcttgtcag attcactgaa aagaggtaca aatctattgt	1740
caagtacaag acagctttct actccttcta ccttcctata gctgcagcca tgtacatggc	1800
aggaattgat ggcgagaagg agcacgcca tgccaagaag atcctgctgg agatggggga	1860
gttctttcag attcaggatg attaccttga cctctttggg gacccagtg tgaccggcaa	1920

189

```

aattggcact gacatccagg acaacaaatg cagctggctg gtgggttcagt gtctgcaacg 1980
ggccactcca gaacagtacc agatcctgaa ggaaaattac gggcagaagg aggctgagaa 2040
agtggcccgg gtgaaggcgc tatatgagga gctggatctg ccagcagtgt tcttgcaata 2100
tgaggaagac agttacagcc acattatggc tctcattgaa cagtacgcag caccctgcc 2160
cccagccgtc tttctggggc ttgctgcgca aatctacaag cggagaaagt gacctagaga 2220
ttgcaagggc ggggagagga ggctctcaat aaataatcgt gtaaccttaa aaaaaaaaaa 2280
tcgggattct ttggggggga aaaagttgaa ggcacggcta ctgttctgcc cttttgacag 2340
gggaatcgcc caagagctat cgaccgacta g 2371

```

```

<210> 182
<211> 261
<212> DNA
<213> Homo sapien

```

```

<400> 182
aaaaagaatg gaacaacttc agtaagaaga acatttttca ttttagattt ctatgcctta 60
ttttactagt tgattccagg cgtgaattcc aagaagaacc aaatgtattt tgactgggggt 120
ccaggggaga tgctggtatg tgaaacctcc ttcaacaaaa aaggtaggggt tttttttctt 180
ccaaattatc catcttggca catttggttg tttttctgtt tattacctca gattttacta 240
gttgtggact gaaacagttg a 261

```

```

<210> 183
<211> 3633
<212> DNA
<213> Homo sapien

```

```

<400> 183
gaaaaaaaaa aagaaaaaaaa acaaaaaaca aaaaatacat cacaataaga ggccgaatgt 60
aaataaagac gagggacgca gaggggtggc cgtggctgag aggagacagc gccgcagcac 120
tgaggggtttg ggcttgcagg cgctgcagga gacgcccagg cggagtcttg tctcgcagcc 180
agctctgagc gggaggcctg agcgggaagc attggcgtcc gagcgacttc taggagcctg 240
gggttcggcg ctatggagga gctcgatggc gagccaacag tcaactgtaag ggtaccccga 300
acaggcttgc tcgtccttgc gggttgagaa ctgcgtctgc ttagttactt caggcttgtc 360
tgcttcccta gtggtcgcga ggcgctcgtc cccttccctc gactcagttg ccacttttcc 420
ggaggtcgca gtgttaacga gttgattcca ggcgtgaatt ccaagaagaa ccaaattgat 480
tttgactggg gtccagggga gatgctggta tgtgaaacct ccttcaacaa aaaagaaaaa 540
tcagagatgg tgccaagttg cccctttatc tatatcatcc gtaaggatgt agatgtttac 600

```

190

tctcaaactct	tgagaaaact	cttcaatgaa	tcccatggaa	tctttctggg	cctccagaga	660
attgacgaag	agttgactgg	aaaatccaga	aaatctcaat	tggttcgagt	gagtaaaaac	720
taccgatcag	tcatcagagc	atgtatggag	gaaatgcacc	aggttgcaat	tgctgctaaa	780
gatccagcca	atggccgcca	gttcagcagc	caggtctcca	ttttgtcagc	aatggagctc	840
atctggaacc	tgtgtgagat	tctttttatt	gaagtggccc	cagctggccc	tctcctcctc	900
catctccttg	actgggtccg	gctccatgtg	tgcgaggtgg	acagtttgtc	ggcagatgtt	960
ctgggcagtg	agaatccaag	caaacatgac	agcttctgga	acttggtgac	catcttggtg	1020
ctgcagggcc	ggctggatga	ggcccagacag	atgctctcca	aggaagccga	tgccagcccc	1080
gcctctgcag	gcatatgccg	aatcatgggg	gacctgatga	ggacaatgcc	cattcttagt	1140
cctgggaaca	cccagacact	gacagagctg	gagctgaagt	ggcagcactg	gcacgaggaa	1200
tgtgagcggg	acctccagga	cagcacattc	gccaccagcc	ctcacctgga	gtctctcttg	1260
aagattatgc	tgggagacga	agctgccttg	ttagagcaga	aggaacttct	gagtaattgg	1320
tatcatttcc	tagtgactcg	gctcttgtag	tccaatccca	cagtaaaacc	cattgatctg	1380
cactactatg	cccagtccag	cctggacctg	tttctgggag	gtgagagcag	cccagaaccc	1440
ctggacaaca	tcttgttggc	agcctttgag	tttgacatcc	atcaagtaat	caaagagtgc	1500
aggaataaaa	cagatttgag	cagaagaagt	ctggttgatg	cagggagtat	aaaaggggaa	1560
agcatcctgc	tgtttccagt	ggcagaagag	aaagagaagt	accatgaaga	ggggtgaaca	1620
acatcactct	cgtgccggac	acagacaagg	aatgattagg	cttgacagtcc	cccagtctca	1680
gcctctctcc	actctcacia	gcaggaaggg	atctgagctc	tgttagtggg	aaatcttgga	1740
gtttgcattt	ctctgatcac	gaggctacct	cctatcctgt	tttgaaagag	gaacagaaaa	1800
gcagagcttg	tcccaggaat	tgtgaaatgg	gctgcaatgt	cttcagaggc	agtagcagtt	1860
ttaggaagtg	tgccctcctg	cctctgggga	aagggtgaat	tggggtcttg	tgggcacttg	1920
ttttctcatg	ggatgtatca	gtcagaccca	tgacacagttc	tgggcggcag	ggaagtgtgt	1980
ctctttctgg	acttgagcca	gtgagctgtt	ggcatgcctt	tttaaaggca	ttagaaaaaa	2040
ggtttctttc	ttttttttcc	tttcctgttc	acaccacctt	catatgaaca	tggagaaggg	2100
aggtttctaa	gtgggcccct	gatttactcc	tatgtcaata	atcgtgccag	accctaaggg	2160
gcagaaaagg	cagccagggg	atcctgactc	agaggctgta	gttcgtcagc	cctgctaaag	2220
ggccaggggt	ttgtctctca	gtgcctgggt	gggcatgctt	gactgctaac	cccttagctg	2280
aaaggagatg	gcaggagtcc	tccacagggg	cccttcttcc	ctcctggctt	acagcttcct	2340
ctgaagacgg	gccagttcct	tgctgtctgg	caagaggaaa	cagctggggg	gcacttcact	2400
gggagttggg	caagatgtcg	gcagtttcct	gggtgcccttc	aagtcctcca	aaagtatcga	2460

191

gctaaaagag gtgacaagtc ttccttcaat aaccaagaag agttccagct taatgtctgc 2520
 tgaatctaga atcttctgac ttgtattttg gccagccca caatcttgga tgcaggggtgc 2580
 agcagtgttt acaaacctca caccocattt ccagaatagc aggtagaggc actggagctt 2640
 tgattactcc agagccccc acaagcaaga tggggcctgg catcgccctg agcaactggg 2700
 ggtttgtggc ccacctgaca gacctgctgg accactgcaa gctcctccag tcacacaacc 2760
 tctatttcgg ttccaacatg agagagttcc tcctgctgga gtacgcctcg ggactgtttg 2820
 ctcatccag cctgtggcag ctgggggtcg attactttga ttactgcccc gagctggggc 2880
 gagtctccct ggagctgcac attgagcggg tacctctgaa caccgagcag aaagccctga 2940
 aggtgctgcg gatctgtgag cagcggcaga tgactgaaca agttcgcagc atttgtaaga 3000
 tcttagccat gaaagccgtc cgcaacaatc gcctgggttc tgccctctct tggagcatcc 3060
 gtgctaaggga tgccgccttt gccacgctcg tgtcagacag gttcctcagg gattactgtg 3120
 agcgaggctg cttttctgat ttggatctca ttgacaacct ggggccagcc atgatgctca 3180
 gtgaccgact gacattcctg ggaaagtatc gcgagttcca ccgtatgtac ggggagaagc 3240
 gttttgcca cgcagcttct ctcttctgt ccttgatgac gtctcggatt gccctcggg 3300
 ctttctggat gactctgctg acagatgcct tgcccccttt ggaacagaaa caggtgattt 3360
 tctcagcaga acagacttat gagttgatgc ggtgtctgga ggacttgacg tcaagaagac 3420
 ctgtgcattgg agaactctgat accgagcagc tccaggatga tgacatagag accaccaagg 3480
 tggaaatgct gagactttct ctggcacgaa atcttgctcg ggcaattata agagaaggct 3540
 cactggaagg ttcttgagaa ctgcttcaat gtggtatctt tgtatggcaa tgtatataga 3600
 ttttttaaaa gaataaatgt tgttttgcaa atg 3633

<210> 184
 <211> 2589
 <212> DNA
 <213> Homo sapien

<400> 184
 gaaaaa aaaa aagaaaaaaa acaaaaaaca aaaaatacat cacaataaga ggccgaatgt 60
 aaataaagac gagggacgca gaggggtggc cgtggctgag aggagacagc gccgcagcac 120
 tgaggggtttg ggcttgcagg cgctgcagga gacgcccagg cggagtcttg tctcgcagcc 180
 agctctgagc gggaggcctg agcgggaagc attggcgtcc gagcgacttc taggagcctg 240
 gggttcggcg ctatggagga gctcgatggc gagccaacag tcaactgtaag ggtaccccga 300
 acaggcttgc tcgtccttgc gggttgagaa ctgcgtctgc ttagttactt caggcttgtc 360
 tgcttcccta gtggtcgcga ggcgtcgtc cccttccctc gactcagttg ccacttttcc 420

ggaggtcgca gtgttaacga gttgattcca ggcgtgaatt ccaagaagaa ccaaattgtat 480
tttgactggg gtccagggga gatgctggta tgtgaaacct ccttcaacaa aaaagaaaaa 540
tcagagatgg tgccaagttg cccctttatc tatatcatcc gtaaggatgt agatgtttac 600
tctcaaatct tgagaaaact cttcaatgaa tcccatggaa tctttctggg cctccagaga 660
attgacgaag agttgactgg aaaatccaga aaatctcaat tgggttcgagt gagtaaaaac 720
taccgatcag tcatcagagc atgtatggag gaaatgcacc aggttgcaat tgctgctaaa 780
gatccagcca atggccgcca gttcagcagc caggtctcca ttttgtcagc aatggagctc 840
atctggaacc tgtgtgagat tctttttatt gaagtggccc cagctggccc tctcctctc 900
catctccttg actgggtccg gctccatgtg tgcgaggtgg acagtttgtc ggcagatgtt 960
ctgggcagtg agaatccaag caaacatgac agcttctgga acttgggtgac catcttggtg 1020
ctgcagggcc ggctggatga ggcccgacag atgctctcca aggaagccga tgccagcccc 1080
gcctctgcag gcatatgccg aatcatgggg gacctgatga ggacaatgcc cattcttagt 1140
cctgggaaca cccagacact gacagagctg gagctgaagt ggcagcactg gcacgaggaa 1200
tgtgagcggg acctccagga cagcacatc gccaccagcc ctacactgga gtctctcttg 1260
aagattatgc tgggagacga agctgccttg ttagagcaga aggaacttct gagtaattgg 1320
tatcatttcc tagtgactcg gctcttgtag tccaatccca cagtaaaacc cattgatctg 1380
cactactatg cccagtccag cctggacctg tttctgggag gtgagagcag cccagaaccc 1440
ctggacaaca tcttggtggc agcctttgag tttgacatcc atcaagtaat caaagagtgc 1500
agcttcctct gaagacgggc cagttccttg ctgtctggca agaggaaaca gctgggggtgc 1560
acttcactgg gagttgggca agatgtcggc agtttccttg tgcccttcaa gtcctccaaa 1620
agtatcgagc taaaagcatc gccctgagca actggtgggt tgtggcccac ctgacagacc 1680
tgctggacca ctgcaagctc ctccagtcac acaacctcta tttcggttcc aacatgagag 1740
agttcctcct gctggagtac gcctcgggac tgtttgctca tcccagcctg tggcagctgg 1800
gggtcgatta ctttgattac tgccccgagc tgggcccaggt ctccctggag ctgcacattg 1860
agcggatacc tctgaacacc gagcagaaag ccctgaaggt gctgcggatc tgtgagcagc 1920
ggcagatgac tgaacaagtt cgcagcattt gtaagatctt agccatgaaa gccgtccgca 1980
acaatcgctt gggttctgcc ctctcttgga gcatccgtgc taaggatgcc gcctttgcca 2040
cgctcgtgtc agacagggtc ctccaggatt actgtgagcg aggtgccttt tctgatttgg 2100
atctcattga caacctgggg ccagccatga tgctcagtga ccgactgaca ttctgggaa 2160
agtatcgca gttccaccgt atgtacgggg agaagcgttt tgccgacgca gcttctctcc 2220

193

ttctgtcctt	gatgacgtct	cggattgccc	ctcgggtcttt	ctggatgact	ctgctgacag	2280
atgccttgcc	cctttttggaa	cagaaacagg	tgatttttctc	agcagaacag	acttatgagt	2340
tgatgcggtg	tctggaggac	ttgacgtcaa	gaagacctgt	gcatggagaa	tctgataccg	2400
agcagctcca	ggatgatgac	atagagacca	ccaagggtga	aatgctgaga	ctttctctgg	2460
cacgaaatct	tgctcgggca	attataagag	aaggctcact	ggaaggttcc	tgagaactgc	2520
ttcaatgtgg	tatcttttga	tggcaatgta	tatagatttt	ttaaaagaat	aaatgttggt	2580
ttgcaaatg						2589

<210> 185

<211> 2695

<212> DNA

<213> Homo sapien

<400> 185

gaaaaaaaaa	aagaaaaaaaa	acaaaaaaaa	aaaaatacat	cacaataaga	ggccgaatgt	60
aaataaagac	gagggacgca	gaggggtggc	cgtggctgag	aggagacagc	gccgcagcac	120
tgagggtttg	ggcttgacag	cgctgcagga	gacgcccagg	cggagtcttg	tctcgcagcc	180
agctctgagc	gggaggcctg	agcgggaagc	attggcgtcc	gagcgacttc	taggagcctg	240
gggttcggcg	ctatggagga	gctcgatggc	gagccaacag	tcactgtaag	ggtaccccga	300
acaggcttgc	tcgtccttgc	gggttgagaa	ctgcgtctgc	ttagttactt	caggcttgtc	360
tgcttcccta	gtggtcgcga	ggcgctcgtc	cccttccctc	gactcagttg	ccacttttcc	420
ggaggtcgca	gtgttaacga	gttgattcca	ggcgtgaatt	ccaagaagaa	ccaaatgtat	480
tttgactggg	gtccagggga	gatgctggta	tgtgaaacct	ccttcaacaa	aaaagaaaaa	540
tcagagatgg	tgccaagttg	cccctttatc	tatatcatcc	gtaaggatgt	agatgtttac	600
tctcaaactc	tgagaaaact	cttcaatgaa	tcccatggaa	tctttctggg	cctccagaga	660
attgacgaag	agttgactgg	aaaatccaga	aaatctcaat	tggttcgagt	gagtaaaaac	720
taccgatcag	tcatcagagc	atgtatggag	gaaatgcacc	aggttgcaat	tgctgctaaa	780
gatccagcca	atggccgcca	gttcagcagc	caggtctcca	ttttgtcagc	aatggagctc	840
atctggaacc	tgtgtgagat	tctttttatt	gaagtggccc	cagctggccc	tctcctcctc	900
catctccttg	actgggtccg	gctccatgtg	tgcgagggtg	acagtttgtc	ggcagatggt	960
ctgggacagt	agaatccaag	caaacatgac	agcttctgga	acttgggtgac	catcttggtg	1020
ctgcagggcc	ggctggatga	ggcccagacg	atgctctcca	aggaagccga	tgccagcccc	1080
gcctctgcag	gcatatgccg	aatcatgggg	gacctgatga	ggacaatgcc	cattcttagt	1140
cctgggaaca	cccagacact	gacagagctg	gagctgaagt	ggcagcactg	gcacgaggaa	1200

194

tgtgagcggg acctccagga cagcacattc gccaccagcc ctcacctgga gtctctcttg 1260
 aagattatgc tgggagacga agctgccttg ttagagcaga aggaacttct gagtaattgg 1320
 tatcatttcc tagtgactcg gctcttgtag tccaatccca cagtaaaacc cattgatctg 1380
 cactactatg cccagtccag cctggacctg tttctgggag gtgagagcag cccagaaccc 1440
 ctggacaaca tcttggtggc agcctttgag tttgacatcc atcaagtaat caaagagtgc 1500
 aggaataaaa cagatttgag cagaagaagt ctggttgatg cagggagtat aaaaggggaa 1560
 agcatcctgc tgtttccagt ggcagaagag aaagagaagt accatgaaga ggggtgaa ca 1620
 acatcactct cgtgccggac acagacaagg aatgattagg cttgcagtcc cccagtct ca 1680
 gcctctctcc actctcacia gcaggaaggg atctgagctc tgttagtggg aaatcttgga 1740
 gtttgcatth ctctgatcac gaggtacct cctatcctgt tttgaaagag gaacagaaaa 1800
 gcagagcttg tcccaggaat tgtgaaatgg gctgcaatgt cttcagaggc agtagcagtt 1860
 ttaggaagtg tgccctcctg cctctgggga aaggttgaat tgggggtctg tgggcacttg 1920
 ttttctcatg ggatgtatca gtcagaccga tgcacagttc tgggcggcag ggaagtgtgt 1980
 ctctttctgg acttgagcca gtgagctgtt ggcatgcctt tttaaaggca ttagaaaaaa 2040
 ggtttctttc ttttttttcc tttcctgttc acaccacctt catatgaaca tggagaaggg 2100
 aggtttctaa gtgggcccct gatttactcc tatgtcaata atcgtgccag accctaaggg 2160
 gcagaaaagg cagccagggg atcctgactc agaggctgta gttcgtcagc cctgctaaag 2220
 ggccaggggt ttgtctctca gtgcctgggt gggcatgctt gactgctaac cccttagctg 2280
 aaaggagatg gcaggagtcc tccacagggg cccttcttcc ctcttggtt acagcttctct 2340
 ctgaagacgg gccagttcct tgctgtctgg caagaggaaa cagctggggg gcacttca ct 2400
 gggagtggg caagatgtcg gcagtttctt ggtgcccttc aagtcctcca aaagtatcga 2460
 gctaaaagca tcgccctgag caactgggtg tttgtggccc acctgacaga cctgctggac 2520
 cactgcaagc tctccagtc acacaacctc tatttcgggt ccaacatgag agagttctct 2580
 ctgctggagt acgcctcggg actgtttgct catcccagrc ctgtggctgc ctgggggtcc 2640
 ggctgtctgg tactagcttt ttcataccgg cgctcgcgg gggccctttt acgcg 2695

<210> 186

<211> 2267

<212> DNA

<213> Homo sapien

<400> 186

gaaaaaaaaa aagaaaaaaaaa acaaaaaaca aaaaatacat cacaataaga ggccgaatgt 60

aaataaagac gagggacgca gaggggtggc cgtggctgag aggagacagc gccgcagcac 120

195

tgaggggtttg	ggcttgcagg	cgctgcagga	gacgcccagg	cggagtcttg	tctcgcagcc	180
agctctgagc	gggaggcctg	agcgggaagc	attggcgtcc	gagcgacttc	taggagcctg	240
gggttcggcg	ctatggagga	gctcgatggc	gagccaacag	tcactgtaag	ggtaccccga	300
acaggcttgc	tcgtccttgc	gggttgagaa	ctgcgctctgc	ttagttactt	caggcttgtc	360
tgcttcccta	gtggtcgcga	ggcgctcgtc	cccttccctc	gactcagttg	ccacttttcc	420
ggaggtcgca	gtgttaacga	gttgattcca	ggcgtgaatt	ccaagaagaa	ccaaatgtat	480
tttgactggg	gtccagggga	gatgctggta	tgtgaaacct	ccttcaacaa	aaaagaaaaa	540
tcagagatgg	tgccaagttg	cccctttatc	tatatcatcc	gtaaggatgt	agatgtttac	600
tctcaaactc	tgagaaaact	cttcaatgaa	tcccatggaa	tctttctggg	cctccagaga	660
attgacgaag	agttgactgg	aaaatccaga	aaatctcaat	tggttcgagt	gagtaaaaac	720
taccgatcag	tcatcagagc	atgtatggag	gaaatgcacc	aggttgcaat	tgctgctaaa	780
gatccagcca	atggccgcca	gttcagcagc	caggtctcca	ttttgtcagc	aatggagctc	840
atctggaacc	tgtgtgagat	tctttttatt	gaagtggccc	cagctggccc	tctcctcctc	900
catctccttg	actgggtccg	gctccatgtg	tgcgagggtg	acagtttgtc	ggcagatgtt	960
ctgggcagtg	agaatccaag	caaacatgac	agcttctgga	acttggtgac	catcttggtg	1020
ctgcagggcc	ggctggatga	ggcccagacag	atgctctcca	aggaagccga	tgccagcccc	1080
gcctctgcag	gcatatgccg	aatcatgggg	gacctgatga	ggacaatgcc	cattcttagt	1140
cctgggaaca	cccagacact	gacagagctg	gagctgaagt	ggcagcactg	gcacgaggaa	1200
tgtgagcggg	acctccagga	cagcacattc	gccaccagcc	ctcacctgga	gtctctcttg	1260
aagattatgc	tgggagacga	agctgccttg	ttagagcaga	aggaacttct	gagtaattgg	1320
tatcatttcc	tagtgactcg	gctcttgtag	tccaatccca	cagtaaaacc	cattgatctg	1380
cactactatg	cccagtccag	cctggacctg	tttctggggag	gtgagagcag	cccagaaccc	1440
ctggacaaca	tcttgttggc	agcctttgag	tttgacatcc	atcaagtaat	caaagagtgc	1500
aggaataaaa	cagatttgag	cagaagaagt	ctggttgatg	cagggagtat	aaaaggggaa	1560
agcatcctgc	tgtttccagt	ggcagaagag	aaagagaagt	accatgaaga	ggggtgaaca	1620
acatcactct	cgtgccggac	acagacaagg	aatgattagg	cttgcagtcc	cccagtctca	1680
gcctctctcc	actctcacia	gcaggaaggg	atctgagctc	tgttagtggg	aaatcttgga	1740
gtttgcattt	ctctgacac	gaggctacct	cctatcctgt	tttgaaagag	gaacagaaaa	1800
gcagagcttg	tcccaggaat	tgtgaaatgg	gctgcaatgt	cttcagaggc	agtagcagtt	1860
ttaggaagtg	tgccctcctg	cctctggggg	aaggttgaat	tggggctctg	tgggcacttg	1920
ttttctcatg	ggatgtatca	gtcagaccca	tgacacagttc	tgggcggcag	ggaagtgtgt	1980

196

ctctttcttg acttgagcca gtgagctggt ggcattgcctt tttaaaggca ttagaaaaaa 2040
ggtttctttc ttttttttcc tttcctgttc acaccacctt catatgaacg atgatgacat 2100
agagaccacc aaggtggaaa tgctgagact ttctctggca cgaaatcttg ctctgggcaat 2160
tataagagaa ggctcactgg aagggttcctg agaactgctt caatgtggta tctttgtatg 2220
gcaatgtata tagatttttt aaaagaataa atgttggttt gcaaatg 2267

<210> 187
<211> 548
<212> DNA
<213> Homo sapien

<400> 187
ggctctgaat tcctgacctc gtgatctgcc tgccttggcc tcccaaagtg ctgggattat 60
aggcaagagc caccatgccc ggccacagaa aattttttta gagtagattc acttttggag 120
atgatcataa tagatgttaa attttttttt tctgttttgt ttcagaaaaa tcagagatgg 180
tgccaagttg cccctttatc tatatcatcc gtaaggatgt agatgtttac tctcaaactc 240
tgagaaaact cttcaatgaa tcccatggaa tctttctggg cctccagaga attgacgaag 300
agttgactgg aaaatccaga aaatctcaat tggttcgagt gagtaaaaac taccgatcag 360
tcatcagagc atgtatggag gaaatgcacc aggttgcaat tgctgctaaa gatccagcca 420
atggccgcca gttcagcagc caggtctcca tttgtcagc aatggagctc atctggaacc 480
tgtgtgagat tctttttatt gaagtggccc caggtaggca tggaatatct caccataatc 540
tcataggt 548

<210> 188
<211> 1359
<212> DNA
<213> Homo sapien

<400> 188
gaaaaaaaaa aagaaaaaaaa acaaaaaaca aaaaatacat cacaataaga ggccgaatgt 60
aaataaagac gagggacgca gaggggtggc cgtggctgag aggagacagc gccgcagcac 120
tgagggtttg ggcttgacag cgctgcagga gacgcccagg cggagtcttg tctcgcagcc 180
agctctgagc gggaggcctg agcgggaagc attggcgtcc gagcgacttc taggagcctg 240
gggttcggcg ctatggagga gctcgatggc gagccaacag tcaactgtaag ggtaccccca 300
acaggcttgc tcgtccttgc gggttgagaa ctgcgtctgc ttagttactt caggcttgtc 360
tgcttcctta gtggtcgcga ggcgctcgtc cccttccttc gactcagttg ccacttttcc 420
ggaggtcgca gtgttaacga ggtgcccggc ctagggtcgc agtggtcgcg gggtttctgc 480

197

```

caccagtcac aaaccccggc ctggaaggtc ccactccgtc cctttccttc ctttgtgttc 540
ctggcctttt tacttccctt gcttttcctc ttgggcatta gagtgggttc agcccaagca 600
gaggaattta tatttttatt ccagccgtat taagctctgc atcgcggcac attgagcttc 660
tgccctgtgtg gcctaagggtt tattcaacgt attatctcag gagactattc ctgttttatac 720
gctgtgcatt caattccatt tgaactttga agacagtatg tcaactgtgg atgatctgtg 780
atgtgtataa aaaaaattca cgcgcttttt tccaaagatg gttttgggaa catcactagt 840
taaagaggaa ggagctagca ggaggggcaa aaaaaggag gttaggcagt gaggaggcaa 900
atgattacat tcttgtgagt cggtgattag cctcagtaaa tctgcatttt acctgtgaaa 960
agagggagca gaggaaaatt ttatgtatgc attcatctca gggtaggtag agggattatg 1020
gttattatta ctgttatttt ttagacggag tctcgctctg tctcccaggc tggagtgcag 1080
tggcgcggtc tcggctcact gtaacctccg cctcccgggt tcacaccatt ctctgcctc 1140
agcctcctga gtagctggga ctacagggtc ccgccaccac gcccggttaa tttttgtac 1200
ttttttgtat ttttagtaga gacgggggtt caccgtgttg gccaggatgg tctcaatctc 1260
ctgacctcgt gatccgcca cctcggcctc ccaaagtgtt gggattacag gcgtgagcca 1320
ccgcaccggg ccgatttctg gtcttttact tgtgaagat 1359

```

```

<210> 189
<211> 415
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (277)..(300)
<223> n=a, c, g or t

```

```

<400> 189
ctttgctgat atttataatt tggatcata agaatgtttt cctctacagt atttgtcatg 60
ccagtttata acaaaaaaaaa atgcagggat tttatttcta tgggaaactt tacagctatg 120
ttttactttg ggacagaatt tttatttgta tagagtgtt actaattgtt aaatagttca 180
gagtatataa ctatttactt taaggactca tggtaggttt aagggtggaa atgagttggt 240
gtcatttcaa ttacaaagat aaaagtttgc catatannnn nnnnnnnnnn nnnnnnnnnn 300
tggtagtgta catagtagtc atcaagtctt ttgacagaag tatattttta aagaattcat 360
ctgtgatgaa tccataatgt ctggaacttt gctgagactt gagtgggccc agttt 415

```

```

<210> 190
<211> 1043
<212> DNA

```

198

<213> Homo sapien

<400> 190

```

ggtaggtttcc ttttttggca gccagttttg gttttgttga gcatgaaatc tctgctccct    60
taaaaaatta ttctcggaaa aagatatccc ccccgttttc caggttttga gccgcctctc    120
cttagggcct ggtcggggga ggaaaagttg taaacaaatt gccaccttaa attcgcggtg    180
cgagtctgcg gagctgccgg gttcattgtg ttacgaggc tcgctgaaat gtgtggaatc    240
caggggaaggc gagcaccag acggggggccc gccggggccg cggccagcgc cggggaaatg    300
ccgcgccggg gagcagcctg cgccggcctg agcccttccc ttgcaactcg gctgtttttt    360
acgtttaacc agaaaggaag ggagaggagg gaaagatcca tgtggctgcc ctcttccgat    420
caciaaatatt gtcgtaagtt gcagctggct gcccacttc ctaattcagc tcacacagcc    480
tctccccacg ctatggaaat gcgtcgggag tgaactccgg cggccgcgct caccacgtgg    540
atccccactt actaccattc tcggcggggg tccagttggg ggaaccgcga atatgttggt    600
ccaaagagcg ctgccccta gcgccgtcc ccgaggggtga tggacagagc aggactgggt    660
tgctggctcc tgaaccttgg gctccatcgc tgggattacg cagccccctcc cttctcagct    720
ctgggggtgaa tattgtctgt gtcgagtggg ttctctctcc tctacctcg cttcctcttc    780
tgtattgcag cccagtgcc ccaagtcgct cagggatccc gcgggtgggg gcgccctgat    840
gtccccgagg tgcagctccc acgctgcggc ccggctttat gaccgagccc cccatgacgc    900
tcagatccgc cggggctgca gtctcgaggg cgagtccgtg tgccgcggcc acccgcgccc    960
ccacggctgt tgggggctca ccgggcgggt gcgcgcaagc gggcgtgggc gcgcgggccc   1020
cgactccccg gcgctcactc ctc                                     1043

```

<210> 191

<211> 955

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (564)..(588)

<223> n=a, c, g or t

<400> 191

```

cggctcgagg tgacacgcag cccacggctt gtactgacgc gccctcgctt cttcctcttt    60
ctcgactcca tcttcgcggt agctgggacc gccgttcagt cgccaatatg cagctctttg    120
tccgcgcccc ggagctacac accttcgagg tgaccggcca ggaaacggtc gccagatca    180
aggctcatgt agcctcactg gagggcattg ccccggaaga tcaagtcgtg ctctggcag    240
gcgcgccccct ggaggatgag gccactctgg gccagtgcgg ggtggaggcc ctgactaccc    300

```

199

tggaagtagc aggcgcgatg cttggaggta aagtccatgg ttccctggcc cgtgctggaa	360
aagtgagagg tcagactcct aaggtgagtg agagtattag tggatcatggg gttaggactt	420
tttttccttt cacagctaaa ccaagtcctt gggctcttac tcggtttgcc ttctccctcc	480
ctggagatga gcttgagggg agggatgcta ggtgtggaag acaggaacca gggcctgatt	540
aaccttcctt tctccagggt gccnnnnnnnn nnnnnnnnnn nnnnnnnnca ggtcgggcta	600
agcggcggat gcagtacaac cggcgctttg tcaacgttgt gccaccttt ggcaagaaga	660
agggcccaat gccaaactctt aagtcttttg taattctggc tttctctaata aaaaaagcca	720
cttagttcag tcatcgcatg gtttcatctt tacttgcaag gcctcaggca gaggtgtgct	780
tctcgcggtt ggtggatgtg ccccttagga gaacagtga gcagaaaagg cagaagcctt	840
tggatgggg ggcagaaatg tgtcaactac aagagaaatt tcctgttgat gaaacagcta	900
cagatcctgg ggggcttcag atgtacaatt ggggttattc ccctatccct aagta	955

<210> 192
 <211> 260
 <212> DNA
 <213> Homo sapien

<400> 192	
aattcaagct tctaacgatg tacggggaag gtaaagtcca tggttccctg gcccggtgctg	60
gaaaagtga aggtcagact cctaagggtg ccaaacagga gaagaagaag aagaagacag	120
gtcgggctaa ggcgcggatg cagtacaacc ggcgctttgt caacgttgtg cccacctttg	180
gcaagaagaa gggccccaat gccaaactctt aagtcttttg taattctggc tttctctaata	240
aaaaaagcca cttagttcag	260

<210> 193
 <211> 187
 <212> DNA
 <213> Homo sapien

<400> 193	
aacacaccgt gaactcaaga ttcttccagt gcgagatgtc acctgtagtg gtacgaagta	60
aactcatgca gatgcagcat tcctgcgtct gtggggaccc tctggccgga gggctccctg	120
gtgtgcttcc tgcacaccgt ggacagggtga ctgtatggta tgagactgtg atcggtggga	180
actttttg	187

<210> 194
 <211> 2206
 <212> DNA
 <213> Homo sapien

200

<220>

<221> misc_feature

<222> (1423)..(1725)

<223> n=a, c, g or t

<400> 194

ggagagcgcg ccgcggccct ttatagcgcg cggggcaccg gctccccaag actgcgagct	60
ccccgcaccc cctcgactc cctctggccg gccagggggc gccttcagcc caacctcccc	120
agccccacgg gcgccacgga acccgctcga tctcgccgcc aactggtaga catggagacc	180
cctgcctggc cccgggtccc gcgccccgag accgcccgtc ctcggacgct cctgctcggc	240
tgggtcttcg ccaggtggc cggcgcttca ggcactacaa atactgtggc agcatataat	300
ttaacttggg aatcaactaa tttcaagaca attttggagt gggaaaccaa acccgtcaat	360
caagtctaca ctgtgtcaaa taagcactaa gtcaggagat tggaaaagca aatgctttta	420
cacaacagac acagagtgtg acctcaccga cgagattgtg aaggatgtga agcagacgta	480
cttggcacgg gtcttctcct acccggcagg gaatgtggag agcaccgggt ctgctgggga	540
gcctctgtat gagaactccc cagagttcac accttacctg gagacaaacc tcggacagcc	600
aacaattcag agttttgaac aggtgggaac aaaagtgaat gtgaccgtag aagatgaacg	660
gacttttagtc agaaggaaca acactttcct aagcctccgg gatgtttttg gcaaggactg	720
aatttataca ctttattatt ggaaatcttc aagttcagga aagaaaacag ccaaaacaaa	780
cactaatgag tttttgattg atgtggataa aggagaaaac tactgtttca gtgttcaagc	840
agtgattccc tcccgaacag ttaaccggaa gagtacagac agcccggtag agtgtatggg	900
ccaggagaaa ggggaattca gagaaatatt ctacatcatt ggagctgtgg tatttgtggg	960
catcatcctt gtcatcatcc tggctatatc tctacacaag tgtagaaagg caggagtggg	1020
gcagagctgg aaggagaact cccactgaa tgtttcataa aggaagcact gttggagcta	1080
ctgcaaattgc tatattgcac tgtgaccgag aacttttaag aggatagaat acatggaaac	1140
gcaaattgagt atttcggagc atgaagaccc tggagttaa aaaactcttg atatgacctg	1200
ttattaccat tagcattctg gttttgacat cagcattagt cactttgaaa tgtaacgaat	1260
ggtactacaa ccaattccaa gttttaattt ttaacaccat ggcacctttt gcacataaca	1320
tgcttttagat tatatatccc gcactcaagg agtaaccagg tcgtccaagc aaaaacaaat	1380
gggaaaatgt cttaaaaaat cctgggtgga cttttgaaaa gcnnnnnnnn nnnnnnnnnn	1440
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn	1500
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn	1560
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn	1620

201

nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn 1680
nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnnnnnnn nnnnnngaaaa gcttttgagg 1740
ggctgacttc aatccatgta ggaaagtaaa atggaaggaa attgggtgca tttctaggac 1800
ttttctaaca tatgtctata atatagtgtt taggttcttt tttttttcag gaatacattt 1860
ggaaattcaa aacaattggc aaactttgta ttaatgtgtt aagtgcagga gacattggta 1920
ttctgggcac cttcctaata tgctttacaa tctgcacttt aactgactta agtggcatta 1980
aacatttgag agctaactat atttttataa gactactata caaactacag agtttatgat 2040
ttaaggtact taaagcttct atgggtgaca ttgtatatat aattttttta aaaggttttc 2100
tatatgggga ttttctattt atgtaggtaa tattgttcta tttgtatata ttgagataat 2160
ttatttaata tacttttaaat aaaggtgact gggaattgtt aaaaaa 2206

<210> 195
<211> 600
<212> DNA
<213> Homo sapien

<400> 195
cacagcggga cgacgagcga aacagcagtc aacagagagc agcatactat cacgatctac 60
gctccagccc aactagaata cagccaagca cgccaccggt acaggaacga gaaatgcgag 120
acgagcagag aactcacagc tcaccaccaa acgagacgcg cacaacatcc cgcgccaact 180
cccacacagc aaatacaagg gcgactaaac aggacaagcg agaacagaca ccactgcttg 240
aagccaaaca aaggggacaa caagagcaaa gaacacacgc gaaaccacgc aaccatagag 300
cccgagctc tgcagggcag ttagaaacac caaaaagggc atacagcacc cccacaggac 360
agcaaagaca atcaacagac acaaccagaa cgcagacaca agaaaagaaa gatagggaga 420
aacacccgcg aaccaggaca aaaacaacaa caacacagga cggaacaccc cacaggacaa 480
caactaccac agctagcgca agacaactgg acacaaaccc agagacaggc tccgccgcga 540
cacgccgcca agcaaaaacc acatacagag aagcaagaga gcacaacaca agacacacaa 600

<210> 196
<211> 4213
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (1239)..(1239)
<223> n=a, c, g or t

<220>
<221> misc_feature

202

<222> (1253)..(1253)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (1259)..(1259)
 <223> n=a, c, g or t

<400> 196
 gaagactcta tgctggaact tggatcctca tcatttatat atataagatc ttttggcatt 60
 tcttttaaact gatacaccaa gcgctgacct tccacttttg ccagaatacc cctttggtaa 120
 tagtacctga gtgctcttcc catggtctca taattcatat caggtttggt tttgtgcttc 180
 cccacaacc tggacactgc tttagaatcc accaatttaa aaatgccttt ctctcgctgg 240
 gtccacttga tgtatttagg acaagtagcc ttgtcctgga gcagtgccag taaaaactcc 300
 caaagataaa ttgtgtttcc ctttcgctct ttgtttttct tcttcacaga tatatttggc 360
 gtagtggctg gggaaatctgg tcgtgggtgg ttagtttttc ttcctttttt cctcttaggc 420
 tgttctgggtg atgaggctcc cggtgagtct gcataatttt cttgcacctg ctgtgtttcc 480
 atcacttcag gaatcccatc taatgtgacg gacacatggg tgactggggc aacaacctatg 540
 tcactctcag gtgaactaaa tatattatta tttattcgtt tttcatccag catagggcca 600
 ggggaatcca tattgaggag tgcctcagca gcctcaatag tttcaattgt ttcacccccg 660
 tcatgacaag aagcttcaac tgtaagggtg atgtcatcat catcatcgtc tatgatttct 720
 tcttcagcaa catccagtga actctcagta atcatgtcac tgggctcttc cacacaggct 780
 agaccggcat aactattgag aatatcagca ccaggaacat gttccacaat tacggcagga 840
 aaaatagctg gatcaccaag ctgtcgttca tcctccatga cgttactagc aaattcaaatt 900
 actaggctcg tctgttggac aacagcagcc ataataaagc attcccctta gatccacatg 960
 agaaaaattc caagaagatt cacgtatcag gcagcaaaat ccagtgactg atttgggtaa 1020
 aaaaccctca gctctgtctg tggagtaatt gtatacccaa gttttcttta gggaagggtgc 1080
 ttcagttttc ctgggttcatt gatattctag tcaaattgag acaatttttc tgaaattttt 1140
 cttctctcaa gcttcttggc ctgacaagca taagtgcctc tgccctcctc gccgcacctc 1200
 tcgccaccgc cgcctctgcg ctactgaagc tgctgcttnt tgccgccgcc gcngccgcng 1260
 ccgccgctgc tgcccacacg ctcccgagct agggacaacag ccccatccga gcgcgtgggc 1320
 gtcgtagggg agaggagggg cggggccgct ccgctgcaac agcaaagttt gaggcgaagc 1380
 ctagcgactc gcagcgccgg tcccgcagtt tcacctcttt tttttttaac tccgccagag 1440
 gaccccgacc cacaggctcc ggttgctccg ctgggtcaaag tgcgtgcgga gtagttggca 1500

203

aagttgagag	cggagacgtc	tctgggaaca	gctgttttgcg	ttccggggcgg	aggcggcgcg	1560
ctgagctcct	tggccttgag	ccagcgagcc	tagaaggagg	atggagggttt	tgggccccag	1620
gggaggacac	agagacggcg	ggatggcgca	gggacttgag	gcttgagatc	ccgtccttca	1680
gctcaggtec	cgtcgcgctt	ttaccccttc	ccggtgacct	caaccctttt	ataccgaccc	1740
cacctctttg	gagccgggag	taccggccct	gtagggggag	gggagaggag	gcgatttcga	1800
acgcggattg	gatcgtctgg	gcacccgtag	ttgggaacag	cggaacgctg	gtcccgggga	1860
ctgagtaagg	tgtctggatc	ggagggagggt	tcgggtgggc	atcggggcggc	tggaagagct	1920
cgactcgtcc	cgtctgggaaa	gcgcgagtct	gagtggaaacc	ctggacgact	tgcagagcgg	1980
ctggcgcagt	catggcggac	tactggaagt	cacagccaaa	gaaattctgt	gattactgca	2040
agtgctggat	agcagacaat	aggcctagtg	ttgaattttca	tgaaagagga	aagaatcata	2100
aggaaaatgt	ggcaaaaagg	atcagtgaga	ttaaacagaa	aagcctggat	aaggcaaagg	2160
aagaagaaaa	ggcatcaaag	gagttttgctg	caatggaggc	agctgccctg	aaagcatacc	2220
aagaggattt	gaaaagactt	ggcttagagt	cagaaatttt	ggagccaagc	ataacaccag	2280
taaccagcac	tatcccacct	acctcgacat	caaataca	gaaagaaaag	aaagacaaga	2340
agaaaagaca	aaaagatcct	tcaaaaggca	gatgggtaga	aggcataacc	tctgagggtt	2400
accattacta	ttatgatctt	atctcaggag	catctcagtg	ggagaaacct	gaaggatttc	2460
aaggagactt	aaaaaagaca	gcagtgaaga	ccgtttgggt	agaaggttta	agtgaagatg	2520
gttttaccta	ttactataat	acagaaacag	gagaatccag	atgggagaaa	cctgatgatt	2580
tcatccaca	cactagtgat	ctgccttcta	gtaagggtcaa	tgaaaattca	cttggcaccc	2640
tagatgaatc	caaatcatca	gattcgcata	gtgattctga	tggggaacag	gaagcagaag	2700
aaggaggggt	ctctacagag	acagaaaagc	caaaaataaa	gtttcaggaa	aaaaataaaa	2760
atagtgatgg	aggaagtgac	ccagaaacac	agaaagaaaa	aagtattcag	aaacagaatt	2820
cattagggtc	aatgaagaa	aatcgaaaa	ctcttaagaa	atcaaaccga	tatggagaat	2880
ggcaagaaat	taaacaagag	gttgagtctc	atgaggagggt	agatttggaa	cttccaagca	2940
ctgaaaatga	gtatgtatca	acttcagaag	ctgatgggtg	cggagaacct	aaagtgggat	3000
ttaaagaaaa	aacagtcact	tctcttggag	ttatggcaga	tggagtggcc	ccagtcttca	3060
aaaagagaag	aactgaaaat	ggaaaatcta	gaaatttaag	gcaacgagggt	gatgatcaat	3120
agttgcagga	gagctttttg	tacatgcttt	taggacagaa	tggagactta	tacacccaaa	3180
gtttatctgt	gtttgtttgt	aagtattatg	atgctaaaaa	tttagattta	ttctaaatgt	3240
atttgatgtg	aattaaaata	aatatttttt	catgtgaaat	ttattttgggt	tcctaaaatg	3300
gaagcctacc	acattgcatt	gtaatacagt	gtattatggt	cagtgtctaa	aaactgctaa	3360

204

```

ttaagtcata atttaagatg ctatgtatct gttattttaa acatggagaa acagggcctt 3420
tattccattc atattcataa gagcatatct atcctgcatt gaaaatgcat tacttttgca 3480
cattgatatt aactgttgtc caacaaataa gtatcggagt acgtgagaat attcccagcc 3540
cagtgatgat ttggttctga ggctgatgtg agaaagctga tgtaaaaaat gtatgcatat 3600
tggcttacct tactcaatct aaagtcaaaa gccaacagcc aggagcagct caggtacttc 3660
agatgtgctt /aatatggagt gaaaactgga ccagaggtgg aaagatgtat ttgccccagt 3720
tcacttcaaa gcagcaaacg ttgtttaagc attttagttt gaaccaggca ttgtgttagg 3780
aatccaggga taaagatgaa tgaaatgtat ttctgttctt caggagtcca cattctagca 3840
tatgcctttt tccccccagt catgcactct ttttagcagt cttatatgta ctagaaaaga 3900
tttttttaaag tttattttaa gctgtgtaga tgaaggcttg atctaaaata gtataaggtc 3960
tccagcttca gtaaaagttt ttagtgttta cttaaattag taatttctca ctttctgtct 4020
ggttaaaatg tcttaaaaag tagaattttc ttctttaatc cgtttagtag ttacctccct 4080
tttacttttc aaattcacaa aattacattt ctcataaatt gtatagtatt taacttataa 4140
tagttaatat ttgtcttttt aagatgactg tacatgtaag aaaaaagctt attaaaaact 4200
tgatcaaaga ata 4213

```

```

<210> 197
<211> 6537
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (3557)..(3557)
<223> n=a, c, g or t

```

```

<220>
<221> misc_feature
<222> (3571)..(3571)
<223> n=a, c, g or t

```

```

<220>
<221> misc_feature
<222> (3577)..(3577)
<223> n=a, c, g or t

```

```

<400> 197
tttttatatg atttatttaa taataaacca attaaagata caaaaatggt tagaggattc 60
caaaatttaa atttttgttt aaatacaaat tcactctgta atatgaaaac atagcattag 120
acctctaaac ataatgattt ttttcatcta caaaaatttc tgttatacta gaaaatttgc 180

```

205

agaagacatt	tttttcttgt	gacattaaat	gtacattatt	tacagttgaa	aagtaatcta	240
aaaacatttc	atttcagaaa	gttggatata	tatgttatct	ttgatatgca	acccccccaa	300
gtccgcccc	agtaaaaaat	gatccaaaat	ataaagcaat	tatgctttta	taactgacta	360
ctcagccaga	ttagcccaag	gctcaagttg	ctttcttggc	ccttaagaaa	gagtcttgac	420
tctctcaaaa	tagcagtatt	ctgttttagca	ccttagcaaca	caagtttact	aatggaccgc	480
aaagcacagt	ggcctaaaga	gttagtaaac	aaattattta	ggaagaattt	atggcagatc	540
ttgacccata	acagatgaat	aaattttgtt	gggtcactta	tttctctgca	acatttttagc	600
tatcttacat	taggaaataa	cctgataatg	atttaattga	cataacttga	aaatataggt	660
attagaatta	aaaaaattag	aactagaaga	gaaagtgggtg	atcatctagt	ctaatccaat	720
acatctcttc	cttttatgag	aggaactaaa	gcccaaagag	gtcaagatta	catagctagt	780
tagtgggagt	gccattctta	ggctgatgct	tttatactat	cctgcttctg	aaacagggtc	840
agccatacca	ccagcacctc	caatttttca	tgttattcta	catattcata	gttctatatt	900
atatagtgca	gtcaactaaa	gtcaatctaa	gtgacaccat	aattttaaca	aagcataaaa	960
taggtttttt	gcatttgaaa	gagtcaagac	ttaacttaca	caagtggaaat	gaaaatagtt	1020
cctatataaa	tttcctgttg	ccttctattt	aagttctgta	tttacaaaag	aatcagaaaa	1080
tctaatacaa	tgtaaaatta	gaaaagaaac	tttaaaaatg	cttatgatat	agcaactgaa	1140
ataaaaatct	caaaagaatg	tcttcatagt	gtaaaatgcc	tgttccttca	cgattgaatt	1200
ctgaaacatt	tagataacaa	agagaaacag	ttgagttttc	ctccctcatc	taacaaagtc	1260
aaaattaact	ctatttttta	caattacaaa	attagaaacc	tccttagaat	ttatcttaga	1320
atcagtcagt	ctgcatataa	ttgaaaatgt	tcaattaaca	aacaattatt	cataagcttt	1380
ggtatatata	ctaaaaagag	ttgggttcca	gcagttcggt	ttgtttcata	gctacctgag	1440
aagtaaatac	attggaactg	gacactacca	tcacataagg	ctgtggctgc	tgctccgttt	1500
tctcagtgtt	ctctttcaaa	tgatcttcag	attccttttt	ctctacttcc	tgtgtaagag	1560
tttttgtttc	ttgagttttg	ataactgaag	tgattacagt	gccaggtggg	tgagcaacca	1620
gctgtgaact	gcgaggagaa	aaggtcacca	caggtgcagt	agcactgaag	gatggagagg	1680
aagccacact	gacggttcca	ttgcaaatgg	tctgaacatt	gctagtaagg	acctgctgaa	1740
cctgggcagg	gcccaagaca	attgaaggag	gagagcccg	cttttgtagc	tgacagcatga	1800
cattttcttt	cagtactgtc	atgggctgtg	atgatggaat	ggcttgtaaa	ataaacttct	1860
gagatccagt	acctgctgat	ggatctgtgc	tggctataac	tgttgtgagt	ggcactgttt	1920
ggagtgttac	tgtatgcaac	tgctgattcc	taggagacac	aaccactgga	acttgggttg	1980

206

gagcctgtat	agtcctaata	ctctgaacgg	aagaatttaa	tgtttcatcc	tgcattggtac	2040
tggttctagc	tgcttctccc	tctgggacag	cctgtactgg	ctgtactaca	tgaacagtcc	2100
ggaagagctg	ggtaggatat	ggagactgcg	tgggctgcac	tgtcctcaaa	acttctgatg	2160
gttgtgcaac	ttccacagga	tctttgggtt	ttgcagcttt	agaattccct	ggtttttagaa	2220
ctgaagtggc	tcctcctttt	acccctggac	ttgaagatac	tctcgaccgg	ctggtttgat	2280
tcctatttga	agtggctgat	gaagatagcg	atggatctga	agactctatg	ctggaacttg	2340
gacctcatc	atttatatat	ataagatctt	ttggcatttc	tttaaactga	tacaccaagc	2400
gctgaccttc	cacttttgcc	agaatacccc	tttggttaata	gtacctgagt	gctcttcca	2460
tggctctata	attcatatca	ggtttggttt	tgtgcttccc	ccacaacctg	gacactgctt	2520
tagaatccac	caatttaaaa	atgcctttct	ctcgctgggt	ccacttgatg	tatttaggac	2580
aagtagcctt	gtcctggagc	agtgccagta	aaaactccca	aagataaatt	gtgtttccct	2640
ttccgtcttt	gtttttcttc	ttcacagata	tatttggcgt	agtggctggg	gaatctggtc	2700
gtggtgggtt	agtttttctt	ccttttttcc	tcttaggctg	ttctgggtgat	gaggctcccg	2760
gtgagtctgc	atatttttct	tgcacctgct	gtgtttccat	cacttcagga	atcccatcta	2820
atgtgacgga	cacatgggtg	actggggcaa	caaccatgtc	atcttcagggt	gaactaaata	2880
tattattatt	tattcgtttt	tcatccagca	tagggccagg	ggaatccata	ttgaggagtg	2940
cctcagcagc	ctcaatagtt	tcaattgttt	catccccgtc	atgacaagaa	gcttcaactg	3000
taaggggtgat	gtcatcatca	tcatcgtcta	tgatttcttc	ttcagcaaca	tccagtgaac	3060
tctcagtaat	catgtcactg	ggctcttcca	cacaggctag	accggcataa	ctattgagaa	3120
tatcagcacc	aggaacatgt	tccacaatta	cggcaggaaa	aatagctgga	tcaccaagct	3180
gtcgttcatc	ctccatgacg	ttactagcaa	attcaaatac	taggtcgttc	tgttggacaa	3240
cagcagccat	aataaagcat	tccccttaga	tccacatgag	aaaaattcca	agaagattca	3300
cgtatcaggc	agcaaaatcc	agtgactgat	ttgggtaaaa	aaccctcagc	tctgtctgtg	3360
gagtaattgt	ataccaagt	tttcttttagg	gaagggtgctt	cagttttcct	ggttcattga	3420
tattctagtc	aaattgagac	aatttttctg	aaatttttct	tctctcaagc	ttcttggcct	3480
gacaagcata	agtgcctctg	cctccttcgc	cgcacctctc	gccaccgccg	cctctgcgct	3540
actgaagctg	ctgcttnttg	cgcgcgcgcg	ngccgcngcc	gccgctgctg	cccacacgct	3600
cccgagctag	ggaacaagcc	ccatccgagc	gcgtgggcgt	cgtaggggag	aggaggggag	3660
gggcgcgtcc	gctgcaacag	caaagtttga	ggcgaagcct	agcgactcgc	agcgccggtc	3720
ccgcagtttc	acctcttttt	tttttaactc	cgcagagagga	ccccgaccca	caggtcccgg	3780
ttgctccgct	ggtcaaagtg	cgtgcggagt	agttggcaaa	gttgagagcg	gagacgtctc	3840

tgggaacagc	tgtttgcgtt	ccgggcggag	gcggcgcgct	gagctccttg	gccttgagcc	3900
agcgagccta	gaaggaggat	ggaggttttg	ggccccaggg	gaggacacag	agacggcggg	3960
atggcgcagg	gacttgaggc	ttgagatccc	gtccttcagc	tcagggtccc	tcgcgccttt	4020
accccttccc	ggtgacctca	acccctttat	accgacccca	cctcttttga	gccgggagta	4080
ccggccctgt	agggggaggg	gagaggaggc	gatttcgaac	gcggattgga	tcgtctgggc	4140
acccgtagtt	gggaacagcg	gaacgctggc	cccggggact	gagtaagggt	tctggatcgg	4200
agggaggttc	gggtgggcat	cgggcggctg	gaagagctcg	actcgtccc	ctgggaaagc	4260
gcgagtctga	gtggaaccct	ggacgacttg	cagagcggct	ggcgcagtca	tggcggacta	4320
ctggaagtca	cagccaaaga	aattctgtga	ttactgcaag	tgctggatag	cagacaatag	4380
gcctagtgtt	gaatttcatt	aaagaggaaa	gaatcataag	gaaaatgtgg	caaaaaggat	4440
cagtgagatt	aaacagaaaa	gcctggataa	ggcaaaggaa	gaagaaaagg	catcaaagga	4500
gtttgctgca	atggaggcag	ctgccctgaa	agcataccaa	gaggatttga	aaagacttgg	4560
cttagagtca	gaaatttggg	agccaagcat	aacaccagta	accagcacta	tcccacctac	4620
ctcgacatca	aatcaacaga	aagaaaagaa	agaaaagaag	aaaagaaaaa	aagatccttc	4680
aaagggcaga	tgggtagaag	gcataacctc	tgagggttac	cattactatt	atgatcttat	4740
ctcaggagca	tctcagtggg	agaaacctga	aggatttcaa	ggagacttaa	aaaagacagc	4800
agtgaagacc	gtttgggtag	aaggtttaag	tgaagatggc	tttacctatt	actataatac	4860
agaaacagga	gaatccagat	gggagaaacc	tgatgatctc	attccacaca	ctagtgatct	4920
gccttctagt	aagggtcaatg	aaaattcact	tggcacccta	gatgaatcca	aatcatcaga	4980
ttcgcatagt	gattctgatg	gggaacagga	agcagaagaa	ggaggggtct	ctacagagac	5040
agaaaagcca	aaaataaagt	ttaaggaaaa	aaataaaaaat	agtgatggag	gaagtgaccc	5100
agaaacacag	aaagaaaaaa	gtattcagaa	acagaattca	ttagggttcaa	atgaagaaaa	5160
atcgaaaact	cttaagaaat	caaaccata	tggagaatgg	caagaaatta	aacaagaggt	5220
tgagtctcat	gaggaggtag	atgttgaact	tccaagcact	gaaaatgagt	atgtatcaac	5280
ttcagaagct	gatggtggcg	gagaacccaa	agtgggtattt	aaagaaaaaa	cagtcacttc	5340
tcttggagtt	atggcagatg	gagtggcccc	agtcttcaaa	aagagaagaa	ctgaaaatgg	5400
aaaatctaga	aatttaaggc	aacgaggtga	tgatcaatag	ttgcaggaga	gctttttgta	5460
catgccttta	ggacagaatg	gagacttata	cacccaaagt	ttatctgtgt	ttgtttgtaa	5520
gtattatgat	gctaaaaatt	tagatttatt	ctaaatgtat	ttgatgtgaa	ttaaaataaa	5580
tattttttca	tgtgaaattt	attttgggtc	ctaaaatgga	agcctaccac	attgcattgt	5640

208

```

aatacagtgt attatgttca gtgtctaaaa actgctaatt aagtcataat ttaagatgct 5700
atgtatctgt tatttataaac atggagaaac agggccttta ttccattcat attcataaga 5760
gcatatttat cctgcattga aaatgcatta cttttgcaca ttgatattaa ctgttgtcca 5820
acaaataagt atcggagtag gtgagaatat tcccagccca gtgatgattt ggttctgagg 5880
ctgatgtgag aaagctgatg taaaaaatgt atgcatattg gcttacctta ctcaatttaa 5940
agtcaaaagc caacagccag gagcagctca ggtacttcag atgtgcttaa tatggagtga 6000
aaactggacc agaggtggaa agatgtatct gccccagttc acttcaaagc agcaaacggt 6060
gtttaagcat tttagtttga accaggcatt gtgttaggaa tccagggata aagatgaatg 6120
aaatgtatct ctgttcttca ggagttcaca ttctagcata tgcctttttt ccccagtc 6180
tgcactcttt ttagcagctt tatatgtact agaaaagatt ttttaaagtt tatttaaagc 6240
tgtgtagatg aaggcttgat ctaaaatagt ataaggcttc cagcttcagt aaaagttttt 6300
agtgtttact taaattagta atttctcact ttctgtctgg ttaaaatgtc ttaaaaagta 6360
gaattttctt ctttaatccg tttagtagtt acctcccttt tacttttcaa attcacaaaa 6420
ttacatttct cataaattgt atagtattta acttataata gttaatatct gtctttttta 6480
gatgactgta catgtaagaa aaaagcttat taaaacttg atcaaagaaa aaaaaaa 6537

```

```

<210> 198
<211> 1853
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (502)..(502)
<223> n=a, c, g or t

```

```

<400> 198
gtcatcgatg tcatccacga ggtggccac agttgggtcg gcaacgctgt caccaacgcc 60
acgtgggaag agatgtggct gagcgagggc ctggccacct tatgcccagc gccgtatcac 120
caccgagacc tacggtgctg ccttcacctg cctggagact gccttccgcc tggacgccct 180
gcaccggcag tcgagtacct acccgaaacg accgcggggc agcggggcct tggtagccg 240
gtggagacgc aggcgaggac tccagcggga ggaagaagag gcctttgcca gcagtcagag 300
cagccaaggg gcccaatccc tcatattctc caagtttgaa ggaaagaaaa ccaacaagaa 360
gacccgcaag gttaccacag tgaagaaatc ttcagtagct cttccagggc tcggatcaaa 420
gaaggatatt gaaatggatt ccaggcgtgt gcctcgagac aagctggcct gcacaccaa 480
gtgcagcaag cacatcttgc gntgccatca agatcaccta gaacgagctg gcgtcagcag 540

```

209

```

atgacttccc tccccaccct catctacatt gttttgaagg gcaacccccca tgccttcagt      600
ctaatatcca gtatatcacg cgcttctgca atccaagccg acggcatgac tggagaggat      660
ggctactatt tcaccaatct ggtgagtaaa gtgagttctt ggcgttgtgg agaacggact      720
aggaaggtgg tggttttggg gatgtgatag gtcactcagg ccccatgaca ggtgaatgct      780
tctgtgtgag aaggcagcac ggctgaggaa gtcacttttg catcagggag cacaaggacc      840
caggccgtac agacactccg cctcccagca cttgatcaga gatttgtgtt atcctacaga      900
aacagatgac atgtgttggg catcactccc ccacggtcct gggtaggaaa gaggtccttc      960
cacttggcag ggctttttca accaatgaat aaggcaaatt atatataagg taattaatgc     1020
ccatttcgaa ccgagacaga tggcagctag aatgaagctt taatgtaaga gtaaagtaga     1080
agcaatgagt gctggggccc tttttattgg gtactggcat tctactttcg accacaaaag     1140
acgaagtgac cccaactttc aaggaacagg ctggttgagat ggaaggaaaag aaacaggagc     1200
tttgctcaag gaggagagct gggctttccc aagttacctg accttaaaga tgctgaagct     1260
gttccagaag tttctttcct tgaaggaaat acagcttggg gaagagttac tagctgcaag     1320
gtgaatatga gaaggggctg agacccatct gacaaatggg aattgctgtg tgtggacagc     1380
ccacagccag tttactgcag ggccttacag caaactcttc ccaccactag tgttcccaga     1440
tgcttttgac taagctccca acaattagag aattctaagt gctcagagct tggctgaaga     1500
tgatgtggaa tgagaaacaa atgttaacat aataaaatct cagttaaaaa tatttaaaaa     1560
attcttggtg gcttgagcag ctctggggga ataagggcaa atatgcttgt tatgaactac     1620
actgaaatct accaaagtta atgtttactt tgtgtagatc catttgtcta ttttatttat     1680
ttttcccagt gaaaagtgta ttttgataga gaacttttca ttcataataa tacactatga     1740
gttactgaaa attcatatca tggatttcat ttattcctga aacatagtta aaatgtacat     1800
atgacatggc ttatgttaaa aataccagct gctcaagttt tgaaagatag gca              1853

```

<210> 199

<211> 564

<212> DNA

<213> Homo sapien

<400> 199

```

ccccgcacgc gccccagcag cccagcaaac caaaccgcac gccggcacac caccaccacg      60
aaccaccgcg cgaccacaac cgccccccgg ggaggacacc ggccacagaa gagagggggc     120
ccaccgggtg gcacgaccgg aagcggagtg gcaccgggcg gaccaccgag tgagcaagac     180
gccagcgcag caactgcacg cggacaggga gcggaagacg cgcggcacaa gcggagggag     240
gccagcaccg aacagacaca acagagccga gcagaaggaa cgacggggcg ccgaaagaag     300

```

210

ctgacaaccg agcaacggag ccagacagcc agaagagggc gaaggatcgg gagtgcgagc 360
 ggacagcaca ggacgcaaaa gcagaaggag aagaggaggg aggaggagaa gaggggggag 420
 caagaaggta gcaaggcgaa accgcaggag agggggacgcg cgcagggaca gagcgagccg 480
 ccgcaagcaa gcccaccacg cgagagcgcg ggagcacgcc gcgcgacctg acgcacacac 540
 agccgcagtc gcacgcgcat ccgg 564

<210> 200
 <211> 277
 <212> DNA
 <213> Homo sapien

<400> 200
 accgacaggc acatatcaca gatacccagg cgtccaacac cccagagaca acgcgtcacg 60
 atacggtgca gcaactacac ttgtatccga gaacaccact gcacgacata aaccagggga 120
 taaccacagg accaggccat cacgctgcca ctttccgacg caaggcggtg ggaccggcaa 180
 caccgtcagt caagactaca cagaatgccg agcgaatcct ccacgacaca ggaccacagg 240
 gctccgagac ggcaccgaaa gacaggggctc ggcttgc 277

<210> 201
 <211> 674
 <212> DNA
 <213> Homo sapien

<400> 201
 cgtcgctggc gtctctccat aggcacccgc caccacaaga cgagcatccc caaccacacg 60
 acacgcacaa cgacaccctt cgccgacccc ccgcccccaa caccaacaat acccaaggct 120
 actccgcctt ggcactcccc cctcggcgac aatcctcctt gatccgcgag acgtgcagca 180
 tcactagggc cccacacgca ccacgaccga caccctcgctg cgcgcaacac gggcgagccc 240
 cgagtgactc aaccgccaac gcagtcaggc caaccacaca cacgacgacc cgctccgcac 300
 tggcgagccc accacgcaa gctcagcaac aaccacgacc ggctccgacc caacaccaag 360
 cgccacagca ccctgcagca cacgcccattg gcggctcgca gcgaggctac gagagagtgc 420
 cgacccagca gaggaggctg cgagcgaccg gggcctggcc aagcggcggg gctcgcccca 480
 cgcgtggacc gccccagcg cgaccggcgc gggccgcggg gacggcgccg gcgcctgtcg 540
 agacttgggc caacaggagg agcgcacacg cgcgggtagg caagccgaga cggcgaggcc 600
 gcgggctagc ggcattgacc cgccccgccc ccccgcacac acccgaccat gggccacagg 660
 cgggcgcggc cgaa 674

<210> 202
 <211> 955

211

<212> DNA
 <213> Homo sapien
 <220>
 <221> misc_feature
 <222> (564)..(588)
 <223> n=a, c, g or t

<400> 202
 cggctcgagg tgacacgcag cccacggctct gtactgaagc gccctcgctt cttcctcttt 60
 ctcgactcca tcttcgcggt agctgggacc gccgttcagt cgccaatatg cagctctttg 120
 tccgcgcccc ggagctacac accttcgagg tgaccggcca ggaaacggtc gccagatca 180
 aggctcatgt agcctcactg gagggcattg ccccggaaga tcaagtcgtg ctcttggcag 240
 gcgcgccccct ggaggatgag gccactctgg gccagtgcgg ggtggaggcc ctgactaccc 300
 tggaagtagc aggcgcgatg cttggaggta aagtccatgg ttccctggcc cgtgctggaa 360
 aagtgcgagg tcagactcct aaggtgagtg agagtattag tggatcatgg gttaggactt 420
 tttttccttt cacagctaaa ccaagtcctt gggctcttac tcggtttgcc ttctccctcc 480
 ctggagatga gcctgaggga agggatgcta ggtgtggaag acaggaacca gggcctgatt 540
 aaccttcctt tctccagggt gccnnnnnnn nnnnnnnnnn nnnnnnnnca ggtcgggcta 600
 agcggcggat gcagtacaac cggcgctttg tcaacgttgt gccaccttt ggcaagaaga 660
 agggcccaat gccactcctt aagtcttttg taattctggc tttctctaata aaaaagcca 720
 cttagtctcag tcatcgcatg gtttcatctt tacttgcaag gcctcaggca gaggtgtgct 780
 tctcgcgggt ggtgggtatgt ccccttagga gaacagtgcg gcagaaaagg cagaagcctt 840
 tgggtatgggg ggcagaaatg tgtcaactac aagagaaatt tcctgttgat gaaacagcta 900
 cagatcctgg ggggcttcag atgtacaatt ggggttattc ccctatccct aagta 955

<210> 203
 <211> 184
 <212> DNA
 <213> Homo sapien

<400> 203
 aatcggtaat aaagcacagt ttggtttggg cggtgaccag tcctcgacaa aatggtccta 60
 tcggacacaa ccgaacgggt ttgggcagca atcgcatact gaaaccgttt agagcgccga 120
 caacgaggcg aaacactcca caccacaaac actaactaaa agagaacacc agcactgaat 180
 tacc 184

<210> 204
 <211> 118
 <212> DNA

212

<213> Homo sapien

<400> 204

acaacgcaac aaacacaaac ccaaaaacca gagccgacca cagacgcacc acgttcaacc 60

acacaaccag acaaccccac gaacacacca ccccccaaac agagaccaac accacaac 118

<210> 205

<211> 155

<212> DNA

<213> Homo sapien

<400> 205

aaaaagaaaa aaaagtctgg gcggtagatc ttgggtccta aagctggttc cctgggtggtg 60

aatattgggtt ttcccgtctc acatattcca cacaacaacg gaaccaaggg tctgttcaca 120

taccattggtt ctggtggaga cgtcagctga cacca 155

<210> 206

<211> 1851

<212> DNA

<213> Homo sapien

<400> 206

gggcggggcc acctcccggg gcggggccgg ggcctgatgg gcgtggtcag ctccctggggc 60

ggggacgtga ggggcggggg cagctcctag gggggcatgg ggcgtgaggg gcgcggtcag 120

ttccctgggtt gtggacatga agggcggggc cagctcctgg ggcgggggtcg tgaggggctg 180

ggtcagctcc tggggcgggg atgtgagggg cggggtcac cctgggggcg gggatgtgag 240

gggcgtgggc agctcctggg gcggagatgt gaggggcggg gtcacctcct ggggcgggga 300

ttgaggggctg ggggtcagtt cctgggggctg ggcgtgaggg gcgtggctgc tcgggggatt 360

gggcgtgggg gcggggccgg gttggagacc ggaggagtag acggcagagg cgcccccgca 420

ggtaggcgca ggtgggtccg gagggtcctg gccgacgcgg gtgggggtcg ctgcgcgcag 480

ttcctggggc gctggttcag cgcgggcctc gcctccaact cgagctggct ccgggagaag 540

aaggcggcgt tgtccatgtg caagtctgtg gtggcccctg ccacggatgg tggcctcaac 600

ctgacctcca ccttcctcag gaaaaaccag tgtgagacct gaaccatgct gctgcagccc 660

gcgggggtccc tcggctccta cagctaccgg agtccccgtg agtggggcct ccaccggccc 720

cctgggcccga gcctggggggc gacacttgcc gggacgactc tgggcccagcc ccctgccgcg 780

gagatccatg ggggtgggagg tgatggctgc cccaccagcg tcagaggcaa aggccaggcc 840

tgggcgtgac taccatgca caagtgttag ggacagagag acccttcctc caggggggtg 900

gacccctctt ggagcccacc attgtcttgt caggcccctt ccctgcctc tggagttttc 960

cccacataag cagcccccca aggcccctcc atatgcctcc tcccaattct cctccccagg 1020

213

```

accaggggt  ttctcactc  ccacctgggg  aatggctccc  acgggggaaac  ctcttcactt  1080
ccggttctgg  cagcgacttc  tgcggctgca  ccaggaatcc  tggttttctg  agcctggctc  1140
ccccagattc  tggtttgggg  acagggttca  caggctgtgc  aggcgagagc  agggcactgg  1200
ctggagagca  gccgggtggg  ggagcatccc  gggccagccg  aggggctgag  tgcccccaa  1260
gccacaggt  gcaccccttc  cctgaagcag  aggtgaggtt  tggggggctg  agtccccgac  1320
agggttgtct  cttgggttcc  cagactgggg  cagcacctac  tccgtgtcag  tggtgagagc  1380
cgactacgac  cagtacgcgc  tgctgtacag  ccagggcagc  aagggccctg  gcgaggactt  1440
ccgcatggcc  accctctaca  gccgaaccca  gacccccagg  gctgagttaa  aggagaaatt  1500
cacgccttc  tgcaaggccc  agggcttcac  agaggatacc  attgtcttcc  tgccccaaac  1560
cgataagtgc  atgacggaac  aataggactc  ccagggctg  aagctgggat  cccggccagc  1620
caggtgacct  ccacgctctg  gatgtctctg  ctctgttctt  tccccgagcc  cctgccccgg  1680
ctccccgcca  aagcaaccct  gccactcgg  gcttcctcct  gcacaataaa  ctccggaagc  1740
aagtcagtag  agctggctcc  tggctgtctg  cgctgtcatc  acccgtcctg  ggcttgccc  1800
tggccacccg  gacctcccc  tctaaaatct  cagcctgacg  tcaacaaagg  a  1851

```

<210> 207

<211> 874

<212> DNA

<213> Homo sapien

<400> 207

```

gggaaacaag  gcattccaag  tacaggaaaa  agcattttta  aaggctcagg  accttttggc  60
tggaacaacc  atcttccagt  aatttgccaa  aatgacaaat  acaaaggga  agaggagatg  120
cacccaatat  atgtcctcta  ggctttttag  aaaatatgga  gttgttctt  tggccacatg  180
gtacatgtga  atctatgaga  caggtgatac  tgtagacatc  aagggaatgg  gtactgttca  240
aaaaggaatg  tcccacaaat  gttaccatgg  caaaactgga  agagtctacg  gtattacca  300
acgtgctgtt  ggcattgttg  taaacaaata  agttacaggc  cagattcttg  ccaagagaat  360
tgtgcctatt  gagcacatta  agcacactaa  gagccaatag  agcttcctga  aatgtgtgaa  420
ggaaaatgat  cagaaaaaga  aagaagccaa  agagaaagg  acctgggttc  aaattaagcg  480
ccagcctgct  ccacccagag  aagcatatct  tgtgagaacc  agtgggaagg  agcctgagct  540
gctggaacct  attccctatg  aattcatggc  ataatagggt  ttaaaaaaat  aaaagacttc  600
tggactgtta  aaaaaaaaaa  aaagggttaa  taattttccc  aaggtcacaa  agctgttggg  660
taaaacagcg  tattgtgttt  tccaagcct  tgccttggtt  cttcattcat  ttttatttaa  720
caataatttc  ttgagttatc  taccacagac  taagtgttat  tctaaggcac  ataagatttg  780

```

214

tccatgaaga aaacagaaaa aaacacattg tggcttcatg gagtttattt tcccacagac 840
 aataagcaac aatttttata acagaaggaa gtga 874

<210> 208
 <211> 2244
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (962)..(962)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (980)..(980)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (984)..(984)
 <223> n=a, c, g or t

<400> 208
 gctctgtgaa ggcacggtat gaggctagag gagccctggg tctgccttta cttaccggg 60
 tctgctctag ccctagccct cgggagtcag ggaaggggaa ttgcctaagt aacaaagggg 120
 gcttttgggt ggggtttccc acccaagttc aagaggagga gcagacatct gtctctgccc 180
 ccttcctttg gtcttcttcc tccaggatct gtgtctcagc tctgcctct cactccctct 240
 ctatctgcct tctgtttctc tttgggtctc tctgctctc ctctttctgg cctgcctcct 300
 ctctctaata ctgcctctct tctctctccc cccttgcctt gcccctctc actctaggcc 360
 ctcagctcca gcctctggcc ctgacctga gctgtgtcct gattctgtct ctgccccagg 420
 actgcagggc tccaggaggt ctgggctgcc tccagcttcc cactcccagg ttgcggctgg 480
 actgggactg gttcctttcc agttgaatct ggcagccaaa cctctcctcc ccctcacctg 540
 acaggtgcag cggcctgggt ggggagcccg cccgccggcc ggccagggat ggaagcgaca 600
 ggaatctcat tagcatctca attaaaggtg cctccatatg cgtcggagaa ccagacctgc 660
 agggaccagg aaaaggaata ctatgagccc cagcaccgca tctgctgctc ccgctgcccg 720
 ccaggcacct atgtctcagc taaatgtagc cgcctccggg acacagtttg tgccacatgt 780
 gccgagaatt cctacaacga gcactggaac tacctgacca tctgccagct gtgccgcccc 840
 tgtgacctag tgatgggcct cgaggagatt gcccctgca caagcaaacg gaagacctag 900
 tgccgctgcc agccgggaat gttctgtgct gcctgggccc tcgagtgtac aactgcgag 960

215

```

cnactttctg actgcccgcg tggcnactgaa gccgagctca aagatgaagt tgggaagggg 1020
aacaaccact gcgtcccctg caaggcaggg cacttccaga atacctcctc ccccagcgcc 1080
ctgctgccag ccccacacca ggtgtgagaa ccaaggtctg gtggaggcag ctccaggcac 1140
tgcccagtcc gacacaacct gcaaaaatcc attagagcca ctgccccag agatgtcagg 1200
atcgctgctc aagaggcgctc cgcagggaga gggaccaat cctgtagctg gaagctggga 1260
gcctccgaag gcccatccat acttccctga cttggtacag ccactgctac ccatttctgg 1320
agatgtttcc ccagtatcca ctgggctccc cgcagcccca gttttggagg caggggtgcc 1380
gcaacagcag agtcctctgg acctgaccag ggagccgcag ttggaacccg gggagcagag 1440
ccaggtggcc cacggtacca atggcattca tgtcaccggc gggctctatga ctatcactgg 1500
caacatctac atctacaatg gaccagtact ggggggacca ccgggtcctg gagacctccc 1560
agctaccccc gaacctccat accccattcc cgaagagggg gacctggcc ctcccgggct 1620
ctctacaccc caccaggaag atggcaaggc ttggcaccta gcggagacag agcactgtgg 1680
tgccacaccc tctaacaggg gcccaaggaa ccaatttatc acccatgact gactgagtct 1740
gagaaaaggc agaagaaggg gggcacaagg gcaccttctc ccttgaggct gccctgcccc 1800
cgtgggattc acaggggcct gagtagggcc cggggaagca gagccctaag ggattaaggc 1860
tcagacacct ctgagagcag gtgggcactg gctgggtacg gtgccctcca caggactctc 1920
cctactgcct gagcaaacct gagggcacac ggtcacctgc aaggacgtca cgggcccctc 1980
taaaggattc gtggtgctca tccccagct tcagagaccc tttgggggtc cacacttcac 2040
gtggactgag gtagaccctg catgaagatg aaattatagg gaggacgtc cttccctccc 2100
ctcctagagg agaggaaagg gagtcattaa caactagggg gttgggtagg attcctaggt 2160
atggggaaga gttttggaag gggaggaaaa tggcaagtgt atttatattg taaccacatg 2220
caaataaaaa gaatgggacc taga 2244

```

<210> 209

<211> 299

<212> DNA

<213> Homo sapien

<400> 209

```

ggacccatcc aacgatacca ggagagtcac ccaacctgtg acacaaccaa tccgatacta 60
caatcctcca ttaactgaac ccactcgctc cttacaacag tgactaacca tagacaacga 120
catcacgcaa acacatacaa gaggatcact cactagctag ccataactcg acatatgccc 180
actgccatca gacaacacta actcatccta caatatcccg aaatataaag caaaacgcat 240
acagcactcc acgaacactg accatcaaaa tacaaccgac aacactcccc agaacaaca 299

```

216

<210> 210
 <211> 491
 <212> DNA
 <213> Homo sapien

<400> 210
 agtgggttcca agaatgtacg aggaagcgag agaaggtata aagtatggag agggtcagtg 60
 aaaggtatca tggctggggg atatgtagaa tatgtggagt agaatgggag tctgttaaac 120
 aatatagtga gtaagcgatt aaatttatta tcatgcgagg tattttacca gatgatgtgt 180
 cctagttcag cagtattgtc aacgtatgca aagataaggc ttactgttga ttatctaattg 240
 agtcagtcaa tgaaagtgat gtaaggaggg cctgagagaa ttgtgtgcca tttctgcagt 300
 tgcggatagt gaactgacct ggcaaaaggc ttacataaat accgtactca actgtgggga 360
 gtttaaattgt ctggtggctg ccgtgctgag ttgtcaagaa attaaagctg caagaggact 420
 ccaaggaggc aaaagaaaaa acaatataga ggggtggagg ttgttaagaa atttcaattc 480
 aaaaatgcc a 491

<210> 211
 <211> 375
 <212> DNA
 <213> Homo sapien

<400> 211
 ccgacagcga ggcccaacgc agccagaacg ccgcaacgac gcacacgcac cagccacgcc 60
 ccacagccga cacacagacc gcaggagccg caccgacagc acagccgccc cgccaccgca 120
 cccgcccaca caggcccga cagggcagcg aacgcagcgc aggggaagacg caggcaaccg 180
 aagcgacacg acaccagac caaccaacga acccacacaa cgagagacaa ccgaacaaca 240
 accaggccag agacgacacc aagacacagc ccggacaggc aacgaagacg ccgcaaagaa 300
 cgccgccccg aacaaagcag acgcaaaagg aggcagagcc accgcggcga gcgcagaaac 360
 agaggcaagc gagag 375

<210> 212
 <211> 1052
 <212> DNA
 <213> Homo sapien

<400> 212
 ttactgtctg tattccaagc agaaagggtg gcatacagga gacctcaaaa atacgtact 60
 ttgatcttga ggagagtga aaatcttact catTTTTatgt acaaagcaca gatgtgcata 120
 cattatataa aaagaaatag ttacgtatg gcattaagat ttcatgaaga ttagaaaaac 180
 aatgtttaca aaaggtcctt acaaaggtag taattcaaga aaagatcaat aaacgatgtg 240

217

ttaaagtaag attttttgga gctcaaattc aggcaataca aaagccagca atatatcttg 300
 ctactcgaat gcctctatatt cacctcaaac tcacagataa aactgaaccc aatatgtcct 360
 tgtccattaa aaagcaaattc accaagaaag ctaacaaaag attcccttca atgtctcttt 420
 tattgacagt ggtcccaaaa ctcttggtca atgaattcaa aacccaaattc ttgcaggtag 480
 gacttaacct catctgctgc caaatagctg gctatgtgac cttgggcaga gccacagcct 540
 cccgcgcctc gctcagctcc aacatggcaa aaatctccag ccctacagag actgagcggc 600
 gcatcgagtc cctgattgct gtcttccaga agtatgctgg aaaggatggc tataactaca 660
 ctctctccaa gacagagttc ctaagcttca tgaatacaga actagctgcc ttcacaaaga 720
 accagaagga ccctgggtgct cttgaccgca tgatgaagaa actggacacc aacagtgatg 780
 gtcagctaga tttctcagaa tttcttaattc tgattgggtgg cctagctatg gcttgccatg 840
 actccttcct caaggctgct ccttcccaga agcggacctg aggaccctt ggccctggcc 900
 ttcaaaccga ccccttttcc ttccagcctt tctgtcatca tctccacagc ccacccatcc 960
 cctgagcaca ctaaccacct catgcaggcc ccacctgcca atagtaataa agcaatgtca 1020
 cttttttaaa acatgaaaaa aaacaaaaaa gg 1052

<210> 213
 <211> 199
 <212> DNA
 <213> Homo sapien

<400> 213
 ggccactcca gaacagtacc agatcctgaa gaaggaggct gagaaagtgg cccgggtgaa 60
 ggcgctatat gaggagctgg atctgccagc agtggttcttg caatatgagg aagacagtta 120
 cagccacatt atggctctca ttgaacagta cgcagcacc cgtccccag cgtctttct 180
 ggggcttgcg cgaaaattc 199

<210> 214
 <211> 289
 <212> DNA
 <213> Homo sapien

<400> 214
 aaaccgaca ggacatactc aacgataccg aagcagtatc acccactgga aacatccctc 60
 agttgcagcc tcattctgct ccagaccctg cacgctctac cgggatacgc tgatccggcc 120
 ctcaaactcc acctatcacg gaacagcgag agcgccgaac cctacaataa gcaccagcc 180
 atgtcaaggt aatcatcgag catagcgtgt agcgtccgct cgagaccaag cctgcgctcg 240
 atgagcctga aacacacacg tccacgacca aaccgcccgg ccgaacacg 289

218

<210> 215
 <211> 415
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (277)..(300)
 <223> n=a, c, g or t

<400> 215
 ctttgctgat atttataatt tggatcata agaattgtttt cctctacagt atttgtcatg 60
 ccagtttata acaaaaaaaaa atgcagggat tttatttcta tgggaaactt tacagctatg 120
 ttttactttg ggacagaatt tttatttgta tagagtgcctt actaattggtt aaatagttca 180
 gagtatataa ctatttactt taaggactca tggtaggttt aagggtggaa atgagttggt 240
 gtcatttcaa ttacaaagat aaaagtttgc catatannnn nnnnnnnnnn nnnnnnnnnn 300
 tggtagtgta catagtagtc atcaagtctt ttgacagaag tatattttta aagaattcat 360
 ctgtgatgaa tccataatgt ctggaacttt gctgagactt gagtgggccc agttt 415

<210> 216
 <211> 610
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (459)..(459)
 <223> n=a, c, g or t

<400> 216
 acccagcaca ccacaacacc cctgagccca caacccaagc gccgactcga cagcatatgg 60
 gcgaactggg ccttttagatg catgctccga gcggccgcag tgtgatggat gagcggccgc 120
 ccgggcaggg ttgcacgctg cctgcatgtg tcttgaacat ttctgtgtg cctttctcaa 180
 gcgagaggat gtagcccagc gaactgtgtc cccgactcat gtctttgagc gagcccactt 240
 ctcgctggat tgtgtcctac tgcgcctcat gaggcgtccg tggagccatc catcgcttgt 300
 cttaatccgt cctgctgctg ctgccgcttc cggcgctcag cgtcgccaca ccgtttggac 360
 cctgaggctc gctcagattg atgagctcct ctctggctca gacactcgct ggaggaatga 420
 atagccaggc tctgacctca agcaaggcat gaactcagnc tttattaaga aaattcacat 480
 tttccagggg cagcagaccg ggatcgatgc gtggcgcttg tctcctgttg cccacaccgt 540
 cttcgaaatc tctgttactg ctcccagatg cccttctagt attcactgct ctctctcgat 600
 tcttgatttt 610

219

<210> 217
 <211> 1435
 <212> DNA
 <213> Homo sapien

<400> 217
 gctttttttt tttttttttt ttttttttaa ataagaaaaa cccggtaatg attttcgggg 60
 ttgtagagga aataggagag aaaatggggg gaaatagggtg tattaaacta taagggtttt 120
 tccctcgggtg taaatagagg gtttaatgtt gtaaattgggtg gtgtgggggtg aagggtgtgcc 180
 ccattgtggt ggtgggtggt taaatactgt taaagggtac tactagggtc ggtaactagc 240
 tagtgggtgga gttccgtgtt aagataggag ggctgatatg tgtgactcag ggaaaacggt 300
 ggttcactac ccacagaaga gtttcttccc agtatagggt taactagcgg gcggggctta 360
 cagcgcgacg cagttcaacg cgaagcctct gtgcctaaca aagcttcctc cacaaacgtc 420
 tctatcacag cgcgggacgc tcacagtttg tgaaaagtcc ctctgaacaa aaaggctatc 480
 acctgacatg cccacactgg gtcacgtgcc cgtccgatac ttttctgaac atatgtgccc 540
 aagcgcccaa caatccttca cttcccggca tgtgtaaacg caccagtggg gcgcgcaagt 600
 aactcgcaca aaacatgacg tgagcccccg gacaaaaccg tggggcggtc aaccacact 660
 gggcccaaca agcgtggtat ccctgggtggt gcgaccattg cggtcactcc cggcgtccca 720
 caactgtccc accacaacac caaccgtcaa gccacaccac accacaccaa ccacaaacac 780
 acaccccaca tcaccaccac ccacacccca ccaccaacac aacacttaac acaacgatac 840
 cctaaccac cctcactcaa cactacacaa ctacaacaac cccctaccta caacaccgaa 900
 ctctaattct caacctacac tcacacatca caataacata aatatatacc ctcttctcca 960
 cacaccctac cctccactac tctcacttcc acatctccaa tcacaactac ctctcaactc 1020
 cctcctacta tacacatcac acacatatta acataccccc catccccacc cccactact 1080
 catcactaca caccctaacc accctaccaa acaactccac caataacca aaccgataat 1140
 cccactaaca ccatccactc agtagacact accaatccca atctacaaca tccacattcc 1200
 cacacactcc actccccac tactaacttt acaacacacc accaccata cacatcttct 1260
 acaccaccct cataccaca tacaacaaca taaaaactca accacaccac aataacccaa 1320
 cacaaaaacc accccaccct acaccactaa caccacatca cacaccccc acactcaaca 1380
 cacaaacaca accacacaac aaaacacgac ctccccacc accctcaca caccc 1435

<210> 218
 <211> 534
 <212> DNA
 <213> Homo sapien

220

<400> 218
ataaatttga tcctggctgt ggtggacatg gtctacgagg aacagaatca ggccaccttg 60
gaagaagcag aacagaaaga ggccgaattt cagcagatga ttgaacagct taaaaagcaa 120
caggaggcag ctcaggcagc aacggcaact gcctcagaac attccagaga gcccaagtgc 180
gcaggcaggc tctcagacag ctcatctgaa gcctctaagt tgagttccaa gagtgctaag 240
gaaggaagaa atcggaggaa gaaaagaaaa cagaaagagc agtctggtgg ggaagagaaa 300
gatgaggatg aattccaaaa atctgaagct ggggacccac acggcagagc catggtactg 360
gaggagccat taacaaagct ttcaataaac ctctctttct tgaagttacc tgagaatgga 420
tccattccct gcaactgaag attctaagga actgggtttc tcagtataca atgggaatgg 480
ttgggaggag gtaaagagta gaagacagta tcaagaatcc agagcccagc acct 534

<210> 219
<211> 173
<212> DNA
<213> Homo sapien

<400> 219
catcagcagg cgcgggcgcc accgcgggcc cacgcggcac ccgtgggcca cacggtaccc 60
cggtcacact ccacaaattg ccgcacaacc ggcgaccaga gaagaagccg ccagcaagcg 120
ccagaccgcc agcacgacgt aaccaacgac ctaccacaca cagacgcaac cag 173

<210> 220
<211> 515
<212> DNA
<213> Homo sapien

<400> 220
tgcgtatgct cggcggttatt tccactagag actactacag cgcaatactg acgcatacaa 60
aacactctta gagcataaca acagacacac gtagactaca caaccagaa aaagaacaat 120
aataaaaaga ataaacacta catagtaaac acccacatag agaaagcaca accaacacag 180
aacacgcaac atcccacacg aaaaccagac aacaccacga accacagaca cacagcgcca 240
cacacagaag accgcagacc gaacacaaca cgacccatac aagaacaaag aaccacgega 300
caggcaccaa acaaacgaca tcacaccagc caagacacca gaaacaaagc acataaacia 360
cggaaacgaa agatcacgca cacgacaacc accacacacc acaccacgac agcacagcaa 420
acgagacacc ccaccacac aaacgcgaca acacgacca aaacgcacaa ccacaaacca 480
accacacaga acaacaacac aacaaaaaca acaca 515

<210> 221
<211> 261
<212> DNA

221

<213> Homo sapien

<400> 221

```
aaaaagaatg gaacaacttc agtaagaaga acattttttca ttttagattt ctatgcctta      60
ttttactagt tgattccagg cgtgaattcc aagaagaacc aaatgtattt tgactggggt      120
ccagggggaga tgctgggtatg tgaaacctcc ttcaacaaaa aaggtagggt tttttttctt      180
ccaaattatc catcttggca catttggttg tttttctggt tattacctca gattttacta      240
gttgtggact gaaacagttg a                                          261
```

<210> 222

<211> 284

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (162)..(162)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (172)..(172)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (230)..(230)

<223> n=a, c, g or t

<400> 222

```
cttttgtctt tccgtggagc tgtcgccatg aaggtcgagc tgtgcagttt tagcgggtac      60
aagatctacc ccggacacgg gaggcgctac gccagggacc gacgggaagg ttttccagt      120
ttcttaatgc gaaatgcgga gttcggcttt tccttttcca angagggaaat tncctcggca      180
agattaaact tgggacttgt ccctcttacc aggaagggaa ggcaccaaanaaaggggacc      240
agttcgggaa aggaaaattt tcaaaaaagg aaaaaaggaa cccc                      284
```

<210> 223

<211> 424

<212> DNA

<213> Homo sapien

<400> 223

```
gaggtctgtg aggaccaatt tgtgggtagt tcattttccc tcgattgggt aactccttag      60
tttcagacca cagactcaag attggctctt ccagagggc agcagacagt caccccaagg      120
caggtgtagg gagcccaggg aggccaatca gccccctgaa gactctgggt ccagtcagcc      180
```


222

tgtggcttgt ggcctgtgac ctgtgacctt ctgccagaat tgtcatgcct ctgaggcccc 240
 ctcttaccac actttaccag ttaaccactg aagcccccaa tttccacagc ttttccatta 300
 aaatgcaa at ggtgggtggt caatctaata tgatattgac atattagaag gcaattaggg 360
 tgtttcctta agcaactaca caccaacctg ctggcttttag aataaaagcc ccaactgaac 420
 tgag 424

<210> 224
 <211> 314
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (307)..(307)
 <223> n=a, c, g or t

<400> 224
 gtgccaatgg cccgctatga ggaggtgagc gtgtccggct tgcaggagtt ccaccgggccc 60
 gtggaacagc acaatgttgg aaagatccaa ataatgactt cagaaaaaac ttgaaagtaa 120
 cagcagtgcc tacactactt aagtatggaa cacctcaaaa actggtagaa tctgagtgtc 180
 ttcaggccaa cctgggtggaa atgttggttct ctgaagatta agatttttagg atggcaatca 240
 tgtcttgatg tcctgatttg ttctagtatc aataaactgt atacttgctt tgaattcatg 300
 ttagcantaa atga 314

<210> 225
 <211> 2528
 <212> DNA
 <213> Homo sapien

<400> 225
 gtccgggtga ctatatgctt ccatcaagac tagtgaagaa tgggtgtttt ttccattcat 60
 ccctacattt ctttttttaa taatgataaa catgcaactt ttttgtagct ttacaacaaa 120
 taccagatg ctgtggccac atggctaaac cctgacccat ctcagaagca gaatctccta 180
 gccccacagg tattttttaa cttctcataa ttaaactaca gtgatgaaag atagccacac 240
 tcaggccatt tgggctgctc agatgaatcc tgcctgcctg ctggcaaaca tgtgcttagg 300
 acattgactg atctgccatg ttggcttctc tctgtgttaa gccatccaca gatgaggctg 360
 aaaaataaaa actgcttttg attaaaaagg ttaacttttg aataaaaaag ctaggcatgt 420
 gtgatgcgca ctaacacgtg ccattccttc ttcagaatgc tgtgtcctct gaagaaacca 480
 atgactttaa acaagaggta agttctcatt ttcaatcaga ggcccatcat gccttgaaga 540
 gatgaaagaa ggcattgcct ggattctctt ctgatgaaat ttcattagca agttttccag 600

223

ctaattggca gtctaaaact tgctcataaa taaaacatgt atttactaaa tatcagaaat	660
actaggtttc ctcgataag tttagcatta cagaagatgt ttattaatgc ctgttatttg	720
aaacattaat ctgcttgcaa tttatttaag gtattttgta gatatactaat atctaataag	780
catctaatta atgcgtatca aagctaagat tttgccttta ggaaagtttt ctttcctaata	840
aaaatagttt atttgacaac tattcttttt attaggatca ttcataatatt tgctaagcaa	900
agagtaaatt tatttttcctt aagattcaat ttgaatatac taagaatatt aaagcaagtt	960
agataaatta cccaatatat ttgtcaattt gaaatttgat agacattagt tgtttaattc	1020
aatgggcagt tttgagctgc agtttataca cacatgcata acagagtcac ctttcaatta	1080
tccatgttaa taggaaagtg gttatagatt ttagtacaca cattaaaata tggatactct	1140
tctcttttga taaatctcat ttcaaataaa aaaaccagtc tcataattat gtatctgtat	1200
ctattacatc attgaattta gtaaataatg tttaatatgt ataaggaaaa acaatgttat	1260
tgacatgaag attatactca catatttggc ttgaaaatat ctataaaaaat aatttctggt	1320
gcaaagtaag aaatgttctt cagaatgtta ttaatccctg tgttaaaaga gaaattggaa	1380
gatgctcact ttagctccta aaagccatgg tatgtactgt gaatgcaaag attctgaaac	1440
taaataaaaa gaaagatagt aaaagactaa tgtgctataa aggctaaggg aaaataaaaa	1500
cccatatatt aattttcccg gccatcttaa ttttcagacc cttccaagta agtccaacga	1560
aagccatgac cacatggatg atatggatga tgaagatgat gatgaccatg tggacagcca	1620
ggactccatt gactcgaacg actctgatga tgtagatgac actgatgatt ctcaccagtc	1680
tgatgagtct caccattctg atgaatctga tgaactggtc actgattttc ccacggacct	1740
gccagcaacc gaagttttca ctccagttgt cccacagta gacacatatg atggccgagg	1800
tgatagtgtg gtttatggac tgaggtcaaa atctaagaag tttcgcagac ctgacatcca	1860
gtaccctgat gctacagacg aggacatcac ctcacacatg gaaagcgagg agttgaatgg	1920
tgcatacaag gccatccccg ttgcccagga cctgaacgcg ccttctgatt gggacagccg	1980
tgggaaggac agttatgaaa cgagtcagct ggatgaccag agtgctgaaa cccacagcca	2040
caggcagtcc agattatata agcggaaagc caatgatgag agcaatgagc attccgatgt	2100
gattgatagt caggaacttt ccaaagtcag ccgtgaattc cacagccatg aatttcacag	2160
ccatgaagat atgctgggtg tagaccccaa aagtaaggaa gaagataaac acctgaaatt	2220
tcgtatttct catgaattag atagtgcac ttctgaggtc aattaaaagg agaaaaata	2280
caatttctca ctttgcattt agtcaaaaga aaaaatgctt tatagcaaaa tgaaagagaa	2340
catgaaatgc ttctttctca gtttattggt tgaatgtgta tctatttgag tctggaaata	2400

224

actgatgtgt ttgataatta gtttagtttg tggctcatgg aaactccctg taaactaaaa 2460
 gcttcagggt tatgtctatg ttcattctat agaagaaatg caaactatca ctgtatttta 2520
 atatttgt 2528

<210> 226
 <211> 2734
 <212> DNA
 <213> Homo sapien

<400> 226
 ggagggggca agggagaagc tgctggtcgg actcacaatg aaaacgctcc ttctttttgct 60
 gctgggtgctc ctggagctgg gagaggccca aggatccctt cacagggtgc ccctcaggag 120
 gcatccgtcc ctcaagaaga agctgcgggc acggagccag ctctctgagt tctggaaatc 180
 ccataatttg gacatgatcc agttcaccga gtcctgctca atggaccaga gtgccaagga 240
 acccctcatc aactacttgg atatggaata cttcggcact atctccattg gctccccacc 300
 acagaacttc actgtcatct tcgacactgg ctctccaac ctctgggtcc cctctgtgta 360
 ctgcactagc ccagcctgca agacgcacag caggttccag ccttcccagt ccagcacata 420
 cagccagcca ggtcaatctt tctccattca gtatggaacc gggagcttgt ccgggatcat 480
 tggagccgac caagtctctg tgggaaggact aaccgtggtt ggccagcagt ttggagaaag 540
 tgtcacagag ccaggccaga cctttgtgga tgcagagttt gatggaattc tgggcctggg 600
 ataccctcc ttggctgtgg gaggagtgc tccagtattt gacaacatga tggctcagaa 660
 cctgggtggac ttgccgatgt tttctgtcta catgagcagt aaccagaag gtggtgccgg 720
 gagcgagctg attttcggag gctacgacca ctccatttc tctgggagcc tgaattgggt 780
 ccagtcacc aagcaagctt actggcagat tgcactggat aatatgctgt ggagtgtgcc 840
 aaccttaacg tcatgccgga tgtcaccttc accattaacg gagtccccta taccctcagc 900
 ccaactgcct acaccctact ggacttcgtg gatggaatgc agttctgcag cagtggcttt 960
 caaggacttg acatccaccc tccagctggg ccctctgga tcctggggga tgtcttcatt 1020
 cgacagtttt actcagtctt tgaccgtggg aataaccgtg tgggactggc ccagcagtc 1080
 ccctaaggag gggccttgtg tctgtgctg cctgtctgac agaccttgaa tatgttaggc 1140
 tggggcatte ttacaccta caaaaagtta tttccagag aatgtagctg tttccagggt 1200
 tgcaacttga attaagacca aacagaacat gagaatacac acacacacac acatatacac 1260
 acacacacac ttcacacata cacaccactc ccaccaccgt catgatggag gaattacgtt 1320
 atacattcat attttgtatt gatTTTTgat tatgaaaatc aaaaattttc acatttgatt 1380
 atgaaaatct ccaaacatat gcacaagcag agatcatggt ataataaatc cctttgcaac 1440

225

tccactcagc cctgacaacc catccacaca cggccaggcc tgtttatcta cactgctgcc 1500
 cactcctctc tccagctcca catgctgtac ctggatcatt ctgaagcaaa ttccgagcat 1560
 tacatcattt tgtccataaa tatttctaac atccttaaata atacaatcgg aattcaagca 1620
 tctcccattg tcccacaaat gtttggctgt ttttgtagtt ggattgtttg tattaggatt 1680
 caagcaaggc ccatatattg catttatttg aaatgtctgt aagtctcttt ccatctacag 1740
 agtttagcac atttgaacgt tgctgggtga aatcccgagg tgtcatttga catgggttctc 1800
 tgaacttatc tttcctataa aatggtagtt agatctggag gtctgatttt gtggcaaaaa 1860
 tacttcttag gtgggtgctgg gtacttcttg ttgcatcctg tcaggaggca gataatgctg 1920
 gtgcctctct attggtaatg ttaagactgc tgggtggggt tggagttctt ggctttaatc 1980
 attcattaca aagttcagca ttttacctga tcgtttcagt ggtcattgat gatcattgct 2040
 gagatccaca ctataattag gggcggcaga acaggtgttt ttctaattct gctatccctt 2100
 tggcatttgt tagttggaat tcttctataa aaaacatagg ccgggtacag tggctcacgc 2160
 ctgtaatcct agcactttcg gaggccaagg caggcagatc acgaggtcaa gagatggaga 2220
 ctatcctggc caacatgggt aaacccttc tctactaaaa gtacaaaaat tagccaggca 2280
 tgggtggcaca cccctgtagt cccagctacc caggaagctg aggcaggaga atcgcatgaa 2340
 cccaggagac agaggctgca gtgagccaag atcacgccac tgcactccag actggcaaca 2400
 gagcgagact ccttctcaaa ataaaaacaa aaataataat ctttggctgg gccacgatgg 2460
 ctcacgtctg tcccagcact ctgggaaccc aaggaaggag gattgcttga cccagggtg 2520
 tcaaagttgc agtgatctat gaccttgcca ctgtactcca atctgggtga tagagcaaga 2580
 ccttgtcttg aaaacaagat aaaacaagat aaaacctttc cctcatcaac catttgccca 2640
 ggaaagaaga caattacttg gggttttgtt tcctttgttt accagttttc agaatgagtt 2700
 ggtactatat taaacaccaa agaattttaa acat 2734

<210> 227

<211> 193

<212> DNA

<213> Homo sapien

<400> 227

gatccaacca cttgggggctg tgggtgcaacg aacaccccgc atacaaccgc acgaaggcgc 60
 tttaacacgg tacaccaaca gcactcgaac tccaaaccag gcacacacga cttaacgacc 120
 actggcaacg aactgcaca caggactacc acacgcagca ttacgcggg acacaccccg 180
 cagccagggg cca 193

<210> 228

226

<211> 1457
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (1024)..(1024)
 <223> n=a, c, g or t

<220>
 <221> misc_feature
 <222> (1073)..(1073)
 <223> n=a, c, g or t

<400> 228
 ctgagtatgt ggttgctctg aatagccatc tcaaaattga ccacagaatc tgttttgggg 60
 tggcatagat tagtctccca cacaggtcaa gccaggggaac cccacccagt gcctccgtcc 120
 ctcgttcagg cccagcctga gtgagcccac cccagtggga ggagagggca tggccagggc 180
 agggaggggg tctgagtgtc ctctggctg ctgaaggcac cagtcagctg ccgctccagc 240
 cactgccccca gtggagttct ttggttccaa gccacagaa gaaggtggtg ggtgggccag 300
 tgtgccctga ggcttcttac tggggaggga gagagtcagg tcctccactg ttaggtggcc 360
 aagcgcccaa acgcatctc cactctcacc ctggatgcaa gaagtgacct cggaggcctg 420
 agtcctggcc ttggtctggt ttgatgcat ccaccgcaga ggctgttctg agggcaggtg 480
 gtcagtgcag agtggcgcg cttgtggatg gcagcctccc ccattacta ggaatctgac 540
 tgccagccca gtagccctgg gctgcctgct caggcccat cacctgtggg gcaggtgctt 600
 tagtcccctt aagaggatga ggaggggtgag gcatcagcag gcttgagcgc cttgctcagg 660
 gcagttccgt gggaccctgc tgaacagcac gtggctgccc aacgcctgcc tggagcatcc 720
 cctatcccca cccagcccaa cccatgttct cagcagcagg gatggttcta ggctggctga 780
 atgagggacc agggcagaga ctgcaaaagc ttgagagcca agggggcagc acagagcggg 840
 gagggggctg ggcttgggct gtgctcctgt tgggtttcca ttaaccaggg gaccagctgg 900
 gctgctgtga tttcactttc gcagaaaatg aaactgaagc cgtgggtcacg tgacaggaca 960
 tgtagtatat agcaggctgc cagcgactcc tgctcttgct tctggatctg cagggcagtc 1020
 gccngcagga ccccatggag tgtccttcgt gccagcatgt ctccaagggg ggnaaccccc 1080
 aagttctgca gccagtgcgg agagaggctg cctcctgcag ccccatagc agattctgag 1140
 aacaataact ccacaatggc gtcggcctcg gagggtgaaa ctggagtgtg ggcaggagct 1200
 gaaggaggaa gggggcccgt gcttggtccc gggctcagac agttggcaag aaaaccccga 1260
 ggagccctgt tccaaagcct cctgggaccg tccaagaagg agctacatca gaggttttgg 1320

227

tagatgctgc tgtagacctc atatccgatg aatgggaagc tgctaatagcc ataccagca 1380
 agagaaggaa gcaggatgca gccccgcttg aggccgccag cgtgccttct gcagactgtg 1440
 agcagagcaa aaaaaaa . 1457

<210> 229
 <211> 1527
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (457)..(457)
 <223> n=a, c, g or t

<400> 229
 gcggggggggg aaggtggtgg gggaggaggc aaaagaggag ggagagggga gggtagtggg 60
 gggggggagga tttagagtgg accgctctgc tcacagtctg cagaaggcac gctggcggcc 120
 tcaagcgggg ctgcactctg cttccttctc ttgctgggta tggcattagc agcttcccat 180
 tcatcggata tgaggtctac agcagcatct accaaaacct ctgatgtagc tccttcttgg 240
 acggtccagg aggctttgga acagggctcc tcgggggtttt cttgccaaact gtctgagccc 300
 ggggaacaagc acggggccccc ttctctcttc agctcctgcc cacactccat ttcacctcc 360
 gaggccgacg ccattgtgga gttattgttc tcagaatctg ctatgggggc tgcaggaggc 420
 agcctctctc cgcactggct gcagaacttg ggggttnccc cccttggaga catgctggca 480
 cgaaggacac tccatgggtc ctgctgggac tgccctgcag atccagaagc aagagcagga 540
 gtcgctggca gcctgctata tactacatgt cctgtcacgt gaccacggct tcagtttcat 600
 tttctgcgaa agtgaaatca cagcagccca gctgggtcccc tggttaatgg aaaccaaca 660
 ggagcacagc ccaagcccag cccctcccc gctctgtgct gccccttgg ctctcaagct 720
 tttgcagtct ctgccctggc ccctcattca gccagcctag aaccatccct gctgctgaga 780
 acatgggttg ggctgggtgg ggatagggga tgctccaggc aggcgttggg cagccacgtg 840
 ctgttcagca ggggtcccacg gaactgccct gagcaaggcg ctcaagcctg ctgatgcctc 900
 accctcctca tcctcttaag gggactaaag cacctgcccc acaggtgatg gggcctgagc 960
 aggcagccca gggctactgg gctggcagtc agattcctag taatgggggg aggctgccat 1020
 ccacaaagcg cgccactctg cactgaccac ctgccctcag aacagcctct gcggtggatg 1080
 gcatcaaacc agaccaaggc caggactcag gcctccgggg tcacttcttg catccagggt 1140
 gagagtggag atggcgtttg ggcgcttggc cacctaacag tggaggacct gactctctcc 1200
 ctccccagta agaagcctca gggcacactg gccacccac caccttcttc tgctggcttg 1260

228

gaaccaaaga actccactgg ggcagtggct ggagcggcag ctgactgggtg ccttcagcag 1320
 ccaggaggac actcaggccc cctccctgcc ctggccctgc cctctcctcc cactgggggtg 1380
 ggctcactca ggctgggcct gaacgagggga cggaggcact gggctgggggtt ccctggccttg 1440
 acctgtgtgg gagactaatc tatgccaccc caaaacagat tctgtgggtca attttgagat 1500
 ggctattcag agcaaccaca tactcag 1527

<210> 230
 <211> 697
 <212> DNA
 <213> Homo sapien

<400> 230
 aactccgacc aaccgcgagg cctaaaccgc cgcgctccgc cgctatacgg agccgctcgt 60
 caccgcgcga tacctcagcc caactagacc tccgcctgcc acgtctcccc cccaccggtc 120
 ctgcgcgcga cgcgcgctac tcacactccg cctccacatg agcctccact acgcctatc 180
 ccgccccccc tcccgggcgt ctaccgcgcc cgcgcgggcc acccctcgt gcgcggggct 240
 caggggcgcg gcgtcgcacg gcgcgcgcgc gccgcgctcc gccccggctc gcggtcgccc 300
 gctccgttca cgcacctca ggcgctcgcg cccccctcg accgcgcgac tgcgcgcac 360
 tcttcccgcc ccgacgcgc caccgcgtgg ccgcgcctc ccgcgcgcgg cgcgccatag 420
 ccgcctaccg ccggccctat ccgcacctgc caccgcgtccg cctctctcgc gccccccctg 480
 gtcccgcccc tccgccttg cggcatccct gtgccccttc cctccccctcg ccgcctggcg 540
 tctgcggccc cgcgcgcgtc cccgcgggcc tctccacgct gtgcgccctc gccacgcccc 600
 cctcggact gtccgcgcgc ccggcccccc cgcgcccctc cctcccgccc cccccctc 660
 tcccgcgcgc ctgcccctc cctctgcct cccccc 697

<210> 231
 <211> 342
 <212> DNA
 <213> Homo sapien

<400> 231
 catgcagatg atcctacact cacagttgaa cttggcgtgg ccgctcacct gcccgacatt 60
 tccacgtcgt ggaaaacgct gtcgctgcca gcttgcaatt aactgaatct ccggccagac 120
 tgcggccagt gggaccaggg cagcgcattg cgtaataagg gcggctcttc cagccgctcc 180
 actcggcctc acctgagcta cggcctcgca gcacgcggga ccggtacagc ggtgggacgc 240
 gacgcgtgga ctacgcctc agctcaaacg tgccaggga ccaagggtca acaccaccaa 300
 gacagccacg gagactaacg ggagagaaga aaaccatagc ga 342

229

<210> 232
 <211> 250
 <212> DNA
 <213> Homo sapien

<400> 232
 gtgcaagtct gtggtggccc ctgccacgga tgggtggcctc aacctgacct ccaccttcct 60
 caggaaaaac cagtgtgaga cccgaaccat gctgctgctg cccgcgggggt ccctcggctc 120
 ctacagctac cggagtcccc actggggcag cacctactcc gtgtcagtgg tggagaccga 180
 ctacgaccag tacgcgctgc tgtacagcca aggcccaggg cttcacagag gataccattg 240
 tcttcctgcc 250

<210> 233
 <211> 438
 <212> DNA
 <213> Homo sapien

<400> 233
 ggggaggacg gagactttga tcgactccat atggagaggg aacctgtctt ggaagttgac 60
 tatagcctgg agtcccaggc gtgcggggcga ggtggaggac atacatttca cagatgagag 120
 acaggcagat tccccacaat tctgcatgct ttggagacct gtacaatgag aagccattgg 180
 tatgtcccat gctcttgctg tagtggggaa ccttgagcgt gctctgtttc aagtctcctc 240
 agatcatcaa gtagtatcct gggggaaaaa cagagcgtgg tagacattga agagggagcg 300
 aattgagtgt ggggatggca ttttgtgact ttgcactgag aaattcggag atacatttgt 360
 catcactcca cttgtatatt ggttccggat gacgctcccc gacaagagaa taagataaat 420
 aaattattgg gctgcttt 438

<210> 234
 <211> 1536
 <212> DNA
 <213> Homo sapien

<400> 234
 ctgatgtcta tttaggaaga aacaaactgg tgtatatattg cttgttttcta cattttctag 60
 gcactgcttt gttatctgtg gtggcttttc ccttggaaga tttctatctg ggcacttacc 120
 atgcagttaa caacatacca aaaacagagc agcacaggct gttttatgta gcactgctga 180
 ccatttgcc tggcattgga ggcgtaagag ccatcgtctg tccactgggt gcttttggcc 240
 ttcaggagta tggatcacia aaaacgatgt ctttttttaa ctgattcctt caggatatta 300
 tctgcaaact atgaattcca acctgaattt ggatggattt cttctgccga ttgcagtaat 360
 gaatgccat agcagcctac cattactaat tctggctcct tttctggagt atttcagcac 420
 ctgcctgttt ccctctaaga gagttggatc atttctgtca acatgcatca ttgctggaaa 480

230

```

tcttttttgct gcattgtctg tgatgatagc tggcttcttt gaaatacacc gaaaacattt 540
ccctgcagtg gagcagcccc tttcaggaaa agttctcact gtttcctcca tgccctgttt 600
ctacctgatt cttcagtatg ttttacttgg agtggcggaa acactggtaa acccagcccg 660
aggggacatc gtgacaaagc aaattgtctg gtatcatgaa tttggaacac cattccagac 720
caaaattgaa aaaatgggtg acctcaccca ggtaatggat gatgaagtat tcatggcttt 780
tgcatcctat gcaacaatta ttctttcaaa aatgatgctt atgagtactg caactgcatt 840
ctatagattg acaagaaagg tttttgccaa tccagaagac tgtgtagcat ttggcaaagg 900
agaaaatgcc aagaagtatc ttcgaaacaga tgacagagta gaacgtgtac gcagtcattg 960
taaagctgtt acgattagca tatttgaacg gcagagccag aatggggcta caaatgaagt 1020
gaaaagtatg ctttaccgtg tgcaacaatt gtgaaagtta atacatacac atatggaaca 1080
attaactaaa gacttaagag cccacctgaa tgaccttgaa aatattattc catttcttgg 1140
aattggcctc ctgtattcct tgagtggctc cgacccctct acagccatcc tgcacttcag 1200
actatttgtc ggagacacgg atctaccaca ccattgcata tttgacaacc cccttgcgcc 1260
agcaaataag agcttgagtt tttgttggat atgggagtta ctctttccat ggcttacagg 1320
ttgctgaaag taacatgtcc tgtacaggaa ttatacactc agcatccagt ggtctaagaa 1380
tcggattcat tatatgcata tctctggatt aggagggggg ccgagattga agggtagcct 1440
gataagtgca cacgttccgt taatgttgag acaacattat gtgtaaacct taaggagtgt 1500
aaccacctga aaacgaaatc cgacgaaaaa atcgtc 1536

```

```

<210> 235
<211> 351
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (274)..(274)
<223> n=a, c, g or t

```

```

<400> 235
cgcgcgaccc ggcgggcggga caggcttgct gcttcctcct cctcggcctc accgtttttg 60
ccaatccaga agactgtgta gcatttggca aaggagaaaa tgccaagaag tatcttcgaa 120
cagatgacag agtagaacgt gtacgcagtt cattgtaaag ctgttacgat tagtcatatt 180
tgaacggcag agccagaatg gggctacaaa tgaagtgaaa agtatgcttt accgtgtgca 240
acaattgtga aagttaatac atacacatat gganacaatt aactaaagac ttaagagccc 300
acctgaatga cctgaaaata ttattccatt tctgggaatt ggccctcctgt a 351

```

231

<210> 236
 <211> 1523
 <212> DNA
 <213> Homo sapien

<400> 236
 tttttttttt tttttttttg gttttttttt tttttttttt ttttttttgg ggggtggccc 60
 cttttttttt taccaagtct ttcccttttc ccaccaagaa aacaaacccc cgtgatttct 120
 ccgagccccc atattaaaca acatgggtga ccactatct gtccctccct gtgggagtaa 180
 tctcctcttt ttttaacaaca cacacacaaa ccatcccgcg agaaaatatt tgtcgcgccc 240
 acataaatat ttccgctggg ccactcata tttctcacag aacaatctcc catattatct 300
 atcacactgt ggaaacatat tatgtatgtg ccgctctaca acatctgcgc gacaacagcg 360
 ggaagaggag aacctcctct tgtgggcccc actctcccag agactccaac ctataccccg 420
 cggaaggagg cggggagaca ctctccggcc ccacaagag agaataact ctctccacgg 480
 cgccccaca cacacacaac aacaacaaaa ccccccca cgccacctc tctctccaca 540
 gggacaaaac cgggcccaca ggcggcgtct ttctcggagc gccacaaata ttatattccc 600
 cggagtgggc cccccgagg cttgtggccg ccacaaatcc tccctatcc ccgcgcggcc 660
 tctgacaacc ctggcgcccc tggggcgcaa cgcgtggccc ccgcgccat atcttctcgc 720
 gctcgcccc ccacacata tcaactctctt ttccggacaaa acacacctct ccacacgag 780
 gaccgcgcag ggaaatctat ctctctctca ccgccccaaa caagaattcc cccaaccaa 840
 ccagcgcggc ggctctcca cagaaatatt ttcgtgccca acacgtgcg ggggcaaac 900
 cccacggcg cccaaccgcg gtccccccgc ggcgcgccac acgtggcgat ccgcgcgcc 960
 ccacatttcc cccacatac tctgccacca ccacaccccc cccccccca cccacccac 1020
 cccaccacc acatccacc cccaccacc accaccccc accaccacc ccaccacca 1080
 cacaccacc aacccccacc acaccaacc caccacacc accacccca cccacctcc 1140
 cccacccca cccctcaac ccacccacc ccacacccc ctgccaccg gaccctcacc 1200
 ccccccacc ctcccactc cgcaccacc accctcagc cccctcccc ctcttccaa 1260
 ccgtcaccca ccccccacc ctcccatcca ccccaactcc acctctccac tcaccacca 1320
 ctcccacta ccactacac tctctctcgc ctacctctc acttctctc acccttacct 1380
 cactcctcca cttctcatcc tcacacgcta ctctatctac acttccctct cctcccccc 1440
 cctcatcgca cacaccacc accacatcc ctctacagtc tctcctacac cccccccctc 1500
 atcacacca ccacacacc cca 1523

232

<210> 237
<211> 194
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (92)..(92)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (99)..(99)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (160)..(160)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (168)..(168)
<223> n=a, c, g or t

<220>
<221> misc_feature
<222> (179)..(179)
<223> n=a, c, g or t

<400> 237
actcctccaa gaggcgacaa gttcaaagct gagtaaaggg gggaaatgaa ggaaacttct 60
tgcacaagga gcttgcccaa gctttttgtg gngggggang aaaagtggat tgaagggagg 120
ggggcttgta aggaaagcct tgatggggcc agcccttggn attgaagnaa ccaaggtgna 180
ccccaggcca aggg 194

<210> 238
<211> 121
<212> DNA
<213> Homo sapien

<400> 238
agggcccaag tccccactac acttctcact ctctacaaa ttattctctc atccaccaca 60
atatacacc tacgaacca cccataccca cgacttgcca acaaagcaca cacaattttt 120
c 121

<210> 239
<211> 1807
<212> DNA

233

<213> Homo sapien

<400> 239

cccgccagg ccgggagtg cgtgctgggc gtgcgcggct gcggttacgg cgtggtggtc	60
ccaggcgggt caactgaagg ttaggaagtt ccgtaagccg ggaatggtaa ccggctgttg	120
gatcttgccg atgaggagga ggatcctggc ggaggaggat tgcctagaa ttggttcccc	180
caatgggaga cgacgcaaaa gcgaggcagg agggaaaagt tcctggcctt cgggcgccaa	240
gatcccagtt cacaattatc accgggtatt taggttgctg ggaaaggaac aacacttctt	300
ggaactatat ttttgacaga gcaaccatag ttaaaagagt agccgggtcat tttaaataaa	360
tcctggggaa ggaagtgccg ctggagaaat ccttaagctg tcagccaagg tggagagctc	420
tattgaagag tggcttgga cttagaaacg gttgcctctg cttgttcagt tgaagtgagg	480
aatgtgttta ctgtgtacat ggtttactag aaatgtttat tgattatatt tccatgcttt	540
aattttcttg gagtaattta actgaattta cacagttttg cttcattgta ttttcaaaca	600
aatagaaaat taaacttatt aggaagcatt ttcttaaagt gtttcttgct gtcttttcta	660
tcctgctctaa tgttttggtc cttttattga gtttttattg cttttgatgt cagggcttat	720
ttaatctcta gtgcatgaaa gtctcatatg taaaaaatga ttattctgaa tttaatctgt	780
cattgggtcat atttctaagt gttcaacctt ataaaaaaaa taaatgacta tcataaaaga	840
gaaaaacctt acattatggt ctactagtta agttttcaag gacagtgttc actagtctac	900
catagaccct agaagagtta cccaacacat agttagcact caaatatttg tttgaatgaa	960
ttataaaaat gactacttgt actgttaatt tgtggtaatc taagggaatt aaatctcttc	1020
ggcatcattt actcccttag gtatttgact ttgtgtcaaa tgttttggca aggataaaat	1080
tataacagac tttcttgaac aaccaaataa taatctatta aggattttcc ttcacttttg	1140
ataaaataag aaaaaaggaa attaaacctt tgcacccata tgtaaaatag aattatatgg	1200
tgtttaatat cagtgtctaa tatagctatt atattgacct cctatagtta atacatttta	1260
tcattatttt gtatgttggt ttttaaaaat ttcataaagc tataaaaaga tacttggtca	1320
gataaagttt cctctgcttt taattttaat aaagtattat tatgtatatg atttcttttt	1380
acctattata tatatgcac tattgttttc tcaactggta atatgggaca gacattttgt	1440
tagaaggtta gaagtgagtt aaattttcac attcctaagg atacttttgt ctgggttgt	1500
tgaatacatt ttaaagtgtt tataataatc acttcaaaat atttaggtaa ttaactgtaa	1560
attatgtttc ggtattctcc agggacaatg gccttagagc tattgagaat ttgatgcaaa	1620
agaaggggaa atttgattac atactgttag agaccactgg attagcagac cctggtaaga	1680
agtgagatta ttaataacca gaatatagtt ctgtgatata ttgtaaatag atgtattaga	1740

234

ggaatatcta aaatgagtat taaagctttt gttagtatta aacaaaaaac tttttttggt 1800
 ttttaaag 1807

<210> 240
 <211> 376
 <212> DNA
 <213> Homo sapien

<400> 240
 gcaaccttgt gttaggtaat agcattacca ttctgtagag gagtaaactg agacgcagca 60
 agattaagtt atatgtgcaa ggataaatag ggagtaatgg aagagccgga gtttgaatct 120
 gaataatcca acttcaaagt gttaatcacc actccaggct gcctctcagc cagttgaacc 180
 tcataaaaatt caagactata ataagtggtc aaaaacctaa gacgaaactc tgcttacatg 240
 gttattttaat atttgattga caatgaaaaa taattttaat gcataaagtc atgttgaatg 300
 taactacaat attaaagatc ataaagagta aagtaagtaa aatagaaaaa tcaaaataaa 360
 ataaaaataa ttatgt 376

<210> 241
 <211> 739
 <212> DNA
 <213> Homo sapien

<400> 241
 ctaagatctt ttcactattg ttcctcttac acccctctcc acatggcttt gactgccttc 60
 aaccttttgt agctgaatta catcatccac aaagtttgcc aaatagcccg tccagagctg 120
 ctggatgacc agcacctgt ggtccggttg ctgcgagtt ttcctctga ctgtacaggg 180
 ggccggccag tctccttgga tgccacgctg gcgcatcacc tgcaccagtg ctctaccac 240
 ctgcgctct tccggaactg gatctgacat gagagttatg gcctctagag catgaccttc 300
 ctcttgatgt tgctgctcat cttcttctac atttttgctg tgactgggtg ctacgtcttc 360
 tcagagtaca cccgttcacc tcgtcaggac ctggagtacc atgtgttctt ctogtaagca 420
 gagctgggga cagctgggtg aggggagaaa atttggctaa gagaccagga agcttgtcca 480
 aagtatagta atataaaaag tgcagtctat tccaagaaac tgaaatagaa cacaataggg 540
 agagggaaag agaaagcaaa agaatagtga atggtattag ctctgatctt gaggttaggg 600
 cagctagttc catgtttatt ctgggttttg caaattcaaa ccacactgtc atcaggcatc 660
 tttaaatagc agtacactcc agtggttaag cttggtttct gtgactcagt tacctctttt 720
 gaaaaatggg ggcagggcg 739

<210> 242
 <211> 695

```
<212> DNA
<213> Homo sapien
```

<400>	242								
tatgattcag	atgaaagaga	atgtcagatc	agtgaaacag	aataaatgaa	cccagaccag			60	
aatctcgtac	atgcgggcag	aagacaggaa	gggcagaggt	gtctagggca	gaggtggaac			120	
tagaacaaat	ggtagttact	tggggaaaag	gtgaagttag	atctgtacct	tatgccaaaa			180	
tgaatttcaa	atgagtttaa	aagttaaata	aaaaatagaa	tacaacatat	ttgaaagata			240	
gtcactttta	atttgactgt	taatatctgt	attacataaa	aagtcttccc	aaagtcaata			300	
aggaaaacat	taaaaacttc	aaatagcaaa	aagggcagac	agttcacaaa	aattttctcac			360	
agtaaatacg	aatgactaat	aaatatgggg	agagggtgaa	ttttgggtgat	ttttagcttt			420	
acagatagta	aaaaatgcca	aaaggggtgtc	cttttgatct	atcaaattag	taaaaataaa			480	
atttttactc	atccttactc	atcagtgtta	ataacttgtg	tattagcact	gataaaactgt			540	
tggtctgtaa	attggtaaaa	gtgggttaaaa	attgattaaa	tttttcggat	tataaaaaag			600	
cttagatggc	ggcgggtggc	acaccgttaa	tcccagcact	tggaaggccg	aagcgggtga			660	
ttttcgaaat	ctgactcaag	tgatccactg	cctga					695	

```
<210> 243
<211> 733
<212> DNA
<213> Homo sapien
```

<400>	243						
tgccaaaggc	gtataccaaa	aaaaaaagag	agagagagaa	aatagttgac	agagagaaaa		60
tagttgagaa	cagttagtag	acatagtaga	cgaaaaggct	gttgacctgag	gaagtcgcag		120
taactaagac	cgtatgattc	agatgaaaga	gaatgtcaga	tcagtgaaac	agaataaatg		180
aaccagacc	agaatctcgt	acatgcgggc	agaagacagg	aagggcagag	gtgtctaggg		240
cagaggtgga	actagaacaa	atggtagtta	cttggggaaa	aggtgaagtt	agatctgtac		300
cttatgccaa	aatgaatttc	aaatgagttt	aaaagttaaa	tgaaaaatag	aatacaacat		360
atttgaaaga	tagtcacttt	aaatttgact	gttaatatct	gtattacata	aaaagtcttc		420
ccaaagtcaa	taaggaaaac	attgaaaact	tcaaatagca	aaaagggcag	acagttcaca		480
aaaatttctc	acagtaaata	cgaatgacta	ataaatatgg	ggagaggggtg	aatttttggtg		540
atttttagct	ttacagatag	taaaaaatgc	caaaaggggtg	tccttttgat	ctatcaaatt		600
agtaaaaata	aaatttttac	tcatccttac	tcatcagtgc	taataacttg	tgtattagca		660
ctgataaact	gttggtctgt	aaattggtaa	aagtgggtaa	aaattgatta	aatttttcgg		720
attataaaaa	agc						733

236

<210> 244
 <211> 684
 <212> DNA
 <213> Homo sapien

<400> 244
 agggaaagag ggagaacaag aagagatgag agaaaagggg aaagtaaaaa agacgagaga 60
 ggaagaaaaa gaaagaaaag aaagagataa gcgagacaac gcaagtcagt gccaagagt 120
 gacgacgtga acagcagacc cagaccaaac agcccaacgc cgagcagagg caggaaacgc 180
 gctcacagag agccgccgga tcacgaccac accaacgaca gccaacgtgc accaccgcgg 240
 agggccctca ggagcagcac acggccgacc accgcgcagc acagcaggac aagacgccac 300
 caacatcaaa caggccggcg acatagcgag agaacctgaa caccacaaac ggccagcgcg 360
 cgaatcacgc gaccgcgcca gagcacacac ggcttgaggg ccacgccgcc ggccaagaca 420
 gagcagggag ccacggccac acgccagcga aagacgagaa gaaacgcaag gaggagcagc 480
 gccaaagtagc agcccgagcg cgcacaggaa gaagcaagag cgaaacgaag cagaagccca 540
 cccaccgcag gacaacaaag caagacagac agcaacagac aaatacggga ggagggaaaa 600
 acagagagga gggaaagaca agcaagacag gcgacacgcg aacagacacc accaaaccgg 660
 agagcgagcc ggcagagcac gaga 684

<210> 245
 <211> 154
 <212> DNA
 <213> Homo sapien

<400> 245
 agacacaccg caagacaaag acagacgcgg ccgcaccaac taacagagaa caccacacac 60
 aagacaacca gccaggaaac cagccgcccc aacaggaccc ccacacacca acaccacac 120
 aagacgccag accaccacga caccaaacca acca 154

<210> 246
 <211> 152
 <212> DNA
 <213> Homo sapien

<400> 246
 gttagagccg atatcactgg aagatatcca aacgctctct atgcttacga acctgcagat 60
 acagctctgt tgcttgacaa catgaagaaa gctctcaagt tgctgaagac tgaattgtaa 120
 atgtctgtca ggccttgaga cttgaaacca ga 152

<210> 247
 <211> 968
 <212> DNA

237

<213> Homo sapien

<400> 247

```

tttttttttt tttttttttt ttggtttttt tttttttttt ttataaaaaa aaaaataggc      60
ctcgtttata tttttctctt gtgttcaagc tgtggcattt ttgaaaaccc gtgcgtgtgt      120
ttgccaaccc ttcccccaa gaggagaatt atccgtgggg tggaccaag tctcttcagg      180
gtgtgtaaaa gggccctgtg gccacacac agcaggactc tccagagccc tccctcatta      240
tgtggccagg aatctcaagc ctggggagtt acctcagtgg gccaataagc cgtgttccgc      300
gtggtgataa taattgtgtt atctccgctt catcaatttc ccaaccaaca ttcgcaaaca      360
caatggctcg cggactcaca aaatctcaca acaacagaca attacggaga caccaactca      420
caaaacacat aacaccaagc accgctgcaa ccgacaacga aaagccggaa atcccaagac      480
caccaaccga tccaacacag caccacacaa ccaaccacag ccacacaaca cgcaaccca      540
cccaccaccc acaaccacca ccaaaccagc acacaacaca ccaacacca actaatcaca      600
aaacaaacaa aaaacatcac aacgcaaac acaacaatac aacgcaacca acaccaaccc      660
cgacaccac aacaacacca caaccccacg ccagcacag cctagacaac aacaacaaaa      720
acacaaaaca aacacactca cacagacaca ccacgccac agacgcacgc cgccgccacc      780
cacccccccc cagcgacccc cgcccgcgcc gacgcacaca cgcccagcc acgcacacga      840
ccgaaccccc accagcaac ccacacagca cagcacaac acgccccacc cagcgccaca      900
cacgcaacag accagcacc cacacacaa caccacacac gccctcacgc gaccgccacg      960
ccgcaccc                                     968

```

<210> 248

<211> 291

<212> DNA

<213> Homo sapien

<400> 248

```

gatacctgtc ccgacctctc atccccttcc cggcgaacga ccgtggccgc atttactcat      60
acgctccacc agctggtagc gctactcttc caacgctctc cgcgtagtaa tagagtgaag      120
gtcacaagat tatcacaaga gcattggggc atccgctggg cgcacccgac aaccagcaca      180
cccccgatt tcatggcacc tagtaccagg ctatgccac actaaacata cccgagtaaa      240
tgtccattcc agtcatttcg aacatcctaa accccgcgca ccacaagaac g                                     291

```

<210> 249

<211> 28

<212> PRT

<213> Homo sapien

<400> 249

238

Met Phe Cys Ile Cys Phe Leu Ala Val Ser Tyr Leu Val Cys Phe Pro
 1 5 10 15

Asp Leu Pro Gln Leu Phe Asn Phe Tyr Tyr Tyr Leu
 20 25

<210> 250
 <211> 108
 <212> PRT
 <213> Homo sapien

<400> 250

Met Arg Arg Trp Val Trp Ser Gln Lys Arg Tyr Arg Gln Thr Gln Ile
 1 5 10 15

Leu Asn Gly Phe Ala Phe Leu Ser Met Thr Cys Ser Gln Ala Pro Gln
 20 25 30

Ser Pro His Gly Leu Pro Ser Ile Trp Pro Leu Gln Pro Thr Leu Pro
 35 40 45

Lys Ala Phe Cys Pro Arg Ser Pro Gly Gly Ser Pro Ala Leu Gln Ala
 50 55 60

Ser His Ser Pro Met Ala Gly Gly Cys Cys Trp Ser Ala Val Lys Trp
 65 70 75 80

Lys Gly Gly Pro Arg Gly Gly Leu Gly Ser Ala Pro Gly Thr Arg Ala
 85 90 95

Val Ala Leu Ile Leu Thr Asn Leu Arg Arg Cys Pro
 100 105

<210> 251
 <211> 108
 <212> PRT
 <213> Homo sapien

<400> 251

Met Arg Arg Trp Val Trp Ser Gln Lys Arg Tyr Arg Gln Thr Gln Ile
 1 5 10 15

Leu Asn Gly Phe Ala Phe Leu Ser Met Thr Cys Ser Gln Ala Pro Gln
 20 25 30

Ser Pro His Gly Leu Pro Ser Ile Trp Pro Leu Gln Pro Thr Leu Pro
 35 40 45

239

Lys Ala Phe Cys Pro Arg Ser Pro Gly Gly Ser Pro Ala Leu Gln Ala
50 55 60

Ser His Ser Pro Met Ala Gly Gly Cys Cys Trp Ser Ala Val Lys Trp
65 70 75 80

Lys Gly Gly Pro Arg Gly Gly Leu Gly Ser Ala Pro Gly Thr Arg Ala
85 90 95

Val Ala Leu Ile Leu Thr Asn Leu Arg Arg Cys Pro
100 105

<210> 252
<211> 71
<212> PRT
<213> Homo sapien

<400> 252

Cys Lys Ser Val Val Ala Pro Ala Thr Asp Gly Gly Leu Asn Leu Thr
1 5 10 15

Ser Thr Phe Leu Arg Lys Asn Gln Cys Glu Thr Arg Thr Met Leu Leu
20 25 30

Leu Pro Ala Gly Ser Leu Gly Ser Tyr Ser Tyr Arg Ser Pro His Trp
35 40 45

Gly Ser Thr Tyr Ser Val Ser Val Val Glu Thr Asp Tyr Asp Gln Tyr
50 55 60

Ala Leu Leu Tyr Ser Gln Gly
65 70

<210> 253
<211> 120
<212> PRT
<213> Homo sapien

<400> 253

Lys Lys Ala Ala Leu Ser Met Cys Lys Ser Val Val Ala Pro Ala Thr
1 5 10 15

Asp Gly Gly Leu Asn Leu Thr Ser Thr Phe Leu Arg Lys Asn Gln Cys
20 25 30

Glu Thr Arg Thr Met Leu Leu Gln Pro Ala Gly Ser Leu Gly Ser Tyr

240

35

40

45

Ser Tyr Arg Ser Pro His Trp Gly Ser Thr Tyr Ser Val Ser Val Val
 50 55 60

Glu Thr Asp Tyr Asp Gln Tyr Ala Leu Leu Tyr Ala Thr Leu Tyr Ser
 65 70 75 80

Arg Thr Gln Thr Pro Arg Ala Glu Leu Lys Glu Lys Phe Thr Ala Phe
 85 90 95

Cys Lys Ala Gln Gly Phe Thr Glu Asp Thr Ile Val Phe Leu Pro Gln
 100 105 110

Thr Asp Lys Cys Met Thr Glu Gln
 115 120

<210> 254
 <211> 235
 <212> PRT
 <213> Homo sapien

<400> 254

Ala Gly Lys Thr Thr Leu Leu Asn Tyr Ile Leu Thr Glu Gln His Ser
 1 5 10 15

Lys Arg Val Ala Val Ile Leu Asn Glu Ser Gly Glu Gly Ser Ala Leu
 20 25 30

Glu Lys Ser Leu Ala Val Gly Gln Gly Gly Glu Leu Tyr Glu Glu Trp
 35 40 45

Leu Glu Leu Arg Asn Gly Cys Leu Cys Cys Ser Val Lys Glu Asn Gly
 50 55 60

Leu Arg Ala Ile Glu Asn Leu Met Gln Lys Lys Gly Lys Phe Asp Asp
 65 70 75 80

Ile Leu Leu Glu Thr Thr Gly Leu Ala Asp Pro Gly Ile Ile Thr Ile
 85 90 95

Val Asp Ser Lys Tyr Trp Ile Lys Ser Glu Ile Pro Leu Lys Ala Glu
 100 105 110

Glu Asn Glu Ile Ile Pro Pro Thr Asp Pro Phe Pro Ile Ala Tyr Gly
 115 120 125

241

Gly Pro Lys Gln Gln Arg Ile Gly Gln Arg Asn Asp Ser Ser Leu Phe
130 135 140

Gly Leu Asp Thr Arg Ala Thr Asp Ile Val Leu Phe Ser Ser Thr Asn
145 150 155 160

Val Asp Ser Ile Cys Asn Arg Ser Asn Glu Ser Tyr Pro Glu Lys His
165 170 175

Leu Thr Glu Glu Lys Pro Asp Gly Leu Ile Asn Glu Ala Thr Arg Gln
180 185 190

Val Ala Leu Ala Asp Ile Ile Leu Ile Asn Lys Thr Asp Leu Val Pro
195 200 205

Glu Glu Asp Val Lys Lys Leu Arg Thr Thr Leu Arg Ser Ile Asn Gly
210 215 220

Leu Gly Gln Ile Leu Glu Thr Gln Arg Ser Arg
225 230 235

<210> 255

<211> 953

<212> PRT

<213> Homo sapien

<400> 255

Met Ser His Arg Gln Val His Asp Asp Leu Asn Lys Leu Leu Lys Ile
1 5 10 15

Met Leu Ile Asn Ser Phe Gly Ser Val Ile Ile Phe Val Phe Ile Asn
20 25 30

Ile Leu Ser Gln Phe Ser Ser Phe Ile Phe Ile Ser Glu Ile Ser Met
35 40 45

Ser Trp Asn Lys Ser Cys Val Leu Ile Ser Leu Leu Cys Asn Asn Leu
50 55 60

Val Cys Leu Thr Phe Leu Thr Phe Ile Ser Asn Ile Cys Phe Ile Lys
65 70 75 80

Asn Asn Lys His Ala Val Ile Asp Phe Ser Tyr Phe Lys Trp Met Ser
85 90 95

Glu Gln Val Thr Lys Ile Phe Cys Glu Phe Phe Ser Val Trp Cys Leu

242

100

105

110

Pro Met His Leu Arg Ile Trp Gly Leu Ser Glu Ile Val Leu Pro Cys
 115 120 125

Tyr Gly Thr Glu Val Gly Leu Glu Ser Phe Ser Met Lys Ile Arg Cys
 130 135 140

Pro Glu Tyr Glu Phe Leu Leu Leu Gly Pro Glu Ser Tyr Ile Lys Tyr
 145 150 155 160

Ser Leu Lys Phe Leu Glu Ala Thr Ala Pro Ser Leu Ser Ser Val Ile
 165 170 175

Phe Trp Ala Tyr Val Lys Ile Ile Thr Gln Ser Pro Val Phe Ile Asn
 180 185 190

Cys Phe Phe Ile Phe Lys Pro Asn Leu Met Leu Ile Val Ile Cys Tyr
 195 200 205

Leu Phe Ser Pro Asp Leu Asn His Trp Ile Gln Leu Asn Glu Phe Glu
 210 215 220

Leu Ser Leu Asn Asn Ser Lys Arg Asn Asn Val Tyr Ser Asp Gly Gly
 225 230 235 240

Asn Phe Leu Ser Thr Cys Ser Pro Ile Leu Asn Glu Val Lys Ser Asn
 245 250 255

His Val Thr Ile Arg Val Leu Glu Lys Leu Asn Ile Leu Tyr Ile Gly
 260 265 270

Tyr Leu Thr Pro His Phe Tyr Ile Thr Cys Tyr Ile Lys Gly Gly Gly
 275 280 285

Ile Lys Glu Ile Gln Lys Leu Gln Arg Tyr Leu Glu Cys Thr Tyr Leu
 290 295 300

Leu Ile Leu Phe Val Ile Ser Leu Phe His Leu Leu Ser Asn Lys Leu
 305 310 315 320

Leu Glu Lys Phe Leu Phe Phe Ser Cys Phe Phe Ser Tyr Lys Asn Val
 325 330 335

Phe Glu Lys Leu Ile Asn Phe Arg Ile Glu Lys Ile Ile Glu Ser Leu
 340 345 350

243

Lys Lys Thr Tyr Phe Ile Glu Val Ile Thr Lys Ile Ile Phe Asn Leu
 355 360 365

Asp Ser Thr Val Ile Gln Ile Leu His His Leu Pro Thr Ser Met Asn
 370 375 380

Phe Met Tyr Lys Phe Phe Lys Ser Gln Ser Phe Phe Phe Leu Ile Asn
 385 390 395 400

Trp Met Tyr Phe Thr Glu Phe Pro Thr Ala His Val Ser Phe Leu Pro
 405 410 415

Phe Arg Val Asp Leu Ser Asn Val Leu Asp Leu His Ala Phe Asp Ser
 420 425 430

Leu Ser Gly Ile Ser Leu Gln Lys Lys Leu Gln His Val Pro Gly Thr
 435 440 445

Gln Pro His Leu Asp Gln Ser Ile Val Thr Ile Thr Phe Asp Val Pro
 450 455 460

Gly Asn Ala Lys Glu Glu His Leu Asn Met Phe Ile Gln Asn Leu Leu
 465 470 475 480

Trp Glu Lys Asn Val Arg Asn Lys Asp Asn His Cys Met Glu Val Ile
 485 490 495

Arg Leu Lys Val Gln Phe Thr Val Ala Asp Phe Trp Thr Lys Ser Phe
 500 505 510

Ser Trp Leu Leu Glu Lys Leu Tyr Leu Val Leu Asn Arg Asn Thr Gly
 515 520 525

Phe Ser Thr Asn His Leu Cys Leu Leu Ser Phe Phe Phe Ile Ile Phe
 530 535 540

Met Thr Glu Lys Glu Leu Trp Lys Ser Leu His Lys Ala Gly Phe Ile
 545 550 555 560

Cys Thr Thr Phe Phe Arg Val Ala Ala Arg Thr Asn Leu Cys Ala Leu
 565 570 575

Lys Cys Tyr Leu Leu Leu Ser Val Pro Lys Tyr Arg Glu Ile Met Leu
 580 585 590

244

Gln Ile Ser Leu Leu Leu Asn Ile Met Leu Pro Asp Ala Phe Glu Gln
 595 600 605

Thr Leu Asn Ile Cys Cys Thr Leu Asn Lys Val Gln Arg Thr Arg Arg
 610 615 620

Ile Leu Val Leu Tyr Leu Glu Thr His Ser His Tyr Leu Ile Phe Gly
 625 630 635 640

Tyr Leu Ser His Glu Arg Tyr Phe Phe Tyr Gly Ser Ser Asp Ser Gln
 645 650 655

Ser Val Cys Leu Thr Ser Gln Leu Ser Val Tyr Ser Cys Val Phe Thr
 660 665 670

Ser Val His Lys Val Phe Gly Glu Ile Lys Asn Ile Ile Ser Asn Glu
 675 680 685

Ile Asn Phe Ile Pro Ile Gly Ala Ser Leu Ser Asp Asn Ser Phe Leu
 690 695 700

Ile Ser Ala Asn Gln Tyr Thr Met Ser Ser Tyr Ser Asp Lys Tyr Asn
 705 710 715 720

Ser Phe Ser Leu Phe Gln His Cys Ser Leu Ile Ala Thr His Phe Tyr
 725 730 735

Asn Lys Leu Phe Asn Ile Thr Asn Ser Phe Asn Phe Ser Thr Phe Pro
 740 745 750

Thr Lys Thr Val Lys His Tyr Ile Lys Ser Leu Ser Ile Gly Tyr Asp
 755 760 765

Thr Tyr Phe Ile Ile Leu Phe Gln Val Leu Val Val Ile Asn Asn Thr
 770 775 780

Glu Lys Pro Ser Ile Ile Tyr Val Leu Thr Leu Ser Leu Glu Lys Gly
 785 790 795 800

Ile Val Gln Lys Lys Ile Asn Thr Gln Lys Pro Phe Leu Lys Ile Lys
 805 810 815

Asn Ile Lys Lys Leu Leu Val Ile His Lys Tyr Leu Glu Leu Ser Asn
 820 825 830

245

Phe Leu Ser Phe Lys Ser Leu Tyr Phe Leu Ser Glu Tyr Gln Tyr Ile
 835 840 845

Asn Pro Leu Thr Leu Met Leu Ile Ser Ala Phe Lys Phe Glu Leu Arg
 850 855 860

Leu Ile Asn Val Gln Ser Ile Leu Leu Gly Ala Gly Leu Val Ser Ile
 865 870 875 880

Lys Asp Lys Ser Gln Gln Val Ile Val Gln Gly Val His Glu Leu Tyr
 885 890 895

Asp Leu Glu Glu Thr Pro Val Ser Trp Lys Asp Asp Thr Glu Arg Thr
 900 905 910

Asn Arg Leu Val Leu Ile Gly Arg Asn Leu Asp Lys Asp Ile Leu Lys
 915 920 925

Gln Leu Phe Ile Ala Thr Val Thr Glu Thr Glu Lys Gln Trp Thr Thr
 930 935 940

His Phe Lys Glu Asp Gln Val Cys Thr
 945 950

<210> 256

<211> 728

<212> PRT

<213> Homo sapien

<400> 256

Met Arg Leu Ser Asn Arg Gln Pro Gly Ala Leu Arg Leu Thr Ala Gly
 1 5 10 15

Ser Leu Val Pro Leu Ser Leu Tyr Leu Arg Asn Ser Phe Phe Gly Ser
 20 25 30

Thr Ala Glu Ala Leu Gly Glu Trp Leu Cys Leu Leu Trp Gln Arg Leu
 35 40 45

Glu Val Leu Thr Asp Cys His Lys Tyr Tyr Ala Val Thr Ala Ala Ala
 50 55 60

Ala Tyr Met His Val Asn Ser Trp Gly Ile Asn Leu Val Cys Ile Leu
 65 70 75 80

Arg Ser His Ser Ser Ala Gly Arg Gly Ser Arg Arg Met Pro Phe Ser
 85 90 95

246

Val	Ser	Pro	Leu	Gln	Pro	Tyr	Thr	Lys	Cys	Ala	Pro	Cys	Val	Ser	Asn
			100					105					110		
Ser	Ile	Val	Glu	Val	Ser	Asp	Asn	Leu	Thr	Tyr	Thr	Met	Ser	His	Ser
		115					120					125			
Ser	Val	Ser	Val	Leu	Phe	Leu	Leu	Val	Phe	Tyr	Asn	Ser	Phe	Leu	Leu
	130					135					140				
Asn	Phe	Ser	Pro	Leu	Tyr	Lys	Met	Ser	His	Arg	Gln	Val	His	Asp	Thr
145					150					155					160
Tyr	Asn	Lys	Leu	Leu	Lys	Ile	Met	Leu	Ile	Asn	Ser	Phe	Gly	Ser	Val
			165						170					175	
Ile	Ile	Phe	Val	Phe	Ile	Asn	Ile	Leu	Ser	Gln	Phe	Ser	Ser	Phe	Ile
			180					185					190		
Phe	Ile	Ser	Glu	Ile	Ser	Met	Ser	Trp	Asn	Lys	Ser	Cys	Val	Leu	Ile
		195					200					205			
Ser	Leu	Leu	Cys	Asn	Asn	Leu	Val	Cys	Leu	Thr	Phe	Leu	Thr	Phe	Ile
	210					215					220				
Ser	Asn	Ile	Cys	Phe	Ile	Ile	Glu	Gln	Lys	His	Ala	Val	Ile	Asp	Phe
225					230					235					240
Ser	Tyr	Phe	Lys	Trp	Met	Ser	Glu	Gln	Val	Thr	Lys	Ile	Phe	Cys	Glu
			245						250					255	
Phe	Phe	Ser	Val	Trp	Cys	Leu	Pro	Met	His	Leu	Arg	Ile	Gln	Gly	Leu
			260					265					270		
Ser	Glu	Ile	Val	Leu	Pro	Cys	Tyr	Gly	Thr	Glu	Val	Gly	Leu	Glu	Ser
		275					280					285			
Phe	Ser	Met	Lys	Ile	Arg	Cys	Pro	Glu	Tyr	Glu	Phe	Leu	Leu	Leu	Gly
	290					295					300				
Pro	Glu	Ser	Tyr	Ile	Lys	Tyr	Ser	Leu	Lys	Phe	Leu	Glu	Ala	Thr	Ala
305					310					315					320
Pro	Ser	Leu	Ser	Ser	Val	Ile	Phe	Trp	Ala	Tyr	Val	Lys	Ile	Ile	Thr
				325					330					335	

247

Gln Ser Pro Val Phe Ile Asn Cys Phe Phe Ile Phe Lys Pro Asn Leu
 340 345 350

Met Leu Ile Val Ile Cys Tyr Leu Phe Ser Pro Asp Leu Asn His Trp
 355 360 365

Ile Gln Leu Asn Glu Phe Glu Leu Ser Leu Asn Asn Ser Lys Arg Asn
 370 375 380

Asn Val Tyr Ser Asp Gly Gly Asn Phe Leu Ser Thr Cys Ser Pro Ile
 385 390 395 400

Leu Asn Glu Val Lys Ser Asn His Val Thr Ile Arg Val Leu Glu Lys
 405 410 415

Leu Asn Ile Leu Tyr Ile Gly Tyr Leu Thr Pro His Phe Tyr Ile Thr
 420 425 430

Cys Tyr Ile Lys Gly Gly Gly Ile Lys Glu Ile Gln Lys Leu Gln Arg
 435 440 445

Tyr Leu Glu Cys Thr Tyr Leu Leu Ile Leu Phe Val Ile Ser Leu Phe
 450 455 460

His Leu Leu Ser Asn Lys Leu Leu Glu Lys Phe Leu Phe Phe Ser Cys
 465 470 475 480

Phe Phe Ser Tyr Lys Asn Val Phe Glu Lys Leu Ile Asn Phe Arg Ile
 485 490 495

Glu Lys Ile Ile Glu Ser Leu Lys Lys Thr Tyr Phe Ile Glu Val Ile
 500 505 510

Thr Lys Ile Ile Phe Asn Leu Asp Ser Thr Val Ile Gln Ile Leu His
 515 520 525

His Leu Pro Thr Ser Met Asn Phe Met Tyr Lys Ile Phe Lys Ser Gln
 530 535 540

Ser Phe Phe Phe Leu Ile Asn Trp Met Tyr Phe Thr Glu Phe Pro Thr
 545 550 555 560

Ala His Val Ser Phe Leu Pro Phe Arg Val Asp Leu Ser Asn Val Leu
 565 570 575

248

Asp Leu His Ala Phe Asp Ser Leu Ser Gly Ile Ser Leu Gln Lys Lys
 580 585 590

Leu Gln His Val Pro Gly Thr Gln Pro His Leu Asp Gln Ser Ile Val
 595 600 605

Thr Ile Thr Phe Asp Val Pro Gly Asn Ala Lys Glu Glu His Leu Asn
 610 615 620

Met Phe Ile Gln Asn Leu Leu Trp Glu Lys Asn Val Arg Asn Lys Asp
 625 630 635 640

Asn His Cys Met Glu Val Ile Arg Leu Lys Gly Leu Val Ser Ile Lys
 645 650 655

Asp Lys Ser Gln Gln Val Ile Val Gln Gly Val His Glu Leu Tyr Asp
 660 665 670

Leu Glu Glu Thr Pro Val Ser Trp Lys Asp Asp Thr Glu Arg Thr Asn
 675 680 685

Arg Leu Val Leu Ile Gly Arg Asn Leu Asp Lys Asp Ile Leu Lys Gln
 690 695 700

Leu Phe Ile Ala Thr Val Thr Glu Thr Glu Lys Gln Trp Thr Thr His
 705 710 715 720

Phe Lys Glu Asp Gln Val Cys Thr
 725

<210> 257

<211> 151

<212> PRT

<213> Homo sapien

<400> 257

Met Gly Gly Gly Cys His Pro Gln Ser Ala Pro Leu Cys Thr Asp His
 1 5 10 15

Leu Pro Ser Glu Gln Pro Leu Arg Trp Met Ala Ser Asn Gln Thr Lys
 20 25 30

Ala Arg Thr Gln Ala Ser Gly Val Thr Ser Cys Ile Gln Gly Glu Ser
 35 40 45

Gly Asp Gly Val Trp Ala Leu Gly His Leu Thr Val Glu Asp Leu Thr
 50 55 60

249

Leu Ser Leu Pro Ser Lys Lys Pro Gln Gly Thr Leu Ala His Pro Pro
65 70 75 80

Pro Ser Ser Val Gly Leu Glu Pro Lys Asn Ser Thr Gly Ala Val Ala
85 90 95

Gly Ala Ala Ala Asp Trp Cys Leu Gln Gln Pro Gly Gly His Ser Asp
100 105 110

Pro Leu Pro Ala Leu Ala Met Pro Ser Pro Pro Thr Gly Val Gly Ser
115 120 125

Leu Arg Leu Gly Leu Asn Glu Gly Arg Arg His Trp Val Gly Phe Pro
130 135 140

Gly Leu Thr Cys Val Gly Asp
145 150

<210> 258
<211> 72
<212> PRT
<213> Homo sapien

<400> 258

Met Ala Ser Ala Ser Glu Gly Glu Met Glu Cys Gly Gln Glu Leu Lys
1 5 10 15

Glu Glu Gly Gly Pro Cys Leu Phe Pro Gly Ser Asp Ser Trp Gln Glu
20 25 30

Asn Pro Glu Glu Pro Cys Ser Lys Ala Ser Trp Thr Val Gln Glu Val
35 40 45

Ser Ala Leu Pro Arg Leu Pro Ser Ala Pro Ala His Ser Ala Gln Glu
50 55 60

Asn Leu Thr Ala Gln Leu Pro Ser
65 70

<210> 259
<211> 119
<212> PRT
<213> Homo sapien

<400> 259

Asn Gly Arg Ser Val Leu Glu Ser Ala Phe Glu Arg Arg Pro Gly Arg

Gln Phe Cys Phe Val Leu Gln Gln Pro Met Ile Tyr Glu Gly Gln Ala
85 90 95

251

Gln Leu Trp Thr Asp Leu Gln Tyr Arg Glu Lys Glu Val Ser Gly Leu
 100 105 110

Pro Pro Ala Ala Leu Pro Ala Gly Gln Glu Pro His Leu Thr Cys
 115 120 125

<210> 261
 <211> 130
 <212> PRT
 <213> Homo sapien

<400> 261

Ser Val Leu Lys Pro Gly Lys Arg Gly Glu Lys Ala Leu Gln Arg Ala
 1 5 10 15

Glu Arg Glu Ala Asp His Arg Arg Glu Lys Gly Lys Ile Leu Ala Pro
 20 25 30

Thr Val Ala Arg Val Leu Ser Phe Cys Pro His Glu Cys Asp Ser Ala
 35 40 45

Arg Asn Leu Glu Trp Leu Lys Thr Val Asn Glu Ser His Gly Ser Val
 50 55 60

Glu Arg Ser Ser Leu Thr Leu Ala Thr Ala Ile Asn Gln Arg Gly Ile
 65 70 75 80

Tyr Val Ile Gln Ala Pro Lys Gly Gly Gln Lys Ile Ser Pro Asp Thr
 85 90 95

Val Leu His Leu Ile Leu Pro Glu Ser Pro Gly Ser His Glu Glu Ser
 100 105 110

Arg Glu Tyr Ser Leu Glu Lys Val Ser Arg Val Ser Lys Gln Asn Pro
 115 120 125

Leu Leu
 130

<210> 262
 <211> 160
 <212> PRT
 <213> Homo sapien

<400> 262

Met Thr Asn Thr Lys Gly Lys Arg Arg Cys Thr Gln Tyr Met Ser Ser
 1 5 10 15

252

Arg Pro Phe Arg Lys Tyr Gly Val Val Pro Leu Ala Thr Trp Tyr Met
20 25 30

Arg Ile Tyr Glu Thr Gly Asp Thr Val Asp Ile Lys Gly Met Gly Thr
35 40 45

Val Gln Lys Gly Met Ser His Lys Cys Tyr His Gly Lys Thr Gly Arg
50 55 60

Val Tyr Gly Ile Thr Gln Arg Ala Val Gly Ile Val Val Asn Lys Gln
65 70 75 80

Val Thr Gly Gln Ile Leu Ala Lys Arg Ile Val Pro Ile Glu His Ile
85 90 95

Lys His Thr Lys Ser Gln Asp Ser Phe Leu Lys Cys Val Lys Glu Asn
100 105 110

Asp Gln Lys Lys Lys Glu Ala Lys Glu Lys Gly Thr Trp Val Gln Ile
115 120 125

Lys Arg Gln Pro Ala Pro Pro Arg Glu Ala Tyr Phe Val Arg Thr Ser
130 135 140

Gly Lys Glu Pro Glu Leu Leu Glu Pro Ile Pro Tyr Glu Phe Met Ala
145 150 155 160

<210> 263
<211> 194
<212> PRT
<213> Homo sapien

<400> 263

Trp Arg Glu Phe Thr Gly Asn Arg Leu Gln Gln Leu Arg Leu Leu Pro
1 5 10 15

Thr Gly Ser Tyr Thr Val Cys Phe Ser Gly Cys Ser Arg Leu Ala Leu
20 25 30

Asn Leu Asn Pro Gly Thr Phe Leu Ser Gly Phe Leu Leu Leu Asn
35 40 45

Ile Phe Leu His Thr Phe Gln Glu Ala Leu Leu Ala Leu Ser Val Leu
50 55 60

253

Asn Val Leu Asn Arg His Asn Ser Leu Gly Lys Asn Leu Ala Cys Asn
65 70 75 80

Leu Phe Val Tyr Asn Asn Ala Asn Ser Thr Leu Gly Asn Thr Val Asp
85 90 95

Ser Ser Ser Phe Ala Met Val Thr Phe Val Gly His Ser Phe Leu Asn
100 105 110

Ser Thr His Ser Leu Asp Val Tyr Ser Ile Thr Cys Leu Ile Asp Ser
115 120 125

His Val Pro Cys Gly Gln Arg Asn Asn Ser Ile Phe Ser Lys Arg Pro
130 135 140

Arg Gly His Ile Leu Gly Ala Ser Pro Leu Ser Leu Cys Ile Cys His
145 150 155 160

Phe Gly Lys Leu Leu Glu Asp Gly Cys Ser Ser Gln Lys Val Leu Ser
165 170 175

Leu Leu Lys Cys Phe Phe Leu Tyr Leu Glu Cys Leu Val Ser Arg Ile
180 185 190

Ser Phe

<210> 264
<211> 71
<212> PRT
<213> Homo sapien

<400> 264

Met Ala Arg Tyr Glu Glu Val Ser Val Ser Gly Phe Glu Glu Phe His
1 5 10 15

Arg Ala Val Glu Gln His Asn Cys Trp Lys Asp Pro Asn Asn Asp Phe
20 25 30

Arg Lys Asn Leu Lys Val Thr Ala Val Pro Thr Leu Leu Lys Tyr Gly
35 40 45

Thr Pro Gln Lys Leu Val Glu Ser Glu Cys Leu Gln Ala Asn Leu Val
50 55 60

Glu Met Leu Phe Ser Glu Asp
65 70

254

<210> 265
<211> 243
<212> PRT
<213> Homo sapien

<400> 265

Gln Thr Leu Pro Ser Lys Ser Asn Glu Ser His Asp His Met Asp Asp
1 5 10 15

Met Asp Asp Glu Asp Asp Asp Asp His Val Asp Ser Gln Asp Ser Ile
20 25 30

Asp Ser Asn Asp Ser Asp Asp Val Asp Asp Thr Asp Asp Ser His Gln
35 40 45

Ser Asp Glu Ser His His Ser Asp Glu Ser Asp Glu Leu Val Thr Asp
50 55 60

Phe Pro Thr Asp Leu Pro Ala Thr Glu Val Phe Thr Pro Val Val Pro
65 70 75 80

Thr Val Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Leu
85 90 95

Arg Ser Lys Ser Lys Lys Phe Arg Arg Pro Asp Ile Gln Tyr Pro Asp
100 105 110

Ala Thr Asp Glu Asp Ile Thr Ser His Met Glu Ser Glu Glu Leu Asn
115 120 125

Gly Ala Tyr Lys Ala Ile Pro Val Ala Gln Asp Leu Asn Ala Pro Ser
130 135 140

Asp Trp Asp Ser Arg Gly Lys Asp Ser Tyr Glu Thr Ser Gln Leu Asp
145 150 155 160

Asp Gln Ser Ala Glu Thr His Ser His Arg Gln Ser Arg Leu Tyr Lys
165 170 175

Arg Lys Ala Asn Asp Glu Ser Asn Glu His Ser Asp Val Ile Asp Ser
180 185 190

Gln Glu Leu Ser Lys Val Ser Arg Glu Phe His Ser His Glu Phe His
195 200 205

255

Ser His Glu Asp Met Leu Val Val Asp Pro Lys Ser Lys Glu Glu Asp
 210 215 220

Lys His Leu Lys Phe Arg Ile Ser His Glu Leu Asp Ser Ala Ser Ser
 225 230 235 240

Glu Val Asn

<210> 266
 <211> 62
 <212> PRT
 <213> Homo sapien

<400> 266

Met Leu Gly Val Lys Phe Tyr Val Pro Ser Leu Leu Glu Phe Lys Ile
 1 5 10 15

Tyr Asn Leu Phe Phe Cys Met Leu Thr Phe Leu Lys Arg Ile His Leu
 20 25 30

Leu Ser Gln Ile Ser Lys Ser Lys Glu Arg Lys Ile Ile Ser Tyr Tyr
 35 40 45

Gln Lys Ala Leu Gly Phe Leu Met Gln Asn Asn Pro Ser Asn
 50 55 60

<210> 267
 <211> 305
 <212> PRT
 <213> Homo sapien

<400> 267

Gln Phe Leu Gly Arg Trp Phe Ser Ala Gly Leu Ala Ser Asn Ser Ser
 1 5 10 15

Trp Leu Arg Glu Lys Lys Ala Ala Leu Ser Met Cys Lys Ser Val Val
 20 25 30

Ala Pro Ala Thr Asp Gly Gly Leu Asn Leu Thr Ser Thr Phe Leu Arg
 35 40 45

Lys Asn Gln Cys Glu Thr Arg Thr Met Leu Leu Gln Pro Ala Gly Ser
 50 55 60

Leu Gly Ser Tyr Ser Tyr Arg Ser Pro Arg Glu Trp Gly Leu His Arg
 65 70 75 80

256

Pro Pro Gly Pro Ser Leu Gly Ala Thr Leu Ala Gly Thr Thr Leu Gly
 85 90 95

Gln Pro Pro Ala Ala Glu Ile His Gly Val Gly Gly Asp Gly Cys Pro
 100 105 110

Thr Ser Val Arg Gly Lys Gly Gln Arg Thr Gln Gly Phe Pro His Ser
 115 120 125

His Leu Gly Asn Gly Ser His Gly Glu Thr Ser Ser Leu Pro Val Leu
 130 135 140

Ala Ala Thr Ser Ala Ala Ala Pro Gly Ile Leu Val Phe Ala Trp Leu
 145 150 155 160

Pro Gln Ile Leu Val Trp Gly Gln Gly Ser Gln Ala Val Gln Ala Arg
 165 170 175

Ala Gly His Trp Leu Glu Ser Ser Arg Val Gly Glu His Pro Gly Pro
 180 185 190

Ala Glu Gly Leu Ser Ala Pro Lys Ala His Arg Cys Thr Pro Ser Leu
 195 200 205

Lys Gln Arg Gly Leu Gly Gly Val Pro Asp Arg Val Val Ser Trp Val
 210 215 220

Pro Arg Leu Gly Ser Thr Tyr Ser Val Ser Val Val Glu Thr Asp Tyr
 225 230 235 240

Asp Gln Tyr Ala Leu Leu Tyr Ser Gln Gly Ser Lys Gly Pro Gly Glu
 245 250 255

Asp Phe Arg Met Ala Thr Leu Tyr Ser Arg Thr Gln Thr Pro Arg Ala
 260 265 270

Glu Leu Lys Glu Lys Phe Thr Ala Phe Cys Lys Ala Gln Gly Phe Thr
 275 280 285

Glu Asp Thr Ile Val Phe Leu Pro Gln Thr Asp Lys Cys Met Thr Glu
 290 295 300

Gln
 305

257

<210> 268

<211> 262

<212> PRT

<213> Homo sapien

<400> 268

Arg Arg His Ser Ser Arg Ser Ser Cys Ser Gly Pro Pro Arg Pro Gly
 1 5 10 15

His Leu Pro Arg Ser Pro Thr Pro Leu Ala Pro Gly Pro Gly His Pro
 20 25 30

Leu Cys Cys Arg Arg Met Ala Thr His His Thr Leu Trp Met Gly Leu
 35 40 45

Ala Leu Leu Gly Val Leu Gly Asp Leu Gln Ala Ala Pro Glu Ala Gln
 50 55 60

Val Ser Val Gln Pro Asn Phe Gln Gln Asp Lys Phe Leu Gly Arg Trp
 65 70 75 80

Phe Ser Ala Gly Leu Ala Ser Asn Ser Ser Trp Leu Arg Glu Lys Lys
 85 90 95

Ala Ala Leu Ser Met Cys Lys Ser Val Val Ala Pro Ala Thr Asp Gly
 100 105 110

Gly Leu Asn Leu Thr Ser Thr Phe Leu Arg Lys Asn Gln Cys Glu Thr
 115 120 125

Arg Thr Met Leu Leu Gln Pro Ala Gly Ser Leu Gly Ser Tyr Ser Tyr
 130 135 140

Arg Ser Pro Arg Glu Trp Gly Leu His Arg Pro Pro Gly Pro Ser Leu
 145 150 155 160

Gly Ala Thr Leu Ala Gly Thr Thr Leu Gly Gln Pro Pro Ala Ala Glu
 165 170 175

Ile His Gly Val Gly Gly Asp Trp Gly Ser Thr Tyr Ser Val Ser Val
 180 185 190

Val Glu Thr Asp Tyr Asp Gln Tyr Ala Leu Leu Tyr Ser Gln Gly Ser
 195 200 205

Lys Gly Pro Gly Glu Asp Phe Arg Met Ala Thr Leu Tyr Ser Arg Thr
 210 215 220

258

Gln Thr Pro Arg Ala Glu Leu Lys Glu Lys Phe Thr Ala Phe Cys Lys
 225 230 235 240

Ala Gln Gly Phe Thr Glu Asp Thr Ile Val Phe Leu Pro Gln Thr Asp
 245 250 255

Lys Cys Met Thr Glu Gln
 260

<210> 269
 <211> 450
 <212> PRT
 <213> Homo sapien

<400> 269

Arg Arg His Ser Ser Arg Ser Ser Cys Ser Gly Pro Pro Arg Pro Gly
 1 5 10 15

His Leu Pro Arg Ser Pro Thr Pro Leu Ala Pro Gly Pro Gly His Pro
 20 25 30

Leu Cys Cys Arg Arg Met Ala Thr His His Thr Leu Trp Met Gly Leu
 35 40 45

Ala Leu Leu Gly Val Leu Gly Asp Leu Gln Ala Ala Pro Glu Ala Gln
 50 55 60

Val Ser Val Gln Pro Asn Phe Gln Gln Asp Lys Val Arg Gly Phe Pro
 65 70 75 80

Ala Ser Ser Pro Arg Ala Thr Gly Pro Cys Gln Gly Lys Gly Thr Phe
 85 90 95

Arg Leu Gly Leu Pro Pro Gly Arg Ser Glu Arg Ser Pro Ala Val Pro
 100 105 110

Gly Ser Ala Gly Gln Gly Leu Ser Gly Arg Ala Gly Arg Arg Leu Gly
 115 120 125

Ser Arg Pro Arg Arg Leu Pro Ala Arg Ala Leu Pro Gly His Arg Val
 130 135 140

Pro Ser Pro Leu Met Gly His Ala Asp Thr Gly Pro His Thr Arg Pro
 145 150 155 160

259

Arg Gln Pro Asp Thr Ser Thr Pro Val Gly Thr Arg Pro Pro Glu Asp
 165 170 175

Thr Arg Ala His Val Pro His Leu Gly Ala Arg Thr Arg Ala Gly Gly
 180 185 190

Ala Gln Gly Trp Arg Gln Thr Leu Arg Ala Arg Trp Gly Leu Gly Gly
 195 200 205

Thr Arg Thr Ala Gln Thr Ala Gly Asp Ala Arg Ser Arg Pro Gly Ala
 210 215 220

Ala Arg Gly Ser Ala Gly Ala Arg Val Pro Ala Pro Arg Ala Pro Pro
 225 230 235 240

Trp Arg Arg Gly Glu Pro Gln Arg Ser Ala Glu Leu Ser Arg Arg Pro
 245 250 255

Ala Pro Ile Pro Ala Arg Asn Ala Thr Ser Ser Ala Ala Arg Cys Met
 260 265 270

Gly Gln Ala Leu Ser Gln Gly Thr Glu Ser Gly Pro Gly Ala Glu Gly
 275 280 285

Pro Lys Leu Ala Gly Gly Arg Arg Ala Arg Phe Leu Gly Arg Trp Phe
 290 295 300

Ser Ala Gly Leu Ala Ser Asn Ser Ser Trp Leu Arg Glu Lys Lys Ala
 305 310 315 320

Ala Leu Ser Met Cys Lys Ser Val Val Ala Pro Ala Thr Asp Gly Gly
 325 330 335

Leu Asn Leu Thr Ser Thr Phe Leu Arg Lys Asn Gln Cys Glu Thr Arg
 340 345 350

Thr Met Leu Leu Gln Pro Ala Gly Ser Leu Gly Ser Tyr Ser Tyr Arg
 355 360 365

Ser Pro His Trp Gly Ser Thr Tyr Ser Val Ser Val Val Glu Thr Asp
 370 375 380

Tyr Asp Gln Tyr Ala Leu Leu Tyr Ser Gln Gly Ser Lys Gly Pro Gly
 385 390 395 400

Glu Asp Phe Arg Met Ala Thr Leu Tyr Ser Arg Thr Gln Thr Pro Arg

									260										
				405					410							415			
Ala	Glu	Leu	Lys	Glu	Lys	Phe	Thr	Ala	Phe	Cys	Lys	Ala	Gln	Gly	Phe				
			420					425					430						
Thr	Glu	Asp	Thr	Ile	Val	Phe	Leu	Pro	Gln	Thr	Asp	Lys	Cys	Met	Thr				
		435					440					445							
Glu	Gln																		
	450																		
<210>	270																		
<211>	447																		
<212>	PRT																		
<213>	Homo sapien																		
<400>	270																		
Arg	Arg	His	Ser	Ser	Arg	Ser	Ser	Cys	Ser	Gly	Pro	Pro	Arg	Pro	Gly				
1				5					10					15					
His	Leu	Pro	Arg	Ser	Pro	Thr	Pro	Leu	Ala	Pro	Gly	Pro	Gly	His	Pro				
			20					25					30						
Leu	Cys	Cys	Arg	Arg	Met	Ala	Thr	His	His	Thr	Leu	Trp	Met	Gly	Leu				
		35					40					45							
Ala	Leu	Leu	Gly	Val	Leu	Gly	Asp	Leu	Gln	Ala	Ala	Pro	Glu	Ala	Gln				
	50					55					60								
Val	Ser	Val	Gln	Pro	Asn	Phe	Gln	Gln	Asp	Lys	Val	Arg	Gly	Phe	Pro				
65					70					75					80				
Ala	Ser	Ser	Pro	Arg	Ala	Thr	Gly	Pro	Cys	Gln	Gly	Lys	Gly	Thr	Phe				
				85					90					95					
Arg	Leu	Gly	Leu	Pro	Pro	Gly	Arg	Ser	Glu	Arg	Ser	Pro	Ala	Val	Pro				
			100					105					110						
Gly	Ser	Ala	Gly	Gln	Gly	Leu	Ser	Gly	Arg	Ala	Gly	Arg	Arg	Leu	Gly				
		115					120					125							
Ser	Arg	Pro	Arg	Arg	Leu	Pro	Ala	Arg	Ser	Pro	Pro	Trp	Ala	Pro	Arg				
	130					135					140								
Pro	Val	Ser	Pro	Asp	Gly	Pro	Arg	Arg	His	Arg	Ala	Thr	His	Ala	Pro				
145					150					155					160				

261

Thr Pro Ala Arg His Val His Pro Cys Gly His Ala Thr Pro Arg Gly
 165 170 175

His Thr Ser Ala Arg Ser Thr Pro Gly Cys Gln Asp Thr Gly Gly Trp
 180 185 190

Gly Thr Gly Met Ala Thr Asn Thr Pro Cys Ala Val Gly Val Gly Arg
 195 200 205

Asp Ala His Arg Thr Asp Ser Arg Arg Arg Ala Leu Ser Pro Gly Ser
 210 215 220

Cys Ser Gly Lys Arg Arg Ser Ala Gly Pro Arg Ala Ala Arg Pro Ser
 225 230 235 240

Leu Ala Ser Arg Arg Thr Pro Ala Val Arg Arg Ala Glu Pro Lys Thr
 245 250 255

Arg Pro Asp Pro Arg Gln Glu Cys Asp Val Leu Cys Arg Pro Leu Tyr
 260 265 270

Gly Pro Gly Ala Gln Pro Gly His Arg Ile Gly Thr Gly Gly Gly Gly
 275 280 285

Ala Glu Ala Gly Trp Trp Ala Ala Cys Glu Gly Glu Gly Leu Ser Ser
 290 295 300

Gly Gly Ala Trp Pro Asp Gly Gly Ala Gly Cys Gln Gly Arg Gly Gln
 305 310 315 320

Leu Leu Gly Arg Arg Cys Glu Gly Arg Gly His Leu Leu Gly Arg Gly
 325 330 335

Leu Arg Gly Gly Gly Gln Phe Leu Gly Arg Gly Val Arg Gly Val Ala
 340 345 350

Ala Arg Gly Ile Gly Arg Gly Gly Gly Ala Gly Leu Glu Thr Gly Gly
 355 360 365

Val Asp Gly Arg Gly Ala Pro Ala Gly Arg Arg Arg Trp Val Arg Arg
 370 375 380

Val Leu Ala Asp Ala Gly Gly Gly Arg Ser Pro Gln Phe Pro Gly Ala
 385 390 395 400

262

Leu Val Gln Arg Gly Pro Arg Leu Gln Leu Glu Leu Ala Pro Gly Glu
 405 410 415

Glu Gly Gly Val Val His Val Gln Val Cys Gly Gly Pro Cys His Gly
 420 425 430

Trp Trp Pro Gln Pro Asp Leu His Leu Pro Gln Glu Lys Pro Val
 435 440 445

<210> 271
 <211> 135
 <212> PRT
 <213> Homo sapien

<400> 271

Met Ala Ala Gly Pro Met Ala Ala Glu Pro Cys Gly Pro His Ala Leu
 1 5 10 15

Val Ala Leu Ala Gly Leu Val Thr Gly Ile Pro Thr His His Pro Arg
 20 25 30

Val Tyr Asn Ile His Ser Arg Thr Val Thr Arg Tyr Pro Ala Asn Ser
 35 40 45

Ile Val Val Val Gly Gly Cys Pro Val Cys Arg Val Gly Val Leu Glu
 50 55 60

Asp Cys Phe Thr Phe Leu Gly Ile Phe Leu Ala Ile Ile Leu Phe Arg
 65 70 75 80

Ile Gly Pro Ala Ala Ile Gly Gln Trp Gln Pro Pro Asn Gly Ser Arg
 85 90 95

Thr Gln Thr Pro Arg Ala Glu Leu Lys Glu Lys Phe Thr Ala Phe Cys
 100 105 110

Lys Ala Gln Gly Phe Thr Glu Asp Thr Ile Val Phe Leu Pro Gln Thr
 115 120 125

Asp Lys Cys Met Thr Glu Gln
 130 135

<210> 272
 <211> 150
 <212> PRT
 <213> Homo sapien

<400> 272

263

Ala Leu Leu Glu Ala Trp Ala Arg Asp Arg Gly Val Ser Val Gln Val
1 5 10 15

Arg Thr Ser Leu Pro Gln Pro Leu His Glu Glu Pro Pro Pro Trp Gly
20 25 30

Thr Trp Arg Pro Gly Ala His Ser Val Pro Gly Pro Ser Ser Ser Gln
35 40 45

Asp Val Gly Leu Gln Pro Gly Gly Gly His Arg Val Glu Gly Ala His
50 55 60

Gly Gly Tyr Arg Gly Thr Asn His Thr Gly Leu Arg His Ser Leu Leu
65 70 75 80

Gly Val Asp Ser Leu Leu Leu Ala Glu Val Glu Lys Asp Pro Leu Phe
85 90 95

Val Ser Ser Ala Gln Gly Glu Val Gly Gly Asp Gly Gly Ser Val Gln
100 105 110

Phe Gly Gly Ser Val Lys Thr Ser Ser Ala Leu Arg Glu Glu Gln Glu
115 120 125

Ala Gln Trp Glu Asn Trp Pro Lys Ser Gly Val Leu Thr Thr Ala Pro
130 135 140

Gly Phe Phe Leu Gly Arg
145 150

<210> 273

<211> 227

<212> PRT

<213> Homo sapien

<400> 273

Arg Arg His Ser Ser Arg Ser Ser Cys Ser Gly Pro Pro Arg Pro Gly
1 5 10 15

His Leu Pro Arg Ser Pro Thr Pro Leu Ala Pro Gly Pro Gly His Pro
20 25 30

Leu Cys Cys Arg Arg Met Ala Thr His His Thr Leu Trp Met Gly Leu
35 40 45

Ala Leu Leu Gly Val Leu Gly Asp Leu Gln Ala Ala Pro Glu Ala Gln

264

50

55

60

Val Ser Val Gln Pro Asn Phe Gln Gln Asp Lys Phe Leu Gly Arg Trp
65 70 75 80

Phe Ser Ala Gly Leu Ala Ser Asn Ser Ser Trp Leu Arg Glu Lys Lys
85 90 95

Ala Ala Leu Ser Met Cys Lys Ser Val Val Ala Pro Ala Thr Asp Gly
100 105 110

Gly Leu Asn Leu Thr Ser Thr Phe Leu Arg Lys Asn Gln Cys Glu Thr
115 120 125

Arg Thr Met Leu Leu Gln Pro Ala Gly Ser Leu Gly Ser Tyr Ser Tyr
130 135 140

Arg Ser Pro His Trp Gly Ser Thr Tyr Ser Val Ser Val Val Glu Thr
145 150 155 160

Asp Tyr Asp Gln Tyr Ala Leu Leu Tyr Ser Gln Gly Ser Lys Gly Pro
165 170 175

Gly Glu Asp Phe Arg Met Ala Thr Leu Tyr Ser Arg Thr Gln Thr Pro
180 185 190

Arg Ala Glu Leu Lys Glu Lys Phe Thr Ala Phe Cys Lys Ala Gln Gly
195 200 205

Phe Thr Glu Asp Thr Ile Val Phe Leu Pro Gln Thr Asp Lys Cys Met
210 215 220

Thr Glu His
225

<210> 274
<211> 122
<212> PRT
<213> Homo sapien

<400> 274

Arg Arg Ser Val Met Asp Trp Ser Arg Pro Arg Tyr Pro Asp Ala Thr
1 5 10 15

Asp Glu Asp Ile Thr Ser His Met Glu Ser Glu Glu Leu Asn Gly Ala
20 25 30

265

Tyr Lys Ala Ile Pro Val Ala Gln Asp Leu Asn Ala Pro Ser Asp Trp
 35 40 45

Asp Ser Arg Gly Lys Asp Ser Tyr Glu Thr Ser Gln Leu Asp Asp Gln
 50 55 60

Ser Ala Glu Thr His Ser His Lys Gln Ser Arg Leu Tyr Lys Arg Lys
 65 70 75 80

Ala Asn Asp Glu Ser Asn Glu His Ser Asp Val Ile Asp Ser Gln Glu
 85 90 95

Leu Ser Lys Val Ser Arg Glu Phe His Ser His Glu Phe His Ser His
 100 105 110

Glu Asp Met Leu Val Val Asp Pro Gln Lys
 115 120

<210> 275
 <211> 63
 <212> PRT
 <213> Homo sapien

<400> 275

Val Ile Asp Val Ile His Glu Val Ala His Ser Trp Phe Gly Asn Ala
 1 5 10 15

Val Thr Asn Ala Thr Trp Glu Glu Met Trp Leu Ser Glu Gly Leu Ala
 20 25 30

Thr Tyr Ala Gln Arg Arg Ile Thr Thr Glu Thr Tyr Gly Ala Ala Phe
 35 40 45

Thr Cys Leu Glu Thr Ala Phe Arg Leu Asp Ala Leu His Arg Gln
 50 55 60

<210> 276
 <211> 116
 <212> PRT
 <213> Homo sapien

<400> 276

Met Leu Trp Val Trp Phe His Ile Thr Ala Ile Lys Leu Gln Arg Glu
 1 5 10 15

Glu Glu Glu Ala Phe Ala Ser Ser Gln Ser Ser Gln Gly Ala Gln Ser
 20 25 30

266

Leu Ile Phe Ser Lys Phe Glu Gly Lys Lys Thr Asn Lys Lys Thr Arg
35 40 45

Lys Val Thr Thr Val Lys Lys Ser Ser Val Arg Leu Pro Gly Ser Asp
50 55 60

Gln Arg Arg Ile Leu Lys Trp Ile Pro Gly Val Cys Leu Glu Thr Ser
65 70 75 80

Trp Pro Ala Ser Pro Ser Ala Ala Ser Thr Ser Ser Met Pro Ser Arg
85 90 95

Ser Pro Arg Thr Ser Trp Arg Gln Gln Met Thr Ser Ser Pro Pro Ser
100 105 110

Ser Thr Leu Phe
115

<210> 277
<211> 57
<212> PRT
<213> Homo sapien

<400> 277

Met Asp Arg Val Ser Lys Glu Phe Ile Glu Phe Leu Lys Thr Phe Cys
1 5 10 15

Lys Thr Gly Gln Glu Ile Tyr Lys Leu Thr Lys Leu Phe Leu Glu Gly
20 25 30

Met His Tyr Lys Thr Leu Cys Phe Tyr Val Ile Ile Leu Asn Leu Pro
35 40 45

Phe Cys Asn Ala Ser Leu Pro Lys Gly
50 55

<210> 278
<211> 144
<212> PRT
<213> Homo sapien

<400> 278

Met Ser Ala Gly Ala Leu Phe Ile Gly Tyr Cys Ile Tyr Phe Asp Arg
1 5 10 15

Lys Arg Arg Ser Asp Pro Asn Phe Lys Asn Arg Leu Arg Glu Arg Arg

267

20

25

30

Lys Lys Gln Lys Leu Ala Lys Glu Arg Ala Gly Leu Ser Lys Leu Pro
 35 40 45

Asp Leu Lys Asp Ala Glu Ala Val Gln Lys Phe Phe Leu Glu Glu Ile
 50 55 60

Gln Leu Gly Glu Glu Leu Leu Ala Gln Glu Ala Gly His Ser Leu Gln
 65 70 75 80

Leu Ala Asn Asp Asp His Val Asp Met Leu Ser Gly Leu Gln Asp Leu
 85 90 95

Leu Gln Pro Val Asp Val Val Arg Val Gly Val Pro Glu Arg Asp Val
 100 105 110

Arg Trp Trp Leu Thr Pro Ala Ile Pro Ala Leu Trp Glu Ala Lys Ala
 115 120 125

Gly Gly Ser Leu Glu Pro Arg Arg Ser Arg Pro Val Trp Ala Thr Trp
 130 135 140

<210> 279

<211> 105

<212> PRT

<213> Homo sapien

<400> 279

Phe Phe Leu Gln Asn Ala Val Gly Gln Pro Ala Arg Gly Leu Glu Thr
 1 5 10 15

Arg Leu Leu Arg Ala Gln Ser Ser Gly Trp Ala Ala Ala Leu Cys Ala
 20 25 30

Ala Ser Arg Ser Ser Gly Ser Gly Val Ser Ala Glu Gln Gly Glu Gly
 35 40 45

Arg Arg Ser Arg Ile Leu Asn Thr Ser Ser Leu Lys Arg Gly Lys Glu
 50 55 60

Gly Gly Gly Lys Asn Pro Leu Tyr Trp Lys Thr Asn Asn Pro Arg Lys
 65 70 75 80

Leu Thr Trp Ser Glu Pro Ile Phe Lys Val Arg Lys Tyr Asn Gly Asp
 85 90 95

268

Phe Ala Thr Leu Leu Tyr Gly Lys Asp
 100 105

<210> 280
 <211> 295
 <212> PRT
 <213> Homo sapien

<400> 280

Met Glu Thr Pro Ala Trp Pro Arg Val Pro Arg Pro Glu Thr Ala Val
 1 5 10 15

Ala Arg Thr Leu Leu Leu Gly Trp Val Phe Ala Gln Val Ala Gly Ala
 20 25 30

Ser Gly Thr Thr Asn Thr Val Ala Ala Tyr Asn Leu Thr Trp Lys Ser
 35 40 45

Thr Asn Phe Lys Thr Ile Leu Glu Trp Glu Pro Lys Pro Val Asn Gln
 50 55 60

Val Tyr Thr Val Gln Ile Ser Thr Lys Ser Gly Asp Trp Lys Ser Lys
 65 70 75 80

Cys Phe Tyr Thr Thr Asp Thr Glu Cys Asp Leu Thr Asp Glu Ile Val
 85 90 95

Lys Asp Val Lys Gln Thr Tyr Leu Ala Arg Val Phe Ser Tyr Pro Ala
 100 105 110

Gly Asn Val Glu Ser Thr Gly Ser Ala Gly Glu Pro Leu Tyr Glu Asn
 115 120 125

Ser Pro Glu Phe Thr Pro Tyr Leu Glu Thr Asn Leu Gly Gln Pro Thr
 130 135 140

Ile Gln Ser Phe Glu Gln Val Gly Thr Lys Val Asn Val Thr Val Glu
 145 150 155 160

Asp Glu Arg Thr Leu Val Arg Arg Asn Asn Thr Phe Leu Ser Leu Arg
 165 170 175

Asp Val Phe Gly Lys Asp Leu Ile Tyr Thr Leu Tyr Tyr Trp Lys Ser
 180 185 190

Ser Ser Ser Gly Lys Lys Thr Ala Lys Thr Asn Thr Asn Glu Phe Leu

<400> 282

270

Met Ile Gly Leu Val Pro Ala Ser Ala Arg Val Gly Val Gln Arg Phe
 1 5 10 15

Gly Tyr Tyr Leu Ser Leu Tyr Val His Leu Pro Leu Ile Lys Ser Val
 20 25 30

Pro Gly Leu Phe Leu Ala Ile Phe Val Leu Gly Leu Gly Arg Gly Asn
 35 40 45

Pro Lys Gly Leu Asp Cys Cys Leu Asp Trp Ser Arg Tyr Asn Val Val
 50 55 60

His Ala Pro Tyr Phe Tyr Glu Val Phe Gly Thr Ala
 65 70 75

<210> 283
 <211> 129
 <212> PRT
 <213> Homo sapien

<400> 283

Met Ser Ser Pro Ile Asn Ser Asp Val Arg Leu Phe Gly Ser Arg Ser
 1 5 10 15

Phe Leu Ser His Glu Thr Val Lys Lys Tyr Pro Ala Pro Leu Ala Ala
 20 25 30

Val Leu Ile Lys Val Asp Pro Arg Val Leu Pro Cys Gly Ser Lys Lys
 35 40 45

Arg Gln Leu Ala His Leu Leu Thr Pro Ser Arg Gln Arg Arg Gln Gln
 50 55 60

Gln Ala Gly Pro Pro Pro Ser His Ala Asn His Pro Arg Glu Cys Ser
 65 70 75 80

Trp Ala Pro Pro Ala Pro Pro Arg Gln Cys Ser Trp Gly Val Cys Gly
 85 90 95

Glu Asp Ala Ile Gln Gly Ala Val Arg Ser Ser Ser Ser Pro Ser
 100 105 110

Cys Trp Thr Arg Ser Ala Trp Ser Phe Cys Cys Trp Gly Ser Trp Pro
 115 120 125

Pro

271

<210> 284
 <211> 129
 <212> PRT
 <213> Homo sapien

<400> 284

Met Ser Ser Pro Ile Asn Ser Asp Val Arg Leu Phe Gly Ser Arg Ser
 1 5 10 15

Phe Leu Ser His Glu Thr Val Lys Lys Tyr Pro Ala Pro Leu Ala Ala
 20 25 30

Val Leu Ile Lys Val Asp Pro Arg Val Leu Pro Cys Gly Ser Lys Lys
 35 40 45

Arg Gln Leu Ala His Leu Leu Thr Pro Ser Arg Gln Arg Arg Gln Gln
 50 55 60

Gln Ala Gly Pro Pro Pro Ser His Ala Asn His Pro Arg Glu Cys Ser
 65 70 75 80

Trp Ala Pro Pro Ala Pro Pro Arg Gln Cys Ser Trp Gly Val Cys Gly
 85 90 95

Glu Asp Ala Ile Gln Gly Ala Val Arg Ser Ser Ser Ser Ser Pro Ser
 100 105 110

Cys Trp Thr Arg Ser Ala Trp Ser Phe Cys Cys Trp Gly Ser Trp Pro
 115 120 125

Pro

<210> 285
 <211> 52
 <212> PRT
 <213> Homo sapien

<400> 285

Met Gln Ile Met Pro His Ile Ile Leu Phe Phe Cys Cys Thr Val Ile
 1 5 10 15

Cys Ser Thr Phe Glu Ile Gln Lys Tyr Ile Thr Ile Ser Gln Gly Ala
 20 25 30

Ala Gly Phe Pro Gly Ala Arg Gly Leu Pro Gly Pro Pro Gly Ser Asn

272

35

40

45

Val Ser Asn Cys
50

<210> 286
<211> 347
<212> PRT
<213> Homo sapien

<400> 286

Met Val Asn Leu Val Val Lys Glu Lys Glu Gly Leu Arg Val Arg Lys
1 5 10 15

Val Lys Glu Ala Leu Leu Glu Leu Gln Asp Pro Leu Glu Val Leu Asp
20 25 30

Leu Leu Val Leu Leu Val Pro Lys Val Ser Lys Val Asn Val Ala Val
35 40 45

Leu Val Asp Leu Val Leu Leu Ala Ser Leu Val Leu Val Val Phe Leu
50 55 60

Val Leu Leu Val Val Met Val Thr Gln Asp Pro Gln Val Pro Ala Val
65 70 75 80

Leu Gln Ala Arg Met Gly Pro Gln Val Leu Arg Val Thr Leu Val Leu
85 90 95

Leu Ala Ala Leu Glu Cys Leu Asp Gln Lys Val Met Leu Ala Asn Gln
100 105 110

Glu Arg Arg Asp Arg Leu Val Pro Arg Ala His Gln Glu Leu Gln Ala
115 120 125

His Leu Gly Leu Leu Gly Ser Leu Glu His Gly Val Leu Gln Asp His
130 135 140

Gln Ala Cys Gln Val Leu Gly Glu Ala Leu Ala Leu Arg Val Ser Arg
145 150 155 160

Val Lys Val Gly Asn Gln Glu Leu Thr Val Ser Val Glu Asn Val Val
165 170 175

Pro Leu Asp Pro Arg Val Phe Leu Val Trp Leu Val Gln Leu Val Asn
180 185 190

273

Leu Glu Glu Met Glu Thr Leu Asp Gln Met Val Phe Gln Ala Glu Met
 195 200 205

Asp Leu Leu Val Ala Arg Val Ile Val Val Lys Met Ala Leu Leu Val
 210 215 220

Pro Leu Ala Leu Leu Val Ile Gln Ala His Leu Val Leu Ser Val Gln
 225 230 235 240

Leu Glu Arg Val Val Thr Glu Glu Lys Val Ala Leu Leu Ala Leu Leu
 245 250 255

Val Leu Pro Val Leu Leu Val Pro Glu Val Leu Leu Val Leu Lys Ala
 260 265 270

His Val Val Thr Lys Val Lys Gln Val Asn Val Glu Leu Leu Ala Ser
 275 280 285

Lys Asp Ile Glu Asp Ser Leu Val Ile Gln Val Pro Gln Val Leu Gln
 290 295 300

Ala Leu Leu Val Ser Arg Val Gln Ser Ala Val Gln Asp Leu Gln Ala
 305 310 315 320

Pro Glu Asp Pro Val Gly Pro Met Trp Thr Pro Gly Lys Asp Gly Pro
 325 330 335

Val Gly Ser Arg Pro Trp Thr Thr Gly Leu Glu
 340 345

<210> 287

<211> 327

<212> PRT

<213> Homo sapien

<400> 287

Met Gln Ile Met Pro His Ile Ile Leu Phe Val Cys Cys Thr Val Ile
 1 5 10 15

Cys Ser Thr Phe Glu Ile Gln Lys Tyr Ile Thr Ile Ser Gln Gly Pro
 20 25 30

Gly Ala Ala Gly Phe Pro Gly Ala Arg Gly Leu Pro Gly Pro Pro Gly
 35 40 45

Ser Asn Gly Asn Pro Gly Pro Pro Gly Pro Ser Gly Ser Pro Gly Lys

60

Gln Gln Gly Ala Ile Gly Ser Pro Gly Pro Ala Gly Pro Arg Gly Pro
290 295 300

275

Val Gly Pro Met Trp Thr Pro Gly Lys Asp Gly Pro Val Gly Ser Arg
 305 310 315 320

Pro Trp Thr Thr Gly Leu Glu
 325

<210> 288
 <211> 702
 <212> PRT
 <213> Homo sapien

<400> 288

Gln Gly Pro Pro Gly Glu Pro Gly Gln Ala Gly Pro Ser Gly Pro Pro
 1 5 10 15

Gly Pro Pro Gly Ala Ile Gly Pro Ser Gly Pro Ala Gly Lys Asp Gly
 20 25 30

Glu Ser Gly Arg Pro Gly Arg Pro Gly Glu Arg Gly Leu Pro Gly Pro
 35 40 45

Pro Gly Ile Lys Gly Pro Ala Gly Ile Pro Gly Phe Pro Gly Met Lys
 50 55 60

Gly His Arg Gly Phe Asp Gly Arg Asn Gly Glu Lys Gly Glu Thr Gly
 65 70 75 80

Ala Pro Gly Leu Lys Gly Glu Asn Gly Leu Pro Gly Glu Asn Gly Ala
 85 90 95

Pro Gly Pro Met Gly Pro Arg Gly Ala Pro Gly Glu Arg Gly Arg Pro
 100 105 110

Gly Leu Pro Gly Ala Ala Gly Ala Arg Gly Asn Asp Gly Ala Arg Gly
 115 120 125

Ser Asp Gly Gln Pro Gly Pro Pro Gly Pro Pro Gly Thr Ala Gly Phe
 130 135 140

Pro Gly Ser Pro Gly Ala Lys Gly Glu Val Gly Pro Ala Gly Ser Pro
 145 150 155 160

Gly Ser Asn Gly Ala Pro Gly Gln Arg Gly Glu Pro Gly Pro Gln Gly
 165 170 175

276

His Ala Gly Ala Gln Gly Pro Pro Gly Pro Pro Gly Ile Asn Gly Ser
 180 185 190

Pro Gly Gly Lys Gly Glu Met Gly Pro Ala Gly Ile Pro Gly Ala Pro
 195 200 205

Gly Leu Met Gly Ala Arg Gly Pro Pro Gly Pro Ala Gly Ala Asn Gly
 210 215 220

Ala Pro Gly Leu Arg Gly Gly Ala Gly Glu Pro Gly Lys Asn Gly Ala
 225 230 235 240

Lys Gly Glu Pro Gly Pro Arg Gly Glu Arg Gly Glu Ala Gly Ile Pro
 245 250 255

Gly Val Pro Gly Ala Lys Gly Glu Asp Gly Lys Asp Gly Ser Pro Gly
 260 265 270

Glu Pro Gly Ala Asn Gly Leu Pro Gly Ala Ala Gly Glu Arg Gly Ala
 275 280 285

Pro Gly Phe Arg Gly Pro Ala Gly Pro Asn Gly Ile Pro Gly Glu Lys
 290 295 300

Gly Pro Ala Gly Glu Arg Gly Ala Pro Gly Pro Ala Gly Pro Arg Gly
 305 310 315 320

Ala Ala Gly Glu Pro Gly Arg Asp Gly Val Pro Gly Gly Pro Gly Met
 325 330 335

Arg Gly Met Pro Gly Ser Pro Gly Gly Pro Gly Ser Asp Gly Lys Pro
 340 345 350

Gly Pro Pro Gly Ser Gln Gly Glu Ser Gly Arg Pro Gly Pro Pro Gly
 355 360 365

Pro Ser Gly Pro Arg Gly Gln Pro Gly Val Met Gly Phe Pro Gly Pro
 370 375 380

Lys Gly Asn Asp Gly Ala Pro Gly Lys Asn Gly Glu Arg Gly Gly Pro
 385 390 395 400

Gly Gly Pro Gly Pro Gln Gly Pro Pro Gly Lys Asn Gly Glu Thr Gly
 405 410 415

Pro Gln Gly Pro Pro Gly Pro Thr Gly Pro Gly Gly Asp Lys Gly Asp

277

420

425

430

Thr Gly Pro Pro Gly Pro Gln Gly Leu Gln Gly Leu Pro Gly Thr Gly
 435 440 445

Gly Pro Pro Gly Glu Asn Gly Lys Pro Gly Glu Pro Gly Pro Lys Gly
 450 455 460

Asp Ala Gly Ala Pro Gly Ala Pro Gly Gly Lys Gly Asp Ala Gly Ala
 465 470 475 480

Pro Gly Glu Arg Gly Pro Pro Gly Leu Ala Gly Ala Pro Gly Leu Arg
 485 490 495

Gly Gly Ala Gly Pro Pro Gly Pro Glu Gly Gly Lys Gly Ala Ala Gly
 500 505 510

Pro Pro Gly Pro Pro Gly Ala Ala Gly Thr Pro Gly Leu Gln Gly Met
 515 520 525

Pro Gly Glu Arg Gly Gly Leu Gly Ser Pro Trp Ser Ser Gln Arg Trp
 530 535 540

Phe Arg Leu Gln Leu Pro Ala Pro Ala Thr Ser Arg Glu Gly Ser Arg
 545 550 555 560

Gly Gly Arg Tyr Tyr Arg Ala Asp Asp Ala Asn Val Val Arg Asp Arg
 565 570 575

Asp Leu Glu Val Asp Thr Thr Leu Lys Ser Leu Ser Gln Gln Ile Glu
 580 585 590

Asn Ile Arg Ser Pro Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr Cys
 595 600 605

Arg Asp Leu Lys Met Cys His Ser Asp Trp Lys Ser Gly Glu Tyr Trp
 610 615 620

Ile Asp Pro Asn Gln Gly Cys Asn Leu Asp Ala Ile Lys Val Phe Cys
 625 630 635 640

Asn Met Glu Thr Gly Glu Thr Cys Val Tyr Pro Thr Gln Pro Ser Val
 645 650 655

Ala Gln Lys Asn Trp Tyr Ile Asn Lys Asn Pro Lys Asp Lys Arg His
 660 665 670

278

Val Trp Phe Gly Glu Ser Met Thr Asp Gly Ile Pro Phe Gln Phe Gly
 675 680 685

Gly Gln Gly Phe Asp Pro Ser Asp Val Ala Ile Gln Leu Thr
 690 695 700

<210> 289
 <211> 82
 <212> PRT
 <213> Homo sapien

<400> 289

Gln Val Pro His Ala Ser Gly Cys Ile Gly Glu Asp Pro Gln Gly Ile
 1 5 10 15

Pro Leu Pro Leu Asp Glu Ala His Pro Thr Gly Gly Cys Thr Asn Pro
 20 25 30

Tyr Gly Lys Ser Lys Phe Phe Ile Glu Glu Met Ile Arg Asp Leu Cys
 35 40 45

Gln Ala Asp Lys Gly Trp Thr Ala Ala Leu Gly Leu Asp Arg Met Cys
 50 55 60

Glu Asp Leu Trp Arg Trp Gln Lys Gln Asn Pro Ser Gly Phe Gly Thr
 65 70 75 80

Gln Ala

<210> 290
 <211> 360
 <212> PRT
 <213> Homo sapien

<400> 290

Met Ala Glu Lys Val Leu Val Thr Gly Gly Ala Gly Tyr Ile Gly Ser
 1 5 10 15

His Thr Val Leu Glu Leu Leu Glu Ala Gly Tyr Leu Pro Val Val Ile
 20 25 30

Asp Asn Phe His Asn Ala Phe Arg Gly Gly Gly Ser Leu Pro Glu Ser
 35 40 45

Leu Arg Arg Val Gln Glu Leu Thr Gly Arg Ser Val Glu Phe Glu Glu

279

50		55		60											
Met	Asp	Ile	Leu	Asp	Gln	Gly	Ala	Leu	Gln	Arg	Leu	Phe	Lys	Lys	Tyr
65					70					75					80
Ser	Phe	Met	Ala	Val	Ile	His	Phe	Ala	Gly	Leu	Lys	Ala	Val	Gly	Glu
				85					90					95	
Ser	Val	Gln	Lys	Pro	Leu	Asp	Tyr	Tyr	Arg	Val	Asn	Leu	Thr	Gly	Thr
			100					105						110	
Ile	Gln	Leu	Leu	Glu	Ile	Met	Lys	Ala	His	Gly	Val	Lys	Asn	Leu	Val
		115					120						125		
Phe	Ser	Ser	Ser	Ala	Thr	Val	Tyr	Gly	Asn	Pro	Gln	Tyr	Leu	Pro	Leu
	130					135					140				
Asp	Glu	Ala	His	Pro	Thr	Gly	Gly	Cys	Thr	Asn	Pro	Tyr	Gly	Lys	Ser
145					150					155					160
Lys	Phe	Phe	Ile	Glu	Glu	Met	Ile	Arg	Asp	Leu	Cys	Gln	Ala	Asp	Lys
				165					170					175	
Thr	Trp	Asn	Ala	Val	Leu	Leu	Arg	Tyr	Phe	Asn	Pro	Thr	Gly	Ala	His
			180					185					190		
Ala	Ser	Gly	Cys	Ile	Gly	Glu	Asp	Pro	Gln	Gly	Ile	Pro	Asn	Asn	Leu
		195					200					205			
Met	Pro	Tyr	Val	Ser	Gln	Val	Ala	Ile	Gly	Arg	Arg	Glu	Ala	Leu	Asn
	210					215					220				
Val	Phe	Gly	Asn	Asp	Tyr	Asp	Thr	Glu	Asp	Gly	Thr	Gly	Val	Arg	Asp
225					230					235				240	
Tyr	Ile	His	Val	Val	Asp	Leu	Ala	Lys	Gly	His	Ile	Ala	Ala	Leu	Arg
			245						250					255	
Lys	Leu	Lys	Glu	Gln	Cys	Gly	Cys	Arg	Val	Gly	Arg	Glu	Gly	Arg	Ser
			260					265					270		
Glu	Gly	Gly	Glu	Gly	Pro	Asp	Pro	Gly	Arg	Ala	Ala	Gln	Arg	Arg	Gly
	275						280					285			
Gln	Ser	Ser	Pro	Leu	His	Lys	Pro	Cys	Ser	Pro	Trp	Ala	Arg	Ser	Thr
	290					295					300				

280

Thr Trp Ala Arg Ala Gln Ala Ile Gln Cys Cys Arg Trp Ser Arg Leu
 305 310 315 320

Trp Arg Arg Pro Leu Gly Arg Arg Ser Arg Thr Arg Trp Trp His Gly
 325 330 335

Gly Lys Val Met Trp Gln Pro Val Thr Pro Thr Pro Ala Trp Pro Lys
 340 345 350

Arg Ser Trp Gly Gly Gln Gln Pro
 355 360

<210> 291
 <211> 466
 <212> PRT
 <213> Homo sapien

<400> 291

Met Ala Glu Lys Val Leu Val Thr Gly Gly Ala Gly Tyr Ile Gly Ser
 1 5 10 15

His Thr Val Leu Glu Leu Leu Glu Ala Gly Tyr Leu Pro Val Val Ile
 20 25 30

Asp Asn Phe His Asn Ala Phe Arg Gly Gly Gly Ser Leu Pro Glu Ser
 35 40 45

Leu Arg Arg Val Gln Glu Leu Thr Gly Arg Ser Val Glu Phe Glu Glu
 50 55 60

Met Asp Ile Leu Asp Gln Gly Ala Leu Gln Arg Leu Phe Lys Lys Tyr
 65 70 75 80

Ser Phe Met Ala Val Ile His Phe Ala Gly Leu Lys Ala Val Gly Glu
 85 90 95

Ser Val Gln Lys Pro Leu Asp Tyr Tyr Arg Val Asn Leu Thr Gly Thr
 100 105 110

Ile Gln Leu Leu Glu Ile Met Lys Ala His Gly Val Lys Asn Leu Val
 115 120 125

Phe Ser Ser Ser Ala Thr Val Tyr Gly Asn Pro Gln Tyr Leu Pro Leu
 130 135 140

Asp	Glu	Ala	His	Pro	Thr	Gly	Gly	Cys	Thr	Asn	Pro	Tyr	Gly	Lys	Ser
145					150					155					160
Lys	Phe	Phe	Ile	Glu	Glu	Met	Ile	Arg	Asp	Leu	Cys	Gln	Ala	Asp	Lys
				165					170					175	
Thr	Trp	Asn	Ala	Val	Leu	Leu	Arg	Tyr	Phe	Asn	Pro	Thr	Gly	Ala	His
			180					185					190		
Ala	Ser	Gly	Cys	Ile	Gly	Glu	Asp	Pro	Gln	Gly	Ile	Pro	Asn	Asn	Leu
		195					200					205			
Met	Pro	Tyr	Val	Ser	Gln	Val	Ala	Ile	Gly	Arg	Arg	Glu	Ala	Leu	Asn
	210					215					220				
Val	Phe	Gly	Asn	Asp	Tyr	Asp	Thr	Glu	Asp	Gly	Thr	Gly	Val	Arg	Asp
225					230					235					240
Tyr	Ile	His	Val	Val	Asp	Leu	Ala	Lys	Gly	His	Ile	Ala	Ala	Leu	Arg
				245					250					255	
Lys	Leu	Lys	Glu	Gln	Cys	Gly	Cys	Arg	Val	Gly	Arg	Glu	Gly	Arg	Ser
			260					265					270		
Glu	Gly	Gly	Glu	Gly	Pro	Asp	Pro	Gly	Arg	Ala	Ala	Gln	Arg	Arg	Gly
		275					280					285			
Gln	Ser	Ser	Pro	Leu	His	Lys	Pro	Cys	Ser	Pro	Trp	Ala	Arg	Ser	Thr
	290					295					300				
Thr	Trp	Ala	Arg	Ala	Gln	Ala	Ile	Gln	Cys	Cys	Arg	Trp	Ser	Arg	Leu
305					310					315					320
Trp	Arg	Arg	Pro	Leu	Gly	Arg	Arg	Ser	Gly	Pro	Pro	Thr	Pro	Pro	Thr
				325					330					335	
Ser	Pro	Thr	Ser	Pro	His	Pro	Ala	Leu	Ser	Asn	Arg	Ala	Ala	Leu	Ala
			340					345					350		
Leu	Pro	Thr	His	Leu	Ser	Gly	Gly	Tyr	Leu	Ala	Leu	Pro	Ser	Leu	Leu
		355					360					365			
Ser	Leu	Pro	Ser	Thr	Arg	Cys	Leu	Arg	Ala	Ser	Arg	Cys	Ser	Ala	Leu
	370					375					380				
Leu	Leu	Leu	Lys	Asp	Leu	Ala	Ser	Ser	Trp	Ala	Arg	Ala	Gly	Ser	Ala

282

385

390

395

400

Lys Leu Gln Leu Pro Pro Val Leu Gln Ile Pro Tyr Lys Val Val Ala
 405 410 415

Arg Arg Glu Gly Asp Val Ala Ala Cys Tyr Ala Asn Pro Ser Leu Ala
 420 425 430

Gln Glu Glu Leu Gly Trp Thr Ala Ala Leu Gly Leu Asp Arg Met Cys
 435 440 445

Glu Asp Leu Trp Arg Trp Gln Lys Gln Asn Pro Ser Gly Phe Gly Thr
 450 455 460

Gln Ala
 465

<210> 292
 <211> 328
 <212> PRT
 <213> Homo sapien

<400> 292

Met Ala Glu Lys Val Leu Val Thr Gly Gly Ala Gly Tyr Ile Gly Ser
 1 5 10 15

His Thr Val Leu Glu Leu Leu Glu Ala Gly Tyr Leu Pro Val Val Ile
 20 25 30

Asp Asn Phe His Asn Ala Phe Arg Gly Gly Gly Ser Leu Pro Glu Ser
 35 40 45

Leu Arg Arg Val Gln Glu Leu Thr Gly Arg Ser Val Glu Phe Glu Glu
 50 55 60

Met Asp Ile Leu Asp Gln Gly Ala Leu Gln Arg Leu Phe Lys Lys Tyr
 65 70 75 80

Ser Phe Met Ala Val Ile His Phe Ala Gly Leu Lys Ala Val Gly Glu
 85 90 95

Ser Val Gln Lys Pro Leu Asp Tyr Tyr Arg Val Asn Leu Thr Gly Thr
 100 105 110

Ile Gln Leu Leu Glu Ile Met Lys Ala His Gly Val Lys Asn Leu Val
 115 120 125

283

Phe Ser Ser Ser Ala Thr Val Tyr Gly Asn Pro Gln Tyr Leu Pro Leu
 130 135 140

Asp Glu Ala His Pro Thr Gly Gly Cys Thr Asn Pro Tyr Gly Lys Ser
 145 150 155 160

Lys Phe Phe Ile Glu Glu Met Ile Arg Asp Leu Cys Gln Ala Asp Lys
 165 170 175

Thr Trp Asn Ala Val Leu Leu Arg Tyr Phe Asn Pro Thr Gly Ala His
 180 185 190

Ala Ser Gly Cys Ile Gly Glu Asp Pro Gln Gly Ile Pro Asn Asn Leu
 195 200 205

Met Pro Tyr Val Ser Gln Val Ala Ile Gly Arg Arg Glu Ala Leu Asn
 210 215 220

Val Phe Gly Asn Asp Tyr Asp Thr Glu Asp Gly Thr Gly Val Arg Asp
 225 230 235 240

Tyr Ile His Val Val Asp Leu Ala Lys Gly His Ile Ala Ala Leu Arg
 245 250 255

Lys Leu Lys Glu Gln Cys Gly Cys Arg Val Gly Arg Glu Gly Arg Ser
 260 265 270

Glu Gly Gly Glu Gly Pro Asp Pro Gly Arg Ala Ala Gln Arg Arg Gly
 275 280 285

Gln Ser Ser Pro Leu His Lys Pro Cys Ser Pro Trp Ala Arg Ser Thr
 290 295 300

Thr Trp Ala Arg Ala Gln Ala Ile Gln Cys Cys Arg Trp Ser Arg Leu
 305 310 315 320

Trp Arg Arg Pro Leu Gly Arg Arg
 325

<210> 293

<211> 77

<212> PRT

<213> Homo sapien

<400> 293

Met Pro Ser Leu His Gly Gln Ile Met Lys Ala His Gly Val Lys Asn

6.

285

Tyr Asp Ser Ser Glu Lys Thr His Phe Lys Asp Ala Val Ser Ala Gly
 145 150 155 160

Lys His Thr Ala Asn Ser His His Leu Ser Ala Leu Val Thr Pro Ala
 165 170 175

Gly Lys Ser Tyr Glu Cys Gln Ala Gln Gln Thr Ile Ser Leu Ala Ser
 180 185 190

Ser Asp Pro Gln Lys Thr Val Thr Met Ile Leu Ser Ala Val His Ile
 195 200 205

Gln Pro Phe Asp Ile Ile Ser Asp Phe Val Phe Ser Glu Glu His Lys
 210 215 220

Cys Pro Val Asp Glu Arg Glu Gln Leu Glu Glu Thr Leu Pro Leu Ile
 225 230 235 240

Leu Gly Leu Ile Leu Gly Leu Val Ile Met Val Thr Leu Ala Ile Tyr
 245 250 255

His Val His His Lys Met Thr Ala Asn Gln Val Gln Ile Pro Arg Asp
 260 265 270

Arg Ser Gln Tyr Lys His Met Gly
 275 280

<210> 295
 <211> 173
 <212> PRT
 <213> Homo sapien

<400> 295

Met Asp Leu Gln Gly Arg Gly Val Pro Ser Ile Asp Arg Leu Arg Val
 1 5 10 15

Leu Leu Met Leu Phe His Thr Met Ala Gln Ile Met Ala Glu Gln Glu
 20 25 30

Val Glu Asn Leu Ser Gly Leu Ser Thr Asn Pro Glu Lys Asp Ile Phe
 35 40 45

Val Val Arg Glu Asn Gly Thr Thr Cys Leu Met Ala Glu Phe Ala Ala
 50 55 60

Lys Phe Ile Val Pro Tyr Asp Val Trp Ala Ser Asn Tyr Val Asp Leu

286

65

70

75

80

Ile Thr Glu Gln Ala Asp Ile Ala Leu Thr Arg Gly Ala Glu Val Lys
85 90 95

Gly Arg Cys Gly His Ser Gln Ser Glu Leu Gln Val Phe Trp Val Asp
100 105 110

Arg Ala Tyr Ala Leu Lys Met Leu Phe Val Lys Val Thr Pro Ser Pro
115 120 125

Ala Gly Arg Gly Ala Ala Gly Ser Ala Trp Val Trp Glu Val Ala Ala
130 135 140

Pro Arg Phe Lys Asn Pro Asp Ala Ala Gly Thr Ile Glu Ala His Leu
145 150 155 160

Pro Gly Ser Thr Gly Lys Pro Gln His Val Gln Gly Thr
165 170

<210> 296

<211> 90

<212> PRT

<213> Homo sapien

<400> 296

Met Asp Leu Gln Gly Arg Gly Val Pro Ser Ile Asp Arg Leu Arg Val
1 5 10 15

Leu Leu Met Leu Phe His Thr Met Ala Gln Ile Met Ala Glu Gln Glu
20 25 30

Val Glu Asn Leu Ser Gly Leu Ser Thr Asn Pro Glu Lys Asp Ile Phe
35 40 45

Val Val Arg Glu Asn Gly Thr Thr Leu Trp Pro Gln Pro Val Gly Ala
50 55 60

Ala Ser Val Leu Gly Gly Ser Arg Ile Cys Thr Gln Asn Ala Leu Cys
65 70 75 80

Lys Gly Lys Pro Gln His Val Gln Gly Thr
85 90

<210> 297

<211> 280

<212> PRT

287

<213> Homo sapien

<400> 297

Met Asp Leu Gln Gly Arg Gly Val Pro Ser Ile Asp Arg Leu Arg Val
1 5 10 15

Leu Leu Met Leu Phe His Thr Met Ala Gln Ile Met Ala Glu Gln Glu
20 25 30

Val Glu Asn Leu Ser Gly Leu Ser Thr Asn Pro Glu Lys Asp Ile Phe
35 40 45

Val Val Arg Glu Asn Gly Thr Thr Cys Leu Met Ala Glu Phe Ala Ala
50 55 60

Lys Phe Ile Val Pro Tyr Asp Val Trp Ala Ser Asn Tyr Val Asp Leu
65 70 75 80

Ile Thr Glu Gln Ala Asp Ile Ala Leu Thr Arg Gly Ala Glu Val Lys
85 90 95

Gly Arg Cys Gly His Ser Gln Ser Glu Leu Gln Val Phe Trp Val Asp
100 105 110

Arg Ala Tyr Ala Leu Lys Met Leu Phe Val Lys Glu Ser His Asn Met
115 120 125

Ser Lys Gly Pro Glu Ala Thr Trp Arg Leu Ser Lys Val Gln Phe Val
130 135 140

Tyr Asp Ser Ser Glu Lys Thr His Phe Lys Asp Ala Val Ser Ala Gly
145 150 155 160

Lys His Thr Ala Asn Ser His His Leu Ser Ala Leu Val Thr Pro Ala
165 170 175

Gly Lys Ser Tyr Glu Cys Gln Ala Gln Gln Thr Ile Ser Leu Ala Ser
180 185 190

Ser Asp Pro Gln Lys Thr Val Thr Met Ile Leu Ser Ala Val His Ile
195 200 205

Gln Pro Phe Asp Ile Ile Ser Asp Phe Val Phe Ser Glu Glu His Lys
210 215 220

Cys Pro Val Asp Glu Arg Glu Gln Leu Glu Glu Thr Leu Pro Leu Ile

225					230					235					240
Leu	Gly	Leu	Ile	Leu	Gly	Leu	Val	Ile	Met	Val	Thr	Leu	Ala	Ile	Tyr
				245					250					255	
His	Val	His	His	Lys	Met	Thr	Ala	Asn	Gln	Val	Gln	Ile	Pro	Arg	Asp
			260					265					270		
Arg	Ser	Gln	Tyr	Lys	His	Met	Gly								
		275					280								
<210>	298														
<211>	321														
<212>	PRT														
<213>	Homo sapien														
<400>	298														
Met	Asp	Leu	Gln	Gly	Arg	Gly	Val	Pro	Ser	Ile	Asp	Arg	Leu	Arg	Val
1				5					10					15	
Leu	Leu	Met	Leu	Phe	His	Thr	Met	Ala	Gln	Ile	Met	Ala	Glu	Gln	Glu
			20					25					30		
Val	Glu	Asn	Leu	Ser	Gly	Leu	Ser	Thr	Asn	Pro	Glu	Lys	Asp	Ile	Phe
		35					40					45			
Val	Val	Arg	Glu	Asn	Gly	Thr	Thr	Cys	Leu	Met	Ala	Glu	Phe	Ala	Ala
	50					55					60				
Lys	Phe	Ile	Val	Pro	Tyr	Asp	Val	Trp	Ala	Ser	Asn	Tyr	Val	Asp	Leu
65					70					75					80
Ile	Thr	Glu	Gln	Ala	Asp	Ile	Ala	Leu	Thr	Arg	Gly	Ala	Glu	Val	Lys
				85					90					95	
Gly	Arg	Cys	Gly	His	Ser	Gln	Ser	Glu	Leu	Gln	Val	Phe	Trp	Val	Asp
			100					105					110		
Arg	Ala	Tyr	Ala	Leu	Lys	Met	Leu	Phe	Val	Lys	Val	Thr	Pro	Ser	Pro
		115					120					125			
Ala	Gly	Arg	Gly	Ala	Ala	Gly	Ser	Ala	Trp	Val	Trp	Glu	Val	Ala	Ala
	130					135					140				
Pro	Arg	Phe	Lys	Asn	Pro	Glu	Leu	Arg	Gly	Arg	Leu	Lys	Arg	Thr	Ser
145					150					155					160

289

Pro Ala Gln Gln Glu Ser His Asn Met Ser Lys Gly Pro Glu Ala Thr
 165 170 175

Trp Arg Leu Ser Lys Val Gln Phe Val Tyr Asp Ser Ser Glu Lys Thr
 180 185 190

His Phe Lys Asp Ala Val Ser Ala Gly Lys His Thr Ala Asn Ser His
 195 200 205

His Leu Ser Ala Leu Val Thr Pro Ala Gly Lys Ser Tyr Glu Cys Gln
 210 215 220

Ala Gln Gln Thr Ile Ser Leu Ala Ser Ser Asp Pro Gln Lys Thr Val
 225 230 235 240

Thr Met Ile Leu Ser Ala Val His Ile Gln Pro Phe Asp Ile Ile Ser
 245 250 255

Asp Phe Val Phe Ser Glu Glu His Lys Cys Pro Val Asp Glu Arg Glu
 260 265 270

Gln Leu Glu Glu Thr Leu Pro Leu Ile Leu Gly Leu Ile Leu Gly Leu
 275 280 285

Val Ile Met Val Thr Leu Ala Ile Tyr His Val His His Lys Met Thr
 290 295 300

Ala Asn Gln Val Gln Ile Pro Arg Asp Arg Ser Gln Tyr Lys His Met
 305 310 315 320

Gly

<210> 299

<211> 373

<212> PRT

<213> Homo sapien

<400> 299

Arg Thr Val Thr Val Arg Thr Arg Ile Ala Val Leu Ser Leu Arg Pro
 1 5 10 15

Gln Cys Gly Gly Ile Leu Phe Arg His Val Val Val Leu Thr Leu Gly
 20 25 30

Asn Gly Leu Gly Gln Asn Leu Asp Leu Ala Ser Val Gln Ala His Ala

290

35

40

45

Ala Val Gln Gly Arg Arg Val Leu Ile Pro Gly Val Asn Ile Arg Gln
 50 55 60

Glu Asn Leu Gly Arg Gly Arg Phe His Asp His Val Gln Asp Ala Ala
 65 70 75 80

Val Gly Gly Val Gly Gln Ala Leu Arg Cys His Gln His Lys Ala Val
 85 90 95

Gly Leu Thr Gln His Leu Glu Pro Phe Pro Asp Leu Arg Ala Glu Cys
 100 105 110

Arg Val Ala Glu His Gln Pro Gly Phe Val Gln Asp Asp Glu Arg Pro
 115 120 125

Pro Val Trp Trp Asn Ser Asn Pro Glu Lys Asp Ile Phe Val Val Arg
 130 135 140

Glu Asn Gly Thr Thr Cys Leu Met Ala Glu Phe Ala Ala Lys Phe Ile
 145 150 155 160

Val Pro Tyr Asp Val Trp Ala Ser Asn Tyr Val Asp Leu Ile Thr Glu
 165 170 175

Gln Ala Asp Ile Ala Leu Thr Arg Gly Ala Glu Val Lys Gly Arg Cys
 180 185 190

Gly His Ser Gln Ser Glu Leu Gln Val Phe Trp Val Asp Arg Ala Tyr
 195 200 205

Ala Leu Lys Met Leu Phe Val Lys Glu Ser His Asn Met Ser Lys Gly
 210 215 220

Pro Glu Ala Thr Trp Arg Leu Ser Lys Val Gln Phe Val Tyr Asp Ser
 225 230 235 240

Ser Glu Lys Thr His Phe Lys Asp Ala Val Ser Ala Gly Lys His Thr
 245 250 255

Ala Asn Ser His His Leu Ser Ala Leu Val Thr Pro Ala Gly Lys Ser
 260 265 270

Tyr Glu Cys Gln Ala Gln Gln Thr Ile Ser Leu Ala Ser Ser Asp Pro
 275 280 285

291

Gln Lys Thr Val Thr Met Ile Leu Ser Ala Val His Ile Gln Pro Phe
 290 295 300

Asp Ile Ile Ser Asp Phe Val Phe Ser Glu Glu His Lys Cys Pro Val
 305 310 315 320

Asp Glu Arg Glu Gln Leu Glu Glu Thr Leu Pro Leu Ile Leu Gly Leu
 325 330 335

Ile Leu Gly Leu Val Ile Met Val Thr Leu Ala Ile Tyr His Val His
 340 345 350

His Lys Met Thr Ala Asn Gln Val Gln Ile Pro Arg Asp Arg Ser Gln
 355 360 365

Tyr Lys His Met Gly
 370

<210> 300
 <211> 363
 <212> PRT
 <213> Homo sapien

<400> 300

Met Lys Thr Leu Leu Leu Leu Leu Leu Val Leu Leu Glu Leu Gly Glu
 1 5 10 15

Ala Gln Gly Ser Leu His Arg Val Pro Leu Arg Arg His Pro Ser Leu
 20 25 30

Lys Lys Lys Leu Arg Ala Arg Ser Gln Leu Ser Glu Phe Trp Lys Ser
 35 40 45

His Asn Leu Asp Met Ile Gln Phe Thr Glu Ser Cys Ser Met Asp Gln
 50 55 60

Ser Ala Lys Glu Pro Leu Ile Asn Tyr Leu Asp Met Glu Tyr Phe Gly
 65 70 75 80

Thr Ile Ser Ile Gly Ser Pro Pro Gln Asn Phe Thr Val Ile Phe Asp
 85 90 95

Thr Gly Ser Ser Asn Leu Trp Val Pro Ser Val Tyr Cys Thr Ser Pro
 100 105 110

292

Ala Cys Lys Thr His Ser Arg Phe Gln Pro Ser Gln Ser Ser Thr Tyr
 115 120 125

Ser Gln Pro Gly Gln Ser Phe Ser Ile Gln Tyr Gly Thr Gly Ser Leu
 130 135 140

Ser Gly Ile Ile Gly Ala Asp Gln Val Ser Val Glu Gly Leu Thr Val
 145 150 155 160

Val Gly Gln Gln Phe Gly Glu Ser Val Thr Glu Pro Gly Gln Thr Phe
 165 170 175

Val Asp Ala Glu Phe Asp Gly Ile Leu Gly Leu Gly Tyr Pro Ser Leu
 180 185 190

Ala Val Gly Gly Val Thr Pro Val Phe Asp Asn Met Met Ala Gln Asn
 195 200 205

Leu Val Asp Leu Pro Met Phe Ser Val Tyr Met Ser Ser Asn Pro Glu
 210 215 220

Gly Gly Ala Gly Ser Glu Leu Ile Phe Gly Gly Tyr Asp His Ser His
 225 230 235 240

Phe Ser Gly Ser Leu Asn Trp Val Pro Val Thr Lys Gln Ala Tyr Trp
 245 250 255

Gln Ile Ala Leu Asp Asn Met Leu Trp Ser Val Pro Thr Leu Thr Ser
 260 265 270

Cys Arg Met Ser Pro Ser Pro Leu Thr Glu Ser Pro Ile Pro Ser Ala
 275 280 285

Gln Leu Pro Thr Pro Tyr Trp Thr Ser Trp Met Glu Cys Ser Ser Ala
 290 295 300

Ala Val Ala Phe Lys Asp Leu Thr Ser Thr Leu Gln Leu Gly Pro Ser
 305 310 315 320

Gly Ser Trp Gly Met Ser Ser Phe Asp Ser Phe Thr Gln Ser Leu Thr
 325 330 335

Val Gly Ile Thr Val Trp Asp Trp Pro Gln Gln Ser Pro Lys Glu Gly
 340 345 350

Pro Cys Val Cys Ala Cys Leu Ser Asp Arg Pro

293

355

360

<210> 301
 <211> 282
 <212> PRT
 <213> Homo sapien

<400> 301

Met	Gly	Cys	Trp	Gly	Arg	Asn	Arg	Gly	Arg	Leu	Leu	Cys	Met	Leu	Ala
1				5				10					15		
Leu	Thr	Phe	Met	Phe	Met	Val	Leu	Glu	Val	Val	Val	Ser	Arg	Val	Thr
			20					25					30		
Ser	Ser	Leu	Ala	Met	Leu	Ser	Asp	Ser	Phe	His	Met	Leu	Ser	Asp	Val
		35					40					45			
Leu	Ala	Leu	Val	Val	Ala	Leu	Val	Ala	Glu	Arg	Phe	Ala	Arg	Arg	Thr
	50					55					60				
His	Ala	Thr	Gln	Lys	Asn	Thr	Phe	Gly	Trp	Ile	Arg	Ala	Glu	Val	Met
65					70					75					80
Gly	Ala	Leu	Val	Asn	Ala	Ile	Phe	Leu	Thr	Gly	Leu	Cys	Phe	Ala	Ile
				85					90					95	
Leu	Leu	Glu	Ala	Ile	Glu	Arg	Phe	Ile	Glu	Pro	His	Glu	Met	Gln	Gln
			100					105					110		
Pro	Leu	Val	Val	Leu	Gly	Val	Gly	Val	Ala	Gly	Leu	Leu	Val	Asn	Val
		115					120					125			
Leu	Gly	Leu	Cys	Leu	Phe	His	His	His	Ser	Gly	Phe	Ser	Gln	Asp	Ser
	130					135					140				
Gly	His	Gly	His	Ser	His	Gly	Gly	His	Gly	His	Gly	His	Gly	Leu	Pro
145					150				155						160
Lys	Gly	Pro	Arg	Val	Lys	Ser	Thr	Arg	Pro	Gly	Ser	Ser	Asp	Ile	Asn
				165					170					175	
Val	Ala	Pro	Gly	Glu	Gln	Gly	Pro	Asp	Gln	Glu	Glu	Thr	Asn	Thr	Leu
			180					185					190		
Val	Ala	Asn	Thr	Ser	Asn	Ser	Asn	Gly	Leu	Lys	Leu	Asp	Pro	Ala	Gly
		195					200					205			

294

Glu Pro Gly Lys Ser Leu Pro Gln Val Val Gly Phe Gly Val Pro Arg
 210 215 220

Ala Ser Pro Gly Leu Arg Arg Gly Gly Pro His Ala Pro Cys Cys Pro
 225 230 235 240

Ser Gly Pro Ala Pro Arg Arg Pro Cys Leu Leu Pro Pro Arg Pro Ala
 245 250 255

His Ala Pro Leu Leu Leu Gln Glu Ile Arg Thr Pro Ser Val Gly Cys
 260 265 270

Lys Glu Pro Ala Thr Arg Leu Ala Tyr Leu
 275 280

<210> 302
 <211> 177
 <212> PRT
 <213> Homo sapien

<400> 302

Ala Thr Ala Leu Lys Asp Val Val Lys Val Gly Ala Val Asp Ala Asp
 1 5 10 15

Lys His His Ser Leu Gly Gly Gln Tyr Gly Val Gln Gly Phe Pro Thr
 20 25 30

Ile Lys Ile Phe Gly Ser Asn Lys Asn Arg Pro Glu Asp Tyr Gln Gly
 35 40 45

Gly Arg Thr Gly Glu Ala Ile Val Asp Ala Ala Leu Ser Ala Leu Arg
 50 55 60

Gln Leu Val Lys Asp Arg Leu Gly Gly Arg Ser Lys Asp Val Leu Asp
 65 70 75 80

Ser Glu Asp Val Trp Met Val Glu Phe Tyr Ala Pro Trp Cys Gly His
 85 90 95

Cys Lys Asn Leu Glu Pro Glu Trp Ala Ala Ala Ala Ser Glu Val Lys
 100 105 110

Glu Gln Thr Lys Gly Arg Val Lys Leu Ala Ala Val Asp Ala Thr Val
 115 120 125

Asn Gln Val Leu Ala Ser Arg Tyr Gly Ile Arg Gly Phe Pro Thr Ile

295

130

135

140

Lys Ile Phe Gln Lys Gly Glu Ser Pro Val Asp Tyr Asp Gly Gly Arg
 145 150 155 160

Thr Arg Ser Asp Ile Val Ser Arg Ala Leu Asp Trp Phe Ser Asp Asn
 165 170 175

Ala

<210> 303
 <211> 82
 <212> PRT
 <213> Homo sapien

<400> 303

Met Leu Thr Gln Ser Gln Gln Val Leu Arg Gly Ile Leu Val Phe Leu
 1 5 10 15

Gln Asn Ile Leu Gln Glu Pro Ser Pro Ala Met Cys Phe Pro Lys Lys
 20 25 30

Arg Ser Leu Trp Pro Asn Leu Arg Lys Gln Trp Ala Ser Ile His Ile
 35 40 45

Asn Asp Pro Arg Gly Thr Leu Cys Pro Arg Cys Thr Gly Cys Asn Gln
 50 55 60

Arg Gly Ser Gly Gly Ser Gly Leu Ile Trp Arg Asp Ser Phe Tyr His
 65 70 75 80

His Pro

<210> 304
 <211> 152
 <212> PRT
 <213> Homo sapien

<400> 304

Met Gly Phe Leu Pro Ala Ala His Pro Ser Gly Leu Gly Arg Gly Lys
 1 5 10 15

Gly Glu Val Val Ala Met Gly Glu Val Arg Gly Glu Glu Gly Val Thr
 20 25 30

296

Ala Arg Pro Pro Leu Gly Trp Ala Cys Asp Arg Val Leu Gly Arg Ser
 35 40 45

Arg Ile Leu Ile Arg Ser Val Asn Gly Val Glu Ala Ala Leu Pro Arg
 50 55 60

His Val Leu Pro Thr Thr His Gln Gln Ala Ser Val Ala Cys Arg Cys
 65 70 75 80

Gln Gly Trp Val Gly Thr Leu Gly Gln Ala Gly Cys Leu Gly Gly Ala
 85 90 95

Arg Gln Glu Pro Arg Gly Trp Leu Gln Gly Leu Pro Gly Gly Pro Gln
 100 105 110

Gly Arg Gly Ala Gly Lys Arg Phe Gly Cys Leu Arg Arg Glu Val Val
 115 120 125

Glu Thr Cys Leu Gln Val Arg Ala Val Ala Ser Ser Leu His His Leu
 130 135 140

Ser Ala Tyr Gly Val Pro Asp Thr
 145 150

<210> 305
 <211> 42
 <212> PRT
 <213> Homo sapien

<400> 305

Met Thr Asn Arg Asn Ser Phe Thr Met Asn Cys Val His Val Leu Leu
 1 5 10 15

Cys His Leu Phe Glu Asp Thr Ser Trp His Phe Leu Leu Cys Gln Met
 20 25 30

Leu His Ser Leu Leu Asp Trp Gln Lys Arg
 35 40

<210> 306
 <211> 197
 <212> PRT
 <213> Homo sapien

<400> 306

Met Val Asp Leu Thr Gln Val Met Asp Asp Glu Val Phe Met Ala Phe
 1 5 10 15

297

Ala Ser Tyr Ala Thr Ile Ile Leu Ser Lys Met Met Leu Met Ser Thr
 20 25 30

Ala Thr Ala Phe Tyr Arg Leu Thr Arg Lys Val Phe Ala Asn Pro Glu
 35 40 45

Asp Cys Val Ala Phe Gly Lys Gly Glu Asn Ala Lys Lys Tyr Leu Arg
 50 55 60

Thr Asp Asp Arg Val Glu Arg Val Arg Ser His Cys Lys Ala Val Thr
 65 70 75 80

Ile Ser Ile Phe Glu Arg Gln Ser Gln Asn Gly Ala Thr Asn Glu Val
 85 90 95

Lys Ser Met Leu Tyr Arg Val Gln Gln Leu Lys Leu Ile His Thr His
 100 105 110

Met Glu Gln Leu Thr Lys Asp Leu Arg Ala His Leu Asn Asp Leu Glu
 115 120 125

Asn Ile Ile Pro Phe Leu Gly Ile Gly Leu Leu Tyr Ser Leu Ser Gly
 130 135 140

Pro Asp Pro Ser Thr Ala Ile Leu His Phe Arg Leu Phe Val Gly Thr
 145 150 155 160

Arg Ile Tyr His Thr Ile Ala Tyr Leu Thr Thr Pro Leu Arg Gln Gln
 165 170 175

Ile Arg Ala Ser Val Phe Val Gly Tyr Gly Val Thr Leu Ser Met Ala
 180 185 190

Tyr Arg Leu Leu Lys
 195

<210> 307

<211> 146

<212> PRT

<213> Homo sapien

<400> 307

Gly Arg Cys Leu Arg Pro Ala Arg Ala Ala Thr Val Pro Ala Leu Arg
 1 5 10 15

Ala Thr Arg Arg Arg Asp Arg Leu Ala Ala Ser Ser Ser Ser Ala Ser

298

20

25

30

Pro Phe Gln Thr Lys Ile Glu Lys Met Val Asp Leu Thr Gln Val Met
 35 40 45

Asp Asp Glu Val Phe Met Ala Phe Ala Ser Tyr Ala Thr Ile Ile Leu
 50 55 60

Ser Lys Met Met Leu Met Ser Thr Ala Thr Ala Phe Tyr Arg Leu Thr
 65 70 75 80

Arg Lys Val Phe Ala Asn Pro Glu Asp Cys Val Ala Phe Gly Lys Gly
 85 90 95

Glu Asn Ala Lys Lys Tyr Leu Arg Thr Asp Asp Arg Val Glu Arg Val
 100 105 110

Arg Ser His Cys Lys Ala Val Thr Ile Ser Ile Phe Glu Arg Gln Ser
 115 120 125

Gln Asn Gly Ala Thr Asn Glu Val Lys Ser Met Leu Tyr Arg Val Gln
 130 135 140

Gln Leu
 145

<210> 308
 <211> 187
 <212> PRT
 <213> Homo sapien

<400> 308

Gly Arg Cys Leu Arg Pro Ala Arg Ala Ala Thr Val Pro Ala Leu Arg
 1 5 10 15

Ala Thr Arg Arg Arg Asp Arg Leu Ala Ala Ser Ser Ser Ser Ala Ser
 20 25 30

Pro Phe Gln Thr Lys Ile Glu Lys Met Val Asp Leu Thr Gln Val Met
 35 40 45

Asp Asp Glu Val Phe Met Ala Phe Ala Ser Tyr Ala Thr Ile Ile Leu
 50 55 60

Ser Lys Met Met Leu Met Ser Thr Ala Thr Ala Phe Tyr Arg Leu Thr
 65 70 75 80

299

Arg Lys Val Phe Ala Asn Pro Glu Asp Cys Val Ala Phe Gly Lys Gly
85 90 95

Glu Asn Ala Lys Lys Tyr Leu Arg Thr Asp Asp Arg Val Glu Arg Val
100 105 110

Arg Arg Ala Gln Glu Ile Leu Gly Pro Glu Arg Gln Ile Gln Lys Asn
115 120 125

Leu His Val Asn Glu Thr Gly Val Glu Met Arg Met Ala Gly Asn Ala
130 135 140

Trp Lys Gln Thr Cys Asn Cys Leu Met Ala Trp Ser Ser Lys Ser Gln
145 150 155 160

Arg Met Glu Cys Asn Gly Met Ile Ser Ala His Arg Asn Leu Cys Leu
165 170 175

Pro Asp Ser Ser Asp Ser Pro Ala Ser Ala Ser
180 185

<210> 3 09
<211> 115
<212> PRT
<213> Homo sapien

<400> 3 09

Tyr Ser Cys Val Val Phe His Gly Val Tyr Val Pro His Cys Leu Tyr
1 5 10 15

Pro Ile His Ile Asp Gly His Leu Gly Cys Ile Ser Pro Phe Leu Ile
20 25 30

Leu Cys Glu Ser Leu Lys Pro Leu Pro Arg Phe Leu Gln Ile Pro Leu
35 40 45

Trp His Ile Ile Ser Arg Leu Thr Leu Asp Leu Gly Ser Cys Leu Tyr
50 55 60

Ala Cys Phe His Ile Leu Gln Leu Val Met Leu Asp Val Asn Pro Ala
65 70 75 80

Leu Ser Ser Val Pro Phe Lys Asn Glu Leu Lys Lys Met Trp Leu Lys
85 90 95

Ile Asp Leu Ser Lys Trp Lys Cys Arg Gly Val Tyr Thr Val Ala Ala

300

100 105 110

Gln Thr Phe
115

<210> 310
<211> 149
<212> PRT
<213> Homo sapien

<400> 310

Gly Arg Cys Leu Arg Pro Ala Arg Ala Ala Thr Val Pro Ala Leu Arg
1 5 10 15

Ala Thr Arg Arg Arg Asp Arg Leu Ala Ala Ser Ser Ser Ser Ala Ser
20 25 30

Pro Phe Gln Thr Lys Ile Glu Lys Met Val Asp Leu Thr Gln Val Met
35 40 45

Asp Asp Glu Val Phe Met Ala Phe Ala Ser Tyr Ala Thr Ile Ile Leu
50 55 60

Ser Lys Met Met Leu Met Ser Thr Ala Thr Ala Phe Tyr Arg Leu Thr
65 70 75 80

Arg Lys Val Phe Ala Asn Pro Glu Asp Cys Val Ala Phe Gly Lys Gly
85 90 95

Glu Asn Ala Lys Lys Tyr Leu Arg Thr Asp Asp Arg Val Glu Arg Val
100 105 110

Arg Ser Leu Glu Trp Ser Arg Pro Leu Tyr Ser His Pro Ala Leu Gln
115 120 125

Thr Ile Cys Arg Ser Thr Asp Leu Pro His His Cys Ile Phe Asp Thr
130 135 140

Pro Ser Pro Ala Lys
145

<210> 311
<211> 86
<212> PRT
<213> Homo sapien

<400> 311

301

Gly Arg Cys Leu Arg Pro Ala Arg Ala Ala Thr Val Pro Ala Leu Arg
 1 5 10 15

Ala Thr Arg Arg Arg Asp Arg Leu Ala Ala Ser Ser Ser Ser Ala Ser
 20 25 30

Pro Phe Gln Thr Lys Ile Glu Lys Met Val Asp Leu Thr Gln Val Met
 35 40 45

Asp Asp Glu Val Phe Met Ala Phe Ala Ser Tyr Ala Thr Ile Ile Leu
 50 55 60

Ser Lys Met Met Leu Met Ser Thr Ala Thr Ala Phe Tyr Arg Leu Thr
 65 70 75 80

Arg Lys Ser Pro Pro Glu
 85

<210> 312

<211> 114

<212> PRT

<213> Homo sapien

<400> 312

Gly Arg Cys Leu Arg Pro Ala Arg Ala Ala Thr Val Pro Ala Leu Arg
 1 5 10 15

Ala Thr Arg Arg Arg Asp Arg Leu Ala Ala Ser Ser Ser Ser Ala Ser
 20 25 30

Pro Ala His Leu Asn Asp Leu Glu Asn Ile Ile Pro Phe Leu Gly Ile
 35 40 45

Gly Leu Leu Tyr Ser Leu Ser Gly Pro Asp Pro Ser Thr Ala Ile Leu
 50 55 60

His Phe Arg Leu Phe Val Gly Ala Arg Ile Tyr His Thr Ile Ala Tyr
 65 70 75 80

Leu Thr Pro Leu Pro Gln Pro Asn Arg Ala Leu Ser Phe Phe Val Gly
 85 90 95

Tyr Gly Val Thr Leu Ser Met Ala Tyr Arg Leu Leu Lys Ser Lys Leu
 100 105 110

Tyr Leu

302

<210> 313
<211> 145
<212> PRT
<213> Homo sapien

<400> 313

Ala Val Pro Ala Ser Gly Pro Arg Gly His Ser Pro Cys Ile Ala Arg
1 5 10 15

Asp Pro Ala Ala Gly Gln Ala Cys Cys Phe Leu Leu Leu Gly Leu Thr
20 25 30

Val Phe Ala Asn Pro Glu Asp Cys Val Ala Phe Gly Lys Gly Glu Asn
35 40 45

Ala Lys Lys Tyr Leu Arg Thr Asp Asp Arg Val Glu Arg Val Arg Arg
50 55 60

Ala His Leu Asn Asp Leu Glu Asn Ile Ile Pro Phe Leu Gly Ile Gly
65 70 75 80

Leu Leu Tyr Ser Leu Ser Gly Pro Asp Pro Ser Thr Ala Ile Leu His
85 90 95

Phe Arg Leu Phe Val Gly Ala Arg Ile Tyr His Thr Ile Ala Tyr Leu
100 105 110

Thr Pro Leu Pro Gln Pro Asn Arg Ala Leu Ser Phe Phe Val Gly Tyr
115 120 125

Gly Val Thr Leu Ser Met Ala Tyr Arg Leu Leu Lys Ser Lys Leu Tyr
130 135 140

Leu
145

<210> 314
<211> 530
<212> PRT
<213> Homo sapien

<400> 314

Pro Ser Asp His Arg Thr Gly Leu Gly Arg Asp Val Gly Ala Gly Ala
1 5 10 15

Arg Arg Ala Ala Arg Cys Arg Ala Glu Ala Ala Ala Val Gly Thr

30

Ala Ala Val Asp Ala Thr Val Asn Gln Val Leu Ala Ser Arg Tyr Gly
260 265 270

304

Ile	Arg	Gly	Phe	Pro	Thr	Ile	Lys	Ile	Phe	Gln	Lys	Gly	Glu	Ser	Pro
		275					280					285			
Val	Asp	Tyr	Asp	Gly	Gly	Arg	Thr	Arg	Ser	Asp	Ile	Val	Ser	Arg	Ala
	290					295					300				
Leu	Asp	Leu	Phe	Ser	Asp	Asn	Ala	Pro	Pro	Pro	Glu	Leu	Leu	Glu	Ile
305					310					315					320
Ile	Asn	Glu	Asp	Ile	Ala	Lys	Arg	Thr	Cys	Glu	Glu	His	Gln	Leu	Cys
				325					330					335	
Val	Val	Ala	Val	Leu	Pro	His	Ile	Leu	Asp	Thr	Gly	Ala	Ala	Gly	Arg
			340					345					350		
Asn	Ser	Tyr	Leu	Glu	Val	Leu	Leu	Lys	Leu	Ala	Asp	Lys	Tyr	Lys	Lys
		355					360					365			
Lys	Met	Trp	Gly	Trp	Leu	Trp	Thr	Glu	Ala	Gly	Ala	Gln	Ser	Glu	Leu
	370					375					380				
Glu	Thr	Ala	Leu	Gly	Ile	Gly	Gly	Phe	Gly	Tyr	Pro	Ala	Met	Ala	Ala
385					390					395					400
Ile	Asn	Ala	Arg	Lys	Met	Lys	Phe	Ala	Leu	Leu	Lys	Gly	Ser	Phe	Ser
				405					410					415	
Glu	Gln	Gly	Ile	Asn	Glu	Phe	Leu	Arg	Glu	Leu	Ser	Phe	Gly	Arg	Gly
			420					425					430		
Ser	Thr	Ala	Pro	Val	Gly	Gly	Gly	Ala	Phe	Pro	Thr	Ile	Val	Glu	Arg
		435					440					445			
Glu	Pro	Trp	Asp	Gly	Arg	Asp	Gly	Glu	Glu	Cys	Pro	Gly	Gly	Lys	Leu
	450					455					460				
Cys	Gly	Gln	Gln	Ser	Trp	Phe	Thr	Leu	Leu	Ser	Leu	Cys	Ile	Ser	Ala
465					470					475					480
Pro	Gly	Val	Lys	Ser	Phe	Pro	Ser	Asp	Leu	Ser	Pro	Gly	Ala	Pro	Val
				485					490					495	
Gly	Leu	Leu	Arg	Gly	Ser	Ser	Leu	Lys	Thr	Leu	His	Leu	Pro	Tyr	His
			500					505					510		

305

Lys Phe Lys Cys Cys Met Ala Phe Asp Thr Leu Asp Ser Gln Asp Thr
 515 520 525

Phe Gln
 530

<210> 315
 <211> 376
 <212> PRT
 <213> Homo sapien

<400> 315

Met Ala Asp Tyr Trp Lys Ser Gln Pro Lys Lys Phe Cys Asp Tyr Cys
 1 5 10 15

Lys Cys Trp Ile Ala Asp Asn Arg Pro Ser Val Glu Phe His Glu Arg
 20 25 30

Gly Lys Asn His Lys Glu Asn Val Ala Lys Arg Ile Ser Glu Ile Lys
 35 40 45

Gln Lys Ser Leu Asp Lys Ala Lys Glu Glu Glu Lys Ala Ser Lys Glu
 50 55 60

Phe Ala Ala Met Glu Ala Ala Ala Leu Lys Ala Tyr Gln Glu Asp Leu
 65 70 75 80

Lys Arg Leu Gly Leu Glu Ser Glu Ile Leu Glu Pro Ser Ile Thr Pro
 85 90 95

Val Thr Ser Thr Ile Pro Pro Thr Ser Thr Ser Asn Gln Gln Lys Glu
 100 105 110

Lys Lys Asp Lys Lys Lys Arg Gln Lys Asp Pro Ser Lys Gly Arg Trp
 115 120 125

Val Glu Gly Ile Thr Ser Glu Gly Tyr His Tyr Tyr Tyr Asp Leu Ile
 130 135 140

Ser Gly Ala Ser Gln Trp Glu Lys Pro Glu Gly Phe Gln Gly Asp Leu
 145 150 155 160

Lys Lys Thr Ala Val Lys Thr Val Trp Val Glu Gly Leu Ser Glu Asp
 165 170 175

Gly Phe Thr Tyr Tyr Tyr Asn Thr Glu Thr Gly Glu Ser Arg Trp Glu

306

180

185

190

Lys Pro Asp Asp Phe Ile Pro His Thr Ser Asp Leu Pro Ser Ser Lys
 195 200 205

Val Asn Glu Asn Ser Leu Gly Thr Leu Asp Glu Ser Lys Ser Ser Asp
 210 215 220

Ser His Ser Asp Ser Asp Gly Glu Gln Glu Ala Glu Glu Gly Gly Val
 225 230 235 240

Ser Thr Glu Thr Glu Lys Pro Lys Ile Lys Phe Gln Glu Lys Asn Lys
 245 250 255

Asn Ser Asp Gly Gly Ser Asp Pro Glu Thr Gln Lys Glu Lys Ser Ile
 260 265 270

Gln Lys Gln Asn Ser Leu Gly Ser Asn Glu Glu Lys Ser Lys Thr Leu
 275 280 285

Lys Lys Ser Asn Pro Tyr Gly Glu Trp Gln Glu Ile Lys Gln Glu Val
 290 295 300

Glu Ser His Glu Glu Val Asp Leu Glu Leu Pro Ser Thr Glu Asn Glu
 305 310 315 320

Tyr Val Ser Thr Ser Glu Ala Asp Gly Gly Gly Glu Pro Lys Val Val
 325 330 335

Phe Lys Glu Lys Thr Val Thr Ser Leu Gly Val Met Ala Asp Gly Val
 340 345 350

Ala Pro Val Phe Lys Lys Arg Arg Thr Glu Asn Gly Lys Ser Arg Asn
 355 360 365

Leu Arg Gln Arg Gly Asp Asp Gln
 370 375

<210> 316

<211> 619

<212> PRT

<213> Homo sapien

<400> 316

Met Ala Ala Val Val Gln Gln Asn Asp Leu Val Phe Glu Phe Ala Ser
 1 5 10 15

307

Asn Val Met Glu Asp Glu Arg Gln Leu Gly Asp Pro Ala Ile Phe Pro
 20 25 30

Ala Val Ile Val Glu His Val Pro Gly Ala Asp Ile Leu Asn Ser Tyr
 35 40 45

Ala Gly Leu Ala Cys Val Glu Glu Pro Ser Asp Met Ile Thr Glu Ser
 50 55 60

Ser Leu Asp Val Ala Glu Glu Glu Ile Ile Asp Asp Asp Asp Asp Asp
 65 70 75 80

Ile Thr Leu Thr Val Glu Ala Ser Cys His Asp Gly Asp Glu Thr Ile
 85 90 95

Glu Thr Ile Glu Ala Ala Glu Ala Leu Leu Asn Met Asp Ser Pro Gly
 100 105 110

Pro Met Leu Asp Glu Lys Arg Ile Asn Asn Asn Ile Phe Ser Ser Pro
 115 120 125

Glu Asp Asp Met Val Val Ala Pro Val Thr His Val Ser Val Thr Leu
 130 135 140

Asp Gly Ile Pro Glu Val Met Glu Thr Gln Gln Val Gln Glu Lys Tyr
 145 150 155 160

Ala Asp Ser Pro Gly Ala Ser Ser Pro Glu Gln Pro Lys Arg Lys Lys
 165 170 175

Gly Arg Lys Thr Lys Pro Pro Arg Pro Asp Ser Pro Ala Thr Thr Pro
 180 185 190

Asn Ile Ser Val Lys Lys Lys Asn Lys Asp Gly Lys Gly Asn Thr Ile
 195 200 205

Tyr Leu Trp Glu Phe Leu Leu Ala Leu Leu Gln Asp Lys Ala Thr Cys
 210 215 220

Pro Lys Tyr Ile Lys Trp Thr Gln Arg Glu Lys Gly Ile Phe Lys Leu
 225 230 235 240

Val Asp Ser Lys Ala Val Ser Arg Leu Trp Gly Lys His Lys Asn Lys
 245 250 255

308

Pro Asp Met Asn Tyr Glu Thr Met Gly Arg Ala Leu Arg Tyr Tyr Tyr
 260 265 270

Gln Arg Gly Ile Leu Ala Lys Val Glu Gly Gln Arg Leu Val Tyr Gln
 275 280 285

Phe Lys Glu Met Pro Lys Asp Leu Ile Tyr Ile Asn Asp Glu Asp Pro
 290 295 300

Ser Ser Ser Ile Glu Ser Ser Asp Pro Ser Leu Ser Ser Ser Ala Thr
 305 310 315 320

Ser Asn Arg Asn Gln Thr Ser Arg Ser Arg Val Ser Ser Ser Pro Gly
 325 330 335

Val Lys Gly Gly Ala Thr Ser Val Leu Lys Pro Gly Asn Ser Lys Ala
 340 345 350

Ala Lys Pro Lys Asp Pro Val Glu Val Ala Gln Pro Ser Glu Val Leu
 355 360 365

Arg Thr Val Gln Pro Thr Gln Ser Pro Tyr Pro Thr Gln Leu Phe Arg
 370 375 380

Thr Val His Val Val Gln Pro Val Gln Ala Val Pro Glu Gly Glu Ala
 385 390 395 400

Ala Arg Thr Ser Thr Met Gln Asp Glu Thr Leu Asn Ser Ser Val Gln
 405 410 415

Ser Ile Arg Thr Ile Gln Ala Pro Thr Gln Val Pro Val Val Val Ser
 420 425 430

Pro Arg Asn Gln Gln Leu His Thr Val Thr Leu Gln Thr Val Pro Leu
 435 440 445

Thr Thr Val Ile Ala Ser Thr Asp Pro Ser Ala Gly Thr Gly Ser Gln
 450 455 460

Lys Phe Ile Leu Gln Ala Ile Pro Ser Ser Gln Pro Met Thr Val Leu
 465 470 475 480

Lys Glu Asn Val Met Leu Gln Ser Gln Lys Ala Gly Ser Pro Pro Ser
 485 490 495

Ile Val Leu Gly Pro Ala Gln Val Gln Gln Val Leu Thr Ser Asn Val

309

500

505

510

Gln Thr Ile Cys Asn Gly Thr Val Ser Val Ala Ser Ser Pro Ser Phe
515 520 525

Ser Ala Thr Ala Pro Val Val Thr Phe Ser Pro Arg Ser Ser Gln Leu
530 535 540

Val Ala His Pro Pro Gly Thr Val Ile Thr Ser Val Ile Lys Thr Gln
545 550 555 560

Glu Thr Lys Thr Leu Thr Gln Glu Val Glu Lys Lys Glu Ser Glu Asp
565 570 575

His Leu Lys Glu Asn Thr Glu Lys Thr Glu Gln Gln Pro Gln Pro Tyr
580 585 590

Val Met Val Val Ser Ser Ser Asn Gly Phe Thr Ser Gln Val Ala Met
595 600 605

Lys Gln Asn Glu Leu Leu Glu Pro Asn Ser Phe
610 615

<210> 317

<211> 164

<212> PRT

<213> Homo sapien

<400> 317

Arg Ser Leu Ala Thr Arg Ser Ala Gly Pro Ala Val Ser Pro Leu Phe
1 5 10 15

Phe Phe Asn Ser Ala Arg Gly Pro Arg Pro Thr Gly Pro Gly Cys Ser
20 25 30

Ala Gly Gln Ser Ala Cys Gly Val Val Gly Lys Val Glu Ser Gly Asp
35 40 45

Val Ser Gly Asn Ser Cys Leu Arg Ser Gly Arg Arg Arg Arg Ala Glu
50 55 60

Leu Leu Gly Leu Glu Pro Ala Ser Leu Glu Gly Gly Trp Arg Phe Trp
65 70 75 80

Ala Pro Gly Glu Asp Thr Glu Thr Ala Gly Trp Arg Arg Asp Leu Arg
85 90 95

Leu Glu Ile Pro Ser Phe Ser Ser Gly Pro Val Ala Leu Leu Pro Leu
100 105 110

Glu Tyr Arg Pro Cys Arg Gly Arg Gly Glu Glu Ala Ile Ser Asn Ala
130 135 140

Asp Trp Ile Val Trp Ala Pro Val Val Gly Asn Ser Gly Thr Leu Val
145 150 155 160

```
<210> 318
<211> 361
<212> PRT
<213> Homo sapien
```

Met Glu Leu Glu Asp Gly Val Val Tyr Gln Glu Glu Pro Gly Gly Ser
1 5 10 15

Gly Ala Val Met Ser Glu Arg Val Ser Gly Leu Ala Gly Ser Ile Tyr
20 25 30

Arg Glu Phe Glu Arg Leu Ile Gly Arg Tyr Asp Glu Glu Val Val Lys
35 40 45

Glu Leu Met Pro Leu Val Val Ala Val Leu Glu Asn Leu Asp Ser Val
50 55 60

Phe Ala Gln Asp Gln Glu His Gln Val Glu Leu Glu Leu Leu Arg Asp
65 70 75 80

Asp Asn Glu Gln Leu Ile Thr Gln Tyr Glu Arg Glu Lys Ala Leu Arg
85 90 95

Lys His Ala Glu Glu Lys Phe Ile Glu Phe Glu Asp Ser Gln Glu Gln
100 105 110

Glu Lys Lys Asp Leu Gln Thr Arg Val Glu Ser Leu Glu Ser Gln Thr
115 120 125

Arg Gln Leu Glu Leu Lys Ala Lys Asn Tyr Ala Asp Gln Ser Leu Ser

311

130					135					140					
Ala	Val	Cys	Trp	Gly	Arg	Arg	Gln	Gln	Arg	Trp	Lys	Val	Phe	Gln	Thr
145					150					155					160
Trp	Gln	Arg	Pro	Ser	Ile	Ser	Gly	Val	Ser	Arg	Leu	Glu	Glu	Arg	Glu
				165					170					175	
Ala	Glu	Leu	Lys	Lys	Glu	Tyr	Asn	Ala	Leu	His	Gln	Arg	His	Thr	Glu
			180					185					190		
Met	Ile	His	Asn	Tyr	Met	Glu	His	Leu	Glu	Arg	Thr	Lys	Leu	His	Gln
		195					200					205			
Leu	Ser	Gly	Ser	Asp	Gln	Leu	Glu	Ser	Thr	Ala	His	Ser	Arg	Ile	Arg
	210					215					220				
Lys	Glu	Arg	Pro	Ile	Ser	Leu	Gly	Ile	Phe	Pro	Leu	Pro	Ala	Gly	Asp
225					230					235					240
Gly	Leu	Leu	Thr	Pro	Asp	Ala	Gln	Lys	Gly	Gly	Glu	Thr	Pro	Gly	Ser
				245					250					255	
Glu	Gln	Trp	Lys	Phe	Gln	Glu	Leu	Ser	Gln	Pro	Arg	Ser	His	Thr	Ser
			260					265					270		
Leu	Lys	Asp	Glu	Leu	Ser	Asp	Val	Ser	Gln	Gly	Gly	Ser	Lys	Ala	Thr
		275					280					285			
Thr	Pro	Ala	Ser	Thr	Ala	Asn	Ser	Asp	Val	Ala	Thr	Ile	Pro	Thr	Asp
	290					295					300				
Thr	Pro	Leu	Lys	Glu	Glu	Asn	Glu	Gly	Phe	Val	Lys	Val	Thr	Asp	Ala
305					310					315					320
Pro	Asn	Lys	Ser	Glu	Ile	Ser	Lys	His	Ile	Glu	Val	Gln	Val	Ala	Gln
				325					330					335	
Glu	Thr	Arg	Asn	Val	Ser	Thr	Gly	Ser	Ala	Glu	Asn	Glu	Glu	Lys	Ser
			340					345					350		
Val	Asp	Thr	Phe	Leu	Val	Ser	Trp	Ala							
	355						360								

<210> 319

<211> 122

312

<212> PRT

<213> Homo sapien

<400> 319

Met Gly Gly Phe Lys Tyr Gly Asp Glu Gln Pro Arg Ser Asp Trp Arg
 1 5 10 15

Ser Tyr Arg Arg Asn Leu Glu His Ala Val Leu Glu Leu Thr Leu Phe
 20 25 30

Lys Thr Val Pro Ser Lys Met Glu Ile His Ser Ser Pro Phe Lys Cys
 35 40 45

Ser Thr Ala Pro Pro Cys Asn Thr Ser Gly Gln Gly Lys Ile Thr Glu
 50 55 60

His Ser Cys Glu Pro Asp Phe Cys Cys Leu Trp Ile Asp Lys Lys Gln
 65 70 75 80

Asn Ser Phe Ser Ser Gly Val Gly Asn Arg Ser Leu Asp Ser Leu Leu
 85 90 95

Ile Lys Gly Ser Ser Pro Phe Leu Val Leu Gly Val Arg Gly Ser Phe
 100 105 110

Gly Lys Met His Pro Ser Ile Val Ala Phe
 115 120

<210> 320

<211> 78

<212> PRT

<213> Homo sapien

<400> 320

Met Tyr Lys Gly Thr Ser Ile Thr Leu Gln Gln Gly Arg Arg Ser Gly
 1 5 10 15

Ala Leu Gly Ser Leu Gly Thr Phe Ser Pro Ser Ala Gly Trp Pro Leu
 20 25 30

Arg Leu Trp Leu Leu Cys Thr Leu Asn Phe Asp Leu Cys Pro Cys Gln
 35 40 45

Gly Asp Arg Gly Gln Leu Gly Gln Gln Ala Ser Leu Lys Val Thr Pro
 50 55 60

Glu Pro Leu Phe Ser Phe Thr Val Ala Met Gln Ala Arg Gly

313

65

70

75

<210> 321
<211> 92
<212> PRT
<213> Homo sapien

<400> 321

Val Pro Leu Ile Ile Phe Thr Ile Lys Ala Asn Ser Glu Ala Cys Arg
1 5 10 15

Asp Gly Leu Arg Ala Val Met Glu Cys Arg Asn Val Thr His Leu Leu
20 25 30

Gln Gln Glu Leu Thr Glu Ala Gln Lys Gly Phe Gln Asp Val Glu Ala
35 40 45

Gln Ala Ala Thr Cys Asn His Thr Val Met Ala Leu Met Ala Ser Leu
50 55 60

Asp Ala Glu Lys Ala Gln Asp Ser Ser Ser Ala Ala Ala Pro Gln Leu
65 70 75 80

Leu Ile Val Leu Leu Gly Leu Ser Ala Leu Leu Gln
85 90

<210> 322
<211> 178
<212> PRT
<213> Homo sapien

<400> 322

Met Ala Ser Thr Ser Tyr Asp Tyr Cys Arg Val Pro Met Glu Asp Gly
1 5 10 15

Asp Lys Arg Cys Lys Leu Leu Leu Gly Ile Gly Ile Leu Val Leu Leu
20 25 30

Ile Ile Val Ile Leu Gly Val Pro Leu Ile Ile Phe Thr Ile Lys Ala
35 40 45

Asn Ser Glu Ala Cys Arg Asp Gly Leu Arg Ala Val Met Glu Cys Arg
50 55 60

Asn Val Thr His Leu Leu Gln Gln Glu Leu Thr Glu Ala Gln Lys Gly
65 70 75 80

314

Phe Gln Asp Val Glu Ala Gln Ala Ala Thr Cys Asn His Thr Val Met
85 90 95

Ala Leu Met Ala Ser Leu Asp Ala Glu Lys Ala Gln Gly Gln Lys Lys
100 105 110

Val Glu Glu Leu Glu Gly Glu Ile Thr Thr Leu Asn His Lys Leu Gln
115 120 125

Asp Ala Ser Ala Glu Val Glu Arg Leu Arg Arg Glu Asn Gln Val Leu
130 135 140

Ser Val Arg Ile Ala Asp Lys Lys Tyr Tyr Pro Ser Ser Gln Asp Ser
145 150 155 160

Ser Ser Ala Ala Ala Pro Gln Gln His Asn Gln Gln Leu Gly Arg Arg
165 170 175

Ser Cys

<210> 323

<211> 188

<212> PRT

<213> Homo sapien

<400> 323

Met Ala Ser Thr Ser Tyr Asp Tyr Cys Arg Val Pro Met Glu Asp Gly
1 5 10 15

Asp Lys Arg Cys Lys Leu Leu Leu Gly Ile Gly Ile Leu Val Leu Leu
20 25 30

Ile Ile Val Ile Leu Gly Val Pro Leu Ile Ile Phe Thr Ile Lys Ala
35 40 45

Asn Ser Glu Ala Cys Arg Asp Gly Leu Arg Ala Val Met Glu Cys Arg
50 55 60

Asn Val Thr His Leu Leu Gln Gln Glu Leu Thr Glu Ala Gln Lys Gly
65 70 75 80

Phe Gln Asp Val Glu Ala Gln Ala Ala Thr Cys Asn His Thr Val Met
85 90 95

Ala Leu Met Ala Ser Leu Asp Ala Glu Lys Ala Gln Gly Gln Lys Lys
100 105 110

315

Val Glu Glu Leu Glu Val Thr Thr Leu Asn His Lys Leu Gln Asp Ala
 115 120 125

Ser Arg Pro Gly Phe Leu Phe Ser Val Ala Pro Pro Leu Gln Thr Arg
 130 135 140

Leu Arg Arg Glu Asn Gln Val Leu Ser Val Arg Ile Ala Asp Lys Lys
 145 150 155 160

Tyr Tyr Pro Ser Ser Gln Asp Ser Ser Ser Ala Ala Ala Pro Gln Leu
 165 170 175

Leu Ile Val Leu Leu Gly Leu Ser Ala Leu Leu Gln
 180 185

<210> 324
 <211> 108
 <212> PRT
 <213> Homo sapien

<400> 324

Leu Arg Ser Leu Glu Arg Glu Ala Ala Gly Glu Gly Thr Gly Arg Arg
 1 5 10 15

Gly Glu Gly Pro Trp Gly Arg Arg Glu Asn Pro Val Arg Arg Met Pro
 20 25 30

Trp Ile Gly Gly Gly Leu Ile Ala Val Trp Gly Gly Ala Ile Asn Gly
 35 40 45

Gly Gly Ser Ile Asp Gly Gly Glu Gly Leu Met Asp Gly Trp Gly Gly
 50 55 60

Ser Ser Asp Gly Gly Gly Ala Trp Gly Arg Ala Trp Ser Gly Ala Ser
 65 70 75 80

Ala Cys Cys Leu Gln Ser Ala Leu Ser Pro Ser Ser Gly Pro Leu Gly
 85 90 95

Thr Ser Trp Lys Val Arg Pro Ala Arg Leu Phe Ala
 100 105

<210> 325
 <211> 250
 <212> PRT
 <213> Homo sapien

316

<400> 325

His Pro Val Thr Cys Ile Tyr Met Gln Ile Tyr Trp Phe Met Gln Asn
1 5 10 15

Ser Gly Gly Leu Gly Gly Gly Phe Phe Ser Leu Lys Leu Val Gln Ser
20 25 30

Leu Lys Lys Arg Arg Lys Ala Val Ser Gly Val Leu His Val Arg Leu
35 40 45

Ala Pro Gly Ser Trp Ala Gly Ser Arg Arg Thr Lys Thr Glu Leu Ala
50 55 60

Arg Leu Ala Glu Lys Gly Glu Gln Arg Pro Tyr Thr Glu Ser Ser Gly
65 70 75 80

Ala Pro Thr Lys Ser Arg Met Pro Thr Pro Ala Ser Arg Ser Thr Pro
85 90 95

Lys Ala Gly Gly Glu Ala Glu Cys Ala Ser Ala Ile Arg Arg Arg Arg
100 105 110

Leu Leu Pro Leu Arg Arg Glu His Ala Gly Pro Lys Met Ala Ala Ser
115 120 125

Arg Tyr Arg Arg Phe Leu Lys Leu Cys Glu Glu Trp Pro Val Asp Glu
130 135 140

Thr Lys Arg Gly Arg Asp Leu Gly Ala Tyr Leu Arg Gln Arg Val Ala
145 150 155 160

Gln Ala Phe Arg Glu Gly Glu Asn Thr Gln Val Ala Glu Pro Glu Ala
165 170 175

Cys Asp Gln Met Tyr Glu Ser Leu Ala Arg Leu His Ser Asn Tyr Tyr
180 185 190

Lys His Lys Tyr Pro Arg Pro Arg Asp Thr Ser Phe Ser Gly Leu Ser
195 200 205

Leu Glu Glu Tyr Lys Leu Ile Leu Ser Thr Asp Thr Leu Glu Glu Leu
210 215 220

Lys Glu Ile Asp Lys Gly Met Trp Lys Lys Leu Gln Glu Lys Phe Ala
225 230 235 240

317

Pro Lys Gly Pro Glu Glu Asp His Lys Ala
245 250

<210> 326
<211> 68
<212> PRT
<213> Homo sapien

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> x=any amino acid

<400> 326

Xaa Leu Asp Arg Glu Gln Pro Leu Gly Ser Arg Thr Gln Tyr Pro Arg
1 5 10 15

Pro Arg Asp Thr Ser Phe Ser Gly Leu Ser Leu Glu Glu Tyr Lys Leu
20 25 30

Ile Leu Ser Thr Asp Thr Leu Glu Glu Leu Lys Glu Ile Asp Lys Gly
35 40 45

Met Trp Lys Lys Leu Gln Glu Lys Phe Ala Pro Lys Gly Pro Glu Glu
50 55 60

Asp His Lys Ala
65

<210> 327
<211> 221
<212> PRT
<213> Homo sapien

<400> 327

Met Met Gly Ser Asp Ser Gly Pro Arg Pro Ser Pro Ser Gln Cys Leu
1 5 10 15

Leu Asn Ser Thr Ala Cys Ala Glu Ser Thr His Gln Asp Ser Asn Pro
20 25 30

Cys Ser Thr Ser Gln Leu Cys Asn Leu Ser Lys Leu Leu His Cys Leu
35 40 45

Leu Pro Gln Phe Pro His Leu Lys Thr Gly Asp Arg Lys Gly Cys Val
50 55 60

318

Glu Gln Ala Lys Phe Cys Asp Glu Ala Ser Gly Ser Val Gly Cys Thr
65 70 75 80

Ala Asp Ser Ala Gly Pro Phe Leu Cys Pro His Thr Glu Gln Gly Asn
85 90 95

Glu Gln His Ile Pro Ala Leu Met Pro Arg Val Arg Arg Gly Gln Glu
100 105 110

Thr Thr Asp Ser Val Leu Gly Thr Glu Ser Gly Thr Gln Cys Ser Val
115 120 125

Pro Ala Ser Gly His Phe Cys Tyr Leu Phe Asp Leu Leu Phe Arg Ser
130 135 140

Trp Val Ser Thr Phe Phe Arg Asn Thr Leu Cys Glu Lys Gln Ala Met
145 150 155 160

Leu Val Ser Gly Lys Pro Ser Gly Ser Asn Leu Cys His Gln Val Leu
165 170 175

Asp Phe Ser Pro Ser Leu Phe Leu Ser Ser Pro Phe Ala Asp Thr Leu
180 185 190

Glu Glu Leu Lys Glu Ile Asp Lys Gly Met Trp Lys Lys Leu Gln Glu
195 200 205

Lys Phe Ala Pro Lys Gly Pro Glu Glu Asp His Lys Ala
210 215 220

<210> 328

<211> 108

<212> PRT

<213> Homo sapien

<400> 328

Met Val Ile Ile Cys Cys Leu Gly Ala Pro Arg Thr Gln Pro Phe Gln
1 5 10 15

Ala Gln Leu Pro Asn Leu Ser Ala Lys Leu Leu Ala Phe Pro Ser Thr
20 25 30

Leu Ser Thr Pro Pro Val Ser Glu Leu Glu Ser Ala Leu Gln Met Glu
35 40 45

Pro Ala Ala Phe Gln Ala Leu Tyr Ser Ala Glu Lys Pro Lys Leu Glu

319

50		55		60											
Asp	Glu	His	Leu	Val	Phe	Phe	Cys	Gln	Met	Gly	Lys	Arg	Gly	Leu	Gln
65					70					75					80
Ala	Thr	Gln	Leu	Ala	Arg	Ser	Leu	Gly	Tyr	Thr	Gly	Ala	Arg	Asn	Tyr
				85					90					95	
Ala	Gly	Ala	Tyr	Arg	Glu	Trp	Leu	Glu	Lys	Glu	Ser				
			100					105							
<210> 329															
<211> 172															
<212> PRT															
<213> Homo sapien															
<400> 329															
Gly	Lys	Ala	Leu	Cys	His	Pro	Gln	Ile	Ala	Met	Ala	Gln	Val	Pro	Pro
1				5					10					15	
Gly	Thr	Pro	Arg	Arg	Gly	Leu	Pro	Arg	His	Gln	Gly	Leu	Gly	His	Ala
			20					25					30		
Thr	His	Leu	His	Gln	Ala	Val	Phe	Cys	Trp	Val	Ala	Glu	Gly	Met	Arg
		35					40					45			
Ala	Asp	Thr	Thr	Cys	Ser	Pro	Arg	Val	Ala	Val	Gly	Thr	Ala	Ala	Glu
	50					55					60				
Gly	Leu	Leu	Leu	Arg	Val	His	Met	Trp	Gly	Lys	Glu	Met	Leu	Gln	Ala
65				70						75					80
Pro	Arg	Gly	Arg	Ala	Arg	Ala	Ala	Leu	Arg	Arg	Leu	Ala	Val	Ala	Thr
				85					90					95	
Arg	Thr	Met	Ala	Gly	Val	Ser	Glu	Leu	Glu	Ser	Ala	Leu	Gln	Met	Glu
			100					105					110		
Pro	Ala	Ala	Phe	Gln	Ala	Leu	Tyr	Ser	Ala	Glu	Lys	Pro	Lys	Leu	Glu
		115					120					125			
Asp	Glu	His	Leu	Val	Phe	Phe	Cys	Gln	Met	Gly	Lys	Arg	Gly	Leu	Gln
	130					135					140				
Ala	Thr	Gln	Leu	Ala	Arg	Ser	Leu	Gly	Tyr	Thr	Gly	Ala	Arg	Asn	Tyr
145					150					155					160

320

Ala Gly Ala Tyr Arg Glu Trp Leu Glu Lys Glu Ser
 165 170

<210> 330
 <211> 335
 <212> PRT
 <213> Homo sapien

<400> 330

Met Gly Thr Lys Ala Gln Val Glu Arg Lys Leu Leu Cys Leu Phe Ile
 1 5 10 15

Leu Ala Ile Leu Leu Cys Ser Leu Ala Leu Gly Ser Val Thr Val His
 20 25 30

Ser Ser Glu Pro Glu Val Arg Ile Pro Glu Asn Asn Pro Val Lys Leu
 35 40 45

Ser Cys Ala Tyr Ser Gly Phe Ser Ser Pro Arg Val Glu Trp Lys Phe
 50 55 60

Asp Gln Gly Asp Thr Thr Arg Leu Val Cys Tyr Asn Asn Lys Ile Thr
 65 70 75 80

Ala Ser Tyr Glu Asp Arg Val Thr Phe Leu Pro Thr Gly Ile Thr Phe
 85 90 95

Lys Ser Val Thr Arg Glu Asp Thr Gly Thr Tyr Thr Cys Met Val Ser
 100 105 110

Glu Glu Gly Gly Asn Ser Tyr Gly Glu Val Lys Val Lys Leu Ile Val
 115 120 125

Leu Val Pro Pro Ser Lys Pro Thr Val Asn Ile Pro Ser Ser Ala Thr
 130 135 140

Ile Gly Asn Arg Ala Val Leu Thr Cys Ser Glu Gln Asp Gly Ser Pro
 145 150 155 160

Pro Ser Glu Tyr Thr Trp Phe Lys Asp Gly Ile Val Met Pro Thr Asn
 165 170 175

Pro Lys Ser Thr Arg Ala Phe Ser Asn Ser Ser Tyr Val Leu Asn Pro
 180 185 190

Thr Thr Gly Glu Leu Val Phe Asp Pro Leu Ser Ala Ser Asp Thr Gly

321

195

200

205

Glu Tyr Ser Cys Glu Ala Arg Asn Gly Tyr Gly Thr Pro Met Thr Ser
 210 215 220

Asn Ala Val Arg Met Glu Ala Val Glu Arg Asn Val Gly Val Ile Val
 225 230 235 240

Ala Ala Val Leu Val Thr Leu Ile Leu Leu Gly Ile Leu Val Phe Gly
 245 250 255

Ile Trp Phe Ala Tyr Ser Arg Gly His Phe Asp Arg Thr Lys Lys Ser
 260 265 270

Ala Pro Arg Gly Ser Pro Leu Tyr Cys Pro His Pro Arg Ala Trp His
 275 280 285

Gly Cys His Leu Ser Thr Asp Pro Asp Thr Val Leu Met Cys Val Gly
 290 295 300

Val Val Pro Trp Gly Thr Leu Ile Thr His Leu Thr Pro Arg Ala Gly
 305 310 315 320

Gly Leu Pro Leu His Leu Pro Lys Pro Cys Cys Leu Leu Ser Cys
 325 330 335

<210> 331

<211> 351

<212> PRT

<213> Homo sapien

<400> 331

Met Gly Thr Lys Ala Gln Val Glu Arg Lys Leu Leu Cys Leu Phe Ile
 1 5 10 15

Leu Ala Ile Leu Leu Cys Ser Leu Ala Leu Gly Ser Val Thr Val His
 20 25 30

Ser Ser Glu Pro Glu Val Arg Ile Pro Glu Asn Asn Arg Glu Leu Gly
 35 40 45

Gly Ala Met Glu Gly Val Arg Val Ser Ser Cys Arg Pro Pro Gly Asp
 50 55 60

Leu Glu Ser Thr Gln Pro Ser Leu Gln Phe Gly Ala Val Pro His Leu
 65 70 75 80

322

Val	Tyr	Leu	Leu	Leu	Phe	Phe	Leu	Arg	Leu	Ile	Leu	Thr	Leu	Ser	Ala	
				85					90					95		
Ala	Val	Lys	Leu	Ser	Cys	Ala	Tyr	Ser	Gly	Phe	Ser	Ser	Pro	Arg	Val	
			100					105					110			
Glu	Trp	Lys	Phe	Asp	Gln	Gly	Asp	Thr	Thr	Arg	Leu	Val	Cys	Tyr	Asn	
		115					120					125				
Asn	Lys	Ile	Thr	Ala	Ser	Tyr	Glu	Asp	Arg	Val	Thr	Phe	Leu	Pro	Thr	
	130					135					140					
Gly	Ile	Thr	Phe	Lys	Ser	Val	Thr	Arg	Glu	Asp	Thr	Gly	Thr	Tyr	Thr	
145					150					155					160	
Cys	Met	Val	Ser	Glu	Glu	Gly	Gly	Asn	Ser	Tyr	Gly	Glu	Val	Lys	Val	
				165				170						175		
Lys	Leu	Ile	Val	Leu	Val	Pro	Pro	Ser	Lys	Pro	Thr	Val	Asn	Ile	Pro	
			180					185					190			
Ser	Ser	Ala	Thr	Ile	Gly	Asn	Arg	Ala	Val	Leu	Thr	Cys	Ser	Glu	Gln	
		195				200						205				
Asp	Gly	Ser	Pro	Pro	Ser	Glu	Tyr	Thr	Trp	Phe	Lys	Asp	Gly	Ile	Val	
	210					215					220					
Met	Pro	Thr	Asn	Pro	Lys	Ser	Thr	Arg	Ala	Phe	Ser	Asn	Ser	Ser	Tyr	
225					230					235					240	
Val	Leu	Asn	Pro	Thr	Thr	Gly	Glu	Leu	Val	Phe	Asp	Pro	Leu	Ser	Ala	
				245					250					255		
Ser	Asp	Thr	Gly	Glu	Tyr	Ser	Cys	Glu	Ala	Arg	Asn	Gly	Tyr	Gly	Thr	
			260					265					270			
Pro	Met	Thr	Ser	Asn	Ala	Val	Arg	Met	Glu	Ala	Val	Glu	Arg	Asn	Val	
		275					280					285				
Gly	Val	Ile	Val	Ala	Ala	Val	Leu	Val	Thr	Leu	Ile	Leu	Leu	Gly	Ile	
	290					295					300					
Leu	Val	Phe	Gly	Ile	Trp	Phe	Ala	Tyr	Ser	Arg	Gly	His	Phe	Asp	Arg	
305				310						315				320		

323

Thr Lys Lys Gly Thr Ser Ser Lys Lys Val Ile Tyr Ser Gln Pro Ser
 325 330 335

Ala Arg Ser Glu Gly Glu Phe Lys Gln Thr Ser Ser Phe Leu Val
 340 345 350

<210> 332

<211> 250

<212> PRT

<213> Homo sapien

<400> 332

Lys Gly Ala Ser Ala Pro Arg Arg Gly Val Ala Ala Gly Phe His Leu
 1 5 10 15

Ala Ala Gly Leu Ser Val Leu Lys Ser Ser Gly Ser Leu His Gln Ser
 20 25 30

Glu Arg Ala Gly Val Gly Ser Trp Pro Ile Arg Arg Gly Gly Arg Gly
 35 40 45

Arg Ala Gly Phe His Leu Ala Ala Gly Ser Gln Ser Pro Arg Cys Ser
 50 55 60

Arg Gly Ala Val Ser Val Pro Arg Ser Pro Ser Ala Ala Val Val Ser
 65 70 75 80

Val Ser Leu Ile Ala Met Gly Thr Lys Ala Gln Val Glu Arg Lys Leu
 85 90 95

Leu Cys Leu Phe Ile Leu Ala Ile Leu Leu Cys Lys Phe Pro Glu Phe
 100 105 110

Arg Glu Glu Ser Val Gly Arg Val Arg Gly Trp Arg Lys Ala Leu Pro
 115 120 125

Thr Pro Leu Ala Arg Gly Arg Gly Gly Ala Gln Lys Pro Ser Tyr Ile
 130 135 140

Val Leu Arg Ile Ile Phe Ser Thr Pro Gly Trp Ser Leu Phe His His
 145 150 155 160

Ser His Ser Trp Val Ser Gly Trp Leu Pro Ser Pro Thr Leu Val Ser
 165 170 175

Cys Asp Arg Thr Pro His Gly His Gln Glu Gly Ala Asp Pro Ser Ala
 180 185 190

324

His Thr Arg Gly Thr Leu Leu Val Leu Thr Gly Glu Gly Arg Arg Ala
 195 200 205

Lys Asp Pro Ser Thr Leu Ile Tyr Pro Ala Arg Ala Pro His Ala Pro
 210 215 220

Gly Lys Gly Gln Pro Ala Pro Pro Thr Ala Thr Gln His Pro Arg Thr
 225 230 235 240

Pro Leu Arg Ser Arg Glu Pro Trp Leu Leu
 245 250

<210> 333
 <211> 66
 <212> PRT
 <213> Homo sapien

<400> 333

Pro Val Ser Glu Leu Glu Ser Ala Leu Gln Met Glu Pro Ala Ala Phe
 1 5 10 15

Gln Ala Leu Tyr Ser Ala Glu Lys Pro Lys Leu Glu Asp Glu His Leu
 20 25 30

Val Phe Phe Cys Gln Met Gly Lys Arg Gly Leu Gln Ala Thr Gln Leu
 35 40 45

Ala Arg Ser Leu Gly Tyr Thr Gly Tyr Gly Glu Val Trp Leu Leu Ala
 50 55 60

Gly Arg
 65

<210> 334
 <211> 113
 <212> PRT
 <213> Homo sapien

<400> 334

Gly Asp Ser Glu Asp Pro Arg Phe Asp Pro Asp Gly Pro Gly Ser Ser
 1 5 10 15

Thr Cys Ala Leu Ala Arg Arg Arg Gln Leu Gly Pro Ser Gln Gly Arg
 20 25 30

Ser Thr Ser Arg Cys Pro Ser Trp Arg Val Leu Cys Arg Trp Ser Gln

325

35

40

45

Leu Pro Ser Arg Leu Tyr Ile Leu Leu Arg Ser Gln Ser Trp Lys Met
 50 55 60

Ser Ile Ser Phe Ser Ser Val Arg Trp Ala Ser Gly Ala Ser Arg Pro
 65 70 75 80

Arg Ser Trp Pro Gly Val Leu Asp Thr Leu Gly Leu Ala Thr Thr Leu
 85 90 95

Glu Pro Ile Glu Asn Gly Trp Arg Lys Arg Val Arg Gln Glu Ala Ala
 100 105 110

Tyr

<210> 335
 <211> 220
 <212> PRT
 <213> Homo sapien

<400> 335

Gly Lys Ala Leu Cys His Pro Gln Ile Ala Met Ala Gln Val Pro Pro
 1 5 10 15

Gly Thr Pro Arg Arg Gly Leu Pro Arg His Gln Gly Leu Gly His Ala
 20 25 30

Thr His Leu His Gln Ala Val Phe Cys Trp Val Ala Glu Gly Met Arg
 35 40 45

Ala Asp Thr Thr Cys Ser Pro Arg Val Ala Val Gly Thr Ala Ala Glu
 50 55 60

Gly Leu Leu Leu Arg Val His Met Trp Gly Lys Glu Met Leu Gln Ala
 65 70 75 80

Pro Arg Gly Arg Ala Arg Ala Ala Leu Arg Arg Leu Ala Val Ala Thr
 85 90 95

Arg Thr Met Ala Gly Gly Cys Arg Ala Pro Ser Ser Ala Pro Thr Val
 100 105 110

Ser Leu Pro Glu Leu Arg Ser Leu Leu Ala Ser Gly Arg Ala Arg Leu
 115 120 125

326

Phe Asp Val Arg Ser Arg Glu Glu Ala Ala Ala Gly Thr Ile Pro Gly
 130 135 140

Ala Leu Asn Ile Pro Val Ser Glu Leu Glu Ser Ala Leu Gln Met Glu
 145 150 155 160

Pro Ala Ala Phe Gln Ala Leu Tyr Ser Ala Glu Lys Pro Lys Leu Glu
 165 170 175

Asp Glu His Leu Val Phe Phe Cys Gln Met Gly Lys Arg Gly Leu Gln
 180 185 190

Ala Thr Gln Leu Ala Arg Ser Leu Gly Tyr Thr Gly Ala Arg Asn Tyr
 195 200 205

Ala Gly Ala Tyr Arg Glu Trp Leu Glu Lys Glu Ser
 210 215 220

<210> 336

<211> 199

<212> PRT

<213> Homo sapien

<400> 336

Gly Lys Ala Leu Cys His Pro Gln Ile Ala Met Ala Gln Val Pro Pro
 1 5 10 15

Gly Thr Pro Arg Arg Gly Leu Pro Arg His Gln Gly Leu Gly His Ala
 20 25 30

Thr His Leu His Gln Ala Val Phe Cys Trp Val Ala Glu Gly Met Arg
 35 40 45

Ala Asp Thr Thr Cys Ser Pro Arg Val Ala Val Gly Thr Ala Ala Glu
 50 55 60

Gly Leu Leu Leu Arg Val His Met Trp Gly Lys Glu Met Leu Gln Ala
 65 70 75 80

Pro Arg Gly Arg Ala Arg Ala Ala Leu Arg Arg Leu Ala Val Ala Thr
 85 90 95

Arg Thr Met Ala Gly Ala Gly Arg Ala Arg Leu Phe Asp Val Arg Ser
 100 105 110

Arg Glu Glu Ala Ala Ala Gly Thr Ile Pro Gly Ala Leu Asn Ile Pro

327

115

120

125

Val Ser Glu Leu Glu Ser Ala Leu Gln Met Glu Pro Ala Ala Phe Gln
 130 135 140

Ala Leu Tyr Ser Ala Glu Lys Pro Lys Leu Glu Asp Glu His Leu Val
 145 150 155 160

Phe Phe Cys Gln Met Gly Lys Arg Gly Leu Gln Ala Thr Gln Leu Ala
 165 170 175

Arg Ser Leu Gly Tyr Thr Gly Ala Arg Asn Tyr Ala Gly Ala Tyr Arg
 180 185 190

Glu Trp Leu Glu Lys Glu Ser
 195

<210> 337
 <211> 105
 <212> PRT
 <213> Homo sapien

<400> 337

Met Leu Gln Ala Pro Arg Gly Pro Gly Arg Ala Arg Leu Phe Asp Val
 1 5 10 15

Arg Ser Arg Glu Glu Ala Ala Ala Gly Thr Ile Pro Gly Ala Leu Asn
 20 25 30

Ile Pro Val Ser Glu Leu Glu Ser Ala Leu Gln Met Glu Pro Ala Ala
 35 40 45

Phe Gln Ala Leu Tyr Ser Ala Glu Lys Pro Lys Leu Glu Asp Glu His
 50 55 60

Leu Val Phe Phe Cys Gln Met Gly Lys Arg Gly Leu Gln Ala Thr Gln
 65 70 75 80

Leu Ala Arg Ser Leu Gly Tyr Thr Gly Ala Arg Asn Tyr Ala Gly Ala
 85 90 95

Tyr Arg Glu Trp Leu Glu Lys Glu Ser
 100 105

<210> 338
 <211> 131
 <212> PRT

328

<213> Homo sapien

<400> 338

Met Ala Ala Val Thr Pro Arg Pro Pro Leu Pro Glu Gly Cys Arg Ala
1 5 10 15

Pro Ser Ser Ala Pro Thr Val Ser Leu Pro Glu Leu Arg Ser Leu Leu
20 25 30

Ala Ser Gly Arg Ala Arg Leu Phe Asp Val Arg Ser Arg Glu Glu Ala
35 40 45

Ala Ala Gly Thr Ile Pro Gly Ala Leu Asn Ile Pro Val Ser Glu Leu
50 55 60

Glu Ser Ala Leu Gln Met Glu Pro Ala Ala Phe Gln Ala Leu Tyr Ser
65 70 75 80

Ala Glu Lys Pro Lys Leu Glu Asp Glu His Leu Val Phe Phe Cys Gln
85 90 95

Met Gly Lys Arg Gly Leu Gln Ala Thr Gln Leu Ala Arg Ser Leu Gly
100 105 110

Tyr Thr Gly Ala Arg Asn Tyr Ala Gly Ala Tyr Arg Glu Trp Leu Glu
115 120 125

Lys Glu Ser
130

<210> 339

<211> 134

<212> PRT

<213> Homo sapien

<400> 339

Met Glu Gly Gly Val Arg Glu Arg Glu Gly Ala Ala Ala His Pro Val
1 5 10 15

Leu Pro Thr Pro Gln Phe Ile Gly Thr Ala Ser Leu Ile Val Cys Val
20 25 30

Leu Ala Ile Val Asp Pro Tyr Asn Asn Pro Val Pro Arg Gly Leu Glu
35 40 45

Ala Phe Thr Val Gly Leu Val Val Leu Val Ile Gly Thr Ser Met Gly
50 55 60

329

Phe Asn Ser Gly Tyr Ala Val Asn Pro Ala Arg Asp Phe Gly Pro Arg
65 70 75 80

Leu Phe Thr Ala Leu Ala Gly Trp Gly Ser Ala Val Phe Thr Thr Gly
85 90 95

Gln His Trp Trp Trp Val Pro Ile Val Ser Pro Leu Leu Gly Ser Ile
100 105 110

Ala Gly Val Phe Val Tyr Gln Leu Met Ile Gly Cys His Leu Glu Gln
115 120 125

Pro Pro Pro Ser Asn Glu
130

<210> 340
<211> 76
<212> PRT
<213> Homo sapien

<400> 340

Gln Phe Ile Gly Thr Ala Ser Leu Ile Val Cys Val Leu Ala Ile Val
1 5 10 15

Asp Pro Tyr Asn Asn Pro Val Pro Arg Gly Leu Glu Ala Phe Thr Val
20 25 30

Gly Leu Val Val Leu Val Ile Gly Thr Ser Met Gly Phe Asn Ser Gly
35 40 45

Tyr Ala Val Asn Pro Ala Arg Asp Phe Gly Pro Arg Leu Phe Thr Ala
50 55 60

Leu Ala Gly Trp Gly Ser Ala Val Phe Thr Thr Gly
65 70 75

<210> 341
<211> 367
<212> PRT
<213> Homo sapien

<400> 341

Pro Pro Ala Leu Glu Ala Ala Ala Arg Cys Ala Thr Ala Ser Arg His
1 5 10 15

Pro Cys Pro Pro Asp Ser Ala Ala Ala Cys Pro Ala Met Gly Arg Gln

330

	20	25	30
Lys	Glu	Leu	Val
	35		
Ser	Arg	Cys	Gly
		40	
Glu	Met	Leu	His
			45
Arg	Tyr	Arg	
Leu	Leu	Arg	Gln
	50		
Ala	Leu	Ala	Glu
		55	
Cys	Leu	Gly	Thr
		60	
Leu	Ile	Leu	Val
Met	Phe	Gly	Cys
Gly	Ser	Val	Ala
	70		
Gln	Val	Val	Leu
		75	
Ser	Arg	Gly	Thr
			80
His	Gly	Gly	Phe
Leu	Thr	Ile	Asn
	85		
Leu	Ala	Phe	Gly
	90		
Phe	Ala	Val	Thr
			95
Leu	Gly	Ile	Leu
Ile	Ala	Gly	Gln
	100		
Val	Ser	Gly	Ala
		105	
His	Leu	Asn	Pro
		110	
Ala	Val	Thr	Phe
Ala	Met	Cys	Phe
Leu	Ala	Arg	Glu
Pro	Trp	Ile	Lys
Leu	Pro	Ile	Tyr
Thr	Leu	Ala	Gln
		135	
Thr	Leu	Gly	Ala
Phe	Leu	Gly	Ala
Gly	Ile	Val	Phe
Gly	Leu	Tyr	Tyr
Gly	Lys	His	Ser
		155	
Pro	Pro	Cys	Pro
Pro	Pro	Leu	Pro
Pro	Ser	Leu	Cys
Ser	Gly	Pro	Ala
Gly	Thr	Arg	Pro
		175	
Phe	Asp	Asp	Arg
Arg	Arg	Leu	Asp
Leu	Pro	Arg	Pro
Arg	Ala	His	Asp
Ser			
Leu	Ile	His	Ala
Gln	Gly	Gln	Asp
Ala	Ile	Trp	His
Phe	Ala	Asp	Asn
Gln	Leu	Phe	Val
Ser	Gly	Pro	Asn
Gly	Thr	Ala	Gly
Ile	Phe	Ala	Thr
Tyr	Pro	Ser	Gly
His	Leu	Asp	Met
Ile	Asn	Gly	Phe
Phe	Asp	Gln	Phe
Ile	Gly	Thr	Ala
Ser	Leu	Ile	Val
Cys	Val	Leu	Ala
Ile	Val	Asp	Pro
Tyr	Asn	Asn	Pro
Val	Pro	Arg	Gly
Leu	Glu	Ala	Phe
Thr	Val	Gly	Leu

331

Val Val Leu Val Ile Gly Thr Ser Met Gly Phe Asn Ser Gly Tyr Ala
 275 280 285

Val Asn Pro Ala Arg Asp Phe Gly Pro Arg Leu Phe Thr Ala Leu Ala
 290 295 300

Gly Trp Gly Ser Ala Val Phe Thr Thr Gly Gln His Trp Trp Trp Val
 305 310 315 320

Pro Ile Val Ser Pro Leu Leu Gly Ser Ile Ala Gly Val Phe Val Tyr
 325 330 335

Gln Leu Met Ile Gly Cys His Leu Glu Gln Pro Pro Pro Ser Asn Glu
 340 345 350

Glu Glu Asn Val Lys Leu Ala His Val Lys His Lys Glu Gln Ile
 355 360 365

<210> 342

<211> 214

<212> PRT

<213> Homo sapien

<400> 342

Ala Thr Pro Ser Ala Cys Cys Asn Thr Ala Val Leu Leu Leu Thr His
 1 5 10 15

Asn Ser Trp Glu Gly Gly Glu Gly Thr Pro Glu Arg Glu Val Trp Ala
 20 25 30

Gln Ala Ser Pro Pro Thr His Cys Val Ser Asn Leu Ser Pro Asp Ala
 35 40 45

Ile Trp His Phe Ala Asp Asn Gln Leu Phe Val Ser Gly Pro Asn Gly
 50 55 60

Thr Ala Gly Ile Phe Ala Thr Tyr Pro Ser Gly His Leu Asp Met Ile
 65 70 75 80

Asn Gly Phe Phe Asp Gln Phe Ile Gly Thr Ala Ser Leu Ile Val Cys
 85 90 95

Val Leu Ala Ile Val Asp Pro Tyr Asn Asn Pro Val Pro Arg Gly Leu
 100 105 110

332

Glu Ala Phe Thr Val Gly Leu Val Val Leu Val Ile Gly Thr Ser Met
115 120 125

Gly Phe Asn Ser Gly Tyr Ala Val Asn Pro Ala Arg Asp Phe Gly Pro
130 135 140

Arg Leu Phe Thr Ala Leu Ala Gly Trp Gly Ser Ala Val Phe Thr Thr
145 150 155 160

Gly Gln His Trp Trp Trp Val Pro Ile Val Ser Pro Leu Leu Gly Ser
165 170 175

Ile Ala Gly Val Phe Val Tyr Gln Leu Met Ile Gly Cys His Leu Glu
180 185 190

Gln Pro Pro Pro Ser Asn Glu Glu Glu Asn Val Lys Leu Ala His Val
195 200 205

Lys His Lys Glu Gln Ile
210

<210> 343

<211> 105

<212> PRT

<213> Homo sapien

<400> 343

Met Ala Lys Ile Ser Ser Pro Thr Glu Thr Glu Arg Cys Ile Glu Ser
1 5 10 15

Leu Ile Ala Val Phe Gln Lys Tyr Ala Gly Lys Asp Gly Tyr Asn Tyr
20 25 30

Thr Leu Ser Lys Thr Glu Phe Leu Ser Phe Met Asn Thr Glu Leu Ala
35 40 45

Ala Phe Thr Lys Asn Gln Lys Asp Pro Gly Val Leu Asp Arg Met Met
50 55 60

Lys Lys Leu Asp Thr Asn Ser Asp Gly Gln Leu Asp Phe Ser Glu Phe
65 70 75 80

Leu Asn Leu Ile Gly Gly Leu Ala Met Ala Cys His Asp Ser Phe Leu
85 90 95

Lys Ala Val Pro Ser Gln Lys Arg Thr
100 105

333

<210> 344
 <211> 222
 <212> PRT
 <213> Homo sapien

<400> 344

Gly Leu Glu Phe Glu Arg Trp Leu Asn Ala Thr Gly Pro Pro Leu Ala
 1 5 10 15

Glu Pro Asp Leu Ser Gln Gly Ser Ser Leu Thr Arg Pro Val Glu Ala
 20 25 30

Leu Phe Gln Leu Trp Thr Ala Glu Pro Leu Asp His Ala Ala Ala Ser
 35 40 45

Ala Ser Ala Ile Asp Ile Ser Lys Trp Arg Thr Phe Gln Thr Ala Leu
 50 55 60

Phe Leu Asp Arg Leu Leu Asp Gly Ser Pro Leu Pro Gln Glu Val Val
 65 70 75 80

Met Ser Leu Ser Lys Cys Tyr Ser Ser Leu Leu Asp Ser Met Asn Ala
 85 90 95

Glu Ile Arg Ile Arg Trp Leu Gln Ile Val Val Arg Asn Asp Tyr Tyr
 100 105 110

Pro Asp Leu His Arg Val Arg Arg Phe Leu Glu Ser Gln Met Ser Arg
 115 120 125

Met Tyr Thr Ile Pro Leu Tyr Glu Asp Leu Cys Thr Gly Ala Leu Lys
 130 135 140

Ser Phe Ala Leu Glu Val Phe Tyr Gln Thr Gln Gly Arg Leu His Pro
 145 150 155 160

Asn Leu Arg Arg Ala Ile Gln Gln Ile Leu Ser Gln Gly Leu Gly Ser
 165 170 175

Ser Thr Glu Pro Ala Ser Glu Pro Ser Thr Glu Leu Gly Lys Ala Glu
 180 185 190

Ala Asp Thr Asp Ser Asp Ala Gln Ala Leu Leu Leu Gly Asp Glu Ala
 195 200 205

334

Pro Ser Ser Ala Ile Ser Leu Arg Asp Val Asn Val Ser Ala
 210 215 220

<210> 345

<211> 450

<212> PRT

<213> Homo sapien

<400> 345

Glu Leu Thr Ala Gly Ala Gly Leu Ile Pro Ala Gly Trp Lys Val Gly
 1 5 10 15

Cys Gly Cys Ala Gly Trp Glu Ser Glu Pro Arg Gly Leu Pro Pro Ser
 20 25 30

Pro Pro Ser Arg Cys Arg Tyr Asp Ile Val Phe Leu Pro Pro Ser Phe
 35 40 45

Pro Ile Val Ala Met Glu Asn Pro Cys Leu Thr Phe Ile Ile Ser Ser
 50 55 60

Ile Leu Glu Ser Asp Glu Phe Leu Val Ile Asp Val Ile His Glu Val
 65 70 75 80

Ala His Ser Trp Phe Gly Asn Ala Val Thr Asn Ala Thr Trp Glu Glu
 85 90 95

Met Trp Leu Ser Glu Gly Leu Ala Thr Tyr Ala Gln Arg Arg Ile Thr
 100 105 110

Thr Glu Thr Tyr Gly Ala Ala Phe Thr Cys Leu Glu Thr Ala Phe Arg
 115 120 125

Leu Asp Ala Leu His Arg Gln Met Lys Leu Leu Gly Glu Asp Ser Pro
 130 135 140

Val Ser Lys Leu Gln Val Lys Leu Glu Pro Gly Val Asn Pro Ser His
 145 150 155 160

Leu Met Asn Leu Phe Thr Tyr Glu Lys Gly Tyr Cys Phe Val Tyr Tyr
 165 170 175

Leu Ser Gln Leu Cys Gly Asp Pro Gln Arg Phe Asp Asp Phe Leu Arg
 180 185 190

Ala Tyr Val Glu Lys Tyr Lys Phe Thr Ser Val Val Ala Gln Asp Leu
 195 200 205

335

Leu	Asp	Ser	Phe	Leu	Ser	Phe	Phe	Pro	Glu	Leu	Lys	Glu	Gln	Ser	Val
210						215					220				
Asp	Cys	Arg	Ala	Gly	Leu	Glu	Phe	Glu	Arg	Trp	Leu	Asn	Ala	Thr	Gly
225					230					235					240
Pro	Pro	Leu	Ala	Glu	Pro	Asp	Leu	Ser	Gln	Gly	Ser	Ser	Leu	Thr	Arg
				245					250					255	
Pro	Val	Glu	Ala	Leu	Phe	Gln	Leu	Trp	Thr	Ala	Glu	Pro	Leu	Asp	Gln
			260					265						270	
Ala	Ala	Ala	Ser	Ala	Ser	Ala	Ile	Asp	Ile	Ser	Lys	Trp	Arg	Thr	Phe
		275					280					285			
Gln	Thr	Ala	Leu	Phe	Leu	Asp	Arg	Leu	Leu	Asp	Gly	Ser	Pro	Leu	Pro
	290					295					300				
Gln	Glu	Val	Val	Met	Ser	Leu	Ser	Lys	Cys	Tyr	Ser	Ser	Leu	Leu	Asp
305					310					315					320
Ser	Met	Asn	Ala	Glu	Ile	Arg	Ile	Arg	Trp	Leu	Gln	Ile	Val	Val	Arg
				325					330					335	
Asn	Asp	Tyr	Tyr	Pro	Asp	Leu	His	Arg	Val	Arg	Arg	Phe	Leu	Glu	Ser
			340					345					350		
Gln	Met	Ser	Arg	Met	Tyr	Thr	Ile	Pro	Leu	Tyr	Glu	Asp	Leu	Cys	Thr
		355					360					365			
Gly	Ala	Leu	Lys	Ser	Phe	Ala	Leu	Glu	Val	Phe	Tyr	Gln	Thr	Gln	Gly
	370					375					380				
Arg	Leu	His	Pro	Asn	Leu	Arg	Arg	Ala	Ile	Gln	Gln	Ile	Leu	Ser	Gln
385					390					395					400
Gly	Leu	Gly	Ser	Ser	Thr	Glu	Pro	Ala	Ser	Glu	Pro	Ser	Thr	Glu	Leu
				405					410					415	
Gly	Lys	Ala	Glu	Ala	Asp	Thr	Asp	Ser	Asp	Ala	Gln	Ala	Leu	Leu	Leu
			420					425					430		
Gly	Asp	Glu	Ala	Pro	Ser	Ser	Ala	Ile	Ser	Leu	Arg	Asp	Val	Asn	Val
		435					440					445			

336

Ser Ala
450

<210> 346
<211> 366
<212> PRT
<213> Homo sapien

<400> 346

Gly Ser Glu Gln Gln Ser Gln Trp Cys Val Ser Pro Gln Ser Ser Pro
1 5 10 15

Arg Pro Cys Arg Cys Thr Pro Arg Ala Ser Val His Ile Trp Thr Cys
20 25 30

Glu Gly Gln Trp Arg Leu Ala Leu Ala Ala Pro Arg Ser Leu Thr Thr
35 40 45

Ala Pro Pro Tyr Ser Thr Gly His Trp Trp Phe Arg Thr Pro Ala Gln
50 55 60

Val Gly Val His Leu Ala Gly Val Asn Pro Ser His Leu Met Asn Leu
65 70 75 80

Phe Thr Tyr Glu Lys Gly Tyr Cys Phe Val Tyr Tyr Leu Ser Gln Leu
85 90 95

Cys Gly Asp Pro Gln Arg Phe Asp Asp Phe Leu Arg Ala Tyr Val Glu
100 105 110

Lys Tyr Lys Phe Thr Ser Val Val Ala Gln Asp Leu Leu Asp Ser Phe
115 120 125

Leu Ser Phe Phe Pro Glu Leu Lys Glu Gln Ser Val Asp Cys Arg Ala
130 135 140

Gly Leu Glu Phe Glu Arg Trp Leu Asn Ala Thr Gly Pro Pro Leu Ala
145 150 155 160

Glu Pro Asp Leu Ser Gln Gly Ser Ser Leu Thr Arg Pro Val Glu Ala
165 170 175

Leu Phe Gln Leu Trp Thr Ala Glu Pro Leu Asp Gln Ala Ala Ala Ser
180 185 190

Ala Ser Ala Ile Asp Ile Ser Lys Trp Arg Thr Phe Gln Thr Ala Leu

337

195

200

205

Phe Leu Asp Arg Leu Leu Asp Gly Ser Pro Leu Pro Gln Glu Val Val
 210 215 220

Met Ser Leu Ser Lys Cys Tyr Ser Ser Leu Leu Asp Ser Met Asn Ala
 225 230 235 240

Glu Ile Arg Ile Arg Trp Leu Gln Ile Val Val Arg Asn Asp Tyr Tyr
 245 250 255

Pro Asp Leu His Arg Val Arg Arg Phe Leu Glu Ser Gln Met Ser Arg
 260 265 270

Met Tyr Thr Ile Pro Leu Tyr Glu Asp Leu Cys Thr Gly Ala Leu Lys
 275 280 285

Ser Phe Ala Leu Glu Val Phe Tyr Gln Thr Gln Gly Arg Leu His Pro
 290 295 300

Asn Leu Arg Arg Ala Ile Gln Gln Ile Leu Ser Gln Gly Leu Gly Ser
 305 310 315 320

Ser Thr Glu Pro Ala Ser Glu Pro Ser Thr Glu Leu Gly Lys Ala Glu
 325 330 335

Ala Asp Thr Asp Ser Asp Ala Gln Ala Leu Leu Leu Gly Asp Glu Ala
 340 345 350

Pro Ser Ser Ala Ile Ser Leu Arg Asp Val Asn Val Ser Ala
 355 360 365

<210> 347

<211> 756

<212> PRT

<213> Homo sapien

<400> 347

Val Ala Gly Val Pro Pro Ala Ala Ala Glu Thr Pro Cys Ala Phe Ala
 1 5 10 15

Phe Ser Ala Pro Gly Pro Gly Pro Ala Pro Pro Pro Pro Leu Pro Ala
 20 25 30

Phe Pro Glu Ala Pro Gly Ser Glu Pro Ala Cys Cys Pro Leu Ala Phe
 35 40 45

338

Arg	Val	Asp	Pro	Phe	Thr	Asp	Tyr	Gly	Ser	Ser	Leu	Thr	Val	Thr	Leu
50						55					60				
Pro	Pro	Glu	Leu	Gln	Ala	His	Gln	Pro	Phe	Gln	Val	Ile	Leu	Arg	Tyr
65					70					75					80
Thr	Ser	Thr	Asp	Ala	Pro	Ala	Ile	Trp	Trp	Leu	Asp	Pro	Glu	Leu	Thr
				85					90					95	
Tyr	Gly	Cys	Ala	Lys	Pro	Phe	Val	Phe	Thr	Gln	Gly	His	Ser	Val	Cys
			100					105					110		
Asn	Arg	Ser	Phe	Phe	Pro	Cys	Phe	Asp	Thr	Pro	Ala	Val	Lys	Cys	Thr
		115					120					125			
Tyr	Ser	Ala	Val	Val	Lys	Ala	Pro	Ser	Gly	Val	Gln	Val	Leu	Met	Ser
	130					135					140				
Ala	Thr	Arg	Ser	Ala	Tyr	Met	Glu	Glu	Glu	Gly	Val	Phe	His	Phe	His
145					150					155					160
Met	Glu	His	Pro	Val	Pro	Ala	Tyr	Leu	Val	Ala	Leu	Val	Ala	Gly	Asp
				165					170					175	
Leu	Lys	Pro	Ala	Asp	Ile	Gly	Pro	Arg	Ser	Arg	Val	Trp	Ala	Glu	Pro
			180					185					190		
Cys	Leu	Leu	Pro	Thr	Ala	Thr	Ser	Lys	Leu	Ser	Gly	Ala	Val	Glu	Gln
		195					200					205			
Trp	Leu	Ser	Ala	Ala	Glu	Arg	Leu	Tyr	Gly	Pro	Tyr	Met	Trp	Gly	Arg
	210					215					220				
Tyr	Asp	Ile	Val	Phe	Leu	Pro	Pro	Ser	Phe	Pro	Ile	Val	Ala	Met	Glu
225					230					235					240
Asn	Pro	Cys	Leu	Thr	Phe	Ile	Ile	Ser	Ser	Ile	Leu	Glu	Ser	Asp	Glu
				245					250					255	
Phe	Leu	Val	Ile	Asp	Val	Ile	His	Glu	Val	Ala	His	Ser	Trp	Phe	Gly
			260					265					270		
Asn	Ala	Val	Thr	Asn	Ala	Thr	Trp	Glu	Glu	Met	Trp	Leu	Ser	Glu	Gly
		275					280					285			

339

Leu Ala Thr Tyr Ala Gln Arg Arg Ile Thr Thr Glu Thr Tyr Gly Ala
 290 295 300

Ala Phe Thr Cys Leu Glu Thr Ala Phe Arg Leu Asp Ala Leu His Arg
 305 310 315 320

Gln Met Lys Leu Leu Gly Glu Asp Ser Pro Val Ser Lys Leu Gln Val
 325 330 335

Lys Leu Glu Pro Gly Val Asn Pro Ser His Leu Met Asn Leu Phe Thr
 340 345 350

Tyr Glu Lys Gly Tyr Cys Phe Val Tyr Tyr Leu Ser Gln Leu Cys Gly
 355 360 365

Asp Pro Gln Arg Phe Asp Asp Phe Leu Arg Val Ser Ser Pro Leu Pro
 370 375 380

Gly Thr Ala Leu Leu Pro Ser Ala Pro Ser Pro Ser Pro Ala His Arg
 385 390 395 400

Ala Ala Cys Ser Cys Gly Ser Trp Gly Gly Thr Gly Arg Gly Leu Gly
 405 410 415

Ala Trp Leu Gly Pro Ser Leu Pro Phe Phe Val Gly Ser Ala Trp Val
 420 425 430

Ala Thr Ser Pro Ser Ala Thr Leu Phe Ala Pro Leu Ala Gly Pro Ala
 435 440 445

Cys Gln Val Leu Ala Pro Gln Cys Pro Leu Ala Ala Pro Val Pro Ser
 450 455 460

Thr Tyr Leu Gly Ala Arg Pro Ala Val Pro Cys Arg Pro Leu Val Gly
 465 470 475 480

Leu Pro Val Pro His Pro Ser Arg Pro Ala Glu Ala Pro Pro Pro Ala
 485 490 495

Thr Gln Ala Tyr Val Glu Lys Tyr Lys Phe Thr Ser Val Val Ala Gln
 500 505 510

Asp Leu Leu Asp Ser Phe Leu Ser Phe Phe Pro Glu Leu Lys Glu Gln
 515 520 525

Ser Val Asp Cys Arg Ala Gly Leu Glu Phe Glu Arg Trp Leu Asn Ala

340

530		535		540
Thr Gly Pro Pro Leu Ala Glu Pro Asp Leu Ser Gln Gly Ser Ser Leu				
545		550		555 560
Thr Arg Pro Val Glu Ala Leu Phe Gln Leu Trp Thr Ala Glu Pro Leu				
		565		570 575
Asp Gln Ala Ala Ala Ser Ala Ser Ala Ile Asp Ile Ser Lys Trp Arg				
		580		585 590
Thr Phe Gln Thr Ala Leu Phe Leu Asp Arg Leu Leu Asp Gly Ser Pro				
		595		600 605
Leu Pro Gln Glu Val Val Met Ser Leu Ser Lys Cys Tyr Ser Ser Leu				
		610		615 620
Leu Asp Ser Met Asn Ala Glu Ile Arg Ile Arg Trp Leu Gln Ile Val				
		625		630 635 640
Val Arg Asn Asp Tyr Tyr Pro Asp Leu His Arg Val Arg Arg Phe Leu				
		645		650 655
Glu Ser Gln Met Ser Arg Met Tyr Thr Ile Pro Leu Tyr Glu Asp Leu				
		660		665 670
Cys Thr Gly Ala Leu Lys Ser Phe Ala Leu Glu Val Phe Tyr Gln Thr				
		675		680 685
Gln Gly Arg Leu His Pro Asn Leu Arg Arg Ala Ile Gln Gln Ile Leu				
		690		695 700
Ser Gln Gly Leu Gly Ser Ser Thr Glu Pro Ala Ser Glu Pro Ser Thr				
		705		710 715 720
Glu Leu Gly Lys Ala Glu Ala Asp Thr Asp Ser Asp Ala Gln Ala Leu				
		725		730 735
Leu Leu Gly Asp Glu Ala Pro Ser Ser Ala Ile Ser Leu Arg Asp Val				
		740		745 750
Asn Val Ser Ala				
		755		

<210> 348

<211> 38

341

<212> PRT

<213> Homo sapien

<400> 348

Met	Ser	Lys	Asn	Phe	Ile	Phe	Thr	Asn	Leu	Ile	Asp	Gln	Lys	Asp	Thr
1				5					10					15	

Leu	Leu	Ala	Phe	Phe	Thr	Ile	Cys	Lys	Ala	Lys	Asn	His	Gln	Asn	Ser
			20					25					30		

Pro	Ser	Pro	His	Ile	Tyr
			35		

<210> 349

<211> 231

<212> PRT

<213> Homo sapien

<400> 349

Met	Leu	Glu	Arg	Arg	Ser	Val	Met	Asp	Arg	Arg	Pro	Gly	Arg	Glu	Phe
1				5					10					15	

Asp	Gly	Ile	Leu	Gly	Leu	Gly	Tyr	Pro	Ser	Leu	Ala	Val	Gly	Gly	Val
			20					25					30		

Thr	Pro	Val	Phe	Asp	Asn	Met	Met	Ala	Gln	Asn	Leu	Val	Asp	Leu	Pro
		35					40					45			

Met	Phe	Ser	Val	Tyr	Met	Ser	Ser	Asn	Pro	Glu	Gly	Gly	Ala	Gly	Ser
	50					55					60				

Glu	Leu	Ile	Phe	Gly	Gly	Tyr	Asp	His	Ser	His	Phe	Ser	Gly	Ser	Leu
65					70					75					80

Asn	Trp	Val	Pro	Val	Thr	Lys	Gln	Ala	Tyr	Trp	Gln	Ile	Ala	Leu	Asp
				85					90					95	

Asn	Ile	Gln	Val	Gly	Gly	Thr	Val	Met	Phe	Cys	Ser	Glu	Gly	Cys	Gln
			100					105					110		

Ala	Ile	Val	Asp	Thr	Gly	Thr	Ser	Leu	Ile	Thr	Gly	Pro	Ser	Asp	Lys
		115					120					125			

Ile	Lys	Gln	Leu	Gln	Asn	Ala	Ile	Gly	Ala	Ala	Pro	Val	Asp	Gly	Glu
	130					135					140				

Tyr	Ala	Val	Glu	Cys	Ala	Asn	Leu	Asn	Val	Met	Pro	Asp	Val	Thr	Phe
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

145 150 155 160

His Arg Ile Cys Cys Ser Arg Cys Pro Pro Gly Thr Tyr Val Ser Ala
35 40 45

343

Lys Cys Ser Arg Ile Arg Asp Thr Val Cys Ala Thr Cys Ala Glu Asn
 50 55 60
 Ser Tyr Asn Glu His Trp Asn Tyr Leu Thr Ile Cys Gln Leu Cys Arg
 65 70 75 80
 Pro Cys Asp Pro Val Met Gly Leu Glu Glu Ile Ala Pro Cys Thr Ser
 85 90 95
 Lys Arg Lys Thr Gln Cys Arg Cys Gln Pro Gly Met Phe Cys Ala Ala
 100 105 110
 Trp Ala Leu Glu Cys Thr His Cys Glu Arg Leu Ser Asp Cys Pro Pro
 115 120 125
 Gly Thr Glu Ala Glu Leu Lys Asp Glu Val Gly Lys Gly Asn Asn His
 130 135 140
 Cys Val Pro Cys Lys Ala Gly His Phe Gln Asn Thr Ser Ser Pro Ser
 145 150 155 160
 Ala Leu Cys Gln Pro His Thr Arg Cys Glu Asn Gln Gly Leu Val Glu
 165 170 175
 Ala Ala Pro Gly Thr Ala Gln Ser Asp Thr Thr Cys Lys Asn Pro Leu
 180 185 190
 Glu Pro Leu Pro Pro Glu Met Ser Gly Ser Leu Leu Lys Arg Arg Pro
 195 200 205
 Gln Gly Glu Gly Pro Asn Pro Val Ala Gly Ser Trp Glu Pro Pro Lys
 210 215 220
 Ala His Pro Tyr Phe Pro Asp Leu Val Gln Pro Leu Leu Pro Ile Ser
 225 230 235 240
 Gly Asp Val Ser Pro Val Ser Thr Gly Leu Pro Ala Ala Pro Val Leu
 245 250 255
 Glu Ala Gly Val Pro Gln Gln Gln Ser Pro Leu Asp Leu Thr Arg Glu
 260 265 270
 Pro Gln Leu Glu Pro Gly Glu Gln Ser Gln Val Ala His Gly Thr Asn
 275 280 285
 Gly Ile His Val Thr Gly Gly Ser Met Thr Ile Thr Gly Asn Ile Tyr

344

290 295 300
 Ile Tyr Asn Gly Pro Val Leu Gly Gly Pro Pro Gly Pro Gly Asp Leu
 305 310 315 320
 Pro Ala Thr Pro Glu Pro Pro Tyr Pro Ile Pro Glu Glu Gly Asp Pro
 325 330 335
 Gly Pro Pro Gly Leu Ser Thr Pro His Gln Glu Asp Gly Lys Ala Trp
 340 345 350
 His Leu Ala Glu Thr Glu His Cys Gly
 355 360
 <210> 352
 <211> 399
 <212> PRT
 <213> Homo sapien
 <400> 352
 Met Leu Leu Pro Trp Ala Thr Ser Ala Pro Gly Leu Ala Trp Gly Pro
 1 5 10 15
 Leu Val Leu Gly Leu Phe Gly Leu Leu Ala Ala Ser Gln Pro Gln Ala
 20 25 30
 Val Pro Pro Tyr Ala Ser Glu Asn Gln Thr Cys Arg Asp Gln Glu Lys
 35 40 45
 Glu Tyr Tyr Glu Pro Gln His Arg Ile Cys Cys Ser Arg Cys Pro Pro
 50 55 60
 Gly Thr Tyr Val Ser Ala Lys Cys Ser Arg Ile Arg Asp Thr Val Cys
 65 70 75 80
 Ala Thr Cys Ala Glu Asn Ser Tyr Asn Glu His Trp Asn Tyr Leu Thr
 85 90 95
 Ile Cys Gln Leu Cys Arg Pro Cys Asp Pro Val Met Gly Leu Glu Glu
 100 105 110
 Ile Ala Pro Cys Thr Ser Lys Arg Lys Thr Gln Cys Arg Cys Gln Pro
 115 120 125
 Gly Met Phe Cys Ala Ala Trp Ala Leu Glu Cys Thr His Cys Glu Leu
 130 135 140

345

Leu Ser Asp Cys Pro Pro Gly Thr Glu Ala Glu Leu Lys Asp Glu Val
 145 150 155 160

Gly Lys Gly Asn Asn His Cys Val Pro Cys Lys Ala Gly His Phe Gln
 165 170 175

Asn Thr Ser Ser Pro Ser Ala Arg Cys Gln Pro His Thr Arg Cys Glu
 180 185 190

Asn Gln Gly Leu Val Glu Ala Ala Pro Gly Thr Ala Gln Ser Asp Thr
 195 200 205

Thr Cys Lys Asn Pro Leu Glu Pro Leu Pro Pro Glu Met Ser Gly Ser
 210 215 220

Leu Leu Lys Arg Arg Pro Gln Gly Glu Gly Pro Asn Pro Val Ala Gly
 225 230 235 240

Ser Trp Glu Pro Pro Lys Ala His Pro Tyr Phe Pro Asp Leu Val Gln
 245 250 255

Pro Leu Leu Pro Ile Ser Gly Asp Val Ser Pro Val Ser Thr Gly Leu
 260 265 270

Pro Ala Ala Pro Val Leu Glu Ala Gly Val Pro Gln Gln Gln Ser Pro
 275 280 285

Leu Asp Leu Thr Arg Glu Pro Gln Leu Glu Pro Gly Glu Gln Ser Gln
 290 295 300

Val Ala His Gly Thr Asn Gly Ile His Val Thr Gly Gly Ser Met Thr
 305 310 315 320

Ile Thr Gly Asn Ile Tyr Ile Tyr Asn Gly Pro Val Leu Gly Gly Pro
 325 330 335

Pro Gly Pro Gly Asp Leu Pro Ala Thr Pro Glu Pro Pro Tyr Pro Ile
 340 345 350

Pro Glu Glu Gly Asp Pro Gly Pro Pro Gly Leu Ser Thr Pro His Gln
 355 360 365

Glu Asp Gly Lys Ala Trp His Leu Ala Glu Thr Glu His Cys Gly Ala
 370 375 380

346

Thr Pro Ser Asn Arg Gly Pro Arg Asn Gln Phe Ile Thr His Asp
 385 390 395

<210> 353

<211> 435

<212> PRT

<213> Homo sapien

<400> 353

Met Leu Leu Pro Trp Ala Thr Ser Ala Pro Gly Leu Ala Trp Gly Pro
 1 5 10 15

Leu Val Leu Gly Leu Phe Gly Leu Leu Ala Ala Ser Gln Pro Gln Ala
 20 25 30

Val Pro Pro Tyr Ala Ser Glu Asn Gln Thr Cys Arg Asp Gln Glu Lys
 35 40 45

Glu Tyr Tyr Glu Pro Gln His Arg Ile Cys Cys Ser Arg Cys Pro Pro
 50 55 60

Gly Thr Tyr Val Ser Ala Lys Cys Ser Arg Ile Arg Asp Thr Val Cys
 65 70 75 80

Ala Thr Cys Ala Glu Asn Ser Tyr Asn Glu His Trp Asn Tyr Leu Thr
 85 90 95

Ile Cys Gln Leu Cys Arg Pro Cys Asp Pro Val Met Gly Leu Glu Glu
 100 105 110

Ile Ala Pro Cys Thr Ser Lys Arg Lys Thr Gln Cys Arg Cys Gln Pro
 115 120 125

Gly Met Phe Cys Ala Ala Trp Ala Leu Glu Cys Thr His Cys Glu Leu
 130 135 140

Leu Ser Asp Cys Pro Pro Gly Thr Glu Ala Glu Leu Lys Asp Glu Val
 145 150 155 160

Gly Lys Gly Asn Asn His Cys Val Pro Cys Lys Ala Gly His Phe Gln
 165 170 175

Asn Thr Ser Ser Pro Ser Ala Arg Cys Gln Pro His Thr Arg Cys Glu
 180 185 190

Asn Gln Gly Leu Val Glu Ala Ala Pro Gly Thr Ala Gln Ser Asp Thr
 195 200 205

[illegible]

348

<210> 354
 <211> 450
 <212> PRT
 <213> Homo sapien

<400> 354

Met Leu Leu Pro Trp Ala Thr Ser Ala Pro Gly Leu Ala Trp Gly Pro
 1 5 10 15

Leu Val Leu Gly Leu Phe Gly Leu Leu Ala Ala Ser Gln Pro Gln Ala
 20 25 30

Val Pro Pro Tyr Ala Ser Glu Asn Gln Thr Cys Arg Asp Gln Glu Lys
 35 40 45

Glu Tyr Tyr Glu Pro Gln His Arg Ile Cys Cys Ser Arg Cys Pro Pro
 50 55 60

Gly Thr Tyr Val Ser Ala Lys Cys Ser Arg Ile Arg Asp Thr Val Cys
 65 70 75 80

Ala Thr Cys Ala Glu Asn Ser Tyr Asn Glu His Trp Asn Tyr Leu Thr
 85 90 95

Ile Cys Gln Leu Cys Arg Pro Cys Asp Pro Val Met Gly Leu Glu Glu
 100 105 110

Ile Ala Pro Cys Thr Ser Lys Arg Lys Thr Gln Cys Arg Cys Gln Pro
 115 120 125

Gly Met Phe Cys Ala Ala Trp Ala Leu Glu Cys Thr His Cys Glu Leu
 130 135 140

Leu Ser Asp Cys Pro Pro Gly Thr Glu Ala Glu Leu Lys Asp Glu Val
 145 150 155 160

Gly Lys Gly Asn Asn His Cys Val Pro Cys Lys Ala Gly His Phe Gln
 165 170 175

Asn Thr Ser Ser Pro Ser Ala Arg Cys Gln Pro His Thr Arg Cys Glu
 180 185 190

Asn Gln Gly Leu Val Glu Ala Ala Pro Gly Thr Ala Gln Ser Asp Thr
 195 200 205

Thr Cys Lys Asn Pro Leu Glu Pro Leu Pro Pro Glu Met Ser Gly Thr

349

210					215					220					
Met	Leu	Met	Leu	Ala	Val	Leu	Leu	Pro	Leu	Ala	Phe	Phe	Leu	Leu	Leu
225					230					235					240
Ala	Thr	Val	Phe	Ser	Cys	Ile	Trp	Lys	Ser	His	Pro	Ser	Leu	Cys	Arg
				245					250					255	
Lys	Leu	Gly	Ser	Leu	Leu	Lys	Arg	Arg	Pro	Gln	Gly	Glu	Gly	Pro	Asn
			260					265					270		
Pro	Val	Ala	Gly	Ser	Trp	Glu	Pro	Pro	Lys	Ala	His	Pro	Tyr	Phe	Pro
		275					280					285			
Asp	Leu	Val	Gln	Pro	Leu	Leu	Pro	Ile	Ser	Gly	Asp	Val	Ser	Pro	Val
	290					295					300				
Ser	Thr	Gly	Leu	Pro	Ala	Ala	Pro	Val	Leu	Glu	Ala	Gly	Val	Pro	Gln
305					310					315					320
Gln	Gln	Ser	Pro	Leu	Asp	Leu	Thr	Arg	Glu	Pro	Gln	Leu	Glu	Pro	Gly
				325					330					335	
Glu	Gln	Ser	Gln	Val	Ala	His	Gly	Thr	Asn	Gly	Ile	His	Val	Thr	Gly
			340					345					350		
Gly	Ser	Met	Thr	Ile	Thr	Gly	Asn	Ile	Tyr	Ile	Tyr	Asn	Gly	Pro	Val
		355					360					365			
Leu	Gly	Gly	Pro	Pro	Gly	Pro	Gly	Asp	Leu	Pro	Ala	Thr	Pro	Glu	Pro
	370					375					380				
Pro	Tyr	Pro	Ile	Pro	Glu	Glu	Gly	Asp	Pro	Gly	Pro	Pro	Gly	Leu	Ser
385						390					395				400
Thr	Pro	His	Gln	Glu	Asp	Gly	Lys	Ala	Trp	His	Leu	Ala	Glu	Thr	Glu
				405					410					415	
His	Cys	Gly	Ala	Thr	Pro	Ser	Lys	Gly	Phe	Val	Val	Leu	Ile	Pro	Lys
			420					425					430		
Leu	Gln	Arg	Pro	Phe	Gly	Val	Pro	His	Phe	Thr	Trp	Thr	Glu	Val	Asp
		435					440					445			
Pro	Ala														
	450														

350

<210> 355
 <211> 635
 <212> PRT
 <213> Homo sapien

<400> 355

Met Leu Leu Pro Trp Ala Thr Ser Ala Pro Gly Leu Ala Trp Gly Pro
 1 5 10 15

Leu Val Leu Gly Leu Phe Gly Leu Leu Ala Ala Ser Gln Pro Gln Ala
 20 25 30

Val Pro Pro Tyr Ala Ser Glu Asn Gln Thr Cys Arg Asp Gln Glu Lys
 35 40 45

Glu Tyr Tyr Glu Pro Gln His Arg Ile Cys Cys Ser Arg Cys Pro Pro
 50 55 60

Gly Thr Tyr Val Ser Ala Lys Cys Ser Arg Ile Arg Asp Thr Val Cys
 65 70 75 80

Ala Thr Cys Ala Glu Asn Ser Tyr Asn Glu His Trp Asn Tyr Leu Thr
 85 90 95

Ile Cys Gln Leu Cys Arg Pro Cys Asp Pro Val Met Gly Leu Glu Glu
 100 105 110

Ile Ala Pro Cys Thr Ser Lys Arg Lys Thr Gln Cys Arg Cys Gln Pro
 115 120 125

Gly Met Phe Cys Ala Ala Trp Ala Leu Glu Cys Thr His Cys Glu Leu
 130 135 140

Leu Ser Asp Cys Pro Pro Gly Thr Glu Ala Glu Leu Lys Asp Glu Val
 145 150 155 160

Gly Lys Gly Asn Asn His Cys Val Pro Cys Lys Ala Gly His Phe Gln
 165 170 175

Asn Thr Ser Ser Pro Ser Ala Arg Cys Gln Pro His Thr Arg Cys Glu
 180 185 190

Asn Gln Gly Leu Val Glu Ala Ala Pro Gly Thr Ala Gln Ser Asp Thr
 195 200 205

351

Thr	Cys	Lys	Asn	Pro	Leu	Glu	Pro	Leu	Pro	Pro	Glu	Met	Ser	Glu	Pro
210						215					220				
Ala	Leu	Ser	Lys	Gly	Val	Glu	Asn	Leu	Gln	Ala	Leu	Leu	Tyr	Gln	Ala
225					230					235					240
Ala	Thr	Gly	Ser	Ser	Glu	Ala	Ser	Phe	Pro	Thr	Leu	Ser	Pro	Leu	Tyr
				245					250					255	
Thr	Pro	Pro	Gln	Val	Gln	Val	Gln	Gln	Gly	Asn	Pro	Glu	Leu	Leu	Tyr
			260					265					270		
Ser	Ser	Pro	Ser	Val	Gln	Trp	Leu	Arg	Pro	Gln	Lys	Cys	Gly	Ser	Ser
		275					280					285			
Leu	Cys	Leu	Phe	Thr	Thr	Pro	Ser	Pro	Thr	Leu	Pro	Tyr	Cys	Leu	Pro
	290					295					300				
Ile	Pro	Leu	Pro	Asp	Leu	Glu	Asn	Gln	Leu	Pro	Lys	Leu	Pro	Ser	Cys
305					310					315					320
Thr	His	Lys	Pro	Ala	Gln	Ser	Trp	Ser	Leu	Ser	Arg	Arg	Ala	Pro	Thr
				325					330					335	
Pro	Pro	Pro	Asn	Met	Pro	Ile	His	Asp	Thr	Val	Ser	Pro	Gly	Cys	Gln
			340					345					350		
Glu	Val	Leu	Lys	Ser	Asn	Leu	Val	Pro	Leu	Leu	Tyr	Asn	Pro	Arg	Glu
		355					360					365			
Val	Ser	Leu	Ile	Leu	Pro	Leu	Gly	Ala	Ala	Leu	Cys	Leu	Glu	Gly	Lys
		370				375					380				
Lys	Leu	Leu	Pro	Phe	Leu	Cys	Leu	Gly	Cys	Pro	Gly	Ile	Trp	Lys	Ala
385					390					395					400
Leu	Pro	Ser	Pro	Pro	Pro	Ser	Ala	Leu	Leu	Gly	Ala	Val	Ile	Thr	Leu
				405					410					415	
Leu	Ser	Ala	Val	Leu	Ala	Gly	Thr	Met	Leu	Met	Leu	Ala	Val	Leu	Leu
			420					425					430		
Pro	Leu	Ala	Phe	Phe	Leu	Leu	Leu	Ala	Thr	Val	Phe	Ser	Cys	Ile	Trp
		435					440					445			
Lys	Ser	His	Pro	Ser	Leu	Cys	Arg	Lys	Leu	Gly	Ser	Leu	Leu	Lys	Arg

352

450 455 460
 Arg Pro Gln Gly Glu Gly Pro Asn Pro Val Ala Gly Ser Trp Glu Pro
 465 470 475 480
 Pro Lys Ala His Pro Tyr Phe Pro Asp Leu Val Gln Pro Leu Leu Pro
 485 490 495
 Ile Ser Gly Asp Val Ser Pro Val Ser Thr Gly Leu Pro Ala Ala Pro
 500 505 510
 Val Leu Glu Ala Gly Val Pro Gln Gln Gln Ser Pro Leu Asp Leu Thr
 515 520 525
 Arg Glu Pro Gln Leu Glu Pro Gly Glu Gln Ser Gln Val Ala His Gly
 530 535 540
 Thr Asn Gly Ile His Val Thr Gly Gly Ser Met Thr Ile Thr Gly Asn
 545 550 555 560
 Ile Tyr Ile Tyr Asn Gly Pro Val Leu Gly Gly Pro Pro Gly Pro Gly
 565 570 575
 Asp Leu Pro Ala Thr Pro Glu Pro Pro Tyr Pro Ile Pro Glu Glu Gly
 580 585 590
 Asp Pro Gly Pro Pro Gly Leu Ser Thr Pro His Gln Glu Asp Gly Lys
 595 600 605
 Ala Trp His Leu Ala Glu Thr Glu His Cys Gly Ala Thr Pro Ser Asn
 610 615 620
 Arg Gly Pro Arg Asn Gln Phe Ile Thr His Asp
 625 630 635

<210> 356

<211> 194

<212> PRT

<213> Homo sapien

<400> 356

Lys Lys Arg Glu Gly Gly Arg Glu Lys Lys Gly Ser Gly Ala Leu Ile
 1 5 10 15

Ile Val Trp Val Ser Ile Ser Phe Leu Gln Gly Glu Gly Pro Asn Pro
 20 25 30

353

Val Ala Gly Ser Trp Glu Pro Pro Lys Ala His Pro Tyr Phe Pro Asp
 35 40 45

Leu Val Gln Pro Leu Leu Pro Ile Ser Gly Asp Val Ser Pro Val Ser
 50 55 60

Thr Gly Leu Pro Ala Ala Pro Val Leu Glu Ala Gly Val Pro Gln Gln
 65 70 75 80

Gln Ser Pro Leu Asp Leu Thr Arg Glu Pro Gln Leu Glu Pro Gly Glu
 85 90 95

Gln Ser Gln Val Ala His Gly Thr Asn Gly Ile His Val Thr Gly Gly
 100 105 110

Ser Met Thr Ile Thr Gly Asn Ile Tyr Ile Tyr Asn Gly Pro Val Leu
 115 120 125

Gly Gly Pro Pro Gly Pro Gly Asp Leu Pro Ala Thr Pro Glu Pro Pro
 130 135 140

Tyr Pro Ile Pro Glu Glu Gly Asp Pro Gly Pro Pro Gly Leu Ser Thr
 145 150 155 160

Pro His Gln Glu Asp Gly Lys Ala Trp His Leu Ala Glu Thr Glu His
 165 170 175

Cys Gly Ala Thr Pro Ser Asn Arg Gly Pro Arg Asn Gln Phe Ile Thr
 180 185 190

His Asp

<210> 357

<211> 305

<212> PRT

<213> Homo sapien

<400> 357

Met Leu Leu Pro Trp Ala Thr Ser Ala Pro Gly Leu Ala Trp Gly Pro
 1 5 10 15

Leu Val Leu Gly Leu Phe Gly Leu Leu Ala Ala Ser Gln Pro Gln Ala
 20 25 30

Val Pro Pro Tyr Ala Ser Glu Asn Gln Thr Cys Arg Asp Gln Glu Lys

354

35

40

45

Glu Tyr Tyr Glu Pro Gln His Arg Ile Cys Cys Ser Arg Cys Pro Pro
50 55 60

Gly Thr Tyr Val Ser Ala Lys Cys Ser Arg Ile Arg Asp Thr Val Cys
65 70 75 80

Ala Thr Cys Ala Glu Asn Ser Tyr Asn Glu His Trp Asn Tyr Leu Thr
85 90 95

Ile Cys Gln Leu Cys Arg Pro Cys Asp Pro Val Met Gly Leu Glu Glu
100 105 110

Ile Ala Pro Cys Thr Ser Lys Arg Lys Thr Gln Cys Arg Cys Gln Pro
115 120 125

Gly Met Phe Cys Ala Ala Trp Ala Leu Glu Cys Thr His Cys Glu Leu
130 135 140

Leu Ser Asp Cys Pro Pro Gly Thr Glu Ala Glu Leu Lys Asp Glu Val
145 150 155 160

Gly Lys Gly Asn Asn His Cys Val Pro Cys Lys Ala Gly His Phe Gln
165 170 175

Asn Thr Ser Ser Pro Ser Ala Arg Cys Gln Pro His Thr Arg Cys Glu
180 185 190

Asn Gln Gly Leu Val Glu Ala Ala Pro Gly Thr Ala Gln Ser Asp Thr
195 200 205

Thr Cys Lys Asn Pro Leu Glu Pro Leu Pro Pro Glu Met Ser Gly Thr
210 215 220

Met Leu Met Leu Ala Val Leu Leu Pro Leu Ala Phe Phe Leu Leu Leu
225 230 235 240

Ala Thr Val Phe Ser Cys Ile Trp Lys Ser His Pro Ser Leu Cys Arg
245 250 255

Lys Leu Gly Ser Leu Leu Lys Arg Arg Pro Gln Val Met Ala Gly Ala
260 265 270

Glu Lys Ala Ala Arg Arg Gly Arg Gly Asp Glu Gly Thr Arg Trp Ser
275 280 285

355

Arg Gln Glu Glu Ser Met Gln Ala Asp Ser Thr Leu Ile His Ser Phe
 290 295 300

Asn
 305

<210> 358
 <211> 1127
 <212> PRT
 <213> Homo sapien

<400> 358

Met Trp Ser Leu Thr Ala Ser Glu Gly Glu Ser Thr Thr Ala His Phe
 1 5 10 15

Phe Leu Gly Ala Gly Asp Glu Gly Leu Gly Thr Arg Gly Ile Gly Met
 20 25 30

Arg Pro Glu Glu Ser Asp Ser Glu Leu Leu Glu Asp Glu Glu Asp Glu
 35 40 45

Val Pro Pro Glu Pro Gln Ile Ile Val Gly Ile Cys Ala Met Thr Lys
 50 55 60

Lys Ser Lys Ser Lys Pro Met Thr Gln Ile Leu Glu Arg Leu Cys Arg
 65 70 75 80

Phe Asp Tyr Leu Thr Val Val Ile Leu Gly Glu Asp Val Ile Leu Asn
 85 90 95

Glu Pro Val Glu Asn Trp Pro Ser Cys His Cys Leu Ile Ser Phe His
 100 105 110

Ser Lys Gly Phe Pro Leu Asp Lys Ala Val Ala Tyr Ser Lys Leu Arg
 115 120 125

Asn Pro Phe Leu Ile Asn Asp Leu Ala Met Gln Tyr Tyr Ile Gln Asp
 130 135 140

Arg Arg Glu Val Tyr Arg Ile Leu Gln Glu Glu Gly Ile Asp Leu Pro
 145 150 155 160

Arg Tyr Ala Val Leu Asn Arg Asp Pro Ala Arg Pro Glu Glu Cys Asn
 165 170 175

356

Leu Ile Glu Gly Glu Asp Gln Val Glu Val Asn Gly Ala Val Phe Pro
 180 185 190

Lys Pro Phe Val Glu Lys Pro Val Ser Ala Glu Asp His Asn Val Tyr
 195 200 205

Ile Tyr Tyr Pro Ser Ser Ala Gly Gly Gly Ser Gln Arg Leu Phe Arg
 210 215 220

Lys Ile Gly Ser Arg Ser Ser Val Tyr Ser Pro Glu Ser Ser Val Arg
 225 230 235 240

Lys Thr Gly Ser Tyr Ile Tyr Glu Glu Phe Met Pro Thr Asp Gly Thr
 245 250 255

Asp Val Lys Val Tyr Thr Val Gly Pro Asp Tyr Ala His Ala Glu Ala
 260 265 270

Arg Lys Ser Pro Ala Leu Asp Gly Lys Val Glu Arg Asp Ser Glu Gly
 275 280 285

Lys Glu Ile Arg Tyr Pro Val Met Leu Thr Ala Met Glu Lys Leu Val
 290 295 300

Ala Arg Lys Val Cys Val Ala Phe Lys Gln Thr Val Cys Gly Phe Asp
 305 310 315 320

Leu Leu Arg Ala Asn Gly His Ser Phe Val Cys Asp Val Asn Gly Phe
 325 330 335

Ser Phe Val Lys Asn Ser Met Lys Tyr Tyr Asp Asp Cys Ala Lys Ile
 340 345 350

Leu Gly Asn Thr Ile Met Arg Glu Leu Ala Pro Gln Phe Gln Ile Pro
 355 360 365

Trp Ser Ile Pro Thr Glu Ala Glu Asp Ile Pro Ile Val Pro Thr Thr
 370 375 380

Ser Gly Thr Met Met Glu Leu Arg Cys Val Ile Ala Ile Ile Arg His
 385 390 395 400

Gly Asp Arg Thr Pro Lys Gln Lys Met Lys Met Glu Val Lys His Pro
 405 410 415

Arg Phe Phe Ala Leu Phe Glu Lys His Gly Gly Tyr Lys Thr Gly Lys

357

			420					425					430			
Leu	Lys	Leu	Lys	Arg	Pro	Glu	Gln	Leu	Gln	Glu	Val	Leu	Asp	Ile	Thr	
		435					440					445				
Arg	Leu	Leu	Leu	Ala	Glu	Leu	Glu	Lys	Glu	Pro	Gly	Gly	Glu	Ile	Glu	
	450					455					460					
Glu	Lys	Thr	Gly	Lys	Leu	Glu	Gln	Leu	Lys	Ser	Val	Leu	Glu	Met	Tyr	
465					470					475					480	
Gly	His	Phe	Ser	Gly	Ile	Asn	Arg	Lys	Val	Gln	Leu	Thr	Tyr	Tyr	Pro	
				485					490					495		
His	Gly	Val	Lys	Ala	Ser	Asn	Glu	Gly	Gln	Asp	Pro	Gln	Arg	Glu	Thr	
			500					505					510			
Leu	Ala	Pro	Ser	Leu	Leu	Leu	Val	Leu	Lys	Trp	Gly	Gly	Glu	Leu	Thr	
		515					520					525				
Pro	Ala	Gly	Arg	Val	Gln	Ala	Glu	Glu	Leu	Gly	Arg	Ala	Phe	Arg	Cys	
	530					535					540					
Met	Tyr	Pro	Gly	Gly	Gln	Gly	Asp	Tyr	Ala	Gly	Phe	Pro	Gly	Cys	Gly	
545					550					555					560	
Leu	Leu	Arg	Leu	His	Ser	Thr	Phe	Arg	His	Asp	Leu	Lys	Ile	Tyr	Ala	
				565					570					575		
Ser	Asp	Glu	Gly	Arg	Val	Gln	Met	Thr	Ala	Ala	Ala	Phe	Ala	Lys	Gly	
			580					585					590			
Leu	Leu	Ala	Leu	Glu	Gly	Glu	Leu	Thr	Pro	Ile	Leu	Val	Gln	Met	Val	
		595					600					605				
Lys	Ser	Ala	Asn	Met	Asn	Gly	Leu	Leu	Asp	Ser	Asp	Gly	Asp	Ser	Leu	
	610					615					620					
Ser	Ser	Cys	Gln	His	Arg	Val	Lys	Ala	Arg	Leu	His	His	Ile	Leu	Gln	
625					630					635					640	
Gln	Asp	Ala	Pro	Phe	Gly	Pro	Glu	Asp	Tyr	Asp	Gln	Leu	Ala	Pro	Thr	
				645					650					655		
Arg	Ser	Thr	Ser	Leu	Leu	Asn	Ser	Met	Thr	Ile	Ile	Gln	Asn	Pro	Val	
			660					665					670			

358

Lys	Val	Cys	Asp	Gln	Val	Phe	Ala	Leu	Ile	Glu	Asn	Leu	Thr	His	Gln	
		675					680					685				
Ile	Arg	Glu	Arg	Met	Gln	Asp	Pro	Arg	Ser	Val	Asp	Leu	Gln	Leu	Tyr	
	690					695					700					
His	Ser	Glu	Thr	Leu	Glu	Leu	Met	Leu	Gln	Arg	Trp	Ser	Lys	Leu	Glu	
705					710					715					720	
Arg	Asp	Phe	Arg	Gln	Lys	Ser	Gly	Arg	Tyr	Asp	Ile	Ser	Lys	Ile	Pro	
				725					730					735		
Asp	Ile	Tyr	Asp	Cys	Val	Lys	Tyr	Asp	Val	Gln	His	Asn	Gly	Ser	Leu	
			740					745					750			
Gly	Leu	Gln	Gly	Thr	Ala	Glu	Leu	Leu	Arg	Leu	Ser	Lys	Ala	Leu	Ala	
		755					760					765				
Asp	Val	Val	Ile	Pro	Gln	Glu	Tyr	Gly	Ile	Ser	Arg	Glu	Glu	Lys	Leu	
	770					775					780					
Glu	Ile	Ala	Val	Gly	Phe	Cys	Leu	Pro	Leu	Leu	Arg	Lys	Ile	Leu	Leu	
785					790					795					800	
Asp	Leu	Gln	Arg	Thr	His	Glu	Asp	Glu	Ser	Val	Asn	Lys	Leu	His	Pro	
				805					810					815		
Leu	Tyr	Ser	Arg	Gly	Val	Leu	Ser	Pro	Gly	Arg	His	Val	Arg	Thr	Arg	
			820					825					830			
Leu	Tyr	Phe	Thr	Ser	Glu	Ser	His	Val	His	Ser	Leu	Leu	Ser	Val	Phe	
		835					840					845				
Arg	Tyr	Gly	Gly	Leu	Leu	Asp	Glu	Thr	Gln	Asp	Ala	Gln	Trp	Gln	Arg	
	850					855					860					
Ala	Leu	Asp	Tyr	Leu	Ser	Ala	Ile	Ser	Glu	Leu	Asn	Tyr	Met	Thr	Gln	
865					870					875					880	
Ile	Val	Ile	Met	Leu	Tyr	Glu	Asp	Asn	Thr	Gln	Asp	Pro	Leu	Ser	Glu	
			885						890					895		
Glu	Arg	Phe	His	Val	Glu	Leu	His	Phe	Ser	Pro	Gly	Val	Lys	Gly	Val	
			900					905					910			

359

Glu Glu Glu Gly Ser Ala Pro Ala Gly Cys Gly Phe Arg Pro Ala Ser
 915 920 925

Ser Glu Asn Glu Glu Met Lys Thr Asn Gln Gly Ser Met Glu Asn Leu
 930 935 940

Cys Pro Gly Lys Ala Ser Asp Glu Pro Asp Arg Ala Leu Gln Thr Ser
 945 950 955 960

Pro Gln Pro Pro Glu Gly Pro Gly Leu Pro Arg Arg Ser Pro Leu Ile
 965 970 975

Arg Asn Arg Lys Ala Gly Ser Met Glu Val Leu Ser Glu Thr Ser Ser
 980 985 990

Ser Arg Pro Gly Gly Tyr Arg Leu Phe Ser Ser Ser Arg Pro Pro Thr
 995 1000 1005

Glu Met Lys Gln Ser Gly Leu Gly Ser Gln Cys Thr Gly Leu Phe
 1010 1015 1020

Ser Thr Thr Val Leu Gly Gly Ser Ser Ser Ala Pro Asn Leu Gln
 1025 1030 1035

Asp Tyr Ala Arg Ser His Gly Lys Lys Leu Pro Pro Ala Ser Leu
 1040 1045 1050

Lys His Arg Asp Glu Leu Leu Glu Ser Thr Asn Thr Lys Leu Trp
 1055 1060 1065

Pro Leu Lys Leu Thr Leu Glu Val Ala Ala Trp Phe Ile Leu Leu
 1070 1075 1080

Ile Phe Ile Leu Glu Ile Leu Leu Lys Trp Leu Ser Asn Phe Ser
 1085 1090 1095

Val Phe Trp Lys Ser Ala Trp Asn Val Phe Asp Phe Val Val Thr
 1100 1105 1110

Met Leu Val Arg Ile Glu Ile Leu Arg Val Arg Leu Val Gly
 1115 1120 1125

<210> 359

<211> 55

<212> PRT

<213> Homo sapien

360

<400> 359

Arg Val Thr Val Leu Phe Ser Ser Phe Phe Phe Ser Leu Gln Gln Thr
 1 5 10 15

Val Cys Gly Phe Asp Leu Leu Arg Ala Asn Gly His Ser Phe Val Cys
 20 25 30

Asp Val Asn Gly Phe Ser Phe Val Lys Asn Ser Met Lys Tyr Tyr Asp
 35 40 45

Asp Cys Ala Lys Ile Leu Gly
 50 55

<210> 360

<211> 72

<212> PRT

<213> Homo sapien

<400> 360

Lys Gly Thr Gly His Glu His Ala Val His Gly Glu Pro Gly Pro His
 1 5 10 15

Pro Leu Ala Gly Thr Ala Leu Gln Glu Val Gly Arg Pro Pro Pro Ala
 20 25 30

Phe Pro Ser His Trp Pro Thr Ala Pro Gly Cys Val His His Ser Pro
 35 40 45

Gly Ile Leu His Thr Gly Val Pro Pro Tyr Leu Thr Phe Leu Ser Cys
 50 55 60

Leu Leu Ser Leu Pro Phe Gly Ile
 65 70

<210> 361

<211> 91

<212> PRT

<213> Homo sapien

<400> 361

Phe Leu Pro Asp Ala Cys Gly Leu Ser Asp Val Ala His Val Glu Ser
 1 5 10 15

Leu Gln Glu Lys Ser Gln Cys Ala Leu Glu Glu Tyr Val Arg Ser Gln
 20 25 30

361

Tyr Pro Asn Gln Pro Thr Arg Phe Gly Lys Leu Leu Leu Arg Leu Pro
 35 40 45

Ser Leu Arg Thr Val Ser Ser Ser Val Ile Glu Gln Leu Phe Phe Val
 50 55 60

Arg Leu Val Gly Lys Thr Pro Ile Glu Thr Leu Ile Arg Asp Met Leu
 65 70 75 80

Leu Ser Gly Ser Ser Phe Asn Trp Pro Tyr Met
 85 90

<210> 362

<211> 273

<212> PRT

<213> Homo sapien

<400> 362

Met Gly Arg Ser Arg Ser Arg Ser Ser Ser Arg Ser Lys His Thr Lys
 1 5 10 15

Ser Ser Lys His Asn Lys Lys Arg Ser Arg Ser Arg Ser Arg Ser Arg
 20 25 30

Asp Lys Glu Arg Val Arg Lys Arg Ser Lys Ser Arg Glu Ser Lys Arg
 35 40 45

Asn Arg Arg Arg Glu Ser Arg Ser Arg Ser Arg Ser Thr Asn Thr Ala
 50 55 60

Val Ser Arg Arg Glu Arg Asp Arg Glu Arg Ala Ser Ser Pro Pro Asp
 65 70 75 80

Arg Ile Asp Ile Phe Gly Arg Thr Val Ser Lys Arg Ser Ser Leu Asp
 85 90 95

Glu Lys Gln Lys Arg Glu Glu Glu Glu Lys Lys Ala Glu Phe Glu Arg
 100 105 110

Gln Arg Lys Ile Arg Gln Gln Glu Ile Glu Glu Lys Leu Ile Glu Glu
 115 120 125

Glu Thr Ala Arg Arg Val Glu Glu Leu Val Ala Lys Arg Val Glu Glu
 130 135 140

Glu Leu Glu Lys Arg Lys Asp Glu Ile Glu Arg Glu Val Leu Arg Arg
 145 150 155 160

Val Glu Glu Ala Lys Arg Ile Met Glu Lys Gln Leu Leu Glu Glu Leu
165 170 175

Thr Leu Gly Arg Leu Glu Ser Arg Asp Ser Pro Trp Gln Asn Phe Gln
195 200 205

Tyr Leu Ile Pro Phe Ser Ser Lys Leu Asn Ile Ala Ala Lys Val Asn
225 230 235 240

Phe Tyr Lys Thr Tyr Ser Arg Ile Leu Phe Asp Leu Met Glu Leu Ala
260 265 270

```
<210> 363
<211> 142
<212> PRT
<213> Homo sapien
```

Met Lys Leu Asn Glu Lys Phe Ser Glu Gly Trp Arg Lys Pro Asn Ala
1 5 10 15

Ser Leu Pro His Lys Lys Leu Glu Arg Gly Ser Trp Arg Val Trp Gln
35 40 45

Ala Lys Arg Glu Glu Leu Glu Arg Ile Leu Glu Glu Asn Asn Arg Lys
65 70 75 80

363

Ile Ala Glu Ala Gln Ala Lys Leu Ala Glu Glu Gln Leu Arg Ile Val
85 90 95

Glu Glu Gln Arg Lys Ile His Glu Glu Arg Met Lys Leu Glu Gln Glu
100 105 110

Arg Gln Arg Gln Gln Lys Glu Glu Gln Lys Ile Ile Leu Gly Lys Gly
115 120 125

Lys Ser Arg Pro Lys Leu Ser Phe Ser Leu Lys Thr Gln Asp
130 135 140

<210> 364

<211> 102

<212> PRT

<213> Homo sapien

<400> 364

Met Ser Leu Lys Ser Ala Thr Lys Trp Gly Arg Arg Cys Asn Tyr Tyr
1 5 10 15

Tyr Gln His Leu Glu Ser Ile Met Asn Leu Leu Glu Tyr Phe Leu Ala
20 25 30

Leu Thr Ser Phe Ile Leu Arg Cys Ser Tyr Trp Ile Phe Pro Ser Ala
35 40 45

Asn Asn Met Glu Val Pro Ile Gln Gly Gln Ile Ile Pro Gly Phe Ile
50 55 60

Trp Ser Cys Leu Lys Val Lys Ser Leu Glu Phe Leu Met Ile Pro Phe
65 70 75 80

Leu Tyr Gly Leu Gln Phe Asp Arg Trp Glu Phe Ser Thr Leu Lys Lys
85 90 95

Val Ile Asn Gly Lys Met
100

<210> 365

<211> 92

<212> PRT

<213> Homo sapien

<400> 365

Leu Ser Ser Gln Leu His Gly Cys Ile Ser Val Gly Thr Gln Ala Ser
1 5 10 15

364

Pro Gly Tyr Leu Ser Cys Ser Cys Arg Leu Pro Pro Gly Leu Arg Arg
 20 25 30

Gly Ala Pro Asp Pro Gly Ile Val Arg Leu Arg Pro Ala Lys Glu Gly
 35 40 45

Pro Ala Gly Gly Ala Pro Ala Gly Val Ser Cys Leu Ala Ala Gly Arg
 50 55 60

Gly Asp Leu Glu Asp Arg Val Lys Leu Gln Lys Thr Trp Gly Gly Met
 65 70 75 80

Ala Arg Glu Asp Ala Lys Asp Trp Gly Arg Gly Ser
 85 90

<210> 366

<211> 160

<212> PRT

<213> Homo sapien

<400> 366

Met Ser Leu Lys Ser Ala Thr Lys Trp Gly Arg Arg Cys Asn Tyr Tyr
 1 5 10 15

Tyr Gln His Leu Glu Ser Ile Met Asn Leu Leu Glu Tyr Phe Leu Ala
 20 25 30

Leu Thr Ser Phe Ile Leu Arg Cys Ser Tyr Trp Ile Phe Pro Ser Ala
 35 40 45

Asn Asn Met Glu Val Pro Ile Gln Gly Gln Ile Ile Pro Gly Phe Ile
 50 55 60

Trp Ser Cys Leu Lys Val Lys Ser Leu Glu Phe Leu Met Ile Pro Phe
 65 70 75 80

Leu Tyr Gly Leu Gln Phe Asp Arg Trp Glu Phe Ser Thr Leu Lys Lys
 85 90 95

Thr Leu Leu Leu Ser Gly Asn Pro Cys Pro Pro Leu Thr Ser Thr Gln
 100 105 110

Asn Cys Phe Pro His Ser Leu Thr Ala Arg Val Val Lys Asn Trp Asp
 115 120 125

Val Leu Leu Arg Trp Ala Val Glu Cys His Thr Glu Ser Arg Ser Leu

365

130		135		140
Gly Val Ser Leu Cys Cys Pro Gly Trp Ser Thr Glu Val Ala Val Asn				
145		150		155 160

<210> 367
 <211> 119
 <212> PRT
 <213> Homo sapien

<400> 367

Ser Ser Lys Val Ser Arg Asp Thr Leu Tyr Glu Ala Val Arg Glu Val
1 5 10 15

Leu His Gly Asn Gln Arg Gln Arg Arg Lys Phe Leu Glu Thr Val Glu
20 25 30

Leu Gln Ile Ser Leu Lys Asn Tyr Asp Pro Gln Lys Asp Lys Arg Phe
35 40 45

Ser Gly Thr Val Arg Leu Lys Ser Thr Pro Arg Pro Lys Phe Ser Val
50 55 60

Cys Val Leu Gly Asp Gln Gln His Cys Asp Glu Ala Lys Ala Val Asp
65 70 75 80

Ile Pro His Met Asp Ile Glu Ala Leu Lys Lys Leu Asn Lys Asn Lys
85 90 95

Lys Leu Val Lys Lys Leu Ala Lys Lys Tyr Asp Ala Phe Leu Ala Ser
100 105 110

Glu Ser Leu Ile Lys Gln Ile
115

<210> 368
 <211> 59
 <212> PRT
 <213> Homo sapien

<400> 368

Met Ser Ser Lys Val Ser Arg Asp Thr Leu Tyr Glu Ala Val Arg Glu
1 5 10 15

Val Leu His Gly Asn Gln Arg Lys Ala Ala Arg Lys Phe Leu Glu Thr
20 25 30

366

Val Glu Leu Gln Ile Ser Leu Lys Asn Tyr Asp Pro Gln Lys Asp Lys
 35 40 45

Arg Phe Ser Gly Thr Val Arg Leu Ala Pro Phe
 50 55

<210> 369
 <211> 110
 <212> PRT
 <213> Homo sapien

<400> 369

Met Arg Glu Ala Arg His Cys Lys Leu Thr Ser Gln Val Leu Val Asn
 1 5 10 15

Tyr Asp Leu Glu Ile Phe Thr Leu Arg Cys Leu Gly Ser Gly Ile Arg
 20 25 30

Leu Leu Leu Gln Val Gly Ser Arg His Ser Gln Leu Ser Arg Val Gln
 35 40 45

Gly Pro Gln Leu Arg Asn Arg Gln Asn Ser Ser Pro Gly Ser Leu Asp
 50 55 60

Gln Ser Ile Arg Cys Thr Ala Val Met Pro Trp Ile Met Gly Gln Pro
 65 70 75 80

Gly Phe Leu Arg Ala Cys Phe Gly Thr Ser Glu Gly Pro Glu Asp Phe
 85 90 95

Leu Glu Thr Val Trp Ala Arg Glu Lys Thr Glu Ala Gly Ser
 100 105 110

<210> 370
 <211> 61
 <212> PRT
 <213> Homo sapien

<400> 370

Lys Gly Pro Thr Gly Ala Pro Arg Val Arg Pro Tyr Tyr Thr Val Leu
 1 5 10 15

Ser Ser Asp His Glu Gln Gln Ser Leu Ser Arg His Pro Val Arg Gly
 20 25 30

Gly Ala Gly Ser Pro Ala Arg Glu Pro Ala Gln Gly Cys Ser Gln Val
 35 40 45

367

Pro Gly Asp Gly Gly Val Ala Asp Gln Leu Glu Glu Leu
 50 55 60

<210> 371
 <211> 402
 <212> PRT
 <213> Homo sapien

<400> 371

Met Leu Ser Pro Gln Arg Ala Leu Leu Cys Asn Leu Asn His Ile His
 1 5 10 15

Leu Gln His Val Ser Leu Gly Leu His Leu Ser Arg Arg Pro Glu Leu
 20 25 30

Gln Glu Gly Pro Leu Ser Thr Pro Pro Pro Pro Gly Asp Thr Gly Gly
 35 40 45

Lys Glu Ser Arg Gly Pro Cys Ser Gly Thr Leu Val Asp Ala Asn Ser
 50 55 60

Asn Ser Pro Ala Val Pro Cys Arg Cys Cys Gln Glu His Gly Pro Gly
 65 70 75 80

Leu Glu Asn Arg Gln Asp Pro Ser Gln Glu Glu Glu Gly Ala Ala Ser
 85 90 95

Pro Ser Asp Pro Gly Cys Ser Ser Ser Leu Ser Ser Cys Ser Asp Leu
 100 105 110

Ser Pro Asp Glu Ser Pro Val Ser Val Tyr Leu Arg Asp Leu Pro Gly
 115 120 125

Asp Glu Asp Ala His Pro Gln Pro Ser Ile Ile Pro Leu Glu Gln Gly
 130 135 140

Ser Pro Leu Ala Ser Ala Gly Pro Gly Thr Cys Ser Pro Asp Ser Phe
 145 150 155 160

Cys Cys Ser Pro Asp Ser Cys Ser Gly Ala Ser Ser Ser Pro Asp Pro
 165 170 175

Gly Leu Asp Ser Asn Cys Asn Ala Leu Thr Thr Cys Gln Asp Val Pro
 180 185 190

Ser Pro Gly Leu Glu Glu Glu Asp Glu Arg Ala Glu Gln Asp Leu Pro

368

195	200	205
Thr Ser Glu Leu Leu Glu Ala 210 215	Asp Asp Gly Lys Ile Asp Ala Gly Lys 220	
Thr Glu Pro Ser Trp Lys Ile 225 230	Asn Pro Ile Trp Lys Ile Asp Thr Glu 235 240	
Lys Thr Lys Ala Glu Trp Lys 245	Thr Thr Glu Asn Asn Asn Thr Gly Trp 250 255	
Lys Asn Asn Gly Asn Val Asn 260	Ser Ser Trp Lys Ser Glu Pro Glu Lys 265 270	
Phe Asp Ser Gly Trp Lys Thr 275	Asn Thr Arg Ile Thr Asp Ser Gly Ser 280 285	
Lys Thr Asp Ala Gly Lys Ile 290 295	Asp Gly Gly Trp Arg Ser Asp Val Ser 300	
Glu Glu Pro Val Pro His Arg 305 310	Thr Ile Thr Ser Phe His Glu Leu Ala 315 320	
Gln Lys Arg Lys Arg Gly Pro 325	Gly Leu Pro Leu Val Pro Gln Ala Lys 330 335	
Lys Asp Arg Ser Asp Trp Leu 340	Ile Val Phe Ser Pro Asp Thr Glu Leu 345 350	
Pro Pro Ser Gly Ser Pro Gly 355 360	Gly Ser Ser Ala Pro Pro Arg Glu Val 365	
Thr Thr Phe Lys Glu Leu Arg 370 375	Ser Arg Ser Arg Ala Pro Ala Pro Pro 380	
Val Pro Pro Arg Asp Pro Pro 385 390	Val Gly Trp Ala Leu Val Pro Pro Arg 395 400	

Pro Pro

<210> 372

<211> 243

<212> PRT

<213> Homo sapien

<400> 372

369

Met	Met	Pro	Leu	Ser	Arg	Trp	Leu	Arg	Ser	Val	Gly	Val	Phe	Leu	Leu			
1				5					10					15				
Pro	Ala	Pro	Tyr	Trp	Ala	Pro	Arg	Glu	Arg	Trp	Leu	Gly	Ser	Leu	Arg			
			20					25					30					
Arg	Pro	Ser	Leu	Val	His	Gly	Tyr	Pro	Val	Leu	Ala	Trp	His	Ser	Ala			
		35					40					45						
Arg	Cys	Trp	Cys	Gln	Ala	Trp	Thr	Glu	Glu	Pro	Arg	Ala	Leu	Cys	Ser			
	50					55					60							
Ser	Leu	Arg	Met	Asn	Gly	Asp	Gln	Asn	Ser	Asp	Val	Tyr	Ala	Gln	Glu			
65					70					75				80				
Lys	Gln	Asp	Phe	Val	Gln	His	Phe	Ser	Gln	Ile	Val	Arg	Val	Leu	Thr			
				85					90					95				
Glu	Asp	Glu	Met	Gly	His	Pro	Glu	Ile	Gly	Asp	Ala	Ile	Ala	Arg	Leu			
			100					105					110					
Lys	Glu	Val	Leu	Glu	Tyr	Asn	Ala	Ile	Gly	Gly	Lys	Tyr	Asn	Arg	Gly			
		115					120					125						
Leu	Thr	Val	Val	Val	Ala	Phe	Arg	Glu	Leu	Val	Glu	Pro	Arg	Lys	Gln			
	130					135					140							
Asp	Ala	Asp	Ser	Leu	Gln	Arg	Ala	Trp	Thr	Val	Gly	Trp	Cys	Val	Glu			
145					150					155				160				
Leu	Leu	Gln	Ala	Phe	Phe	Leu	Val	Ala	Asp	Asp	Ile	Met	Asp	Ser	Ser			
				165					170					175				
Leu	Thr	Arg	Arg	Gly	Gln	Ile	Cys	Trp	Tyr	Gln	Lys	Pro	Gly	Val	Gly			
			180					185					190					
Leu	Asp	Ala	Ile	Asn	Asp	Ala	Asn	Leu	Leu	Glu	Ala	Cys	Ile	Tyr	Arg			
		195					200					205						
Leu	Leu	Lys	Leu	Tyr	Cys	Arg	Glu	Gln	Pro	Tyr	Tyr	Leu	Asn	Leu	Ile			
	210					215					220							
Glu	Leu	Phe	Leu	Gln	Val	Tyr	Cys	Arg	Gln	Gly	Pro	Met	Pro	Arg	Gly			
225					230					235					240			

370

Cys Pro Trp

<210> 373

<211> 380

<212> PRT

<213> Homo sapien

<400> 373

Met Tyr Phe Asp Trp Gly Pro Gly Glu Met Leu Val Cys Glu Thr Ser
 1 5 10 15

Phe Asn Lys Lys Glu Lys Ser Glu Met Val Pro Ser Cys Pro Phe Ile
 20 25 30

Tyr Ile Ile Arg Lys Asp Val Asp Val Tyr Ser Gln Ile Leu Arg Lys
 35 40 45

Leu Phe Asn Glu Ser His Gly Ile Phe Leu Gly Leu Gln Arg Ile Asp
 50 55 60

Glu Glu Leu Thr Gly Lys Ser Arg Lys Ser Gln Leu Val Arg Val Ser
 65 70 75 80

Lys Asn Tyr Arg Ser Val Ile Arg Ala Cys Met Glu Glu Met His Gln
 85 90 95

Val Ala Ile Ala Ala Lys Asp Pro Ala Asn Gly Arg Gln Phe Ser Ser
 100 105 110

Gln Val Ser Ile Leu Ser Ala Met Glu Leu Ile Trp Asn Leu Cys Glu
 115 120 125

Ile Leu Phe Ile Glu Val Ala Pro Ala Gly Pro Leu Leu Leu His Leu
 130 135 140

Leu Asp Trp Val Arg Leu His Val Cys Glu Val Asp Ser Leu Ser Ala
 145 150 155 160

Asp Val Leu Gly Ser Glu Asn Pro Ser Lys His Asp Ser Phe Trp Asn
 165 170 175

Leu Val Thr Ile Leu Val Leu Gln Gly Arg Leu Asp Glu Ala Arg Gln
 180 185 190

Met Leu Ser Lys Glu Ala Asp Ala Ser Pro Ala Ser Ala Gly Ile Cys
 195 200 205

371

Arg Ile Met Gly Asp Leu Met Arg Thr Met Pro Ile Leu Ser Pro Gly
 210 215 220

Asn Thr Gln Thr Leu Thr Glu Leu Glu Leu Lys Trp Gln His Trp His
 225 230 235 240

Glu Glu Cys Glu Arg Tyr Leu Gln Asp Ser Thr Phe Ala Thr Ser Pro
 245 250 255

His Leu Glu Ser Leu Leu Lys Ile Met Leu Gly Asp Glu Ala Ala Leu
 260 265 270

Leu Glu Gln Lys Glu Leu Leu Ser Asn Trp Tyr His Phe Leu Val Thr
 275 280 285

Arg Leu Leu Tyr Ser Asn Pro Thr Val Lys Pro Ile Asp Leu His Tyr
 290 295 300

Tyr Ala Gln Ser Ser Leu Asp Leu Phe Leu Gly Gly Glu Ser Ser Pro
 305 310 315 320

Glu Pro Leu Asp Asn Ile Leu Leu Ala Ala Phe Glu Phe Asp Ile His
 325 330 335

Gln Val Ile Lys Glu Cys Arg Asn Lys Thr Asp Leu Ser Arg Arg Ser
 340 345 350

Leu Leu Asp Ala Gly Ser Ile Lys Gly Glu Ser Ile Leu Leu Phe Pro
 355 360 365

Val Ala Glu Glu Lys Glu Lys Tyr His Glu Glu Gly
 370 375 380

<210> 374

<211> 679

<212> PRT

<213> Homo sapien

<400> 374

Met Tyr Phe Asp Trp Gly Pro Gly Glu Met Leu Val Cys Glu Thr Ser
 1 5 10 15

Phe Asn Lys Lys Glu Lys Ser Glu Met Val Pro Ser Cys Pro Phe Ile
 20 25 30

372

Tyr Ile Ile Arg Lys Asp Val Asp Val Tyr Ser Gln Ile Leu Arg Lys
 35 40 45
 Leu Phe Asn Glu Ser His Gly Ile Phe Leu Gly Leu Gln Arg Ile Asp
 50 55 60
 Glu Glu Leu Thr Gly Lys Ser Arg Lys Ser Gln Leu Val Arg Val Ser
 65 70 75 80
 Lys Asn Tyr Arg Ser Val Ile Arg Ala Cys Met Glu Glu Met His Gln
 85 90 95
 Val Ala Ile Ala Ala Lys Asp Pro Ala Asn Gly Arg Gln Phe Ser Ser
 100 105 110
 Gln Val Ser Ile Leu Ser Ala Met Glu Leu Ile Trp Asn Leu Cys Glu
 115 120 125
 Ile Leu Phe Ile Glu Val Ala Pro Ala Gly Pro Leu Leu Leu His Leu
 130 135 140
 Leu Asp Trp Val Arg Leu His Val Cys Glu Val Asp Ser Leu Ser Ala
 145 150 155 160
 Asp Val Leu Gly Ser Glu Asn Pro Ser Lys His Asp Ser Phe Trp Asn
 165 170 175
 Leu Val Thr Ile Leu Val Leu Gln Gly Arg Leu Asp Glu Ala Arg Gln
 180 185 190
 Met Leu Ser Lys Glu Ala Asp Ala Ser Pro Ala Ser Ala Gly Ile Cys
 195 200 205
 Arg Ile Met Gly Asp Leu Met Arg Thr Met Pro Ile Leu Ser Pro Gly
 210 215 220
 Asn Thr Gln Thr Leu Thr Glu Leu Glu Leu Lys Trp Gln His Trp His
 225 230 235 240
 Glu Glu Cys Glu Arg Tyr Leu Gln Asp Ser Thr Phe Ala Thr Ser Pro
 245 250 255
 His Leu Glu Ser Leu Leu Lys Ile Met Leu Gly Asp Glu Ala Ala Leu
 260 265 270
 Leu Glu Gln Lys Glu Leu Leu Ser Asn Trp Tyr His Phe Leu Val Thr

373

275

280

285

Arg Leu Leu Tyr Ser Asn Pro Thr Val Lys Pro Ile Asp Leu His Tyr
 290 295 300

Tyr Ala Gln Ser Ser Leu Asp Leu Phe Leu Gly Gly Glu Ser Ser Pro
 305 310 315 320

Glu Pro Leu Asp Asn Ile Leu Leu Ala Ala Phe Glu Phe Asp Ile His
 325 330 335

Gln Val Ile Lys Glu Cys Ser Phe Leu Leu Lys Thr Gly Gln Phe Leu
 340 345 350

Ala Val Trp Gln Glu Glu Thr Ala Gly Val His Phe Thr Gly Ser Trp
 355 360 365

Ala Arg Cys Arg Gln Phe Pro Gly Ala Leu Gln Val Leu Gln Lys Tyr
 370 375 380

Arg Ala Lys Ser Ile Ala Leu Ser Asn Trp Trp Phe Val Ala His Leu
 385 390 395 400

Thr Asp Leu Leu Asp His Cys Lys Leu Leu Gln Ser His Asn Leu Tyr
 405 410 415

Phe Gly Ser Asn Met Arg Glu Phe Leu Leu Leu Glu Tyr Ala Ser Gly
 420 425 430

Leu Phe Ala His Pro Ser Leu Trp Gln Leu Gly Val Asp Tyr Phe Asp
 435 440 445

Tyr Cys Pro Glu Leu Gly Arg Val Ser Leu Glu Leu His Ile Glu Arg
 450 455 460

Ile Pro Leu Asn Thr Glu Gln Lys Ala Leu Lys Val Leu Arg Ile Cys
 465 470 475 480

Glu Gln Arg Gln Met Thr Glu Gln Val Arg Ser Ile Cys Lys Ile Leu
 485 490 495

Ala Met Lys Ala Val Arg Asn Asn Arg Leu Gly Ser Ala Leu Ser Trp
 500 505 510

Ser Ile Arg Ala Lys Asp Ala Ala Phe Ala Thr Leu Val Ser Asp Arg
 515 520 525

374

Phe Leu Arg Asp Tyr Cys Glu Arg Gly Cys Phe Ser Asp Leu Asp Leu
 530 535 540

Ile Asp Asn Leu Gly Pro Ala Met Met Leu Ser Asp Arg Leu Thr Phe
 545 550 555 560

Leu Gly Lys Tyr Arg Glu Phe His Arg Met Tyr Gly Glu Lys Arg Phe
 565 570 575

Ala Asp Ala Ala Ser Leu Leu Leu Ser Leu Met Thr Ser Arg Ile Ala
 580 585 590

Pro Arg Ser Phe Trp Met Thr Leu Leu Thr Asp Ala Leu Pro Leu Leu
 595 600 605

Glu Gln Lys Gln Val Ile Phe Ser Ala Glu Gln Thr Tyr Glu Leu Met
 610 615 620

Arg Cys Leu Glu Asp Leu Thr Ser Arg Arg Pro Val His Gly Glu Ser
 625 630 635 640

Asp Thr Glu Gln Leu Gln Asp Asp Asp Ile Glu Thr Thr Lys Val Glu
 645 650 655

Met Leu Arg Leu Ser Leu Ala Arg Asn Leu Ala Arg Ala Ile Ile Arg
 660 665 670

Glu Gly Ser Leu Glu Gly Ser
 675

<210> 375

<211> 124

<212> PRT

<213> Homo sapien

<400> 375

Met Val Pro Ser Cys Pro Phe Ile Tyr Ile Ile Arg Lys Asp Val Asp
 1 5 10 15

Val Tyr Ser Gln Ile Leu Arg Lys Leu Phe Asn Glu Ser His Gly Ile
 20 25 30

Phe Leu Gly Leu Gln Arg Ile Asp Glu Glu Leu Thr Gly Lys Ser Arg
 35 40 45

375

Lys Ser Gln Leu Val Arg Val Ser Lys Asn Tyr Arg Ser Val Ile Arg
 50 55 60

Ala Cys Met Glu Glu Met His Gln Val Ala Ile Ala Ala Lys Asp Pro
 65 70 75 80

Ala Asn Gly Arg Gln Phe Ser Ser Gln Val Ser Ile Leu Ser Ala Met
 85 90 95

Glu Leu Ile Trp Asn Leu Cys Glu Ile Leu Phe Ile Glu Val Ala Pro
 100 105 110

Gly Arg His Gly Ile Ser His His Asn Leu Ile Gly
 115 120

<210> 376

<211> 95

<212> PRT

<213> Homo sapien

<400> 376

Lys Lys Lys Lys Lys Lys Asn Lys Lys Gln Lys Ile His His Asn Lys
 1 5 10 15

Arg Pro Asn Val Asn Lys Asp Glu Gly Arg Arg Gly Val Ala Val Ala
 20 25 30

Glu Arg Arg Gln Arg Arg Ser Thr Glu Gly Leu Gly Leu Gln Ala Leu
 35 40 45

Gln Glu Thr Pro Arg Arg Ser Leu Val Ser Gln Pro Ala Leu Ser Gly
 50 55 60

Arg Pro Glu Arg Glu Ala Leu Ala Ser Glu Arg Leu Leu Gly Ala Trp
 65 70 75 80

Gly Ser Ala Leu Trp Arg Ser Ser Met Ala Ser Gln Gln Ser Leu
 85 90 95

<210> 377

<211> 68

<212> PRT

<213> Homo sapien

<400> 377

Met Ser Pro Arg Cys Ser Ser His Ala Ala Ala Arg Leu Tyr Asp Arg
 1 5 10 15

376

Ala Pro His Asp Ala Gln Ile Arg Arg Gly Cys Ser Leu Glu Gly Glu
20 25 30

Ser Val Cys Arg Gly His Pro Arg Pro His Gly Cys Trp Gly Leu Thr
35 40 45

Gly Arg Val Arg Ala Ser Gly Arg Gly Arg Ala Gly Arg Asp Ser Pro
50 55 60

Ala Leu Thr Pro
65

<210> 378

<211> 190

<212> PRT

<213> Homo sapien

<400> 378

Ser Val Ala Asn Met Gln Leu Phe Val Arg Ala Gln Glu Leu His Thr
1 5 10 15

Phe Glu Val Thr Gly Gln Glu Thr Val Ala Gln Ile Lys Ala His Val
20 25 30

Ala Ser Leu Glu Gly Ile Ala Pro Glu Asp Gln Val Val Leu Leu Ala
35 40 45

Gly Ala Pro Leu Glu Asp Glu Ala Thr Leu Gly Gln Cys Gly Val Glu
50 55 60

Ala Leu Thr Thr Leu Glu Val Ala Gly Arg Met Leu Gly Gly Lys Val
65 70 75 80

His Gly Ser Leu Ala Arg Ala Gly Lys Val Arg Gly Gln Thr Pro Lys
85 90 95

Val Ser Glu Ser Ile Ser Gly His Gly Val Arg Thr Phe Phe Pro Phe
100 105 110

Thr Ala Lys Pro Ser Pro Trp Ala Leu Thr Arg Phe Ala Phe Ser Leu
115 120 125

Pro Gly Asp Glu Pro Glu Gly Arg Asp Ala Arg Cys Gly Arg Gln Glu
130 135 140

Pro Gly Pro Asp Pro Ser Leu Leu Gln Val Ala Lys Lys Lys Thr

145 150 155 160

<400> 379

Asn Arg Arg Phe Val Asn Val Val Pro Thr Phe Gly Lys Lys Lys Gly
50 55 60

<400> 380

Thr Asn Phe Lys Thr Ile Leu Glu Trp Glu Pro Lys Pro Val Asn Gln
50 55 60

378

Val Tyr Thr Val Gln Ile Ser Thr Lys Ser Gly Asp Trp Lys Ser Lys
65 70 75 80

Cys Phe Tyr Thr Thr Asp Thr Glu Cys Asp Leu Thr Asp Glu Ile Val
85 90 95

Lys Asp Val Lys Gln Thr Tyr Leu Ala Arg Val Phe Ser Tyr Pro Ala
100 105 110

Gly Asn Val Glu Ser Thr Gly Ser Ala Gly Glu Pro Leu Tyr Glu Asn
115 120 125

Ser Pro Glu Phe Thr Pro Tyr Leu Glu Thr Asn Leu Gly Gln Pro Thr
130 135 140

Ile Gln Ser Phe Glu Gln Val Gly Thr Lys Val Asn Val Thr Val Glu
145 150 155 160

Asp Glu Arg Thr Leu Val Arg Arg Asn Asn Thr Phe Leu Ser Leu Arg
165 170 175

Asp Val Phe Gly Lys Asp Leu Ile Tyr Thr Leu Tyr Tyr Trp Lys Ser
180 185 190

Ser Ser Ser Gly Lys Lys Thr Ala Lys Thr Asn Thr Asn Glu Phe Leu
195 200 205

Ile Asp Val Asp Lys Gly Glu Asn Tyr Cys Phe Ser Val Gln Ala Val
210 215 220

Ile Pro Ser Arg Thr Val Asn Arg Lys Ser Thr Asp Ser Pro Val Glu
225 230 235 240

Cys Met Gly Gln Glu Lys Gly Glu Phe Arg Glu Ile Phe Tyr Ile Ile
245 250 255

Gly Ala Val Val Phe Val Val Ile Ile Leu Val Ile Ile Leu Ala Ile
260 265 270

Ser Leu His Lys Cys Arg Lys Ala Gly Val Gly Gln Ser Trp Lys Glu
275 280 285

Asn Ser Pro Leu Asn Val Ser
290 295

<210> 381

379

<211> 376

<212> PRT

<213> Homo sapien

<400> 381

Met Ala Asp Tyr Trp Lys Ser Gln Pro Lys Lys Phe Cys Asp Tyr Cys
 1 5 10 15

Lys Cys Trp Ile Ala Asp Asn Arg Pro Ser Val Glu Phe His Glu Arg
 20 25 30

Gly Lys Asn His Lys Glu Asn Val Ala Lys Arg Ile Ser Glu Ile Lys
 35 40 45

Gln Lys Ser Leu Asp Lys Ala Lys Glu Glu Glu Lys Ala Ser Lys Glu
 50 55 60

Phe Ala Ala Met Glu Ala Ala Ala Leu Lys Ala Tyr Gln Glu Asp Leu
 65 70 75 80

Lys Arg Leu Gly Leu Glu Ser Glu Ile Leu Glu Pro Ser Ile Thr Pro
 85 90 95

Val Thr Ser Thr Ile Pro Pro Thr Ser Thr Ser Asn Gln Gln Lys Glu
 100 105 110

Lys Lys Asp Lys Lys Lys Arg Gln Lys Asp Pro Ser Lys Gly Arg Trp
 115 120 125

Val Glu Gly Ile Thr Ser Glu Gly Tyr His Tyr Tyr Tyr Asp Leu Ile
 130 135 140

Ser Gly Ala Ser Gln Trp Glu Lys Pro Glu Gly Phe Gln Gly Asp Leu
 145 150 155 160

Lys Lys Thr Ala Val Lys Thr Val Trp Val Glu Gly Leu Ser Glu Asp
 165 170 175

Gly Phe Thr Tyr Tyr Tyr Asn Thr Glu Thr Gly Glu Ser Arg Trp Glu
 180 185 190

Lys Pro Asp Asp Phe Ile Pro His Thr Ser Asp Leu Pro Ser Ser Lys
 195 200 205

Val Asn Glu Asn Ser Leu Gly Thr Leu Asp Glu Ser Lys Ser Ser Asp
 210 215 220

380

Ser His Ser Asp Ser Asp Gly Glu Gln Glu Ala Glu Glu Gly Gly Val
 225 230 235 240

Ser Thr Glu Thr Glu Lys Pro Lys Ile Lys Phe Gln Glu Lys Asn Lys
 245 250 255

Asn Ser Asp Gly Gly Ser Asp Pro Glu Thr Gln Lys Glu Lys Ser Ile
 260 265 270

Gln Lys Gln Asn Ser Leu Gly Ser Asn Glu Glu Lys Ser Lys Thr Leu
 275 280 285

Lys Lys Ser Asn Pro Tyr Gly Glu Trp Gln Glu Ile Lys Gln Glu Val
 290 295 300

Glu Ser His Glu Glu Val Asp Leu Glu Leu Pro Ser Thr Glu Asn Glu
 305 310 315 320

Tyr Val Ser Thr Ser Glu Ala Asp Gly Gly Gly Glu Pro Lys Val Val
 325 330 335

Phe Lys Glu Lys Thr Val Thr Ser Leu Gly Val Met Ala Asp Gly Val
 340 345 350

Ala Pro Val Phe Lys Lys Arg Arg Thr Glu Asn Gly Lys Ser Arg Asn
 355 360 365

Leu Arg Gln Arg Gly Asp Asp Gln
 370 375

<210> 382
 <211> 619
 <212> PRT
 <213> Homo sapien

<400> 382

Met Ala Ala Val Val Gln Gln Asn Asp Leu Val Phe Glu Phe Ala Ser
 1 5 10 15

Asn Val Met Glu Asp Glu Arg Gln Leu Gly Asp Pro Ala Ile Phe Pro
 20 25 30

Ala Val Ile Val Glu His Val Pro Gly Ala Asp Ile Leu Asn Ser Tyr
 35 40 45

Ala Gly Leu Ala Cys Val Glu Glu Pro Ser Asp Met Ile Thr Glu Ser

381

50		55		60											
Ser 65	Leu 66	Asp 67	Val 68	Ala 69	Glu 70	Glu 71	Glu 72	Ile 73	Ile 74	Asp 75	Asp 76	Asp 77	Asp 78	Asp 79	Asp 80
Ile 85	Thr 86	Leu 87	Thr 88	Val 89	Glu 90	Ala 91	Ser 92	Cys 93	His 94	Asp 95	Gly 96	Asp 97	Glu 98	Thr 99	Ile 100
Glu 105	Thr 106	Ile 107	Glu 108	Ala 109	Ala 110	Glu 111	Ala 112	Leu 113	Leu 114	Asn 115	Met 116	Asp 117	Ser 118	Pro 119	Gly 120
Pro 125	Met 126	Leu 127	Asp 128	Glu 129	Lys 130	Arg 131	Ile 132	Asn 133	Asn 134	Asn 135	Ile 136	Phe 137	Ser 138	Ser 139	Pro 140
Glu 145	Asp 146	Asp 147	Met 148	Val 149	Val 150	Ala 151	Pro 152	Val 153	Thr 154	His 155	Val 156	Ser 157	Val 158	Thr 159	Leu 160
Asp 165	Gly 166	Ile 167	Pro 168	Glu 169	Val 170	Met 171	Glu 172	Thr 173	Gln 174	Gln 175	Val 176	Gln 177	Glu 178	Lys 179	Tyr 180
Ala 185	Asp 186	Ser 187	Pro 188	Gly 189	Ala 190	Ser 191	Ser 192	Pro 193	Glu 194	Gln 195	Pro 196	Lys 197	Arg 198	Lys 199	Lys 200
Gly 205	Arg 206	Lys 207	Thr 208	Lys 209	Pro 210	Pro 211	Arg 212	Pro 213	Asp 214	Ser 215	Pro 216	Ala 217	Thr 218	Thr 219	Pro 220
Asn 225	Ile 226	Ser 227	Val 228	Lys 229	Lys 230	Lys 231	Asn 232	Lys 233	Asp 234	Gly 235	Lys 236	Gly 237	Asn 238	Thr 239	Ile 240
Tyr 245	Leu 246	Trp 247	Glu 248	Phe 249	Leu 250	Leu 251	Ala 252	Leu 253	Leu 254	Gln 255	Asp 256	Lys 257	Ala 258	Thr 259	Cys 260
Pro 265	Lys 266	Tyr 267	Ile 268	Lys 269	Trp 270	Thr 271	Gln 272	Arg 273	Glu 274	Lys 275	Gly 276	Ile 277	Phe 278	Lys 279	Leu 280
Val 285	Asp 286	Ser 287	Lys 288	Ala 289	Val 290	Ser 291	Arg 292	Leu 293	Trp 294	Gly 295	Lys 296	His 297	Lys 298	Asn 299	Lys 300
Pro 305	Asp 306	Met 307	Asn 308	Tyr 309	Glu 310	Thr 311	Met 312	Gly 313	Arg 314	Ala 315	Leu 316	Arg 317	Tyr 318	Tyr 319	Tyr 320
Gln 325	Arg 326	Gly 327	Ile 328	Leu 329	Ala 330	Lys 331	Val 332	Glu 333	Gly 334	Gln 335	Arg 336	Leu 337	Val 338	Tyr 339	Gln 340
Phe 345	Lys 346	Glu 347	Met 348	Pro 349	Lys 350	Asp 351	Leu 352	Ile 353	Tyr 354	Ile 355	Asn 356	Asp 357	Glu 358	Asp 359	Pro 360

382

Ser	Ser	Ser	Ile	Glu	Ser	Ser	Asp	Pro	Ser	Leu	Ser	Ser	Ser	Ala	Thr
305					310					315					320
Ser	Asn	Arg	Asn	Gln	Thr	Ser	Arg	Ser	Arg	Val	Ser	Ser	Ser	Pro	Gly
				325					330					335	
Val	Lys	Gly	Gly	Ala	Thr	Ser	Val	Leu	Lys	Pro	Gly	Asn	Ser	Lys	Ala
			340					345					350		
Ala	Lys	Pro	Lys	Asp	Pro	Val	Glu	Val	Ala	Gln	Pro	Ser	Glu	Val	Leu
		355					360					365			
Arg	Thr	Val	Gln	Pro	Thr	Gln	Ser	Pro	Tyr	Pro	Thr	Gln	Leu	Phe	Arg
	370					375					380				
Thr	Val	His	Val	Val	Gln	Pro	Val	Gln	Ala	Val	Pro	Glu	Gly	Glu	Ala
385					390					395					400
Ala	Arg	Thr	Ser	Thr	Met	Gln	Asp	Glu	Thr	Leu	Asn	Ser	Ser	Val	Gln
				405					410					415	
Ser	Ile	Arg	Thr	Ile	Gln	Ala	Pro	Thr	Gln	Val	Pro	Val	Val	Val	Ser
			420					425					430		
Pro	Arg	Asn	Gln	Gln	Leu	His	Thr	Val	Thr	Leu	Gln	Thr	Val	Pro	Leu
		435					440					445			
Thr	Thr	Val	Ile	Ala	Ser	Thr	Asp	Pro	Ser	Ala	Gly	Thr	Gly	Ser	Gln
	450					455					460				
Lys	Phe	Ile	Leu	Gln	Ala	Ile	Pro	Ser	Ser	Gln	Pro	Met	Thr	Val	Leu
465				470						475					480
Lys	Glu	Asn	Val	Met	Leu	Gln	Ser	Gln	Lys	Ala	Gly	Ser	Pro	Pro	Ser
				485					490					495	
Ile	Val	Leu	Gly	Pro	Ala	Gln	Val	Gln	Gln	Val	Leu	Thr	Ser	Asn	Val
			500					505					510		
Gln	Thr	Ile	Cys	Asn	Gly	Thr	Val	Ser	Val	Ala	Ser	Ser	Pro	Ser	Phe
		515					520					525			
Ser	Ala	Thr	Ala	Pro	Val	Val	Thr	Phe	Ser	Pro	Arg	Ser	Ser	Gln	Leu
						535					540				

383

Val Ala His Pro Pro Gly Thr Val Ile Thr Ser Val Ile Lys Thr Gln
 545 550 555 560

Glu Thr Lys Thr Leu Thr Gln Glu Val Glu Lys Lys Glu Ser Glu Asp
 565 570 575

His Leu Lys Glu Asn Thr Glu Lys Thr Glu Gln Gln Pro Gln Pro Tyr
 580 585 590

Val Met Val Val Ser Ser Ser Asn Gly Phe Thr Ser Gln Val Ala Met
 595 600 605

Lys Gln Asn Glu Leu Leu Glu Pro Asn Ser Phe
 610 615

<210> 383
 <211> 63
 <212> PRT
 <213> Homo sapien

<400> 383

Val Ile Asp Val Ile His Glu Val Ala His Ser Trp Phe Gly Asn Ala
 1 5 10 15

Val Thr Asn Ala Thr Trp Glu Glu Met Trp Leu Ser Glu Gly Leu Ala
 20 25 30

Thr Tyr Ala Gln Arg Arg Ile Thr Thr Glu Thr Tyr Gly Ala Ala Phe
 35 40 45

Thr Cys Leu Glu Thr Ala Phe Arg Leu Asp Ala Leu His Arg Gln
 50 55 60

<210> 384
 <211> 190
 <212> PRT
 <213> Homo sapien

<400> 384

Ser Val Ala Asn Met Gln Leu Phe Val Arg Ala Gln Glu Leu His Thr
 1 5 10 15

Phe Glu Val Thr Gly Gln Glu Thr Val Ala Gln Ile Lys Ala His Val
 20 25 30

Ala Ser Leu Glu Gly Ile Ala Pro Glu Asp Gln Val Val Leu Leu Ala
 35 40 45

384

Gly Ala Pro Leu Glu Asp Glu Ala Thr Leu Gly Gln Cys Gly Val Glu
50 55 60

Ala Leu Thr Thr Leu Glu Val Ala Gly Arg Met Leu Gly Gly Lys Val
65 70 75 80

His Gly Ser Leu Ala Arg Ala Gly Lys Val Arg Gly Gln Thr Pro Lys
85 90 95

Val Ser Glu Ser Ile Ser Gly His Gly Val Arg Thr Phe Phe Pro Phe
100 105 110

Thr Ala Lys Pro Ser Pro Trp Ala Leu Thr Arg Phe Ala Phe Ser Leu
115 120 125

Pro Gly Asp Glu Pro Glu Gly Arg Asp Ala Arg Cys Gly Arg Gln Glu
130 135 140

Pro Gly Pro Asp Pro Ser Leu Leu Gln Val Ala Lys Lys Lys Lys Thr
145 150 155 160

Gly Arg Ala Lys Arg Arg Met Gln Tyr Asn Arg Arg Phe Val Asn Val
165 170 175

Val Pro Thr Phe Gly Lys Lys Lys Gly Pro Asn Ala Asn Ser
180 185 190

<210> 385
<211> 305
<212> PRT
<213> Homo sapien

<400> 385

Gln Phe Leu Gly Arg Trp Phe Ser Ala Gly Leu Ala Ser Asn Ser Ser
1 5 10 15

Trp Leu Arg Glu Lys Lys Ala Ala Leu Ser Met Cys Lys Ser Val Val
20 25 30

Ala Pro Ala Thr Asp Gly Gly Leu Asn Leu Thr Ser Thr Phe Leu Arg
35 40 45

Lys Asn Gln Cys Glu Thr Arg Thr Met Leu Leu Gln Pro Ala Gly Ser
50 55 60

385

Leu Gly Ser Tyr Ser Tyr Arg Ser Pro Arg Glu Trp Gly Leu His Arg
 65 70 75 80

Pro Pro Gly Pro Ser Leu Gly Ala Thr Leu Ala Gly Thr Thr Leu Gly
 85 90 95

Gln Pro Pro Ala Ala Glu Ile His Gly Val Gly Gly Asp Gly Cys Pro
 100 105 110

Thr Ser Val Arg Gly Lys Gly Gln Arg Thr Gln Gly Phe Pro His Ser
 115 120 125

His Leu Gly Asn Gly Ser His Gly Glu Thr Ser Ser Leu Pro Val Leu
 130 135 140

Ala Ala Thr Ser Ala Ala Ala Pro Gly Ile Leu Val Phe Ala Trp Leu
 145 150 155 160

Pro Gln Ile Leu Val Trp Gly Gln Gly Ser Gln Ala Val Gln Ala Arg
 165 170 175

Ala Gly His Trp Leu Glu Ser Ser Arg Val Gly Glu His Pro Gly Pro
 180 185 190

Ala Glu Gly Leu Ser Ala Pro Lys Ala His Arg Cys Thr Pro Ser Leu
 195 200 205

Lys Gln Arg Gly Leu Gly Gly Val Pro Asp Arg Val Val Ser Trp Val
 210 215 220

Pro Arg Leu Gly Ser Thr Tyr Ser Val Ser Val Val Glu Thr Asp Tyr
 225 230 235 240

Asp Gln Tyr Ala Leu Leu Tyr Ser Gln Gly Ser Lys Gly Pro Gly Glu
 245 250 255

Asp Phe Arg Met Ala Thr Leu Tyr Ser Arg Thr Gln Thr Pro Arg Ala
 260 265 270

Glu Leu Lys Glu Lys Phe Thr Ala Phe Cys Lys Ala Gln Gly Phe Thr
 275 280 285

Glu Asp Thr Ile Val Phe Leu Pro Gln Thr Asp Lys Cys Met Thr Glu
 290 295 300

Gln

386

305

<210> 386
 <211> 25
 <212> PRT
 <213> Homo sapien

<400> 386

Met Thr Asn Thr Lys Gly Lys Arg Arg Cys Thr Gln Tyr Met Ser Ser
 1 5 10 15

Arg Pro Phe Arg Lys Tyr Gly Val Val
 20 25

<210> 387
 <211> 361
 <212> PRT
 <213> Homo sapien

<400> 387

Thr Gly Ile Ser Leu Ala Ser Gln Leu Lys Val Pro Pro Tyr Ala Ser
 1 5 10 15

Glu Asn Gln Thr Cys Arg Asp Gln Glu Lys Glu Tyr Tyr Glu Pro Gln
 20 25 30

His Arg Ile Cys Cys Ser Arg Cys Pro Pro Gly Thr Tyr Val Ser Ala
 35 40 45

Lys Cys Ser Arg Ile Arg Asp Thr Val Cys Ala Thr Cys Ala Glu Asn
 50 55 60

Ser Tyr Asn Glu His Trp Asn Tyr Leu Thr Ile Cys Gln Leu Cys Arg
 65 70 75 80

Pro Cys Asp Pro Val Met Gly Leu Glu Glu Ile Ala Pro Cys Thr Ser
 85 90 95

Lys Arg Lys Thr Gln Cys Arg Cys Gln Pro Gly Met Phe Cys Ala Ala
 100 105 110

Trp Ala Leu Glu Cys Thr His Cys Glu Arg Leu Ser Asp Cys Pro Pro
 115 120 125

Gly Thr Glu Ala Glu Leu Lys Asp Glu Val Gly Lys Gly Asn Asn His
 130 135 140

387

Cys Val Pro Cys Lys Ala Gly His Phe Gln Asn Thr Ser Ser Pro Ser
 145 150 155 160

Ala Leu Cys Gln Pro His Thr Arg Cys Glu Asn Gln Gly Leu Val Glu
 165 170 175

Ala Ala Pro Gly Thr Ala Gln Ser Asp Thr Thr Cys Lys Asn Pro Leu
 180 185 190

Glu Pro Leu Pro Pro Glu Met Ser Gly Ser Leu Leu Lys Arg Arg Pro
 195 200 205

Gln Gly Glu Gly Pro Asn Pro Val Ala Gly Ser Trp Glu Pro Pro Lys
 210 215 220

Ala His Pro Tyr Phe Pro Asp Leu Val Gln Pro Leu Leu Pro Ile Ser
 225 230 235 240

Gly Asp Val Ser Pro Val Ser Thr Gly Leu Pro Ala Ala Pro Val Leu
 245 250 255

Glu Ala Gly Val Pro Gln Gln Gln Ser Pro Leu Asp Leu Thr Arg Glu
 260 265 270

Pro Gln Leu Glu Pro Gly Glu Gln Ser Gln Val Ala His Gly Thr Asn
 275 280 285

Gly Ile His Val Thr Gly Gly Ser Met Thr Ile Thr Gly Asn Ile Tyr
 290 295 300

Ile Tyr Asn Gly Pro Val Leu Gly Gly Pro Pro Gly Pro Gly Asp Leu
 305 310 315 320

Pro Ala Thr Pro Glu Pro Pro Tyr Pro Ile Pro Glu Glu Gly Asp Pro
 325 330 335

Gly Pro Pro Gly Leu Ser Thr Pro His Gln Glu Asp Gly Lys Ala Trp
 340 345 350

His Leu Ala Glu Thr Glu His Cys Gly
 355 360

<210> 388

<211> 105

<212> PRT

<213> Homo sapien

388

<400> 388

Met Ala Lys Ile Ser Ser Pro Thr Glu Thr Glu Arg Cys Ile Glu Ser
1 5 10 15

Leu Ile Ala Val Phe Gln Lys Tyr Ala Gly Lys Asp Gly Tyr Asn Tyr
20 25 30

Thr Leu Ser Lys Thr Glu Phe Leu Ser Phe Met Asn Thr Glu Leu Ala
35 40 45

Ala Phe Thr Lys Asn Gln Lys Asp Pro Gly Val Leu Asp Arg Met Met
50 55 60

Lys Lys Leu Asp Thr Asn Ser Asp Gly Gln Leu Asp Phe Ser Glu Phe
65 70 75 80

Leu Asn Leu Ile Gly Gly Leu Ala Met Ala Cys His Asp Ser Phe Leu
85 90 95

Lys Ala Val Pro Ser Gln Lys Arg Thr
100 105

<210> 389

<211> 71

<212> PRT

<213> Homo sapien

<400> 389

Met Ala Arg Tyr Glu Glu Val Ser Val Ser Gly Phe Glu Glu Phe His
1 5 10 15

Arg Ala Val Glu Gln His Asn Cys Trp Lys Asp Pro Asn Asn Asp Phe
20 25 30

Arg Lys Asn Leu Lys Val Thr Ala Val Pro Thr Leu Leu Lys Tyr Gly
35 40 45

Thr Pro Gln Lys Leu Val Glu Ser Glu Cys Leu Gln Ala Asn Leu Val
50 55 60

Glu Met Leu Phe Ser Glu Asp
65 70

<210> 390

<211> 243

<212> PRT

<213> Homo sapien

389

<400> 390

Gln Thr Leu Pro Ser Lys Ser Asn Glu Ser His Asp His Met Asp Asp
 1 5 10 15

Met Asp Asp Glu Asp Asp Asp Asp His Val Asp Ser Gln Asp Ser Ile
 20 25 30

Asp Ser Asn Asp Ser Asp Asp Val Asp Asp Thr Asp Asp Ser His Gln
 35 40 45

Ser Asp Glu Ser His His Ser Asp Glu Ser Asp Glu Leu Val Thr Asp
 50 55 60

Phe Pro Thr Asp Leu Pro Ala Thr Glu Val Phe Thr Pro Val Val Pro
 65 70 75 80

Thr Val Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Leu
 85 90 95

Arg Ser Lys Ser Lys Lys Phe Arg Arg Pro Asp Ile Gln Tyr Pro Asp
 100 105 110

Ala Thr Asp Glu Asp Ile Thr Ser His Met Glu Ser Glu Glu Leu Asn
 115 120 125

Gly Ala Tyr Lys Ala Ile Pro Val Ala Gln Asp Leu Asn Ala Pro Ser
 130 135 140

Asp Trp Asp Ser Arg Gly Lys Asp Ser Tyr Glu Thr Ser Gln Leu Asp
 145 150 155 160

Asp Gln Ser Ala Glu Thr His Ser His Arg Gln Ser Arg Leu Tyr Lys
 165 170 175

Arg Lys Ala Asn Asp Glu Ser Asn Glu His Ser Asp Val Ile Asp Ser
 180 185 190

Gln Glu Leu Ser Lys Val Ser Arg Glu Phe His Ser His Glu Phe His
 195 200 205

Ser His Glu Asp Met Leu Val Val Asp Pro Lys Ser Lys Glu Glu Asp
 210 215 220

Lys His Leu Lys Phe Arg Ile Ser His Glu Leu Asp Ser Ala Ser Ser
 225 230 235 240

390

Glu Val Asn

<210> 391

<211> 363

<212> PRT

<213> Homo sapien

<400> 391

Met	Lys	Thr	Leu	Leu	Leu	Leu	Leu	Leu	Val	Leu	Leu	Glu	Leu	Gly	Glu
1			5						10					15	

Ala	Gln	Gly	Ser	Leu	His	Arg	Val	Pro	Leu	Arg	Arg	His	Pro	Ser	Leu
			20					25					30		

Lys	Lys	Lys	Leu	Arg	Ala	Arg	Ser	Gln	Leu	Ser	Glu	Phe	Trp	Lys	Ser
		35					40					45			

His	Asn	Leu	Asp	Met	Ile	Gln	Phe	Thr	Glu	Ser	Cys	Ser	Met	Asp	Gln
	50					55					60				

Ser	Ala	Lys	Glu	Pro	Leu	Ile	Asn	Tyr	Leu	Asp	Met	Glu	Tyr	Phe	Gly
65					70					75					80

Thr	Ile	Ser	Ile	Gly	Ser	Pro	Pro	Gln	Asn	Phe	Thr	Val	Ile	Phe	Asp
				85					90					95	

Thr	Gly	Ser	Ser	Asn	Leu	Trp	Val	Pro	Ser	Val	Tyr	Cys	Thr	Ser	Pro
			100					105					110		

Ala	Cys	Lys	Thr	His	Ser	Arg	Phe	Gln	Pro	Ser	Gln	Ser	Ser	Thr	Tyr
		115					120					125			

Ser	Gln	Pro	Gly	Gln	Ser	Phe	Ser	Ile	Gln	Tyr	Gly	Thr	Gly	Ser	Leu
	130					135					140				

Ser	Gly	Ile	Ile	Gly	Ala	Asp	Gln	Val	Ser	Val	Glu	Gly	Leu	Thr	Val
145					150					155					160

Val	Gly	Gln	Gln	Phe	Gly	Glu	Ser	Val	Thr	Glu	Pro	Gly	Gln	Thr	Phe
				165					170					175	

Val	Asp	Ala	Glu	Phe	Asp	Gly	Ile	Leu	Gly	Leu	Gly	Tyr	Pro	Ser	Leu
			180					185					190		

391

Ala Val Gly Gly Val Thr Pro Val Phe Asp Asn Met Met Ala Gln Asn
 195 200 205

Leu Val Asp Leu Pro Met Phe Ser Val Tyr Met Ser Ser Asn Pro Glu
 210 215 220

Gly Gly Ala Gly Ser Glu Leu Ile Phe Gly Gly Tyr Asp His Ser His
 225 230 235 240

Phe Ser Gly Ser Leu Asn Trp Val Pro Val Thr Lys Gln Ala Tyr Trp
 245 250 255

Gln Ile Ala Leu Asp Asn Met Leu Trp Ser Val Pro Thr Leu Thr Ser
 260 265 270

Cys Arg Met Ser Pro Ser Pro Leu Thr Glu Ser Pro Ile Pro Ser Ala
 275 280 285

Gln Leu Pro Thr Pro Tyr Trp Thr Ser Trp Met Glu Cys Ser Ser Ala
 290 295 300

Ala Val Ala Phe Lys Asp Leu Thr Ser Thr Leu Gln Leu Gly Pro Ser
 305 310 315 320

Gly Ser Trp Gly Met Ser Ser Phe Asp Ser Phe Thr Gln Ser Leu Thr
 325 330 335

Val Gly Ile Thr Val Trp Asp Trp Pro Gln Gln Ser Pro Lys Glu Gly
 340 345 350

Pro Cys Val Cys Ala Cys Leu Ser Asp Arg Pro
 355 360

<210> 392

<211> 151

<212> PRT

<213> Homo sapien

<400> 392

Met Gly Gly Gly Cys His Pro Gln Ser Ala Pro Leu Cys Thr Asp His
 1 5 10 15

Leu Pro Ser Glu Gln Pro Leu Arg Trp Met Ala Ser Asn Gln Thr Lys
 20 25 30

Ala Arg Thr Gln Ala Ser Gly Val Thr Ser Cys Ile Gln Gly Glu Ser
 35 40 45

392

Gly Asp Gly Val Trp Ala Leu Gly His Leu Thr Val Glu Asp Leu Thr
 50 55 60

Leu Ser Leu Pro Ser Lys Lys Pro Gln Gly Thr Leu Ala His Pro Pro
 65 70 75 80

Pro Ser Ser Val Gly Leu Glu Pro Lys Asn Ser Thr Gly Ala Val Ala
 85 90 95

Gly Ala Ala Ala Asp Trp Cys Leu Gln Gln Pro Gly Gly His Ser Asp
 100 105 110

Pro Leu Pro Ala Leu Ala Met Pro Ser Pro Pro Thr Gly Val Gly Ser
 115 120 125

Leu Arg Leu Gly Leu Asn Glu Gly Arg Arg His Trp Val Gly Phe Pro
 130 135 140

Gly Leu Thr Cys Val Gly Asp
 145 150

<210> 393
 <211> 71
 <212> PRT
 <213> Homo sapien

<400> 393

Cys Lys Ser Val Val Ala Pro Ala Thr Asp Gly Gly Leu Asn Leu Thr
 1 5 10 15

Ser Thr Phe Leu Arg Lys Asn Gln Cys Glu Thr Arg Thr Met Leu Leu
 20 25 30

Leu Pro Ala Gly Ser Leu Gly Ser Tyr Ser Tyr Arg Ser Pro His Trp
 35 40 45

Gly Ser Thr Tyr Ser Val Ser Val Val Glu Thr Asp Tyr Asp Gln Tyr
 50 55 60

Ala Leu Leu Tyr Ser Gln Gly
 65 70

<210> 394
 <211> 197
 <212> PRT
 <213> Homo sapien

393

<400> 394

Met Val Asp Leu Thr Gln Val Met Asp Asp Glu Val Phe Met Ala Phe
 1 5 10 15

Ala Ser Tyr Ala Thr Ile Ile Leu Ser Lys Met Met Leu Met Ser Thr
 20 25 30

Ala Thr Ala Phe Tyr Arg Leu Thr Arg Lys Val Phe Ala Asn Pro Glu
 35 40 45

Asp Cys Val Ala Phe Gly Lys Gly Glu Asn Ala Lys Lys Tyr Leu Arg
 50 55 60

Thr Asp Asp Arg Val Glu Arg Val Arg Ser His Cys Lys Ala Val Thr
 65 70 75 80

Ile Ser Ile Phe Glu Arg Gln Ser Gln Asn Gly Ala Thr Asn Glu Val
 85 90 95

Lys Ser Met Leu Tyr Arg Val Gln Gln Leu Lys Leu Ile His Thr His
 100 105 110

Met Glu Gln Leu Thr Lys Asp Leu Arg Ala His Leu Asn Asp Leu Glu
 115 120 125

Asn Ile Ile Pro Phe Leu Gly Ile Gly Leu Leu Tyr Ser Leu Ser Gly
 130 135 140

Pro Asp Pro Ser Thr Ala Ile Leu His Phe Arg Leu Phe Val Gly Thr
 145 150 155 160

Arg Ile Tyr His Thr Ile Ala Tyr Leu Thr Thr Pro Leu Arg Gln Gln
 165 170 175

Ile Arg Ala Ser Val Phe Val Gly Tyr Gly Val Thr Leu Ser Met Ala
 180 185 190

Tyr Arg Leu Leu Lys
 195

<210> 395

<211> 42

<212> PRT

<213> Homo sapien

<400> 395

394

Met Thr Asn Arg Asn Ser Phe Thr Met Asn Cys Val His Val Leu Leu
1 5 10 15

Cys His Leu Phe Glu Asp Thr Ser Trp His Phe Leu Leu Cys Gln Met
20 25 30

Leu His Ser Leu Leu Asp Trp Gln Lys Arg
35 40

<210> 396

<211> 38

<212> PRT

<213> Homo sapien

<400> 396

Met Ser Lys Asn Phe Ile Phe Thr Asn Leu Ile Asp Gln Lys Asp Thr
1 5 10 15

Leu Leu Ala Phe Phe Thr Ile Cys Lys Ala Lys Asn His Gln Asn Ser
20 25 30

Pro Ser Pro His Ile Tyr
35

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number
WO 2004/013311 A3

(51) International Patent Classification:
C12Q 1/68 (2006.01) *C07H 21/04* (2006.01)

(21) International Application Number:
PCT/US2003/024669

(22) International Filing Date: 6 August 2003 (06.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/401,469 6 August 2002 (06.08.2002) US

(71) Applicant (*for all designated States except US*): **DI-ADEXUS, INC.** [US/US]; 343 Oyster Point Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MACINA, Roberto, A.** [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). **SALCEDA, Susana** [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). **LIU, Chenghua** [CN/US]; 1125 Ranchero Way #14, San Jose, CA 95117 (US). **SUN, Yongming** [CN/US]; 551 Shoal Drive., Redwood City., California 94065 (CN). **TURNER, Leah, R.** [US/US]; 939 Rosette Court, Sunnyvale, CA 94086 (US).

(74) Agent: **LICATA, Jane, Massey**; Licata & Tyrrell P.C., 66 E. Main Street, Marlton, New Jersey 08053 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
4 May 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS RELATING TO OVARIAN SPECIFIC GENES AND PROTEINS

(57) Abstract: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and noncancerous disease states in ovarian, identifying ovarian tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research.



WO 2004/013311 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/24669

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-6,8-10,16 and 18

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/24669

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) : C12Q 1/68; C07H 21/04
US CL : 435/6; 91.2; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 435/6; 91.2; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN: Medline, Biosis, Caplus

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/0039760 A1 (WONG et al.) 04 April 2002 (.04.04.2002), SEQ ID NO: 193	1-6, 8-10, 16, and 18

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

23 January 2006 (23.01.2006)

Date of mailing of the international search report

01 MAR 2006

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Authorized officer

Sally Sakelaris

Telephone No. 571-272-1600

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

Group 1, claims 1-6, 8-10, 16, and 18, drawn to isolated nucleic acid molecules, vector, host cells containing, method for producing a protein encoded by the isolated nucleic acids, vaccines consisting of a nucleic acid, and kits containing the isolated nucleic acids.

Group 2, claims 11, 12, 16, 18, drawn to isolated polypeptides, vaccines consisting of polypeptides and kits containing polypeptides.

Group 3, claim 13, drawn to antibodies.

Group 4, claims 14, 15, and 17 drawn to a method for determining the presence of an ovarian specific protein and treatment with administration of a polypeptide.

Group 5, claims 7, 15 and 17 drawn to a method for determining the presence of an ovarian specific nucleotide by which ovarian cancer is diagnosed or monitored, and treating a patient with ovarian cancer through administration of the same polynucleotides.

Further species election required:

For all groups, the species in each group are considered each of the 397 (SEQ ID NO: 249-396 and 1-248) separately recited polynucleotides encoding, polynucleotides, polypeptides, and antibodies recited within the claims.

The first named invention which will be searched is Group 1, claims 1-6, 8-10, 16, and 18, with respect to the first named species which is the polynucleotide of SEQ ID NO: 1.

The inventions listed as Groups 1-5 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The technical feature that joins all of these inventions is the nucleic acids recited in the claim that encode proteins. However, the an isolated nucleic acid molecule comprising a nucleic acid molecule that selectively hybridizes to the nucleic acid sequence of SEQ ID NO: 7 was known at the time the invention was made as taught by US20020039760A1 and Wong et al. in their SEQ ID NO: 193 that shares 90.6% identity to present SEQ ID NO: 7 and as a result could hybridize to the claimed sequence and thus, this is not a special technical feature in view of the PCT rules. Group 1 is the first named invention including isolated polynucleotides. Group 2 includes polypeptides encoded by Group 1's nucleic acids. There is no special technical feature that joins the first named products as the isolated nucleic acid of groups 1 and 2 is anticipated in the prior art. The remaining groups include additional products and methods that are not linked by a unifying inventive concept as they are drawn to unique products and methods and are so separately grouped.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Each is drawn to a unique nucleic acid sequence that does not share a common structure with the others.